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Abstract 
Background and aims: Clefts of the lip and palate are the most common types of 
craniofacial birth defects found worldwide. This study is the first multicentre case-
control triad (of children and their parents) in Saudi Arabia that  aims to: (I) measure 
the prevalence of non-syndromic orofacial cleft (NSOFC) at birth and (II) investigate 
the genetic and environmental risk factors associated with NSOFC in infants 
attending government hospitals in the Western and Central Regions of Saudi Arabia.  
Material and methods: Two hundred and seventeen non-syndromic orofacial cleft 
(NSOFC) triads comprising probands aged 18 months or less were selected from 
eleven hospitals in three main cities of Saudi Arabia (Jeddah, Maddina, and Riyadh). 
Patients were examined to identify cleft phenotype according to the LASHAL 
classification. Cases born in the designated hospitals from January 2010 to January 
2012 were compared with the total number of births, in the same period of time to 
measure the prevalence of CL/P and CP in Saudi Arabia. Cases were compared with 
244 control triads matched for proband age, gender and location to assess the 
environmental and genetic (IRF6 and VAX1 genes) aetiology of NSOFC through a 
questionnaire and infant-parental triad saliva sample. Gene-environmental interaction 
(GEI) was assessed through measuring the distribution of maternal genotypes and 
alleles according to exposure/no-exposure environmental factors.  
Results: The prevalence of NSOFC in government hospitals in the Western and 
Central regions of Saudi Arabia was 1.17/1000 births.  
Environmental risk factors (ERFs) significantly related to NSOFC after the odds 
ratios were adjusted through logistic regression included; family history for NSOFC, 
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folic acid, antibiotic use, common cold/flu, maternal stress, paternal waterpipe 
smoking, incense exposure, maternal exposure to chemicals and maternal main water 
source.  
Genetic analysis revealed significant over-transmission of the common IRF6 allele 
rs2013162 in CL/P families using Family based association test (FBAT) analysis and 
paternal transmission using PLINK testing. Two haplotypes containing the rare alleles 
of VAX1 rs4752028 and IRF6 rs2013162 were significantly associated with NSOFC. 
VAX1 showed significant difference between cases and controls infant parental triad.  
Gene-environment interaction (GEI) found a significant relationship between 
maternal SNP (IRF6 rs2013162 and/or VAX1 rs7078160) and maternal folic acid pre-
gestation ingestion, antipyretic medication ingestion, fever, abdominal pain, high 
blood pressure, passive smoking, maternal stress and paternal waterpipe smoking, and 
/or maternal passive smoking 
Conclusion: 
 The prevalence of NSOFC in Saudi Arabia (1.17/1000 births) is marginally 
lower than global average figures (1.25/1000births)  
 Maternal exposure to common cold/flu, folic acid supplementation, stress, 
antibiotic use, incense, source of drinking water, paternal waterpipe smoking 
and intense paternal tobacco smoking are associated with increased risk of 
CL/P and/or CP in Saudi Arabia. 
 IRF6 rs2013162 showed significant over transmission of the common allele 
(C) with CL/P cases. Also, VAX1 rs4752028 and rs7078160 rare allele are 
xviii 
 
found more frequent in CL/P and CP infant-parental triad cases compared to 
controls except for paternal rs7078160 rare homozygous allele. 
 This study gives a preliminary suggestion of GEI and is considered a valuable 
instrument for public health strategies  
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Summary  
Background and aims: Clefts of the lip and palate are the most common types of 
major craniofacial birth defects and are among the most frequent congenital 
anomalies found worldwide. Affected individuals have a range of functional as well 
as aesthetic problems from birth through adulthood requiring a lifelong series of 
interventions. This study is the first multicentre case-control triad (of children and 
their parents) in Saudi Arabia it aims to: (I) measure the prevalence of non-syndromic 
orofacial cleft (NSOFC) at birth and (II) investigate the genetic and environmental 
risk factors associated with NSOFC in infants attending government hospitals in the 
Western and Central regions of Saudi Arabia.  
Material and methods: Two hundred and seventeen non-syndromic oral cleft 
(NSOFC) triads comprising probands aged 18 months or less were compared with 244 
control triads matched for proband age, gender and location, were selected from 
eleven hospitals in three main cities of Saudi Arabia (Jeddah, Maddina, and Riyadh). 
Patients were examined to identify the cleft phenotype according to the LASHAL 
classification.  
Part I. Prevalence of oral cleft in Saudi Arabia: 
Part I of this study included all cases born in the designated hospitals from January 
2010 to January 2012. Infants born with NSOFC were compared with the total 
number of births, in the same period of time.  
Part II. Aetiology of oral clefts: 
Environmental risk factors:  
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Part II of our study, data were collected on environmental risk factors using a 
modified WHO questionnaire, covering events in the three-month pre-gestation 
through to the first trimester period.  
Genetic risk factors: 
To identify genetic etiological risk factors, DNA was extracted from infants' and 
parents' saliva samples obtained using Oragene sample collection kits. Single 
nucleotide polymorphisms (SNPs) at two candidate gene loci: Interferon regulatory 
factor 6 (IRF6) (rs2013162, rs2235375 and rs2235371) and Ventral anterior 
homeobox 1 (VAX1) (rs7078160 and rs4752028) were genotyped using restriction 
digestion PCR (for IRF6) and real time PCR (for VAX1) methodologies.  
Gene-Environmental Interaction (GEI): 
GEI was assessed through measuring the distribution of maternal genotypes and 
alleles according to exposure/no-exposure to environmental factors. Two types of 
study designs are carried out to assess gene-environmental interaction; case-only and 
case-control study designs. 
 
Results: for the study measured the prevalence and aetiology of NSOFC in Saudi. 
Part I: The prevalence of NSOFC: 
 In government hospitals in the Western and Central regions of Saudi Arabia was 
1.17/1000 births.  
Part II: aetiology of NSOFC: 
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Environmental risk factors (ERFs) significantly related to NSOFC after the odds 
ratios were adjusted through logistic regression were:  
 For cleft lip (CL), the predictor variables were: family history for NSOFC 
(OR:8.79, 95%CI:3.92to19.68); antibiotic ingestion during the pregestation 
(OR:3.01, 95%CI:1.1to8.61) and during the 1st trimester period (OR:3.07, 
95%CI:1.4to6.73); mothers complaining of family problems (OR:2.29, 
95%CI:1.21to4.35); and incense exposure in the 1st trimester period (OR:0.51, 
95%CI:0.27to0.94). 
 For cleft lip and palate (CLP) the associated variables were: family history for 
NSOFC (OR:14.73, 95%CI:5.99to36.17); common cold/flu during the pre-
gestation period (OR:5.82, 95%CI:2.38to14.25); folic acid in the 1
st
 trimester 
(OR: 0.09, 95%CI:0.14to0.51) maternal stress (OR:3, 95%CI:1.49to6.03); 
paternal waterpipe smoking (OR:5.74, 95%CI:2.07to15.9); maternal exposure 
to chemicals in the pregestation period (OR:2.91, 95%CI:1.44to5.89) and 
maternal main water source (P= 0.001). Maternal Zamzam drinking water 
shows a reduced chance of having an infant with CLP compared to well water 
(OR:0.02, 95%CI:0.002to0.2), 
 For cleft palate (CP), the factors were: family history (OR:5.89, 
CI:2.36to14.74); maternal common cold/flu in the pregestation period 
(OR:2.28, 95%CI:1.09 to4.77); abdominal pain in the 1st trimester (OR:5.81, 
95%CI:2.05to16.45); and maternal stress (OR:2.1, 95%CI:1.08to4.06).  
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Genetic risk factors:  
Hardy Weinberg equilibrium (HWE) testing showed no significant differences 
between the expected and observed allele frequencies at one of the tested loci (VAX1 
rs4752028). Family based association test (FBAT) analysis and PLINK testing found 
a significant over-transmission of the common IRF6 allele rs2013162 in NSOFC 
families (P= 0.014 and P= 0.016, respectively) and cleft lip with or without cleft 
palate (CL/P) families (P= 0.018 and 0.015 respectively), with paternal transmission 
of the significant variable (P= 0.05). Two haplotypes containing the rare alleles of 
VAX1 rs4752028 and IRF6 rs2013162 were significantly associated with NSOFC (P= 
0.021 and P= 0.01).  
A paternal VAX1 rs4752028 homozygous common allele genotype (TT) was 
identified significantly more often in controls versus cases and the paternal 
heterozygous genotype (CT) identified to be significantly more frequent in cases 
versus controls across the different cleft phenotypes. The homozygous rare allele 
genotype (CC) was found significantly more often in both infants and mothers in case 
versus in control triads for the NSOFC and CL/P phenotypes; the homozygous 
common allele genotype (TT) occurred significantly more often in control triads for 
NSOFC and CL/P categories; the heterozygous genotype (CT) was present 
significantly more often in NSOFC and its sub-phenotype triad individuals except in 
mothers of probands with CP. The rare C allele was identified significantly more 
often in case versus control triad individuals and was associated with: NSOFC 
(fathers: OR:2.24, 95%CI:1.47to3.4; mothers: OR:2.44, 95%CI:1.61to3.7; and 
infants: OR:2.71, 95%CI:1.78to4.13); CL/P (fathers: OR:2.16 and95%CI:1.38to3.4; 
mothers: OR:2.39, 95% CI:1.53to3.71; and infants with OR:2.77, 95%CI:1.77to4.34); 
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and CP (fathers: OR:2.24 and 95% CI:1.15to4.36; mothers: OR:1.97, 
95%CI:0.99to3.93; and infants: OR:2.43, 95%CI:1.25to4.7). 
 
For VAX1 rs7078160, the homozygous rare allele genotype (AA) was significantly 
present more often in NSOFC and CL/P infants compared to controls. The 
homozygous common allele genotype (GG) was significantly present more often in 
infant-parental control triad individuals than in NSOFC case triad individuals (P< 
0.05). The heterozygous genotype (AG) was significantly more prevalent in parental 
controls compared to parents of NSOFC and CL/P patients (P< 0.05). There were 
statistically significant differences between case and control triad individuals for 
CL/P (fathers: OR: 1.73 and 95% CI: 1.05 to 2.86, mothers: OR: 2.43 and 95% CI: 
1.49 to 3.97; and infants: OR: 2.34 and 95% CI: 1.44 to 3.81) with significantly 
greater frequency of the rare allele in case compared to control triad individuals.  
Analysis of parental consanguinity status versus infants’ genotype identified a 
statistically significant increase in NSOFC infants carrying the VAX1 rs4752028 rare 
C allele compared to control infants: for NSOFC, OR: 3 and 95% CI: 1.55 to 5.4; for 
CL/P, OR: 2.97 and 95% CI: 1.54 to 5.76; and for CP, OR: 6.52 and CI: 3.1 to 13.7. 
Gene-environment interaction (GEI):  
Multi-nominal logistic regression analysis for significant gene-environmental 
interaction among cases found; for maternal rs2013162, homozygous rare allele 
genotype (AA) was significantly related to antipyretic medication in the 1st trimester 
period (OR:10.18, 95%CI:1.31to79.1) and abdominal pain in the 1st trimester period 
(OR:7.4, 95%CI:1.2to45.51) among NSOFC cases. Heterozygous allele genotype 
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(AC) was significantly related to folic acid pre-gestation (OR:6.78, 
95%CI:1.41to33.49) and fever pre-gestation (OR:0.23, 95%CI:0.06to0.83) among 
NSOFC cases.  
For maternal VAX1 rs7078160, homozygous rare allele genotype was significantly 
related to paternal waterpipe (OR:6.95, 95% CI:1.5to32.2) and maternal exposure to 
high blood pressure in the 1
st
 trimester period (OR:11.2, 95%CI:1to125.73) among 
NSOFC; For IRF6 rs2013162, a statistically significant increase in the frequency of 
the homozygous rare allele genotype (AA) was seen in mothers from control versus 
NSOFC triads in those mothers who ingested folic acid supplementation in the 1st 
trimester (P= 0.003). In contrast, there was a statistically significant increase in the 
frequency of the rare (AA) genotype in NSOFC versus control mothers positive for 
maternal passive smoking (P= 0.006); maternal stress (mothers complaining of family 
problems (P= 0.003), of being under stress (P= 0.015), and of suffering abdominal 
pain in the 1st trimester (P= 0.007)); and maternal exposure to chemicals in the pre-
gestation and 1st trimester period.  
for case-control study design; stratification of IRF6 rs2235375 genotypes in mothers 
according to different environmental factors showed a statistically significant 
elevation in the frequency of the maternal rare allele homozygous genotype (GG) in 
case versus control mothers reporting maternal flu/common cold in the pre-gestation 
period (P< 0.001) and fever in the pre-gestation period (P= 0.007).  Maternal VAX1 
rs4752028 GEI analysis showed a statistically significant increase in the homozygous 
common allele genotype (TT) in control versus case mothers positive for maternal 
folic acid supplementation in the 1st trimester period (0.023); maternal multivitamin 
supplementation in the pre-gestation period (0.026); and maternal intake of Zamzam 
water (0.001). There was also a significantly higher frequency of the heterozygous 
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genotype (CT) in NSOFC maternal controls versus cases reporting calcium 
supplementation in the 1st trimester period (0.025). VAX1 rs7078160 genotype 
analysis demonstrated a statistically significant increase in the frequency of NSOFC 
mothers carrying the homozygous rare allele genotype (AA) compared to controls 
mothers, in triads with identified parental consanguinity (0.049). Genotype-
environment interaction analysis demonstrated that there were a significantly greater 
number of controls carrying the maternal homozygous common allele genotype (GG) 
than NSOFC mothers with a history of maternal folic acid supplementation in the 1st 
trimester (0.029) and of drinking Zamzam water (0.001). 
Conclusion: 
 The prevalence of NSOFC in Saudi Arabia (1.17/1000 births) is marginally 
lower than global average figures (1.25/1000births) with CL/P is 0.89/1000 
births and CP (0.28/1000 births). The prevalence of consanguinity in NSOFC 
infants is 81 (65.9%) cases.  
 Maternal exposure to common cold/flu, folic acid supplementation, stress, 
antibiotic use, incense, source of drinking water, intense paternal tobacco 
smoking and paternal waterpipe smoking are associated with increased risk of 
CL/P and/or CP in Saudi Arabia. 
 TDT and PLINK analysis is significant only for IRF6 rs2013162 SNP which 
showed significant transmission of the common allele (C) with CL/P cases. 
Parent of origin is showed significant over transmission of the IRF6 variant 
from the paternal side in CL/P cases.  CL/P and controls for maternal IRF6 
rs2013162 variant showed a significantly more homozygous rare allele 
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genotype (AA) in controls and more heterozygous allele genotype (CA) in 
CL/P cases.    
 VAX1 rs4752028 and rs7078160 rare homozygous allele and rare allele are 
found more frequent in CL/P and CP infant-parental triad cases compared to 
controls except for paternal rs7078160 rare homozygous allele. 
  Two haplotype blocks, consisting of the five SNPs included in this study, 
showed a significant association with NSOFC.  
 Maternal exposure to antipyretic, folic acid, fever, antibiotics, illnesses, 
common cold/flu, paternal waterpipe smoking, stress and chemicals can 
significantly interact with mothers IRF6 (rs2013162 and rs2235375) gene 
variants affecting the risk of having a child with oral cleft.  
 Maternal usage of folic acid and antibiotics; exposure to fever, illness, stress, 
high blood pressure and waterpipe smoking can significantly interact with 
mothers VAX1 (rs4752028) and/or VAX1 (rs7078160) gene variant affecting 
the risk of having a child with oral cleft. 
 This study is considered a valuable instrument for public health strategies as it 
gives preliminary description of GEI for two genes (VAX1 and IRF6) in Saudi 
Arabia. It also directs future research in generating hypothesis to be tested for 
confirmation in studies with adequate sample power. 
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1.1 Introduction 
Orofacial clefting (OFC) is a group of congenital anomalies comprised of cleft lip with or 
without cleft palate (CL/P) and isolated cleft palate (CP) (Mossey, 2001b). It may present as 
a part of a syndrome or associated with other abnormalities (Mossey et al., 2009). Non-
syndromic orofacial cleft (NSOFC) has been described in the literature as OFC that either 
occurs in isolation, or is associated with one other major congenital abnormality or a few rare 
congenital abnormalities (Tolarova and Cervenka, 1998).   
NSOFCs are the most common craniofacial defects globally, occurring in, on average, 
1.25/1000 live births (Mossey and Modell, 2012b). OFC can lead to a series of functional as 
well as aesthetic problems including feeding difficulties (especially at birth), swallowing and 
nasal regurgitation, and hearing and speech difficulties. Although cleft defects can be 
surgically repaired in early childhood, residual deformities due to scarring and abnormal 
facial development, result in long-lasting functional and psychosocial problems (Broder et 
al., 1994). Affected individuals have higher morbidity and mortality throughout life than do 
unaffected people (Ngai et al., 2005).
 
Therefore, clefts has adverse effects on the health and 
social integration of those affected (Christensen et al., 2004; Nopoulos et al., 2007). 
In 2002, the WHO recommended including cleft lip and palate in their Global Burden of 
Disease (GBD). Although not actually included until 2010, this has stimulated interest 
among some member states to place greater emphasis on orofacial cleft treatment, 
epidemiology and research.  
 
The aetiology of NSOFC is complex with many contributing factors: genetic, environmental 
and involve gene-environment interactions (Mossey et al., 2009). Understanding the 
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contribution of each to the aetiology of cleft lip and palate is complex. The number of genes 
involved, the differences between cleft lip and palate versus isolated cleft palate, the 
heterogeneity within each group, the type of inheritance patterns compounded by interaction 
with environmental factors, and the ethnic and geographic variation make it difficult to 
identify causal factors (Mossey and Little, 2009). Moreover, it has been reported in several 
studies that CL/P and isolated CP, with some exceptions, do not segregate in the same family 
(Jones, 1988; Dixon et al., 2011) nor occur as pairs in the same twins (Grosen et al. 2011), 
further suggesting separate genetic and biological aetiological variables. Current research, 
involving a range of different methodologies and strategies is ongoing in an attempt to 
identify the environmental and genetic factors involved. This research is the first multicentre 
study in Saudi Arabia to report the birth prevalence of NSOFC and investigate the genetic 
and environmental factors involved in the aetiology of NSOFC.  
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2.1 The Epidemiology of OFC 
2.1.1 Global epidemiology of NSOFC 
NSOFC comprises approximately 70% and 50% of OFC cases, as cited by Dixon et al. 
(2011) and FitzPatrick and Farrall (1993), respectively, and is the most common craniofacial 
defect found worldwide (Mossey and Castilla, 2001). The estimated overall global 
prevalence of NSOFC is 1.25 in every 1000 live births (Mossey and Modell, 2012b). 
However, birth prevalence varies considerably across geographic areas and ethnic groupings, 
for example, OFC occurs more commonly among Asian and Native American populations 
(about 2 in every 1000 births) than among Africans (about 1 in every 2500 births) (Mossey 
and Little, 2002).
 
Despite efforts to record the frequency of birth defects over the years, 
accurate data on their epidemiology does not exist in many countries (Mossey and Castilla, 
2001).  
NSOFC prevalence also varies by gender. Over 50% of NSOFC cases generally occur in 
males. However, among the different sub-phenotypes of NSOFC, CL/P has a 2:1 male to 
female ratio whereas CP has a 1:2 male to female ratio. The most common NSOFC 
phenotype is cleft lip with cleft palate (CLP), followed by CL and finally CP. Clefting of the 
left side in CL/P is more common than the right side (2:1 ratio) (Dixon et al., 2011; Mossey 
and Modell, 2012b).  
About one third of NSOFCs are associated with other birth defects. However, the reported 
prevalence of associated anomalies varies between 21% and 63.4% depending on diagnostic 
expertise, ascertainment, and definition of associated anomalies (Mossey, 2001b, Shprintzen 
et al., 1985). The most commonly reported associated anomaly is congenital heart disease 
(Milerad et al., 1997; Mossey, 2001b). Other associated anomalies that occur with NSOFC 
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include: anomalies of the head and neck as micrognathia; urogenital and renal anomalies; 
neural defects as neural tube defects; and limb defects. In addition, Rittler et al (2008) 
conducted a study to identify other anomalies in 1416 OFC cases, and found a positive 
correlation between anencephaly and CL/P (P< 0.001, OR: 3.4 and 95% CI: 2.2 to 5.3) and 
CP (P= 0.018, OR: 1.9, and 95% CI: 1.1 to 3.4). Furthermore, a significant relationship was 
identified between both club-foot and ear anomalies with NSOFC (Rittler et al., 2008).   
2.1.2 The Epidemiology of OFC in Saudi Arabia 
In Saudi Arabia, where almost 300,000 children are born per year (Ministry of Health, 2010), 
there is no national registry for OFC. One pioneer project that initiated registration of cleft 
lip and palate anomalies in Saudi Arabia was carried out in the King Faisal Specialised 
Hospital and Research Centre in Riyadh (the capital city of Saudi Arabia). There were 1555 
patients with OFC and/or other craniofacial anomalies registered over a period between 1999 
and 2008, of which 774 were OFC cases (Al-Johar et al., 2009). However, this registration 
was limited only to patients referred to the King Faisal Specialised Hospital and Research 
Centre which is not the only centre that manages OFC in Saudi Arabia. 
In 2012, a systematic review of the prevalence of NSOFC in Saudi Arabia and other Middle 
Eastern countries found a large variation in reported NSOFC birth prevalences, ranging from 
0.3 to 2.19 per 1000 births (Sabbagh et al. 2012). The complete details of the systematic 
review are presented in Appendix B1.  
2.2 OFC Syndromes  
 
Syndromic OFC compromises almost 30% of OFC cases and frequently presents with CP 
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(almost 50% of cases) (Mossey and Castilla, 2001). Potential factors that could lead to 
syndromic OFC include: regional gene deletion in syndromic disorders such as 22q11 
deletion; clinical sequences such as Pierre Robin; Mendelian disorders such as Van der 
Woude syndrome; or teratogenic effects such as seen in foetal alcohol syndrome (Cohen, 
1978). A list of syndromes associated with OFC and their related genes are presented in 
Appendix A1.  
2.2.1 Pierre Robin sequence 
Pierre Robin sequence is a combination of features that can present together, alone or as part 
of a syndrome. These features include CP, micrognathia, and glossoptosis. The sequence of 
developmental defects is explained by the mechanical obstruction caused by a micrognathic 
mandible leading to glossoptosis and a retropositioning of the tongue that prevents palatal 
fusion and causes life threatening respiratory obstruction and feeding difficulties (Smith, 
1975; Tan et al., 2013). The birth prevalence of the Pierre Robin sequence was reported to be 
12.4 per 100,000 live births (Vatlach et al., 2014).  
Printzlau and Andersen (2004) described the clinical presentation and epidemiology of Pierre 
Robin sequence retrospectively in the Danish population from 1990 to 1999. They concluded 
from their research that Pierre Robin sequence could be considered as a separate clinical 
entity with the main feature (in almost 60% of patients) being a U-shaped cleft palate. 
Almost 12% of cases had Stickler syndrome, a rare autosomal dominant connective tissue 
disorder that is associated with ocular abnormalities (Printzlau and Andersen, 2004; Pacella 
et al., 2010). 
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2.3 Classification of NSOFC 
There are many classification systems proposed for OFC in the literature that aim to describe 
the morphology, extension and severity of oral cleft (Shah et al., 2012). This paper will 
present some of these classifications  
2.3.1 Kernahan’s striped Y (Figure 2.1) 
Kernahan’s striped Y is one of the most commonly used systems of OFC classification. It 
provides a graphic classification scheme using a symbolic letter Y. Each line of the Y 
configuration represents a fusion line between two orofacial segments. In order to show the 
clefting area, stippling of the corresponding fusion line is carried out to the degree of 
orofacial clefting that is accordingly divided into: lip clefting; alveolus clefting; premaxilla 
clefting; soft palate and hard palate clefting. Cross-hatching represents a sub-mucous CP. 
(Kernahan, 1971)  
 
Figure 2.1: Kernahan’s striped Y classification     
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2.3.2 Modified Kernahan’s striped Y 
The standard Kernahan’s striped Y classification was modified with the addition of two 
triangles in the upper end of the Y configuration. These triangles represent the fusion line 
between the maxillary prominence and medial nasal prominence. They illustrate nasal 
deformity and allow easy discrimination of Simonart's band. Blackening of the squares 
means that the alveolar segments are collapsed. Furthermore, an arrow was introduced to 
represent the degree of maxillary protrusion (Elsahy, 1973). 
2.3.3 LAHSHAL classification 
LAHSHAL classification subdivides the cleft lip and alveolus according to side (right or 
left), and palate (hard and soft) (Kriens, 1989). In 2005, the Royal College of Surgeons in 
Britain modified the classification by omitting one H from the classification acronym. The 
letters in the LASHAL abbreviation stand for: lip (L); alveolus (A); hard palate (H); soft 
palate (S). If the letter is capitalized it means that the cleft is complete; if lower-case it means 
it is an incomplete cleft. If the letter is on the right it means that the cleft is on the right side 
and vice versa (Shah et al., 2011).   
2.3.4 International Classification of Diseases (ICD) 
The International Classification of Diseases (ICD) is a World Health Organization's (WHO) 
classification used worldwide as the standard diagnostic descriptive tool for epidemiology, 
health management and clinical purposes. One of the major classifications is congenital 
malformations of eye, ear, face and neck that includes OFC (Hill, 2014). In 1995, the WHO 
published a book entitled ‘Application of the ICD to dentistry and stomatology’ (ICD-DA). 
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It concerns all diseases and conditions that occur, manifest or are associated with the oral 
cavity and adjacent structures. It provides a convenient classification for all those working in 
the field of dentistry. OFC is classified into three categories starting with: Q35 for CP; Q36 
for CL; and Q37 for CLP. Appendix A2 lists the codes for NSOFC sub-phenotypes 
according to ICD classification version 10 (World Health Organization, 2015).  
2.3.5 Other rare NSOFC sub-phenotypes 
This category includes a group of NSOFC phenotypes that are rarely diagnosed. They have 
not been investigated by this study but, for the sake of completion, are described here.  
2.3.5.1 Submucous CP: 
Submucous CP is a mild type of CP wherein there is insufficient medial fusion of the 
muscles of the soft palate hidden under the mucous or midline notch at the posterior edge of 
the bony palate. It occurs is 1/2500–5000 births (Gosain et al., 1996). There are only limited 
studies that deal with this sub-phenotype of CP due to difficulties in diagnosis and the 
potential for misdiagnosis in many situations. One case-control study was conducted on 103 
German patients with submucous CP to investigate possible environmental and genetic risk 
factors. Among the 12 candidate genes that were investigated, TGFB3 and MNI showed 
significant association with submucous CP. Furthermore, a significant association with 
maternal smoking was identified in this study (Reiter et al 2012).  
2.3.5.2 Microform cleft lip (MCL): 
MCL is a rare type of OFC that has the characteristic appearance of corrected CL. It is 
considered a CL that has healed intrauterinally. MCL is usually accompanied by a notch in 
the vermilion border and a 'collapsed' nostril. MCL could result from either a partial failure 
in the fusion of the fronto-nasal and maxillary processes before week seven of embryonic 
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life, or from a spontaneous late foetal repair of an open cleft lip (Francesconi et al., 2003; 
Castilla and Martinez-Frias, 1995).   
2.4 Normal development of OFC 
The development of orofacial segments is a complex processes that involve multiple steps.  
2.4.1 Formation of the lip and primary palate 
The development of the lip and palate occur between the 4th and the 15th week of 
embryogenesis, following precise genetic regulatory cascades that direct the migration and 
proliferation of the neural crest mesenchyme cells to form the pharyngeal arches. Arising 
from the first pharyngeal arch dorsal portions where the fronto-nasal prominence is shaped, 
the maxillary processes are formed in the 4
th
 week and then extend forward beneath the eye. 
In the 5
th
 week, the nasal prominences are shaped from thickening of the ridges surrounding 
the nasal pits on either side. From the outer edge of the nasal pits, the lateral nasal 
prominences are formed; and from the inner edge of the nasal pits, the medial nasal 
prominences are formed. The two medial nasal prominences grow and bridge over the 
maxillary prominence laterally and fuse together (Figure 2.2). They also merge medially and 
deeply forming together a prominence known as the intermaxillary segment. This consists of 
a labial component, which forms the philtrum of the upper lip; an alveolar component that 
carries the four incisors; and a jaw component that forms the primary palate. From the 
maxillary processes, two shelves grow out in the 6th week of development and are directed 
obliquely downward on either side of the tongue. Anteriorly, the palatal shelves fuse with the 
primary palate to complete orofacial development (Sperber, 2002). 
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Figure 2.2: Frontal view of the face. (A) Five-week embryo. The nasal prominence 
tissue ridge surrounds the nasal pits and forms the medial and lateral nasal 
prominences. (B) Seven-week embryo. The medial nasal prominences from each 
side fuse with the maxillary prominence. They also merge medially and deeply to 
fuse together forming the intermaxillary segment.  
 
2.4.2 Formation of the secondary palate 
The secondary palate consists of the hard and soft palate. It is called the secondary palate 
because it is formed after the primary palate, which forms the philtrum and anterior portion 
of the alveolar bone. Formation of the soft and hard palates start in the 7th week of 
development from the maxillary processes which consist of two shelves on either side of the 
tongue. In the 8th week, the palatine shelves change their direction horizontally above the 
tongue (see Figure 2.3). This elevation is critical and occurs in a short period of only few 
hours during the 8th week. It is controlled by many factors, including: upright movement of 
the foetal head, away from the heart prominence, which allows the jaw to open and the 
tongue to move downward; and hypoglossal muscle along with jaw movement, directed by 
the pharyngeal arch muscles, which together depress the tongue downward (Wragg et al., 
1972; Diewert, 1985). Foetal flow in amniotic fluid allows the jaw to grow freely. 
45 
 
Furthermore, the forward growth of the mandible provides space for the tongue to move. If 
mandible growth is retarded, as occurs in Pierre Robin sequence, clefting may result (Lavrin 
and Hay, 2000). Elevation of the palatine shelves is also affected by gender; male shelf 
elevation occurs a few days earlier than female elevation.  
Finally, the two palatine shelves fuse with each other from the anterior of the hard palate to 
the posterior of the soft palate, forming the secondary palate. These processes are completed 
by the 10th week (Sperber, 2002).  
 
 
 
Figure 2.3: Frontal section through the head. (A) Seven-week embryo with a 
palatine shelf located on either side of the tongue. (B) Eight-week embryo. The 
palatine shelves change direction above the tongue.     
 
2.5 Molecular biologic control of lip and palate development 
 
The developmental steps of the lip and palate are initiated, controlled, and regulated by many 
genes, growth factors, growth receptors, and local changes that interact together. If any of 
these components or interactions are disturbed through environmental factors, direct 
(A) (B) 
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interference, gene mutation or deficiency of one of the controlling elements, cleft lip and/or 
palate might result (Thomason et al., 2008; Ashique et al., 2002; Sun et al., 2000). 
2.5.1 Primary palatogenesis 
Molecular studies have shown that the initiation, identification and development of the 
orofacial region is controlled by fibroblast growth factors (FGFs), sonic hedgehog (SHH), 
bone morphogenetic proteins (BMPs), the homeobox containing genes BRX1 and MSX1, the 
distal-less homeobox-containing (DLX) genes, and local retinoic acid gradients. Only a few 
limited studies have investigated the molecular control of primary palate fusion, most of 
which were carried out on mice. However, it has been suggested that molecular controlling 
factors included SHH, MSX1, MSX2, BMP, FGF, and TP63 (Sun et al., 2000; Ashique et al., 
2002; Thomason et al., 2008). Other studies have identified different transcription factors, 
growth factors and their receptors including Osr2, Lhx8, Msx1, BMP4, SHH, BMP2, Fgfr2b, 
Tgfb2, Tgfbr2 and Fgf10 (Gritli-Linde, 2007b).  
2.5.2 Elevation of the palatal shelves  
The molecular control of palatal shelf initiation and vertical growth includes a complex of 
signalling incorporating transcription factors, growth factors and their receptors, many of 
which were listed above e.g. Osr2, Lhx8, Msx1, Fgf10, Fgfr2b, Tgfb2, and Tgfbr2 (Gritli-
Linde, 2007a). Moreover, interacting signals between the palatal epithelium and the 
mesenchyme have been suggested to regulate palatal growth as well (Mossey et al., 2009). 
Several explanations have been suggested to account for the initiation of palatal shelf 
elevation above the tongue. A sudden increase in the tissue fluid might initiate the elevation 
by enhancing rapid growth; muscular movement; or an intrinsic shelf force resulting from 
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biochemical transformations in the physical consistency of the connective tissue matrix of 
the shelves, including vascularity and blood flow variation. In addition, the synthesis, 
hydration and accumulation of hyaluronic acid glycosaminoglycan within the extracellular 
matrix has also been suggested to play a role in shelf elevation. Moreover, collagen fibres 
and mesenchymal cells are oriented and organised in the palatal shelves in a way that 
suggests they may affect and direct the elevating force (Brinkley and Morris-Wiman, 1987; 
Meng et al., 2009). 
2.5.3 Fusion of the palatal shelves 
The fusion of the two palatal shelves with the primary palate is a crucial step for the 
completion of palatal development. The epithelium covering the palatal shelves thickens. 
Apoptotic cell death, phagocytosis, and removal of the epithelial cells in the targeted area are 
initiated but this process is not clearly understood. Gaps in the basal lamina, separation of 
epithelial cells and evidence of mesenchymal cell migration have been found in the fusion 
site. Some epithelial cells undergo mesenchymal transformation to display a fibroblastoid 
phenotype and thereafter stay at the fusion site or, in a later step, migrate laterally to 
participate in forming connective tissue (Martínez-Álvarez et al., 2000a; Martínez-Álvarez et 
al., 2000b). Glycoproteins and desmosomes cover the degenerating epithelial cells and 
facilitate palatal fusion. However, desmosomes and hemidesmosomes have been found to be 
minimal in this region, suggesting that their role is not relevant for the adhesion of the palatal 
shelves (Abbott, 2010). The cell adhesion molecule syndecan is expressed while the shelves 
are being elevated; expression subsequently decreases during fusion. (Fitchett, 1990). After 
fusion, the epithelial and mesenchymal cells on the oral cavity side differentiate into oral 
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mucosa (stratified squamous epithelium). Molecular studies have suggested a few factors 
that control this process including MSX1, MSX2, SHH, TGFB3, BMPs and FGFs.  
In the following paragraph we will discuss the different approaches used by molecular 
studies to identify genes involved in the aetiology of oral clefts. 
  
2.6 Genetic aetiological studies for NSOFC 
Genetic aetiological studies have used several approaches to assess genes responsible for or 
involved in the development of oral clefts. These include candidate gene approach and 
genome-wide association studies (GWAS). The following section will discuss genes that 
were analysed using these two approaches.  
2.6.1 Candidate gene approach 
Candidate gene analysis relies upon choosing a known gene that is related to pathways 
thought to be implicated in the aetiology of the disorder under study, especially those that 
regulate gene expression or development and that have detectable levels of expression in 
relevant embryonic tissues in human and/or mouse models (Dixon, 2011; Juriloff and Harris, 
2006; Brown et al., 2003). OFC syndromes and rare Mendelian cleft syndromes are 
considered valid targets for the candidate gene approach in NSOFC for the potential causal 
reasons discussed above, and because candidate gene analysis has an established history of 
success with these categories of disorders (Zucchero et al., 2004; Jugessur et al., 2009; 
Dixon, 2011). Another method for selecting candidate genes is through cytogenetics; 
wherein genes are prioritized because of their location in abnormal (e.g. deleted; rearranged) 
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chromosomal regions identified in patients with the disorder (Brewer et al., 1999; Gong et 
al., 2005; Higgins et al., 2008).  
Several genes have been linked to NSOFC. These genes have been classified according to 
their functional classes that include: transcription factors; extracellular signalling factors; 
growth factors; and cell signalling (Mossey, 2001a; Mossey et al., 2009). 
2.6.1.1 Transcription factors: 
Transcription factors are genes that code for proteins, which bind to specific DNA 
sequences, regulating the expression (transcription) of their target genes (Latchman, 1997). 
Genes in this class play a role in the aetiology of NSOFC include: Msh homeobox 1 (MSX1); 
Interferon regulatory factor 6 (IRF6); Ventral anterior homeobox 1 (VAX1); Small ubiquitin-
like modifier (SUMO); Forkhead box E1 (FOXE1); V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B (MAFB); Tumour protein 63 (TP63); and ATP-binding cassette 
transporter 4 (ABCA4). 
2.6.1.1.1 Msh homeobox 1 (MSX1) 4p16:  
MSX1 is one of the genes responsible for initiation and growth of the facial processes and 
specification of their identity. It also plays an important role in craniofacial development as it 
is required for the activation of BMP2 and BMP4 in the palate mesenchyme (Zhang et al., 
2002). Signals from the mesenchyme during the growth of the palatal shelves regulate the 
expression of BMP2 and BMP4 in the mesenchyme, SHH and BMP4 in the medial edge 
epithelium (Van den Boogaard et al., 2000; Gritli-Linde, 2007b).  
Van den Boogaard et al. (2000) found that mutations in MSX1 in humans are associated with 
OFC and congenital missing teeth. Furthermore, Jezewski et al. (2003) found from 
sequencing the MSX1 gene that 2% of the NSOFC patients in his study had MSX1 mutations 
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(Hu et al., 2003; Jezewski et al., 2003). Furthermore, Jagomägi et al. (2010) genotyped 18 
candidate genes in a case control study in Estonia and found a statistically significant 
relationship between NSOFC and MSX1 for 5 Single nucleotide polymorphism (SNP) 
(rs11726039, rs868257, rs6446693, rs1907998, and rs6832405). 
2.6.1.1.2. Interferon regulatory factor 6 (IRF6) 1q32.2: 
IRF6 was the first identified NSOFC susceptibility locus (Mangold et al., 2010). It has been 
the only candidate gene consistently shown to have a significant association with NSOFC 
across multiple studies (Marazita et al., 2004; Jugessur et al., 2008; Jagomägi et al., 2010). 
Studies have shown that IRF6 is expressed from the epithelium in the ectodermal edge of the 
palatal shelves during and just before primary and secondary palate formation (Ben et al., 
2005; Washbourne and Cox, 2006; Knight et al., 2006; Jugessur, 2009). IRF6 is also 
expressed during palatal shelf fusion (Kondo et al., 2002). IRF6 has thus been proposed to 
play an important role in controlling epithelial cell proliferation and differentiation (Ferretti 
et al., 2011). Consistent with this hypothesis, IRF6 null mice have abnormal skin, limb, and 
craniofacial development (Kondo et al., 2002).  
 
IRF6 mutation is responsible for two autosomal dominant OFC syndromes, Van Der Woude 
and Popliteal pterygium (Kondo et al., 2002; Jugessur et al., 2009; Lima et al., 2009). Van 
Der Woude syndrome is an OFC syndrome that resembles NSOFC; however, in most cases 
it includes an additional clinical feature, a lip pit. Additionally, although syndromic, it is 
caused by mutation of the IRF6 gene alone.  
Rahimov et al. (2008) have identified a SNP (rs642961) that, if mutated, causes OFC 
through disruption of a transcription factor AP-2α binding site in an IRF6 enhancer element. 
This SNP has also been reported to be an important element for cranial closure and orofacial 
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development (Schorle et al., 1996). Furthermore, mutation of TFAP2A, which is the gene 
encoding AP-2α, causes a syndrome that has features similar to Van Der Woude syndrome 
(Milunsky et al., 2008). 
Multiple IRF6 SNPs have been suggested to be associated with NSOFC. In Estonia, the IRF6 
rs590223 SNP was found to be significantly associated with NSOFC (P= 0.039) (Jagomägi 
et al., 2010). In China, Li et al. (2012) assessed the association between IRF6 rs2235371 and 
CL/P in a case-control study of 106 patients. They carried out Transmission Disequilibrium 
Test (TDT), Family Based Association Test (FBAT), and Haplotype-Based Haplotype 
Relative Risk (HHRR) analyses but found no significant differences in rs2235371 genotype 
frequencies (GG, GA and AA) between cases and controls (P> 0.05). However, there was a 
statistically significant difference in allelic frequencies (P< 0.05). There was also a 
statistically significant difference in both genotype and allele frequencies of rs2235371 
variants between family members of CL patients and controls. TDT analysis suggested a 
linkage in the presence of disequilibrium (P= 0.024). Results of HHRR analysis (P= 0.024) 
and FBAT (P= 0.027) also indicated an association between IRF6 rs2235371 variants and 
the risk of NSOFC (Li et al., 2012). 
In west China, Huang et al. (2009) assessed associations between three IRF6 SNPs 
(rs2013162, rs2235375, and rs2235371) and NSOFC, using both case-parent trio and case-
control designs with 332 NSOFC cases. They found a statistically significant over-
transmission of the rs2235371 common ‘C’ allele (P= 0.013) and under-transmission of the 
rs2235375 ‘C’ allele (P< 0.001). There were statistically significant differences between 
cases and controls in the frequencies of the rare rs2235371and rs2235375 alleles. IRF6 
rs2013162 was not related to NSOFC in their population. Furthermore, Blanton (2010a), 
who examined IRF6 variant/NSOFC associations in different ethnic groups, found a 
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significant association between the IRF6 rs2235371 common allele and NSOFC in Non-
Hispanic Whites compared to Hispanics. In addition, Birnbaum et al. (2009) found a 
decrease chance of having an infant with NSOFCwith rs2235371 common allele (C) (OR: 
0.367 and 95% CI: 0.163 to 0.823) in a population of Central European origin. In a hospital-
based case-control study carried out in Chinese Han, Pan et al. (2010) found that the 
rs2235371 rare homozygous allele (TT) and heterozygous (CT) genotypes were associated 
with decreased risk of NSOFC compared to the common allele (CC). They also reported 
higher risk of NSOFC when two polymorphisms (rs642961 rare allele (A) and rs2235371 
common allele (C)) were combined. Furthermore, Zucchero et al. (2004) found a strong 
relationship between IRF6 (rs2235375 and rs2013162) and NSOFC in Italian, American 
(Texan), Belgian, and Asian (Taiwan and Singapore) populations using TDT analysis. 
A recent study in Northeast China assessed the relationship between NSOFC and 12 SNPs in 
7 candidate genes using an allele-specific primer extension technique for case-parent (236 
patients, 185 mothers and 154 fathers); 128 complete trios; and case-control (400 controls) 
analyses. The TGFA and IRF6 genes showed a statistically significant association with 
NSOFC. IRF6 had a statistically significant association between rs2235371 (P= 0.003), 
rs2013162 (P= 0.001) and NSOFC. Furthermore, LD analysis found tight linkage between 
the SNPs in IRF6 and TGFA. Haplotypes of the four TGFA SNPs (rs3771494, rs1058213, 
rs11466285, and rs3771523) and two IRF6 SNPs (rs2013162 and rs2235371) were also 
determined. In addition, FBAT showed a significant over-transmission of the rs2235371 
common allele (C) in CL/P trios (P= 0.007) (Lu et al., 2013). 
2.6.1.1.3 Ventral anterior homeobox 1 (VAX1) 10q25.3: 
The VAX1 gene encodes a transcriptional regulator with a DNA-binding homeobox domain. 
It is a member of the Emx/Not gene family and is mainly expressed in optical regions. 
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However, Vax1 is also expressed widely in developing craniofacial structures (Bertuzzi et 
al., 1999). Recently, VAX1 was found to be located near a locus of high GWAS significance 
(10q25) in two studies using GWAS case-control parental trios (Beaty et al., 2010; Mangold 
et al., 2010). Beaty et al. (2010) carried out a GWAS a CL/P case-triad study on 825 trios of 
European ancestry and 1,038 trios of Asian ancestry. They reported that among the 13 SNPs 
in VAX1 analyzed, two approached genome-wide significance (rs7078160 and rs4752028) in 
both TDT and conditional logistic regression tests (Beaty et al., 2010). VAX1 rs7078160 also 
reached a genome wide significant relationship in CL/P cases (P= 1.92 × 10
−8
) in a GWAS 
study using a central European population (Mangold et al., 2010). Relevance of VAX1 to 
NSOFC is also supported by the observation that the VAX1 null mouse showed CP (Hallonet 
et al., 1999). Therefore, it is expected that variants of the VAX1 gene might play a role in the 
aetiology and pathogenesis of cleft lip and palate.  
 
In a case-control candidate gene approach study, Rojas-Martinez et al. (2010) investigated 
whether IRF6 (rs861020), and SNPs located in 8q24 (rs987525), 10q25 (rs7078160) and 
17q22 (rs227731), regions associated with NSOFC, are implicated in the aetiology of 
NSOFC (CL/P) in non-Europeans (Mayan Mesoamerican population) This study confirmed 
an association between IRF6, 8q24, and 10q25 and NSOFC (CL/P) in the Mesoamerican 
population. 
In a case-control study by Slavotinek et al. (2012), VAX1 was sequenced in 70 patients, 
leading to the first demonstration of homozygosity of two nucleotides in a patient, who was 
of Egyptian origin and consanguineous parents. His clinical feature included 
microphthalmia, small optic nerves, cleft lip/palate, and corpus callosum agenesis, thus 
providing further evidence for a relationship of VAX1 to NSOFC. Another case-control 
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study, by Nasser et al. (2012), studied 384 patients with non-syndromic CL/P. They 
sequenced 17 rare VAX1 variants, not including rs7078160 and rs4752028. They suggested 
that although there were no significant differences found in their study between cases and 
controls, VAX1 was more likely to be associated with CL/P (Nasser et al., 2012). 
Ludwig et al. (2012) identified six new risk loci from their meta-analysis carried out on two 
GWAS studies on non-syndromic CL/P. One was the rs7078160 SNP on 10q25, which 
showed a TDT P-value that reached genome-wide significance (P= 3.96*10
-11
 for European 
and Asian trios and P= 2.81*10
-8
 for European trios).  
In 2013, Butali et al. replicated two of the GWAS signals using 1,326 individuals in 
European and Asian populations. TDT analysis found a strong association between CL/P and 
VAX1 rs7078160 (P= 2.7*10
-6
) and VAX1 rs475202 (P= 0.0002) for the combined Asian 
sample. They also found a statistically significant effect of a parental rare allele, with 
preferential maternal (P= 6.5 × 10
-5
) versus paternal transmission (P= 0.004) (Butali et al., 
2013). 
2.6.1.1.4 Small ubiquitin-like modifier (SUMO) 2q33.1: 
SUMO is a post-translational modification protein that modifies cellular proteins and plays a 
role in some cellular processes like transcriptional regulation, apoptosis and protein stability. 
Alkuraya et al. (2006) found that the SUMO gene was disrupted in a balanced reciprocal 
translocation between chromosomes 2q33 and 8q24 in a female patient born with unilateral 
CLP. Furthermore, they found strong SUMO1 expression in the upper lip and the palate and 
in an established embryonic stem cell line. The study suggested a specific role for SUMO1 in 
the network of genes regulating palatal development. Shi et al. (2009) identified SUMO1 
gene microdeletions following examination of 333 candidate genes in 2823 NSOFC patients. 
Similar results were reported by Carter et al. (2010). In addition, SUMO has been reported to 
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be a gene that is susceptible to environmental changes such as stress. A relationship also 
exists between SUMO and several genes that have been reported to have a strong association 
with OFC such as several in the FGF signalling pathway, MSX1, TP63, TBX22, SATB2, 
TRPS1 and EYA1. Therefore, early modification of SUMO during pregnancy as a result of 
environmental effects might lead to NSOFC indirectly through its impact on other genes 
directly responsible for NSOFC (Andreou et al., 2007; Pauws and Stanier, 2007; Jugessur et 
al., 2009).  
2.6.1.1.5 Forkhead box E1 (FOXE1) 9q22: 
FOXE1 is part of the forkhead/ winged-helix family, which are transcription factors and key 
regulators in embryogenesis. Deficiency of the FOXE1 gene in mouse models leads to a 
severe CP (De Felice et al., 1998). In human, mutation and loss of function of FOXE1 is 
responsible for Bamforth-Lazarus Syndrome, which includes CP as one of its clinical 
features (Clifton-Bligh et al., 1998; Castanet et al., 2002; Brancaccio et al. 2004). In 2005, 
Vieira et al. sequenced 184 NSOFC patients in a matched case-control study and found 
mutations in FOXE1 in two patients compared to none in the controls. Furthermore, a 
GWAS study in 2009 found a significant linkage signal in 9q21 that is close to the FOXE1 
locus (Marazita, 2009). 
2.6.1.1.6 V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) 20q12: 
MAFB is a leucine zipper transcription factor that regulates gene expression. Recently 
MAFB was suggested to be associated with NSOFC by the GWAS GENEVA Cleft Study as 
its locus was near markers that achieved genome-wide significance (Beaty et al., 2010). This 
relationship could be related to the fact that MAFB is a leucine zipper that is responsible for 
binding to other genes associated with OFC such as IRF6 and MSX1. However, this 
relationship showed higher significance among trios of Asian rather than European origins. 
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In addition, a missense mutation in a highly conserved region was found in 3.5% of Filipinos 
with NSOFC compared to 0.7% in the controls, suggesting the presence of a rare variant of 
MAFB in Asians (Beaty et al., 2010; Dixon 2011).   
2.6.1.1.7 Tumour protein 63 (TP63) 19q13.43:  
TP63 is a gene expressed in the branchial arch and it plays a role in induction of factors 
involved in epithelial-mesenchymal signalling in craniofacial development. Mutation of 
TP63 is responsible for five syndromes, four of which carry OFCs as a clinical feature. OFC 
resulting from TP63 mutation has been reported to be associated with other congenital 
defects and syndromes (Rinne et al., 2007). However, Leoyklang et al. (2006) have found 
mutations in TP63 in isolated cleft cases as well. The distribution of mutations along the 
gene was reported by Rinne et al. (2007) to have a clear genotype-phenotype relationship.    
Recently, researchers have studied the relationship between IRF6 and TP63 expecting that 
both genes work together during palatal fusion. They found that IRF6 is a direct 
transcriptional target of TP63 and that both proteins work in a regulatory feedback loop 
necessary for proper epithelial proliferation and differentiation. (Moretti et al., 2010; 
Thomason et al., 2010; Romano, 2012). In their study on the conserved Pbx-Wnt-p63-Irf6 
regulatory module in mice, Ferretti et al. (2011) reported a direct regulatory effect of TP63 
on IRF6 in orofacial development. They also suggested a Pbx-Wnt-p63-Irf6 module, which 
induces apoptosis at the embryonic junction between the nasal and maxillary processes. 
Interruption of this process could cause NSOFC. This model is also supported by Kurosaka 
et al. (2014), who reported an association between interruption of SHH signalling and the 
aetiology and pathogenesis of cleft lip through antagonistic interactions with other gene 
regulatory networks, including TP63/IRFf6 signalling pathways. 
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2.6.1.1.8 ATP-binding cassette transporter 4 (ABCA4) 1p22.1: 
ABCA4 is a gene responsible for the synthesis of a protein that is found in the retina and, if 
mutated, causes an autosomal-recessive retinal degenerative disease. Although ABCA4 
achieved genome-wide significance in the GENEVA cleft GWAS study (Beaty et al., 2010), 
with stronger evidence among trios of Asian origin, ABCA4 is not detected in the palatal 
shelves in mouse models. Therefore, it was suggested that the signal detected in the GWAS 
study was likely related to another gene close to ABCA4 locus (Bille et al., 2007; Beaty et al., 
2010).  
2.6.1.2 Extracellular signalling factors and growth factors: 
Extracellular signalling factors are responsible for the regulation of the secretion of the 
extracellular matrix, which provides structural support and adhesive substrates for body 
tissues. The extracellular matrix plays a significant role in regulating the behaviour of cells, 
cell shape and movement, and facilitates cell-cell and cell-matrix interactions (Schnaper and 
Kleinman, 1993). 
 
2.6.1.2.1 Fibroblast Growth Factors (FGF): 
FGF signalling pathway family members play an important role in craniofacial development 
including neural crest induction, skeletogenesis, and epithelial mesenchymal induction (Nie 
et al., 2006). Many studies have linked members of the FGF family and it's receptors to 
OFC.  
2.6.1.2.1.1  Fibroblast growth factor receptor 1 (FGFR1) 8p11:  
FGFR1 was found to be related to CP (Trokovic et al., 2003). FGFR1 is a growth factor that 
is associated with the autosomal dominant Kallmann syndrome, which presents with OFC as 
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an occasional clinical feature. However, in some cases OFC might be the only or the first 
diagnostic feature (Dode et al., 2003; Dodé & Hardelin, 2009 ).  
2.6.1.2.1.2 Fibroblast growth factor 8 (FGF8)10q24:  
FGF8 is expressed during neural crest migration. When mutated, FGF8 was found to be 
related to CP in conjunction with multiple other defects in studies carried out in mice (Abu-
Issa et al., 2002).  
2.6.1.2.1.3  Fibroblast growth factor 10 (FGF10) 5p13: 
FGFR2b receptors receive signals from the palate mesenchyme, located in the palate 
epithelial region, to regulate the growth of the palatal shelves and maintain Sonic Hedgehog 
signalling-regulated expression in the palate. Failure in any of these steps leads to clefting of 
the palate (Rice et al., 2004; Mossey et al., 2009). 
2.6.1.2.2. Transforming growth factor (TGF): 
Transforming growth factor (TGF) family members play an important role in craniofacial 
development; proliferation, differentiation and apoptosis of epithelium and mesenchyme 
2.6.1.2.2.1 TGF-β1,2 and 3 (14q24): 
TGF-βs are a family of structurally related growth and differentiation factors that influence 
all important cellular process from proliferation, differentiation and apoptosis remodelling 
through epithelial-mesenchymal transformation (Abbott 2010). They are involved in 
regulating skeletal development including cartilage and bone formation and patterning of 
mesoderm and craniofacial development (Wan and Cao, 2005). TGF-βs are expressed at 
early stages in the developing palate and TGF-β3 is expressed in the epithelium of the 
vertically growing palatal shelves (Fitzpatrick et al., 1990). TGF-β3 continues to be 
expressed in the epithelium after elevation until adhesion and fusion starts as it plays an 
important role in this process (Abbott et al., 2005). The epithelium of the two elevated and 
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contacting palatal shelves and of the basement membrane remains intact in TGF-β3 deficient 
mice, resulting in CP in these animals (Proetzel et al., 1995; Kaartinen et al., 1997). 
Furthermore, knocking-out TGF-β3 inhibited palatal shelf fusion in mice (Nawshad et al., 
2004). Murillo et al. (2009) confirmed that TGF-β3 has an active role of in medial edge 
epithelium cell death and suggested a role of TGF-β1 in apoptotic clearance of medial edge 
epithelium cells to allow for palatal fusion. 
Tang et al. 2013 carried out a meta-analysis that included eleven case-control studies to 
investigate the relationship between TGF-β3 genetic polymorphisms and NSOFC risk in 
human. They reported the possibility of TGF-β3 gene polymorphisms contributing to 
NSOFC, especially among Asian populations  
2.6.1.2.2.2 TGF-α (2p13):  
TGF-α is expressed in palatal tissue especially in the midline and subjacent mesenchyme of 
the palatal shelves during palatal fusion (Dixon et al., 1991). In his review (covering 1986 to 
2005) on the evidence for involvement of TGFα in the aetiology of OFC, Vieira (2006) has 
suggested that TGFα acts as only a small risk factor for NSOFC. A 20% increase in the 
prevalence of NSOFC in infants carrying a rare TGF-α variant was also reported, leading to 
the suggestion that TGF-α may act as a modifier rather than being a determinant gene for 
NSOFC (Vieira, 2006).    
In 2014, Lu et al. carried out a meta-analysis of 29 studies to investigate the association 
between TGF-α and NSOFC. A significant increase in the risk of NSOFC was reported with 
a TGF-α/TaqI polymorphism (OR: 1.70 and 95% CI: 1.41 to 2.05) and a reduced risk with a 
GFA/BamHI polymorphism rare allele (OR: 0.44 and 95% CI: 0.30 to 0.64). This study also 
suggested that TGF-α plays a role in the aetiology of NSOFC.  
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2.6.1.2.2.3 Bone morphogenetic protein (BMP):  
BMP is another member of the TGF-β family. The BMP gene encodes the bone morphogenic 
protein (BMP) that binds to membrane bound receptors (serine/threonine kinases) entering 
into a series of receptor translocations and activation of specific target genes. They play a 
role in mediating the interaction between epithelium and mesenchyme during the 
development stage of the embryo (Hogan 1996).   Furthermore, BMP (14q22.2) interacts 
with MSX1 in palatal development as the MSX1 protein causes activation of BMP4. A study 
in embryonic mice has shown that BMP4 mutation led in particular to bilateral CL in all 
embryos on the 12th day of conception. However, most of the clefts fused in the subsequent 
14 day as other bone morphogenic factors (BMFs) are available to complement and cross 
regulate the deficiency caused by the mutated gene (Liu et al., 2005; Jiang et al., 2006). 
Therefore, this gene could be less important than other members of the group as its effect 
could be overcome.   
 
2.6.1.2.3 Hyaluronan Synthase isozymes 1, 2 and 3 (HAS1, 2 and 3) 19q13.3-q13.4, 
8q24.12 and 16q22.1: 
Three HAS genes (HAS 1, 2 and 3) are responsible for the synthesis of hyaluronan in the 
palatal shelves just before their elevation. Hyaluronan becomes the major component of the 
shelves, resulting in a swelling of extracellular matrix and contributing to the elevation of the 
palatal shelves in mouse models studies (Toole, 1997). In humans, HAS deficiency causes 
embryonic death or stillbirth (Girish and Kemparaju, 2007), and therefore the HAS genes 
have not been considered as candidates for OFC in population and case-control studies.         
2.6.1.3 Cell signalling:  
 
Gene activation and regulation of cell signalling functionality are responsible for controlling 
information transmission into and within a cell. Information is transported either through 
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protein-protein interactions or it is transmitted by diffusible elements usually referred to as 
second messengers (Berridge, 2012). This category of cell signalling includes the folate 
pathway (methylenetetrahydrofolate reductase (MTHFR) pathway) which influences nutrient 
metabolism. 
2.6.1.3.1 Folate pathway (Methylenetetrahydrofolate reductase (MTHFR) 1p36.3: 
MTHFR produces methylene-tetrahydrofolate reductase, which is an enzyme that reduces the 
level of homocysteine. MTHFR converts 5,10-methylenetetrahydrofolate to 5-
methylenetetrahydrofolate, which is the methyl donor for remethylation of homocysteine 
into methionine (Wong et al., 1999). In addition, MTHFR play an important role in folic acid 
metabolism. It is responsible for catalysing tetrahydrofolate to methylene- tetrahydrofolate  
by the addition of methylene groups. Tetrahydrofolate is produced by the reduction of folic 
acid to dihydrofolic acid by the enzyme dihydrofolate reductase; dihydrofolic acid is then 
further reduced to tetrahydrofolate (Frosst et al., 1995).  
Pan et al. (2012) carried out a systematic review and meta-analysis to assess the relationship 
between the MTHFR C677T variant and NSOFC among Asian and Caucasians populations. 
The search yielded 17 case-control studies. Among Asian populations, MTHFR C677T 
homozygous rare allele and heterozygous genotypes in infants were more highly associated 
with NSOFC versus common allele homozygotes (CC): (OR: 1.741 and 95% CI: 1.043 to 
2.907) for CT versus CC; OR: 2.311 and 95% CI: 1.313 to 4.041 for TT versus CC; and OR: 
1.740 and 95% CI: 1.051 to 2.882 for CT/TT versus CC, respectively). Similar results were 
observed for the MTHFR C677T ‘T’ allele, when using the ‘C’ allele as a reference in Asians 
(OR: 1.420 and 95% CI: 1.191 to 1.693, for ‘T’ versus ‘C’ alleles). Furthermore, in analyses 
stratified by disease types, CT/CC was suggested to reduce susceptibility to CL/P under a 
recessive genetic model (OR: 0.854, 95% CI: 0.730 to 1.000). For Caucasians, the MTHFR 
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1298C allele in the case group was of significantly lower frequency than that in the control 
group, suggesting a reduced chance of having an infant with NSOFC for this allele (OR: 
0.711 and 95% CI: 0.641 to 0.790, for ‘C’ versus ‘A’ alleles).  
Recently, a systematic review and meta-analysis of Asian populations that further considered 
the association between MTHFR (C677T and A1298C genotypes) and CL/P by updating the 
previous meta-analysis and adding papers that was included. Nine case-control studies met 
the inclusion. The met-analysis showed a significant relationship and increase in the risk of 
CL/P in children (OR: 1.41 and 95% CI: 1.23 to 1.61) and mothers (OR: 1.70 and 95% CI: 
1.19 to 2.42) with MTHFR C677T genotypes (TT versus CC) (Zhao et al., 2014).  
Furthermore, a case-control triads study in China found a significant relationship between 
MTHFR and NSOFC, but only in Northern China, suggesting an etiological variant (Zhu et 
al., 2010). Also, Schultz et al. (2004) study which was not included in the meta-analysis, 
scanned 50 genomic regions for association with NSOFC, and found a significant 
relationship between over-transmission of the MTHFR C677T allele in 36 families from the 
Philippines (P= 0.01). 
Therefore, MTHFR 677T rare allele seems to be associated with an increased risk of CL/P 
with an ethnic variation. 
The candidate gene approach have preliminary listed multiple genes associated with NSOFC. 
Confirmation of their association can be achieved either through having several studies 
concluding a positive interaction or by GWAS study.  
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2.6.2 Genome-wide association studies (GWAS) 
Genome Wide Association (GWA) is an approach that involves rapid scanning for markers 
across the complete sets of DNA, or genomes, of many people and is used to find genetic 
variations associated with a particular disease. Several GWAS parental triad case-control 
studies were carried out on different populations to identify possible genes involved in birth 
defects. Birnbaum et al. (2009) conducted a GWAS triad case-control study involving 224 
CL/P and 383 controls of Central European origin. 8q24 showed highly significant markers 
that reached genome wide significance with a P= 3.34 × 10
-24
, OR: 2.57 and 95% CI: 2.02 to 
3.34. Grant et al. (2009) performed a case-control cohort study in Philadelphia using 111 
study subjects and 5951 controls of European descent and confirmed a strong association 
between the 8q24 locus (rs987525) and CL/P. However, to date this locus does not harbour a 
characterized gene. Furthermore, Beaty et al. (2010) carried out ‘the GENEVA study’ on 
Asian and European ethnic groups, including 1908 case-parent trios (825 European, 1038 
Asian, and 45 African), and identified genome wide significant SNPs on 8q24 (rs987525), 
IRF6 (rs2073485, rs2013162, rs8610020, rs10865790), MAFB 20q12 (rs6072081, 
rs6065259, rs17820943, rs13041247, rs11696257, and rs102085), ABC4 (1p22.1) 
(rs4147811, rs481931, and rs560426) and SNPs approaching genome wide significance on 
10q25 (VAX1) (rs7078160 and rs4752028), PAX7, and NTNI. Another GWAS in the same 
year was carried out in Germany using 401 CL/P, 1,323 controls and 793 triads, and 
identified two loci that reached genome wide significance (10q25.3 and 17q22). Two genes 
have been reported to be near the 10q25.3 locus: VAX1 and KIAAI598 (Mangold et al., 
2010). 
Therefore, loci identified in NSOFC GWAS studies include; 
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2.6.2.1 8q24.21: 
8q24 is a susceptibility locus that has been previously reported to be strongly associated with 
OFC in genome-wide association studies (Mangold et al., 2010). Although no gene has been 
identified in this region (Grant et al., 2009; Blanton et al., 2010b), the strength of the 
association indicates the region to be highly important.  
Birnbaum et al. (2009) conducted a study to look for a susceptibility locus for CL/P in 146 
SNPs on 8q24 in a GWAS case-control and case-control family-based study. In the GWAS 
study, three SNPs were identified as having the most significant markers (rs987525, 
rs17241253 and rs1530200). In the case-control family-based study, only one SNP reached a 
significant level (rs987525). This SNP also reached a highly significant result in a 
Mostowska et al. (2010) study of the Polish population. In addition, in his GWAS study on 
CL/P patients of European decent, Grant et al. (2009) reported a strong genome-wide 
significant relationship between SNP rs987525 and CL/P, with P= 9.18×10
-8
,
 
OR: 2.09 and 
95 % CI: 1.59 to 2.76. 
In his family based study on Hispanic and non-Hispanic white families, Blanton et al. 
(2010b) studied six SNPs located in 8q24 and found a strong association with non-Hispanic 
whites but not with Hispanics. Furthermore, the 8q24 association reached significance in a 
Mesoamerican population in Mexico. Rojas-Martinez et al. (2010) similarly carried out a 
case-control study to investigate whether the IRF6, 8q24, 10q25, or 17q22 loci contribute to 
CL/P in a Mesoamerican population. Their finding confirmed the relationship between both 
8q24 and 10q25 with CL/P. 
Pan et al. (2011) aimed to replicate three novel susceptibility loci findings including 
rs987525 on 8q24 that was reported to be significantly related to NSOFC in previous 
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research on European Caucasians (Birnbaum et al., 2009; Mangold et al., 2009). The study 
included 199 NSOFC patients compared to 210 controls in a Chinese Han population. 
However, the frequency of the rs987525 SNP variant in this population was not sufficient to 
be effectively genotyped (Pan et al., 2011).  This finding was supported by Murray et al. 
(2012), who investigated the association between 8q24 and CL/P in both European and 
Asian populations. They reported a low power of association between 8q24 and CL/P in the 
Asian population that was suggested to be due to lower variant allele frequencies in Asians 
(Murray et al., 2012).  
2.6.2.2 10q25: 
The 10q24 locus has reached a genome-wide significance level in several NSOFC/ GWAS 
studies (Beaty et al., 2010; Mangold et al., 2010). A significant association of 10q25 with 
NSOFC was also confirmed in Scandinavian (Norway and Denmark), Mesoamerican, Mayan 
origin and Polish populations in a case-control study (Rojas-Martinez et al., 2010), and in a 
Baltic population case-control study (P= 0.0016) (Nikopensius et al., 2010).   
In their case-control study that assessed a replication of two of the novel loci (10q25 and 
17q22), Pan et al. (2011) found no significant difference between cases and controls for 
10q25 in China's population. A more recent case-control study (2012) on 206 Polish patients 
analysed chromosomal regions located at 1p22.1, 10q25.3, 17q22, and 20q12. Significant 
results were observed in 10q25.3 (rs7078160 and rs4752028) and in 17q22 (rs227731). Both 
rs7078160 and rs4752028 were associated with more than a four-fold increase in the risk of 
CLP (P= 0.001, OR: 4.53 and 95% CI: 1.678 to 12.265; and OR: 4.57 and P= 0.0004, 95% 
CI: 1.81 to 11.51; respectively) (Mostowska et al., 2012).  
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These were the main GWAS studies and their identified loci associated with NSOFC. 
Further GWAS studies are recommended in different populations and for different NSOFC 
phenotypes to verify their genetic risk factors.    
 
This was a brief review of the literature on two of their main approaches used to identify 
genes responsible for NSOFC.  However, in order to carry out genotyping for these genes, 
several field and laboratory steps are required. The following section discusses these steps.   
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2.7 DNA, collection, extraction, analyzing and genotyping 
The methodology of genetic aetiological studies involves; DNA extraction, DNA analysis, 
polymerase chain reaction (PCR) and/or sequencing and genotyping. This section discusses 
these steps  
2.7.1 Sample collection  
DNA can be extracted from EDTA-anticoagulated whole blood, buccal swabs, cheek swabs, 
or saliva.   
2.7.1.1 Whole blood samples: 
Whole blood sampling has the following advantages and disadvantages; 
Advantages:  
1. Greater DNA quality and quantity sufficient for genome-wide research that requires 
approximately 20 micrograms of high quality DNA.  
2. Offers the potential for saving plasma or serum for analysis of other analytics, such 
as micronutrients or for storing cells for subsequent RNA or protein studies. 
Disadvantages: 
1. Invasive procedure with challenges in acquisition from subjects especially small 
infants (blood draw from healthy ‘control’ infants is generally discouraged).  
2. Available quantities might not be sufficient especially from infants.  
2.7.1.2 Buccal or cheek swabing: 
Buccal swabs and cheek swabbing have the following advantage and disadvantages; 
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      Advantages:  
1. Easy to collect and acquire. 
Disadvantages: 
1. Quality and quantity might not be sufficient. 
2. Potential contamination by food debris/micro-organisms. 
 
2.7.1.3 Saliva samples: 
Saliva sampling has the following advantages and disadvantages; 
Advantages: 
1. Relatively easy to acquire and collect. 
2. Usually provides a sufficient amount of DNA, depending on (a) method used to 
obtain sample and (b) quantity of saliva required. 
Disadvantages: 
1. Age dependent (more difficult in infants). 
2. Expensive. 
2.7.2 DNA Extraction 
After saliva is collected, DNA is extracted and isolated, with the goal of purifying the DNA 
sample (Genomic DNA purification). The process involves several steps:  
 Disruption and lysis of the cells to open and expose the DNA using chemical and 
physical means; 
 Removal of proteins and contaminants by digestion with proteinase K; and  
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 Recovery of DNA using ethanol.  
Purified DNA is ready to undergo amplification through the polymerase chain-reaction 
(PCR) or freezing and storage for future analysis. Purified DNA can remain stable for 
several years. 
 
2.7.3 Polymerase chain-reaction (PCR) 
PCR is a technique used to replicate a specific region of DNA. Its main advantage lies in the 
rapid amplification of a small region of interest in the DNA in a, generally, sequence-
independent manner. Starting with single stranded DNA, PCR replaces the missing strand 
using Taq DNA polymerase, starting from an annealed primer in a manner similar to that by 
which DNA normally undergoes replication (Figure 2.4).  
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Figure 2.4: Diagram for the PCR method (adapted from Madigan et al., 1999). The 
target DNA is amplified through three steps: first (a), the DNA is heated to produce 
single strands (denaturing); second (b), primers are added that are complimentary 
to the ends of the target DNA; third (c,d), the primer extension is catalysed by the 
Taq DNA polymerase enzyme to produce a new strand. The 3 steps are repeated 
(e) until the desired amount of product is reached (f). 
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2.7.4 PCR with restriction-digestion enzymes 
The restriction digestion procedure is used subsequent to PCR amplification of DNA, and 
involves using restriction endonuclease enzymes to cleave the DNA at sites with a specific 
nucleotide sequence. The restriction enzymes are chosen to recognize a sequence motif 
containing either the normal or variant allele, which is then cleaved (or not) depending on the 
experimental design. For example, if the enzyme recognizes the DNA strand carrying the 
variant site, the DNA carrying the common allele will not be cut. (Pritchard and Korf, 2008). 
The DNA fragments carrying a sequence difference can then be differentiated by size or 
other means. This technique has the advantage of being simple and inexpensive to perform in 
studies where known mutations are being investigated. 
2.7.5 Real-time PCR 
Real-time PCR is used for detecting and/or relative quantitating variant sequence using 
fluorescent probes (oligonucleotides with attached fluorescence resonance energy transfer 
molecules) that are complimentary to each strand of (usually) the variant sequence in the 
gene after amplification of the exons. The process is applied during or following polymerase 
replication, depending on specific methodologies used. This procedure has the advantage of 
being less expensive than direct genome sequencing and is easier to apply than restriction-
enzyme digestion after PCR.   
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2.7.6 Sequencing 
Genomic DNA sequencing provides a complete transcript of the DNA strand or fragment in 
order to detect any site of error or mutation, traditionally using fluorescent labelled 
nucleotides and a DNA polymerase reaction mix. The end-result will appear as a ladder of 
bands that is read directly from a single lane capillary gel (Figure 2.5).  
Genome-sequencing is indicated when the location or type of gene mutation is unknown, 
scanning of large gene segments is needed or there are scattered mutations along the gene. 
However, it is not recommended when the goal is to investigate a limited repertoire of 
known mutations, as time, expense are major concerns. 
 
Figure 2.5: Diagram of DNA sequencing method. The DNA to be sequenced is 
mixed with a fluorescent labelled primer (ddNTPs) complementary to the 3' end of 
the sequence. Four parallel specific reaction mixes, which contain the four normal 
nucleotide precursors with a single fluorescent terminating nucleotide in each mix. 
The DNA fragments produced are then separated by capillary electrophoresis and 
the sequence read with a laser beam. (Adapted from: 
http://commons.wikimedia.org/wiki/File:Sanger-sequencing.svg) 
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2.8 Environmental factors related to OFC 
Environmental risk factors were reported to play an important role in the aetiology of oral 
clefts. Previous research has proposed a number of factors, including; socioeconomic status, 
maternal medication ingestion, infections, contact with chemicals/ smoking during the first 
trimester and consanguinity. In the following section the environmental risk factors related to 
NSOFC will be discussed in the light of previous literature. 
2.8.1 Demographic variables  
This section discusses demographic variables that have been linked to NSOFC 
2.8.1.1. Gestation age, weight and twin pregnancies: 
Czeizel (2002) reported no significant relationship between NSOFC and gestation age. 
However, a significant association between lower birth weight and NSOFC has been 
reported (Czeizel, 2002; Jia et al., 2011). This apparent discrepancy has been explained as 
arising from a retardation of intrauterine growth resulting from an alteration in the activity of 
TGF (Czeizel, 2002). Twin pregnancies have been reported to be associated with birth 
defects (Glinianaia et al., 2008). Furthermore, Nordström et al. (1996) reported a higher 
prevalence of monozygotic (versus dizygotic) twins with NSOFC. They also reported a 
higher prevalence of twin pregnancies in CP.  
 
2.8.1.2 Parental age: 
 
Increased parental age has been suggested to be associated with an increase in birth defects. 
Elahi et al. (2004) found a statistically significant relationship between NSOFC and parental 
ages (P< 0.05). Furthermore, Rajab and Thomas (2001) reported that the mean parental age 
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of infants with NSOFC in Oman were significantly greater than that of the general 
population (P< 0.001). Bille et al. (2005) reported paternal age to be a risk factor for NSOFC 
but not maternal age. Furthermore, Zandi and Heidari (2011) reported that maternal age was 
not a risk factor for development of NSCLP (Zandi and Heidari, 2011). On the other hand, 
Jia et al. (2011) found a significant difference in maternal age between cases and controls P< 
0.001. In 2012, Herkrath et al. carried out a meta-analysis on the relationship between OFC 
and parental age using the data from 13 studies and found no significant relationship. 
However, they suggested that the risk of NSOFC is increased to 58% when fathers are older 
than 40 years and 20 to 29% higher when mothers are older than 35 years (Herkrath et al., 
2012). Further investigation is needed to verify this suggestion and include studies that were 
not included in the meta-analysis.  
2.8.2 Socioeconomic status (SES)  
Familial SES could be measured by several ways. It could be estimated by looking at certain 
dimensions such as; family income, parental occupation, parental education and the 
description of the family neighbourhood (Bornstein, 2014). These points are discussed in the 
following section.  
 
2.8.2.1: Parental education 
Furthermore, Krapels et al. (2006) and Carmichael et al. (2009) reported significantly lower 
maternal and paternal education in NSOFC cases compared to controls.  According to 
Krapels et al. (2006) paternal education is associated with CL/P (OR: 1.6 and 95% CI, 1.0 to 
2.3) and CP (OR: 4.5 and 95% CI: 2.1 to 9.4). However, maternal education was associated 
with CL/P (OR: 1.6 and CI: 1.1 to 2.3) (Krapels, 2006). Further studies are needed to clarify 
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the association between paternal education and NSOFC in different geographic locations, 
and whether there are any other factors associated with this relationship as part of SES of the 
infant.  
 
2.8.2.2 Parental occupation 
Occupation could be related to NSOFC in several ways: (a) through affecting the SES of the 
family or (b) through occupational exposure to hazardous substances. Studies have reported 
occupations that may result in maternal exposure to certain chemicals such as aliphatic 
aldehydes, ethyl-ether, aliphatic acids, trichloroethylene and pesticides. Maternal exposure to 
these chemicals could result in offspring with congenital abnormalities (Desrosiers et al., 
2012; Garlantézec et al., 2009; Chevrier et al., 2006; Lorente et al., 2000). A population-
based case-control study in Norway found an association between parental occupation and 
NSOFC (Nguyen et al., 2007). For maternal occupation, there was a statistically significant 
relationship with mothers working as hairdressers (for CL/P: OR: 4.8 and 95% CI: 0.99 to 
23) and in manufacturing and in food production (for CL/P: OR: 3.8 and 95% CI: 1.3 to 11, 
and for CP: OR: 7.1 and 95% CI: 1.5 to 33). For paternal occupations, no significant 
relationship was reported between woodworking and CL/P (OR: 1.7 and 95% CI: 0.85 to 
3.2) or CP (OR: 2.0 and 95% CI: 0.82 to 4.7); whereas paternal housekeepers showed an 
increased CP only (OR: 12 and 95% CI: 3.3 to 46) (Nguyen et al., 2007). Mirilas et al. 
(2011) reported a significant relationship between CL/P and farmers (P= 0.039, OR: 3.00 
and 95% CI: 1.03 to 8.70). On the other hand, Czeizel (2002) found no significant 
relationship between parents working with acrylonitrile and having an offspring with 
NSOFC. It therefore seems from the limited research available that maternal occupation is 
more related to CP than to CL/P. However, further investigation is needed to verify the 
relationship between parental occupation and NSOFC phenotypes.  
76 
 
 
2.8.2.3 Description of the family neighbourhood 
Alsahafi (2010) had described SES as a risk factor for NSOFC in Saudi Arabia and found 
that although there was lower SES for families with NSOFC children, this relationship was 
not statistically significant. However, he reported a statistically significant higher risk of 
OFC at birth in children living in rural areas compared to controls (P< 0.001 and 95% CI: 4.2 
to 42.9).    
In addition, Messer et al. (2010) assessed the variation of oral clefts (CL/P and CP) across 
Texas urban-rural areas from 1999 to 2003. They reported an increased CL/P risk in rural 
areas compared to urban areas. On the other hand, Stoll et al. (1991) found no significant 
differences in the prevalence of both CL/P and CP, in rural compared to urban areas. Further 
investigation in different geographic region is needed to verify the relationship. 
2.8.3 Pregnancy planning and the effect of sibling order in the family 
Pregnancy planning, parental health care, and affected sibling order in the family are all 
related to maternal healthcare, which could affect infants. In a Netherlands case-control 
study, Krapels (2006) reported a 50% decrease in NSOFC risk in planned pregnancies (OR, 
0.5; 95% CI, 0.2 to 0.99). In addition, Mossey et al. (2007) reported a significant decreased 
risk of NSOFC after pregnancy planning in the United Kingdom (Scotland and the 
Manchester and Merseyside regions of England) from 1997 to 2000 in a case-control study 
utilizing 191 case/247 control participants (OR: 0.51 and 95% CI: 0.33 to 0.79). In Saudi 
Arabia, Alsahafi (2010) reported a 1.3-fold increased chance of NSOFC in offspring of 
unplanned pregnancies (OR:1.3, CI: 0.7 to 2.3), a doubled risk in children who were 4th or 
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later in birth order (P= 0.02, OR: 2.0, CI: 1.1 to 3.6), and born to families with less parental-
physician interaction than the controls (P= 0.6).  
Studies have shown that birth order may be associated with birth defects including NSOFC. 
Rajab and Thomas (2001) conducted a case-control study in Oman, where they found a 
significantly increased chance of NSOFC in younger versus older siblings. Vieira and Orioli 
(2002) carried out a meta-analysis on published data discussing the relationship between 
birth order and NSOFC from 1966 to 2000. They found that children with higher birth order 
are more likely to have NSOFC. In addition, they reported an increase in NSOFC risk with 
increased birth order with an OR peak of 3.0 in children with a birth order of 4th or higher. 
The conclusion of this meta-analysis suggested the need for further studies taking into 
consideration sample size and factors that might influence birth order such as income status, 
paternal age, and vitamin intake (Vieira and Orioli, 2002). However, a more recent study 
(Martelli et al., 2010) used a case-control design to evaluate environmental risk factors for 
CL/P in 100 children in Minas Gerais. They reported no relationship between CL/P and 
paternal age, pregnancy order or interpregnancy interval.  
2.8.4 Dietary factors and supplementation 
Nutritional factors and supplementations could have a direct effect on preventing NSOFC, or 
an indirect effect through interactions with other nutrients or genes or through epigenetic 
effects. Because of theses possible mechanisms, many dilatory factors and supplements have 
been investigated for their role in NSOFC.  
2.8.4.1 Dietary factors  
Nutritional factors have been suggested to play an important role in oral cleft prevention. In 
their case-control study in the Netherlands, Krapels (2005) concluded that a higher 
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preconception intake of nutrients with predominant amount of fruits and vegetables reduced 
the risk of having a child with NSOFC. She also reported that intake of vegetable protein, 
fibre, ascorbic acid, iron, and magnesium might provide a reduced chance of having an 
infant with NSOFC. Neural tube defect (NTD) and NSOFC are similar in origin as the 
developmental origins of the structures that are malformed in both conditions arise from 
neural crest cells. Therefore, it has been suggested that vitamins such as folic acid and 
multiple vitamins, which prevent NTD might also prevent NSOFC. Other nutrients that 
could be related to NSOFC are Vitamin A, zinc, ascorbic acid, β-carotene, α-tocopherol, 
pantothenic acid, biotin, iron, and magnesium (Mossey, 2001a). Conversely, it has been 
suggested that a maternal diet with a high fat content might induce NSOFC in mice (Zhou 
and Walker, 1993). A systematic review carried out to investigate the effect of multivitamins 
supplements and folic acid fortification on birth defect reported on papers from January 1966 
to July 2005. They reported a significant decrease chance of having an infant with CL/P in 
case-control studies (OR: 0.63 and 95% CI: 0.54 to 0.73) and CP (OR: 0.76 and 95% CI: 
0.62 to 0.93); but was not significant in cohort and randomized controlled studies (Goh et al., 
2006). 
Recently, Wallenstein et al. (2013) carried out a population based, case-control study in 
California from 1999–2003 that included 170 CP, 425 CL/P and 534 control individuals. 
They investigated the association between the intake of vitamin supplements and dietary 
nutrients and the risk of developing CL/P and CP during maternal periconception. Generally, 
a reduced risk of NSOFC was observed with maternal ingestion of vitamin supplements. In 
addition, they reported a twofold elevated risk of CP with low intake of riboflavin, 
magnesium, calcium, vitamin B12, and zinc and a twofold elevated risk of CL/P with low 
intake of niacin, riboflavin, vitamin B12, and calcium. 
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The best way to measure the association between nutrient intake and birth defects is by 
analysing the levels of nutrient biomarkers. The advantage of certain biomarkers is that their 
blood levels after pregnancy could be a useful indicator of the levels of the nutrient during 
the first week of pregnancy. Moreover, maternal biochemical markers could be useful even 
years following delivery if used in case-control studies (Munger et al., 2011). Therefore, 
studies that aim to measure the association between nutrient intake and NSOFC by nutrient 
biomarkers are recommended. 
 
2.8.4.2 Folic acid: 
Folic acid has been suggested to prevent NSOFC through its role in remethylation of 
homocysteine into methionine and S-adenosylmethionine by carbon donation (Krapels, 
2005). Lin et al. (1989) who examined the effect of folate deficiency on homocysteine 
metabolism through giving rats folate-deficient diet, reported an increase in levels of 
homocysteine, up to four-fold in rats folate-deficient diet compared to the control group with 
normal diet. If homocysteine does not undergo recycling, it alters embryo development by 
affecting neural crest cell migration leading to malformations (Rosenquist et al., 1996). In a 
human case-control study, Wong et al. (1999) found a higher level of homocysteine in 
NSOFC mothers as compared with controls. Another case-control study carried out in the 
Netherlands measured red blood cell, serum folate and plasma homocysteine concentration 
in venous blood sample of infants. They found 15% lower level of mean serum folate levels  
in infants with NSOFC compared to controls but the differences were not significant (P= 
0.06) (van Rooij et al., 2003a).  
In 2002, a Hungarian intervention cohort based case-control study which was not included in 
Molina-Solana et al. (2013) meta-analysis, reported no relationship between folic acid and 
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NSOFC when using an 0.8 mg dose combined with multivitamins (Czeizel, 2002). However, 
in his Hungarian Case-Control Surveillance of Congenial Abnormality (HCCSCA) study he 
found a decrease chance of having an infant with NSOFC when using folic acid in high dose 
(6 mg per day), which could indicate a dose-dependent protective effect (Czeizel et al., 
1999). However, Wilcox et al. (2007) conducted a national population based case-control 
study in Norway and found that folic acid supplementation (≥400 μg/day) reduced the risk of 
CL/P but not CP after adjustment of multivitamins and smoking (OR:0.61 and 95% CI: 0.39 
to 0.96). Also, Krapels (2005) case-control study in the Netherlands found about 40% 
reduction in the chance of having an infant with NSOFC when ingesting a minimal dose of 
400 µg per day of folic acid supplementation  
Molina-Solana et al. (2013) carried out a systematic review and meta-analysis to 2011, 
investigating the effect of environmental factors, including maternal ingestion of folic acid 
supplementation during pregnancy, on the incidence of CL/P. Twenty-eight case-control 
studies were analysed, seven of which discussed folic acid. An overall decrease chance of 
having an infant with CL/P was reported with an OR of 0.78 and 95% CI: 0.62 to 0.97. 
Following, a case-control study in China, Jia et al. (2011) reported a decrease chance of 
having an infant with NSOFC  of maternal folic acid supplementation but this was 
statistically significant only for CP (P= 0.004, OR: 0.52, 95% CI: 0.33 to 0.81). 
Although the preliminary results suggest a relationship between folic acid and NSOFC, 
description of the effective dose, duration and timing of the supplementation ingestion, still 
need further investigation. In addition, research needs further to clarify and confirm to which 
NSOFC phenotype folic acid is related. 
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2.8.4.3 B Vitamins: 
The B vitamin group contain important factors for various metabolic processes involved in 
the synthesis of normal DNA and RNA, critical for normal body development. Vitamin B1 
(thiamine) is involved in the metabolism of amino acids and carbohydrates (Thurnham, 
2000; Russell, 2001). Vitamin B2 (riboflavin) is involved in fat, carbohydrate and protein 
metabolism as well as in folate metabolism (Rivlin, 1970). Vitamin B3 (niacin) is involved 
in the synthesis of pentose, steroids, red blood cells, and fatty acids and in the metabolism of 
proteins, carbohydrates and fats as well as glycolysis. In addition, vitamin B3 alters the 
metabolism of certain drugs and toxins (Thurnham, 2000; Russell, 2001;). Vitamin B6 
(pyridoxine) is involved in the metabolism of carbohydrates, fats, amino acids and glycogen. 
It also acts as a cofactor for the trans-sulphuration of homocysteine to cysteine. In addition, 
vitamin B6 is involved in regulating the activity of hormones that bind to the nuclear 
receptor and influence gene expression (Jacobsson and Granstrom, 1997; Thurnham, 2000; 
Russell, 2001). Therefore, a suggestion of alteration of the levels of B vitamins during 
pregnancy has been suggested to be associated with NSOFC. 
Krapels et al. (2004b) reported that dietary intake of energy and of vitamin B was lower in 
mothers of NSOFC compared with controls. This relationship was significant for vitamin B1, 
vitamin B3, vitamin B6 and energy (P= 0.007, P= 0.01, P= 0.007 and P= 0.04, respectively). 
They also reported that there was a decrease in NSOFC risk of about 21-64% when 
consumption of vitamin B1 was above 1.08 mg per day. For vitamin B6, the decrease in the 
NSOFC risk was 29-65% when consumption was above 1.51 mg per day.  
Li et al. (2009) conducted a case-control study to measure the effects of vitamin B6 
supplementation against having an infant with NSOFC. They injected pregnant mice with 
toxic material that caused OFC and administered one of the groups with vitamin B6. 
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Although OFC rates were low in animals administered vitamin B6, the difference was not 
significant. Munger et al. (2004) also reported a decrease chance of having an infant with 
NSOFC when ingesting vitamin B6 supplementation in humans. van Rooij et al. (2003a) 
concluded that low serum levels of vitamin B6 and vitamin B12 in mothers increased the risk 
of NSOFC in infants. Vitamin B1was also reported to reduce the risk of NSOFC (Krapels et 
al., 2004b; Munger et al., 2004).  
2.8.4.4 Vitamin A: 
Vitamin A has a specific inhibitory effect on cranial crest cells, from which the development 
of the craniofacial structure originates (Teratology Society, 1987). The relationship between 
OFC and Vitamin A is inconsistent. It has been suggested that vitamin A supplementation 
might reduce the risk of NSOFC, although it is teratogenic in high doses (Czeizel and 
Rockenbauer, 1998; Soprano and Soprano, 1995). In Norway, enhanced vitamin A levels 
through supplementation and diet has been shown to reduce the risk of CP by about 53% 
(Johansen et al., 2008).   
2.8.4.5 Zinc (Zn): 
Low levels of zinc are associated with multiple malformations, as zinc has a role in the 
absorption of folate and is involved in conversion of 5-methylene tetrahydrofolate into 
tetrahydrofolate (Krapels, 2005). Zinc is also a cofactor for several metalloenzymes, is a 
constituent of proteins, hormones and neuropeptides, and is important for cellular 
multiplication, differentiation and apoptosis, which are integral in embryonic development. It 
also has a role in genetic control of embryonic development (Tamura and Goldenberg, 
1996). Hurley and Swenerton (1966) have reported that 34% of foetal rats had CP after their 
mothers received diets containing low levels of zinc during gestation. In human, the 
relationship between zinc and NSOFC was analysed through measuring the serum 
83 
 
concentration of zinc among NSOFC mothers or infants and comparing them with controls 
(Krapels et al., 2004b; Tamura et al., 2005). 
Molina-Solana et al. (2013) carried out a meta-analysis on four case-control studies assessing 
the relationship between zinc and CL/P. In general, the meta-analysis reported no significant 
relationship between zinc serum concentration and CL/P (OR 1.82; 95% CI 0.88 to 3.79). 
However, there was a tendency of relationship that needs further investigation in future 
studies with larger sample size. 
2.8.4.6 Calcium:  
Calcium has also been suggested to have an effect on NSOFC development. In a case-control 
study from China, a significant decrease chance of having an infant with CL/P was reported 
for calcium supplementation , (P= 0.019, OR: 0.66 and 95% CI: 0.47 to 0.93) (Jia et al., 
2011). Recently, Wallenstein et al. (2013) reported a decrease in the risk of CP and CL/P 
associated with maternal ingestion of calcium supplementation in the pre-gestation period in 
his population based case-control study, but the relationship was not significant (OR: 0.5, 
and 95% CI: 0.2 to 1.3 for CP and OR: 0.7, and 95% CI: 0.4 to 1.4 for CL/P). 
2.8.4.7 Food fortification: 
Fortification of flour with folic acid has been suggested as a source of nutrient and a means 
to prevent birth defects. Examination of the effects of flour fortification in Chile showed a 
significant decrease in the prevalence of neural tube defects. However, there was no 
significant reduction in NSOFC, which might indicate that folic acid only has a limited effect 
in the prevention of NSOFC (Cortés et al., 2012).  
In 2008, Johnson and Little carried out a systematic review and meta-analysis to assess the 
role of folate, including folate fortification, in the aetiology of NSOFC. Seven studies were 
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analysed in which five measured compulsory fortification and two measured optional 
fortification. Compulsory fortification was found to have a mild effect (OR: 0.93 and 95% 
CI: 0.90 to 0.98 for CL/P and OR: 0.92 and 95% CI: 0.85 to 0.99 for CP) whereas no effect 
was identified following optional fortification (OR: 1.02 and 95% CI: 0.93 to 1.12) in 
relation to the prevalence of NSOFC (Johnson and Little, 2008).  
In Saudi Arabia, the site of the current study, the National Flour Mills Organization ordered 
mandatory folate fortification of flour starting in 2001 (Arabic date: 1421) with the minimum 
requirement being 1.653% (16.53 grams of folic acid for per kilogram of flour) (Saudi 
Standard of fortification, 1421H (2001)). The other sources of flour in Saudi Arabia are the 
flours that are imported from Kuwait and the UAE which are also fortified.   
2.8.5 Maternal medication and illness 
Studies have investigated the association between maternal exposures to medication and 
illness, with both CL/P and CP. In the following paragraphs we will discuss the possibility of 
this association and the different medications involved:    
2.8.5.1 Maternal medication: 
Maternal exposure to medication has been suggested to play a role in the development of 
NSOFC. Zandi and Heidari (2011) have confirmed a significant relationship between 
maternal drug ingestion, trauma and exposure to radiation with CLP. 
2.8.5.1.1Antibiotics 
Antibacterial agents including antibiotics have also been reported to be associated with 
NSOFC (OR: 2.1 and 95% CI: 1.2 to 3.9) (Crider et al., 2009). In a cohort study, Molgaard-
Nielsen and Hviid (2012) investigated the association between maternal antibiotic ingestion 
and the risk of having an offspring with NSOFC, but found no association. However, when 
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further classification of antibiotic usage was performed, they found a significantly increased 
risk for infant CL/P for mothers taking doxycycline/tetracycline (OR: 7.30 and 95% CI: 1.81 
to 29.46) and sulfamethizole (OR: 1.76 and 95% CI: 1.10 to 2.81), specifically. Furthermore, 
there was an increased risk of CP in offspring of mothers taking trimethoprim (OR: 14.29 
and 95% CI: 3.46 to 59.05) or using pivmecillinam (OR: 2.34 and 95% CI: 1.20 to 4.54). In 
addition, Lin et al. (2012) carried out a case-control study on 877 NSOFC cases to 
investigate the relationship between maternal amoxicillin ingestion in early pregnancy and 
NSOFC occurrence. They found an increased risk for CL/P (OR: 2.0 and 95% CI: 1.0 to 4.1) 
and CP risk (OR: 1.0 and 95% CI: 0.4 to 2.3) in offspring. For ingestion during the third-
gestational-month the risk was higher for both CL/P (OR: 4.3 and 95% CI: 1.4 to 13.0) and 
for CP (OR: 7.1 and 95% CI: 1.4 to 36). Further investigation to clarify the relationship 
between antibiotics and NSOFC is required.   
2.8.5.1.2 Corticosteroid 
Carmichael et al. (2007a), conducted a case-control study on 1141 NSOFC cases to measure 
the relationship between maternal corticosteroid ingestion during pregnancy and the chance 
of having an infant with NSOFC. They concluded that there was a moderately increased risk 
of infants with CL/P in mothers using corticosteroids (OR: 1.7 and 95% CI: 1.1 to 2.6) but 
not CP (OR: 0.5 and 95% CI: 0.2 to 1.3) (Carmichael et al., 2007a). Other studies support the 
relationship between maternal corticosteroid ingestion and NSOFC (Pradat et al., 2003; 
Rodriguez-Pinilla and Martinez-Frias, 1998). On the other hand, Chi et al. (2013) conducted 
a retrospective cohort study on 2658 pregnant women exposed to topical corticosteroids 
compared to 7246 controls, and found no significant relationship between NSOFC and 
maternal topical corticosteroid ingestion (Chi et al., 2013). This finding is also is supported 
by other studies (Kallen, 2003; Czeizel and Rockenbauer, 1997). Recently, Skuladottir et al, 
(2014) investigated maternal first-trimester exposure to corticosteroids and oral clefts in 
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offspring using two population-based studies. Thy reported inconsistent finding for the two 
populations suggesting that meta-analyses will be required to determine whether a 
relationship between NSOFC and maternal corticosteroid ingestion exists.  
2.8.5.1.3 Antithyroid drugs 
The relationship between antithyroid drugs and oral cleft were also studied. Andersen et al. 
(2013) found a significant relationship between maternal antithyroid drug ingestion and 
malformations in the face and neck region of their offspring in a nationwide register-based 
cohort study on 817,093 live-births from 1996 to 2008 in Denmark (P < .001). However, 
future cohort or longitudinal studies to identify any teratogenic effects of antithyroid 
medication ingested by pregnant mothers is needed to confirm this supposition.  
EUROCAT (European Surveillance of Congenital Anomalies), a multicentre European 
network of registries for the epidemiologic surveillance of congenital anomalies, has 
established policies (Scope of Policy Actions Needed for Primary Prevention of Congenital 
Anomalies) to be considered for the primary prevention of congenital anomalies when 
developing guidelines for national plans and strategies on rare diseases, including guidelines 
on medication ingestion. They recommend appropriate medical and clinical care for pregnant 
women starting from the preconception period especially for those at a high-risk of epilepsy, 
diabetes, as well as those who require medication (EUROCAT, 2013; Little, 2004). 
2.8.5.2 Maternal illness: 
Maternal illness has been suggested to have an effect on embryonic development (Mossey, 
2001a). Maternal illness is accompanied by infection, inflammation, high fever and the 
ingestion of medication. The association between maternal illness and birth defects could be 
explained by direct effects from infection of the foetus or indirect effects from hyperthermia, 
toxic metabolites, or the side effects of medications (Edwards, 2006). A case-control study in 
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Hungary reported a higher occurrence of CL/P in mothers affected by herpes, whereas their 
medication did not show an association with clefting (Czeizel, 2002). A maternal common 
cold infection in the first trimester was reported to significantly increase the risk of CLP in 
girls (OR: 3.3 and 95% CL: 1.6 to 7.1), but no effect was found in boys (Krapels, 2005). In 
addition, maternal fever has also been reported to increase the risk of CL/P (OR: 1.28 and 
95% CI: 1.01 to 1.63), and mothers who took antipyretic drugs showed a lower risk of 
NSOFC than did mothers who did not control their fever (Hashmi et al., 2010).   
Diabetes in pregnancy has been reported to increase the risk of having infants with neural 
defects and NSOFC (Spilson et al., 2001), which could be explained by the possible effects 
of hyperglycaemia on gene expression (Fine et al., 1999). Finally, Murphy et al. (2013) 
carried out a meta-analysis on cohort studies from 1975 to 2012 to determine the association 
between maternal asthma and birth defects. After analysing 21 studies that met their 
inclusion criteria, they found a significantly increased risk of CL/P in offspring of mothers 
with asthma (RR: 1.30 and 95% CI: 1.01 to 1.68). This association could be related to 
maternal steroid consumption during critical period of CL/P and CP development. 
The effect of maternal diseases on orofacial structure development still needs further 
investigation to clarify the relationship and its pathophysiology.  
2.8.6 Maternal life-style 
Maternal life style factors are suggested to influence the development of oral clefts such as; 
weight changes, smoking, and alcohol consumption  
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2.8.6.1 Maternal weight changes: 
Maternal weight changes could be related to the aetiology of NSOFC. Jia et al. (2011) 
reported that a decline in maternal weight during pregnancy was associated with a higher risk 
of having an infant with NSOFC (P< 0.005) and increased maternal weight had a lower risk 
of having an infant with CL/P (OR: 0.20 and 95% CI: 0.06 to 0.60) and CP (OR: 0.2 and CI: 
0.045 to 0.56). On the other hand, maternal obesity has been related to birth defects such as 
spina bifida and anencephaly (Waller et al., 2007). A systematic review and meta-analysis 
was carried out by Stothard et al. (2009) to assess the relationship between maternal 
overweight status and congenital anomalies including NSOFC. Thirty-nine articles were 
reviewed and eighteen were analysed in the meta-analysis, which identified a significantly 
increased risk of CP (OR: 1.23 and 95% CI: 1.03 to1.47) and CL/P (OR: 1.20 and 95% CI: 
1.03 to 1.40) in obese mothers. In addition, Block et al. (2013) conducted a study of the 
relationship between maternal pre-pregnancy body mass index (BMI) and 26 birth defects 
identified through the Florida Birth Defects Registry. They found a direct dose-response 
relationship between maternal pre-pregnancy BMI and both CL/P and CP (Block et al., 
2013). Further studies to clarify the relationship between maternal weight and weight 
changes and NSOFC are needed. 
 
2.8.6.2 Smoking: 
Previous studies have consistently identified a positive association between maternal 
smoking and NSOFC (Hackshaw et al., 2011; Zandi and Heidari, 2011). A 2004 meta-
analysis has suggested a modest positive association between active smoking and NSOFC: 
OR: 1.34 and 95% CI: 1.25 to 1.44 for CLP; and OR: 1.22 and 95% CI: 1.10 to 1.35 for CP 
(Little et al., 2004b).  
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In 2011, another systematic review and meta-analysis was conducted to clarify the 
relationship between smoking and the prevalence of birth defects and included studies from 
the previous meta-analysis. Literature was reviewed from 1959 to 2010 and 172 articles were 
used in the meta-analysis. Following odds ratio (OR) adjustment for maternal age and 
alcohol consumption, a significant relationship between smoking and NSOFC was reported 
(OR: 1.28 and 95% CI: 1.20 to 1.36) (Hackshaw et al. 2011). In addition, Meyer et al. (2004) 
reported a dose-response effect in smoking/ CP association. Such an effect was also 
suggested by Little et al. (2004a) in their case-control study designed to investigate the 
relationship between smoking and orofacial clefts in the United Kingdom. They found that 
maternal smoking of more than 10 cigarettes per day increased the chance of having an 
infant with NSOFC from (1.5 to 2) to (2.5 to 3) fold for the various NSOFC phenotypes 
(Little et al., 2004a). Moreover, Honein et al. (2007) found a statistically significant 
relationship between maternal smoking and NSOFC (OR: 1.3 and 95% CI: 1 to 1.6). 
However, when relating maternal smoking to cleft severity, a stronger association was 
reported with bilateral CL/P (OR: 1.7 and 95% CI: 1.2 to 2.6).    
On the other hand, although there has been a decrease in maternal smoking in Denmark in 
the last 20 years, the prevalence of NSOFC has not decreased (Bille et al., 2005). Also, in a 
French case-control study conducted in 2008 it was reported that although a significant 
relationship between maternal smoking and NSOFC was not identified, there was a 
statistically significant relationship and an increased chance of NSOFC offspring with 
maternal exposure to environmental tobacco smoke (Chevrier et al., 2008). Therefore, a 
systematic review and meta-analysis including fourteen case-control studies, on the 
relationship between passive smoking and NSOFC has been carried out by the author and 
colleagues. It concluded that maternal passive smoking exposure approximately doubles the 
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risk of having a child with NSOFC (OR: 2.11, 95% CI: 1.54 to2.89) (Sabbagh et al., 
published/ in press 2014). The paper is presented in (appendix B2)  
Paternal smoking has also been reported to increase the risk of NSOFC by 1.5 fold (Krapels, 
2005), and specifically of CL/P (OR: 1.92 and 95% CI: 1.40 to 2.64) and CP (OR: 2.09, 95% 
CI: 1.40 to 3.13) (Jia et al., 2011).  
From these studies it could be concluded that there is a consistent positive relationship 
between smoking and NSOFC. Therefore, avoidance of smoking to reduce this risk is a 
common public health message (World Health Organization, 2013). 
In Saudi Arabia, the median prevalence of smoking in adults is 22.6%, which is considered 
high compared to global figures. However, in females alone the prevalence is low (9%) 
(Bassiony, 2009). A higher figure was reported by Fida and Abdelmoneim (2013), reaching 
37% among males ranging from 16 to 22 years old attending secondary schools. The main 
types of smoking utilized were tobacco and waterpipe. Previous research has found that 
waterpipe smokers have significantly higher carboxyhaemoglobin concentrations than do 
cigaratte smokers; have higher carbon monoxide levels and also higher serum cotinine levels 
due to the larger amount of tobacco consumed during sheesha smoking compared with 
cigarette smoking (Zahran et al., 1985; Ardawi et al., 2007;). In addition, Shihadeh (2003) in 
his study to elucidate the mainstream smoke aerosol and thermal-fluid processes of the 
waterpipe, has suggested that smoking a single waterpipe session produces as much "tar" as 
20 cigarettes. A systematic review on the effects of waterpipe smoking on health outcomes 
was carried out in 2010 and concluded that there is a significant association between 
waterpipe smoking and multiple adverse health outcomes (Akl et al., 2010). However, the 
relationship between these different smoking formats and NSOFC has yet to be established.  
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2.8.6.3 Alcohol consumption: 
Alcohol consumption during pregnancy and the pregestation period has been associated with 
multiple birth defects, the constellation defining Foetal Alcohol Syndrome (FAS) or other 
alcohol related birth defects (ORBD) and neurotoxicity (Committee to study Foetal Alcohol 
Syndrome, 1996). Cartwright and Smith (1995) reported increased cell death in embryos, 
especially of cranial neural crest cells with ethanol exposure. They proposed that this could 
lead to birth defects following maternal alcohol consumption. Consistent with this, a cohort 
population based study that included 4714 woman and associated prenatal alcohol 
consumption with birth defects found a significant, four-fold increase in birth defects 
(OR:4.6 and 95% CI: 1.5 to 14.3) (O'Leary et al., 2010).  
Alcohol consumption has also been considered a risk factor in the aetiology of 
NSOFC. It could be directly associated with OFC or could act as a confounding factor for 
other risk variables such as SES and maternal stress (Mossey, 2001a; Carmichael et al., 
2007b). Werler et al. (1991) carried out a case-control study on 1464 infants to assess the 
relationship between alcohol consumption and selected birth defects including CL/P, and 
reported an increased risk of CL/P with severe alcohol consumption (five or more drinks per 
day) (OR: 3.0 and 95 % CI: 1.1 to 8.5).  In addition, in a hospital-based case-control study 
including 274 cases and 548 controls, Leite and Koifman (2009) reported an increased 
NSOFC risk with maternal alcohol consumption during the 1st trimester (for CL/P: OR: 2.08 
and 95% CI: 1.27 to 3.41, and for CP: OR: 2.89 and 95% CI: 1.25 to 8.30). They also found 
an increased NSOFC risk with increased dosage of maternal alcohol consumption (Leite and 
Koifman, 2009).  
Molina-Solana et al. (2013) carried out a meta-analysis on other five case-control 
studies investigating the relationship between alcohol and CL/P and also reported an 
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increased risk of CL/P with maternal alcohol consumption (OR: 1.5 and 95% CI: 0.99 to 
1.66).  
A systematic review that assesses the relationship between parental alcohol 
consumption and NSOFC is still needed. Studies that confirm dose related effect of alcohol 
is also required.    
2.8.7 Maternal stress 
Studies have reported a relationship between maternal stress and NSOFC (Carmichael and 
Shaw, 2000; Laumon et al., 1996; Czeizel and Nagy, 1986; Saxen, 1974). Measurement of 
maternal stress is carried out through identification and scoring of stressful maternal life 
events including family problems, difficult pregnancies and occupational stress. Most studies 
have only incorporated one or two of these life events (Carmichael et al., 2007b).  
2.8.7.1 Family problems and other maternal stressful events: 
The effect of maternal stress on NSOFC could be related to elevated maternal corticotrophin-
releasing hormone and corticosteroid levels resulting from stressful-events (Montenegro et 
al., 1995; Hobel et al., 1999), suggested by findings that corticosteroid medication can 
increase the risk of NSOFC (Carmichael et al., 2007a). Another explanation of how stress 
might cause birth defects is through negative coping behaviours that might be associated 
with stress, such as smoking (Baker et al., 2002; Azagba and Sharaf, 2011).  
In Chile, Montenegro et al. (1995) measured the prevalence of NSOFC in mothers exposed 
to a severe shock from a large earthquake in 1985, compared to the prevalence of NSOFC in 
previous years. A significant increase was identified in the prevalence of NSOFC following 
severe shock, from 1.6/1000 births to 2.01/1000 births. To further strengthen their hypothesis 
they conducted similar stress intensity tests on pregnant mice and found a similar effect 
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(Angelica Montenegro et al., 1995). Furthermore, in a meta-analysis carried out on 28 case-
control studies, Molina-Solana et al. (2013) analysed two studies assessing the relationship 
between stress and CL/P and found a significant relationship as well (OR:1.41 and 95% CI: 
1.2 to 1.65). In addition, Radojicic et al. (2007) carried out a study on 96 OFC infants and 
their mothers compared to 122 controls in Belgrade after  war to measure the effect of stress 
on OFC prevalence. Stress, anxiety, and disorganized emotional life were greater in cases 
compares to controls, 
Further cohort longitudinal studies and studies that measures stress biomarkers are required 
to verify the relationship between maternal stress and NSOFC. 
2.8.7.2 Hyperemesis gravidarum: 
Hyperemesis gravidarum, a severe maternal nausea and vomiting, which accompanies 
pregnancy (usually in the 1st trimester), has been suggested as having a negative association 
decreasing NSOFC risk. A reduced chance of having an infant with NSOFC was  reported to 
be associated with nausea and vomiting in the HCCSCA study to be (Czeizel et al., 1999). 
Krapels et al. (2006) reported that mothers with extreme vomiting were identified more 
frequently in a control population compared to in mothers of cases (for CL/P, OR:0.8 and 
95% CI: 0.5 to 1.3; for CP, OR: 0.9 and 95% CI: 0.5 to 2). One hypothesis behind the 
suggested protective effect is that initiation of nausea and palatal fusion processes are related 
and are both positively affected by the changes in hormones and diet that accompany 
maternal vomiting. Another explanation could be related to the medication ingested to treat 
hyperemesis gravidarum. On the other hand, Czeizel and Vargha (2003) reported a greater 
ingestion of thiethylperazine in the treatment of severe vomiting in maternal cases with CL/P 
than in controls in his Hungarian population based case-control study (OR: 2.0 and 95% CI: 
1.0 to 4.0). They also reported in 2005, no significant differences between mothers of infants 
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with congenital anomalies using dimenhydrinate which is an anti-emetic drug, and mothers 
with normal infants (OR: 0.9 and 95% CI: 0.8 to 1.0) (Czeizel and Vargha, 2005). In 2004, a 
prospective cohort-control study was carried out to compare pregnancy outcomes in women 
not experiencing nausea and vomiting during pregnancy with those experiencing nausea and 
vomiting at two levels of clinical severity. No association was found between lack of nausea 
and vomiting during pregnancy and an increase in the overall rates of major malformations 
(Boskovic et al., 2004). In addition, a Chinese case-control study reported a significant 
relationship between maternal nausea or vomiting during pregnancy and CP (OR: 1.82, 95% 
CI: 1.21 to 3.13) (Jia et al., 2011). 
The relationship between nausea and vomiting during pregnancy and NSOFC is complex and 
needs further investigation to clarify. 
 
2.8.8 Maternal domestic environmental exposure 
Maternal domestic exposure could be from different sources. Pregnant women could be 
exposed to chemicals while she is at home or during her work.  The following section 
discusses some of these exposures. 
2.8.8.1 Maternal exposure to chemicals: 
Studies have reported an increased risk of NSOFC after maternal exposure to chemicals such 
as; aromatic solvents, chlorinated solvents and Stoddard solvent (Desrosiers et al., 2012); 
organic solvents, lead compounds, and non-ionising and ionizing radiations (Chevrier et al., 
2006); aromatic solvent and Stoddard (Garlantézec et al., 2009) 
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Testud et al. (2010) conducted a prospective cohort study on 206 mothers exposed to organic 
solvents using bio-monitoring for risk assessment and found no increased adverse outcome. 
In 2007, Romitti et al. conducted a meta-analysis on maternal exposure to pesticides and its 
association to NSOFC. Their results suggested that maternal exposure to pesticides is 
associated with a modest but marginally significant risk of clefting (Romitti et al., 2007). 
Further studies are required to identify maternal chemical exposure effects and its interaction 
with genes in the aetiology of NSOFC phenotypes. . 
2.8.8.2 Occupational exposures: 
Occupational exposure has been suggested to play a role in the aetiology of NSOFC. 
Desrosiers et al. (2012) found no significant relationship between occupational exposure to 
organic solvents chlorinated solvents during early pregnancy and risks of neural tube defects 
and orofacial clefts (OR:1.32 and 95% CI: 0.77 to 2.29). Langlois et al. (2013) carried out a 
population-based case-control study in the United States to investigate the relationship 
between polycyclic aromatic hydrocarbons and NSOFC. Occupational exposure was 
assessed by two to three industrial hygienists. The study included 805 CL/P and 439 CP 
cases compared to 2989 controls. There was a significant increase in the incidence of CL/P 
with maternal occupational exposure (OR: 1.69 and 95% CI: 1.18 to 2.40) but not of CP 
(Latchman, 1997). Qi et al. (2013) carried out a hospital based case-control study in Hubei 
Province, China that included 180 CL/P cases matched by age and sex with 108 controls. 
Paternal occupational exposure including noise, gasoline, radiation, and high temperature 
was significantly associated with CL/P (OR: 13.08 and 95% CI: 2.35 to 72.86). 
Occupational exposures still need further investigation in cohort longitudinal studies. Also, 
genetic-occupational exposure interactions should be investigated to clarify their association 
with NSOFC. 
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2.8.8.3 Environmental contamination: 
Dolk et al. (1998) carried out a multi-centre case-control study that assessed the risk of 
congenital anomalies associated with maternal residence near hazardous-waste landfill sites 
in Europe. An increased risk of congenital anomalies was observed for babies with mothers 
living within 3 km of hazardous chemical waste landfills (OR: 1.33 and 95% CI: 1.11 to 
1.59). However, although there was an increase in the OR for OFC, the relationship was not 
significant (CL/P: OR: 1.18 and 95% CI: 0.66 to 2.12; and CP: OR: 1.63 and 95% CI: 0.77 
to 3.41). The OR reported by the author was adjusted for SES and maternal age.  
Ramakrishnan et al. (2013) conducted a case-control study assessing the association between 
estimated maternal residential exposure to benzene, toluene, ethyl benzene, and xylene 
(BTEX) and the risk of NSOFC. Agents were selected using the U.S. Environmental 
Protection Agency 2005 Hazardous Air Pollutant Exposure Model (HAPEM5). The study 
included 6045 NSOFC cases (3915 CL/P and 2130 CP individuals born between 1999 and 
2008), with 6000 age-matched controls. Maternal residential exposure to benzene was not 
associated with oral clefts (OR: 0.95 and 95% CI: 0.81 to 1.12 for CL/P; and OR: 0.85 and 
95% CI: 0.67 to 1.09 for CP).  
Radiation contamination has also been considered in the aetiology of birth defects in a study 
by Mangones et al. (2013) in New York. Four zones of 5-mile increments were used to 
categorize proximity to the Indian Point nuclear reactor for individuals identified by 
analysing New York State Vital Statistics and Congenital Malformations Registry data (from 
1992 to 2001). Over the 10-year period, 328,124 infants were born with 702 malformations 
yielding a regional rate of 2.1 major malformations per 1000 births. This prevalence is lower 
than the total malformation rate in New York (5.9/ 1000 births). Therefore, the prevalence of 
birth defects was not related to proximity to the nuclear power plant (Mangones et al., 2013). 
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From these studies we can conclude that although different environmental contamination 
exposures such as; radiation, hazardous-waste and chemicals, seems to have a relationship 
with NSOFC, further investigation to confirm or reject this relationship is still needed. 
2.8.9 Family history and parental consanguinity 
Family history and parental consanguineous marriages were reported to be associated with 
NSOFC. In the following section we will discuss this association  
2.8.9.1 Family history 
Family history of NSOFC has been reported to have a significant association with NSOFC 
increasing the chance of having a child with clefting (Jia et al., 2011). Lie et al. (1994) 
carried out a population based study that investigated the risk of birth defect recurrence 
among Norway woman who delivered their first and second children between 1967 and 
1989. Clefting was considered to have a higher recurrence risk in the second infant (CL 
relative risk was 31.4 with 95% CI: 19 to 52 and CP relative risk was 44.5 with 95% CI: 9 to 
134) compared to other birth defects with relative risk 7.6 and CI: 6.5 to 8.8. Zandi and 
Heidari (2011) reported a significant relationship between the presence of clefting in siblings 
or parents and having a child with OFC. Furthermore, in a case-control study in the 
Netherlands, Krapels et al. (2005) reported that the most significant variable related to 
NSOFC was family history (OR: 19, CI: 1.1 to 2).  
 
2.8.9.2 Parental consanguinity 
Consanguinity has been reported to be higher in parents of children with orofacial clefts than 
in those without (Zeiton et al., 1993; Zlotogora, 1997; Elahi et al., 2004; Reddy et al., 2010). 
It has been suggested that consanguinity could play a role in the aetiology of clefts. Saudi 
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Arabia has a high prevalence of consanguinity (57.7%) (El-Hazmi et al., 1995) and presents 
an opportunity to carry out such an investigation. In King Faisal Hospital and Research 
Centre, it was found that 28% of patients with clefting were first cousins, rather a high rate 
when compared to the prevalence of 1st cousin consanguineous marriages reported in the 
general Saudi population (Al-Johar et al., 2009). To clarify the relationship between 
consanguinity and NSOFC, a systematic review and meta-analysis has been carried out for 
all case-control studies that have measured the relationship between consanguinity and 
NSOFC, concluding that consanguinity is indeed a risk factor for NSOFC (OR: 1.83 and 
95% CI: 1.31 to 2.54) (Sabbagh et al., 2014) (appendix B3). One of the studies included in 
the systematic review was carried out in Saudi Arabia and reported an association between 
orofacial clefts and consanguinity (Alsahafi, 2010). 
  
2.8.9.3 Family history with parental consanguinity 
The presence of consanguineous marriages in a community has been suggested to increase 
the prevalence of congenital anomalies related to recessive gene disorders (Pritchard and 
Korf, 2008). Moreover, in consanguineous marriages where there is known family histories 
of birth anomalies, the chances of inheritance and occurrence of defects are expected to 
increase further (Saggar and Bittles, 2008). In a Saudi Arabian study, Al-johar (2008) 
reported positive family history in almost a quarter of the cleft patients with related parents. 
Moreover, in Saudi Arabia, Ravichandran et al. (2012) found a statistically significant 
difference between consanguineous and non-consanguineous marriages in relation to family 
history of clefting. Further investigations confirming the relationship between consanguinity 
and family history and their relationship to NSOFC are needed, as well as to identify the risk 
potential in these families and to provide suitable information for prenatal and premarital 
genetic consultation.   
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2.9 Gene-environmental interaction 
Gene-environmental interactions (GEI) have been suggested to play an important role in the 
aetiology of NSOFC. It is defined biologically as the coparticipation of the genetic and 
environmental risk factors in the same causal mechanism to promote disease development 
(Zhu et al. 2009). One of the important applications of GEI studies is to help public health 
researchers develop strategies for targeted intervention for risk-factor modification based on 
individual genetic profile (Hunter 2005).   
The most common study designs used to assess GEI include: population-based cohort study, 
case-control study, case-only study and family-based design. The advantage, disadvantage 
and indication were discussed in several papers (Umbach and Weinberg 2000; Zhu et al. 
2009; Hutter et al. 2013).  Case-control studies tend to be more feasible and cost efficient 
than cohort studies. However, they suffer from the possibility of stratification bias. Case-
only studies has the advantage of being simple, do not need controls, and are more efficient 
than case-controls when the main goal is studying gene-environmental interaction and 
distribution of the different exposures according to their genotypes. However, they do not 
measure the joint effect of gene and environmental exposures in relationship to the aetiology 
of the disease.  Family-based designs have the advantage of overcoming confounding due to 
population stratification. However, error can arise when the variant allele affects the disease 
risk or where the test considers that transmission from heterozygous parents as independent 
events when they are actually not (Umbach and Weinberg, 2000).    
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2.9.1 Maternal supplementation-gene interaction 
The effects of folic acid supplementation and its interaction with genes have been 
investigated in multiple studies. For NSOFC, it has been found that the unfavourable effects 
of low folate intake on the risk of developing an OFC infant were more pronounced in 
mothers with MTHFR 677TT or MTHFR 1298CC genotypes (Van Rooij et al., 2003b).  
In 2008, Boyles et al. studied the association between twelve polymorphisms in nine genes 
related to one-carbon metabolism, and clefts in a Norwegian population-based study that 
including 362 CL/P and 191 CP infant-parental triads. They stratified maternal 
periconception intake of folic acid to investigate gene-supplementation interactions, and 
reported a reduced risk of CL/P in mothers who carried the CBS C699T variant (rs234706) 
(Czeizel and Rockenbauer, 1998; Soprano and Soprano, 1995) (P= 0.008, relative risk (RR): 
0.50 and 95% CI: 0.26 to 0.96). However, they found no evidence of significant interaction 
between the MTHFR C677T variant (rs1801133) and maternal folate intake (Boyles et al., 
2008). 
In 2009, Boyles et al. further investigated the effects of genes involved in folate and vitamin 
A metabolism on the occurrence of NSOFC using pathway associated study. They analysed 
29 genes involved in folate /one carbon metabolism and 16 genes involved in vitamin A 
metabolism. Their analysis, stratified for maternal intake of both folate and Vitamin A, found 
that the strongest association identified was between foetal FOLH1 and CP only (Boyles et 
al., 2009). Further evidence for interaction is provided by Velázquez-Aragón et al. (2012), 
who investigated the association and interaction between IRF6 (rs2235371 and rs2235375), 
8q24 and maternal folic acid intake in a case-control study. Using logistic regression 
analysis, they found a statistically significant relationship between maternal folic acid intake 
and the 8q24 SNP rs17241253 in NSOFC infants. 
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In addition, Wu et al. (2010) carried out family-based design in China that aims to 
investigate the interaction between 21 SNPs on IRF6 and maternal multivitamins 
supplementations among CL/P cases.  A significant interaction was found with IRF6 
rs2076153 (P= 0.019) and rs17015218 (P= 0.012).  
Further investigation is needed to clarify the interaction between folic acid and genes in the 
aetiology of NSOFC. In addition, the effect of maternal supplementation (multivitamins and 
folic acid) and their doses should be considered.  
2.9.2 Maternal smoking-gene interaction  
Gene-environment interaction has also been observed between maternal exposure to smoking 
and the ability of the mother and fetal enzymes to detoxify the toxic compounds of smoking 
as demonstrated from studies that examined genes involved in the detoxification pathway 
(Shi et al., 2008). Krapels (2005) identified roles for polymorphisms in EPHX exons 3 and 4 
and in GSTPI exon 5, as well as an interaction between parental EPHX exon 4 and 
periconception smoking in the aetiology of OFC. 
In 2008, Shi et al. carried out a review of studies investigating interaction between genetic 
and maternal smoking in contributing to oral cleft. They comprised 19 studies with different 
methodologies and results. Genes that were investigated includes: TGFA, MSX1, BCL3, 
MTHFR GSTP1, GSTT1, GSTM1, GSTM3, HIF1A, NAT2, EPHX1, UGT1A7, GST, AhR, 
TGFA, NOS3, RARA. Studies were either case-control or case-triad. The interaction 
between genetic variation at the TGFA locus and maternal smoking in the aetiology of OFC 
was investigated by Shaw et al. (1996), who found that the risk of CL/P increased from three 
to eleven-fold for infants with rare TGFA allele when mothers smoked more than 20 
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cigarettes per day. Lammer et al. (2004) have found that infants with a NAT1 polymorphism 
are at increased risk of NSOFC in mothers who smoke. In addition, Shi et al. (2007) found a 
significant interaction between maternal smoking, the UGT1A7 and GSTT1 null-gene in 
mother and  the occurrence of NSOFC in a case-control study (Shi et al., 2007). Zeiger et al. 
(2005) found a significant joint effect along with interaction between maternal smoking and 
TGFA for CP only.  Shi et al (2008) review concluded that GEI studies are still in their early 
stage. 
Further GEI was carried out by Chevrier et al. (2008) which did not confirm the relationship 
or interaction between maternal smoking and GSTT1 in NSOFC children. Recently, Wu et al. 
(2010) reported a significant relationship between maternal passive smoking and rs1044516 
(P= 0.041) using condition logistic regression and family based association test.   
The interaction between genes and smoking is still in its preliminary stage. There are many 
factors that need to be considered in future smoking-gene interaction NSOFC research. For 
example; the fact that NSOFC is a multifactorial birth defect with many genes to be 
investigated. In addition, researcher needs to consider smoking intensity levels and the type 
of smoking devices.    
 
2.10 Gene-gene interaction 
Blanton (2010) found a significant interaction between IRF6 (rs642961) and three SNPs 
located in 8q24 (rs1530300, rs17241253, and rs987525) in a non-Hispanic white population 
with NSOFC. In addition, in an Asian cohort, Butali et al. (2013) found statistically 
significant interactions between MAFB rs17820943 and PAX7 rs4920520 (P= 0.03), VAX1 
rs7078160 (P= 0.05) and VAX1 rs4752028 (P= 0.03); and between VAX1 rs7078160 and 
FOXE1 rs3758249 (P= 0.01). Moreover, there was evidence for interaction in a combined 
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sample across all populations between VAX1 rs4752028 and both 8q24 rs987525 (P= 0.03) 
and MAFB rs17820943 (P= 0.05).  
 
2.11 Review summary 
The aetiology of NSOFC is still unclear and needs further research and analysis. The 
literature reviled several important environmental factors such as; smoking, dietary 
factors and supplementations, medications and illness, and maternal exposure to 
chemicals.  However, most of these factors still need additional confirmation from future 
studies. For genetic factors, the only gene consistently found to be associated with oral 
cleft is IRF6. However, the aetiology of oral cleft varies geographically. Therefore, it still 
needs to be studied in Saudi Arabia   
2.12 Rationale for candidate gene selection 
2.12.1 Interferon regulatory factor 6 (IRF6)  
 IRF6 is the only gene to have shown consistently significant results across studies. 
 Results for IRF6 and OFC association reached genome wide significance. 
 IRF6 has shown genetic interaction with the locus (8q24) demonstrating the most 
significant association to NSOFC. 
2.12.2. Ventral Anterior Homeobox (VAX1) 
  Homozygosity of a rare variant of VAX1 has been found in a patient with 
consanguineous parents and NSOFC.   
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 Saudi Arabia has a high prevalence of consanguinity, suggesting the potential for 
high efficiency in detecting recessive genetic effects. 
 The locus containing VAX1, 10q25 has reached genome wide significance in NSOFC 
association studies. 
 There is a new evidence for significant association between VAX1 and NSOFC in the 
literature exposing an under-researched area.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
 
 
 
 
 
 
Chapter 3: Aims and objectives 
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3.1 Aims 
To investigate the birth prevalence, environmental risk factors, genetic risk factors, and 
gene-environmental interactions associated with non-syndromic orofacial cleft (NSOFC) in 
the Central and Western Region of Saudi Arabia. 
3.2. Objectives 
3.2.1 Prevalence of NSOFC and the influence of paternal consanguinity 
among CL/P and CP in Saudi Arabia 
1. Compare and describe the birth prevalence and other epidemiological 
characteristics of NSOFC in the Central and Western Region of Saudi Arabia. 
2. Compare and describe the birth prevalence of CL/P and CP in the Central 
and Western Region of Saudi Arabia. 
3. Investigate the prevalence of paternal consanguinity among different 
NSOFC sub-phenotypes and their severity. 
3.2.2 Environmental risk factors associated with CL/P and CP in Saudi 
Arabia 
4. Investigate the relationship between different demographic variables and NSOFC 
phenotypes (CL/P and CP). 
5. Investigate the relationship between socioeconomic status (SES) and NSOFC 
phenotypes (CL/P and CP). 
6. Investigate the relationship between family history and NSOFC phenotypes 
(CL/P and CP). 
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7. Investigate the relationship between maternal illnesses, medications, and 
multivitamin supplementation three months prior to pregnancy and in the 1st 
trimester period, and having offspring with CL/P or CP.  
8. Investigate the relationship between the different forms of parental smoking and 
having an infant with CL/P or CP. 
9. Investigate the relationship between maternal chemical exposure and maternal 
drinking water source type three months prior to pregnancy and in the 1st 
trimester period and having a child with CL/P or CP. 
3.2.3 Genetic risk factors associated with CL/P and CP 
10. Investigate the association between the infant-parental IRF6 gene polymorphisms 
and the parent of origin effect with regard to NSOFC and its phenotypes (CL/P 
and CP) in the Saudi population. 
11. Investigate the association between infant-parental VAX1 gene polymorphisms 
and the parent of origin effect with regard to NSOFC and its phenotypes (CL/P 
and CP) in the Saudi population. 
12. Investigate the relationship between IRF6 and VAX1 haplotypes and NSOFC 
occurrence among infants in Saudi Arabia. 
13. Investigate the relationship between parental consanguinity and infants' VAX1 
polymorphisms in the risk of NSOFC and its phenotypes (CL/P and CP) among 
infants in Saudi Arabia.  
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3.2.4 Gene-environmental interactions associated with NSOFC in Saudi 
Arabia 
14. Investigate the role of maternal gene-environmental interactions in the aetiology 
of orofacial clefts. 
 
3.3 Null hypotheses 
The following null hypotheses will be tested 
3.3.1  Prevalence of NSOFC and the influence of paternal consanguinity on 
CL/P and CP in Saudi Arabia 
1. There is no difference between the prevalence of CL/P and CP in Saudi Arabia and 
global figures. 
2. Parental consanguinity does not influence the prevalence of CL/P and CP in Saudi 
Arabia. 
3.3.2 Environmental variables 
3. There is no difference between cases and controls in their epidemiological variables. 
4. There is no difference between cases and controls in their socioeconomic status.  
5. Maternal medication, illness, fever or dietary supplementation in the pre-gestation 
and 1st trimester period do not influence the risk of having an infant with CL/P or CP 
in Saudi Arabia. 
6. There is no difference between cases and controls in the frequency of mothers 
experiencing stress during the pre-gestation and 1st trimester periods. 
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7. Maternal exposures to smoking, chemicals and paternal smoking do not increase the 
risk of having an infant with CL/P or CP in Saudi Arabia.  
8. The source or type of drinking water for pregnant woman does not play a role in 
NSOFC occurrence in Saudi Arabia. 
3.3.3  Genetic factors 
9. In an infant-parental triad study design, IRF6 and VAX1 polymorphic variants, 
transmission and frequency do not play a role in the occurrence of NSOFC (CL/P or 
CP) among infants in Saudi Arabia. 
10. IRF6 and VAX1 haplotypes are not risk factors in the occurrence of NSOFC among 
infants in Saudi Arabia.  
11. Parental consanguinity does not increase the risk of NSOFC in infants with VAX1 
rare alleles in Saudi Arabia.  
 3.3.4  Gene-environment interactions  
12. The interaction between maternal environmental exposures during the pre-gestation 
and 1st trimester periods and maternal IRF6 and VAX1 polymorphic variants does not 
play a role in the aetiology of NSOFC among infants in Saudi Arabia. 
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CHAPTER 4: Materials and Methods 
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4.1 Study design  
4.1.1. Study design (Part I) 
The case-control study was preceded by a retrospective descriptive study to measure the 
birth prevalence and characteristics of NSOFC in the Western and Central regions of Saudi 
Arabia, and to examine the influence of consanguinity on these statistics. 
4.1.2 Study design (Part II) 
A case-control study to investigate the environmental and genetic risk factors related to 
NSOFC using parent-child triads and matched controls in the Central and Western regions of 
Saudi Arabia was planned. One of the requirements of the Federal government for 
establishment of the study was to carry out the genetic analysis within Saudi Arabia. 
Therefore, the research was coordinated and funded by King Abdulaziz University in Jeddah, 
Saudi Arabia and the genetic analyses were carried out in the Princess Al-Johara Hereditary 
Centre. 
 
4.2 Study setting (Part I and II) 
Saudi Arabia is divided to three regions: Central, Western, and Eastern. The Western region 
comprises one third of the Saudi population and is further divided into Makkah and Maddina 
regions. The Central region consists mainly of the Riyadh region and comprises one-third the 
population (Ministry of Health, 2010). Cities with the highest population in each area were 
selected for this study (Riyadh, Jeddah, and Maddina), encompassing almost 50% of the 
Saudi population (Ministry of Health, 2010; Central Department of Statistics and 
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Information, 2013) (Figure 6). Each city was divided in to five districts (central, north, south, 
west and east), and from each district, the hospital with the highest number of referrals and 
births was selected (Table 4.1). These hospitals were governmental hospitals and were 
defined by the Ministry of Health (MOH) (2006) to include Ministry of Health hospitals, 
University hospitals, National Guard Hospitals, and the King Faisal Specialized Hospital and 
Research Centre. According to Almalki et al. (2011) the governmental hospitals delivers 
health care services to 79% of the Saudi population in Saudi Arabia. 
4.2.1 Subjects 
4.2.1.1. Subjects (Part I): 
Part I of the study included all infants born in the designated hospitals between the 1st 
of January 2010 and the 1st of January 2012. Hospitals that were excluded from part I 
were: the King Fahad Hospital in Jeddah as it is a trauma centres and do not have 
delivery units; and the Riyadh Military Hospital as it did not approve this part of the 
research because it has similar ongoing research.   
In Jeddah, the Al-Messadia Maternity Hospital and the Al-Azizia Maternity Hospital 
account for 67.3% of the total births in the Ministry of Health hospitals (Ministry of 
Health, 2010). In addition, Maternity and Children's Hospital is the only governmental 
maternity hospital and referral centre for OFC in Maddina. 
4.2.1.2 Subjects (Part II): 
Part II included infants with NSOFC, and their parents, born at or referred to the selected 
hospitals from January 2010 to January 2012. The age of inclusion for children ranged from 
0 to 18 months. These child-parent triads were clustered under the ‘study group’.  
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The ‘control group’ consisted of infants without clefts born at the hospital, or attending for 
vaccination or trauma. The control group was matched with the study group for age, gender, 
and hospital where they were seen. Ethnicity was not included in the matching criteria. 
 
 
Figure 4.1: Map of Saudi Arabia showing the cities that were included in the study 
(stars) and their associated regions. 
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Table 4.1: List of medical centres included in the study according to their regional location in each 
city. 
 
City Center North South West East 
Jeddah 
Maternity Hospital 
Almesadiah & 
King Fahad 
Hospital (KFH) 
King Abdulaziz 
University 
Hospital 
(KAUH) 
King 
Abdulaziz 
Medical City 
(KAMC) 
King Fahad 
Armed Hospital 
(KFAH) 
 
Maternity 
Hospital 
Alaziziah 
 
Riyadh 
King Fahad 
Medical City 
(KFMC) 
 
 
King Faisal 
Specialized 
Hospital and 
Research Centre 
(KFSHRC) 
King Saud 
Medical City 
Hospital 
Riyadh Military 
Hospital 
(RMH) 
 
 
Riyadh 
National 
Guard 
Hospital 
(RNGH)   
Maddina Maddina Maternity and Children Hospital 
 
4.2.2 Sample size prediction: 
 Preliminary sample size was predicted from the total births recorded for the Western 
and Central regions of Saudi Arabia as described in the statistical book of the MOH 
(2006) at 74,000 births/year. Comparing this figure with the global NSOFC birth 
prevalence (1.25/1000 births), it was expected that 185 infants would be born with 
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NSOFC over a 24 month period (Ministry of Health, 2006). However, when the 
prevalence was calculated for the total births reported by MOH in 2010 (98,000 
births/year), the number of NSOFC patients expected was 245 infants over two years. 
 The second approach to predicting sample size was through writing a systematic 
review for the prevalence of NSOFC in Saudi Arabia and Middle Eastern countries 
that have similar and comparable population characteristics (Sabbagh et al., 2012) 
(Appendix B1). Only eight articles were cited. Four studies were carried out in two 
regions in Saudi Arabia (Riyadh and Al-Qaseem). The prevalence of NSOFC 
reported varied greatly from 0.3 to 2.4 per 1000 live births with a mean prevalence of 
1.25 per 1000 births. The total births per year in the three cities included in the study 
were about 98,000, according to the MOH (2010) (Ministry of Health, 2010). 
Therefore, the expected number of NSOFC births in 24 months was calculated to be 
245 patients. 
 The third approach used to predict the sample size was through retrospective 
measurement of the prevalence of NSOFC in Jeddah in the year 2009. This was 
carried out by checking the medical records of the five hospitals selected in Jeddah. 
There were 15 non-syndromic cleft lip and/or palate living births born in 2010. This 
number was compared with the total number of live-births in 2010 at the same 
hospitals (23,970). Accordingly, the prevalence of cleft lip and/or palate in Jeddah 
was calculated to be 0.62 for every 1000 live-births. This leads to an estimated 
sample size much smaller than that calculated using the first approach. If we consider 
the other cities to have the same birth prevalence, the estimated number of patients 
with NSOFC in 24 months would only be 121 patients. 
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 Finally, the sample size was measured using Open Source Epidemiologic Statistics 
for Public Health (OpenEpi) online software for epidemiologic statistics: 
o  For part I (NSOFC prevalence) the sample size was measured using a 95% 
confidence interval and using the global prevalence figure (1.25/1000), 
yielding a recommended the sample size of 61,055 live-births.  
o For part II (case-control study) the sample size was measured using values of 
a 20% expected control exposure, an 80% power (the study has an 80% 
chance of ending up with a p value of less than 5%) and an OR of 2. The 
expected exposures and OR used were suggested according to the previous 
literature reports. By convention, the 80% statistical power is considered the 
standard and an acceptable power.  This resulted in a sample size of 187 cases 
and 187 controls. When the OR used was 2.5 the sample size was 105 cases.  
http://www.openepi.com/oe2.3/menu/openepimenu.htm. 
Therefore, on the basis of this sample size calculation and expecting 60% participation, it 
was decided that for part II case-control analysis a reasonable power could be achieved by 
recruiting a study sample of between 105 and 187 patients and a similar number of controls 
over a 24 month period.  
4.2.3 Methods 
4.2.3.1 Ethical approval: 
The following were submitted to each Institutional Research Review Board (IRB) in every 
research centre and medical health institution (Appendix A3 to A9): 
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 A research proposal describing the research purpose, materials and methods, 
projected outcome and patients’ expectations from the research. 
 The required request for research approval papers for each hospital and for the 
Ministry of Health were completed, signed by the Head of Preventive Dental 
Sciences Department in King Abdulaziz University, and attached to the research 
proposal. 
 A principle investigator (PI) working in each of the included hospitals was named. 
 Patient consent form that included a summary on the project, the procedure, what is 
expected from the patient, what is expected from the research, patient confidentiality, 
if any side effects exist and a space for patient signature. 
All of this information was sent with the ethical approval request (in both English and 
Arabic), along with the name of the person assigned to collect the data, to each IRB 
committee for approval.  
The dates for requesting and receipt of approval are listed in Appendices A10.   
 
4.2.3.2 Patients' Consent form: 
A consent form was prepared in Arabic and given to parents for signature after they were 
provided with verbal and written information concerning what, why and how the research 
was to be carried out. The form also included information on the side effects, confidentiality, 
freedom of participation, and what the family should expect from the research (see Appendix 
A4 and A8). Families were given 50 Saudi Riyals as a payment to compensate for their 
transportation and additional time. The consent form was signed prior to examination of the 
infant and was checked by the nurses in the unit as required by the Ministry of Health.  
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4.2.3.3 Principal Investigator (PI): 
All hospitals, except the Ministry of Heath, required a PI to receive research approval. In 
Jeddah, the PI was not directly involved in the research. However, in Riyadh and Maddina 
they were involved in data collection. The PIs were chosen either because they were 
interested in the research or were recommended by the institute. These PIs were our research 
collaborators and are listed in Table 4.2. 
Table 4.2: List of principal investigators (PI) that were chosen as a requirement for the research 
approval request for each medical centre in each city. 
 
City Hospital Name of PI 
Jeddah KAUH Prof. Najlaa Alamoudi 
NGH Dr. Mamoon Daghistani 
KFH Dr. Hassan Alamary 
Riyadh KFMC Dr. Sari Rabah 
KFSHRC Dr. Azizah Al-Johar 
KAMC Dr. Nasir Alhamlan 
KFH  Dr. Mustafa Hamdan 
RMH Dr. Eman Alnamnakani 
Maddina Maternity and Children Hospital Dr. Fatma Abdulhameed 
 
 
4.2.3.4 Ascertainment: 
In order to ensure that the best possible standards were utilized for ascertainment, procedures 
were followed according to the recommendations of the Global Registry and Database on 
Craniofacial Anomalies (2003) (World Health Organization, 2003). These procedures were 
adapted to suit local practice without allowing consistency and rigor to be negatively 
impacted as follows: 
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4.2.3.4.1 Number of examiners:  
The least possible number of examiners were selected in each city for recruitment of cases 
and controls. In Jeddah, all data were gathered by a single person, who was the main 
research coordinator for the Saudi-cleft project. In Maddina, there a single plastic surgeon 
was responsible for collecting the data. However, in Riyadh four examiners were trained for 
data collection: two were plastic surgeons and two were orthodontists. 
4.2.3.4.2. Examiner training:  
The examiners were trained at a formal meeting that provided detailed explanations 
regarding the questionnaire and the questionnaire coding manual (see Appendix A9). 
Furthermore, examiners were trained on how to use Oragene kits for saliva collection from 
parents and infants and how to store collected samples.  
4.2.3.4.3. Flexibility of the research protocol:  
The protocol for data collection was modified according to the needs and circumstances of 
each institution. It was distributed in files and listed under the institution name and code. A 
copy of the protocol was given to each research coordinator. Protocols were designed 
specifically for each hospital’s requirements. For example, the details of the storage and 
travelling protocols for hospitals in Riyadh and Maddina were modified respectively. 
4.2.3.4.4 Illustrative material to ensure clarity of the research protocol:  
A file containing complete information on the project including the summary of the research; 
proposal; materials and methods; flow chart, patients’ coding manual, and questionnaire is 
provided (see Appendix A3 to A9).  
4.2.3.4.5 Assurance of patient recruitment and sample size fulfilment:  
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For part I, the medical records were reviewed retrospectively every 6 months to ensure that 
all cases born in the designated hospitals were contacted.  
4.2.3.5 Methods of sample recruitment: 
4.2.3.5.1 Study group (part I and II): 
The study group was recruited and ascertained in three ways: 
 Nurses working in the neonatal unit, neonatal intensive care unit, plastic surgery and 
orthodontic clinics were instructed to contact the research coordinator immediately 
once a child with OFC was signed into their unit. Furthermore, the research 
coordinator inquired regarding new cases every two weeks.  
 Records of the neonatal units since June 2009 were reviewed retrospectively for all 
infants born with non-syndromic OFC. These infants were contacted and given an 
appointment in the dental clinic for examination and sample collection. 
 Every 6 months the neonatal unit records were reviewed to ensure that all cases born 
in the selected hospitals were examined. If not, missing cases were contacted.   
4.2.3.5.2 Control group (part II): 
In part II of the study, the control group was recruited from the same institutions in the same 
period of time as were the study group (from January 2010 to January 2012). Controls were 
recruited according to the following criteria: 
 If an NSOFC infant was encountered immediately after birth, the next infant to be 
born in the same hospital with the same gender was selected as a matched control; or  
  If the NSOFC infant was a referred case, a control matched for age and gender was 
recruited from primary health care clinics (vaccination clinics) or from infants 
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admitted to the pediatric unit for reasons other than birth defects or chronic disease 
(e.g., trauma or GIT infections).  
 
4.2.3.5.3 Comparison group (part I): 
To measure the NSOFC prevalence in part I of the research, the total births in the designated 
hospitals from the 1st of January 2010 to the 1st of January 2012 were retrieved from the 
statistical records of each hospital.  
 
4.2.3.6. Clinical examination: 
Clinical examination of NSOFC infants in parts I and II was carried out in pediatric neonatal 
unit, pediatric plastic surgery units or in orthodontic clinics using lights and mirrors to detect 
the type and characteristics of the clefts utilizing the International Clearinghouse for Birth 
Defects Monitoring System (ICBDMS 1991; ICBDMS 2001). The research coordinator in 
each institution relied upon the diagnosis of the clinical geneticist, if available, or 
pediatrician for syndrome exclusion following cleft examination. If the case was ascertained 
prior to surgery, a picture was taken to document the cleft phenotype. The NSOFC was 
classified according to the LASHAL classification system as follows (Kriens, 1989): 
 LASHAL stands for Lip, Alveolus, Soft Palate, Hard Palate, Alveolus and Lip. 
 When read with left sided letters, it indicates a right side cleft. 
 When in UPPER CASE, it indicates a complete cleft. 
 When in lower case, it indicates partial or incomplete clefting. 
Submucosal cleft palate was excluded from the diagnoses because of poor ascertainment and 
therefore variable detection rates. In many instances it was overlooked by the nurses and 
upon subsequent diagnosis, the research team was not contacted. 
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4.2.3.7 Data collection: 
4.2.3.7.1. Questionnaire (environmental factors in part I and part II): 
The questionnaire was written in both Arabic and English on separate forms. The Arabic 
form was for parents to view while in the waiting area to be aware of the questionnaire’s 
content. The research coordinator then interviewed the parents after the consent form was 
signed. It took approximately 15 minutes to fulfill these steps. The questionnaire included 
questions related to (see Appendix A5): 
o general information, including: date of participation, name of the hospital, place of 
birth, residence, day of birth (Arabic or English), the, name of the patient and their 
parents, and contact numbers; 
o demographic data and pregnancy history, including: maternal age at delivery, 
maternal weight/height, length of pregnancy, time interval between the NSOFC 
infant and prior sibling where applicable, prenatal visits, child birth order, neonatal 
length, neonatal weight, and neonatal head circumference;  
o socioeconomic status: parents’ educational level, mother’s working status, type of 
occupation during pregnancy, family monthly income "less than 4000RS (threshold 
for Saudi Salary, https://online.hrdf.org.sa/FAQ/faq.html), 4000 to 10,000, more than 
10,000" and residency; 
o family history of parental consanguinity and type of consanguinity; 
o maternal exposures prior to pregnancies and in the 1st trimester periods including: 
medication, illness, disease, supplementation, tobacco, and chemicals; 
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o maternal stress as estimated by relevant questions on stressful events for the mother 
that occurred prior to pregnancies and in the 1st trimester periods. The questionnaire 
included family problems, severe morning sickness, abdominal pain, and depression.  
 
4.2.3.8 Sources of DNA for genetic analysis (part II): 
Sources of DNA for genetic analysis included saliva or blood samples. Our rationale for 
choosing the source of DNA and methods for DNA extraction and storage is explained 
below. 
4.2.3.8.1 Saliva samples:  
Saliva samples were collected from infants and parents in both groups. The donor was 
instructed not to eat, drink, or smoke up to 30 minutes prior to providing the sample. For 
parents, OG-500 Oragene kits were used (see Appendix A6). Parents were asked to spit 2 ml 
of saliva into the collection tube of the kit in order to obtain 110 μg of purified DNA, 
according to the manufacturer’s instructions. It took about 7 minutes to obtain the required 
amount.   
For infants, the OG-575 Oragene Kit was used to collect 0.75 ml of saliva. This kit contained 
a sponge that was applied to the sublingual area in the infant’s mouth to absorb saliva. The 
sponge was then was squeezed against the V-notch in the collection tube and reapplied as 
necessary (see Appendix A7). It could take from 15 to 40 minutes to collect a sufficient 
amount of saliva from infants depending on the circumstances. If the newborn infant was 
asleep a much longer collection period was needed. The collected saliva was expected to 
yield 17.3 μg of DNA according to the manufacturer’s instructions.  
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Both kinds of samples were then at room temperature (less than 30°C) until they were sent 
for DNA extraction processing in the genetics laboratory, where they were stored at 4°C. 
4.2.3.8.1 Blood samples:  
A blood sample was taken only if the clefted infants were undergoing surgery under general 
anaesthesia and had an intravenous (IV) line. In this circumstance, it was considered more 
convenient to collect blood than to obtain saliva. The blood samples were collected in an 
EDTA anticoagulant tube and stored at temperatures less than 4°C until they were sent to the 
genetics laboratory for DNA extraction. If they were obtained from another city they were 
transported and stored in wet ice. In the genetics laboratory they were stored at 0°C. 
 
4.2.3.9 Coding system: 
Each questionnaire from the study and control groups had a code consisting of two parts with 
6 digits as follows: 
4.2.3.9.1 The questionnaire code: 
 Centre code: consisted of two digits. The first digit indicated the name of the city; the 
second digit indicated the name of the hospital. The list of included medical centres is 
presented in Appendix A10. 
 Family code: started with either a 1 (study group) or a 2 (control group). The 
remaining number indicated the serial number. 
4.2.3.9.2 Sample collection tube code: 
Each sample tube was coded with the same code as on the questionnaire label, with the 
addition of a letter identifying from which family member the sample was obtained: 
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 M: mother’s sample; 
 F: father’s sample; and 
 C: child’s sample.   
4.2.3.9.3 Genetic laboratory coding:  
DNA extracted from saliva or blood samples of cases and controls was labelled with new 
family codes serialized from 1 to 300 with addition of the family member code (M, F, and I 
[infant]). The code was matched with the data collection code in SPSS tables for 
identification. 
4.2.3.10 Pilot study: 
A pilot study was carried out to check the validity of the questionnaire. Ten patients were 
interviewed using the proposed questionnaire. Accordingly, some questions were rephrased 
or modified for the final version of the questionnaire. 
In addition, three saliva samples were collected to check the quality and quantity of DNA 
extracted from saliva using the Oragene kits. The DNA extracted proved to be satisfactory in 
terms of yield and quality (genomic DNA were intact and appear as a compact, high-
molecular-weight band with no low-molecular-weight smears in agarose gel electrophoresis).  
4.2.3.11 Molecular genetic analysis: 
Molecular genetic analysis included two main steps: DNA extraction and PCR. For IRF6 the 
three SNPs included in this study were analysed using restriction-digestion PCR. For VAX1, 
real-time PCR was used for analysis of variant alleles.  
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4.2.3.11.1 DNA extraction: 
DNA extraction was carried out using the QIAamp DNA Mini Kit (Catalogue # 51306; 
Qiagen, Canada) according to manufacturer’s protocol with modification of the starting 
quantity saliva (500 µl instead of 200 µl). The detailed protocol is presented in Appendix 
A11.   
The purity and quantity of extracted DNA was measured using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, Delaware, USA). Estimation of the DNA 
concentration in different samples was carried out by measuring the optical density at 260 
nm according to the following equation:  
Conc. (μg/ml) = OD260 × 50 × dilution factor.  
The DNA quality was also evaluated using agarose gel electrophoresis (1% in 1× TBE 
(Tris/Borate/EDTA) buffer stained with Sybr Safe DNA Gel Stain (Invitrogen, California 
USA)). The result showed good quality DNA bands (genomic DNA were intact and appear 
as a compact, high-molecular-weight band with no low-molecular-weight smears in agarose 
gel electrophoresis) (Figure 4.2). DNA passing quality control measures was subject to 
subsequent amplification by polymerase chain-reaction (PCR) and genotyping. 
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Figure 4.2: A) A Nanodrop 2000 spectrophotometer used to measure DNA purity 
and quantity. B) Gel electrophoresis apparatus (1% agarose in 1× TBE buffer) 
used to evaluate the quality of extracted DNA. C) Gel Electrophoresis image 
showing good quality bands of DNA extracted from saliva (genomic DNA were 
intact and appear as a compact, high-molecular-weight band with no low-
molecular-weight smears) (analysis carried out by Edris and Al-Mahdi). 
4.2.3.11.2 Genotyping for IRF6:  
4.2.3.11.2 .1 Primer design: 
Three primers pairs were designed to be specific for the three SNPs in IRF6. The primers 
designed for rs2013162 and rs2235375 were identical to those used by Huang et al. (2009), 
as was a universal M13 primer used for sequencing purposes. However, a new primer was 
designed for rs2235371 for this study using Primer Blast. Primers for IRF6 SNPs are listed in 
Table 4.3. 
 
  
A 
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Table 4.3: List of primers and amplification annealing temperature/melting condition used for 
IRF6 SNP PCR. 
 
IRF6 SNP Primers Annealing temperature 
rs2013162 
F: 5′- TGTAAAACGACGGCCAGTCCCTGGGAT 
GAGAAGGATAA - 3′ 
R: 5′- CAGGAAACAGCTATGACCACCTCTGACT 
CCCACTTGCT - 3′ 
57°C 
rs2235375 
F: 5′ - ACAGGAAAGAGTCTATAATAG 
AAGCAGAAGATC - 3′ 
R: 5′ - CCCAAAACTGAACCCCTGGAGAT - 3' 
63°C 
rs2235371 
F: 5′ - TGTAAAACGACGGCCAGTCTCTGTCC 
ATGACGTCCAGC - 3′ 
R: 5′- CAGGAAACAGCTATGACCGAGTACGGG 
CAGACCATGAC - 3′ 
57°C 
 
a. PCR: 
The PCR amplification reaction was carried out in a 25-µl reaction volume using the 
GoTaq
®
 Green Master Mix (Promega USA, Cat. #M7122) containing 1× PCR buffer, 1.5 
mM MgCl2, 0.2 mM dNTPs, and 2 units of Taq-DNA polymerase. Ten picomoles of each 
forward and reverse primers were added to the reaction mix along with 25 ng template DNA. 
PCR amplification was performed in a Veriti Applied Biosystems thermal cycler (Applied 
Biosysems, California USA) (Figure 4.3), programmed to complete 35 cycles after an initial 
denaturation cycle of 4 min at 94°C. Each amplification cycle consisted of a denaturation 
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step (94°C for 30 s), an annealing step (as indicated in Table 4.3 for 30 s), and an extension 
step (72°C for 30 s), followed by a final extension cycle (7 min at 72°C) in the final cycle. 
 
Figure 4.3: Applied Biosystems (AB) machine used for PCR. 
 
b. Restriction digestion: 
Three single-nucleotide polymorphisms (SNPs) in the IRF6 gene were evaluated: rs2013162, 
rs2235375, and rs2235371, using restriction digestion of the PCR products, which was 
carried out using Thermo Scientific*HpyF3I (DdeI), Thermo Scientific Taql, and Thermo 
Scientific*MboI (Dpnll) restriction enzymes (Table 4.4). Positive controls for restriction 
endonuclease digestion were used for 3 to 5 of the samples in each of the restriction 
digestion reaction groups. Few study samples (10 cases) were sequenced to insure the quality 
of the PCR and of restriction digestion as an effective method to identify the presence of 
SNP variants (see section d, below).  
c. Detection of PCR products: 
PCR products were detected using agarose gel electrophoresis (2% in 1× TBE buffer), 
stained with Sybr Safe DNA Gel Stain (Invitrogen, California USA) and visually examined 
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using a UV transilluminator and photographed using a CCD camera (Gel Doc XR+, Bio-Rad 
Laboratories, California, USA) (Figure 9 (B) and Figure 9). 
   
(A)                            (B)                            (C) 
Figure 4.4: Agrose gel electrophoresis of Restriction fragment length polymorphism 
paterns for IRF6 SNPs. (A) IRF6 rs2235371; lane M is the 50-bp DNA marker, lane 
1 is homozygous C/C and lane 2 & 3 is heterozygous C/T. (B) IRF6 rs2013162; 
lane M is the 100-bp DNA marker, lane 1 is homozygous C/C and lane 2 
heterozygous C/A and lane 3 is homozygous A/A. (C) IRF6 rs2235375; lane M is 
the 100-bp DNA marker, lane 1 is homozygous G/G and lane 2 heterozygous C/G 
and lane 3 is homozygous C/C (analysis carried out by Edris and AL-Mahdi). 
 
Table 4.4: List of; IRF6 SNPs mutation sites and alleles; restriction enzymes used and expected 
fragment size formed for IRF6 gene analysis 
 
Gene SNP Position Allele Restriction Enzyme Fragments size after digestion (bp) 
IRF6 
rs2013162 In 5 exon C*/A HpyF3I (TC^TC) CC 300, AA 220, CA 80 
rs2235375 6,7 splice C*/G Taql (T^CGA) CC 151, GG 118, CG 33 
rs2235371 In 7 exon C*/T MboI (^GATC) CC 232, TT 135, CT 97 
*Common allele 
 
d. Sequencing: 
Sequencing was performed using the 3500 Genetic Analyzer (Applied Biosystems, 
California, USA) on a random collection of 10 samples following IRF6 SNP PCR 
M     1      2       3  M     1      2       3  M     1      2       3  
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amplification to determine the accuracy of the restriction-digestion PCR technique (Figure 
4.5). There was no difference between the results from both techniques; therefore, we 
continued our study using the restriction digestion PCR procedure. 
 
Fig 4.5: The 3500 Genetic Analyzer used for sequencing a random sample of IRF6 
amplification products. A, B and C show the resulting chromatograms from 
sequencing three samples for rs2235371. (A) A sample containing the 
homozygous common allele genotype (CC); (B) A sample containing the 
homozygous rare allele genotype (TT); and (C) A sample that carries the 
heterozygous allele genotype (CT) (analysis carried out by Edris and Al-Mahdi)  
 
4.2.3.11.3 Genotyping of VAX1:  
a. DNA probes: 
Two DNA probes were used to detect the VAX1 rs7078160 and rs4752028 SNPs. They were 
purchase from Applied Biosystems which was commercial, provided with reference 
numbers; C_27883342_10 for rs4752028 and C_3197518_10 forrs7078160 (TaqMan® SNP 
Genotyping Assay).  
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b. Real-time PCR: 
The 7500 Fast Real-Time PCR System (Applied Biosystems), TaqMan
®
 Genotyper Software 
(Applied Biosystems) and TaqMan
®
 SNP Genotyping Assays were used for genotyping the 
two VAX1 SNPs. Once the SNPs were identified within the program, the sample could be 
applied to the system and the readout was displayed as seen in Figure 4.6. Each colour 
represents a SNP genotype: red indicates the homozygous minor allele; green represents the 
heterozygous genotype; and blue represents the homozygous normal allele. Results were 
analysed using TaqMan® Genotyper Software, a SNP genotyping data analysis tool 
specifically for use with TaqMan® SNP Genotyping Assays. 
  
Figure 4.6: Real time PCR used for genotyping VAX1 rs4752028 and rs7078160 
SNPs. A and B are scatter plots (Allelic Discriminations Plots) generated by the 
7500 Fast Real Time PCR Software for rs4752028 and rs7078160, respectively. 
 
4.3 Gene-Environment Interaction (GEI) 
 
We hypothesized that environmental factors and maternal exposures strengthen or diminish 
the effect of maternal rare alleles, which in turn affect the risk of having an infant with 
NSOFC. These factors include maternal medication and supplementation, maternal diseases, 
133 
 
maternal stress and parental smoking. Oral cleft was not sub-grouped to CL/P and CP, as the 
number of cases was not large enough to subdivide or stratify. Two study designs were used 
to measure GEI: case-only and case-control study designs. In the case-only study design, the 
interaction between maternal SNPs (genotypes and allele) and environmental factors were 
analysed by measuring the distribution of maternal genotypes and alleles according to 
exposure/no-exposure to environmental factors among oral cleft cases. In the second 
approach, the frequencies of maternal genotypes (homozygous common allele, homozygous 
rare allele and heterozygous allele) in cases were compared to controls according to the 
different environmental factors. 
 
4.4 Statistical analysis 
4.4.1 Questionnaire data entry 
The data entry was carried out by the main research coordinator using the SPSS Statistics 19 
program (SPSS Inc., Chicago, IL, USA).  
4.4.1.1 Double data entry: 
Twenty percent of the data points entered into the SPSS program were re-entered to ensure 
that discrepancies in data entry were minimized. 
4.4.2 Descriptive data 
The data was analysed and compared using SPSS.  Groups were displayed by frequencies 
and percentages. The type of clefts and their descriptive statistics were displayed by 
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frequency and percentage values for categorical variables, or by means and standard 
deviation values for continuous variables. Chi square and t-tests were used for comparisons. 
4.4.3 Environmental factors related to oral cleft (CL, CLP and CP) 
The different environmental factors and their degree of association to CL, CLP and CP were 
estimated by measuring the odds ratio (OR), respective 95% confidence intervals (95% CI) 
and using logistic regression analysis.  Chi square and t-tests were used for comparisons.  
4.4.4 Genetic factors 
Several genetic statistical analyses were carried out for IRF6 (rs2013162, rs2235375, and 
rs2235371) and VAX1 (rs4752028 and rs7078160) to measure their associations with CL/P 
and CP. 
 
4.4.4.1 Hardy-Weinberg equilibrium 
Hardy-Weinberg equilibrium was determined using an online program 
(http://www.oege.org/software/hwe-mr-calc.shtml) that compares differences between the 
observed and expected values of the included homozygous and heterozygous genotype 
frequencies. The chi-squared goodness of fit test was measured with P-values at 0.05 
considered significant. 
 
4.4.4.2 Family-based analysis 
Transmission disequilibrium testing (TDT) was performed using the Family-Based 
Association Test (FBAT) test. PLINK (version  v1.07), an open-source whole genome 
association toolset that is designed to perform a range of basic, large-scale analyses in a 
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computationally efficient manner, was also used to measure TDT and to separately analyse 
parental genotype transmission in order to determine the parent of origin (POO) of alleles 
(Purcell et al., 2007) (http://pngu.mgh.harvard.edu/purcell/plink/). 
4.4.4.3 Case-control infant parental triad study design  
Infant-parental triad genotypes (homozygous common allele, homozygous rare allele and 
heterozygous allele) and allele types (rare vs. common) and their degree of association with 
NSOFC were estimated by measuring the odds ratio (OR) and respective 95% confidence 
intervals (95% CI). Genotype and allele frequencies among cases (NSOFC, CL/P and CP) 
and controls were compared using a chi square test with a P-value level of 0.05 using SPSS. 
Chi square test and the P-value were adjusted using Bonferroni correction methods between 
cases and controls. The degree of association between genotype and allele frequencies with 
NSOFC were estimated by measuring the OR and respective 95% confidence intervals (95% 
CI) using an online program found at http://www.quantpsy.org/chisq/chisq.htm.  
 
4.4.4.4 Haplotype-based association test (HBAT) 
The haplotype-based association test (HBAT) was used to investigate haplotypes associated 
with CL/P and CP.  
4.4.4.5 Maternal infant gene-gene interaction  
The interaction between maternal variants and infant variants was analysed using general 
log-linear model using SPSS software. The P-value level indicating a significant interaction 
prediction was set at a 0.05 confidence interval (CI).     
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4.4.5 Gene-environmental interaction 
Two study designs were used to assess gene-environmental interactions including case-only 
and case-control.  
 
4.4.5.1 Case-only study design 
Interactions between maternal SNPs (genotypes and allele) and environmental factors were 
analysed by measuring the distribution of maternal genotypes and alleles according to 
exposure/no-exposure to environmental factors among oral cleft cases.  The common allele 
and null maternal exposure were set as references in our calculation. For the type of drinking 
water source, tap water with the common allele was set as the reference. Analysis was 
carried out using chi square test and P-value level at 0.05 using SPSS. Their degrees of 
association with NSOFC were estimated by measuring the OR and respective 95% 
confidence intervals (95% CI). If one cell contained a zero value, only the P-value was 
calculated. No analyses were carried out if more than one cell contained a zero value   
Finally, multinominal logistic regression analysis was carried out using SPSS to overcome 
confounding factors. Factors that showed significant gene-environmental interactions when 
analysed alone in the previous analysis were entered in the logistic regression.   
 
4.4.5.2 Case-control design  
For the case-control design, we compared differences between the frequency of maternal 
genotypes (homozygous common allele, homozygous rare allele and heterozygous allele) to 
environmental factors using a chi-square test, and the P-value was adjusted by Bonferroni 
correction methods between cases and controls using SPSS. OR and 95% CI were measured 
for factors with P-values≥ 0.05 using MedCalc (user-friendly statistical software). For the 
type of drinking water source, tap water with the common allele was set as a reference. If 
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one cell contained a zero value, only the P-value was calculated. No analyses were carried 
out if more than one cell contained a zero value.   
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Chapter 5: Results  
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5.1 Ethical approval 
The research and ethical approval took an average of 3 months to be established in most of 
the medical institutes. However, some institutions took longer time (9 months and more). 
One hospital, King Faisal Specialized Hospital and research center did not accept the 
research as they had other similar researches being conducted in their hospital and did not 
want to distress their patients further. Ethical approvals are presented in appendix A4.   
5.2 Sample characteristics 
The total number of cases recruited in the two-year study was 217 infant-parental triad; 136 
(62.7%) males and 81 (37.3%) females. Of these, 208 (95.9%) answered the questionnaire 
and were included in the case-control study to measure the effect of environmental factors; 
171 (68.8%) infant-parental triad participated in genetic analysis by consenting to saliva 
sample collection; 133 (61.3%) infant were born in the designated hospitals and their data 
was used to measure the prevalence of cleft phenotypes. Sample distribution according to 
recruitment site and NSOFC phenotype description is presented in Appendix A13. Some of 
the infants (45) included in the prevalence data did not participate in the case-control study. 
Two hundred and forty-five normal non-cleft infants participated in the study as controls: 
141(57.6) males and 104 (42.4) females. Of these, 244 (99.6%) answered the questionnaire, 
and 173 (70.6%) complete infant-parental triads participated in the genetic analysis by 
providing saliva samples. The sample description is displayed in Figure (5.1). However, 
more infant-mother pairs (189 (74.4%)) agreed to give their saliva.   
There was no statistically significant difference between cases and controls with respect to 
gender.  
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Figure 5.1: Bar chart showing subjects who participated in the study from January 
2010 to January 2012. (a) Total subjects recruited for our study. (b) Subjects with 
NSOFC born in the designated hospitals from January 2010 to January 2012 were 
compared to the total number of births (114,035 births) to measure the prevalence 
of NSOFC. (c) Subjects who completed the questionnaire to assess environmental 
risk factors. (d) Infant-parental triads that agreed to give saliva for genetic analysis 
 
 
5.3 Part I: Prevalence of NSOFC and the influence of paternal 
consanguinity among CL/P and CP in Saudi Arabia  
 
From January 2010 to January 2012 there were 114,035 infants born in the designated 
hospitals. A hundred and thirty-three of these infants were born with NSOFC. Therefore, the 
total birth prevalence of NSOFC in Saudi Arabia was found to be 1.17/1000 live births.  
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5.3.1 Characteristics of NSOFC epidemiology in Saudi Arabia 
Table 5.1 shows the prevalence of NSOFC cases according to their sub-phenotype and city of 
origin. The prevalence of CL (0.46/1000 live births) was higher than that of CLP (0.42/1000 
live births) and CP (0.28/1000 live births). The prevalence of CL/P was 0.88/1000 live births.  
The prevalence of NSOFC was the highest in Maddina (1.88/1000 live births), followed by 
Riyadh (1.07/1000 live births) with the lowest prevalence in Jeddah (0.8/1000 live births).  
Table 5.2 shows the distribution of NSOFC sub-phenotypes in the three cities of Saudi 
Arabia according to city of birth and gender. In unilateral CL/P, the prevalence of the left-
side CL/P sub-phenotype (29 (21.7%) CL cases and 16 (12.5) CLP cases) was higher than for 
right-side CL/P cases (13 (9.7%) CL or CLP cases). In bilateral CL/P, the frequency of 
bilateral CLP was 19 (14.2%) cases, which was higher than the frequency of bilateral CL (12 
(9%) cases). Complete bilateral CLP (13 (9.7%) cases) frequency was high compared to the 
frequency of incomplete bilateral CLP (6 (4.5%) cases) and bilateral complete CL (2 (1.5%) 
cases) with higher male ratio (10 cases ( 76.9%)) compared to females (3 cases (23.1%)).       
The prevalence of NSOFC and CL/P was higher in males (82 cases (61.7%) and 66 cases 
(65.3%) respectively) than in females (51 cases (38.3%) and 35 cases (34.7%), respectively). 
On the other hand, females and males showed a similar ratio for CP (1:1). There were 
statistically significant differences between the three NSOFC phenotypes (CL, CLP and CP) 
based on gender (P= 0.035). After adjustment using Bonferroni’s correction methods, CL 
was found to occur at levels significantly higher in males than in females. The prevalence of 
NSOFC was also described and discussed in paper 4, 5& 6  (Appendix B 4, 5 & 6). Bilateral 
complete CLP was more frequent in males (10 cases) compared to females (three cases) 
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Table 5.1: Birth prevalence of NSOFC from Jan 2010 to Jan 2011 according to place of birth and 
OFC phenotype in three large cities in Saudi Arabia. 
 
City Hospital 
Total 
births 
CL CLP CP 
Total 
NSOFC 
Birth 
prevalence 
NSOFC/1000 
births 
Riyadh 
King Saud Medical City 13,252 6 4 6 16 1.2 
Riyadh National Guard Hospital 16,926 2 6 9 17 1.0 
King Fahad Medical City 9,827 5 4 1 10 1.0 
Total 40,005 13 14 16 43  
Birth prevalence /1000 births  0.32 0.35 0.4  1.07 
Jeddah 
Al-Messadia Maternity Hospital 13,004 3 3 2 8 0.62 
King Abdulaziz University 8,725 3 7 3 13 1.5 
National Guard Hospital 9,690 5 4 0 9 0.93 
King Fahad Armed Hospital 10,969 3 1 1 5 0.46 
Al-Azizia Maternity Hospital 3,508 2 0 0 2 0.57 
Total 45,896 16 15 6 37  
Birth prevalence /1000 births  0.35 0.33 0.13  0.81 
Maddina 
Maddina Maternity Hospital 28134 24 19 10 53  
Births prevalence /1000 births  0.85 0.67 0.36  1.88 
Three cities together 
Total births in three cities 114,035 53 48 32  133 
Total births prevalence in three 
cities /1000 births 
 0.47 0.42 0.28  1.17 
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Table 5.2: Distribution of NSOFC sub-phenotypes born in 2010 and 2011 in the three cities of 
Saudi Arabia according to city of birth and gender. 
 
Phenotype Sub-phenotype 
Riyadh (%) Jeddah (%) Maddina (%) Total  
(%)  Male  Female Male  Female Male  Female 
CL 
N= 53 
Male: 40 
Female: 13 
Right incomplete CL 1 (3.7) 1 (6.3) 3 (9.7) 0 3 (9.7) 1 (4.5) 9 (6.7) 
Right complete CL 0 1 (6.3) 0 0 2 (6.5) 1 (4.5) 4 (3) 
Left incomplete CL 6 (22.2) 1 (6.3) 2 (6.5) 2 (8.7) 5 (16.1) 2 (9.1) 18 (14.2) 
Left complete CL 1 (3.7) 1 (6.3) 2 (6.5) 0 6 (19.3) 0 10 (7.5) 
Bilateral incomplete CL 1 (3.7) 0 4 (12.9) 2 (8.7) 3 (9.7) 0 10 (7.5) 
Bilateral complete CL 0 0 1 (3.2) 0 0 1 (4.5) 2 (1.5) 
CLP 
N= 48 
Male: 26 
Female: 22 
Right incomplete CLP 0 0 2 (6.5) 0 0 0 2 (1.5) 
Right complete CLP 1 (3.7) 1 (6.3) 2 (6.5) 2 (8.7) 2 (6.5) 3 (13) 11 (8.2) 
Left incomplete CLP 1 (3.7) 1 (6.3) 0 0 1 (3.2) 1 (4.5) 4 (3) 
Left complete CLP 1 (3.7) 3 (18.8) 0 1 (4.3) 2 (6.5) 5 (21.7) 12 (9) 
Bilateral incomplete CLP 1 (3.7) 0 3 (9.7) 0 0 2 (9.1) 6 (4.5) 
Bilateral complete CLP 4 (14.8) 1 (6.3) 3 (9.7) 2 (8.7) 3 (9.7) 0 13 (9.7) 
CP 
N= 32 
 Male: 16  
Female: 16 
CP  10 (37) 6 (37.5) 2 (6.5) 4 (17.3) 4 (12.9) 6 (46.1) 32 (23.9) 
 Total 27 (100) 16 (100) 24 (100) 13 (100) 31 (100) 22 (100) 133 (100) 
 
5.3.2 Prevalence of parental consanguinity in NSOFC infants 
The prevalence of parental consanguinity was measured for NSOFC infants born in the 
designated hospitals. Paternal consanguinity information was missing for ten cases, which 
were excluded from this analysis. The number of NSOFC infants with parental consanguinity 
144 
 
was 81 (65.9%) cases: 41 (77.4%) in Maddina; 23 (56.1%) in Riyadh; and 17 (58.6%) in 
Jeddah, with no significant differences between the values (P= 0.063). Consanguineous 
marriages involved first cousins in 44 NSOFC cases, which accounted for 54.3% of 
consanguineous marriages in NSOFC: 22 (53.7%) in Maddina, 12 (52.2%) in Riyadh and 10 
(58.8%) in Jeddah. 
The prevalence of consanguinity was higher in CP (78.6%) than CL/P (61.1%) but the 
difference was not significant (P= 0.119). Additionally, the prevalence of severe CL/P 
(complete clefting of the lip or of bilateral cleft) was higher in infants with consanguineous 
parents than with non-consanguineous parents, but the differences were not significant (P= 
0.123; P= 0.534, respectively). (See Table 5.3). 
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Table 5.3: Distribution of cases in all three cities combined according to consanguinity and their 
relationship to NSOFC gender, phenotype and severity. 
 
Type of cleft 
phenotype  
Consanguinity 
N (%) 
Non-consanguinity 
N (%) 
Total 
N (%) 
X2 (df), P-value 
OR (95% CI) 
Gender  
Male 49 (63.3) 28 (36.4) 77 (100) 
0.45 (1), 0.559 
0.77 (0.35-1.67) 
Female 32 (69.6) 14 (30.4) 46 (100) 
Total  81 (65.9) 42 (34.1) 123* (100) 
Type of NSOFC 
CL/P 59 (61.1) 36 (37.9) 95 (100) 
2.61 (1), 0.119 
0.45 (0.17-1.21) 
CP 22 (78.6) 6 (21.4) 28 (100) 
Total 81 (65.9) 42 (34.1) 123* (100) 
Type of CL/P 
CL 31 (63.3) 18 (36.7) 49 (100) 0.06 (1), 0.835  
1.11 (0.48-2.54) CLP 28 (60.9) 18 (39.1) 33 (100) 
Total 59 (62.1) 36 (37.9) 95 (100) 
CL extension in CL/P 
Complete CL 33 (70.2) 14 (29.8) 47 (100) 0.39 (1), 0.123 
1.96 (0.83-4.65) 
Incomplete CL 24 (54.5) 20 (45.5) 44 (100) 
Total 57 (62.6) 34 (34.4) 91 (100) 
CL site in CL/P 
Unilateral CL 39 (60) 26 (40) 46 (100) 2.38 (1), 0.534 
0.75 (0.3-1.86) 
Bilateral CL 20 (66.7) 10 (33.3) 30 (100) 
Total 59 (62.1) 36 (37.9) 65 (100) 
*The total number is less than 133 because of ten cases with missing information. 
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  5.4 Part II: Environmental risk factors in the aetiology of 
NSOFC 
Of the 217 NSOFC cases, 208 completed the questionnaire for this part of the study as well as 
244 controls. Three of NSOFC group answered the questionnaire but were not examined. 
Therefore; they were excluded from the analysis. 
5.4.1 Sample characteristics 
Most of the NSOFC cases and controls were of Saudi descent: 184 (88.4%) of the cases and 
214 (87.7%) of the controls. Other nationalities included other Middle Eastern countries (16 
(7.7%) cases and 15 (6.1%) controls); North African (2 (1%) cases and 5 (2%) controls); 
Asian (6 (2.9%) cases and 6 (2.5%) controls); and other African countries (4 (1.6%) 
controls). There was no significant difference between cases and controls with respect to 
infant nationality (P= 0.32) (see Appendix A14). Prenatal diagnosis was reported in 199 
NSOFC cases. Of these, the prevalence of NSOFC cases that were prenatally diagnosed 
were: 16 (8%) CL, 25 (12.6%) CLP and 4 (2%) CP. There was a statistically significant 
difference between the three NSOFC sub- phenotypes (P= 0.002). 
NSOFC phenotype was described for 205 cases: 78 (38%) CL; 74 (36.8%) CLP; and 53 
(25.8%) CP. The cases and controls were aged 18 months or less and were matched in age, 
gender and hospital where they were ascertained. 71 cases and 104 controls were from 
Jeddah; Riyadh provided 100 cases and 103 controls; and Maddina provided 34 cases and 37 
controls (see Appendix A13). There was no statistically significant difference between cases 
(129 (62% males and 79 (38%) females) and controls (140 (57.4%) males and 104 (42%) 
females) with respect to gender (P= 0.3). 
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The prevalence of NSOFC cases with associated anomalies was 42 (20.8%) cases (9 CL 
cases (11.7%); 17 CLP cases (23.9%); 16 CP cases (31.4%)). These anomalies were single or 
combined in NSOFC infants and included cardiovascular defects (17 (27%) cases); limb 
anomalies (8 (12.7%) cases); renal defects (11 (17.5%) cases); facial defects including eye or 
ear deformities (18 (28.6%) cases); cranial hydrocephalus defects (4 (6.3%) cases); failure to 
thrive (2 (3.2%) cases); pulmonary stenosis (2 (3.2) cases); and congenital hernia (1 (1.6%) 
case).  Prenatal diagnosis was more common in CLP (12.6%) than CL (8%) and more 
common in isolated cases than those combined with associated anomalies (15.6% for isolated 
CL/P compared to 5% for CL/P with associated anomalies (see table 5.4).  
Table 5.4: Case-control comparison according to cleft phenotype and prenatal diagnosis. 
 
 Oral cleft type Prenatal diagnosis 
Yes No Total 
 Associated anomalies Associated anomalies  
 Yes No Yes No  
CL 3(1.5) 13 (6.5) 6 (3) 55 (27.6) 77
C
 (38.7) 
CLP 7 (3.5) 18 (9.1) 10 (5.1) 36 (18.1) 71
C
 (35.7) 
CP 1 (0.5) 3 (1.5) 15 (7.5) 32 (16.1) 51
C
 (25.6) 
Total 11 (5.5) 34 (17.1) 31 (15.6) 123 (61.8) 199
C
 (100) 
X
2
 (df), P-value 0.453 (2), 0.797 9.34 (2), 0.053  
C
 Number less than the total cases (Total: 205; CL:78; CLP:74 and CP:53) because of missing 
information. 
    
5.4.2 Parental age and infant characteristics 
The sample was distributed according to parental age and infant characteristics including 
neonatal weight, neonatal head circumference, neonatal length and number of twin births. 
The numbers of infants with missing information were 14 cases and 21 controls for infant 
neonatal weight; 157 cases and 191 controls for neonatal head circumference; 144 cases and 
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179 controls for neonatal length; and six controls for number of twin births (table 5.5 and 
5.6). 
The number of infants for which neonatal head circumference and length were able to be 
recorded were limited: 48 (23.4% of the sample) NSOFC and 53 (21.7% of the total controls) 
control individuals had data for head circumference; and 61 (29.8% of the sample) NSOFC 
and 65 (26.6%) of the total controls) control infants had data for infant neonatal length, 
respectively. There were no significant differences between cases and controls according to 
parental age and neonatal infant characteristics (P >0.05).  
The number of infants that were part of twin births was significantly higher for NSOFC 
(CL/P phenotype) infants than controls; P= 0.002, OR: 13.2 and 95% CI: 1.69 to 103.4 for 
NSOFC; P= 0.019, OR: 9.48 and 95% CI: 0.9 to 92.5 for CL; P< 0.001, OR: 24.66 and CI: 3 
to 203.94 for CLP) (see Table 5.6). 
 
 
Table 5.5: Case-control comparison according to parental age in years, and neonatal infant 
characteristics: 
 
Variable Group N Mean  Significance 
Father's age (years) 
NSOFC 205 35.89 ± 8.18  0.192  
CL 78 36.75 ± 9.09 0.062 
CLP 73 34.89 ± 6.96  0.982 
CP 53 35.81 ± 8.3  0.457  
Control 244 34.95 ± 6.86   
Mother's age (years) 
NSOFC 202
c
  29.62 ± 5.9 0.484 
CL 78 29.47 ± 5.3 0.777 
CLP 72
c
 29.04 ± 6 0.579 
CP 52
c
 30.65 ± 6.68 0.267 
Control 244 29.24 ± 5.7   
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Infant weight (Kg) 
NSOFC 191
c
 2.93 ± 0.58 0.201 
CL 77
c
 2.94 ± 0.54 0.276  
CLP 61
c
 3 ± 0.58  0.113 
CP 53 2.83 ± 0.6  0.732  
Control 223
c
 2.86 ± 0.58   
Infant neonatal head 
circumference (cm) 
NSOFC 48
c
 34.9 ± 2.2 0.359 
CL 17
c
 34.64 ± 1.98  0.832  
CLP 19
c
 35.34 ± 2.24  0.064 
        CP     12
c
 34.92 ± 2.71 0.554  
Control 53
c
 34.52 ± 1.92  
Infant neonatal length 
(cm) 
NSOFC 61
c
 49.68 ± 4.77 0.937 
CL 22
c
 50.91 ± 4.56 0.23  
CLP 25
c
 48.4 ± 5.5 0.315 
CP    14
c
 50.07 ± 4.03 0.764 
Control 65
c
 49.74 ± 3.7  
c
 Number less than the total sample (NSOFC: 205; CL:78; CLP:74 and CP:53; controls 244) 
because of missing information. 
 
Table 5.6: Case-control comparison according to NSOFC sub-phenotype and number of twin or 
singleton foetuses at birth: 
 
 NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
Twins 11 (5.4) 3 (3.8) 7 (9.5) 1 (1.9) 1 (0.4) 
Singletons 194 (94.6) 75 (96.2) 67 (90.5) 52 (98.1) 237 (99.6) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 238
c
 (100) 
P-value 0.002** 0.019** <0.001** 0.24  
OR 
(95% CI) 
13.2 
(1.69–103.4) 
9.48 
(0.9–92.5) 
24.66 
(3–203.94) 
4.54 
(0.28–73.75) 
 
X
2
 =17.99, df=3 and P<0.001** 
** Significance value P≤ 0.05 
c
 Number less than the total controls (244) 
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5.4.3 Socioeconomic status (SES)  
The SES included information on family income, parental education level and the description 
of the place of family residence. Table 5.7 shows the distribution of cases and controls 
according to SES-related proposed risk factors. There were no statistically significant 
differences between cases (CL, CLP and CP) and controls for family monthly income (X
2
= 
6.51, df=6, and P= 0.369), paternal education level (X
2
= 1.79, df=3, and P= 0.617), and 
maternal education level (X
2
= 2.91, df=3, and P= 0.405). There were more cases living in 
rural areas compared to controls but the difference was not statistically significant except for 
CP (P= 0.005, OR: 2.73 and 95% CI: 1.32 to 5.66).  
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Table 5.7: Case-control comparison according to cleft phenotype and monthly family income in 
Saudi Riyals (SR), parental education and parental residency if rural or urban. 
 
SES NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Family income in SR : (X
2
 =6.51, df=6, and  P= 0.369) 
< 4000 39 (19) 10 (12.8) 19 (26.4) 10 (18.9) 51 (21) 
4000-10,000 128 (62.9) 54 (69.2) 39 (53.4) 35 (66) 155 (63.8) 
> 10,000 37 (15.3) 14 (17.9) 15 (20.5) 8 (15.1) 37 (15.2) 
Total 204
C
  (100) 78 (100) 73
C
 (100) 53 (100) 243 (100) 
P value 0.683 0.22 0.23 0.95  
Paternal education level  (X
2
 =1.79, df=3, and  P= 0.617) 
< High school  55 (27.7) 17 (21.8) 23 (31.1) 15 (28.8) 68 (28.1) 
≥ High school  149 (72.3) 61 (78.2) 51 (68.9) 37 (71.2) 174 (71.9) 
Total 204
C
 (100) 78 (100) 74 (100) 52
C
  (100) 242 (100) 
P-value 0.92 0.44 0.65 0.95  
OR  
(95% CI) 
0.99  
(0.65–1.48) 
0.79  
(0.44–1.42) 
1.14  
(0.65–2.01) 
1.02  
(0.53–1.98) 
 
Maternal education level  (X
2
 =2.91, df=3, and  P= 0.405) 
< High school  66 (32) 23 (29.5) 21 (28.4) 22 (41.5) 81 (33.5) 
≥ High school  139 (68) 55 (70.5) 53 (71.6) 31 (58.5) 161 (66.5) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.666 0.514 0.46 0.27  
OR  
(95% CI) 
0.92  
(0.62–1.36) 
0.83  
(0.48–1.45) 
0.81  
(0.46–1.43) 
1.4  
(0.77–2.59) 
 
Residency description:  (X
2
 =8.27, df=3 and P= 0.041**) 
Rural 32 (16.1) 8 (10.3) 11 (14.9) 13 (25) 26 (10.7) 
Urban 173 (83.9) 70 (89.7) 63 (85.1) 40 (75) 216 (89.3) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242 (100) 
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P-value 0.096 0.91 0.28 0.005**  
OR  
(95% CI) 
1.59  
(0.92–2.77) 
0.95 
(0.47–2.34) 
1.5 
(0.72–2.68) 
2.73  
(1.32–5.66) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; 78; CP:53 and control: 244) because of missing 
information 
 
 
5.4.4 Pregnancy planning and the effect of sibling order 
Pregnancy planning was reported by more than 40% of case and control families (Table 5.8). 
Although there was more mothers reporting pregnancy planning in the control (45.4%)  
compared to CLP (40.5%)  and CP (40%) cases, there was no statistically significant 
difference found between cases and controls with respect to pregnancy planning (CLP: P= 
0.504, OR: 0.84, and 95% CI: 0.49 to 1.42; and CP: P= 0.52, OR: 0.81 and 95% CI: 0.44 to 
1.52). 
Child order was the similar between all groups. The duration between infant and next-oldest 
sibling pregnancies is presented in Table 5.9. The number of controls with shorter periods 
between siblings was more than those seen for cases but was statistically significant only for 
CL. After Bonferroni correction, the number of CL infants with longer duration between 
infant and next-oldest sibling (three or more years) was higher than for control infants (P= 
0.01). 
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Table 5.8: Case-control comparison to pregnancy planning. 
 
Pregnancy 
planning 
NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
Yes 87 (43.3) 37 (48.1) 30 (40.5) 20 (40) 109 (45.4) 
No 114 (56.7) 40 (51.9) 44 (59.5) 30 (60) 131 (54.6) 
Total 201
C
 (100) 77
C
 (100) 74 (200) 50
C
(100) 240
C
 (100) 
P-value 0.681 0.713 0.504 0.52  
OR  
(95% CI) 
0.92  
(0.63–1.35) 
1.1  
(0.66–1.85) 
0.84  
(0.49–1.42) 
0.81  
(0.44–1.52) 
 
X
2
 =1.28, df=3 and P= 0.734 
C 
number less than the total sample (NSOFC: 205; CL: 78; CP:53 and control: 244) because of 
missing information 
 
Table 5.9 Case-control comparison according to infant family order position and the duration 
between infant and next-oldest sibling. 
 
Variable  NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
Child  
group order 
X
2
 =9.38, df=3 P= 
0.67 
 
1st 55 (27.7) 24 (32.9) 18 (25) 13 (24.5) 64 (27.1) 
2nd 40 (20.2) 12 (16.4) 21 (29.2) 7 (13.2) 53 (22.5) 
3rd and 4th 43 (21.7) 17 (23.3) 13 (18.1) 13 (24.5) 42 (17.8) 
5th or more 60 (30.3) 20 (27.4) 20 (27.8) 20 (37.7 77 (32.6) 
Total 193 (100)
C
 73
C
 72
C
 53
C
 236
C
 
P-value 0.661 0.38 0.704 0.344  
Duration between 
the child and 
their next-oldest 
sibling in years 
(y) 
X
2
 =31.51, df=3, 
P= 0.002** 
1 y or less 17 (10.9) 7 (12.7) 7 (12.1) 3 (7) 1 (16.1) 
1.2 - 2 y 44 (28.2) 10 (18.2) 18 (31) 16 (37.2) 58 (32.4) 
2.1- 3 y 33 (21.2) 7 (12.7) 14 (24.1) 12 (27.9) 43 (24.0) 
3.1 y or more 62 (39.7) 31 (56.4) 19 (32.8) 12 (27.9) 67 (37.4) 
Total 156 (100)
C
 55 (100)
C
 58 (100)
C
 43 (100)
C
 169 (100)
C
 
P-value 0.369 0.01** 0.528 0.721  
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; CL: 78; CLP: 74; CP:53 and control: 244) because 
of missing information 
154 
 
5.4.5. Family history and consanguinity 
Factors measured for positive family history included family history for birth defects, family 
history for NSOFC defects, and parental consanguineous marriages. Family history and 
parental consanguinity are reported in Tables 5.10 to 5.13.  
The prevalence of infants with a family history of birth defect was significantly higher in 
cases compared to controls, with X
2
 =15.89, df=6 and P= 0.014 for the three oral cleft 
phenotypes, but was significant only for CL (P= 0.012). These congenital anomalies included 
CL/P (56 NSOFC and 9 controls); CP (10 cases and 6 controls); limb anomalies (1 case and 
3 controls); CVD (3 cases and 5 controls); facial deformities (1 case and 2 controls); multiple 
defects (6 cases and 6 controls); sickle cell anomalies (3 cases and 2 controls); neural tube 
defects (2 cases and 4 controls); cerebral palsy (5 controls); and other congenital anomalies 
(5 cases and 35 controls).  
There were statistically significant differences between cases and controls with respect to 
NSOFC family history: NSOFC (P< 0.001, OR: 7.07, 95% CI: 3.88 to 12.88); CL (P= 0.001, 
OR: 6.51 and 95% CI: 3.18 to 13.32); CLP (P= 0.001, OR: 9.67 and 95% CI: 4.8 to 19.48); 
and CP (P< 0.001, OR: 4.88 and 95% CI: 2.16 to 11.02).  
Information on parental consanguinity was missing from 5 cases and 11 controls. There were 
more cases reporting parental consanguineous marriages in CP (34 (65.4%) cases) compared 
to controls (138 (59.2) cases), but the difference was not statistically significant (P>0.05). 
For the type of consanguineous marriages, 1st cousin consanguineous marriages were greater 
in cases than controls, especially in CP, but the difference was not statistically significant (P> 
0.62).  
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Table 5.10: Case-control comparison according to family history of birth defects. 
 
Family history   NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes 84 (41.2) 32 (41.6) 37 (50) 15 (28.3) 79 (32.4) 
No 116 (55.8) 44(57.1) 36 (48.6) 36 (67.9) 161 (66) 
unknown 4 (2) 1 (1.3) 1 (1.4) 2 (3.8) 4 (1.6) 
Total 204
C 
(100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.062 0.212 0.012** 0.6  
X
2
 =15.89, df=6 and P= 0.014** 
** Significant value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; CL: 78) because of missing information 
 
Table 5.11: Case-control comparison according to family history of NSOFC defects. 
 
Family history  NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes 66 (32.2) 23 (29.9) 29 (39.2) 13 (24.5) 15 (6.2) 
No 139 (67.8) 54 (70.1) 45 (60.2) 40 (75.5) 228 (93.8) 
Total 205 (100) 77
C
 (100) 74 (100) 53 (100) 243 (100) 
P-value <0.001** <0.001** <0.001** <0.001**  
OR (95% CI) 
7.07  
(3.88–12.88) 
6.51  
(3.18–13.32) 
9.67  
(4.8–19.48) 
4.88  
(2.16–11.02) 
 
X
2
 =63.99 df=3 and P<0.001 
** Significance value P≤ 0.05 
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Table 5.12: Case-control comparison according to parental consanguinity. 
 
Consanguinity  NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes 113 (56.5) 39 (50) 40 (57.1) 34 (65.4) 138 (59.2) 
No 87 (43.5) 39 (50) 30 (42.9) 18 (34.6) 95 (40.8) 
Total 200
C
 (100) 78 (100) 70
C
 (100) 52
C
 (100) 233
C
 (100) 
P-value 0.597 0.17 0.718 0.44  
OR (95% CI) 0.9  
(0.62–1.32) 
0.7  
(0.42–1.17) 
0.91  
(0.53–1.56) 
1.28  
(0.68–2.41) 
 
X
2
 =3.47, df=3 and P= 0.325 
C 
number less than the total sample (NSOFC: 205; CLP: 74; CP: 53 and control: 244) because of 
missing information 
 
 
Table 5.13: Case-control comparison according to type of parental consanguinity among infant 
with consanguineous parents (113 NSOFC cases; and 129 controls). 
 
Type of 
consanguinity 
NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
1st cousins 69 (60.5) 22 (56.4) 25 (62.5) 22 (64.7) 76 (58.9) 
1st cousins once 
removed 
8 (7) 4 (10.3) 2 (5) 2 (5.9) 8 (6.2) 
2nd cousins 20 (17.5) 7 (17.9) 7 (17.5) 6 (17.6) 18 (14) 
Same tribe 16 (13.2) 6 (15.4) 6 (15) 4 (11.8) 27 (20.9) 
Total 113(100) 39 (100) 40 (100) 34 (100) 129
C
 (100) 
P-value 0.643 0.779 0.942 0.62  
X
2
 =3.46, df=8, and P= 0.903 
C 
number less than the total controls with consanguineous parents by nine cases because of 
missing information 
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5.4.6 Maternal ingestion of supplements 
Maternal ingestion of supplements three months prior to pregnancy and during the 1st 
trimester period include: multivitamins and/or supplementation with folic acid, calcium, and 
iron. Tables 5.14 to 5.15 and appendix 15 to 16 show the sample distribution according to 
maternal supplement ingestion in the three months prior to pregnancy and during the 1st 
trimester period.  
Folic acid supplementation in the pregestation period was more frequently ingested by 
mothers with CL (14.5%) compared to controls (9.4%), but the difference was not significant 
(P= 0.22). Folic acid supplementation in the 1st trimester period was significantly more 
likely to be reported by the mothers of control infants compared to NSOFC mothers (P= 
0.009) and CLP mothers (P<0.001). Therefore, can be concluded that folic acid could 
decreases the risk of having an infant with NSOFC (OR: 0.59 and 95% CI: 0.39 to 0.88) and 
CLP (OR: 0.34 and 95% CI: 0.2 to 0.58) when ingested in the 1
st
 trimester period. 
There were less CL/P mothers using multivitamins supplements compared to controls. 
However, there was no significant difference (OR: 0.74 and 95% CI: 0.38 to 1.45 for CL; and 
OR: 0.7 and 95% CI: 0 .3 to 1.4 for CLP) 
 
 Calcium supplementation was not ingested in the pre-gestation period by mothers of cases or 
controls. However, when ingested in the 1st trimester period, it showed a statistically 
significant decreased risk of having an infant with NSOFC (P= 0.014, OR: 0.37 and 95% CI: 
0.16 to 0.84) and with CP phenotype (X
2
=5.13 and P= 0.017). 
For maternal iron supplementation, no statistically significant differences were identified 
between cases and controls. 
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Table 5.14: Case-control comparison according to cleft phenotype and maternal ingestion of 
folic acid during the three month pre-gestation and 1st trimester periods. 
  
Duration     Folic acid 
ingestion 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-
gestation 
X
2
 =6.93 
df=3 
P= 0.074   
Yes  17 (8.4) 11 (14.5) 3 (4.1) 3 (5.7) 23(9.4) 
No  186 (91.6) 65 (85.5) 71 (95.9) 50 (94.3) 221 (90.6) 
Total 203
C
  (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.79  0.22 0.16 0.41   
OR 
(95% CI) 
0.915 
(0.48–1.75) 
1.62 
(0.75–3.5) 
0.42 
(0.12–1.45) 
0.6 
(0.17–2.07) 
 
1st trimester 
X
2
 =18.03 
df=3 
P<0.001  
Yes  127 (62.6) 55 (72.4) 37 (50) 35 (66) 181 (74.2) 
No  76 (37.4) 21 (27.6) 37 (50) 18 (34) 63 (25.8) 
Total 203
C
 (100) 76
 C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.009** 0.71 <0.001** 0.18  
OR  
(95% CI) 
0.59  
(0.39–0.88) 
0.9  
(0.5–1.6) 
0.34  
(0.2–0.58) 
0.65  
(0.34–1.22) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; CL: 78) because of missing information 
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Table 5.15: Case-control comparison according to maternal ingestion of calcium supplements in 
the 1st trimester. 
 
Calcium supplement NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
Yes 8 (3.9) 5 (6.6) 3 (4.1) 0 24 (9.8) 
No 197 (96.1) 73 (93.4) 71 (95.9) 53 (100) 220 (90.2) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.014** 0.347 0.125 0.024**  
OR 
(95% CI) 
0.37 
(0.16–0.84) 
0.62 
(0.23–1.7) 
0.38 
(0.11–1.31) 
a  
X
2
=8.05, df=3 and P= 0.045**                                                                                                          
** Significance value P≤ 0.05                                                                                                       
The OR and CI were not measured because one group contains zero value. 
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5.4.7 Maternal disease 
Diseases experienced and maternal exposure to X-rays by NSOFC mothers and controls were 
recorded for the three months prior to pregnancy and 1st trimester periods and are illustrated 
in Tables 5.16 to 5.20 and appendix (A17 to A21). These diseases include: common cold/ flu, 
renal diseases, asthma, convulsions, diabetes, high blood pressure, vaginal bleeding, and 
fever. Furthermore, maternal exposure to X-rays and the reason for exposure was recorded 
for the same periods of time.  
Maternal illness in the three month pre-gestation period was reported significantly more often 
by NSOFC mothers and by mothers of infants with all three sub-phenotypes compared to 
mothers of controls. For NSOFC: P< 0.001, OR: 2.6 and 95% CI: 1.64 to 4.17; for CL, P= 
0.024, OR: 2.04 and 95% CI: 1.1 to 3.82; for CLP, P< 0.001, OR: 3.62 and 95% CI: 2 to 
6.53; and for CP, P= 0.013, OR: 2.39, 95% CI: 1.19 to 4.81. However, for illness during the 
first trimester period, there was a statistically significant difference between cases and 
controls for NSOFC (P= 0.017, OR: 1.6 and 95% CI: 1.09 to 2.35) and CL (P= 0.037, OR: 
1.74 and 95% CI: 1.04 to 2.94). 
Table 5.17 shows the distribution of NSOFC mothers reporting a common cold/ flu 
experience during the three months prior to pregnancy and the 1st trimester period. Maternal 
cold/flu infection in the three months prior to pregnancy was significantly reported more 
frequently by mothers of case infants compared to mothers of control infants for all three 
NSOFC sub-phenotypes (NSOFC, P< 0.001, OR: 3.99 and 95% CI: 2.14 to 7.43; CL, P= 
0.014, OR: 2.45, 95% CI: 1.23 to 6.28; CLP, P< 0.001, OR: 6.34 and 95% CI: 3.11 to 13.18; 
and CP, P= 0.031, OR: 2.66 and 95% CI: 1.06 to 6.63).  For the 1st trimester period, there 
was a statistically significant difference between the total CP cases compared to controls in 
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maternal reporting of common cold/ flu infection (P= 0.037, OR: 2.03 and 95% CI: 1.03 to 
3.98). However, this difference was not statistically significant for CL/P. 
Maternal fever was also significantly associated with NSOFC, with more NSOFC and CLP 
mothers reporting having experienced fever in the three month pre-gestation period than 
control mothers (P= 0.048, OR: 1.98 and 95% CI: 1.01 to 3.63 for NSOFC and P= 0.008, 
OR: 2.78 and 95% CI: 1.28 to 6.05 for CLP) (Table 5. 18). 
Other diseases including renal diseases, asthma, convulsions, diabetes, high blood pressure, 
and vaginal bleeding were rarely reported as having been experienced by mothers three 
months during and prior to pregnancy (See appendix A17 to A21). In addition, these 
disorders were not associated with NSOFC, with the exception of diabetes, which was 
significantly associated with CP if experienced in the 1st trimester period (P= 0.018, OR: 4.8 
and 95% CI: 1.16 to 19.84) (see Table 5.19).  
For maternal exposure to X-rays during the 1
st
 trimester period of pregnancy, four (1.9%) 
NSOFC cases reported exposure to X-rays compared to 6 (2.5%) of controls with no 
statistically significant difference (P= 0.705). For maternal exposure to X-rays in the 1st 
trimester period, four (5.1%) CLP cases reported exposure to X-rays compared to three 
(1.2%) controls with statistically significant difference (P= 0.05, OR: 4.59, and 95% CI: 1-
21). The general reason given for X-ray exposure were dental X-ray procedures (see Table 
5.20).  
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Table 5.16: Case-control comparison according to maternal illness during the three month pre-
gestation and 1
st
 trimester periods. 
 
Duration  Illness NSOFC (%) CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-
gestation 
X
2
 =21.36 
df= 3 
P<0.001 
Yes  63 (30.6) 20 (25) 28 (37.8) 15 (28.3) 35 (14.4) 
No  142 (69.4) 58 (75) 46 (62.2) 38 (71.7) 208 (85.6) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 243
C
 (100) 
P-value <0.001** 0.024** <0.001** 0.013**  
OR  
(95% CI) 
2.6  
(1.64–4.17) 
2.04 
(1.1–3.82) 
3.62  
(2–6.53) 
2.39  
(1.19–4.81) 
 
1st 
trimester 
X
2
 =6.65 
df= 3 
P= 0.084 
Yes  88 (42.7) 35 (43.4) 30 (40.5) 23 (43.4) 77 (31.8) 
No  117 (57.3) 43 (56.6) 44 (59.5) 30 (56.6) 165 (68.2) 
Total 205
C
 (100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value 0.017** 0.037** 0.167 0.094   
OR  
(95% CI) 
1.6 
(1.09–2.35) 
1.74 
 (1.04–2.94) 
1.46 
(0.86–2.5) 
 1.7 
 (0.95–3.1) 
 
** Significance value 
C 
number less than the total sample (Control: 244) because of missing information 
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Table 5.17: Case-control comparison according to maternal self-report of experiencing common-
cold/ flu during the three month pre-gestation and 1st trimester periods. 
 
Duration  Cold/flu NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls      
    (%)   
Pre-gestation  
X
2
 =28.76 
df= 3 
P<0000 
Yes  42 (20.9) 12 (15.8) 22 (29.7) 8 (15.1) 15 (6.2) 
No  163 (79.1) 66 (84.2) 52 (70.3) 45 (84.9) 227 (93.8) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value <0.001** 0.014** <0.001** 0.031**  
OR  
(95% 
CI) 
3.99 
(2.14–7.43) 
2.45 
(1.23–6.28) 
6.4 
(3.11–13.18) 
2.66 
(1.06–6.63) 
 
1st trimester 
 X
2
 =4.92 
df= 3 
P= 0.178 
Yes  50 (24.8) 16 (21.1) 18 (24.3) 16 (30.2) 42 (17.4) 
No  155 (74.9) 62 (78.9) 56 (75.7) 37 (69.8) 200 (82.6) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value 0.054 0.53 0.183 0.037**  
OR  
(95% 
CI) 
1.57 
(0.99–2.48) 
1.23 
(0.65–2.34) 
1.53 
(0.81–2.86) 
2.03 
(1.03–3.98) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (control: 244) because of missing information 
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Table 5.18: Case-control comparison according to maternal fever during the three month pre-
gestation and 1st trimester periods. 
 
Duration  Fever NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-gestation  
X
2
 =7.1 
df= 3 
P= 0.069  
Yes  26 (12.7) 8 (10.5) 13 (17.6) 5 (9.4) 17 (7) 
No  179 (87.3) 70 (89.5) 61 (82.4) 48 (91.2) 225 (93) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value 0.048** 0. 36 0.008** 0.562  
OR  
(95% CI) 
       1.98  
(1.01–3.63) 
      1.51  
(0.63–3.65) 
2.78  
(1.28–6.05) 
1.3  
(0.48–3.87) 
 
1st trimester  
X
2
 =2.97 
df= 3 
P= 0.397  
Yes  34 (16.6) 17 (22.4) 9 (12.2) 8 (15.1) 36 (14.9) 
No  171 (83.4) 61 (77.6) 65 (78.8) 45 (84.9) 206 (85.1) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C 
(100) 
P-value 0.636 0. 155 0.534 0.967  
OR  
(95% CI) 
1.13  
(0.68–1.9) 
1.59  
(0.84–3.04) 
0.78  
(0.36–1.71) 
1.02  
(0.44–2.33) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (control: 244) because of missing information 
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Table 5.19: Case-control comparison according to maternal diabetes during three month pre-
gestation and 1st trimester periods. 
 
Duration  Diabetes NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)  
Pre-
gestation  
X
2
 =4.6 
df= 3 
P= 0.204 
Yes  3 (1.5) 0 2 (2.7) 1 (1.9) 1 (0.4) 
No  202 (98.5) 78 (100) 72 (97.3) 52 (98.1) 241 (99.6) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value 0.242 0.988 0.123 0.241  
OR 
(95% CI) 
3.56 
(0.37–34.5) 
a 
6.69 
(0.59–74.974) 
4.58 
(0.28–74.37) 
 
1st 
trimester 
 X
2
 =5.55 
df= 3 
P= 0.136 
Yes 9 (4.4) 3 (3.9) 2 (2.7) 4 (7.5) 4 (1.7) 
No 196 (95.6) 75 (96.1) 72 (97.3) 49 (92.5) 238 (98.3) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C 
(100) 
P-value 0.088 0.26 0.573 0.018**  
OR 
(95% CI) 
2.7 
(0.8–8.9) 
2.38 
(0.52–10.87) 
1.63 
(0.29–9.09) 
4.8 
(1.16–19.84) 
 
** Significance value P≤ 0.05 
a. The OR and CI were not measured because one group contains zero value. 
b. C Number less than the total number (controls: 244) because of missing information 
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Table 5.20: Case-control comparison according to maternal exposure to X-rays in the three 
months pre-gestation and 1st trimester periods. 
 
Duration  X-ray NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-
gestation 
X
2
 =2.67 
df= 3 
P= 0.445 
Yes  4 (1.9) 1 (1.3) 3 (3.8) 0 6 (2.5) 
No  201 (98.1) 77 (98.7) 71 (96.2) 53 (100) 238 (97.5) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.705 0.542 0.473 0.468  
OR  
(95% CI) 
0.78 
(0.22–2.81) 
0.51 
(0.06–4.34) 
1.68  
(0.41-6.87) 
a 
 
1st 
trimester 
X
2
 =4.44 
df= 3 
P= 0.218 
Yes  7 (3.4) 2 (2.6) 4 (5.1) 1 (1.9) 3 (1.2) 
No  198 (96.6) 76 (97.4) 70 (94.9) 52 (98.1) 241 (98.8) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.122 0.417 0.05** 0.709  
OR  
(95% CI) 
2.81 
(0.72–11.01) 
2.11 
(0.35–12.89) 
4.59 
(1–21) 
1.54 
(0.16–
15.15) 
 
** Significance value P≤ 0.05 
a. The OR and CI were not measured because one group contains zero value. 
 
5.4.8 Maternal medications ingestion  
Medications ingested by NSOFC and control mothers during the three months prior to 
pregnancy and 1st trimester period were recorded. These medications included antibiotics, 
antipyretics, contraceptives, anti-emetics, and progesterone (Tables 5.28 to 5.32).  
Table 5.21 shows the sample distribution according to maternal antibiotics ingestion in the 
three month pre-gestation and the 1st trimester periods. There was a statistically significant 
difference between NSOFC, including CL/P, and controls in relationship to maternal 
antibiotics, in the three month pre-gestation period (P= 0.003, OR: 2.81 and 95% CI: 1.38 to 
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5.72 for NSOFC; P= 0.012, OR: 2.96 and 95% CI: 1.22 to 7.16 for CL; and P= 0.03, OR: 
2.64 and 95% CI: 1.07 to 6.55 for CLP). For the 1st trimester period, there was a statistically 
significant difference between NSOFC, including CL, and controls (P= 0.023, OR: 1.95 and 
95% CI: 1.09 to 3.51 for NSOFC and P= 0.003, OR: 2.82 and 95% CI: 1.39 to 5.74 for CL). 
Although there was more frequent CP mothers using antibiotics in the pregestation and 1
st
 
trimester periods compared to controls, the differences were not significant (P>0.05).   
Table 5.22 shows the sample distribution according to maternal antipyretic in the three month 
pre-gestation and the 1st trimester periods. Maternal ingestion of antipyretic medications in 
the 1st trimester period showed a statistically significant difference between NSOFC and 
controls (P= 0.033, OR: 0.48 and 95% CI: 0.24 to 0.94). However, this difference was not 
significant for NSOFC sub-phenotypes.    
For anti-emetic medication, Table 5.23 shows a significant difference between NSOFC and 
CL, and controls in relation to maternal ingestion of anti-emetics in the first trimester period 
(NSOFC: P= 0.042, OR: 1.97 and 95% CI: 1.02 to 3.8; CL: P= 0.019, OR: 2.34 and 95% CI: 
1.06 to 5.75). However, this difference was not significant for the various CLP and CP sub-
phenotypes.     
Contraceptive ingestion showed no statistically significant differences between cases and 
controls in the pre-gestation and 1st trimester periods (Appendix 22). Although more mothers 
in the control group reported using progesterone tablet compared to NSOFC and its three 
phenotypes, the differences were not significant (P>0.05) (see Appendix A23).  
Other medications that were rarely reported by mothers were: anti-hypertensive, anti-
coagulant, anti-fungal, insulin, motilium (domperidone; dopamine antagonist anti-sickness 
medicine), thyroxin, anti-convulsive, and anti-histamine. ingestion of these medications was 
reported by only one to three mothers. Cortisone ingestion was reported by 8 mothers: 6 
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(2.9%) cases and 2 (0.8%) controls, and there was no statistically significant difference 
between cases and controls (P= 0.096, OR: 3.6 and 95% CI: 0.72 to 18.05).  
 
 
Table 5.21: Case-control comparison according to cleft phenotype and maternal ingestion of 
antibiotics in the three month pre-gestation and 1st trimester periods. 
 
Duration  Anti- 
biotics 
NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-
gestation 
X
2
 =7.79 
df= 3 
P= 0.051 
Yes 25 (12.3) 10 (13.3) 9 (12.2) 6 (11.3) 12 (4.9) 
No 177 (87.7) 65 (86.7) 65 (87.8) 47 (88.7) 232 (95.1) 
Total 202
C
 (100) 75
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.003** 0.012** 0.030** 0.08  
OR 
(95% CI) 
2.81 
(1.38–5.72) 
2.96 
(1.22–7.16) 
2.64 
(1.07–6.55) 
2.44 
(0.87–6.82) 
 
1st 
trimester 
X
2
 =7.95 
df=3 
P= 0.047** 
Yes 32 (15.5) 16 (21.1) 9 (12.3) 7 (13.2) 21 (8.6) 
No 170 (84.5) 60 (78.9) 64 (77.7) 46 (86.8) 223 (91.4) 
Total 202
C
  (100) 76
C
 (100) 73
C
 (100) 53 (100) 244 (100) 
P-value 0.023** 0.003 ** 0.35 0.31  
OR 
(95% CI) 
1.95 
(1.09–3.51) 
2.82 
(1.39–5.74) 
1.48 
(0.65–3.39) 
1.59 
(0.64–3.97) 
 
** Significance value P≤ 0.05 
C
 Number less than the total number (NSOFC: 205 cases, CL: 78 cases and controls: 244) because of 
missing information. 
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Table 5.22: Case-control comparison according to maternal antipyretic medication ingestion 
during the three month pre-gestation and the in 1st trimester periods. 
 
Duration  Anti- 
pyretic 
NSOFC (%) CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-
gestation 
X
2
 =4.26 
df=3 
P= 0.235 
Yes  14 (6.8) 6 (6.2) 6 (8.1) 2 (3.8) 30 (12.3) 
No  191 (93.2) 72 (93.3) 68 (91.9) 51 (96.2) 214 (87.7) 
Total 205 (100) 78(100) 74 (100) 53 (100) 244 (100) 
P-value 0.033** 0.266 0.323 0.088  
OR  
(95% CI) 
     0.48  
(0.24–0.94) 
      0.59 
(0.24–1.49) 
0.62  
(0.25–1.58) 
0.28  
(0.06–1.21) 
 
1st 
trimester  
X
2
 =3.77 
df=3 
P= 0.287 
Yes  25 (12.3) 9 (11.2) 8 (10.8) 8 (15.4) 45 (18.8) 
No  179 (87.7) 69 (88.8) 66 (89.2) 44 (84.6) 195 (81.2) 
Total 204
c
  (100) 78 (100) 74 (100) 52
c
 (100) 240 (100) 
P-value 0.056 0.121 0.12 0.6  
OR 
(95% CI) 
0.6 
(0.35–1.02) 
0.55 
(0.26–1.18) 
0.5 
(0.24–1.19) 
0.8 
(0.35–1.82) 
 
** Significance value P≤ 0.05 
C
 Number less than the total number (NSOFC: 205 cases, CL: 78 cases and controls: 244) because of 
missing information. 
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Table 5.23: Case-control comparison according to maternal exposure to anti-emetic medications 
during the three month pre-gestation and 1st trimester periods. 
 
Duration  Anti-emetic NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-gestation 
X
2
 =5.04  
df=3 
P= 0.169 
 
Yes 1 (0.5) 0 1 (1.4) 0 0 
No 204 (99.5) 78 (100) 73 (98.6) 53 (100) 244 (100) 
Total 205  (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.437 a 0.07 a  
OR 
(95% CI) 
2.10 
(0.14-88) 
a 
4.36 
(3.56–5.34) 
a  
1st trimester  
X
2
 =7.16 
df=3 
P= 0.067 
 
Yes 25 (12.1) 12 (14.5) 7 (9.6) 7 (13.2) 16 (6.6) 
No 181 (87.9) 66 (85.5) 67(90.4) 46 (86.8) 228 (93.4) 
Total 205  (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.043** 0.019** 0.401 0.108  
OR 
(95% CI) 
1.97 
(1.02–3.8) 
2.34 
(1.06–5.75) 
1.49 
(0.59–3.77) 
2.17 
(0.84–5.57) 
 
** Significance value P≤ 0.05 
a. Cannot be analysed because it contain zero values  
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5.4.9 Maternal stress 
Maternal stressors during the three month period prior to pregnancy and during the 1st 
trimester were measured by recording information on: maternal reporting of having 
experienced stress; maternal reporting of having experienced family problems; maternal 
depression; maternal reporting having experienced severe morning sickness, threatened 
abortion and/or abdominal pain (Tables 5.24 to 5.26 and Appendix 24 to 26).    
There was a significant difference between cases and controls regarding mothers reporting 
having experienced stress and having family problems during the three month pre-gestation 
and/or the 1st trimester periods. Stress and family problems were significantly related to 
NSOFC and its sub-phenotypes and experience of these increased the chances of having an 
infant with NSOFC (maternal stress: P< 0.001, OR: 2.1 and 95% CI: 1.43 to 3.11 for 
NSOFC; P= 0.04, OR: 1.74 and 95% CI: 1.01 to 3 for CL; P= 0.001, OR: 2.53 and 95% CI: 
1.48 to 4.32 for CLP; and P= 0.009, OR: 2.23 and 95% CI: 1.2 to 4.09 for CP; and maternal 
family problems: P= 0.001, OR: 1.97 and 95% CI: 1.31 to 2.95 for NSOFC; P= 0.04, OR: 
1.79 and 95% CI: 1.03 to 3.13 for CL; P= 0.004, OR: 2.21 and 95% CI: 1.28 to 3.84 for 
CLP; and P= 0.04, OR: 1.96 and 95% CI: 1.04 to 3.67 for CP). In addition, maternal 
depression in the pre-gestation and 1st trimester periods was reported more in NSOFC 
mothers compared to controls and showed a statistically significant relationship with CP 
when it occurred in the pre-gestation period (P= 0.049, OR: 3.87 and 95% CI: 1.003 to 
14.93) and with CL when it occurred in the 1
st
 trimester (P= 0.032, OR: 2.96 and 95% CI: 
1.1 to 7.96) 
. 
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Appendix A26 shows the sample distribution according to maternal experience of abdominal 
pain in the three months prior to pregnancy and the 1st trimester period. Abdominal pain was 
reported significantly more in NSOFC cases and CP compared to controls in the 1st trimester 
period (P= 0.04, OR: 2.06 and 95% CI: 1.03 to 4.11 for NSOFC and P= 0.004, OR: 3.59 and 
95% CI: 1.43 to 8.83 for CP). Other factors that increase maternal stress such as threatened 
abortion and severe morning sickness were not statistically related to NSOFC (P> 0.05). 
 
Table 5.24: Case-control comparison according to cleft phenotype and maternal experience of 
stress in the pre-gestation and/or 1st trimester periods. 
 
Stress NSOFC CL (%) CLP (%) CP (%) Controls (%)  
Yes  95 (46.6) 32 (41.6) 38 (51.4) 25 (47.2) 71 (29.1) 
No  109 (53.4) 45 (58.4) 36 (58.6) 28 (52.8) 173 (90.9) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value <0.001** 0.04** 0.001** 0.009**  
OR  
(95% CI) 
2.1 
(1.43–3.11) 
1.74 
(1.01–3) 
2.53 
(1.48–4.32) 
2.23 
(1.2–4.09) 
 
X
2
=16.84, df=3 and P= 0.001** 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL:78) because of missing information 
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Table 5.25: Case-control comparison according to cleft phenotype and maternal experience of 
family problems during the three month pre-gestation and/or 1st trimester periods. 
 
Family problem NSOFC 
(%) 
CL (%) CLP(%) CP (%) Controls (%) 
Yes  78 (38.4) 28 (36.4) 30 (41.1) 20 (37.7) 59 (24.2) 
No  125 (61.6) 49 (63.6) 43 (58.9) 33 (62.3) 185 (75.8) 
Total 203
C
 (100) 77
C
 (100) 73
C
 (100) 53 (100) 244 (100) 
P-value 0.001** 0.04** 0.004** 0.04**  
OR 
(95% CI) 
1.97 
(1.31–2.95) 
1.79 
(1.03–3.13) 
2.21 
(1.28–3.84) 
1.96 
(1.04–3.67) 
 
X
2
 =12.41, df=3 and P= 0.006** 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL:78) because of missing information 
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Table 5.26: Case-control comparison according to NSOFC phenotype and maternal depression in 
the three months pre-gestation and 1st trimester periods.  
 
Duration  Depression NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-
gestation 
X
2
 =4.52 
df=3 
P= 0.211  
Yes  9 (4.4) 2 (2.6) 3 (4.1) 4 (7.5) 5 (2.1) 
No  196 (95.6) 76 (97.4) 71 (95.9) 49 (92.5) 237 (97.9) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.163 0.794 0.34 0.049**  
OR  
(95% CI) 
2.17 
(0.71–6.57) 
1.25 
(0.24–6.56) 
2.01 
(0.47–8.64) 
3.87 
(1.003–14.93) 
 
1st 
trimester 
 X
2
 =6.03 
df=3 
P= 0.11 
Yes  17 (8.3) 8 (10.2) 5 (6.8) 4 (7.5) 9 (3.7) 
No  188(91.7) 70 (89.8) 69 (93.2) 49 (92.5) 233 (96.3) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.045** 0.032** 0.273 0.228  
OR 
(95% CI) 
2.34 
(1.02–5.37) 
2.96 
(1.1–7.96) 
1.87 
(0.61–5.78) 
2.11 
(0.63–7.14) 
 
** Significance value P≤ 0.05 
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5.4.10 Parental smoking 
Parental smoking, and the type and intensity of smoking were recorded for the three months 
prior to pregnancy and the 1st trimester period. Table 5.27 shows the sample distribution 
according to cleft phenotype and maternal smoking in the three month pre-gestation and 1st 
trimester periods. Only six (2.9%) mothers reported smoking in the pre-gestation period and 
three (1.5%) mothers reported smoking in the 1st trimester period. Therefore, the differences 
between cases and controls were not significant (P= 0.35 and P= 0.47, respectively). 
Maternal type and intensity of smoking differences were too insignificant to report. 
Paternal smoking and their type and intensity in the three month pre-gestation and 1st 
trimester periods are reported in Tables 5.28 to 5.32. There were more CP fathers reporting 
smoking in general and smoking tobacco in both periods compared to controls. However, the 
differences were not significant (P= 0.098). On the other hand, more fathers in the control 
group reported smoking compared to CL fathers (in the pregestation period: P= 0.018, OR: 
0.51, and 95% CI: 0.28 to 0.92, for smoking in general; and P= 0.001, OR: 0.29 and 95% CI: 
0.13 to 0.63, for tobacco smoking; and in the 1
st
 trimester period: P= 0.002, OR: 0.28 and 
95% CI: 0.13 to 0.62, for smoking in general; and P= 0.001, OR: 0.3 and 95% CI: 0.14 to 
0.65, for tobacco smoking).  Intense parental smoking (more than 20 cigarettes per day) was 
significantly associated with an increased risk of having an infant with NSOFC (P= 0.013, 
OR: 3.07 and 95% CI: 1.25 to 7.55) and CP (P= 0.012, OR: 5.23, 95 % CI 1.33 to 20.58).  
A statistically significant relationship was found between paternal waterpipe smoking and 
NSOFC including CL/P. For NSOFC: in the pre-gestation period: P= 0.013, OR: 2.33 and 
95% CI: 1.18 to 4.62; and in the 1st trimester period P= 0.016, OR: 2.47 and 95% CI: 1.16 to 
5.27. For CL: in the pre-gestation period P= 0.04, OR: 2.45 and 95% CI: 1.04 to 5.77; and in 
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the 1st trimester period P= 0.046, OR: 2.56 and 95% CI: 1 to 6.62. For CLP: in the pre-
gestation period P< 0.001, OR: 3.83 and 95% CI: 1.73 to 8.48; and in the 1st trimester period 
P= 0.001, OR: 4.11 and 95% CI: 1.73 to 9.77. However, the relationship was not significant 
for CP (P> 0.05).  
Paternal waterpipe smoking was sub-grouped into Jorak and Moasel. Jorak smoking was 
associated with a statistically significant increased risk of having an infant with NSOFC 
including CL/P if it occurred in the three months prior to pregnancy: P= 0.001, OR: 6.34 and 
95% CI: 1.8 to 22.23 for NSOFC; P= 0.01, OR: 5.58 and 95% CI 1.3 to 23.95 for CL; and P< 
0.001, OR: 9.62 and 95% CI: 2.48 to 37.27 for CLP. For the first trimester period, paternal 
Jorak smoking was also associated with significantly increased NSOFC risk; P= 0.01, OR: 
4.66 and 95% CI: 1.28 to 16.93 for NSOFC; P= 0.03, OR: 4.55 and 95% CI: 1 to 2.82 for 
CL; P= 0.002, OR: 7.1 and 95% CI: 1.73 to 29.16 for CLP. However, although NSOFC 
fathers smoked Moasel more frequently (15 (7.3%)) and CL/P (6 (8%) for CL and 8 (10.8%) 
for CLP) compared to controls (12 (4.9%)), the relationship was not statically significant: P= 
0.287, OR: 1.53 and 95% CI: 0.7 to 3.34 for NSOFC; P= 0.338, OR: 1.64 and 95% CI: 0.59 
to 4.52 for CL; and P= 0.072, OR: 2.31 and 95% CI: 0.91 to 6 for CLP. For CP the 
relationship was also not significant (P= 0.321, OR: 0.37 CI: 0.05 to 2.89). The results of the 
two types of waterpipe smoking (Moasel and Jorak) are presented in Appendix A27.1 and 
A27.2.    
Maternal second-hand smoking was reported by 45 (22%) of NSOFC mothers and 21 
(28.4%) CLP mothers compared to 47 (19.3%) of controls. As mothers were mainly house 
wives (87.3% of NSOFC and 86.4% of controls' mothers), family members are the primary 
source for maternal second hand smoking. 
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Although maternal second-hand smoking was more frequently reported in mothers of 
NSOFC and its sub-phenotypes compared to controls, and especially among those with who 
were exposed more than 12hours/ week (25% NSOFC, 40% CL and 23% CP compared to 
19% controls), there were no statistically significant differences between cases and controls 
(P> 0.05) (see Tables 5.33 and 5.34). For tobacco smoking fathers, 77.8% of CL mothers 
reported exposure to 2
nd
 hand smoking compared to 46.1% of controls but the difference was 
not significant (OR: 4.1 and 95% CI: 0.8 to 21.03). However, there were significantly more 
CLP and CP mothers reported being exposed to 2
nd
 hand smoking compared to controls (OR: 
10.54 and 95% CI: 2.29 to 48.64 for CLP; and OR: 15.23 and 95% CI: 1.9 to 122.3 for CP) 
among tobacco smoking fathers.  Comparison between cases and controls according to cleft 
phenotype and maternal exposure to paternal tobacco smoking is presented in appendix 
(A27.3).  
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Table 5.27: Case-control comparison according to cleft phenotype and maternal smoking in the 
three month pre-gestation and 1st trimester periods. 
  
Duration  Smoking NSOFC (%) CL (%) CLP (%) CP (%) Controls 
(%)   
pre-gestation  
X
2
 =3.03 
df= 3 
P= 0.387 
Yes  6 (2.9) 2 (2.7) 4 (4.1) 0 10 (4.1) 
No 198 (97.1) 75 (97.3) 70 (95.9) 53 (100) 234 (95.9) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.35 0.67 0.99 0.15  
OR 
(95% CI) 
0.6 
(0.2–1.7) 
0.71 
(0.15–3.37) 
0.99 
(0.27–3.71) 
a  
1st trimester  
X
2
 =1.66 
df= 3 
P= 0.647 
Yes 3 (1.5) 2 (2.6) 1 (1.4) 0 6 (2.5) 
No 201 (98.5) 75 (97.4) 73 (98.6) 53 (100) 236 (97.5) 
Total 204
C 
(100) 77
C
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.47 0.92 0.57 0.25  
OR 
(95% CI) 
0.6 
(0.15–2.4) 
1.08 
(0.21–5.48) 
0.55 
(0.07–4.61 
1.23 
(1.16–1.3) 
 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information. 
a. The OR and CI were not measured because one group contains zero value. 
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Table 5.28: Case-control comparison according to cleft phenotype and paternal smoking during the 
three month pre-gestation and/or 1st trimester periods. 
 
Duration Smoking NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Pregestation 
X
2
=17.63 
df= 3 
P= 0.001** 
Yes 74 (36.3) 17 (22.1) 33 (44.6) 24 (45.3) 90 (36.9) 
No 130 (63.7) 60 (77.9) 41 (55.4) 29 (54.7) 154 (63.1) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.967 0.018** 0.236 0.258  
OR 
(95% 
CI) 
1.01  
(0.69–1.48) 
0.51  
(0.28–0.92) 
1.38  
(0.81–2.33) 
1.14  
(0.78–2.58) 
 
1st trimester 
X
2
=17.02 
df= 3 
P= 0.001** 
Yes 52 (25.5) 8 (10.4) 22 (29.7) 22 (41.5) 70 (29) 
No 152 (74.5) 69 (89.6) 52 (70.3) 31 (58.5) 171 (71) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 241
C 
(100) 
P-value 0.452 0.002** 0.91 0.079  
OR 
(95% CI) 
0.85 (0.56-
1.29) 
0.28 (0.13-
0.62) 
1.03 (0.58-
1.83) 
1.73 (0.94-
3.2) 
 
X
2
 =10.77, df= 2, P= 0.013** 
** Significance value P≤ 0.05  
C 
number less than the total sample (NSOFC: 205; CL: 78; and controls: 244) because of missing 
information. 
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Table 5.29: Case-control comparison according to cleft phenotype and paternal smoking of 
tobacco in the three month pre-gestation and 1st trimester periods. 
 
Duration Tobacco NSOFC (%) CL (%) CLP (%) CP (%) 
Controls 
(%) 
Pregestation 
X
2
=17.63 
df= 3 
P= 0.001** 
Yes 57 (27.9) 9 (11.7) 25 (33.8) 23 (43.4) 77 (31.6) 
No 147 (72.1) 68 (88.3) 49 (66.2) 30 (56.6) 167 (68.4) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.524 0.001** 0.717 0.098  
OR 
(95% CI) 
0.88 
(0.58–1.32) 
0.29 
(0.13–0.63) 
1.11 
(0.64–1.93) 
1.66 
(0.91–3.06) 
 
1st trimester 
X
2
=17.03 
df= 3 
P= 0.001 
Yes 51 (25.4) 8 (10.7) 21 (28.8) 22 (41.5) 71 (29.1) 
No 150 (74.6) 67 (89.3) 52 (71.2) 31 (58.5) 173 (70.9) 
Total 201
C
 (100) 75
C
 (100) 73
C
 (100) 53 (100) 244 (100) 
P-value 0.38 0.001** 0.93 0.08  
OR 
(95% CI) 
0.83 
(0.54–1.26) 
0.3 
(0.14–0.65) 
0.97 
(0.55–1.73) 
1.7 
(0.94–3.2) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information. 
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Table 5.30: Case-control comparison according to cleft phenotype and paternal smoking of ≥ 20 
cigarettes/ day in the pregestation period and/or 1
st
 trimester. 
 
Smoking ≥ 20 
cigarettes/ 
day 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Yes  30 (73.8) 4 (71.4) 11 (61.1) 15 (83.3) 22 (47.8) 
No  11 (26.2) 1 (28.6) 7 (38.9) 3 (16.7) 24 (52.2) 
Total 41
C
 (100) 5
C
 (100) 18
C
 (100) 18
C
 (100) 46
 C
 (100) 
P-value       0.013** 0.187 0.380 0.012**  
OR  
(95% CI) 
3.07  
(1.25–7.55) 
4.18  
(0.43–40.39) 
1.64  
(0.54–5) 
5.23  
(1.33–20.58) 
 
X
2
 =7.26, df=3 and P= 0.064
 
 
** Significance value P≤ 0.05 
C 
number less than the total fathers that smoked tobacco (NSOFC: 57; CL: 9; CLP: 25; CP: 23; 
and controls: 77) because of missing information. 
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Table 5.31: Case-control comparison according to cleft phenotype and paternal non-smoking 
tobacco in the three month pre-gestation and 1
st
 trimester periods. 
 
Duration  Nonsmoking  
Tobacco 
     NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls  
      (%)   
Pre-gestation 
X
2
=7.13 
df=9 
P= 0.672 
Yes 2 (1) 1 (1.3) 1 (1.4) 0 1` 
No 201 (99) 76 (98.7) 72 (98.6) 53 (100) 243 
Total 203
C
 (100) 77
 C
  (100) 73
 C
 (100) 53 (100) 244 
P-value 0.477 0.38 0.36 0.64  
OR  
(95% CI) 
2.4  
(0.22 - 27.1) 
3.27  
(0.2 - 52.93) 
3.34  
(0.21 - 54.19) 
a   
1st trimester 
X
2
=3.84 
df= 3 
P= 0.28 
Yes 3 (1.5) 1 (1.3) 1 (1.4) 1 (2) 0 
No 199 (98.5) 76 (98.7) 73 (98.6) 50 (98) 244 (100) 
Total 202
C
 (100) 77
C
  (100) 74 (100) 51
C
 (100) 244 (100) 
P-value     0.057 0.07 0.068 0.029**  
OR  
(95% CI) 
a a a a  
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; CL: 78; and CLP: 74) because of missing information 
a. The OR and CI were not measured because one group contains zero value  
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Table 5.32: Case-control comparison according to cleft phenotype and paternal waterpipe smoking 
in the three month pre-gestation and 1st trimester periods. 
 
Duration 
Paternal 
waterpipe 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) 
Controls 
(%) 
Pre-gestation 
X
2
=15.17 
df= 3 
P= 0.002** 
Yes 26 (12.2) 10 (13) 14 (18.9) 2 (3.8) 14 (5.7) 
No 178 (87.8) 67 (87) 60 (81.1) 51 (96.2) 230 (94.3) 
Total 204
C 
 (100) 77
C 
(100) 74 (100) 53 (100) 244 (100) 
P-value 0.013** 0.04** <0.001** 0.58  
OR 
(95% CI) 
2.33 
(1.18–4.62) 
2.45 
(1.04–5.77) 
3.83 
(1.73–8.48) 
0.639 
(0.14–2.9) 
 
1st trimester 
X
2
=15.28 
df= 3 
P= 0.002** 
Yes 21 (10.5) 8 (10.5) 12 (16.2) 1 (1.9) 11 (4.5) 
No 182 (89.5) 68 (98.5) 62 (83.8) 52 (98.1) 232 (95.5) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 243 (100) 
P-value 0.016** 0.046** 0.001** 0.372  
OR 
(95% CI) 
2.47 
(1.16–5.27) 
2.56 
(1–6.62) 
4.11 
(1.73–9.77) 
0.4 
(0.05–3.18) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information 
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Table 5.33: Case-control comparison according to cleft phenotype and maternal second-hand 
smoking in the three month pre-gestation and 1st trimester periods.  
 
Maternal 2nd- 
hand smoking 
NSOFC (%) CL (%) CLP (%) CP (%) 
Controls 
(%) 
Yes 45 (22) 10 (13) 21 (28.4) 14 (26.4) 47 (19.3) 
No 159 (78) 67 (87) 53 (71.6) 39 (73.6) 197 (80.7) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.482 0.237 0.088 0.231  
OR  
(95% CI) 
1.18  
(0.75–1.87) 
0.64  
(0.31–1.34) 
1.68  
(0.93–3.06) 
1.52  
(0.76–3.03) 
 
 
X
2
 =6.93, df=3 and P= 0.074 
C 
number less than the total sample (NSOFC: 205; CL: 78; and CLP: 74) because of missing information 
Table 5.34: Case-control comparison according to duration of maternal secondary smoke exposure 
in hours per week among the different cleft phenotype. 
 
Number of 
hours/week (h/w) 
NSOFC (%) CL (%) CLP (%) CP (%) 
Control 
(%) 
<6 h/w (reference) 11 (25) 4 (40) 4 (19) 3 (23.1) 8 (19) 
6-12 h/w 18 (30.9) 3 (30) 11 (52.4) 4 (30.8) 22 (52.4) 
P value 
OR (95% CI) 
0.357 
1.68 (0.56-5.07) 
 
0.13 
3.66 (0.67-20.1) 
1 
1 (0.25-4.06) 
0.404 
2.06 (0.38-11.31) 
 
>12 h/w 15 (34.1) 3 (30) 6 (28.6) 6 (46.2) 12 (28.6) 
P value 
OR (95% CI) 
0.875 
1.1 (0.34-3.6) 
0.436 
2 (0.35-11.44) 
1 
1 (0.21-4.7) 
0.733 
0.75 (0.14-3.9) 
 
Total 44
C
 (100) 10 (110) 21 (100) 13
C
 (100) 42
C
 (100) 
X
2
 =4.3, df=6 and P= 0.637 
C 
number less than the total number of maternal secondary smoke exposure (NSOFC: 205; CP: 14; and 
controls: 47) because of missing information 
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5.4.11 Domestic exposure 
Domestic maternal exposure during the three month period prior to pregnancy and 
the 1st trimester includes exposure to any chemicals, solvents (thinner and/or acetone), 
pesticides, and incense. Table 5.35 shows the sample distribution according to maternal 
exposure to chemicals during the three month pre-gestation and the 1
st
 trimester periods. 
There was a significant difference between CLP cases and controls in maternal reporting of 
exposure to chemicals in the pre-gestation period (P= 0.003, OR: 2.23 and 95% CI: 1.3 to 
3.82) and in the 1st trimester period (P= 0.043, OR: 1.74 and 95% CI: 1.02 to 2.99). Table 
6.36 shows that there was also a significant difference between CLP cases and controls in the 
proportion of mothers reporting exposure to solvents (P= 0.011, OR: 2.25 and 95% CI: 1.18 
to 4.28) in the pre-gestation period. 
Maternal exposure to incense in the first trimester showed significant association with a 
reduced risk of having an infant with NSOFC (P= 0.037, OR: 0.67 and 95% CI: 0.46 to 0.98) 
and CL (P= 0.005, OR: 0.47 and 95% CI: 0.28 to 0.8). Incense exposure in the pre-gestation 
period was also associated with a reduced risk of having an infant with CL (P= 0.011, OR: 
0.51 and 95% CI: 0.3 to 0.86) (Table 5.37). 
Other domestic maternal exposures such as pesticides (Appendix A28), microwaves and 
computers were not associated with NSOFC and were reported in appendix A29.  
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Table 5.35: Case-control comparison according to cleft phenotype and maternal exposure to any 
chemicals reported by the mothers in the three month pre-gestation and the 1st trimester periods. 
 
Duration  Chemicals  NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-gestation  
 
X
2
=11.95 df=3 
P= 0.008 
Yes  68 (33) 17 (22.4) 34 (45.9) 17 (32.1) 67 (27.7) 
No  136 (67) 60 (77.6) 40 (54.1) 36 (67.9) 175 (72.3) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.208 0.366 0.003** 0.515  
OR  
(95% CI) 
1.3  
(0.87 - 1.94) 
0.76  
(0.41 - 1.39) 
2.23  
(1.3 - 3.82) 
1.24  
(0.65 - 2.35) 
 
1st trimester 
 
Chi-squared 
=5.49  
df=3 
P= 0.139  
Yes  69 (33.8) 20 (25) 31 (41.9) 18 (34) 72 (29.8) 
No  135 (66.2) 57 (75) 43 (58.1) 35 (66) 170 (70.2) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.437 0.469 0.043** 0.502  
OR  
(95% CI) 
1.17  
(0.79 - 1.75) 
0.81  
(0.45 - 1.45) 
1.74  
(1.02 - 2.99) 
1.2  
(0.66 - 2.34) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information. 
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Table 5.36: Case-control comparison according to cleft phenotype and maternal exposure to 
solvents (thinner and/or acetone) in the three month pre-gestation and the 1st trimester periods. 
 
Duration  Solvent  NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls (%)   
Pre-gestation 
 X
2
=9.17 
df= 3 
P= 0.027 
Yes  33(16.2) 8 (10.4) 19 (25.7) 6 (11.3) 33 (13.5) 
No  171 (83.8) 69 (89.6) 55 (74.3) 47 (88.7) 211 (86.5) 
Total 204
C
 (100) 77
C
  (100) 74 (100) 53 (100) 244 (100) 
P-value 0.43 0.473 0.011** 0.701  
OR  
(95% CI) 
1.23 
(0.37 - 082) 
0.74 
(0.33 - 1.7) 
2.25 
(1.18 - 4.28) 
0.83 
(0.33 - 2.11) 
 
1st trimester 
 X
2
=0.871 
df= 3 
P= 0.832 
Yes  28 (13.7) 10 (12) 12 (16.2) 6 (11.3) 31 (12.7) 
No  176 (86.3) 67 (88) 62 (83.8) 47 (88.7) 213 (87.3) 
Total 204
C
 (100) 77
C
  (100) 74 (100) 53 (100) 244 (100) 
P-value 0.883 0.86 0.404 0.821  
OR  
(95% CI) 
1.04 
(0.6 - 1.8) 
0.93 
(0.42 - 2.06) 
1.36 
(0.66 - 2.81) 
0.9 
(0.35 - 2.28) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information 
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Table 5.37: Case-control comparison according to cleft phenotype and maternal exposure to 
incense during the pre-gestation and the first trimester periods. 
Duration  Incense  NSOFC (%) CL (%) CLP  CP (%) Controls (%) 
Pre-gestation 
 X
2
=7.05 
df= 3 
P= 0.07 
Yes  88 (43.1) 28 (36.8) 35 (47.3) 25 (47.2) 129 (52.9) 
No  116 (56.9) 49 (63.2) 39 (52.7) 28 (52.8) 115 (47.1) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.058 0.011** 0.348 0.401  
OR 
(95% CI) 
0.7 
(0.48 - 1.01) 
0.51 
(0.3 - 0.86) 
0.78 
(0.46 - 1.31) 
0.78 
(0.43 - 1.41) 
 
1st trimester 
 X
2
=8.61 
df= 3 
P= 0.035 
Yes 87 (42.6) 27 (35.5) 34 (45.9) 26 (49.1) 130 (53.3) 
No 117 (57.4) 50 (64.5) 40 (54.1) 27 (50.9) 114 (46.7) 
Total 204
C
 (100) 77
C
  (100) 74 (100) 53 (100) 244 (100) 
P-value 0.037** 0.005** 0.228 0.519  
OR 
(95% CI) 
0.67 
(0.46 - 0.98) 
0.47 
(0.28 - 0.8) 
0.73 
(0.43 - 1.22) 
0.82 
(0.45 - 1.49) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information 
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5.4.12 Type of main maternal drinking water 
The main maternal drinking water sources in Saudi Arabia include tap, bottled, Zamzam and 
well waters. Table 5.38 shows the sample distribution according to type of maternal drinking 
water. The prevalence of mothers drinking bottled water was greater than other water 
sources: 131 (64.9%) of cases; and 159 (66%) of controls. There were statistically significant 
differences between NSOFC and CL/P compared to controls with respect to the type of 
maternal drinking water source (P= 0.001 for NSOFC; P= 0.016 for CL; P= 0.02 for CLP and 
P= 0.225 for CP). After adjusting for pairwise comparisons between cases and controls for 
the four water source types using Bonferroni correction methods, there were significantly 
more NSOFC and CL/P mothers who had drunk well water compared to controls. In addition, 
there were significantly more control mothers who had drunk Zamzam water compared to 
NSOFC and CL/P mothers (P<0.05).   
Table 5.38: Case-control comparison according to type of maternal drinking water. 
 
Type of water NSOFC (%) CL (%) CLP (%)  CP (%) Controls (%)   
Tap 56 (28.2) 19 (24.7) 21 (29.6) 16 (30.2) 60 (24.9) 
Bottled 131 (64.9) 54 (70.1) 43 (60.6) 34 (64.2) 159 (66) 
Well 11 (5.4) 4 (5.2) 5 (7) 2 (3.8) 3 (1.2) 
Zamzam 3 (1.5) 0 2 (2.8) 1 (1.9) 19 (7.9) 
Total 201
C
 (100) 77
C
 (100) 71
C
 (100) 53 (100) 241
C
 (100) 
P-value 0.001** 0.016** 0.02** 0.225  
X
2
=18, df=9, and P= 0.033** 
C 
number less than the total sample (NSOFC: 205; and CL: 78;CLP: 74 ; and controls:244) because 
of missing information 
** Significance value P< 0.05 
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5.4.13 Multiple logistic regression analysis 
Table 5.39 shows variables that had statistical significant relationship with NSOFC, CLP and 
CP in multiple logistic regression analyses with the significant adjusted OR and 95% CI.  
Stepwise logistic regression analysis identified eight factors as significant predictors for 
NSOFC, five as significant predictors for CL, seven as significant predictors for CLP and 
four as significant predictors for CP risk. For NSOFC the factors were: family history for 
NSOFC (P<0.001, OR: 8.78 and 95% CI: 4.43 to 17.39); maternal common cold/flu during 
the three months pre-gestation (P= 0.002, OR: 3.28 and 95% CI: 1.57 to 6.64); maternal 
ingestion of anti-emetic medication during the 1st trimester (P= 0.006, OR: 3.00 and CI: 1.38 
to 6.55); antipyretic medication (P= 0.004, OR: 0.27 and 95% CI: 0.11 to 0.66); Calcium 
supplementation in the 1
st
 trimester (P= 0.053, OR: 0.4 and 95% CI: 0.15 to 1.01); mother 
complaining of being under stress during pregestation and 1
st
 trimester period (P= 0.003, 
OR: 2 and 95% CI: 1.27 to 3.14); paternal waterpipe smoking (P= 0.03 and OR: 2.38 and 
95% CI: 1.09 to 5.22); and maternal drinking water (P= 0.007). Maternal Zamzam drinking 
water shows a marginally significant effect compared to bottled water (P= 0.033, OR: 0.23 
and 95% CI: 0.06 to 0.89), Tap water (P= 0.049, OR: 0.25 and 95% CI: 0.06 to 0.99) and 
well water (P= 0.001, OR: 0.03 and 95% CI: 0.005 to 0.23).   
For CL, the predictor variables were: family history for NSOFC (P<0.001, OR: 8.79 and 
95% CI: 3.92 to 19.68); antibiotics during the pregestation (P= 0.033, OR: 3.01 and CI: 1.1 
to 8.61) and  during the 1st trimester (P= 0.005, OR: 3.07 and 95% CI: 1.4 to 6.73); mothers 
complaining of family problems (P= 0.011, OR: 2.29 and 95% CI: 1.21 to 4.35); and incense 
exposure in the 1st trimester (P= 0.031, OR: 0.51 and 95% CI: 0.27 to 0.94). 
For CLP the associated variables were: family history for NSOFC (P< 0.001, OR: 14.73 and 
95% CI: 5.99 to 36.17); common cold/flu during the pre-gestation period (P< 0.001, OR: 
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5.82 and 95% CI: 2.38 to 14.25); folic acid in the 1
st
 trimester (P= 0.007, OR: 0.09 and 95% 
CI: 0.14 to 0.51) maternal stress (P= 0.002, OR: 3 and 95% CI: 1.49 to 6.03); paternal 
waterpipe smoking (P= 0.001, OR: 5.74 and 95% CI: 2.07 to 15.9); maternal exposure to 
chemicals in the pregestation period (P= 0.003, OR: 2.91 and 95% CI: 1.44 to 5.89) and 
maternal main water source (P= 0.001). Maternal Zamzam drinking water shows a 
significant effect compared to well water (P= 0.001, OR: 0.02 and 95% CI: 0.002 to 0.2), 
For CP the factors were: family history (P< 0.001. OR: 5.89 and 95% CI: 2.36 to 14.74); 
maternal common cold/flu in the pregestation period (P= 0.029, OR: 2.28 and 95% CI: 1.09 
to 4.77); abdominal pain in the 1st trimester (P= 0.001, OR: 5.81 and 95% CI: 2.05 to 16.45); 
and maternal stress (P= 0.028, OR: 2.1 and 95% CI: 1.08 to 4.06).  
 
Table 5.39: Multiple logistic regression analysis showing the most significant factors related to NSOFC, CL, 
CLP and CP. 
 
Factors P-value  
OR (95% Cl) 
NSOFC* CL** CLP*** CP**** 
Factors increasing the chance of NSOFC 
Family history  <0.001**          
8.78 (4.43-17.39) 
<0.001**          
8.79 (3.92-19.68) 
<0.001**        
14.7 (5.99-36.2) 
<0.001**       
5.89(2.36-14.74) 
Common cold/flu 
pre-gestation 
0.002**            
3.28 (1.57-6.64) 
a 
<0.001**        
5.82 (2.38-4.25) 
0.029                
2.28 (1.09-4.77) 
Abdominal pain in 
the 1st trimester 
a a a 
0.001                 
5.81 (2.05-16.45) 
Antibiotic in pre-
gestation  
a 
0.033                 
3.01 (1.1-8.61) 
a a 
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Factors P-value  
OR (95% Cl) 
NSOFC* CL** CLP*** CP**** 
Antibiotic in 1st 
trimester 
a 
0.005                
3.07 (1.4-6.73) 
a a 
Anti-emetic 
medication 
0.0063             
(1.38-6.55) 
a a a 
Maternal stress 0.003                     
2 (1.27-3.14) 
a 
0.002                   
3 (1.49-6.03) 
0.028                  
2.1 (1.08-4.06) 
Family problems 
a 
0.011                 
2.29 (1.21-4.35) 
a a 
Paternal waterpipe 
smoking  
0.03                  
2.38 (1.09-5.22) 
a 
0.001               
5.74 (2.07-15.9) 
a 
Maternal exposure 
to chemical in the 
pregestation period 
a a 
0.003               
2.91 (1.44–5.89) 
a 
Factors decreasing the chance of NSOFC: 
Folic acid in the 
1st trimester 
a a 
0.007              
0.09 (0.14-0.51) 
a 
Calcium 
supplementation 
0.053                  
0.4 (0.15-1.01) 
a a a 
Antipyretic in 
pregestation  
0.004                
0.27 (0.11-0.66) 
a a a 
Incense in the 1st 
trimester  
a 
0.031                 
0.51 (0.27-0.94) 
a 
a 
Maternal main 
water source   
0.007 a 0.001 
a 
Zamzam water 
compared to 
bottled water 
0.033                
0.23 (0.06-0.89) 
a 
0.67                 
0.71 (0.14-3.48) 
a 
When compared to 0.049                a 0.701               a 
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Factors P-value  
OR (95% Cl) 
NSOFC* CL** CLP*** CP**** 
tap water 0.25 (0.06-0. 99) 0.72 (0.14-38) 
When compared to 
well water 
0.001                
0.03 (0.005-0.23) 
a 
0.001               
0.02 (0.002-0.2) 
a 
* Factors entered in the multiple regression included: family history of NSOFC, twins versus singleton 
birth frequency , antibiotics in the pre-gestation and 1st trimester periods, antipyretic medication in the 
pre-gestation period, anti-emetic medication in the 1
st
 trimester, maternal illness in the pre-gestation and 
1st trimester periods, flu/ common cold during pre-gestation and 1
st
 trimester periods, fever in the pre-
gestation period, folic acid in the 1st trimester periods, calcium supplementation in the 1
st
 trimester 
period, mothers complaining of stress, mothers with family problems, abdominal pain in the 1st trimester 
period, paternal waterpipe smoking, and type of maternal drinking water source. 
** Factors entered in the multiple regression include: family history of NSOFC, twins versus singleton 
birth frequency, antibiotics in the pre-gestation and 1st trimester periods, anti-emetic medication, 
maternal illness in the pre-gestation period, flu/ common cold in the pre-gestation period, mothers 
complaining of stress, mothers with family problems, paternal waterpipe smoking, type of maternal 
drinking water source, and maternal incense exposure in the pre-gestation and 1st trimester periods.  
 
***Factors entered in the multiple regression includes: family history of NSOFC, twins versus singleton 
birth frequency, folic acid in the 1st trimester period, antibiotic in the pre-gestation period, maternal 
illness in the pre-gestation period, flu/ common cold in the pre-gestation period, maternal fever in the pre-
gestation period, mothers complaining of stress, mothers with family problems, paternal waterpipe 
smoking, maternal exposure to chemicals in the pre-gestation and 1st trimester periods, maternal solvent 
exposure during the pre-gestation period, and type of maternal drinking water source. 
**** Factors entered in the multiple regression include: family history, calcium supplementation in the 
1st trimester period, maternal illness in pre-gestation period, flu/ common cold in the pre-gestation and 
1st trimester period, abdominal pain in the 1st trimester period, mothers complaining of stress, and 
mothers with family problems.  
a. No values either because the variable were not entered in the logistic regression or had no significant 
relationship with cleft.  
 
(Appendix A30 shows variables not in the equation which is not significant) 
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5.5 Genetic analysis results 
Genetic analysis was carried out for IRF6 (rs2013162, rs2235375, and rs2235371) and VAX1 
(rs4752028 and rs7078160) and their associations with CL/P and CP using 171 case parental 
triad family-based approach and case-control infant-parental triad-approach by comparing 
cases to 189 infant-parental triad controls. However, 16 fathers in the control group did not 
provide saliva. In addition, 10 of the cases were not sub-grouped according to cleft 
phenotype, resulting in 127 CL/P and 34 CP cases in our analysis.  
5.5.1 Hardy-Weinberg equilibrium 
Table 5.40 shows the Hardy-Weinberg equilibrium calculations for the IRF6 (rs2013162, 
rs2235375 and rs2235371) and VAX1 (rs4752028 and rs7078160) genotypes in case and 
control infant-parental triads. VAX1 rs4752028 showed no significant differences between 
the observed and expected values for the included homozygous and heterozygous genotype 
frequencies with P-values greater than 0.05, indicating that the case and control triad samples 
were in Hardy-Weinberg equilibrium at this locus. However, the other loci were not in 
Hardy-Weinberg equilibrium, including; among NSOFC cases: IRF6 rs2013162 paternal 
gene variance (2 = 7.85 and P = 0.002) and maternal IRF6 rs2235375 gene variance (2 = 
6.04 and P = 0.05); among controls: IRF6 rs2013162 maternal gene variance (2 = 8.92 and 
P = 0.01) and VAX1 rs7078160 paternal gene variance (2 = 21.76 and P< 0.001); among 
both cases and controls: VAX1 rs7078160 maternal gene variance (2 = 18.23 and P< 0.001, 
and 2 = 20.9 and P< 0.001) respectively. 
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Table 5.40 The observed frequency (OF) and expected frequency (EF) for the included genotypes 
(IRF6 and VAX1) using the Hardy Weinberg frequency calculation. 
 
Groups Cases Controls 
Genotype Common 
homozygous  
Heterozygous  Rare 
homozygous  
Common 
homozygous  
Heterozygous  Rare 
homozygous  
Paternal IRF6 rs2013162 Cases=163, controls=158 
Observed 70 85 8 81 66 11 
Expected 77.65 69.71 15.65 82.25 63.49 12.25 
X
2
(df), P value 7.85 (2), 0.002** 0.25 (2), 0.25 
                    Maternal IRF6 rs2013162 cases=171, controls=185   
Observed 79 79 13 94 63 28 
Expected 82 72.76 16.12 85.14 80.73 19.14 
X
2
(df), P value 1.25(2), 0.536 8.92(2), 0.01** 
Paternal IRF6 rs2235375 cases=165, controls=169 
Observed 23 84 58 82 68 19 
Expected 25.61 78.79 60.6 79.62 72.76 16.62 
X
2
(df), P value 0.72(2), 0.697 0.72(2), 0.697 
                     Maternal IRF6 rs2235375 cases=171, controls=189   
Observed 36 67 68 41 84 64 
Expected 28.25 82.51 60.25 36.45 93.1 59.45 
X
2
(df), P value 6.04 (2), 0.05** 1.81(2), 0.405 
Paternal IRF6 rs2235371 cases=163, controls=170 
Observed 162 1 0 168 1 1 
Expected 161 3 0 167 3 0 
X
2
(df), P value 1.34 (2) 0.512 1.34 (2), 0.512 
                   Maternal IRF6 rs2235371cases=169 controls=189   
Observed 169 0 0 184 5 0 
Expected 169 0 0 184 5 0 
X
2
(df), P value <0.001(2), 1  <0.001(2), 1  
Paternal VAX1 rs4752028 cases=165, controls=168 
Observed 95 65 5 134 29 5 
Expected 98.5 58 8.5 131.3 34.47 2.26 
X
2
(df), P value 2.41 (2), 0.3 4.25(2), 0.12 
Maternal VAX1 rs4752028 cases=168, controls=187 
Observed 104 52 12 151 32 4 
Expected 100 58.8 8.6 149 35.7 2.14 
X
2
(df), P value 2.14 (2), 0.318 2.03 (2), 0.363 
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Paternal VAX1 rs7078160 cases=163, controls=165 
Observed 120 35 8 141 18 6 
Expected 116 43 4 135.6 29.7 1.63 
X
2
(df), P value 5.63(2), 0.06 21.76 (2), <0.001** 
  Maternal VAX1 rs7078160 cases=170, controls=189 
Observed 127 31 12 164 19 6 
Expected 119.45 46.1 4.45 159.27 28.46 1.27 
X
2
(df), P value 18.23 (2), <0.001** 20.9 (2), <0.001** 
**The Chi-square statistic is significant at the 0.05 level 
5.5.2 IRF6 rs2013162 analysis 
Out of the 171 cases and 189 controls; 23 (8 cases and 15 controls) paternal samples, four 
maternal control samples and 17 infant samples (6 cases and 11 controls) did not produce 
genotyping values for IRF6 rs2013162. The phenotype diagnosis for ten NSOFC cases are 
missing.  Sixteen control fathers refused to give their saliva. This resulted in; 153 NSOFC (120 
CL/P, and 33 CP) paternal genotypes compared to 158 controls; 161 NSOFC (127 CL/P and 34 CP) 
maternal genotypes compared to 185 controls; and 155 NSOFC (123 CL/P and 32 CP) infant 
genotypes compared to 178 controls, according to IRF6 rs2013162genotype variance (Figure 
5.2). 
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33 CP 
127 CL/P 
34 CP 
32 CP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The saliva sample did not produce genotyping values for IRF6 rs2013162 
Figure 5.2: Sample flaw description for IRF6 rs2013162 genotype variance infant-
parental triad  
 
5.5.2.1 Transmission Disequilibrium Test (TDT): 
Table 5.41 shows the Transmission Disequilibrium Test (TDT) for IRF6 rs2013162 common 
and rare alleles using the Family Based Association Test (FBAT) gene analysis among 
NSOFC, CL/P and CP infant-parental triads. A statistically significant over-transmission of 
the common allele (C) in NSOFC families including CL/P cases (P= 0.014 and P= 0.018, 
respectively) was found. PLINK testing also found a significant reduction of NSOFC and 
CL/P risk with the IRF6 rs2013162 rare allele (P= 0.016 and OR: 0.667 for NSOFC and P= 
Paternal:  171 NSOFC  
   Not genotyped= 8 
   Missing diagnosis= 10 
Final NSOFC=163       
Sub-phenotyped= 153 
120 CL/P 
Total 
Cases 
Deductions 
Paternal: 189 Controls 
 Missing sample= 16 
   Not genotyped= 15* 
Final controls= 158 
Deductions 
Deductions 
Maternal: 171 NSOFC Missing diagnosis= 10 
 
NSOFC sub-phenotyped= 161 
Maternal: 189 controls Not genotyped= 4* Final controls= 185 
Infant: 189 Controls    Not genotyped= 11* Final controls= 178 
Deductions 
Infant:  171 NSOFC 
   Not genotyped= 6 
   Missing diagnosis= 10 
Final NSOFC cases= 165 
Sub-phenotyped=155 
123 CL/P 
Total 
Cases 
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0.018 and OR: 0.644 for CL/P). The IRF6 variant was significantly over-transmitted from 
the paternal side (P= 0.05) which shows that the significant association observed for IRF6 
rs2013162 was mainly driven from variants coming from the father (Table 5.42). 
IRF6 rs2013162 variants did not show an association with CP infant-parental triads 
following either FBAT or PLINK testing.   
 
5.5.2.2. Comparison between case and control IRF6 rs2013162 genotypes:  
Table 5.43 shows the distribution of IRF6 rs2013162 infant-parental triad genotypes for 
NSOFC, CL/P and CP cases compared to controls. There were no significant differences 
between cases and controls in paternal IRF6 rs2013162 genotype (P= 0.166 for NSOFC, P= 
0.08 for CL/P and P= 0.92 for CP), infant IRF6 rs2013162 genotype (P= 0.33 for NSOFC, 
P= 0.18 for CL/P and P= 0.32 for CP) and maternal CP IRF6 rs2013162 genotype (P= 
0.187). However, there were significant differences in maternal IRF6 rs2013162 genotypes 
for NSOFC (P= 0.018) and CL/P (P= 0.024) in cases compared to controls.  
After chi-square adjustment and Bonferroni correlation was carried out, it was found that the 
maternal homozygous rare allele genotype (AA) was significantly more prevalent in controls 
than in NSOFC cases and in CL/P. Furthermore, the heterozygous genotype (CA) was 
significantly more prevalent in cases than in controls. 
5.5.2.3 Comparison between case and control IRF6 rs2013162 alleles: 
Table 5.44 shows the distribution of IRF6 rs2013162 infant-parental triad allele frequencies 
in NSOFC, CL/P and CP cases compared to controls. There were no statistical significant 
differences between the different NSOFC phenotypes and controls.  
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Table 5.41: Transmission Disequilibrium test (TDT) results for IRF6 rs2013162 variants among 
NSOFC infant-parental triads and its sub-phenotypes (CL/P and CP) using FBAT analysis. 
     
Type of 
NSOFC 
Allele  afreq    fam# SE       Var(S)        Z test P value 
NSOFC C 0.697     104 15.000       37.500    2.449     0.014** 
A 0.303     104 -15.000       37.500   2.449     -0.014** 
CL/P C 0.696 79 13 30 2.373     0.018** 
A 0.304 79 -13 30 -2.373     0.018** 
CP C 0.623 21 1.5 6.75 0.577 0.564 
A 0.377 21 -1.5 6.75 -0.577 0.564 
**Significant at the 0.05 level. 
afreq :Estimating allele frequencies 
fam#: Number of families 
SE: Standard error 
Var(S): Value of the average of the squared differences from the mean  
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Table 5.42: Testing IRF6 rs2013162 alleles for transmission disequilibrium and parent of origin 
using PLINK analysis for NSOFC infant-parental triads and its sub-phenotypes (CL/P and CP).   
 
NSOFC 
Transmitted/ 
Untransmitted 
minor allele 
P-value OR A:U_PAR P-value 
Combined 
statistics 
P-value 
NSOFC 58/88 0.016** 0.667 01:02 0.564 0.014** 
CL/P 47/73 0.018** 0.644 1:02 0.564 0.015** 
CP 12/15 0.564 0.8 00:00 NA 0.257 
Parent of origin effect 
 T:U_PAT 
Paternal 
P-value 
T:U_MAT 
Maternal 
P-value 
POO 
Z 
POO 
P 
NSOFC 29:46:00 0.05** 29:41:00 0.152 -0.339 0.735 
CL/P 24.5:39.5 0.061 22.5:33.5 0.142 -0.212 0.832 
CP 05:07 0.564 07:08 0.796 -0.26 0.795 
A:U PAR: Parental discordance counts 
POO: Parents of Origin 
T:U PAT: Paternal transmitted: untransmitted counts 
T:U MAT: Maternal transmitted: untransmitted counts 
**Significant relationship P≤0.05  
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Table 5.43 Distribution of IRF6 rs2013162 infant-parental triad genotypes according to NSOFC 
phenotypes (CL/P and CP) and compared to controls. There were missing samples; 23 (8 cases and 
15 controls) paternal samples, four maternal control samples and 17 infant samples (6 cases and 11 
controls). The phenotype diagnosis of ten NSOFC cases are missing.       
 
Genotype NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2013162 (X
2
=5.02, df=4, P= 0.285) 
CC* 70 (42.9) 51 (42.5) 16 (48.5) 81 (51.3) 
AA 8 (4.9) 4 (3.3) 2 (6.1) 11 (7) 
CA 85 (52.1) 65 (54.2) 15 (45.5) 66 (41.8) 
Total 163
C
 (100) 120 33 (100) 158(100) 
P-value 0.166 0.08 0.92  
Maternal IRF6 rs2013162 (X
2
=9.22, df=4, P= 0.056) 
CC* 79 (46.2) 62 (48.8) 14 (41.2) 94 (50.8) 
AA 13 (7.6) 8 (6.3) 3 (8.8) 28 (15.1) 
CA 79 (46.2) 57 (44.9) 17 (50) 63 (34.1) 
Total 171
C
 (100) 127 (100) 34 (100) 185 (100) 
P-value 0.018** 0.024** 0.19  
Infant IRF6 rs2013162 (X
2
=5.42, df=4, P= 0.247) 
CC* 86 (52.1) 67 (54.5) 13 (40.6) 95 (53.4) 
AA 11 (6.1) 6 (4.9) 3 (9.4) 19 (10.7) 
CA 68 (41.2) 50 (40.7) 16 (50) 64 (36) 
Total 165
C
 (100) 123 (100) 32 (100) 178 (100) 
P-value 0.33 0.18 0.32  
* The common homozygous allele genotype 
**The Chi-square statistic is significant at the 0.05 level. 
C
 Ten NSOFC cases was not sub-phenotyped  
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Table 5.44 Distribution of IRF6 rs2013162 infant-parental triad allele frequencies in NSOFC, 
CL/P and CP cases and compared to controls. 
  
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2013162(X
2
=0.44, df=2, P= 0.803) 
C* 225 (69) 167 (69.6) 47 (71.2) 228 (72.2) 
A 101 (31) 73 (30.4) 19 (28.8) 88 (27.8) 
Total 326
C
 (100) 240 (100) 66 (100) 316 (100) 
P-value 0.38 0.508 0.877  
OR (95% CI) 1.16 (0.83–1.63) 1.13 (0.78–1.64) 
1.05 (0.58–1.88) 
 
Maternal IRF6 rs2013162(X
2
=1.09, df=2, P= 0.58) 
C* 237 (69.7) 181 (71.3) 45 (66.2) 251 (67.1) 
A 105 (30.7) 73 (28.7) 23 (33.8) 119 (32.9) 
Total 342
C
 (100) 254 (100) 68 (100) 370 (100) 
P-value 0.675 0.363 0.788  
OR (95% CI) 0.93 (0.68–1.28) 1.18 (0.8–1.67) 1.08 (0.62–1.86)  
Infants IRF6 rs2013162(X
2
=2.32, df=2, P= 0.313) 
C*  240 (72.7) 184 (74.8) 42 (65.6) 254 (71.3) 
A 90 (27.3) 62 (25.2) 22 (34.4) 102 (28.7) 
Total 330
C
 (100) 246 (100) 64 (100) 356 (100) 
P-value 0.688 0.26 0.425  
OR (95% CI) 1.07 (0.77–1.5) 0.84 (0.58–1.21) 1.30 (0.74–2.29)  
* The common homozygous allele genotype 
C
 Ten NSOFC cases were not sub-phenotyped 
5.5.3 IRF6 rs2235375 analysis    
Out of the total 171 cases and 189 controls; 10 (6 cases and 4 controls) paternal samples, and 
one infant control did not produce genotyping values for IRF6 rs2235375. The phenotype 
diagnosis for ten NSOFC cases are missing.   This resulted in; 122 CL/P, and 33 CP paternal 
genotype compared to 169 controls; 127 CL/P and 34 CP maternal genotype compared to 189 
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33 CP 
127 CL/P 
34 CP 
35 CP 
controls; and 126 CL/P and 35 CP infant genotype compared to 188 controls, according to IRF6 
rs2235375 genotype variance (Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The saliva sample did not produce genotyping values for IRF6 rs2013162 
Figure 5.3: Sample flaw description IRF6 rs2235375 genotype variance infant-
parental triad  
 
 
 
Paternal:  171 NSOFC  
   Not genotyped= 6* 
   Missing diagnosis= 10 
Final NSOFC cases= 165 
sub-phenotyped= 155 
122 CL/P 
Total 
Cases 
Deductions 
Paternal: 189 Controls 
 Missing sample= 16 
   Not genotyped= 4* 
Deductions 
Deductions 
Final controls= 189 
Final controls= 169 
Maternal: 171 NSOFC  Missing diagnosis= 10 
 
NSOFC sub-phenotyped=161 
Maternal: 189 controls     Not genotyped= 0 
Infant: 189 Controls    Not genotyped= 1* Final controls= 188 
Deductions 
Infant:  171 NSOFC 
   Not genotyped= 0 
   Missing diagnosis= 10 
Final NSOFC cases= 165 
sub-phenotyped= 155 
126 CL/P 
Total 
Cases 
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5.5.3.1 TDT gene analysis: 
Tables 5.45 and 5.46 show the TDT analyses using the FBAT and PLINK tests for IRF6 
rs2235375 common and rare alleles. No significant over-transmission of the IRF6 rs2235375 
rare allele in NSOFC families (FBAT: P= 0.61 for NSOFC; P= 0.441 for CL/P; and P= 
0.577 for CP. For PLINK: P= 0.667 for NSOFC; P= 0.441 for CL/P; and P= 0.578 for CP).     
5.5.3.2 Comparison between case and control IRF6 rs2235375 genotypes: 
Table 5.47 shows the distribution of IRF6 rs2235375 genotypes in NSOFC, CL/P and CP 
cases compared to controls in infant-parental triads. There was a statistically significant 
difference found between paternal genotypes of NSOFC infants and controls (P= 0.047). 
After chi-square adjustment using Bonferroni correction for the IRF6 rs2235375 relationship 
with NSOFC, the homozygous rare genotype (GG) was found to be significantly more 
frequent in fathers of the controls than in fathers of cases with NSOFC. However, no 
statistically significant differences were found between cases and controls in mothers or 
infants (P= 0.14 and P= 0.18, respectively). 
5.5.3.3 Comparison between case and control IRF6 rs2235375 alleles: 
Table 5.48 shows the frequency of IRF6 rs2235375 alleles in case and control infant-
parental triads. There was no statistical significant difference found between cases compared 
to controls in infant-parental triads for this SNP except for paternal rare allele (G) which 
shows a statistical significant lower frequency of NSOFC cases compared to control (P= 
0.03, OR:0.7 and 95% CI: 0.5 to 0.93).   
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Table 5.45: Transmission Disequilibrium test (TDT) results for IRF6 rs2235375 variants among 
NSOFC infant-parental triads and its sub-phenotypes (CL/P and CP) using FBAT analysis. 
     
Type of 
NSOFC 
Allele afreq fam# SE Var(S) Z test P value 
NSOFC C* 0.360 91 -3.000 34.500 -0.511 0.61 
G 0.640 91 3.000 34.500 0.511 0.61 
CL/P C* 0.634 69 4 27 0.77 0.441 
G 0.366 69 -4 27 -0.77 0.441 
CP C* 0.636 20 -1.5 7.250 -0.557 0.577 
G 0.364 20 1.5 7.250 0.557 0.577 
*The common allele 
afreq :Estimating allele frequencies 
fam#: Number of families 
SE: Standard error 
Var(S): Value of the average of the squared differences from the mean  
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Table 5.46: Testing IRF6 rs2235375 alleles for transmission disequilibrium and parent of origin 
using PLINK analysis for NSOFC infant-parental triads and sub-phenotypes (CL/P and CP).   
 
NSOFC 
Transmitted/ 
Untransmitted 
minor allele 
P-value OR A:U_PAR 
P-
value 
Combined 
statistics 
P-value 
NSOFC 65/70 0.667 0.929 00:00 NA 0.667 
CL/P 50/58 0.441 0.862 00:00 NA 0.441 
CP 16/13 0.578 1.23 00:00 NA 0.257 
Parent of origin effect 
 T:U_PAT 
Paternal 
P-value 
T:U_MAT 
Maternal 
P-value 
POO 
Z 
POO 
P 
NSOFC 37:40:00 0.732 28:30:00 0.793 -0.026 0.979 
CL/P 28.5:34.5 0.45 21.5:23.5 0.766 -0.261 0.794 
CP 09:06 0.439 07:07 1 -0.54 0.595 
A:U PAR: Parental discordance counts 
POO: Parents of Origin 
T:U PAT: Paternal transmitted: untransmitted counts 
T:U MAT: Maternal transmitted: untransmitted counts 
**Significant relationship  
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Table 5.47: Distribution of IRF6 rs2235375 infant-parental triad genotypes according to NSOFC 
phenotypes (CL/P and CP) and compared to control infant-parental triads. Ten (6 cases and 4 
controls) paternal samples, and one infant control did not produce genotyping values for IRF6 
rs2235375.  
 
Genotype  NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2235375( X
2
=6.04, df=4, P= 0.196) 
  CC* 23 (13.9) 16 (13.1) 3 (9.1) 19 (11.2) 
GG 58 (35.2) 45 (36.9) 11 (33.3) 82 (48.5) 
CG 84 (50.9) 61 (50) 19 (57.6) 68 (40.2) 
Total 165
C
 (100) 122 (100) 33 (100) 169 (100) 
P-value 0.047* 0.14 0.18  
Maternal IRF6 rs2235375 (X
2
=2.2, df=4, P= 0.7) 
CC* 36 (21.1) 25 (19.7) 8 (23.5) 41 (21.7) 
GG 68 (39.8) 54 (42.5) 11 (32.4) 84 (44.4) 
CG 67 (39.2) 48 (37.8) 15 (44.1) 64 (33.9) 
Total 171
C
 (100) 127 (100) 34 (100) 189 (100) 
P-value 0.554 0.76 0.39  
Infant IRF6 rs2235375 (X
2
=1.01, df=4, P= 0.908) 
CC* 34 (19.9) 26 (20.6) 7 (20) 38 (20.2) 
GG 77 (45) 57 (45.2) 13 (37.1) 83 (44.1) 
CG 60 (35.1) 43 (34.1) 15 (42.9) 67 (35.6) 
Total 171
C
 (100) 126 (100) 35 (100) 188 (100) 
P-value 0.99 0.96 0.69  
* The common homozygous allele genotype 
**The Chi-square statistic is significant at the 0.05 level. 
C
 Ten NSOFC cases were not sub-phenotyped 
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Table 5.48: Distribution of IRF6 rs2235375 infant-parental triad allele frequencies in NSOFC, 
CL/P and CP cases and compared to controls. 
  
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2235375(X
2
=3.21, df=2, P= 0.2) 
C* 130 (41.2) 93 (38.1) 25 (37.9) 106 (31.4) 
G 200 (38.8) 151 (61.9) 41 (62.1) 232 (68.6) 
Total 330 (100) 244 (100) 66 (100) 338 (100) 
P-value 0.03** 0.09 0.301  
OR (95% CI) 
0.7 (0.5 -0.97) 1.35 (0.95 - 1.90) 1.33 (0.77 - 2.31) 
 
Maternal IRF6 rs2235375(X
2
=1.25, df=2, P= 0.534) 
 C* 139 (40.6) 98 (38.6) 31 (45.6) 146 (38.6)  
G 203 (59.4) 156 (61.4) 37 (44.4) 232 (61.4) 
Total 342 (100) 254 (100) 68 (100) 378 (100) 
P-value 0.58 1 0.28  
OR (95% CI) 1.09 (0.81 - 1.47) 1.00 (0.72 - 1.38) 1.33 (0.79 - 2.24)  
Infant IRF6 rs2235375 (X
2
=0.46, df=2, P= 0.793) 
C* 128 (37.4) 95 (37.7) 29 (41.4) 143 (37.1) 
G 214 (62.6) 157 (62.3) 41 (58.6) 242 (62.9) 
Total 342 (100) 252 (100) 70 (100) 385 (100) 
P value 0.916 0.867 0.5  
OR-(95% CI) 0.97 (0.72 - 1.32) 0.99 (0.71 - 1.37) 0.84 (0.5 - 1.4)  
   **The Chi-square statistic is significant at the 0.05 level. 
 
5.5.4 IRF6 rs2235371 analysis 
Out of the total 171 cases and 189 controls; 11 (8 cases and 3 controls) paternal samples, two 
maternal NSOFC samples and four infant samples (two cases and two controls) did not 
produce genotyping values for IRF6 rs2235371. The phenotype diagnosis for ten NSOFC 
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126 CL/P 
33 CP 
33 CP 
35 CP 
cases are missing.  This resulted in; 120 CL/P, and 33 CP paternal genotype compared to 170 
controls; 126 CL/P and 33 CP maternal genotype compared to 189 controls; and 124 CL/P and 35 CP 
infant genotype compared to 187 controls, according to IRF6 rs2235371 genotype variance 
(Figure 5.4). 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
* The saliva sample did not produce genotyping values for IRF6 rs2013162 
Figure 5.4: Sample flaw description for IRF6 rs2235371 genotype variance infant-
parental triad  
 
 
Deductions 
Maternal: 171 NSOFC  
   Missing diagnosis= 10 
 
Final NSOFC cases=169 
sub-phenotyped=159 
Maternal: 189 controls     Not genotyped= 0* Final controls= 189 
  Not genotyped= 2 
Paternal:  171 NSOFC  
   Not genotyped= 8* 
   Missing diagnosis= 10 
Final NSOFC cases= 163 
sub-phenotyped= 153 
120 CL/P 
Total 
Cases 
Deductions 
Paternal: 189 Controls 
 Missing sample= 16 
   Not genotyped= 3* 
Final controls= 170 
Deductions 
Infant: 189 Controls    Not genotyped= 2* Final controls= 187 
Deductions 
Infant:  171 NSOFC 
   Not genotyped= 2* 
   Missing diagnosis= 10 
Final NSOFC cases= 159 
124 CL/P 
Total 
Cases 
210 
 
5.5.4.1 TDT gene analysis: 
Table 5.49 shows the frequency of IRF6 rs2235371 genotypes for case and control infant-
parental triads. Almost all cases and controls were homozygous for the common allele (CC) 
(99.4% and 98.8% respectively). Therefore TDT using FBAT and PLINK analyses was not 
carried out as the number of rare alleles was negligible.   
5.5.4.2 Comparison between case and control IRF6 rs2235371 genotypes: 
There was no statistically significant differences between IRF6 rs2235371 genotypes in 
NSOFC families compared with controls even after chi square correction except in mothers 
where there were 5 (2.5%) maternal controls with a heterozygous genotype (CT) compared 
to zero NSOFC mothers with the CT genotype (P= 0.03) (table 5.49). 
 
5.5.4.3 Comparison between case and control IRF6 rs2235371 alleles: 
Table 5.51 shows the frequency of IRF6 rs2235371 alleles in case and control infant-parental 
triads. There were significantly more controls with the IRF6 rs2235371 rare allele (T) 
compared to NSOFC (P= 0.002, OR: 0.05 and 95% CI: 0.0 to 0.86) (Table 5. 50). 
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Table 5.49: Distribution of IRF6 rs2235371 infant-parental triad genotypes according to NSOFC 
phenotypes (CL/P and CP) and compared to controls. Eleven (8 cases and 3 controls) paternal 
samples, two maternal NSOFC samples and four infant samples (two cases and two controls) did 
not produce genotyping values for IRF6 rs2235371. The phenotype diagnosis for ten NSOFC cases 
are missing 
 
Genotype  NSOFC (%)  CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2235371 (X
2
=1.2, df=4, P= 0.878) 
CC* 162 (99.4)  119 (99.2) 33 (100) 168 (98.8) 
TT 0 0 0 1 (0.6) 
CT 1 (0.6) 1 (0.8) 33 (100) 1 (0.6) 
Total 163
C
 (100) 120 33 (100) 170 (100) 
P-value 0.62 0.68 0.82  
Maternal IRF6 rs2235371( X
2
=4.27, df=2, P= 0.118) 
CC* 169 (100) 126 (100) 33 (100) 184 (97.4) 
TT 0 0 0 0 
CT 0 0 0 5 (2.6) 
Total 169
C
 (100) 126 (100) 33 (100) 189 (100) 
P-value 0.03** 0.066 0.35  
Infant IRF6 rs2235371( X
2
=2.57, df=2, P= 0.276) 
CC* 169 (100) 124 (100) 35 (100) 184 (98.4) 
TT 0 0 0 3 (1.6) 
CT 0 0 0 0 
Total  169
C
 (100) 124 (100) 35 (100) 187 (100) 
P-value 0.1 0.16 0.32  
*The common homozygous allele genotype 
**The Chi-square statistic is significant at the 0.05 level 
C
 Ten NSOFC cases were not sub-phenotyped. 
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Table 5.50: Distribution of IRF6 rs2235371 infant-parental triad allele frequencies in NSOFC, 
CL/P and CP cases and compared to controls. 
  
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal IRF6 rs2235371(X
2
=10.95, df=2, P= 0.621 
C 325 (99.7) 239 (99.6) 66 (100) 337 (99.1) 
T 1 (0.3) 1 (0.4) 0 3 (0.9) 
Total 326
C
 (100) 240 (100) 66 (100) 340 (100) 
P-value 0.336 0.505 0.444  
OR (95% CI) 0.35 (0.04 - 3.34) 0.47 (0.05 - 4.55) a  
Maternal IRF6 rs2235371(X
2
=8.54, df=2, P= 0.014**) 
C 338 (100) 252 (100) 66 (100) 368 (97.4) 
T 0 0 0 10 (2.6) 
Total 338
C
 (100) 252 (100) 66 (100) 378 (100) 
P-value 0.002** 0.009** 0.18  
OR (95% CI) a a a  
Infant IRF6 rs2235371(X
2
=3.53, df=2, P= 0.171) 
C 338 (100) 248 (100) 70 (100) 368 (98.4) 
T 0 0 0 6 (1.6) 
Total 338
C
 (100) 248 (100) 70 (100) 374 (100) 
P-value 0.019** 0.045** 0.3  
OR (95% CI) a a a  
**The Chi-square statistic is significant at the 0.05 level. 
a. Not possible to analyse because the groups contain zero values  
If one of the cells contains zero value, the OR and 95% CI are not calculated  
C
 Ten NSOFC cases were not sub-phenotyped. 
 
5.5.5 VAX1 rs4752028 analysis 
In addition to the 10 NSOFC cases with missing phenotype diagnosis out of the 171 NSOFC 
cases and 189 controls; 11 (6 cases and 5 controls) paternal samples, 3 (one case and two 
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33 CP 
126 CL/P 
34 CP 
35 CP 
controls) maternal samples and 7 infant samples (6 cases and one controls) did not produce 
genotyping values for VAX1 rs4752028. This resulted in; 122 CL/P, and 33 CP paternal genotype 
compared to 168 controls; 126 CL/P and 34 CP maternal genotype compared to 187 controls; and 
120 CL/P and 35 CP infant genotype compared to 188 controls, according to VAX1 rs4752028 
genotype variance (Figure 5.5) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
* The saliva sample did not produce genotyping values for IRF6 rs2013162 
Figure 5.5: Sample flaw description for VAX1 rs4752028 genotype variance infant-
parental triad  
 
Paternal:  171 NSOFC  
   Not genotyped= 6* 
   Missing diagnosis= 10 
Final NSOFC cases= 165 
Sub-phenotyped= 155 
122 CL/P 
Total 
Cases 
Deductions 
Paternal: 189 Controls 
 Missing sample= 16 
   Not genotyped= 5* 
Final controls= 168 
Deductions 
Deductions 
Maternal: 171 NSOFC  
   Missing diagnosis= 10 
 
Final NSOFC cases=170 
Sub-phenotyped= 160 
Maternal: 189 controls     Not genotyped= 2* Final controls= 187 
Infant: 189 Controls    Not genotyped= 1* Final controls= 188 
Deductions 
Infant:  171 NSOFC 
   Not genotyped= 6* 
   Missing diagnosis= 10 
Final NSOFC cases= 165 
Sub-phenotyped= 155 
120 CL/P 
Total 
Cases 
  Not genotyped= 1* 
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5.5.5.1 TDT gene analysis: 
Tables 5.51 and 5.52 shows the TDT analyses for VAX1 rs4752028 using FBAT and PLINK 
tests. No statistically significant over-transmission of the rare allele (C) was found in 
NSOFC, CL/P or CP families (FBAT: P= 0.769 for NSOFC; P= 0.651 for CL/P; and P= 1 
for CP. For PLINK: P= 1 for NSOFC; P= 0.651 for CL/P; and P= 686 for CP). 
5.5.5.2 Comparison between case and control VAX1 rs4752028 genotypes: 
Table 5.53 shows the distribution of VAX1 rs4752028 genotypes in case and control infant-
parental triads. There was a statistically significant difference between case and control 
VAX1 rs4752028 genotype in infant-parental triads for NSOFC, CL/P and CP cases: P< 
0.001 for NSOFC infant-parental triads and infant CL/P; P= 0.001 for maternal and paternal 
CL/P and paternal CP; and P= 0.02 for infant CP. 
After chi square adjustment using Bonferroni correlation in infant-parental trios, it was found 
that in fathers; the homozygous common allele genotype (TT) was found significantly more 
often in controls than in cases for NSOFC, CL/P and CP (P≤0.05). Furthermore, the 
heterozygous genotype (CT) was significantly more prevalent in cases than in controls for 
the different cleft phenotypes. For mothers and infants, the homozygous rare allele genotype 
(CC) occurred significantly more often in cases than in controls for NSOFC and the CL/P 
sub-phenotype; the homozygous common allele (TT) was significantly found more often in 
controls for NSOFC and CL/P; the heterozygous genotype (CT) was significantly present 
more in NSOFC and its sub-phenotypes except in mothers of CP infants. 
  5.5.5.3 Comparison between case and control VAX1 rs4752028 alleles: 
Table 5.54 shows the frequency of the VAX1 rs4752028 rare allele in case and control infant-
parental triads for NSOFC, CL/P and CP. In all comparisons the rare allele was found 
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significantly more often in cases than in controls and was associated with: NSOFC (fathers: P< 
0.001, OR: 2.24 95% CI: 1.47 to 3.4; mothers: P< 0.001, OR: 2.40, 95% CI: 1.61 to 3.7; and 
infants: P< 0.001, OR: 2.71, 95% CI: 1.78 to 4.13); CL/P (fathers: P= 0.001, OR: 2.16 and 95% 
CI: 1.38 to 3.4; mothers: P< 0.001, OR:2.39, 95% CI: 1.53 to 3.71; and infants with P< 0.001, 
OR: 2.77, and 95% CI: 1.77 to 4.34); and CP (fathers: P= 0.015, OR: 2.24 and 95% CI: 1.15 to 
4.36; mothers: P= 0.049, OR: 1.97 and 95% CI: 0.99 to 3.93; and infants: P= 0.009, OR: 2.43 
and 95% CI: 1.25 to 4.7). 
 
Table 5.51: Transmission Disequilibrium test (TDT) results for VAX1 rs4752028 variants among 
NSOFC infant parental triads and its sub-phenotypes (CL/P and CP) using FBAT analysis. 
     
Type of 
NSOFC 
Allele afreq fam# SE Var(S) Z test P value 
NSOFC 
T* 0.785 71 -1.500 .250 -0.293 0.769 
C 0.215 71 1.500 26.250 0.293 0.769 
CL/P 
T* 0.767 53 -2 19.5 -0.453 0.651 
C 0.233 53 2 19.5 0.453 0.651 
CP 
T* 0.779 14 0 5.5 0 1 
C 0.221 14 0 5.5 0 1 
* The common allele  
afreq :Estimating allele frequencies 
fam#: Number of families 
SE: Standard error 
Var(S): Value of the average of the squared differences from the mean  
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Table 5.52: Testing VAX1 rs4752028 for transmission disequilibrium and parent of origin using 
PLINK analysis for NSOFC infant-parental triads and its sub-phenotypes (CL/P and CP).   
 
Transmission disequilibrium Test 
NSOFC 
Transmitted/ 
Untransmitted 
minor allele 
P-value OR A:U_PAR 
P-
value 
Combined 
statistics 
P-value 
NSOFC 51/47 0.686 1.09 01:01 1 0.689 
CL/P 41/37 0.651 1.11 01:01 1 0.655 
CP 11/11 1 1 00:00 NA 1 
Parent of origin effect 
 T:U_PAT 
Paternal 
P-value 
T:U_MAT 
Maternal 
P-value 
POO 
Z 
POO 
P 
NSOFC 29:27:00 0.789 22:20 0.757 -0.058 0.954 
CL/P 22.5:20.5 0.76 18.5:16.5 0.735 -0.047 0.962 
CP 07:07 1 04:04 1 0 1 
A:U PAR: Parental discordance counts 
POO: Parents of Origin 
T:U PAT: Paternal transmitted: untransmitted counts 
T:U MAT: Maternal transmitted: untransmitted counts 
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Table 5.53: Distribution of VAX1 rs4752028 infant-parental triad genotypes according to NSOFC 
phenotypes (CL/P and CP) and compared to controls. Eleven (6 cases and 5 controls) paternal 
samples, 5 (3 cases and two controls) maternal samples and 7 infant samples (6 cases and one 
controls) did not produce genotyping values for VAX1 rs4752028. The phenotype diagnosis for ten 
NSOFC cases are missing 
 
Genotype NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal VAX1 rs4752028 X
2
=20.31, df=4, P<0.001** 
TT* 95 (57.6) 73 (59.8) 18 (54.5) 134 (79.8) 
CC 5 (3) 5 (4.1) 0 5 (2.9) 
CT 65 (39.4) 44 (36.1) 15 (45.5) 29 (17.3) 
Total 165
 C
 (100) 122 (100) 33 (100) 168(100) 
P-value <0.001** 0.001** 0.001**  
Maternal VAX1 rs4752028 X
2
=13.61, df=4, P= 0.009 
TT* 106 (62.4) 80 (63.5) 23 (67.6) 151 (80.7) 
CC 12 (7.1) 10 (7.9) 2 (5.9) 4 (2.1) 
CT 52 (30.6) 36 (28.6) 9 (26.5) 32 (17.1) 
Total 170
C
 (100) 126 (100) 34 (100) 187(100) 
P-value 0.000** 0.001** 0.18  
Infant VAX1 rs4752028 X
2
=21.96, df=4, P<0.001** 
TT* 98 (59.4) 72 (60) 21 (60) 153 (81.4) 
CC 10 (6.1) 9 (7.5) 1 (2.9) 3 (1.6) 
CT 57 (34.5) 39 (32.5) 13 (37.1) 32 (17) 
Total 165
C
 (100) 120 (100) 35 (100) 188 (100) 
P-value <0.001** <0.001** 0.02**  
* The homozygous common allele genotype 
**The Chi-square statistic is significant at the 0.05 level. 
C
 Ten NSOFC cases were not sub-phenotyped  
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Table 5.54: Distribution of VAX1 rs4752028 infant-parental triad allele frequencies in NSOFC, 
CL/P and CP cases compared to controls. 
 
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal VAX1 rs4752028 (X
2
=13.15, df=2, P= 0.002**) 
T* 255 (77.3) 190 (77.9) 51 (77.3) 297 (87.9) 
C 75 (22.7) 54 (22.1) 15 (22.7) 39 (2.9) 
Total 330
C
 (100) 244 (100) 66 (100) 336 (100) 
P-value <0.001** 0.001** 0.015**  
OR (95% CI) 2.24 (1.47 - 3.41) 2.16 (1.38 - 3.40) 2.24 (1.15 - 4.36)  
Maternal VAX1 rs4752028 (X
2
=15.77, df=2, P<0.001**) 
T* 264 (76.5) 196 (77.7) 55 (80.8) 334 (89.3) 
C 76 (23.5) 56 (22.2) 13 (19.1) 40 (10.7) 
Total 400
C
 (100) 252 (100) 68 (100) 374 (100) 
P-value <0.001** <0.001** 0.049  
OR (95% CI) 
2.44 (1.61 - 3.7) 2.39 (1.53 - 3.71) 1.97 (0.99 - 3.93) 
 
Infant VAX1 rs4752028(X
2
=21.94, df=2, P<0.001**) 
T* 253 (76.7) 183 (68.8) 55 (78.6) 338 (89.9) 
C 77 (23.3) 57 (31.2) 15 (21.4) 38 (10.1) 
Total 330
C
 (100) 240 (100) 70 (100) 376 (100) 
P-value <0.001** <0.001** 0.009**  
OR (95% CI) 2.71 (1.78 - 4.13) 2.77 (1.77 – 4.34) 2.43 (1.25 - 4.7)  
* The homozygous common allele.  
**The Chi-square statistic is significant at the 0.05 level. 
C
 Ten NSOFC cases were not sub-phenotyped. 
5.5.6 VAX1 rs7078160 analysis 
Fourteen (8 cases and 6 controls) paternal samples, one maternal samples and 7 infant 
samples (5 cases and 3 controls) did not produce genotyping values for IRF6 rs2013162. The 
phenotype diagnosis for ten NSOFC cases are missing. This resulted in; 119 CL/P, and 34 CP 
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34 CP 
34 CP 
126 CL/P 
35 CP 
paternal genotype compared to 167 controls; 126 CL/P and 34 CP maternal genotype compared to 
189 controls; and 122CL/P and 35 CP infant genotype compared to 186 controls, according to 
VAX1 rs2013162 genotype variance. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
* The saliva sample did not produce genotyping values for IRF6 rs2013162 
Figure 5.6: Sample flaw description for VAX1 rs7078160 genotype variance infant-
parental triad  
 
5.5.6.1 TDT gene analysis: 
Tables 5.55 and 5.56 show TDT for VAX1 rs7078160 using FBAT and PLINK analyses. No 
statistically significant over-transmission of the rare allele was found in NSOFC and CL/P 
Paternal:  171 NSOFC  
   Not genotyped= 8 
   Missing diagnosis= 10 
Final NSOFC cases= 163 
sub-phenotyped=153 
119 CL/P 
Total 
Cases 
Deductions 
Paternal: 189 Controls 
 Missing sample= 16 
   Not genotyped= 6* 
Final controls= 167 
Deductions 
Deductions 
Maternal: 171 NSOFC  
   Missing diagnosis= 10 
 
 Final NSOFC cases=160 
Maternal: 189 controls     Not genotyped= 0 Final controls= 189 
Infant: 189 Controls    Not genotyped= 3* Final controls= 186 
Deductions 
Infant:  171 NSOFC 
   Not genotyped= 5 
   Missing diagnosis= 10 
Final NSOFC cases= 156 
122 CL/P 
Total 
Cases 
  Not genotyped= 1 
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families (FBAT: P= 0.293 for NSOFC; and P= 0.327 for CL/P. For PLINK: P= 0.233 for 
NSOFC; P= 0.327 for CL/P; and P= 0.257 for CP). For CP, the number of included 
heterozygous alleles was not enough to produce a P-value in FBAT analysis.   
5.5.6.2 Comparison between case and control VAX1 rs7078160 genotypes: 
Table 5.57 shows the distribution of VAX1 rs7078160 genotype frequencies between case 
and control infant-parental triads. Fathers of NSOFC infants genotypes were significantly 
different than controls (P= 0.03). Mothers and infants had significant differences between 
cases and controls for NSOFC (P= 0.02 and P= 0.04, respectively) and CL/P phenotypes (P= 
0.004 and P= 0.003, respectively). 
After chi square adjustment using Bonferroni correction, the homozygous genotype rare 
allele (AA) was found to be significantly more frequent in NSOFC and CL/P infants 
compared to controls (P≤0.05). The homozygous genotype common allele (GG) was 
significantly more frequent in infant-parental control triads than in NSOFC cases (P< 0.05). 
The heterozygous genotype (AG) was significantly more frequent in parental controls 
compared to parents of NSOFC and CL/P infants (P< 0.05).  
5.5.6.3 Comparison between case and control VAX1 rs7078160 genotype alleles: 
Table 5.58 shows the frequency of alleles in case and control infant-parental triads. In 
infant-parental triads, there were statistically significant differences between cases and 
controls in: NSOFC (fathers: P= 0.026, OR: 1.69 and 95% CI: 1.06 to 2.70; mothers: P= 
0.001, OR: 2.16 and 95% CI: 1.35 to 3.45; and infants: P= 0.021, OR: 1.74 and 95% CI: 
1.08 to 2.80); and CL/P (fathers: P= 0.03, OR: 1.73 and 95% CI: 1.05 to 2.86; mothers: P< 
0.001, OR: 2.43 and 95% CI: 1.49 to 3.97; and infants: P<0.001, OR: 2.34 and 95% CI: 1.44 
to 3.81) with significantly greater frequency of the rare allele in cases compared to controls.  
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Table 5.55: Transmission Disequilibrium test (TDT) results for VAX1 rs7078160 variants among 
NSOFC infant parental triads and its sub-phenotypes (CL/P and CP) using FBAT analysis.     
 
Type of 
NSOFC 
Allele afreq fam# SE Var(S) Z test P value 
NSOFC    G* 0.881 50 4.0 14.500 1.050 0.293 
A 0.119 50 -4.0 14.500 -1.050 0.293 
CL/P    G* 0.872      45 3.5 12.75 0.98 0.327 
A 0.128      45 -3.5 12.75 -0.98 0.327 
* The common allele 
afreq :Estimating allele frequencies 
fam#: Number of families 
SE: Standard error 
Var(S): Value of the average of the squared differences from the mean  
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Table 5.56: Testing VAX1 rs7078160 for transmission disequilibrium and parent of origin using 
PLINK analysis for NSOFC infant-parental triads and its sub-phenotypes (CL/P and CP).   
 
NSOFC 
Transmitted/ 
Untransmitted 
minor allele 
P-value OR A:U_PAR 
P-
value 
Combined 
statistics 
P-value 
NSOFC 24/33 0.233 0.727 01:02 0.563 0.302 
CL/P 22/29 0.327 0.759 02:01 0.564 0.414 
CP 2/5 0.257 0.4 00:00 NA 0.257 
Parent of origin effect 
 T:U_PAT 
Paternal 
P-value 
T:U_MAT 
Maternal 
P-value 
POO 
Z 
POO 
P 
NSOFC 11.5:17.5 0.265 12.5:15.5 0.571 -0.381 0.703 
CL/P 10:15 0.317 12:14 0.695 -0.443 0.658 
CP 1.5:2.5 0.617 0.5:2.5 1 0.59 0.555 
A:U PAR: Parental discordance counts 
POO: Parent of Origin 
T:U PAT: Paternal transmitted: untransmitted counts 
T:U MAT: Maternal transmitted: untransmitted counts 
**Significant relationship  
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Table 5.57: Distribution of VAX1 rs7078160 infant-parental triad genotypes in NSOFC, CL/P and 
CP cases compared to controls. Fourteen (8 cases and 6 controls) paternal samples, one maternal 
samples and 7 infant samples (5cases and 3 controls) did not produce genotyping values for VAX1 
rs7078160. The phenotype diagnosis for ten NSOFC cases are missing 
 
Genotype  NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal VAX1 rs7078160 (X
2
=1021, df=4, P= 0.037**) 
GG* 120 (73.6) 86 (72.3) 26 (76.5) 141 (84.4) 
AA 8 (4.9) 5 (4.2) 3 (8.8) 7 (4.2) 
AG 35 (21.5) 28 (23.5) 5 (14.7) 19 (11.4) 
Total 163
C
 (100) 119 (100) 34 (100) 167 (100) 
P-value 0.03** 0.15 0.32  
Maternal VAX1 rs7078160 (X
2
=12.21, df=4, P= 0.016**) 
GG* 127 (74.7) 90 (71.4) 29 (85.3) 164 (86.8) 
AA 12 (7.1) 9 (7.1) 2 (5.9) 6 (3.2) 
AG 31(18.2) 27 (21.4) 3 (8.8) 19 (10.1) 
Total 170
C
 (100) 126 (100) 34 (100) 189 (100) 
P-value 0.02** 0.004** 0.73  
Infant VAX1 rs7078160 (X
2
=15.7, df=4, P= 0.003) 
GG* 132 (79) 90 (73.8) 32 (91.4) 157 (84.4) 
AA 12 (7.2) 12 (9.8) 0  3 (1.6) 
AG 23 (13.8) 20 (16.4) 3 (8.6) 26 (14) 
Total 167
C
 (100) 122 (100) 35 (100) 186 (100) 
P-value 0.04** 0.003** 0.49  
* The common allele 
**The Chi-square statistic is significant at the 0.05 level 
C
 Ten NSOFC cases were not sub-phenotyped 
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Table 5.58: Distribution of VAX1 rs7078160 infant-parental triad allele frequencies in NSOFC, 
CL/P and CP cases compared to controls. 
  
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
Paternal VAX1 rs7078160 (X
2
=5.38, df=2, P= 0.068) 
   G* 275 (84.4) 200 (84) 57 (83.8) 301 (90.1) 
A 51(15.6) 38 (16) 11(16.2) 33 (9.9) 
Total 326
C
 (100) 238  (100) 68 (100) 334 (100) 
P-value 0.026** 0.03** 0.129  
OR (95% CI) 1.69 (1.06 - 2.70) 
1.73  
(1.05 - 2.86) 
1.76 (0.84 - 3.68)  
Maternal VAX1 rs7078160 (X
2
=13.64, df=2, P= 0.001**) 
G* 285 (83.8) 207 (82.1) 61 (89.7) 347 (87.8) 
A 55 (16.2) 45 (17.9) 7 (10.3) 31 (8.2) 
Total 340
C
 (100) 252 (100) 68 (100) 378 (100) 
P-value 0.001** <0.001** 0.569  
OR (95% CI) 2.16 (1.35 - 3.45) 
2.43  
(1.49 - 3.97) 
1.28 (0.54 - 3.05) 
 
Infants VAX1 rs7078160 (X
2
=16.86, df=2, P<0.001**) 
G* 287 (85.9) 200 (82) 67 (95.7) 340 (91.4) 
A 47 (14.1) 44 (18) 3 (8.6) 32 (1.6) 
Total 334
C
 (100) 244 (100) 70 (100) 372 (100) 
P-value 0.021** 0.000** 0.23  
OR (95% CI) 
1.74 (1.08 - 2.80) 2.34  
(1.44 - 3.81) 
0.48 (0.14-1.6) 
 
* The common allele 
**The Chi-square statistic is significant at the 0.05 level. 
C
 Ten NSOFC cases were not sub-phenotyped. 
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5.5.7 Infant VAX1 genotype variants and paternal consanguinity as risk 
factors for NSOFC 
VAX1 gene (rs4752028 and rs7078160) variances among CL/P and CP infants were 
compared to controls according to paternal consanguinity.  
 
5.5.7. 1 Infant VAX1 rs4752028 
The distribution of the included sample (cases and control together) according to parental 
consanguinity and its relationship to infant VAX1 rs4752028 genotype is presented in 
Appendix A31. It showed a statistically significant differences between the three infant 
VAX1 rs4752028 genotypes according to parental consanguinity (P= 0.04). The prevalence 
of the infant homozygous rare allele and heterozygous genotypes (CC and CT, respectively) 
were significantly higher in consanguineous parents compared to non-consanguineous 
parents.   
Moreover, the distribution of infant VAX1 rs4752028 genotypes in cases and in controls 
according to consanguinity is presented in Appendix A32. It showed that out of the total 
sample with VAX1 rs4752028 genotype recorded (120 CL/P and 35 CP infant genotypes 
compared to 188 controls), there were 118 CL/P and 35 CP compared to 167 controls that 
had been genotyped and their parental consanguinity status recorded. The oral cleft 
phenotype of two of the NSOFC cases was not reported. There were no statistically 
significant differences between the three VAX1 rs4752028 genotypes in cases (P= 0.123) or 
in controls (P= 0.19). In addition, Appendix A33 shows the distribution of infant VAX1 
rs4752028 genotypes in NSOFC cases compared to controls according to parental 
consanguinity. No significant differences were found (P> 0.05). 
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Table 5.59 show the distribution of infant VAX1 rs4752028 alleles in NSOFC 
consanguineous parents compared to controls. More NSOFC including CL/P and CP cases 
with consanguineous parents were found with the rare C allele compared to controls. 
However the difference was not significant for CP. For NSOFC, P< 0.001, OR: 3 and 95% 
CI (1.55 to 5.4); for CL/P, P= 0.001, OR: 2.97 and 95% CI (1.54 to 5.76); and for CP, P= 
0.059, OR: 2.44 and 95% CI (0.97 to 6.16). 
Table 5.59: Distribution of infant VAX1 rs4752028 alleles in cases and controls with 
consanguineous parents. 
  
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
T* 135 (78.5) 101 (77.7) 34 (81.4) 166 (91.2) 
C 37 (21.5) 29 (22.3) 8 (18.6) 16 (8.8) 
Total 172 (100) 130 (100) 42 (100) 182 (100) 
P-value 
OR (95% CI) 
<0.001**         
3 (1.55-5.4) 
0.001** 
2.97 (1.54-5.76) 
0.059 
2.44 (0.97-6.16) 
 
X
2
=28.28, df=2, P<0.001** 
* Common allele 
**Significant level at P≤ 0.05 
 
5.5.7.2 Infant VAX1 rs7078160 
The prevalence of the rare homozygous genotype (AA) according to parental consanguinity 
is presented in Appendix A34. This genotype was found to be more frequent in infants with 
consanguineous parents (61.5% compared to 38.5%) but when the correlation was corrected 
for column comparison, this difference was not statistically significant (P> 0.05). 
Table 5.60 shows the distribution of infant VAX1 rs7078160 genotypes in cases and in 
controls according to consanguinity. Out of the total sample with VAX1 rs7078160 genotype 
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record (157 NSOFC; 122 CL/P and 35 CP infant genotype compared to 186 controls), there was 
149 NSOFC (116 CL/P and 33 CP) compared to 164 controls that had been both genotyped 
and their parental consanguinity recorded.  
 After Bonferroni correction for column comparison for NSOFC cases, there was a 
significantly higher prevalence of the homozygous common allele genotype (GG) in infants 
with consanguineous parents compared to the prevalence of the heterozygous genotype (AG) 
(P<0.05). Appendix A35 showed no statistically significant differences between NSOFC 
cases and controls infant VAX1 rs7078160 genotypes.  
The prevalence of the rare (A) allele in NSOFC compared to controls in infants with 
consanguineous parents is presented in Appendix A36. Although the rare allele prevalence 
was greater in NSOFC (11%) than in controls (7.7%), and the chi square and P value was 
statistically significant (X
2
=6.11, df=2, P= 0.047) when comparing CL/P, CP and controls, 
the differences between each phenotype (CL/P and CP compared to controls) was not 
statistically significant (P>0.05). 
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Table 5.60: Distribution of infant VAX1 rs7078160 genotypes in cases and controls according to 
parental consanguinity. (d) Four undiagnosed NSOFC cases 
 
Consanguinity NSOFC CL/P CP Control 
GG* AA AG GG* AA AG GG* AA AG GG* AA AG 
Yes (%) 73 
(62) 
6 
(54.5) 
7 
(33.3) 
53 
(60.9) 
6 
(54.4) 
6 
(33.3) 
20 
(66.7) 
0 1 
(33.3) 
79 
(56.4) 
2 
(100) 
10 
(45.5) 
No (%) 44 
(38) 
5 
(45.5) 
14 
(66.7) 
34 
(39.1) 
5 
(45.5) 
12 
(66.7) 
10 
(33.3) 
0 2 
(66.7) 
61 
(43.6) 
0 12 
(54.5) 
Total (%) 117 
(100) 
11 
(100) 
21 
(100) 
87 
(100) 
11 
(100) 
18 
(100) 
30 
(100) 
0 3 
(100) 
140 
(100) 
2 
(100) 
22 
(100) 
Total infants 149
C,d
 116
C
 33
C
 164
C
 
X
2
(df), P-value 6.05 (2), 0.048** 4.62 (2), 0.099 1.31 (1), 0.252 2.55 (2), 0.279 
* Homozygous common allele genotype is the reference 
**Significant level P≤ 0.05 
C
 Out of the157 NSOFC (122 CL/P and 35 CP) 186 controls, 8 NSOFC (6 CL/P, two CP), and 22 controls, 
did not have their genotype and/or their paternal consanguinity information completed. 
5.5.8 Haplotype-Based Association Test (HBAT) 
The haplotype-based association test (HBAT) was carried out on the five SNPs included in 
this study (rs7078160, rs4752028, rs2235371, rs2013162 and rs2235375) and showed that 
two significant haplotype blocks were associated with NSOFC (Table 5.61). The first 
significant block (GCCCC (# 3)) included the common alleles of four SNPs and the rare 
allele of VAX1 rs4752028 (P= 0.021). The second significant block (GTCAC (#6)) included 
the common four SNPs and the rare allele of allele of IRF6, rs2013162 (P= 0.01) 
  
Table 5.61: Haplotypes showing transmission distortion. 
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Number Haplotype Estimation of frequency Z P-value 
1 GTCCC 0.446 0.928 0.353 
2 GTCAG 0.212 -1.045 0.295 
3 GCCCC 0.086 2.299 0.021* 
4 GTCCG 0.076 1.744 0.081 
5 ACCCC 0.051 -0.929 0.977 
6 GTCAC 0.037 -2.578 0.01** 
7 GCCAG 0.026 -0.879 0.379 
8 ACCAG 0.018 0.007 0.995 
**Significant level P≤ 0.05 
 
 
5.6 Gene-environmental interaction (GIE)   
 
Maternal gene-environmental interactions (GEI) for IRF6 (rs2013162, rs2235375 and 
rs2235371) and VAX1 (rs4752028 and rs7078160) were examined using two study designs: 
case-only and case-control study designs. The case-only study design includes assessment of 
GEI for maternal gene variants and alleles. We selected maternal gene for GEI analysis 
according to the literature (shi et al., 2008) and the log-linear model on the interaction 
between maternal genetic variants and infant genetic variants. Although the sample size is 
not adequate, the preliminary results of log-linear model showed a significant interaction 
between maternal gene and infant gene (P<0.05). This analysis result is presented in 
Appendix (A37).   
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5.6.1 Maternal IRF6 rs2013162 gene-environmental interaction     
The interactions between maternal IRF6 rs2013162 variants and environmental factors were 
analysed using two approaches: case-only and case-control approaches.  
 
5.6.1.1 Case-only study design approach 
 
The maternal IRF6 rs2013162 rare homozygous allele genotype (AA) and heterozygous 
genotype (CA) were compared to the common homozygous allele genotype (CC) in NSOFC 
cases with regard to different environmental factors (Appendix A38). Mothers with 
homozygous rare allele genotype (AA) who were using antipyretic medication in the 1st 
trimester period   (P= 0.012, OR: 9 and 95% CI: 1.62 to 49.91), folic acid supplement in the 
pregestation period (P= 0.047, OR: 8.22 and 95% CI: 1.03 to 65.72), experiencing abdominal 
pain in the 1st trimester period (P= 0.013, OR: 6.57 and 95% CI: 1.49 to 29.01) and 
depression in the 1st trimester (P = 0.048, OR: 8.11 and 95% CI: 1.01–64.84) are more likely 
to have a NSOFC offspring. Mothers with heterozygous allele genotype (CA) who were 
exposed to fever during the three-month pregestation period (OR: 0.26 and 95% CI: 0.08 to 
0.84) and X-ray in the 1st trimester period (P<0.001, OR: 0.09 and 95% CI: 0.03 to 0.34) 
were significantly less likely to have NSOFC infants.  Mothers with heterozygous allele 
genotype (CA) who were using folic acid supplement in the pregestation period were 
significantly more likely to have NSOFC infants (P= 0.014, OR: 6.83 and 95% CI: 1.47 to 
31.66).  
The maternal IRF6 rs2013162 rare A allele was compared to the common C allele in NSOFC 
cases in relation to different environmental factors (Appendix A39). Mothers with rare A 
allele who were using antipyretic medication in the 1st trimester period (P= 0.025, OR: 2.34 
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and 95% CI: 1.12 to 4.9) and folic acid supplement during the pregestation period (P= 0.012, 
OR: 2.57 and 95% CI: 1.23 to 5.37) were significantly more likely to have NSOFC infants. 
Mothers with rare A allele who were exposed to fever during the three-month pregestation 
period (P= 0.019, OR: 0.28 and 95% CI: 0.09 to 0.81), X-ray in the 1st trimester period (P < 
0.001, OR: 0.19 and 95% CI: 0.07 to 0.5), drank tap water as their main drinking water 
source compared to bottled water (P= 0.043, OR: 0.51, 95% CI: 0.26 to 0.98) and ingested 
iron supplement in the 1st trimester period (P= 0.04, OR: 0.57 and 95% CI: 0.33 to 0.97) 
were significantly less likely to have NSOFC infants. 
 
 
 
 
 
 
 
5.6.1.2 Case-control study design approach. 
 
Appendix A40 shows the distribution of the maternal IRF6 rs2013162 genotypes in NSOFC 
cases compared to controls according to different environmental factors including maternal 
illness, medication, stress, supplements, paternal smoking and maternal domestic chemical 
exposure.  
5.6.1.2.1 IRF6 rs2013162 maternal homozygous rare allele genotype (AA): 
Statistically significant differences between cases and controls were found for the interaction 
between the homozygous rare allele genotype (AA) and environmental factors: maternal 
folic acid supplementation was significantly less utilized by NSOFC mothers in the 1st 
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trimester period (P= 0.003, OR: 0.1 and 95% CI: 0.02 to 0.50) and significantly more 
utilized by NSOFC mothers in the pre-gestation period compared to controls (P= 0.023); 
maternal multivitamin supplementation in the pre-gestation period was significantly more 
utilized by NSOFC mothers compared to controls (P= 0.023); paternal Jorak waterpipe  
smoking occurred significantly more often in NSOFC families compared to controls (P= 
0.005); and maternal passive smoking was significantly more likely to be identified in 
NSOFC mothers exposed to secondary smoking compared to controls (P= 0.006, OR: 10.42 
and 95% CI: 1.61 to 67.34). Maternal stress was reported significantly more often in NSOFC 
mothers compared to controls: P= 0.003, OR: 10.06 and 95% CI: 1.98 to 51.04 for mothers 
complaining of family problems; P= 0.015, OR: 6.13 and 95% CI: 1.33 to 28.21 for mothers 
complaining of being under stress; P= 0.023 for maternal depression in the 1st trimester and 
P= 0.007, OR: 14.86 and 95% CI: 1.42 to 154.99 for maternal abdominal pain in the 1st 
trimester. Maternal exposure to chemicals in pre-gestation and the 1st trimester period was 
significantly more likely in NSOFC mothers compared to controls (P= 0.012, OR: 6.9 and 
95% CI: 1.4 to 33.92).  
5.6.1.2.2 IRF6 rs2013162 maternal homozygous common allele genotype (CC): 
There were statistically significant differences between cases and controls for the maternal 
homozygous common allele genotype (CC) frequency in: maternal exposure to antibiotics in 
the pre-gestation period, with significantly more NSOFC mothers reporting antibiotics 
ingestion compared to controls (P= 0.003, OR: 5.8 and 95% CI: 1.58 to 21.24); pre-gestation 
maternal illness with significantly more NSOFC mothers complaining of illness in the pre-
gestation period compared to controls (P= 0.01, OR: 2.73, and 95% CI: 1.25 to 5.97); pre-
gestation maternal common cold/ flu with significantly more infection reported by NSOFC 
mothers compared to controls (P< 0.001, OR: 10.06 and 95% CI: 2.85 to 35.48); pre-
gestation maternal fever (P= 0.009, OR: 4.3 and 95% CI: 1.34 to 13.82) and paternal 
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waterpipe smoking (P= 0.022, OR: 4.26 and 95% CI: 1.13 to 16.1), also significantly more 
reported by NSOFC mothers compared to controls; and there were significant differences in 
maternal drinking water types between tap water and Zamzam water (P= 0.024).   
5.6.1.2.3 IRF6 rs2013162 maternal heterozygous genotype (CA): 
The heterozygous genotype (CA) of IRF6 rs2013162 was significantly higher in cases 
compared to controls in: mothers exposed to illness in the pre-gestation period (P= 0.004, 
OR: 4.2 and 95% CI:1.48 to 11.92); mothers exposed to common cold/flu in the pre-
gestation period (P= 0.032, OR: 5.37 and 95% CI: 1.44 to 19.98); family problems (P= 
0.034, OR:2.24 and 95% CI: 1.05 to 4.74); maternal complaints of being under stress (P= 
0.36, OR: 2.14 and 95% CI: 1.04 to 4.39); and family history for birth defects (P= 0.037, 
OR:2.78 and 95% CI: 1.31 to 5.86). The heterozygous genotype (CA) was significantly 
higher in controls than cases with maternal exposure to incense in the pre-gestation and 1st 
trimester periods (P= 0.029, OR: 0.46, CI: 0.23 to 0.93) and ( P= 0.028, OR: 0.46 and 95% 
CI: 0.23 to 0.92) respectively.  
 
5.6.1.2.4 Chi square correction using Bonferroni correlation:  
Chi square correlations using Bonferroni corrections for the three maternal IRF6 rs2013162 
genotypes in cases compared to controls according to different environmental factors showed 
a statistically significant case and control difference in the maternal homozygous rare allele 
genotype (AA) frequency for: mothers using folic acid supplementation, with significantly 
more control mothers ingested folic acid supplementation in the 1st trimester compared to 
NSOFC mothers; maternal passive smoking, which was significantly elevated in NSOFC 
mothers exposed to secondary smoking compared to controls; maternal stress, was reported 
significantly more often in NSOFC mothers compared to controls (including mothers 
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complaining of family problems, being under stress, and abdominal pain in the 1st trimester); 
maternal exposure to chemicals in the pre-gestation and 1st trimester period, occurring 
statistical significantly more often in NSOFC mothers compared to controls. There was a 
significantly higher frequency of the common maternal homozygous genotype (CC) in cases 
compared to controls in groups with: maternal exposure to antibiotics in the pre-gestation 
period; pre-gestation maternal illness; pre-gestation maternal common cold/ flu; and pre-
gestation maternal fever. The heterozygous genotype (CA) was significantly more likely to 
be observed in cases compared to controls in: mothers exposed to illness in the pre-gestation 
period, mothers exposed to common cold/flu in the pre-gestation period; mothers 
experiencing family problems; mothers complaining of being under stress; and family 
history for birth defects. The heterozygous genotype (CA) was significantly higher in 
controls than in cases for mothers exposed to incense in the pre-gestation and 1st trimester 
periods. 
5.6.2 Maternal IRF6 rs2235375 GEI     
The maternal IRF6 rs2235375 genotypes in NSOFC cases were compared to each other to 
determine the influence of different environmental factors in a case-only study design and 
were compared to controls. 
5.6.2.1 Case-only study design approach 
 
The maternal IRF6 rs2235375 rare homozygous allele genotype (GG) and heterozygous 
genotype (CG) were compared to the common homozygous allele genotype (CC) in NSOFC 
cases to determine the influence of different environmental factors (Appendix A41). 
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Mothers with rare homozygous allele genotype (AA) who were using folic acid supplement 
during the pregestation period (P= 0.045, OR: 0.23 and 95% CI: 0.05 to 0.97) and 
complaining of being under stress (P= 0.016, OR: 0.3 and 95% CI: 0.1 to 0.8) were 
significantly less likely to have NSOFC infants. 
The relationship between different environmental factors and the maternal IRF6 rs2235375 
rare G allele was compared to the common C allele in NSOFC cases (Appendix A42). 
Mothers with rare G allele who had consanguineous marriages (P= 0.042, OR: 1.6 and 95% 
CI: 1.02 to 2.52) were significantly more likely to have NSOFC infants. Mothers with rare G 
allele who were complaining of being under stress (P= 0.01, OR: 0.52 and 95% CI: 0.32 to 
0.84) and were exposed to X-ray during the 1st trimester period (P= 0.02, OR: 0.21 and 95% 
CI: 0.05 to 0.87) were significantly less likely to have infants with NSOFC  
 
5.6.2.2 case-control study design approach. 
 
Appendix A43 shows the distribution of maternal IRF6 rs2235375 genotypes for NSOFC 
cases compared to controls according to environmental factors including maternal illness, 
medication, stress, supplements, paternal smoking and maternal domestic exposure.  
5.6.2.2.1 IRF6 rs2235375 maternal homozygous rare allele genotype (GG): 
There were significantly more NSOFC cases with the maternal homozygous IRF6 rs2235375 
rare allele genotype (GG) compared to controls for: maternal common cold/flu in the pre-
gestation period (P< 0.001, OR: 12.08 and 95% CI: 2.66 to 54.89); maternal fever in the pre-
gestation period (P= 0.007, OR:6.73 and 95% CI: 1.42 to 31.94); maternal high blood 
pressure in the 1st trimester period (P= 0.028); paternal waterpipe smoking (P= 0.018, OR: 
4.48 and 95% CI:1.18 to 17.07) and paternal Jorak smoking (P= 0.013). There was a 
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statistically significant difference between cases and controls for the maternal rare allele 
genotype (GG) in maternal drinking water between tap water and bottle waters (P= 0.033).  
5.6.2.2.2 IRF6 rs2235375 maternal common allele genotype (CC): 
There were significantly more NSOFC cases with the maternal IRF6 rs2235375 common 
allele genotype (CC) compared to controls in: maternal illness in the pre-gestation (P= 0.005, 
OR:7.92and 95% CI: 1.6 to39.29) and 1st trimester periods (P= 0.013, OR:3.56 and 95% CI: 
1.27 to 9.92 ); maternal common cold/flu in the pre-gestation period (P= 0.013, OR: 10.11 
and 95% CI:1.18 to 86.98); folic acid supplementation in the pre-gestation period (P= 0.026, 
OR: 0.12 and 95% CI: 0.04 to 0.31); paternal waterpipe (P= 0.041 OR:4.93 and 95% CI: 
0.95 to 25.58) including Jorak smoking (P= 0.026); and maternal stress including mothers 
experiencing family problems (P= 0.001, OR: 5.67 and 95% CI:1.89 to 16.99)and mothers 
complaining of being under stress (P= 0.014, OR: 4.22 and 95% CI: 1.57 to 11.36). There 
was a statistically significant difference between cases and controls for the maternal common 
allele genotype (CC) in maternal drinking water types (Zamzam compared to tap water P= 
0.027, OR16 and 95% CI: 1.32 to 194.63).  
 
5.6.2.2.3 IRF6 rs2235375 maternal heterozygous genotype (CG): 
There were statistically significant differences between cases and controls for the maternal 
heterozygous IRF6 rs2235375 genotype (CG) in: maternal illness in the pre-gestation period 
(P= 0.009, OR: 3.59 and 95% CI: 1.31 to 9.78); folic acid supplementation in the 1st 
trimester ((P= 0.02); mother complaining of being under stress (P= 0.019); mothers 
complaining of family problems (P= 0.036, OR: 2.32 and 95% CI: 1.05 to 5.14); and family 
history of birth defects (P= 0.027, OR: 2.62 and 95% CI:1.22 to 5.62).  
 
237 
 
5.6.2.2.4 Chi square correlation using Bonferroni correction: 
Chi square correlation using Bonferroni correction for maternal IRF6 rs2235375 genotypes 
in cases compared to controls according to different environmental factors showed a 
significantly higher rate of possessing the maternal homozygous rare allele genotype (GG) in 
cases compared to controls in maternal flu/common cold infection in the pre-gestation 
period; and in fever in the pre-gestation period. There were significantly higher maternal 
homozygous common allele genotype (CC) frequencies in cases compared to controls in: 
maternal illness in the pre-gestation and 1st trimester periods; flu/common cold infection in 
the pre-gestation period; fever in the pre-gestation period; maternal folic acid 
supplementation; and maternal stress (mothers complaining of being under stress and having 
family problems). There were significantly higher findings of the maternal heterozygous 
genotype (CG) in cases compared to controls for: maternal illness in the pre-gestation period; 
lack of maternal folic acid supplementation; maternal stress (mothers complaining of family 
problems and being under stress); and family history of birth defects. 
5.6.3 Maternal IRF6 rs2235371 
Maternal IRF6 rs2235371 genotypes in NSOFC cases could not be compared to each other in 
relation to the different environmental factors as no mothers had a homozygous rare allele 
genotype (TT).   
Appendix A44 shows the distribution of NSOFC maternal IRF6 rs2235371 genotypes for 
NSOFC cases compared to controls according to environmental factors including maternal 
illness, medication, stress, supplements, paternal smoking and maternal domestic exposure. 
There were significantly more NSOFC cases with the maternal homozygous common allele 
genotype (CC) compared to controls for: maternal antibiotics ingestion in the pre-gestation 
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period (P= 0.004); maternal anti-emetic medication ingestion in the 1st trimester period (P= 
0.027); maternal illness in the pre-gestation and 1st trimester periods (P< 0.001 and P= 
0.011, respectively); common cold/flu infection in the pre-gestation and 1st trimester periods 
(P< 0.001 and P= 0.032 respectively); fever in the pre-gestation period (P= 0.011); paternal 
Jorak smoking (P= 0.002), maternal stress exposure (mothers complaining of family 
problems (P= 0.003) and stress (P= 0.003)); and family history of birth defects (P= 0.014). 
There were significantly more controls with the common maternal homozygous allele 
genotype (CC) compared to NSOFC cases for: maternal folic acid supplementation in the 1st 
trimester period; maternal calcium supplementation in the 1st trimester period (P= 0.031); 
incense exposure in the pre-gestation and 1st trimester periods (P= 0.026 and P= 0.02, 
respectively); and mothers drinking Zamzam water (P= 0.015). 
All variables shown to be significant in 5.86 were proven to be significant after Chi square 
correlation using Bonferroni correction for the three maternal IRF6 rs2235371 genotypes in 
cases compared to controls stratified according to different environmental factors.  
 
5.6.4 Maternal VAX1 rs4752028 GEI 
The maternal VAX1 rs4752028 genotypes in NSOFC cases were compared to each other with 
regard to different environmental factors and were compared to controls. 
5.6.4.1 Case-only study design approach  
The maternal VAX1 rs4752028 rare homozygous allele genotype (CC) and heterozygous 
genotype (CT) were compared to the common homozygous allele genotype (TT) in NSOFC 
cases with regard to different environmental factors (Appendix A45). 
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Mothers with rare homozygous allele genotype (CC) who were exposed to high blood 
pressure during the 1st trimester period were significantly more likely to have NSOFC infant 
(P= 0.022, OR: 11.22 and 95 % CI: 1.41 to 89.4) 
The maternal VAX1 rs4752028 rare C allele was compared to the common T allele in 
NSOFC cases with regard to different environmental factors (Appendix A46). Mothers with 
a rare C allele genotype who were exposed to fever during the 1st trimester period (P<0.001, 
OR: 0.11 and 95% CI: 0.05 to 0.26) and experiencing depression in the 1
st
 trimester (P= 
0.04) were significantly less likely to have NSOFC infants 
 
5.6.4.2 Case-control study design approach 
Appendix A47 shows the distribution of maternal VAX1 rs4752028 genotypes for NSOFC 
cases compared to controls according to environmental factors including: maternal illness, 
medication, stress, supplements, paternal smoking and maternal domestic exposure. 
5.6.4.2.1 VAX1 rs4752028 maternal homozygous rare allele genotype (CC): 
There were significantly fewer NSOFC cases with the maternal homozygous rare allele 
genotype (CC) compared to controls in: maternal asthma in the pre-gestation period (P= 
0.047); maternal iron supplementation in the pre-gestation period (P= 0.047) and maternal 
exposure to incense (0.024). 
5.6.4.2.2 VAX1 rs4752028 maternal homozygous common allele genotype (TT): 
There were significantly more maternal homozygous VAX1 rs4752028 common allele 
genotypes (TT) in NSOFC cases compared to controls in: maternal antibiotics ingestion in 
the pre-gestation period (P= 0.004, OR: 3.6 and 95% CI:1.42 to 9.1); maternal anti-emetic 
medication ingestion in the 1st
 
trimester period (P= 0.018, OR:2.49 and 95% CI: 1.15 to 
5.39); maternal illness in the pre-gestation and 1st trimester periods (P< 0.001, OR: 4.48 and 
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95% CI:2.11 to 9.51 and P= 0.01, OR: 2.03 and 95% CI: 1.18 to 3.5 respectively); maternal 
common cold/flu infection in the pre-gestation period (P< 0.001, OR: 7.02 and 95%: 2.55 to 
19.32); maternal fever in the pre-gestation period (P= 0.03, OR: 2.79 and 95% CI: 1.07 to 
7.25); multivitamin supplementation ingestion in the pre-gestation period (P= 0.044, 
OR:5.12 and 95% CI: 1.04 to 25.19); paternal Jorak smoking (P= 0.024, OR: 5.23 and 95% 
CI:1.06 to 25.73); mothers complaining of being under stress and suffering from maternal 
depression in the 1st trimester period (P= 0.05, OR: 1.7 and 95% CI: 1 to 2.9 and P= 0.027, 
OR: 5.1 and 95% CI: 1.04 to 25.1, respectively); and family history of birth defects (P= 
0.005, OR: 2.13 and 95% CI: 1.24 to 3.64). There were significantly more maternal 
homozygous common allele genotypes (TT) in controls compared to cases for maternal folic 
acid supplementation in the 1st trimester period, (P= 0.023, OR: 0.54 and 95% CI: 0.32 to 
0.92) and type of maternal drinking water (P= 0.001).  
5.6.4.2.3 VAX1 rs4752028 maternal heterozygous genotype (CT):  
There was a statistically significant difference between cases and controls for the maternal 
heterozygous genotype (CT) in maternal calcium supplementation in the 1st trimester period 
(P= 0.025, OR: 0.17 and 95% CI: 0.033 to 0.93) and in paternal waterpipe smoking (P= 
0.018).   
5.6.4.2.4 Chi square correlation using Bonferroni correction: 
Chi square correlation using Bonferroni correction for the three maternal VAX1 rs4752028 
genotypes in NSOFC cases compared to controls according to different environmental 
factors found a significantly higher frequencies of maternal homozygous common allele 
genotypes (TT) in NSOFC cases compared to controls in: maternal antibiotics ingestion in 
the pre-gestation period; maternal anti-emetic medication ingestion in the 1st
 
trimester 
period; maternal illness in the pre-gestation and 1st trimester periods; maternal common 
cold/flu infection in the pre-gestation period; maternal fever in the pre-gestation period; 
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paternal Jorak smoking; and maternal stress and depression in the 1st trimester period. There 
was significantly more maternal homozygous common allele genotypes (TT) in controls 
compared with cases in maternal folic acid supplementation in the 1st trimester period, 
maternal multivitamin supplementation in the pre-gestation period, and in mothers drinking 
Zamzam water. There was a significantly higher level of maternal heterozygous genotypes 
(CT) in NSOFC controls compared to cases in maternal calcium supplementation in the 1st 
trimester period.  
5.6.5 Maternal VAX1 rs7078160 GEI 
The relationships between maternal VAX1 rs7078160 genotypes in NSOFC cases were 
compared to each other and to controls. 
 
5.6.5.1 Case-only study design approach 
The maternal VAX1 rs7078160 rare homozygous allele genotype (AA) and heterozygous 
genotype (AG) were compared to the common homozygous allele genotype (GG) in NSOFC 
cases with regard to different environmental factors (Appendix A48). 
Mothers with a homozygous rare allele genotype (AA) who were exposed to high blood 
pressure (P= 0.011, OR: 15 and CI: 1.86 to 120.86), had infants' fathers using a waterpipe 
(P= 0.016, OR: 5.54 and 95% CI: 1.38 to 22.23) were significantly more likely to have 
NSOFC infants. In contrast, they were less likely to have NSOFC infant when exposed to 
chemicals during the pregestation period (P< 0.001, OR: 0.06, CI: 0.01 to 0.24) if they had 
homozygous rare AA allele genotype.  
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Mothers with heterozygous allele genotype (AG) who were exposed to incense during the 1st 
trimester period (P= 0.008, OR: 8.15 and 95% CI: 1.71 to 38.87) and ingested iron 
supplements during the pregestation period (P= 0.011, OR: 4.83 and 95% CI: 1.44 to 16.27) 
were significantly more likely to have NSOFC infants. However, they were less likely to 
have NSOFC infant with parental consanguinity when having a heterozygous allele AG 
genotype (P= 0.04, OR: 0.42 and 95% CI: 0.18 to 0.96). 
 
The maternal VAX1 rs7078160rare allele (A) was compared to the common allele (G) in 
NSOFC cases with regard to different environmental factors (Appendix A49).  
Mothers with rare A allele that were exposed to high blood pressure during the 1st trimester 
(P = 0.01, OR: 5.87 and 95% CI: 1.42 to 24.3) and fathers were using waterpipe smoking 
device (P = 0.01, OR: 2.67 and 95% CI: 1.28 to 5.56) were significantly more likely to have 
NSOFC infants. Mothers with rare A allele who were exposed to chemicals during the 
pregestation period (P< 0.001, OR: 0.19 and 95% CI: 0. 11 to 0.34) were significantly less 
likely to have NSOFC infants. 
 
5.6.5.2 Case-control study design approach  
Appendix A50 shows the distribution of maternal VAX1 rs7078160 genotypes among 
NSOFC cases compared to controls with regard to various environmental factors, including 
maternal illness, medication, stress, supplements, paternal smoking and maternal domestic 
exposure.  
5.6.5.2.1 VAX1 rs7078160 maternal homozygous rare allele genotype (AA) 
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There were statistically significant differences between cases and controls for GEI between 
the maternal homozygous rare allele (AA) and maternal smoking (P= 0.032).  
5.6.5.2.2 VAX1 rs7078160 maternal homozygous common allele genotype (GG)  
There was a statistically significant increase in NSOFC cases compared to controls for GEI 
between maternal homozygous common allele genotype (GG) and maternal antibiotic 
ingestion during the pre-gestation period (P= 0.013, OR: 2.81 and 95% CI: 1.21 to 6.5), 
maternal anti-emetic medication ingestion during the 1st trimester period (P= 0.041, OR: 
2.14 and 95% CI: 1.02 to 4.5); maternal illness in the pre-gestation and 1st trimester periods 
(P< 0.001, OR: 3.54 and 95% CI: 1.75 to 7.13; and P= 0.029, OR: 1.77 and 95% CI: 1.06 to 
2.96, respectively); maternal common cold/flu infection during the pre-gestation period (P< 
0.001, OR: 5.39 and 95% CI: 2.11 to 13.77); paternal Jorak smoking (P= 0.01, OR: 6.15 and 
95% CI: 1.3 to 29); family problems and mothers complaining of being under stress (P = 
0.025, OR: 1.82 and 95% CI: 1.08 to 3.09; and P= 0.033, OR: 1.7 and 95% CI: 1.04 to 2.84) 
respectively); and family history of congenital anomalies (P=33, OR: 0.01.73 and 95% CI: 
1.04 to 2.89). There were significantly more controls compared to NSOFC cases with the 
maternal common allele genotype (GG) in maternal folic acid supplementation during the 1st 
trimester (P= 0.028, OR: 0.57 and 95% CI: 0.35 to 0.94) and in mothers drinking Zamzam 
water compared to tap water (P= 0.005, OR: 8.92 and 95% CI: 1.92 to 41.52). 
5.6.5.2.3 Chi square correction using Bonferroni correlation 
Chi square correlation using Bonferroni correction for the three infant VAX1 rs7078160 
genotypes in NSOFC cases compared to controls according to different environmental 
factors revealed a significantly larger number of NSOFC cases with the maternal 
homozygous rare allele genotype (AA) compared to controls with parental consanguinity. 
Moreover, there was a significantly larger number of NSOFC cases with the maternal 
homozygous common allele genotype (GG) compared to controls in maternal antibiotics 
244 
 
ingestion in the pre-gestation period; maternal anti-emetic medication ingestion during the 
1st trimester period; maternal illness during the pre-gestation period; maternal common 
cold/flu infection during the pre-gestation period; mothers complaining of being under stress; 
family problems; and family history of congenital anomalies. There were significantly more 
controls compared to NSOFC cases for GEI between maternal homozygous common allele 
genotype (GG) and maternal folic acid supplementation during the 1st trimester and mothers 
drinking Zamzam water. 
 
5.6.6 Multi-nominal logistic regression analysis for case-only study design 
gene-environmental interaction  
Multi-nominal logistic regression analysis was carried out to identify significant gene-
environmental interactions among NSOFC cases. The homozygous common allele genotype 
for each included SNP was set as a reference for analysis (see Table 5.62). For maternal 
rs2013162, the homozygous rare allele genotype (AA) was significantly related to antipyretic 
medication in the 1st trimester period (P= 0.027, OR: 10.18 and 95% CI: 1.31 to 79.1) and 
abdominal pain in the 1st trimester period (P= 0.031, OR: 7.4 and 95% CI: 1.2 to 45.51) 
among NSOFC cases. The heterozygous allele genotype (AC) was significantly related to 
folic acid pre-gestation (P= 0.0167, OR: 6.78 and 95% CI: 1.41 to 33.49) and fever pre-
gestation (P= 0.025, OR: 0.23 and 95% CI: 0.06 to 0.83) among NSOFC cases.  
For maternal VAX1 rs7078160, the homozygous rare allele genotype was significantly 
related to paternal waterpipe (P= 0.013, OR: 6.95 and 95% CI: 1.5 to 32.2) and maternal 
exposure to high blood pressure during the 1st trimester period (P= 0.05, OR: 11.2 and 95% 
CI: 1 to 125.73) among NSOFC.  
245 
 
There was no significant gene-environmental interaction as shown by regression analysis for 
maternal IRF6 rs2235375
 
and maternal VAX1 rs4752028.  
 
 
 
 
Table 5.62: Multi-nominal logistic regression analysis for case-only study design gene-
environmental interaction including significant factors.  
SNP P value 
OR 95% (CI) 
Maternal rs2013162
b
 
Variables AA CA 
Antipyretic medication 1st 
trimester 
0.027** 
10.18 (1.31-79.1) 
0.132 
2.74 (0.74 -10.13) 
Folic acid pre-gestation 0.351 
3.83 (0.23-64.42) 
0.017** 
6.87 (1.41-33.49) 
Maternal exposure to X-ray 
1st trimester 
a 0.947 
1.07 (0.16-7.01) 
Fever pre-gestation a 0.025** 
0.23 (0.06-0.83) 
Depression in the 1
st
 
trimester 
0.274 
6.22 (0.24-164.39) 
0.56 
1.96 (0.2-18.98) 
Abdominal pain 1st 
trimester 
0.031** 
7.4 (1.2-45.51) 
0.61 
1.36 (0.42-4.38) 
Maternal IRF6 rs2235375
b
 
Variables GG CG 
Folic acid pre-gestation 0.051 
0.23 (0.05-1) 
0.385 
0.59 (0.18-1.94) 
Mother complains of being 
under stress 
0.508 
0.75 (0.32-1.75) 
0.76 
0.88 (0.38-2.03) 
Maternal VAX1 rs4752028
 C
 
Variables CC CT 
Exposure to incense 1st 
trimester 
0.51 
0.63 (0.16-2.51) 
0.811 
0.92 (0.45-1.88) 
Fever 1st trimester 0.48 
0.46 (0.06-3.85) 
0.14 
0.42 (0.14-1.33) 
246 
 
Maternal VAX1 rs7078160
d
 
Variables AA AG 
Iron supplementation 
pregestation  
a 0.017 
5.18 (1.34-20.11) 
High blood pressure 1
st
 
trimester 
0.05** 
11.2 (1-125.73) 
a 
Paternal waterpipe 0.013**  
6.95 (1.5-32.2) 
0.622 
0.69 (0.16-2.95) 
Exposure to chemicals 
pregestation  
0.909 
0.9 (0.15-5.55) 
0.362 
1.56 (0.6-4.02) 
Exposure to incense 1st 
trimester 
0.346 
0.42 (0.07-2.54) 
0.8 
0.88 (0.34-2.31) 
Consanguinity 0.662 
1.41 (0.3-6.7) 
0.073 
0.45 (0.19-1.08)) 
            ** Significant value P≤ 0.05 
a. No value either because the parameter is set to zero or the value is redundant   
b. The reference category is the common homozygous allele genotype CC. 
C
. The reference category is the common homozygous allele genotype TT 
d. The reference category is the common homozygous allele genotype GG 
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Chapter 6: Discussion 
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6.1 Introduction 
This thesis is the first report of a national multicentre based study that measured the 
prevalence and investigated the aetiology of NSOFC in Saudi Arabia. Knowing that the 
prevalence and aetiology of NSOFC varies geographically and in different ethnic groups, it 
is important that this is investigated in every population (Mossey and Little, 2002). Although 
the ethnicity of the Middle East is considered Caucasian or ‘white’, defined as a person 
having origins in any of the original peoples of Europe, the Middle East, or North Africa 
(Risch et al., 2002; Lewonin 2005), geographically, the Middle East is located between the 
three main continents (Asia, Africa and Europe) which makes it unique in in its genetic 
admixture of the three populations.   
Saudi Arabia is the largest country in the Middle East with a population of 29 million and 
estimated 300,000 births per year. It consists of three main regions: Central, Western and 
Eastern. The Western region, which encompasses one third of the Saudi population, is 
further divided into Makkah and Maddina regions. The Central region also encompasses one 
third of the Saudi population, and consists mainly of the Riyadh region (Ministry of Health, 
2010).   
6.1.1 Barriers and facilitators in carrying out this research: 
This retrospective case triad/control triad study on NSOFC in Saudi Arabia faced some 
methodological difficulties and barriers throughout its fieldwork, during data collection and 
genotyping. There were also other aspects that went well. These difficulties and facilitators 
are described in the following points. 
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6.1.1.1 Ethical approval: 
The sample design in our research was aiming to include referral centres from each region 
covering most of the NSOFC cases in the three included cities. This was achieved in Jeddah 
and Maddina. However, in Riyadh, King Faisal Specialised Hospital and Research Center 
which is a cleft centre in Riyadh had an ongoing research project that is already underway on 
oral cleft patients. As they did not want to exhaust their patients, approval to carry out our 
research was not gained in their hospital. Therefore, we recruited our sample from four 
hospitals in Riyadh. 
Moreover, the request for research and ethical approval were preformed multiple times with 
a structured proposal form unique for almost each hospital (nine requests for the 11 included 
hospitals). In addition, some of the ethical requests took almost a year to receive an approval 
by some hospitals. It would be useful if a more standardized procedure could be used for 
obtaining ethical permission across Saudi Arabia; and perhaps other parts of the Middle East 
also, especially for rare diseases and low exposures research. 
 In Jeddah, funding support was received from King Abulaziz University Research Centre in 
King Abulaziz University, which also provided the genetic lab (Princess Al-Jawhara 
Albrahim Center of Excellence in Research of Hereditary Disorders) and technicians. In 
addition, the Ministry of Health supported the research by facilitating the ethical approval in 
their hospitals. 
Moreover, support was received from the staff of the hospitals by directing us during the 
paper work and helping us to find a Principle Investigator (PI working in the same hospital 
was one of the requirement for research approval). 
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6.1.1.2 Identification of cases and ascertainment    
Although nurses and doctors were very supportive and tried to facilitate the researcher 
reaching NSOFC patients, sub-mucosal cleft palate and bifid uvula are known to be difficult 
to identify clinically (Gosain et al., 1996). Therefore, it was excluded from the investigation. 
In addition, as our research was carried out in three cities at the same time, with long 
destination (almost 10 hours by car) between cities, one research coordinator was not 
enough, Therefore, more than one research coordinators were assigned for collecting the 
saliva and filling the questionnaire. However, efforts were made to limit their number and 
improve the research ascertainment as was discussed in the material and method section 
(4.2.3.4).  
 
6.1.1.3 Sample collection  
Once nurses and doctors identified a NSOFC case, they facilitated parental contact with the 
researcher. Nevertheless, some of the parents were reluctant to provide saliva sample or 
allow us to take saliva from their infants.  Consequently, the sample size for assessing 
environmental risk factors that needed only a questionnaire exceeded that assessing the 
genetic risk factors. In addition, fathers were more reluctant than mothers in providing their 
saliva (16 fathers out of 189 infant-parental triad controls did not give their saliva).  
The sample was transported from Riyadh and Maddina to the genetic lab in Jeddah through a 
very hot atmosphere that reaches over 40 degrees. Thus it needed transportation on wet ice, 
hand-to-hand, to ensure sample protection.  
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6.1.1.4 Questionnaire responses  
Most of the parents agreed to answer the questionnaire. Even though, we faced some 
difficulties in getting the general characteristics of the infant (neonatal head circumferential 
and infant neonatal length) when the infant was not born in the same hospital. As the 
neonatal head circumferential and infant neonatal length are not always written on the 
infant's vaccination card.  
Also, there are some points that need to be considered in measuring SES level for Saudis.  
Parental income, by some, was considered "personal information". However, this problem 
was managed by asking about their occupation. Occupation type could give an estimated 
value for the salary. In addition, measuring the household income is different from other 
populations. The majority of the Saudi population families are financially supported by the 
fathers, even if the mother is working. Still, as most of the mothers are not working (86% of 
our sample), the household income could be considered equal to paternal income.   
For questions related to maternal medication ingestion (yes/no questions) in the 1
st
 trimester, 
mothers answered directly and clearly. But, they did not always remember their names 
or/and their doses.  
Further, there was a risk of bias in questions related to smoking. The social acceptance of 
smoking, especially for woman, was expected to lead to underestimation of this risk factor. 
However, as this problem is in both cases and controls, it should not have had a significant 
effect on our results. Still, we tried to overcome this problem by asking more questions 
related to; smoking type and severity.  
Passive smoking intensity was reported in another research to be difficult to measure 
(Sabbagh et al., published/ in press 2015). Still, as most of the mothers in cases and controls 
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were not working (87% of mothers in cases and controls), exposures to 2nd hand smoking 
were easier to measure as it is mainly in houses from other family members. 
Moreover, stress level is difficult to measure. The differences in abilities to cope with stress; 
the secrecy of private life when it comes to family problems; and the differences in abilities 
to describe stress, make stress a challenging area to study. However, these difficulties were 
found in both cases and controls. In addition, measures were taken through; asking questions 
lightly in comfortable tone; and assuring confidentiality of the information as much as 
possible, in order to gain a correct answer.  
On the other hand, information related to parental consanguinity was easy to get and directly 
answered by the parents.  
Finally, parents answered most of the question willingly. However, these points mentioned 
above are important to consider in future research carried out in Saudi Arabia, in order to 
reduce the risk of bias. 
 
6.1.1.5 Genotyping  
Genotyping was carried out in Saudi Arabia according to the Saudi Government rules. The 
genetic lab in Princess Al-Jawhara Albrahim Center of Excellence in Research of Hereditary 
Disorders accepted to carry out the research in their lab, providing the technician and most of 
the hardware equipment required for genotyping. However, enzymes were bought abroad 
and transferred through the Saudi border. This process needed the Saudi FDA approval 
which took longer time than expected resulting in ruining the enzymes. Therefore, materials 
were requested and bought multiple times. These problems prolonged the research laboratory 
procedure timeline. 
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 6.1.1.6 Saudi Arabia as a place for research   
Saudi Arabia is a good environment for research in many aspects. The government of Saudi 
Arabia supports research. Funds are provided through research centres. Labs and technicians 
with good experience are available. Governmental hospitals assess the researcher in 
providing and facilitating sample recruitment.  
In addition, Saudi Arabia's unique population characteristics such as; their high birth rate and 
high consanguinity prevalence, makes it a good candidate for parental consanguinity, 
hereditary disease and birth defect research. In addition, Saudis, especially in the Western 
Region, have been of mixed ethnicity for hundreds of years. People from all over the world, 
of different ethnic origins, have travelled to Makkah and Maddina on pilgrimage, then, 
settled and mixed races through marriage.  Additionally, Saudi Arabia has a unique 
geographic location between the three continents; Asia, Africa and Europe. As a result of 
this, it can be difficult to group people according to their ethnicity in Saudi Arabia, although 
they are, generally considered Caucasian (Risch et al., 2002; Lewonin 2005). 
Moreover, as mothers in Saudi Arabia are mainly housewives, maternal domestic exposures 
could be easier to measure than other parts of the world were women are exposed to both 
occupational and household exposures.  
Finally, it is recommended that the awareness is roused amongst the Saudi population about 
the importance of research. This would help to improve the population support and research 
approval. 
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6.2 Part I: The prevalence of NSOFC in Saudi Arabia 
The birth prevalence of NSOFC in the three main cities in Saudi Arabia over the two-year 
period was 1.17/1000 live-births, which was lower than the global birth prevalence 
(1.25/1000) for NSOFC (Mossey and Modell, 2012a) and also lower than the mean overall 
prevalence of NSOFC for all studies carried out in Saudi Arabia and in neighbouring Middle 
Eastern countries (1.25 per 1000 live-births) (Sabbagh et al., 2012). Only two studies have 
previously reported the prevalence of NSOFC in Saudi Arabia. These studies were based 
from single hospitals, conducted in 1991 and in 1993 and carried out in Riyadh and in 
Alqaseem (Borkar et al., 1993; Kumar et al., 1991). The Borkar et al. (1993) study reported a 
lower incidence of 0.3/1000 births in Riyadh, whereas the Kumar et al. (1991) study reported 
a much higher incidence of 2.19/1000 births in Al-Quasseem as compared to the global 
prevalence of NSOFC.  
6.2.1 Comparisons between the prevalence of NSOFC in different cities 
(table 5.1)  
In Jeddah city, the prevalence of NSOFC (0.8/1000 births) was lower than in Riyadh 
(1.07/1000 births). However, the highest NSOFC prevalence was for Maddina city 
(1.88/1000 births); this prevalence was also higher than the global figure. It is notable that 
there is a higher prevalence of consanguinity reported in Maddina (67.2%) compared to 
Jeddah (44%) and Riyadh (60%) (El-Hazmi et al., 1995; El Mouzan et al., 2008). The 
differences in prevalence between cities might also indicate different aetiological risk factors 
for each region that would need further investigation by studies with larger sample sizes to 
elucidate accurately. 
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6.2.2 Prevalence of NSOFC phenotypes and description of its sub-
phenotypes (table 5.2) 
The prevalences of CL/P (0.89/ 1000 live births) and CP (0.28/ 1000 live births) were lower 
than the global prevalences (0.94 and 0.31 /1000 live births, respectively). However, the 
prevalences of CP in Riyadh (0.4/ 1000 live births) and in Maddina (0.36/ 1000 live births) 
were higher than both the Jeddah CP prevalence (0.13/1000 live births) and the global figure 
(0.31/ live 1000) (Mossey and Modell, 2012a). This could be explained by the high 
prevalence of consanguinity for both Riyadh and Maddina compared to Jeddah, as 
consanguinity was reported in previous studies to be associated with CP more than with 
CL/P (Sabbagh et al., 2013). The relationship between consanguinity and NSOFC will be 
discussed in more detail in the following section.  
The finding from our study that the birth prevalence of CL (0.47/1000) is higher than that of 
CLP (0.42/1000) differs from the global finding and those of previous studies, which 
reported a higher birth prevalence of CLP (from 40 to 45%) compared to CL (20 to 25%) 
(Mossey and Modell, 2012a). Our findings, especially in Maddina (where the CL prevalence 
is 0.85 compared to the CLP prevalence of 0.67 /1000 births and which also has a higher 
NSOFC prevalence), do not support Mossey and Modell (2012a), who suggested that 
decreases in the ratio between CLP and CL are found in regions with a low prevalence of 
NSOFC. They also suggested that a trend for less severe NSOFC would be associated with 
low prevalence of NSOFC, which is different from what we found in this study as the 
prevalence of bilateral CL/P in Jeddah, which has low NSOFC prevalence, was 48.4% (15 
cases out of the total 31 CL/P cases), higher than the prevalence of bilateral CL/P (20.9%; 9 
cases out of the total 43 CL/P cases) in Maddina which has the highest NSOFC prevalence. 
These differences were significant (P= 0.02). These findings and the differences in the 
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prevalence of NSOFC sub-phenotypes could indicate the involvement of different 
aetiological factors and may highlight a specific trend of NSOFC phenotypes in the 
respective cities.  
Our study showed that the prevalence of NSOFC (133 cases) and CL/P (101 cases)  in males 
((82 cases (61.7%) and 66 cases (65.3%) respectively) was higher than in females (51 cases 
(38.3%) and 35 cases (34.7%), respectively). The severity of CL/P is related to this, with an 
increase in the male to female ratio reaching almost 4:1 in complete bilateral CLP. This 
finding was also reported by Mossey and Modell (2012), who conveyed a male to female 
ratio of about 2:1 and that the M:F ratio increased with the severity of CL/P.  
The prevalence of CP was higher in females (10 (62.5%)) compared to males (6 (37.5) in 
Jeddah and Maddina. These findings are similar to the global figures (Mossey and Modell, 
2012a). Riyadh, on the other hand, had a higher number of males (10 cases) compared to 
females (6 cases) in the CP group. Only one other study in the Arabian Middle Eastern 
countries has reported a higher prevalence of CP in males (Aqrabawi, 2008). A local 
aetiological factor or poor ascertainment of CP could lie behind the increase in CP ratio in 
males during the two year period that was included in this research. Additional studies are 
needed to further clarify the relationship between various risk factors and the manifestation 
of CP, and how this might differ between genders.   
For OFC sub-phenotypes, our study found that left sided unilateral CL (29 cases (21.7%)) 
and CLP (16 (12.5%)) was more common than the right sided CL/P (13 cases (9.7%)), 
similar to global figures (Mossey and Modell, 2012a; Rakotoarison et al., 2012; Rajab and 
Thomas, 2001; Rajabian and Sherkat, 2000).   
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6.2.3 Prevalence of consanguinity in NSOFC cases (table 5.3) 
Consanguineous relationships have been suggested to increase the prevalence of congenital 
anomalies especially in recessive gene disorders (Pritchard and Korf, 2008). Saudi Arabia 
has a high rate of consanguineous marriages although this rate varies across regions (El-
Hazmi et al., 1995). 
The prevalence of consanguinity in NSOFC cases reported by this study was 81 cases 
(65.9%), which is higher than the prevalence reported by Al-Johar et al. (2008) (54.4%) and 
the prevalence reported by both El Mouzan et al. (2008) and EL-Hazmi et al. (1995) for the 
Saudi community (57% and 57.7%, respectively) (El-Hazmi et al., 1995Al-Johar et al., 2008; 
El Mouzan et al., 2008;). In addition, the prevalence of consanguinity in NSOFC infants in 
Maddina (77.4%), in Riyadh (56.1%) and in Jeddah (58.6%) were almost similar or slightly 
higher than the prevalence of consanguinity in the general population as reported by El 
Mouzan et al. (2008), which were 67.2%, 60% and 44% for each city respectively. Of the 
total infants with consanguineous parents, 44 cases (54.3%) were first cousins, which was 
also almost similar to the El-Hazmi et al. (1995) findings (41%) for the general population of 
the Saudi community. The higher prevalence of consanguineous marriages in NSOFC cases 
compared to the general population could indicate that consanguinity is a risk factor in the 
aetiology of NSOFC; a theory supported by previous research (Stoll et al., 1991; Reddy et 
al., 2010; Sabbagh et al., 2014). However, in order to confirm this relationship, a case-
control design study is needed. Therefore, the role of consanguinity will be re-examined in 
part II of this thesis.  
Looking at the different NSOFC phenotypes, the prevalence of CP cases with 
consanguineous parents was more than that of CL/P. Although this difference was not 
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statistically significant (P= 0.11), it is supported by other studies that found a higher 
prevalence of CP infants related to consanguineous parents (Ravichandran et al., 2012; 
IPDTOC Working Group, 2011). This relationship could explain the higher prevalence of CP 
in Maddina compared to Jeddah, as Maddina has a higher prevalence of consanguinity. 
Furthermore, our study found no relationship between consanguinity and gender in NSOFC 
(P= 0.559).  
The prevalence of CL was also higher in infants with consanguineous parents (63.3%) 
than those with non-consanguineous parents (36.7%). Although this relationship was not 
statistically significant, it could explain why the prevalence of CL was higher than CLP in 
the Saudi population. In addition, the relationship between consanguinity and CL could 
explain the higher prevalence of CL compared to CLP in Maddina (0.89 compared to 
0.67/1000 births) as compared to Jeddah (0.35 compared to 0.33/1000 births). Studies in 
countries with low consanguinity demonstrated a higher prevalence of CLP compared to CL 
(Bonaiti et al., 1982; Zlotogora, 1997; Cooper et al., 2006), supporting these models. 
Furthermore, 70.2% of complete clefting of the lip and 66.7% of bilateral clefting of the lip 
occurred in infants with consanguineous parents. This could suggest that consanguinity could 
be related to the pattern and severity of NSOFC phenotypes rather than the prevalence. More 
details on the relationship between consanguinity and NSOFC identified from previous 
research is discussed in the paper “Parental consanguinity and non-syndromic orofacial clefts 
in children; a systematic review and meta-analyses” (Sabbagh et al., 2014) presented in 
Appendix B3. 
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6.3 Part II: Aetiology of NSOFC 
The aetiology of NSOFC is multifactorial and includes three groups of risk factors; 
environmental risk factors, genetic risk factors and an interaction between the gene and 
environmental risk factors.    
6.3.1 Environmental risk factors 
A case-control study was designed to investigate the environmental risk factors for NSOFC. 
This type of study plays an important role in disease prevention strategies (Mossey and 
Castilla, 2001). The most important environmental factors that were described to be 
associated with NSOFC in previous research include: maternal exposure to antibiotics, 
disease, stress, smoking and chemicals, and these factors were investigated in this project. 
A questionnaire was used to retrospectively record exposure to environmental factors. This 
method of collecting data could be subjected to recall bias which results from parents of 
cases over reporting exposures compared to controls. However, previous studies that 
assessed recall bias in case-control studies measuring the influence of exposures on birth 
defects, reported minimal or irrelevant bias effect. They compared the use of affected 
controls with unaffected controls and reported minimal changes in OR between both control 
groups. Accordingly, they concluded satisfactory results in using unaffected controls 
(Khoury et al., 1994; Swan et al., 1992). 
 
To determine the sample size required for our study to yield statistically significant results, 
we measured the sample size that was expected to be obtainable in two years (as mentioned 
in the material and methods section (Paragraph 4.2.2)) and we also included referred cases 
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that were 18 months or less in age that attended the targeted hospitals to increase the sample 
size. Two other methods were carried out to further define the sample size: a systematic 
review of the prevalence of clefting in Saudi Arabia (Sabbagh et al., 2012); and estimation of 
the prevalence of NSOFC from exposure to the risk factors identified from previous studies. 
Accordingly, to reach 80% sample power, we need at least 105 cases compared to 105 
controls. Our sample exceeded this number reaching 205 cases and 244 controls.    
The proportion of CP (25.8%) in the study sample is similar to the global proportion, ranging 
from 20-25% (Mossey and Modell, 2012). The overall proportions of CL (38%) in the 
included sample were slightly higher than CLP (36.8%) which differs from the global figures 
which show a higher proportion of CLP (40-45%) compared to CL (20 to 25%) (Mossey and 
Modell, 2012); however, these values from this part of the study were similar and supported 
to our findings that was discussed in the prevalence part 1 section of this study.  
 
The frequency prenatal diagnosis of CLP (12.6%) was more common than for CL (8%), 
which is supported by the results of Stoll et al. (2000). However,  CL (8%) diagnosis 
frequency was higher than that reported by Stoll et al. (2000) (3.7% for isolated CL) and did 
not agree with their report stating that there were more diagnosed cases with associated 
anomalies compared to isolated anomalies (15.6% for isolated CL/P compared to 5% for 
CL/P with associated anomalies).  
However, similar findings regarding the prevalence of associated anomalies was reported by 
Stoll et al., (2000), and CP appeared to be more closely associated with other anomalies 
compared with other oral cleft phenotypes (Stoll et al., 2000). This could be explained by 
Mossey and Modell, (2012) who suggested the possibility of other birth anomalies 
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stimulating detailed examination, leading to detecting mild CP, which could be overlooked if 
it occurred alone. Besides, Rittler et al. 2011 reported that 7.1% of NSOFC cases diagnosed 
as isolated cleft at birth were found to be associated with other birth anomalies after one 
year. Additional details regarding the prevalence of associated anomalies are described in 
Appendix B (B1, B4 and B5). 
 
6.3.1.1 Parental age and infant characteristics (table 5.5 and 5.6): 
This study found no association between NSOFC and parental age, in concordance 
with findings of previous studies (Jamilian, 2007; Kanaan, 2008; Al-Sahafi, 2010). In 2012, 
a meta-analysis carried out to assess the relationship between parental age and NSOFC found 
heterogeneity between studies looking at parental age and their relationship to CL/P. 
However, a relationship was found between parental age and CP only (Herkrath et al., 2012). 
Neonatal weight was similar in both groups (cases and controls) in our study, in line 
with previous findings (Leitte and Koifman, 2009; Welch and Hunter, 1980), although in 
their epidemiological study in France, Bonaiti et al. (1982) reported lower birth weights for 
infants with CP. 
Congenital anomalies have been reported to be higher in twins compared to singletons 
(Glinianaia et al., 2008). Although the number of twins in this study sample was low (12 
pairs of infants) and they were not monozygotic, there were a significantly higher number of 
twins in the study group (11 pairs of infants) compared to controls (one pair) (P= 0.002). 
Twinning was associated with CL/P (P= 0.019 for CL and P< 0.001 for CLP) but not with 
CP (P= 0.24). Previous research did not support this relationship (Kot and Kruk-Jeromin, 
2005; Nordström et al., 1996). However, these were not case-control study and they included 
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both mono and dizygotic twins. In 2012, a Danish national research study found no increased 
risk of NSOFC in twins compared to singletons although they reported that the recurrence 
risk for clefts was greater in twins than in non-twin siblings and that the heritability estimate 
was over 90% which indicates a genetic factor effect (Grosen et al., 2012). Finally, the 
relationship found in this study with dizygotic twins suggested an environmental risk factor 
rather than a genetic risk factor. In addition, the relationship with twins being significant 
with CL/P cases rather than CP could suggest a mechanical interference risk factor 
interrupting the development of the craniofacial structure. Further investigation to clarify the 
relationship is suggested. 
6.3.1.2 Socio-economic status (SES) (table 5.7): 
It has been suggested that SES was associated with NSOFC. This was explained by the 
adverse effect of low SES on parental healthcare and lifestyle (Taghavi et al., 2012). 
However, our study did not support this relationship. Our finding could be related to the 
generally higher SES of Saudis compared to other communities (Trading economics; 
http://www.tradingeconomics.com/saudi-arabia/gdp), the availability of free governmental 
healthcare and education. Also medication and supplementations are provided free in 
the Ministry of Health and governmental hospitals (Saudi Ministry of Economy and Planning 
statistical book, 2013).  
The number of CP cases identified in our study from rural areas was significantly greater 
than urban areas as compared to controls. This finding is supported by another study (Al-
Sahafi, 2010). This could be a valid relationship, or it could be an artefact, because families 
with NSOFC infants tend to seek treatment in cities, whereas unaffected infants from rural 
areas tend to have vaccinations locally, potentially skewing ascertainment of the ‘matched’ 
control group for residency comparison. Nevertheless, our study found no significant 
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difference in the prevalence of CL/P between rural and urban areas which is similar to Stoll 
et al. (1991) in north-eastern France. Future study that includes new-born cases and controls 
from rural and urban areas is recommended for confirming their relationship to CP.   
6.3.1.3 Pregnancy planning and the effect of sibling order (table 5.8 and 5.9): 
Recently, Martelli et al. (2010) carried out a case-control study in Minas Gervais to evaluate 
environmental risk factors for CL/P in 100 children. They reported no relationship between 
CL/P and paternal age, pregnancy order or inter-pregnancy interval. Although our study did 
not find a relationship between NSOFC phenotypes and sibling order (P>0.05), a significant 
relationship between CL and inter-pregnancy interval duration was anticipated (P= 0.01). 
Further investigation followed by a systematic review and meta-analysis is recommended to 
clarify this relationship.    
Our study reported more mothers planning their pregnancy in the control group (45.4%) 
compared to CLP (40.5%) and CP (40%). Although this finding was not significant 
(P>0.05), it is supported by Mossey et al. (2007) who reported a statistically significant 
relationship between pregnancy planning and NSOFC based on a case-control study. 
However, they also found a greater difference between cases and controls if the mother was a 
smoker, which is an aetiological factor (maternal smoking) rarely reported in our sample.  
6.3.1.4 Family history and consanguinity (table 5.10 to table 5.13): 
Family history of NSOFC was reported to increase the chance and recurrence of NSOFC 
(Krapels, 2005; Jia et al., 2011; Zandi and Heidari, 2011). In our study the prevalence of 
NSOFC with a family history of birth defects was 41.2% (84 cases), lower than what was 
reported by Aljohar et al. (2008) (54.4%) but similar to the findings of Borkar et al. (1993) 
(42%). Another study in Riyadh, Saudi Arabia reported a very low number of patients with 
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family history of congenital anomalies (8%) (Kumar et al., 1991). In our study, the 
difference between cases and controls in the prevalence of reported family history for all 
types of birth defects was statistically significant only for CLP infants (P= 0.012). However, 
the difference between cases and controls in the prevalence of reported family history of 
OFC was significantly higher in cases compared to controls for all types of NSOFC (P< 
0.001) with the highest prevalence of family history for CLP (39.2%). This was similar to 
findings from Jia et al. (2011), who reported a significant difference between cases and 
controls (P= 0.001) and a higher prevalence of family history for CL/P (13.6%) compared to 
CP (4.5%). 
Prevalence of consanguinity in the case-control section of our study (Part II) (56.7%) was 
lower than the prevalence section (Part I) (65.5%). However, it was similar to the prevalence 
of the control group (59.2%). In addition, the prevalence of CP cases with consanguineous 
parents was higher (65.4%) than controls which agrees with results presented in Part I. A 
role for consanguinity in OFC is also supported by previous research some of which, 
although not all, found a significant relationship between consanguinity and NSOFC. 
Grouping these studies in meta-analysis resulted in the identification of a significant 
relationship (OR: 1.83 and 95% CI: 1.31 to 2.54). Moreover, consanguinity in this meta-
analysis was also reported to be more related to CP (OR: 1.89 and 95% CI: 1.14 to 3.31) 
compared to CL/P (OR: 1.56 and 95% CI: 1.18 to 2.07) (Sabbagh et al., 2014) (Appendix 
B3). However, in order to confirm parental consanguinity relationship with NSOFC, it is 
necessary to match cases with controls in residency or take controls from rural areas, as they 
are more likely to be involved in consanguineous marriages. 
The most prevalent type of consanguineous marriage in our study group was between first 
cousins (60.5%), as compared to other types of consanguineous marriages and compared to 
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controls (58.9%) but there was no significant difference between these (P= 0.643). Similar 
findings were reported by the Sabbagh et al. (2014) meta-analysis which identified a 
significant association between first cousin consanguineous marriages and NSOFC (OR: 
1.49 and 95% CI: 1.07 to 2.07) (Appendix B3).  
6.3.1.5 Maternal supplementation (table 5.14 and 5.15): 
Maternal supplement ingestion during the first trimester showed a significant decrease in the 
chance of having a child with NSOFC for both folic acid and calcium supplementation. Folic 
acid supplementation was associated with decreased risk of NSOFC (P= 0.009, OR: 0.59 and 
95% CI: 0.39 to 0.88) and of CLP (P< 0.001, OR: 0.34 and 95% CI: 0.2 to 0.58). This 
association was in accordance with a meta-analysis carried out by Bodovinac et al. (2007) that 
included five prospective studies, from which a significant relationship was identified between 
folic acid and NSOFC occurrence (OR: 0.55 and 95% CI: 0.32 to 0.95). This association was 
statistically significant for CL/P (OR: 0.51 and 95% CI: 0.32 to 0.95) but not for CP (P= 0.18, 
OR: 1.19 and 95% CI: 0.43 to 3.28) (Badovinac et al., 2007).  On the other hand, although not 
significant, our study found a tendency of increased risk of CL in mothers using folic acid in the 
pregestation period (P= 0.22, OR: 1.62 and 95% CI: 0.75 to 3.5). This finding is supported by a 
recent population base case-control study in Northern Netherlands that investigated the 
relationship between peri-conceptional folic acid supplementation and the different oral cleft 
phenotypes. They reported "duration of exposure-response effect" for folic acid maternal 
ingestion that increased the risk of cleft lip when ingested in the pregestation period (Rozendaal 
et al., 2013). 
Although many studies have reported a significant association between CL/P and   maternal 
multivitaminsingestion, others found no significant relationship (Goh et al., 2006). This 
supports our findings of a non-significant association betweenmultivitamins and CL/P (P= 
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0.38, OR: 0.74 and 95% CI: 0.38 to 1.45 for CL; and P= 0.31, OR: 0.7 and 95% CI: 0 .3 to 
1.4 for CLP). 
For calcium supplementation, a statistically significant decreased risk of having an infant with 
NSOFC was observed (P= 0.014, OR: 0.37 and 95% CI: 0.16 to 0.84).  
Although calcium supplementation was more often utilized by the mothers in the control group 
compared to the mothers in the three NSOFC phenotype groups (CL, CLP and CP), CP was the 
only phenotype that showed a statistically significant difference with supplementation compared 
to the control group (P= 0.024). This finding was different from that reported by Jia et al. (2011), 
who found a statistically significant decrease chance of having an infant with CL/P after  
maternal calcium supplementation (P= 0.02, OR: 0.66 and 95% CI: 0.47 to 0.93) but not for CP 
(P= 0.33, OR: 0.81 and 95% CI: 0.52 to 1.24). The significant relationship for calcium 
supplementation and CP in the Saudi population could be related to the severe levels of Vitamin 
D deficiency in Saudi women who have one of the highest Vitamin D deficiency levels in the 
world (Elshafie et al., 2012). Vitamin D is known to play an important role in the maintenance of 
serum (ionised) calcium levels (Nordin, 2010). 
Finally, Public Health Organizations in planning their policies for preventing oral clefts 
should call for further research that confirms the relationship between folic acid and NSOFC. 
The differences in reports suggesting; decrease in CL/P if folic acid is ingested in the 1
st
 
trimester; increase of CL if folic acid is ingested in the pregestation period; and, the presence 
of mandatory folate fortification of flour in Saudi Arabia (Saudi Standard of fortification, 
2001) makes it a challenging intervention. 
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6.2.1.6 Maternal illnesses (table 5.16 to 5.19):  
Maternal illness and maternal common-cold/flu infection in the three months pre-gestation 
were significantly reported more frequently by CL/P and CP mothers (for maternal illness: 
P= 0.024, OR: 2.04 and 95% CI: 1.1 to 3.82 for CL; P< 0.001, OR: 3.69 and 95% CI: 2.04 to 
6.68 for CLP; and P= 0.013, OR: 2.39, 95% CI: 1.19 to 4.81 for CP; and for common-
cold/flu: CL, P= 0.014, OR: 2.45, 95% CI: 1.23 to 6.28; CLP, P< 0.001, OR: 6.34 and 95% 
CI: 3.11 to 13.18; and CP, P= 0.031, OR: 2.66 and 95% CI: 1.06 to 6.63) compared to 
controls. For the 1st trimester, maternal illness was more frequent in CL/P and CP mothers 
compared to control. However, it was only significant for CL (P= 0.037, OR: 1.74 and 95% 
CI: 1.04 to 2.94). For maternal common-cold/flu in the 1st trimester, the statistical 
significant relationship was only for CP (P= 0.037, OR: 2.03 and 95% CI: 1.03 to 3.98). This 
could be because mothers might not be aware of their pregnancies until the end of their 
second gestation month, which is a critical time for craniofacial development. Furthermore, 
the three-month pre-gestation period covers the time around conception, which could affect 
embryonic development (Mossey and Castilla, 2001). The positive relationship between 
maternal illness and having a child with NSOFC has been reported by other studies as well 
(Czeizel, 2002; Krapels, 2005; Edwards, 2006; Hashmi et al., 2010). Recently, Luteijn et al., 
(2014) carried out a meta-analysis to assess the relationship between maternal influenza 
infection in the 1st trimester and birth defects. They reported a significant relationship with 
NSOFC (OR: 1.96 and 95% CI: 1.33 to 2.91) including CL (OR: 3.12 and 95% CI: 2.20 to 
4.42).  
The adverse outcome of maternal illness and common-cold/flu infection could be the result 
of an associated adverse effect that accompanies the illness such as hyperthermia, stress or 
268 
 
from the medication ingested to manage these illnesses. Therefore, we will further discuss 
maternal fever and antipyretics in the coming paragraphs to clarify this relationship.  
Our study also found a significant relationship between maternal diabetes and CP (P= 0.018). 
This finding is supported by that of Carinci et al. (2005), who reported a significant 
association between familial diabetes and CP only (P = 0.001) in Southern Italy. Another 
case-control population-based study in the US reported a significant relationship with CL/P 
(Spilson et al., 2001).  It is noteworthy, however that the prevalence of diabetes among 
pregnant women in the control group was lower than what was reported in previous studies 
carried out in a one hospital set in Saudi Arabia which ranged from 8 to 12% (Khwaja et al., 
1989; Ardawi et al., 2000; Al-Hakeem, 2006).  
Other diseases were rarely reported by mothers, suggesting a larger sample size is needed to 
measure their exposure effects.  
 
6.3.1.7 Maternal hyperthermia (fever) and antipyretics (table 5.20 and 5.29): 
Researchers have reported an association between hyperthermia and many adverse outcomes 
ranging from abortion to birth defects depending on the development stage, duration of 
hyperthermia and the severity of fever (Graham and Edwards, 1998; Walsh et al., 1998; 
Edwards, 2006). This could be explained by the effects of hyperthermia that can cause the 
death of proliferating cells, interruption of the normal sequence of developmental gene 
activities, or damage to the embryonic vascular system during a critical stage of development 
(Rockett et al., 2001; Omori et al., 2014).  
In our study hyperthermia was associated with an increased risk of NSOFC in general and of 
CLP (P= 0.048, OR: 1.98 and 95% CI: 1.01 to 3.63 for NSOFC and P= 0.008, OR: 2.78 and 
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95% CI: 1.28 to 6.05 for CLP). In addition, we observed that a higher number of mothers in 
the control group ingested antipyretics (12.3%) compared to the NSOFC group (6.3%) 
including all its phenotypes. However, a statistically significant difference was only 
observed in the total NSOFC cases compared to controls in the pregestation period (P= 0.03, 
OR: 0.48 and 95% CI: 0.24 to 0.94). The idea of  decreasing the chance of having an infant 
with NSOFC by maternal antipyretic medication ingestion is also supported by results from 
Hashmi et al. (2010). The effect of antipyretic medications could explain the relationship 
between maternal illness and NSOFC, suggesting that the disease symptoms might be the 
underlying reason behind development of NSOFC. To understand the effect of hyperthermia 
directly, future research is needed that recognizes the source of hyperthermia, along with the 
severity, duration and cause. Also, studies assessing the relationship between hyperthermia 
and cleft phenotype severity are recommended.  
 
6.3.1.8 Other medications (table 5.21 to 23):  
The main medications that were reported to be ingested by mothers were antibiotics. 
Maternal ingestion of antibiotics was found to increase the risk of NSOFC and CL/P 
(NSOFC: P= 0.003, OR: 2.81 and 95% 1.38 to 5.72 for the pre-gestation period and P= 
0.023, OR: 1.95 and 95% CI: 1.09 to 3.51 for the 1st trimester period; and CL/P: P= 0.012, 
OR: 2.96 and 95% CI: 1.22 to 7.16 for CL; and P= 0.03, OR: 2.64 and 95% CI: 1.07 to 6.55 
for CLP for the pregestation period). Although there were more mothers reporting  ingesting 
antibiotics in CP cases compared to controls, the difference was not statistically significant 
(P= 0.08). Similar findings were reported by Lin et al. (2012) who found significantly 
increased CL/P risk (OR: 2.0 and 95% CI: 1.0 to 4.1) among mothers using Amoxicillin in 
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pregestation period. They also found that the relationship was not significant for CP (OR: 1.0 
and 95% CI: 0.4 to 2.3).  
Moreover, a nationwide cohort study of 806,011 live births in Denmark concluded that 
although maternal antibiotic ingestion was not a major risk factor for NSOFC, there was a 
significant relationship between certain classifications of antibiotics (tetracycline, 
sulfamethizole, doxycycline, trimethoprim) and NSOFC (Mølgaard-Nielsen and Hviid, 
2012). These types of antibiotics and amoxicillin were reported to cross the placenta 
(Nathanson et al., 2000). However, the exact mechanism of its effect on cleft lip and palatal 
development remains unknown. One explanation suggested is that the increase in NSOFC 
incidence is due to the underlying diseases treated with these antibiotic rather than the 
antibiotic itself. In our study there was a significant relationship between maternal diseases 
in the pregestation period and NSOFC. However, Lin et al. (2012) reported that after 
adjusting the OR for maternal infection, a relationship still exist between CL/P and 
amoxicillin.  Besides, trimethoprim was reported to be a dihydrofolate reductase inhibitor 
that may counteract the effect of folic acid in pregnant women (Zimmerman et al., 1997). 
Our study was not able to stratify the sample according to maternal antibiotic types because 
mothers in both cases and controls were not able to remember the name of their medication. 
Therefore, future research that assesses the amount, type, duration and dosage of antibiotics 
is still needed. The mechanism of action for these antibiotics on infant development also 
needs to be clarified in upcoming research. 
 
6.3.1.9 Maternal stress (table 5.24 to 5.26): 
Maternal stress was considered one of the risk factors for NSOFC and was investigated 
through measuring the effect of stressful events (Carmichael et al., 2007).  In this study, 
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maternal stress was measured through recording information on maternal experience of: 
general stress, family problems, depression, severe morning sickness, threatened abortion 
and abdominal pain.   
Maternal stress was found to significantly increase the risk of NSOFC and its different 
phenotypes to almost double the baseline chance (maternal experience of stress: P< 0.001, 
OR: 2.1 and 95% CI: 1.43 to 3.11 for NSOFC; P= 0.04, OR: 1.74 and 95% CI: 1.01 to 3 for 
CL; P= 0.001, OR: 2.53 and 95 % CI: 1.48 to 4.32 for CLP; and P= 0.009, OR: 2.53 and 
95% CI: 1.2 to 4.09 for CP). Family problems during the pre-gestation and 1st trimester 
period were significantly over-reported by mothers in the study group: P= 0.001, OR: 1.97 
and 95% CI: 1.31 to 2.95 for NSOFC; P= 0.04, OR: 1.79 and 95% CI: 1.03 to 3.13 for CL; 
P= 0.004, OR: 2.21 and 95% CI: 1.28 to 3.84 for CLP; and P= 0.04, OR: 1.96 and 95% CI: 
1.04 to 3.67 for CP. A relationship between stress and NSOFC has been supported by many 
studies (Saxen, 1974; Czeizel and Nagy, 1986; Laumon et al., 1996; Carmichael and Shaw, 
2000; Radojicic et al., 2007). The effect of maternal stress resulting from stressful events 
could be related to elevated maternal corticotrophin-releasing hormones and corticosteroid 
levels (Hobel et al., 1999; Angelica Montenegro et al., 1995), a hypothesis reinforced by 
findings that corticosteroid medication itself could increase the risk of NSOFC (Carmichael 
et al., 2007a). Another explanation by which stress might cause birth defects is from the 
negative behaviours that might result from or cope with stress such as reduced nutrient intake 
or smoking (Carmichael et al., 2007b).  
Our study has identified more mothers experiencing severe morning sickness or using 
anti-emetic medication in the NSOFC group compared to controls. Anti-emetic medications 
were reported to be consumed by 12.1% of NSOFC, 14.5% CL and 6.6% of controls, a 
statistically significant difference with P= 0.043 and 0.019 has been identified respectively. 
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It has been suggested that the occurrence of severe morning sickness or ingestion of anti-
emetic medication predicts a less favourable pregnancy outcome. This model is supported by 
Miller (2002), who suggested that severe morning sickness can lead to loss of about 5% of 
original maternal weight, which could result in birth defects (Miller, 2002). Moreover, Jia et 
al. (2011) found a reduced chance of having an infant with NSOFC after maternal weight 
gain during pregnancy (OR: 0.15, 95% CI: 0.034–0.63).  
Zhang and Cai (1991) carried out a cross-sectional study on 1867 women to assess 
possible causes for maternal severe vomiting during pregnancy. They reported a twofold 
increase in the prevalence of severe maternal vomiting associated with paternal smoking. 
Moreover, an association between severe maternal smoking and foetal growth retardation 
was reported (OR: 1.4, 95% CI: 0.9 to 2.3) (Zhang and Cai, 1991). Accordingly, the 
relationship found between severe morning sickness and NSOFC could be related to 
maternal passive smoking and paternal smoking. More studies that stratify samples 
according to paternal smoking and maternal passive smoking are indicated to clarify this 
relationship.      
On the other hand, other studies suggested a reduced chance of having an infant with 
NSOFC  or no relationship with maternal nausea and vomiting (Czeizel et al., 1984; Czeizel 
et al., 2002; Badovinac et al., 2007; Molina-Solana et al., 2013). One explanation for these 
findings was that woman experiencing nausea and vomiting tend to stop their consumption 
of alcohol; however, this is not the situation for Saudi woman who do not drink alcohol 
because of their Islamic beliefs. Another explanation suggested for the effect of nausea 
reported by some studies was because of the effects of hormonal and high oestrogen levels in 
early pregnancy and/ or dietary changes, although this possibility still needs further 
clarification (Hook, 1976; Mossey, 2001a). 
 
273 
 
6.3.1.10 Smoking (table 5.27 to 5.34) 
A significant relationship between maternal smoking and having an infant with NSOFC has 
been reported by multiple studies (Little et al., 2004; Jia et al., 2011; Zhang et al., 2011). In 
this study, the number of maternal smokers was quite low, making it impractical to analyse 
this risk factor. Bassiony (2009) also reported a low prevalence of smoking in females (9%) 
compared to males (22.6%) in Saudi Arabia. However, smoking statistics may be 
underestimated because of tradition and social stigma associated with smoking, particularly 
for females (Bassiony, 2009). In the current study, the prevalence of paternal smoking (36%) 
was higher than that reported by Bassiony (2009), but similar to the findings of Fida and 
Abdelmoneim (2013).  
Paternal smoking was suggested to play a role in the aetiology of NSOFC either directly by 
affecting sperm development and increasing the frequency of abnormal sperm or indirectly 
through environmental contamination with tobacco, increasing maternal exposure to smoke 
(Weisberg, 1985; Zhang et al., 1992; De and Aitken, 2000; Berthiller and Sasco, 2000).  
In general, we found no significant relationship between paternal smoking and NSOFC, 
although a significant relationship was reported by previous studies (Little et al., 2004a; 
Jianyan et al., 2010). However, in these studies, the intensity and the types of paternal 
smoking was not assessed. Our study showed that paternal smoking of 20 or more 
cigarettes/day was associated with a higher risk of having a child with NSOFC (P= 0.013, 
OR: 3.07 and 95% CI: 1.25 to 7.55) and CP (P = 0.012, OR: 5.23, 95 % CI 1.33 to 20.58) 
compared to controls, indicating a dose-response relationship. This finding is supported by 
the results of Shaw et al. (1996), who also reported a dose-response relationship between 
paternal smoking and NSOFC for fathers smoking 20 cigarettes or more. In addition, our 
study examined the type of smoking device and found a significant relationship between 
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paternal waterpipe smoking and CL/P (for CL: in the pre-gestation period P= 0.04, OR: 2.45 
and 95% CI: 1.04 to 5.77, and in the 1st trimester period P= 0.046, OR: 2.56 and 95% CI: 1 
to 6.62; for CLP: in the pre-gestation period P< 0.001, OR: 3.83 and 95% CI: 1.73 to 8.48, 
and in the 1st trimester period P= 0.001, OR: 4.11 and 95% CI: 1.73 to 9.77). Other previous 
studies found that waterpipe smokers have significantly higher carboxyhaemoglobin 
concentrations than cigaratte smokers as well as higher carbon monoxide levels, and they 
have higher serum cotinine levels because of the larger amount of tobacco consumed during 
waterpipe smoking compared with cigarette smoking (Zahran et al., 1985; Ardawi et al., 
2007). Also, waterpipe contains heavy metals such as arsenic, cobalt, chromium, and lead 
(Shihadeh, 2003). The knowledge of the effect of waterpipe and its content on infants' 
development in the literature is still in its preliminary stage. However, waterpipe smoking 
component that are similar to other tobacco smoking devices were described by The Centers 
for Disease Control Prevention and Surgeon General in their report (2010) to have adverse 
effect on spermatogenesis and infant development. For instance, carbon monoxide is thought 
to have a direct effect on spermatogenisis through oxidative DNA damage (Fraga et al., 
1996; Shen et al., 1997). In addition, it has an indirect effect through maternal second hand 
smoking causing fetal hypoxia that lead to fetal growth retardation (Li et al., 2004). Also, 
nicotine was suggested to play a role in inducing tobacco birth defects and still birth when 
combined with other smoking component (Gupta and Subramoney, 2006). The possibility of 
waterpipe component causing second hand smoking has not been yet investigated. 
Nevertheless, waterpipe is expected to produce different teratogenic effect than other 
devices. This is because the structure of the device and the waterpipe size has an effect on 
the amount of tobacco consumption. In addition, the heating temperature of the waterpipe 
device (450C) is less than other devices (half that of cigarette smoking) (Maziak et al., 
2004).  
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In their review of waterpipe smoking, Maziak et al. (2004) addressed waterpipe smoking as 
an important epidemic global concern and identified a lack of knowledge and awareness 
concerning dealing with waterpipe smoking and its effects. In addition, they recommended 
the need to assess differences and similarities among the different waterpipe types (Maziak 
et al., 2004). Following their recommendations, we sub-grouped the paternal waterpipe 
smoking into Jorak and Moasel smokers. Both types of waterpipe smoking are smoked by 
the Saudi population; Jorak is an older, traditional form, which is typically smoked by older 
people, while Moasel is a newer form that is smoked by younger generations, and contains 
different fruit incenses (Shihadeh, 2003). We found that Jorak smoking was associated with 
statistically significant increased risks of having an infant with NSOFC, including CL/P, if 
smoking occurred in the three months prior to pregnancy (P= 0.001, OR: 6.34 and 95% CI: 
1.8 to 22.23 for NSOFC; P= 0.01, OR: 5.58 and 95% CI: 1.3 to 23.95 for CL; and P< 0.001, 
OR: 9.62 and 95% CI: 2.48 to 37.27 for CLP). For the first trimester period, paternal Jorak 
smoking was also associated with significant increased NSOFC risk: P= 0.01, OR: 4.66 and 
95% CI: 1.28 to 16.93 for NSOFC; P = 0.03, OR: 4.55 and 95% CI: 1 to 2.82 for CL; P= 
0.002, OR: 7.1 and 95% CI: 1.73 to 29.16 for CLP. However, although Moasel was more 
frequently smoked by NSOFC fathers than those of the controls, the relationship was not 
statistically significant (P> 0.5). The differences between the effect of Jorak and Moasel are 
yet to be discovered. It could have resulted from dissimilarities in the device structure, 
waterpipe size, amount of tobacco consumed, and/or the device heating temperature.  There 
could also be variation in the intensity of toxic content and consumption between the two 
devices. Further research on the effect and variations between the two waterpipe devices are 
required.   
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Consideration of the type of smoking device as a potential cofactor provides important 
information regarding the aetiology of NSOFC and further support to the argument for a 
smoking dose-response relationship. Although generally paternal smoking showed no 
increase in  CL in our study, those who reported smoking were mainly waterpipe smokers 
(11 (64.7%) of 17 CL smoking fathers compared to 15 (16.7%) of 90 control smoking 
fathers) and heavy smokers compared to controls (71.4% of those reporting their smoking 
frequency were heavy smokers compared to 47.8% of the controls).  
In 2014, the Surgeon General’s Report highlighted a wide range of acute and chronic adverse 
health effects in infants and increased risk of adverse health outcomes resulting from second 
hand smoking. Our study found more frequent CL mothers (77.8%) reporting 2
nd
-hand 
smoking exposures from their husbands compared to controls (47%). Thus indicates that 
although the prevalence of paternal smoking is more frequent in controls compared to CL 
cases, they were avoiding smoking in front of their families. Moreover, there was 
significantly more mothers with smoking husbands in CLP and CP reported being exposed to 
2
nd
-hand smoke compared to controls (OR: 10.54 and 95% CI: 2.29 to 48.64; and OR: 15.23 
and 95% CI: 1.9 to 122.3 respectively) as most of the mothers included in our sample are 
housewife's (86.5%).   
Maternal passive smoking has been associated with NSOFC in several other studies in 
addition to the current study (Jia et al., 2011; Li et al., 2011; Zhang et al., 2011). This 
association was confirmed in our systematic review and meta-analysis for the effect of 
passive smoking on oral cleft (Sabbagh et al., published/ in press 2015) (Appendix B2). 
Passive smoking has also been suggested to be the reason underlying why NSOFC remains a 
constant issue despite a decline in maternal smoking levels (Bille et al., 2005; Chevrier et al., 
2008). Although we found no significant relationship between passive smoking and NSOFC 
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for the total sample, there was a trend towards an association, particularly for CLP (P= 
0.088, OR: 1.68 and 95% CI: 0.93 to 3.06) and CP (P = 0.231, OR: 1.52 and 95% CI: 0.76 to 
3.03). In addition, the analysis for two of the cities (Jeddah and Maddina) presented in 
"Environmental risk factors in the aetiology of non-syndromic orofacial clefts in the Western 
Region of Saudi Arabia" (Appendix B7) demonstrated a significant relationship between 
passive smoking and NSOFC (P= 0.05, OR: 2.05, 95% CI: 1.05 to 4.01).   
Therefore, paternal smoking could be assumed to be a more public health concern in 
considering the risk of NSOFC as it is not only found to be associated with oral clefts but 
also is more common than maternal smoking. However, its effect depends on the intensity of 
smoking, device used and the existence of maternal passive smoking exposure. Further 
studies including larger sample sizes and smoking intensity measurements are warranted to 
confirm these issues. Also, investigating the effect of waterpipe on infant development is 
strongly recommended.  
 
6.3.1.11 Maternal domestic exposure (Table 5.35 to 5.38)   
During the pre-gestation period, a significant relationship between CLP and maternal reporting 
of exposure to chemicals was reported (P= 0.003, OR: 2.23 and 95% CI: 1.3 to 3.82) as well as 
in the 1st trimester period (P= 0.043, OR: 1.74 and 95% CI: 1.02 to 2.99) and also with exposure 
to solvents (P= 0.011, OR: 2.25 and 95% CI: 1.18 to 4.28). These findings are supported by 
similar results from several other studies (Lorente et al., 2000; Chevrier et al., 2006; Garlantézec 
et al., 2009; Alsahafi, 2010; Desrosiers et al., 2012). The effect of exposure was greatest in the 
pre-gestation period, as were our findings regarding the ingestion of maternal antibiotics and 
maternal illness discussed previously. 
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To the best of our knowledge, this is the first study to identify an association between 
the occurrence of NSOFC and both maternal exposure to incense and the source of maternal 
drinking water. This is an important preliminary observation and, if confirmed in future 
studies, raises the possibility of community prevention programs in the future through 
modification of the mineral content concentration of water and incense exposure in air in 
various enclosed areas. The relationship between maternal water supply and NSOFC may be 
related to the concentration of minerals in water, with a greater mineral content in Zamzam 
water compared to in either tap or bottled water. Zamzam contains the highest comparable 
amount of several minerals, including calcium, fluoride, zinc and magnesium (Alfadul and 
Khan, 2011; Zamzam Studies and Research Centre, 2011; Al Zuhair and Khounganian 2012; 
Shomar, 2012). Two of these minerals (zinc and calcium) were previously reported to have a 
significant  association with decrease chance of having an infant with NSOFC (Tamura and 
Goldenberg, 1996; Krapels et al., 2004b; Munger et al., 2009; Hozyasz et al., 2009; Jia et al., 
2011). In addition, Ruckart et al. (2013) conducted a unique study that was the 1st to suggest 
a relationship between contaminated drinking water and both neural tube defects (NTD) and 
oral cleft in their case-control study in North Carolina. They found a significant relationship 
between NTD and contaminated water, but the finding was not significant for oral clefts. 
However, because their sample size was small, further studies should be conducted to 
confirm their findings.  
 While our study has demonstrated a reduced risk of CL with maternal exposure to incense in 
the 1st trimester (P= 0.005, OR: 0.47 and 95% CI: 0.28 to 0.8), it is unclear what the 
underlying protective mechanism, if any, might be.  There is however other evidence of 
incense’s beneficial effect which may result from the putative antibacterial effects of burned 
incense on the surrounding air as reported by Twort and Baker (1940) and Bevilacqua et al. 
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(1997)). In one study carried out in Hong Kong, looking at the confounding effect of the 
association between air pollution and female lung cancer, although incense was found to 
have no effect on lung cancer risk among non-smokers, it significantly reduced the risk of 
cancer in smokers (P= 0.01) (Koo and Ho, 1996).  No explanation was offered on how this 
effect might be mediated.  Future study is required to confirm these preliminary findings and 
suggestions. 
  
6.3.1.12 Multiple logistic regression analysis (table 5.39):  
Variables that were found to be significant following logistic regression analysis and 
increased CL/P and/or CP risk included: maternal common cold/flu infection three months 
pre-gestation; maternal ingestion of antibiotics in the pre-gestation and 1st trimester periods; 
maternal stress; and paternal waterpipe smoking. On the other hand, folic acid 
supplementation, antipyretic medication ingestion in the pre-gestation period, maternal 
exposure to incense in the 1st trimester period and Zamzam as the maternal drinking water 
source significantly decreased CL/P and/or CP risk as determined by logistic regression 
analysis. Variables that were considered confounding factors in the aetiology of NSOFC 
were excluded by the logistic regression analysis (Appendix A30). 
6.3.2 Genetic risk factors 
The genetic aetiology of NSOFC worldwide remains unclear and enquiries are in the 
preliminary stages of exploration especially in the Middle East. Researchers have reported 
geographic variation in genetic risk factors (Blanton et al., 2010b; Lace et al., 2011; Mangold 
et al., 2011) and highlighted the need for research in this area among different populations, 
recommending that research with a study design as in the current investigation be performed.  
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This study is the first multicentre case-control study carried out in Saudi Arabia that has 
explored the genetic aetiology of NSOFC. Candidate genes were selected according to recent 
literature findings. Although IRF6 was reported to be associated with NSOFC worldwide, in 
a study on the ethnic heterogeneity of the IRF6, Blanton et al. (2010) confirmed that the 
association of SNPs in IRF6 to NSOFC varied between different ethnic groups. Thus, they 
supported the need for evaluation of IRF6 variation across multiple populations to better 
determine its role in NSOFC (Blanton et al., 2010a). Therefore, this study aimed to 
investigate whether IRF6 was also associated with NSOFC in Saudi Arabia in the Middle 
East. The second gene that was selected for study was VAX1, which is located in a region 
with high genome wide significance for OFC and was recently suggested to be a candidate 
for NSOFC trios (Beaty et al., 2010; Mangold et al., 2010)..   
6.2.2.1 Hardy-Weinberg equilibrium (HWE) (Table 5.40) 
Our sample was in HWE for VAX1 rs4752028, which means that the allele and genotype 
frequencies in the population remained stable across generations in the absence of other 
evolutionary influences, indicating optimal performance of sampling and genotyping (i.e. 
without significant data loss). On the other hand, HWE was not met for the rs7078160 
polymorphism in both cases and controls and this may be explained by the non-random 
mating that results from parental consanguinity (El-Hazmi 1996; Pritchard and Korf, 2008).  
We recommend matching paternal consanguinity in future studies in an attempt to overcome 
any HWE variations between cases and controls.  
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6.2.2.2 Interferon regulatory factor 6 (IRF6) gene analysis (table 5.41 to 5.50): 
Three Single Nucleotide Polymorphisms (SNPs) were selected in the IRF6 gene and were 
analysed (rs2013162, rs2235375, and rs2235371). These SNPs were previously reported by 
several studies to have a significant association with NSOFC (Jugessur et al., 2008; Huang et 
al., 2009; Lu et al., 2013). 
The first SNP selected was IRF6 rs2013162. The Family Based Association Test (FBAT) 
showed significant over-transmission of the common C allele in NSOFC and CL/P cases (P= 
014 and P= 0.018, respectively). In addition, PLINK analysis showed an association between 
the rare allele and NSOFC including CL/P (P= 0.016 and OR: 0.667 for NSOFC and P= 
0.018 and OR: 0.644 for CL/P). A similar finding was reported by Scapoli et al. (2005), who 
detected an over-transmission of the common allele for rs2013162 (P= 0.004) and all 
haplotypes carrying these common alleles among 219 Italian CL/P trios. Similar finding was 
reported by Park et al. (2005). An allelic/OFC association was also supported by Blanton et 
al. (2005) who found a significant over-transmission of IRF6 rs2013162 common C allele 
(P= 0.05) among CL/P cases. In addition, the rs2013162 rare allele reached a genome-wide 
significant relationship with CL/P in a study by Beaty et al. (2010). Stratification of the 
sample population using Asian ancestry as a factor yielded stronger evidence of association 
with IRF6 rs62013162 (Beaty et al., 2010). 
In contrast, Lu et al. (2013) carried out an FBAT and case-control analyses to investigate the 
effect of IRF6 rs2013162 on the prevalence of CL/P in Northeast China. They reported a 
significantly increased risk of CL/P with the rare allele (P = 0.0001) and under transmission 
of the common allele in both case-control and FBAT analysis. Our findings do not support 
this finding which could be due to differences in the study setting and population. In our 
study, PLINK analysis showed significant transmission of the IRF6 rs2013162 variants from 
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the paternal side (P= 0.05) rather than the maternal side (P= 0.152). This could be supported 
by Anderson et al. (2014) review on male-mediated developmental toxicity that suggested 
more frequency inherited mutated DNA from fathers compared to mothers. Brinkworth 
(2000) Suggested explanatory hypothesis for paternal genetic inherence effect through 
genomic instability or apoptosis suppression of the germ cell. However, our study found that 
maternal gene variants showed significant differences between cases and controls, with the 
more heterozygous allele genotype in CL/P mothers and the more homozygous rare allele 
genotype in controls mothers (P= 0.024). This suggests a maternal rare allele effect that was 
not previously described. Ludwig et al. (2009), in their Weinberg's log-linear model analysis 
on IRF6 gene variants in Central European patients, found no difference in risk of CL/P 
between maternal- and paternal-driven alleles.  
The other two IRF6 SNPs that were analysed in this study were rs2235375 and rs2235371. 
Our research did not find any association between the transmission of rs2235375 and 
NSOFC nor did it find any differences between case and control allele frequencies in either 
SNP. However, although a statistically significant increased frequency of the paternal 
homozygous rs2235375 rare allele genotype (GG) and rare allele (G) was observed in 
controls compared to NSOFC cases in general, there was no significant relationship found 
with CL/P and CP. A recent case-control study in a Mexican population with 132 cases and 
370 controls found a result similar to our finding. They reported no significant difference 
between CL/P cases and controls in the frequency of rs2235375 (P= 0.08) (Velázquez-
Aragón et al., 2012). Other studies do not support the null-hypothesis for this allele, such as 
that performed by Huang et al. (2009) in Western China, who reported a strong association 
between the transmission of rs2235375 and rs2235371 (C/T) markers and CL/P. In addition, 
in their population-based case-control study on facial clefts in Norway, Jugessur et al. (2008) 
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reported a strong correlation (LD) between rs2235371, rs2235375, and NSOFC. They also 
reported a relationship between rs2235371 rare allele in infants and CL/P (P= 0.031, RR: 
0.38 and 95% CI: 0.16 to 0.92). Furthermore, Scapoli et al. (2005) detected over- 
transmission of the common C alleles for rs2235375 (P= 0.002). Moreover, in a hospital-
based case-control study carried out in Chinese Han, Pan et al. (2009) found that the 
rs2235371 homozygous rare allele (TT) and heterozygous genotype were associated with 
decreased risk of CL/P compared to the common allele (CC). They also reported a higher 
risk of CL/P when two polymorphisms (rs642961 rare A allele and rs2235371 common C  
allele) were combined. On the other hand, a recent case-control triad study by Zhou et al. 
(2013), using a smaller size sample (106 cases and 129 controls) in the Chinese population, 
found no significant association between rs2235371 and CL/P using FBAT analysis. 
The frequency of the rs2235371 rare allele was very low in our study, which made it 
irrelevant to carry out FBAT analysis. However, this low number was supported by the 
report of the Ensemble Genome project, which produced a genome database that calculated 
the prevalence of the rare T allele in rs2235371 to be only 2% in the European population 
compared to 41% in the Asian population. 
(http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=1:209963580-
209964580;v=rs2235371;vdb=variation;vf=1807176). Similarly, in their four population case-
parent trios, Park et al. (2007) found that the rare allele frequency of rs2235371 in European 
Americans was too low to be reported. Therefore, to verify the relationship between 
rs2235371 and CL/P in the Saudi population, a much larger sample size would be required. 
Our study did not find any relationship between IRF6 and CP. This finding is supported by 
other studies that investigated the relationship between NSOFC and IRF6 and included CP 
cases in their sample. They also found no significant relationship between IRF6 and CP 
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(Huang et al., 2009; Jugessur et al., 2008; Scapoli et al., 2005). Other studies for IRF6 exist 
as well, but these did not include CP cases in their sample. 
In conclusion, the differences between our findings and previous studies could indicate that 
the Saudi population has different genetic aetiology of NSOFC than elsewhere in the world. 
A well designed GWAS study is recommended to clarify genetic aetiology of NSOFC. 
6.2.2.3 Ventral anterior homeobox 1 (VAX1) (table 5.51 to 5.58): 
Our study showed that although FBAT analysis did not show a significant over-transmission 
of the VAX1 SNP alleles in NSOFC cases, there were significant differences in the frequency 
of genotypes and minor alleles between NSOFC cases and control infant-parental triads. 
Moreover, the prevalence of the parental rare allele in NSOFC cases for both rs7078160 and 
rs4752028 were significantly more than controls, indicating a parental effect. An association 
between VAX1 and NSOFC was supported by Mangold et al. (2010) in their GWAS study of 
Central Europeans, reporting that rs7078160 reached a statistical significance at whole 
genome level. In addition, Beaty et al. (2010) found that VAX1 rs7078160 approached 
genome-wide significance in Transmission disequilibrium test (TDT) and conditional 
logistic regression. 
Our VAX1 association finding was further supported by the results of Butali et al. (2013) in 
their replication of GWAS signals on 651 case-parental triads (Asian (494 infant-parental 
triads) and European (157 infant-parental triads) populations). FBAT analysis reported a 
statistically significant strong association in the transmission of the VAX1 rs7078160 SNP 
among the Asian population (P< 0.001). However, a VAX1 association was not significant 
for the European population, similar to our findings. Moreover, Butali et al. (2013) compared 
cases with controls in the Asian population and found an increased frequency of the common 
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variant (G) compared to controls, which differs from our findings. Such differences could 
indicate ethnic and geographic variation between the Saudi population, considered 
Caucasians, and the Asian population in the genetic aetiology of NSOFC 
Our finding differed from those of Nasser et al. (2012), who reported no significant 
association between NSOFC and VAX1 in a case-control study. However, the SNPs they 
sequenced did not include the two variants included in this study.  In addition, Nasser et al. 
(2012) did report the possibility of a relationship between VAX1 and OFC.  
VAX1 rs4752028 was the only SNP examined that showed association with CP compared to 
controls (P = 0.049 for the fathers, P = 0.015 for the mothers and P = 0.009 for infants). 
Butali et al. (2013) reported no significant association between rs4752028 and CP. However, 
their finding was concluded from TDT (FBAT) analysis and not from a case-control design. 
As VAX1 is a recently discovered gene in terms of risk for CL/P and CP, studies that clarify 
the relationship between NSOFC and VAX1 are still needed. 
6.2.2.4 Infant VAX1 and parental consanguinity (table 5.59 to 5.60): 
VAX1 has been reported to be associated with OFC in consanguineous marriages (Slavotinek 
et al., 2012) and by this current research project (P= 0.04) (Appendix A31). The relationship 
between VAX1 (rs7078160 and rs4752028) and consanguinity in case compared to control 
infants were analysed. For rs4752028 SNP, the rare allele was found more often in CL/P 
cases with consanguineous parents compared to controls (P= 0.001, OR: 2.97 and 95% CI: 
1.54 to 5.76). 
 In addition, VAX1 rs7078160 rare A allele was more frequent in CL/P cases with 
consanguineous parents compared to control (P= 0.081, OR: 1.93 and 95% CI: 0.92 to 4.04). 
That could explain the significant association of this gene in the Saudi population with the 
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high prevalence of consanguineous marriages. If these rare alleles are found to be associated 
with NSOFC it should encourage counsellors to advice against consanguineous marriages. 
 
6.2.2.5 Haplotype based association (table 5.61): 
This research found two significant haplotypes. The 1st significant blocks included IRF6 
rs2235371 and rs2013162 common alleles, which was similar to the findings of Park et al. 
(2007) who reported that the rs2013162 and rs2235371 common C allele haplotypes were 
associated with increased risk of CL/P in all their included four populations (77 European 
Americans, 146 Taiwanese, 34 Singaporean, and 40 Korean) (Park et al., 2007). It also 
included VAX1 rs4752028 rare C allele. On the other hand, the other significant haplotype 
block in our study included an IRF6 rs2013162 rare allele. Further investigation for 
significant haplotypes is recommended in future population-based study.  
 
6.3.3 Gene-environmental interaction 
Only a few studies have considered gene-environmental interactions (GEI) in the aetiology 
of NSOFC. The factors that were studied were mainly folic acid and vitamin supplements, 
smoking and maternal passive smoking. Furthermore, only a small number of gene variants 
were analysed, including IRF6 but not VAX1 (Chevrier et al., 2008; Krapels et al., 2008; Shi 
et al., 2008; Wu et al., 2010). A role for IRF6 interaction with environmental factors in the 
aetiology of NSOFC, however, still needs further clarification as Wu et al. (2010) did find 
evidence for an IRF6 gene-environmental effect with maternal multivitamin supplementation 
and environmental tobacco smoke.   
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Studies have different scopes to consider when evaluating GEI in the aetiology of NSOFC; 
the effect of environmental exposures on the infant's genes and/or the interaction between 
environmental exposures and maternal genes influence the intra-uterine environment, 
resulting in favourable or unfavourable surroundings in which the foetus develops (Shi et al. 
2008). In our study, we focussed on the interaction between environmental exposures and 
maternal genes. To confirm the existence of significant reaction between the included 
maternal and infant gene SNPs, log-linear model was carried out (see appendix A37). . 
However, this finding is different from the PLINK findings, which did not find a parent of 
origin effect from mother side at all. This is because the PLINK measured the transmission 
effect. But, the log-linear measured the direct maternal effect that could occur during 
pregnancy in the uterus.  
One of the public health concerns in the GEI studies is the study power. False-positive and 
false-negative outcomes were reported in studies with small sizes (Dempfle et al., 2008). To 
improve the reliability of our results, two study designs and three statistical analyses were 
carried out for GEI. A case-only study design evaluated maternal SNP genotype variant 
(homozygous common allele genotype, heterozygous allele genotype and homozygous rare 
allele genotype) and allele types (common vs. rare) and their interaction with environmental 
factors. A case-control study design was used to evaluate the association between maternal 
SNP genotypes and environmental factors. The gene-environmental interactions that were 
confirmed by both study designs and/or multi-nominal logistic regression analysis (table 
5.62), are given more consideration.  
Moreover, because only a minimal number of rare allele genotypes for IRF6 rs2235371 were 
observed in our sample, the attempt to investigate any interaction between this SNP and 
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environmental factors produced values that were similar to those produced by analysing 
environmental factors alone. Therefore, we did not carry out further analysis for this SNP.  
 
6.3.3.1. Gene-environmental interaction between maternal IRF6 rs2013162 and 
environmental risk factors (Appendix A38 to A40) 
The environmental risk factor that showed a significant interaction with maternal IRF6 
rs2013162 in both study designs and statistical approaches used in this research was maternal 
folic acid supplementation during the pregestation period. The analysis showed that mothers 
with an IRF6 rs2013162 homozygous rare AA genotype and rare A allele that ingested folic 
acid supplementation in the pregestation period were statically significant more likely to 
have a child with NSOFC compared to those with common allele genotype (OR: 8.22 and 
95% CI: 1.03 to 65.72 for AA compared to CC; and OR: 2.57 and 95% CI: 1.23 to 5.37 for 
A compared to C). In addition, in our case-control design, 18% of NSOFC mothers with the 
homozygous rare AA allele genotype consumed folic acid supplementation during the 
pregestation period when no mothers reported using it in the control group (P= 0.023). This 
indicates a synergistic effect that increases the risk of NSOFC, when using folic acid in the 
pregestation period. The significant association follow a recent population base case-control 
study in Northern Netherlands that reported a "duration of exposure-response effect" that 
increased the risk of cleft lip (Rozendaal et al., 2013). 
Moreover, the maternal homozygous rare AA genotype was reported in this study to be 
significantly less frequent in cases compared to controls. In addition, folic acid 
supplementation was thought to decrease the risk of cleft. Therefore, mothers with the 
common C allele that are exposed to folic acid during the pregestation period are less likely 
to have a child with NSOFC. Finally, although wide confidence interval reported in the case-
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only genotype analysis may indicate insufficient sample size, confirmation of the 
relationship was repeatedly observed in the different statistical analysis methods. In contrast, 
in the case-control study design, maternal folic acid in the 1st trimester period were 
significantly more ingested by the controls with homozygous rare AA allele genotype 
mothers compared to cases (P= 0.003), indicating a suggested protective joint effect.  
Other environmental risk factors were either significant in the case-only study design or in 
the case-control study designs.  In the case-only study design, antipyretic medication and 
fever showed GEI in both analysis (genotypes and allele analysis). Mothers with rare allele 
(A) and homozygous rare AA allele genotype using antipyretics in the 1st trimester period 
were significantly more likely to have an infant with NSOFC (OR: 9 and 95% CI: 1.62 to 
49.91 when the AA genotype is compared to CC; and OR: 2.34 and 95% CI: 1.12 to 4.9 
when the A allele was compared to the C allele). This could also indicate that mothers with 
homozygous common CC allele and using antipyretics during the 1st trimester period are 
significantly less likely to have an infant with NSOFC. In addition, maternal fever in the 
pregestation period was significantly less common in mothers with the homozygous AA rare 
allele genotype (OR: 0.26, and 95% CI: 0.08 to 0.84) and rare A allele (OR: 0.28 and 95% 
CI: 0.09 to 0.81) among NSOFC mothers, indicating that mothers with common 
homozygous CC genotype variant that are exposed to fever are significantly more likely to 
have an infant with oral cleft. These relationships suggest a synergic effect of environmental 
risk factors that influence the effect of the maternal common allele. It also highlights the 
importance of future studies aimed at verifying the influence of maternal disease symptoms 
on the function of maternal genes and their effect on the embryonic development.  
Moreover, in the case-control study, mothers who were homozygous for the common allele 
(CC), and consumed antibiotics during the pregestation period or were exposed to illness and 
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common cold/ flu were significantly more likely to have an infant with NSOFC.  In addition, 
paternal waterpipe smoking when associated with maternal common allele (CC) they are 
more likely prone to have an infant with NSOFC. This indicates a synergic effect between 
environmental risk factors and gene variant that when isolated were also shown in this thesis 
to be associated with an increased risk of oral clefts.   
Other environmental factors that showed a significant interaction with the homozygous rare 
allele (AA) but only in one of the analysis were multivitamins and iron supplementations; x-
ray exposure; maternal smoking, maternal passive smoking and; maternal stress; abdominal 
pain, maternal exposure to chemicals and maternal drinking water (Bottle and Zamzam 
drinking water source vs. tap water).  
Nevertheless, these associations highlight the possibility of developing a prevention 
program. Future studies including larger sample sizes are needed to clarify the relationship, 
interactions and different supplementation doses.     
 
6.3.3.2. Gene-environmental interaction between maternal IRF6 rs2235375 and 
environmental risk factors (Appendix A41 to A43) 
The environmental risk factor showing a significant interaction with maternal IRF6 
rs2235375 in both study designs and all GEI statistical approaches used in this study was 
maternal stress. Our analysis showed that mothers with the IRF6 rs2235375 homozygous 
rare GG allele genotype and rare G allele that are exposed to stress during the pregestation 
and 1st trimester periods were statistically significant less likely to have a child with NSOFC 
(P= 0.016, OR: 0.3 and 95% CI: 0.1 to 0.8 in genotype analysis; and P= 0.01, OR: 052, 95% 
CI: 0.32 to 0.84 in allele analysis). It also indicates that mothers with the homozygous 
common C allele that were exposed to stress are more likely have an infant with NSOFC. In 
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addition, the case-control study design showed a significant interaction between stress and 
NSOFC mothers with the homozygous common allele (CC), who were significantly more 
likely to be exposed to stress compared to controls (P= 0.014). 
An interaction between folic acid supplementation in the pregestation period and maternal 
IRF6 rs2235375 was found to be associated with NSOFC. The case-only study design 
showed that mothers with the homozygous rare allele (GG) and ingested folic acid 
supplementation in the pregestation period were significantly less likely to have an infant 
with NSOFC compared to those with the homozygous common allele (CC) (P= 0.045, 
OR:0.23 and 95% CI: 0.05 to 0.97). Case-control analysis also revealed statistically more 
NSOFC mothers with the homozygous common allele (CC) that ingested folic acid 
supplementation in the pregestation period compared to controls (P= 0.026). However, this 
finding was not supported by Velázquez-Aragón et al (2012) study that was carried out in 
Mexico did not find an interaction between IRF6 rs2235375 and folic acid in the aetiology of 
oral clefts. However, the differences in the results may be related to differences in study 
setting   
Although multivitamins supplementations interaction with IRF6 rs2235375 was significant 
in the case-control analysis (P= 0.026) it was not supported by Wu et al (2010) population 
based study that was carried out in China. In addition, the number of subjects exposed to 
multivitamins in our study was small and the significant relationship was only found in one 
of the analysis and in the pregestation period only. Therefore, the relationship is only a 
preliminary report. 
Other environmental factors showing a positive interaction with the homozygous common 
allele but were only significant in one of the analysis included maternal fever, illness, 
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common cold/flu, x-ray exposure, paternal waterpipe smoking and consanguinity. Future 
studies will clarify the relationship we presented in this study.  
 
6.3.3.3. Gene-environmental interaction between maternal VAX1 rs4752028 and 
environmental risk factors (Appendix A45 to A47) 
The environmental risk factor showing a significant interaction with maternal VAX1 
rs4752028 in both study design approaches used was maternal fever. The analysis showed 
that mothers with the VAX1 rs4752028 homozygous common T allele, which were 
considered to decrease the likelihood of NSOFC, that were exposed to fever were 
statistically significant more likely to have a child with NSOFC (for allele analysis: P< 
0.001, OR: 0.11 and 95% CI: 0.05 to 0.26 in the 1
st
 trimester period; and for case control: P= 
0.03, OR: 2.79 and 95 % CI: 1.07 to 7.25 in the pregestation period, and P= 0.053 in the 1
st
 
trimester). 
This interaction between maternal genotype which was considered to decrease the chance of 
having an infant with NSOFC ; with an environmental risk factor that was previously 
suggested to increase the risk of NSOFC, could indicate a strong environmental risk factor 
that can overcome the effects of the genetic factors. Another explanation may be that 
although these genotypes were expected to protect the individuals from NSOFC, when 
exposed to negative environmental factors, they contributed to the opposite effect. 
Alternatively, putative conflicting effects indicate that other, potentially related genes are 
involved in the interactive pathway, or that a relevant gene-gene interaction remains 
unknown.  
Mothers with the homozygous rare allele genotype (CC) that had high blood pressure during 
the 1st trimester were significantly more likely to have an infant with oral cleft compared to 
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those with the homozygous common allele (TT). Other environmental factors that were more 
likely to increase the occurrence of NSOFC offspring in mothers with homozygous common 
allele (TT) were antibiotics ingestion, illness, common cold/flu infection, multivitamins and 
stress. Mothers with the homozygous common allele (TT) that ingested folic acid were less 
likely to  have NSOFC infant. Finally, incense showed a reduced chance of having an infant 
with NSOFC when interacting with the homozygous rare allele, which is considered to 
increase the risk of NSOFC. 
 
6.3.3.4. Gene-environmental interaction between maternal VAX1 rs7078160 and 
environmental risk factors (Appendix A48 to A50) 
None of the environmental risk factor showed significant interactions with maternal VAX1 
rs7078160 in both study designs approaches and analysis together. However, in the case-only 
study design analysis, paternal waterpipe showed a significant interaction with the VAX1 
rs7078160 homozygous rare allele (AA) and rare allele (A).  The analysis showed that 
mothers with the VAX1 rs7078160 homozygous rare allele (AA) and rare allele (A) were 
considered to increase the likelihood of NSOFC, and those exposure to paternal waterpipe 
smoking were statistically significant more likely to have a child with NSOFC (P= 0.016, 
OR: 5.54 and 95% CI: 1.38 to 22.23 for the genotype analysis; and P= 0.01, OR: 2.67 and 
CI: 1.28 to 5.56 for allele analysis). The interaction between smoking and genetic variants 
has been studied previously. In 2008, Shi et al. reviewed studies that investigated the 
interaction between genetic variants and maternal smoking in the aetiology of oral cleft and 
reported that GEI studies were still in early stages. In addition, paternal smoking including 
types of smoking and the VAX1 gene were not previously investigated (Shi et al., 2008).        
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 Other environmental factors in case-control study that showed a significant positive 
interaction with the VAX1 rs7078160 homozygous common allele (GG), which was 
considered to be associated with a decreased risk of NSOFC are; maternal antibiotic 
ingestion, illness, common cold/flu and family history. Maternal exposure to chemicals in 
the pregestation period was significantly less associated with NSOFC mothers with rare A 
allele compared to those with the common G allele. This indicates that mothers with the 
common allele G and exposed to chemicals were more likely to have a child with oral cleft. 
Other environmental factors showing a significant positive interaction with VAX1 rs7078160 
homozygous rare AA genotype and rare A allele in case-only study included high blood 
pressure in the 1st trimester and paternal consanguinity. It is important to carefully address 
the synergic effect between environmental and genetic factors for future public health 
intervention.   
 
To draw conclusions regarding a definitive gene-environmental interaction, a larger sample 
size is necessary in a GWAS study using a log-linear modelling approach. However, 
obtaining the number of cases for an adequate sample size for genetic analysis and 
environmental risk factor exposures is difficult, particularly because NSOFC is a rare disease 
and sub-phenotyping is necessary. In addition, there are multiple risk factors that contribute 
to these diseases (Zhu et al., 2009; Hutter, 2013). The value in preliminary studies that may 
be underpowered for definitive findings lies in them being valuable instruments for 
preliminary description of GEI and for generating hypotheses that can be tested with 
adequate power (Dempfle et al., 2008; Hutter, 2013).  Accordingly, we expect that our 
findings will play an important role in directing and assessing future research to identify 
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possible gene-environmental risk factors that may have a role in prevention of NSOFC 
through public health strategies.   
 
This study shows many risk factors; genetic, environment and gene-environmental 
interaction that are suggested to play a role in the aetiology of oral clefts in Saudi Arabia. 
However, the aetiological risk factors that we analysed in this study could be of real 
importance to the Saudi population if the population attributable risk (PAR) was high. 
However, In order to assess PAR we need to analyse and compare our data with the 
prevalence of exposures to these risk factors in the Saudi population. The prevalence of 
exposures to some of these environment risk factors among the Saudi population were 
somewhat possible when found in the literature. For example; the prevalence of smoking 
(Bassiony, 2009; Fida & Abdelmoneim, 2013), diseases such as diabetes (Khwaja et al., 
1989; Ardawi et al., 2000; Al-Hakeem, 2006), hypertention (Al-Ghamdi et al., 1999) and 
heart diseases (Ministry of Health, 2009), and paternal consanguinity (Elhazmi et al., 1996). 
However, other factors such as the prevalence of pregnant mothers using supplementations, 
antibiotics, or exposed to stress and diseases among the Saudi population are not found in the 
literature. In addition the incidence of exposure to environmental factors in the population 
was not always specific to pregnant woman which makes it difficult to estimate PAR. In 
addition, genetic mapping specifically designed for Saudi population does not yet exist. 
 Therefore, future research that aims to affirm NSOFC risk factors relationship; calculate the 
risk of environmental exposures in the population; genotype the population DNA; and 
measure the population attributable risk, is important for public health prioritization, 
approaches and strategies designed to prevent and control NSOFC in the Saudi population 
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6.4 Strengths and Limitations 
6.4.1 Strengths 
 Geographic and ethnic variations have been shown to play a part in influencing the 
aetiology and prevalence of NSOFC (Mossey at al.,2009). There has been little 
investigation into these factors and their genetic and environmental origins in the 
Middle East, and therefore the study is a useful contribution to addressing significant 
data gaps. 
 
 Previously studied risk factors such as consanguinity and dietary factors have also 
been explored in this study, and the unique combination of factors makes Saudi 
Arabia, the largest country in the Middle East a useful part of the world for studying 
risk factors in NSOFC.  
 Some factors, not previously investigated, including maternal drinking water supply 
and different types of tobacco smoking have emerged as a result of this careful 
investigation as possible risk factors, and these should be explored further in future 
studies. 
 The sample included three main cities in Saudi Arabia that covers almost 60% of the 
population according to the Ministry of Health. 
 To try to obtain as comprehensive ascertainment as possible, we pooled most cleft 
cases living in Jeddah and Maddina: Jeddah city was divided geographically into five 
districts. We included all governmental referral hospitals for NSOFC in Jeddah city, 
distributed across the five districts, in this study. In Maddina, the only referral center, 
which was also the main maternal children hospital in Maddina city, was included. 
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Therefore we have made efforts to include as many of the NSOFC cases in the two 
cities as possible. 
 The study is novel as it is the first study that describes the birth prevalence of NSOFC 
and its phenotypes in three cities of Saudi Arabia. 
 The study was carried out in a population with high prevalence of paternal 
consanguinity which provided good baseline numbers to examine the effect of 
consanguinity although the type of consanguineous unions in the Middle East is 
different from those in other parts of the world, for example India. 
 This case-control study is the first, to the best of our knowledge, to investigate the 
environmental risk factors for NSOFC in the Western and Central Region of Saudi 
Arabia.   
 It is the first study to look into the association between the different type of tobacco 
smoking devices and both CL/P and CP. 
 Water-pipe smoking is considered an emerging global epidemic concern that is 
largely understudied (Fakhreddine et al. 2014). This paper provides further evidence 
of the need to study the association between different smoking exposure devices and 
mechanisms including water-pipe and passive smoking in relation to congenital 
anomalies. 
 It is the first study to look into the association between the maternal drinking water 
source and both CL/P and CP.  
 This study investigate VAX1 which was recently examined and IRF6 gene, and it is 
relationship to CL/P and CP for the 1
st
 time in Saudi Arabia   
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 One of the strengths of this study is investigating VAX1 gene in a population with a 
high prevalence of paternal consanguinity. 
 The study presents preliminary information on gene-environmental interaction in the 
aetiology of oral clefts. 
6.4.2 Limitations 
There were some limitations to this study that should be considered: 
o Although we expect to have included almost all cases in Jeddah and Maddina, 
we were not able to include King Faisal Hospital and research centre in 
Riyadh which is considered an important cleft centre. However, this does not 
affect part I of our study (prevalence assessment), because King Faisal 
Hospital and research centre is not a maternity hospital.  
o Stillbirths were not included in this study, which may have caused bias in 
assessing the prevalence of OFC (Al-Omari and Al-Omari, 2004; Welch and 
Hunter, 1980). However, stillbirth prevalence is expected to be low, 
accounting for only 15.7 in every 1000 births recorded by the Ministry of 
Health, Saudi Arabia (Ministry of Health, 2010). 
o Recall bias was considered to have minimal effect on our findings according 
to previous studies ((Khoury et al., 1994; Swan et al., 1992). Also, it could be 
overcome through increasing of the proportion of exposed controls (Poletta et 
al., 2012) 
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o Bias could have occurred from questions related to smoking. This could have 
resulted from social stigma associated with smoking. However, this attitude is 
expected from parents of both cases and controls. 
o The attitude toward questions related to family problems and the different in 
maternal coping with stress are expected. However, it is anticipated in both 
groups (cases and controls)  
o The frequencies of maternal exposure to some of the environmental 
aetiological risk factors were inadequate to produce a definitive conclusion 
for factors such as maternal smoking, type of smoking device, and maternal 
water drinking source. Therefore, a larger sample size is needed to confirm 
our findings. However, these factors were still discussed because of their 
importance in future studies and their significance in the development of 
community preventive programs. 
o There is a possibility that some of the associations found in this study 
between NSOFC and exposures have arisen from chance (the probability of 
statistically significant relationship arising by chance alone is one in twenty 
for each tested exposure) (Scialli, 2014).  
o There was potential for confounding factor effects, which we tried to 
overcome by carrying out logistic regression analysis. 
o Cases and controls were recruited from medical centres located solely in 
urban areas.  
o The sample did not meet Hardy-Weinberg equilibrium in some situations. 
o The sample size was not sufficient to draw a final conclusion for the gene-
environmental interaction (GEI) or to investigate the role of GEI in NSOFC 
sub-phenotypes (CL/P and CP).   
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Chapter 7: Conclusion and future plans  
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7.1 Conclusions  
This study was carried out in three main cities in Saudi Arabia from January 2010 to January 
2012 to measure the prevalence and aetiology of non-syndromic orofacial cleft. We report 
the following conclusions:  
7.1.1 Prevalence of NSOFC and the influence of parental consanguinity on 
CL/P and CP in Saudi Arabia 
Saudi Arabia and some Middle Eastern countries do not have a baseline data on orofacial 
cleft prevalence which would be essential pre-request information for any intervention. This 
multicentre study assessed the prevalence of NSOFC and its phenotype in three main cities 
in Saudi Arabia:  
 
 The prevalence of NSOFC in Saudi Arabia (1.17/1000 live births) was found to be 
marginally lower than the global average figures (1.25/1000 live births).  
 The prevalence of NSOFC was found to be highest in Maddina (1.88/1000 births), 
followed by Riyadh (1.07/1000 live births), with the lowest prevalence in Jeddah 
(0.81/1000 live births).   
 The overall mean birth prevalence of CL/P was found to be 0.89/1000 births across 
all three cities. 
  The prevalence of CL (0.47/1000 live births) was found to be higher than that of 
CLP (0.42/1000 live births) and CP (0.28/1000 live births). 
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 The prevalence of consanguinity in NSOFC infants was found to be 81 (65.9%) out 
of 123 cases. This value was higher in CP than in CL/P, and higher in severe CL/P 
(complete clefting of the lip or bilateral cleft), but the difference was not significant. 
7.1.2 Environmental risk factors associated with CL/P and CP in Saudi 
Arabia 
Maternal exposure to common cold/flu, folic acid supplementation, stress, antibiotic 
ingestion, chemicals, incense, source of drinking water and paternal waterpipe are associated 
with increased / or decreased risk of CL/P and/or CP in Saudi Arabia 
 There was no significant relationship between demographic variables and both CL/P 
and CP in Saudi Arabia.  
 There was no significant relationship between socioeconomic status and both CL/P 
and CP in Saudi Arabia, except for residency description, and there are significantly 
more CP cases live in rural areas than there are controls. 
 Family history of oral cleft was found to be significantly associated with increased 
risk of CL/P and CP in Saudi Arabia 
 Maternal common cold/flu infection during the pre-gestation period were found to be 
associated with an increased risk of CL/P and CP in Saudi Arabia 
  Maternal antibiotic ingestion in the pre-gestation and 1st trimester period were found 
to be associated with an increased risk of CL in Saudi Arabia. 
 Folic acid supplementation in the 1st trimester period was found to be associated with 
a decrease risk of CLP in Saudi Arabia. 
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 Maternal stress was found to be significantly associated with an increased risk of 
CL/P and CP in Saudi Arabia. 
 Paternal waterpipe smoking and intense paternal smoking were found to be 
significantly associated with an increased risk of CL/P and CP, in Saudi Arabia.  
 Maternal exposure to chemicals during the pregestation period was found to be 
significantly associated with an increased risk of CLP in Saudi Arabia. 
 Maternal exposure to incense appears to influence CL risk.  
 Source of drinking water appears to influence oral cleft risk. Maternal drinking water 
that contains higher amount of minerals such as zinc, calcium, or magnesium, and is 
alkaline was found to decrease the chance of having an infant with NSOFC. 
 Other maternal exposures such as anti-pyretic medication, anti-emetic medication,    
fever, passive smoking, duration of inter-pregnancy interval, and x-ray were 
significantly associated with CL/P and/or CP, but were not found to be significant in 
the logistic regression analysis. 
The above findings raise the possibility of introducing community preventive programs 
through changing a range of behavioural and lifestyle factors or altering the mineral content 
of drinking water. 
7.1.3 Genetic risk factors associated with CL/P and CP in Saudi Arabia 
To the best of our knowledge, this is the first multicentre study that investigates the genetic 
aetiology of NSOFC in Saudi Arabia. IRF6 rs2013162 showed significant over transmission 
of the common allele (C) with CL/P cases. Also, VAX1 rs4752028 and rs7078160 rare allele 
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are found more frequent in CL/P and CP infant-parental triad cases compared to controls 
except for paternal rs7078160 rare homozygous allele. 
 
 The transmission disequilibrium test (TDT) and PLINK analysis showed that the 
IRF6 rs2013162 rare A allele is not a marker for CL/P risk as the common C allele 
(C) was the one showing significant transmission in CL/P cases.  
  Parent of origin was found to be significant for the IRF6 rs2013162 SNP, which 
showed significant over-transmission of the IRF6 variant from the paternal side in 
NSOFC cases. But, it was not significant when subdividing NSOFC to CL/P and CP.   
 There was a significant difference found between CL/P cases and controls for the 
maternal IRF6 rs2013162 variant, with a significantly more homozygous rare allele 
genotype (AA) in controls and more heterozygous allele genotype (CA) in CL/P 
cases.    
 There are no significant differences found between CL/P and CP cases compared to 
controls for the IRF6 rs2235375 and 2235371 variants. 
 The IRF6 rs2235371 homozygous rare allele genotype was found to be rarely present 
in the Saudi population (less than 3%).  
 The VAX1 rs4752028 and rs7078160 rare allele and homozygous rare allele were 
found more frequently in CL/P infant parental triad cases compared to controls, 
except for the paternal rs7078160 homozygous rare allele genotype. 
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  The VAX1 rs4752028 rare allele and homozygous rare allele were found more 
frequently in CP infant parental triad cases compared to in controls, but was not 
significant for the maternal homozygous rare allele genotype.  
 Two haplotype blocks, consisting of the five SNPs included in this study, showed a 
significant association with NSOFC. The first block included the common alleles of 
four SNPs and the rare allele of VAX1 rs4752028, while the second block included 
four common alleles and IRF6 rs2013162 rare allele. 
 The VAX1 rs4752028 rare allele was found more frequent in CL/P and CP cases with 
consanguineous parents compared to the frequency of this SNP in controls but was 
statistically significant only for CL/P.   
7.1.4 Genetic-environmental interaction associated with oral clefts in Saudi 
Arabia 
The information gained from this study on GEI is valuable for public health strategies as it 
gives a preliminary description of GEI for two genes (VAX1 and IRF6) in Saudi 
Arabia. 
 Maternal exposure to antipyretic, folic acid, fever, antibiotics, illnesses, common 
cold/flu, paternal waterpipe smoking, stress, x-ray and/or chemicals could 
significantly interact with the maternal IRF6 (rs2013162 and rs2235375) gene 
variants, affecting the risk of having a child with oral cleft.  
 Maternal usage of folic acid, multivitamin, antibiotics, exposure to fever, illness, 
stress, high blood pressure and incense could significantly interact with the maternal 
VAX1 (rs4752028) gene variant, affecting the risk of having a child with oral cleft. 
306 
 
  Waterpipe smoking, and chemicals are significantly associated with VAX1 
(rs7078160) variants in relationship to orofacial cleft.  
 This study directs future GEI research and guide future hypotheses to be tested for 
confirmation in larger studies in the future. 
7.2 Future plans and recommendations 
  
This study recommends future plans and direct coming research on the aetiology of NSOFC 
as follow: 
 Large-scale national researches program including the private sector which covers 
20% of the Saudi health services (Almalki, 2011), should be considered in order to 
adequately and nationally assess NSOFC sub-phenotype prevalence.  
 Further investigation is required to examine the influence of consanguinity on the 
prevalence of CL/P and CP in Saudi Arabia and the Middle East. 
 The effect of less frequently exposed environmental factors with genotype should be 
investigated using a larger sample size and cohort study.   
 The distribution of sample recruitment across both urban and rural areas, particularly 
for controls, should be determined in order to more accurately measure the SES and 
regional variation effects on the prevalence of NSOFC.   
 The timing, duration, amount and relationship between folic acid and oral cleft 
phenotypes need to be addressed in more details 
 Measures and social strategies should aim to decrease maternal stressors.  
 Prospective studies that investigate the effect of different types of smoking devices, 
maternal smoking, and maternal tobacco second-hand exposure to different smoking 
devices are important for public health policies aiming for prevention.  
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  Prospective studies aiming to clarify the relationship between drinking water (source 
and content) with the risk of having an infant with CL/P and CP should be considered 
in the future in order to confirm the possibility of using drinking water as a method 
for NSOFC public health prevention  
 Consanguinity could be matched between cases and controls in future genetic risk 
studies. A GWAS study is required to confirm and investigate genes responsible for 
the aetiology of CL/P and CP in Saudi Arabia and the Middle East. 
 Future studies measuring the population attributable risk for the different 
environmental, genetic risk factors and epigenetics are required for public health 
planning, prioritization and strategies for the control of CL/P and CP. 
 Further studies are required to determine the potential role of the interaction between 
environmental and genetic risk factors in primary prevention of CL/P and CP 
 Further studies are required to determine the potential role of the interaction between 
different environmental risk factors in primary prevention of CL/P and CP. A larger 
sample size study involving a log-linear modelling approach is needed to draw 
conclusions supportive of a definitive gene-environment interaction for CL/P and CP. 
 Finally, further systematic reviews and meta-analysis are required to draw a final 
conclusion on the risk factors attributing to oral clefts.  We suggest to review the 
following topics: 
o SES including parental education, occupation, Description of the family 
neighbourhood and their relationship to CL/P and CP. 
o Maternal ingestion of Folic acid; timing and doses and their relationship to 
CL/P and CP.  
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o Maternal ingestion of multivitamins and their relationship to CL/P and CP. 
o Maternal ingestion of antipyretics and exposure to fever and their relationship 
to CL/P and CP. 
o Smoking device type, intensity and paternal smoking and their relationship to 
CL/P and CP.  
o Parental alcohol consumption and their relationship to CL/P and CP.  
o Stress and different type of stressors and their relationship to CL/P and CP.  
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A1 : List of Syndromes associated with OFC:   
OFC phenotype Syndrome Gene involved 
CL/P  Autosomal Dominant developmental malformation ACTB 
Deafness and dystonia 
342 
 
Familial gastric cancer and CLP CDH1 
Cranio-fronto-nasal  EFNB1 
Roberts ESCO2 
Holoprosencephaly  GLI2 
Oro-facial-digital GLI3 
Hydrolethalus HYLS1 
Van-der-woude/ Popliteal pterygium IRF6 
X-Linked mental retardation and CLP PHF8 
Ectodermal dysplasia and CLP PVRL1 
Gorlin PTCH1 
Holoprosencephaly SHH, SIX3, TGIF1 
Bronchio-oculo-facial TFAP2A 
Ectrodactyly-ectodermal dysplasia-clefting TP63 
Ankyloblepharon-ectodermal dysplasia-clefting TP63 
Tetra-anemlia with CLP WNT3 
CP oculofaciocardidental BCOR 
CHARGE CHD7 
Lethap and Escobar multiple pterygium CHRNG 
Stickler type 1, 2 and 3 COL2A1, COL11A1, COL11A2 
Desmosterolosis DHCR24 
Smith-Lemli-Optiz DHCR7 
Miler DHODH 
Craniofrontonasal EFNB1 
Kallmann FGFR1 
Crouzon FGFR2 
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Apert FGFR2 
Otopalatodigital type 1 and 2 FLNA 
Larsen syndrome FLNB 
Hereditary lymphedema FOXC2 
Bamforth-Lazarus FOXE1 
Andersen KCNJ2 
Kabuki MLL2 
Cornelia de Lange NIPBL 
X-Linked mental retardation PQBP1 
Isolated cleft palate SATB2 
Diastrophic dysplasia SLC26A2 
Ccompomelic dysplasia SOX9 
Pierre Robin SOX9 
DiGeorge TBX1 
X-linked cleft palate and ankyloglossia TBX22 
Treacher Collins TCOF1 
Loeys-Dietz TGFBR1 and TGFBR2 
Saethre-Chotzen TWIST1 
 
 
A2: The International Classification of Diseases (ICD) World Health Organization's 
(WHO) classification codes for NSOFC 
ICD: 
Q35 
Description: 
CP 
ICD: 
Q36 
Description: 
CL 
ICD: Q37 Description: 
CLP 
Q35.1 Cleft hard palate Q:36.0 Cleft lip, Q37.0 Cleft hard palate with 
344 
 
bilateral bilateral cleft lip 
Q35.3 cleft soft palate Q:36.1 Cleft lip, 
median 
Q37.1 Cleft hard palate with 
unilateral cleft lip 
Q35.5 Cleft hard palate with cleft 
soft palate 
Q:36.9 Cleft lip, 
unilateral 
Q37.2 Cleft soft palate with 
bilateral cleft lip 
Q35.7 Cleft uvula   Q37.3 Cleft soft palate with 
unilateral cleft lip 
Q35.9 Cleft palate, unspecified   Q37.4 Cleft hard and soft palate 
with bilateral cleft lip 
    Q37.5 Cleft hard and soft palate 
with unilateral cleft lip 
    Q37.8 Unspecific cleft palate 
with bilateral cleft lip 
    Q37.9 Unspecific cleft palate 
with unilateral cleft lip  
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Investigation in the aetiology of Orofacial Clefts in Saudi Arabia 
Summary: 
 Orofacial cleft is a multifactorial defect that varies in incidence geographically 
and within different ethnic groups.  The aim of this study is to find out the genetic 
and environmental risk factors related to cleft lip and/or palate (CL/P) in infants 
attending governmental hospitals in the Western and Central region of Saudi 
Arabia prospectively using a matched case-control triads.  
 Material and methods: Infants with non-syndromic CLP from birth to 18 months 
and their parents in three main cities of Saudi Arabia (Jeddah, Maddina and 
Riyadh) will be included. A matched control triad with the same infant's age, 
gender, and hospital will be chosen. Saliva samples will be collected from infants 
and their parents in both groups using Oragene: DNA (Oragene 500 for adult 
and Oragene 575 for infants) for selective gene analysis. A questionnaire is used 
to collect information about the infant's mothers and fathers three months before 
and during pregnancy, and family history to detect any environmental risk factors 
for CLP in Saudi Arabia.  
 Statistical analysis: The descriptive epidemiology of CL/P will be presented, 
with statistics displayed in frequency and percentage for categorical variables, or 
means and standard of deviation for continuous variables. SNPs at candidate 
genes such as FGFR2, IRF6 will be analysed for their association with CL/P in 
the Saudi population. Gene-gene and gene-environment interaction will also be 
examined in this context. 
___________________________________________________________________ 
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Introduction: 
Orofacial clefts consist of cleft lip with or without cleft palate (CL/P)1 and isolated 
cleft palate (CP). They may present as part of a syndrome or other associated 
abnormalities2. Cleft lip and palate can lead to a series of functional as well as 
aesthetic problems including feeding difficulties especially at birth, swallowing and 
nasal regurgitation, hearing difficulties, and speech difficulties. Although these cleft 
defects can be surgically repaired in early childhood, residual deformity due to 
scarring and abnormal facial development, results in long-lasting functional and 
psychosocial problems 3,4. Affected children have higher morbidity and mortality 
throughout life than do unaffected children.5,6 which mean that clefts have long-
lasting, adverse effects on the health and social integration of affected individuals 
7,8. 
Cleft lip and palate are known to be the most common craniofacial defects 
throughout the world. 5 It is estimated that the overall global prevalence of OFC is 
one individual in every 700 births. 9 However, the prevalence varies in different parts 
of the world and different ethnic groups. They occur 4 to 6 times more often among 
Asian populations but are less common in Africans. 9 Despite efforts to record the 
frequency of birth defects over the years, accurate data on the epidemiology does 
not exist in many countries 11.  
 
In Saudi Arabia, where almost 300,000 children are born per year 12, no data on the 
precise prevalence of craniofacial cleft and lip anomalies are found in the dental 
literature. Research carried on craniofacial defects has demonstrated ranging 
incidence from 0.3 to 2.19 cleft infants in every 1000 live births. However, these 
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were hospital based studies that cannot be generalized to the Saudi population 13-17.  
One pioneer project that initiated registration of cleft lip and palate anomalies was 
carried out in King Faisal Specialised Hospital and Research Centre. 1555 patients 
with cleft lip and palate and craniofacial anomaly were registered over a period 
between 1999 to 2008 was 774 cleft lip and/ or palate.18,19 However, more 
investigations is needed on the prevalence and aetiology of OFC in order to build 
the foundation for controlling or even preventing  OFC in the future.  
The aetiology of cleft lip and palate is complex. There are many factors that 
contribute to cleft lip and palate; genetics, environmental, and gene-environmental 
interaction risk factors.9 Genes that are involved in the aetiology of cleft lip and 
palate are those that are responsible for their embryonic development. However, 
understanding their contribution in the aetiology of cleft lip and palate is complex.  
The number of genes involved the differences between cleft lip and palate and 
isolated cleft palate 21, the heterogeneity of each group, the type of inheritance and 
interaction with the environmental factors makes it difficult to identify the etiology.22 
Therefore several approaches should be advocated to identify the genes; the use of 
a combination of family collection, careful phenotyping, high-throughput genotyping, 
robust analytical strategies, final structural mapping and mutation characterization. 
23,24       
Genome Wide Association (GWA) is an approach that involves rapid scanning 
markers across the complete sets of DNA, or genomes, of many people and is used 
to find genetic variations associated with a particular disease. At least three genes 
(MSX1, IRF6, and FGFR1) appear to play a significant role in orofacial clefts.24    
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MSX1 is located on chromosome 4p. It is one of the genes responsible for initiation 
and growth of the facial processes and specification of its identity.25  The  mutation 
of this gene is responsible for 2% of nonsyndromic cleft lip and palate.26,27 The gene 
that encodes the transcription factor interferon regulatory factor 6 (IRF6) is located 
on chromosome 1q. It is related to the formation of connective tissue in the palate. 
Studies have found that mutations in this gene results in the autosomal dominant 
disorder Van der Woude syndrome (VWS).28 VWS resembles an isolated cleft, but is 
accompanied in most cases by lip pits, caused by mutations in a single gene, 
whereas the more common isolated cleft is a complex trait caused by multiple gene 
mutations and/or environmental insults. Very recently it was demonstrated that a 
common haplotype associated with IRF6 contains a mutation that provides a risk of 
approximately 12% to all common forms of cleft lip and palate. 24 
The other gene, FGFR1 was identified on chromosome 8p 29 in cases of Kallmann 
syndrome, an autosomal dominant disorder typically characterized by infertility and 
anosmia. Approximately 5% of Kallmann syndrome cases have clefts of the lip 
and/or palate and, as with VWS, some individuals may present with clefts as the 
only component of the phenotype.30  
Epidemiological and experimental evidence suggest that environmental risk factors 
such as maternal exposure to tobacco smoke, alcohol, poor nutrition, viral infection, 
medications, and teratogens in the workplace and at home in early pregnancy are 
important factors in aetiology. 24,31 
Consanguinity has been reported to be higher in parents with orofacial cleft children 
than non-cleft children.32  It was suggested that this could play a role in the aetiology 
350 
 
of clefts.  Saudi Arabia has a high prevalence of consanguinity (57.7%)33 and it 
would present an opportunity to carry out such an investigation. In King Faisal 
Hospital and Research Centre 19 they found that 53.3% of the cases were of first 
cousins which is rather a high rate compared to the prevalence of 1st cousin 
consanguineous marriages reported in the general Saudi population.33  On the other 
hand, Alsahafi Y (2010) concluded in his study on the association between orofacial 
clefts and consanguinity in Saudi Arabia, that it had a protecting effect against 
having a cleft child.34  Therefore, further investigation is needed to identify the effect 
of consanguinity on oral clefts. 
The presence of risk factors, if identified, could be manipulated to control or reduce 
the incidence of the anomalies.  Therefore, studying and understanding the 
aetiology of cleft lip and palate is significant to prevent and limit the occurrence of 
these defects in the future. 
This study Aim is to investigate the prevalence and aetiology of cleft lip and/ or 
palate in the western and central region in Saudi Arabia.   
Material and Method: 
The proposed prospective study is designed to investigate the risk factors related to 
cleft lip or/and palate using parents-child trios in the central and western regions in 
Saudi Arabia. 
Subjects: 
The study will take place in three cities in Saudi Arabia which contain most of the 
Saudi population (Riyadh, Jeddah and Maddina).  
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The government hospitals in these areas, as described by the ministry of health 
book (2006), 52 includes the hospitals of the Ministry of Health, University Hospitals, 
National Guard Hospitals, and King Faisal Specialised Hospitals and research 
Centres.  In each city the sample will be stratified according to geographic location 
to five districts (central, north, south, west and east).  Random sample of hospitals 
will be selected according to proportional allocation methods. The hospitals that will 
be included in the study are illustrated in table 1.  
The subjects selected will include all cleft patients born or referred to the selected 
hospitals from August/2010 and their age range from 0 to 12 months and their 
parents.   
Sample group: 
Study group: 
Group I: Infants with non-syndromic cleft lip and/or palate 
Group II: Infants with syndromic cleft lip and/or palate.  
Control group:  
They are normal healthy infants attending the hospitals for other reasons than 
clefts and their parents. The control will be matched with the study group in 
their age, gender, and hospital where they were located. 
Method: 
A formal consent form will be given to the parents after they are provided with verbal 
and written information concerning the importance and the procedures of the study.  
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Clinical examination for the Infants in the study group will be carried on in paediatric 
clinic using light and mirror to detect the type and characteristic of the clefts 
depending on the international clearinghouse for birth defects monitoring system 
(1991,2001)35,36 the cleft lip and/ or palate will be defined by the examiners as: 
I. Cleft lip with or without cleft palate: it is a congenital malformation 
characterised by partial or complete clefting of the upper lip with or without 
clefting of the alveolar ridge(ICBDMS 2001) 36 
1. Isolated Unilateral Cleft lip 
2. Isolated bilateral cleft lip 
3. Unilateral Cleft lip with clefting of alveolar bone 
4. Bilateral cleft lip with clefting of alveolar bone. 
II.  Cleft palate without cleft lip: it is a congenital malformation characterized by 
a closure defect of the hard and/ or soft palate behind the foramen incisive 
without cleft lip. (ICBDMS 1991) 35 
1. Complete palatal cleft 
2. Sub-mucous cleft palate 
3. Soft palate (bifid uvula). 
III. Both cleft lip and palate (Shaw WC 1993) 37: 
1. Unilateral complete cleft lip and palate. 
2. Bilateral complete cleft lip and palate. 
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3. Unilateral Incomplete cleft lip and palate. 
4. Bilateral Incomplete cleft lip and palate. 
Part II:  
A questionnaire will be given to parents of the control and study groups. The co-
coordinator will interview them in paediatric clinic. The average time of answering 
the questionnaire is 15 minutes. The questionnaire includes (see appendix A4):   
 General information: date of participation, name of the hospital, place of birth, 
residence, day of birth, child birth order, the, name of the patients and his 
parents, contact numbers,  
 Demographic data and pregnancy history: maternal age at delivery, maternal 
weight/height, length of pregnancy, duration between the last two births, 
prenatal visits, parents educational level, mother working status and type of 
occupation during pregnancy, family monthly income.  
 Consanguinity and family history of birth defects: parents, grandparents, 
parent’s sibling, 1st degree cousins, 2nd degree cousins, tribe.  
  Maternal exposure to chemical and drugs during pregnancy: measure 
prenatal primary and secondary exposure to nicotine, glycol ether, prenatal 
nutrition including vitamins and folic acid.  Drugs exposure; including 
hormones and adrenaline, stress,   
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Saliva sample: 
Saliva sample will be collected from infants and parents from both groups. For 
parents, OG-500 Oragene kit will be used. Adult will be asked to spit 2ml of saliva in 
collecting tube to obtain 110µg DNA 
For infants, OG-575 Oragene Kit will be used. The kit contains a sponge that 
collects saliva and then squeezed in an Oragene tube collecting tube. The saliva will 
be sent to the genetic lab for DNA extraction and genotyping using. It will be 
analysed using candidate gene approach with polymerase chain reaction (PCR). 
The association of various genetic polymorphisms with the different types of clefts 
will be analysed on a number of candidate genes to reflect state of the science/ best 
evidence at the time of DNA analysis. Due to GWAS and on-going research on the 
genetic aetiology of cleft lip and/or palate, the choice of candidate gene will be 
updated shortly before the analysis. However, it is expected, depending on recent 
publications that the candidate genes to be studied will include:  
 IRF 6 
 FGFR2 
Information on environmental risk factors will be correlated, compared and analysed 
with the DNA analysis results to examine gene-gene and gene-environmental 
interactions. 
 
On-going plane: 
Data collection will continue from the three cities in Saudi Arabia; Jeddah, Madinah 
and Riyadh. It is expected to continue for at least 6 months more to reach the 
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target sample size which is 150 infant-parents triad. The same number or more of 
matched control will be collected during the second year of this project for 
comparison analysis. 
 
Table 1: Name of selected hospital in each geographic area from every city  
City Central North South West East 
Riyadh King Faisal 
Specialised hospital 
and research centre 
King Fahad 
Medical City  
King Saud 
Medical City 
King 
Fahad 
Armed 
forces 
Hospital  
King 
Abdulaziz 
Medical City  
Jeddah Maternity and 
children hospital, 
Almusaadiah and 
King Fahad Hospital  
King Abdulaziz 
University 
Hospital 
King 
Abdulaziz 
Medical City 
King 
Fahad 
Armed 
Forces 
Hospital 
Maternity and 
children 
Hospita,  Al-
Aziziah. 
Madinah Maternity and Children Hospital 
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A4: Ethical approval and consent form 
Dear Parents,  
I am a Paediatric Dentist from King Abdulaziz University. I and my research group 
are doing a study on cleft lip and palate. I am going to give you information and 
invite you to be part of this research. You do not need to decide today whether or 
not you will participate. Before you decide, you can talk to anyone you feel 
comfortable with about the research.   
 
There may be some words that you do not understand. Please ask me to stop as we 
go through the information and I will take time to explain.  If you have questions 
later, you can ask them to me, the study doctor or the staff.  
 
What is cleft lip and palate? 
Cleft lip and palate is a defect in the growth of the upper jaw and lip of the baby. 
Affected children suffer from difficult to eat and swallow, food goes back to their 
nose and they have hearing and speech difficulties. They also have an appearance 
problem.  
 
Why do some babies have cleft lip and palate and some not? 
The cause of cleft lip and palate is still unclear. It could be caused by certain 
medication, food or life style that affected the mother of the child during her 
pregnancy. Specific gene could be also the cause or both together. When there is a 
cause it means it could be prevented.  
 
Why are we doing this study? 
Through this study we will try to find out the cause of cleft lip and palate in Saudi 
Arabia, in order to control and prevent in the future. This means that you could help 
in protecting and saving other children from having this disease. 
 
How can you help? 
The study will need to ask you some questions regarding your pregnancy, 
medication, lifestyle, height/weight and occupational exposure. We will also need to 
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ask you information regarding family medical history, the child medical history. The 
questionnaire will be a personal interview and will take about 20 min. We will also 
need to take from your baby, mother and father a sample of blood one time only and 
an amount less than a tea spoon. If you do not prefer blood sample to be taken from 
you or your baby, you will be asked to spit saliva in a small container. However, 
blood is more convenient for us.  
 
Who can help? 
The persons who could participate in this study are babies born after September of 
2010 and their parents. Their age should not exceed 6 months. They could have or 
do not have cleft lip or palate. 
 
What will happen to the information and sample we will take? 
1. Blood sample or saliva taken to the genetic lab. 
2. Cells will be taken out from the sample. 
3. DNA will be seen and analysed. 
4. The DNA of cleft children and their parents will be compared with the DNA 
with non-cleft patients and their parents. 
5. Information about your pregnancy and life style will be compared with the 
genes to find any relation.  
6. If there is any relation between the gene and medication or life style we will 
take action to prevent cleft in the future. 
 
The confidentiality of the research: 
This information will be completely confidential. No one will be allowed to see or use 
it for other purpose. For the blood and saliva sample it will be stored and analysed 
for this research in a two years period. Any leftover blood will be destroyed or used 
in other researches under your permeation.  
  
Freedom of participation: 
Your participation in this research is entirely voluntary. It is your choice whether to 
participate or not. Whether you choose to participate or not, all the services you 
receive at this clinic will continue and nothing will change. If you choose not to 
participate in this research project, you will offered the treatment that is routinely 
offered in this cleft clinic in King Abdulaziz university hospital, and we will tell you 
more about it later. You may change your mind later and stop participating even if 
you agreed earlier 
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The duration of the research: 
The procedure of the research will take about two years until the end of 2012. 
 
 
Prick  
Thank you for your help and time….. 
 
Yours sincerely, 
 
 
 
 
 
 
Note:  
It is your right to take money to pay for your travel to the clinic/parking and we will give you 
[50RS] for lost work time. You will not be given any other money or gifts to take part in this 
research. 
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Question to elucidate understanding 
Dear parents, 
 
Please answer these questions before participating in the research: 
 Do you know why we are asking you to take part in this study? 
Yes  No 
 Do you know what the study is about?  
Yes  No 
 If you decide not to take part in this research study? Do you know what your options 
are? 
Yes  No 
 Do you know that you do not have to take part in this research study if you do not 
wish to?, Yes  No 
 
 Do you know that you can withdraw anytime?  
Yes  No 
 
 Can you tell me if you have understood correctly the benefits that you will have if you 
take part in the study? 
Yes  No 
 Do you know if the study will pay for your travel costs and time lost, and do you 
know how much you will be re-imbursed? 
Yes  No 
 Do you have any questions?  
Yes  No 
 
 
Name of the parents:_____________    Date:______________  
 
 
Signature:________________ 
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Name of the hospital:      Code #: 
Contact person      Date: 
Team contact details 
 
Table1: members of the cleft and palate collaborating team 
Speciality  Name  Contact number email 
Maxillofacial 
surgeon 
   
Paediatrician     
Plastic Surgeon     
ENT    
Paediatric dentist    
Gynaecologist    
Orthodontics    
Collaborating 
personal 
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A5: Questionnaire  
Date: _____/_______/______                                       Saudicleft project 
Questionnaire includes:                                       
 Section 1: Information section  
i. Family information * 
 ii. Pregnancy information 
 iii. Environmental information 
 Section 2: Child examination section  
*Mother’s information includes 3 months pregestation and 3 months after postgestation).                                   
 
 
Child’s name  
File number  
Home Address 
 
 
 
Region  
Telephone number  
Father’s mobile number  
Mother’s mobile number  
Parent’s email  
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Section 1: Family information: 
Father’s information 
1. Work and work address 
 
 
 
2. Family income/month 
1Less than 4000 RS       24000-7000 RS              37001-10000 RS            
410001-16000 RS            516001-23000 RS          623001 or more 
3. Date of birth  Age  
4. Education level 
1No                          2Primary     
3Intermediate          4High  School   
5Bachelor                6Postgraduate         
7Others_________________________ 
 
 
Child’s information 
5. Date of birth  Age   
6. Place of birth:      Country  City  
7. Hospital where child born  
8. Nationality  Sex 1Male         2Female   
9. Gestation 125-28w   229-32w      333 -36w      437-42 weeks 
10. Neonatal weight 
11-1.5kg    21.5-2kg      32.1-2.5kg     42.6-3kg  53.1 3.5kg   
63.6-4kg     74.1-4.5kg 
11. Head circumference 1 <30cm   232.1-34cm 334.1-36cm  436.1-38cm      538.1-40cm 
12. Length 
1<38cm    238-42cm    343-47cm     448-52cm  553-57cm    
6More than 57cm 
13. Multiple birth? 
1Yes (what type?)  1Twins     2Triplets      3Quadruplets 
2No (go to Q15)        
14. Type of multiple birth 1All affected     2Same sex      3Different sex        
 
 
Mother’s information 
15. Name  Nationality  
16. Residency 3 months before and after 
pregnancy: Country 
 City  
17. Type of area in which you lived 1Rural      2Metropolis/Urban     3Urban      4Industrial        
18. Date of birth  
 
Age 
 
19. Educational level  1No     2Primary     3Intermediate     4High school     5Bachelor     
6Postgraduate    
20. Work in pregnancy and work 
address 
 
 
 
21. Height  1 <140cm   2141-150cm 3151-160cm   4161-170cm     5>171cm   
22. Weight 1<40Kg      241-50Kg     351-60Kg       461-70Kg          571-80Kg   
681-90Kg     791-100Kg     8101 -110Kg     9111Kg or more      
23. How many children do you have? (Circle the correct answer):  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 
24. What is the birth order of the child? (Circle the correct answer):  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15    
25 What is the duration between this 
child and the one before in years? 
11 or less         21.1-2Y        32.1-3Y        43.1-4Y        54.1-5Y        
65.1-6   76.1-7  6more than 7 
26. Did you have any miscarriages? How 
many? 
(Circle the correct number):  0   1   2   3   4   5   6  
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Section 1: Pregnancy information: 
29. How many times did you visit your Dr. 3 months before your pregnancy? Circle the number: 0 
1 2  3 
30. How many times did you visit your Dr. in the first trimester? Circle the correct number:  0  1  2  
3  4  5  6 
31. Was the pregnancy planned?   1Yes     2No     
30. Did you have medication, X-rays or Ultrasounds?   1Yes (please answer from 31-42)    2No 
(go to Q43)         
Please record the  type and duration of the drugs you used: 
 Before pregnancy In the 1
st 
trimester  
Medication Dose #/day #of days Brand Dose in mg #/day #of days Brand  
31. Antibiotics 
Name:__________ 
          1250 
          2500 
     31000            
1  2  
3  4 
  11-4  
 25-8   
 39-12  
 4>12 days 
            1250 
           2500 
31000 
1  2  
3  4 
 11-4 
 25-8   
 39-12   
 4>12 
 
 
32. Folic Acid   14  
 25 
 3With 
multivitamin 
1 2   
3 4 
    1<30 
    231-60      
   361-90 
       14     
      25   
      3With 
multivitamin 
1  2  
3  4 
1<30    
231-60  
361-90 
 
33. Multivitamins          
34. Iron         
35. Sickness Drug          
36. Cortisone         
37. Anticonvulsant         
38. Insulin         
39. Contraceptive         
40. Other, please 
list  
a. paracetamol: 
b. 
 
 
        
 # of times  When?   # of times  When?   
41. X-Ray, CT, etc 0 1 2 3 4     0 1 2 3 4     
42. Ultrasound 0 1 2 3 4     0 1 2 3 4     
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43. Did you suffer from any illnesses during your pregnancy? 1Yes (answer 44-59)   2No (go to 
Q60)         
Type of disease Before pregnancy 1
st
 trimester 
Severity # of days Severity # of days 
44. Viral infection 1Mild 2Mod 3Severe 11-3 
   24-6  3>7  1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
45. Flu 1Mild 2Mod 3Severe 11-3 
   24-6  3>7 1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
46. Fever 1Mild 2Mod 3Severe 11-3 
   24-6  3>7 1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
47. High blood pressure 1Mild 3Severe 11-5
 26-10 311-15 4 >15 1Mild  3Severe 11-5
 26-10 311-15 4 >15 
48. Diabetes 1Mild 2Mod 3Severe <14 215-303>30 1Mild  2Mod 3Severe 1<14 215-303>30 
49. Depression  1Mild 2Mod 3Severe 1<14 215-303>30 1Mild  2Mod 3Severe 1<14 215-303>30 
50. Convulsion 1Mild 2Mod 3Severe 11-3 
   24-6  3>7 1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
51. Renal disease 1Mild 2Mod 3Severe 1<14 215-303>30 1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
52. Liver Disease 1Mild 2Mod 3Severe <14 215-303>30 1Mild  2Mod 3Severe 1<30 231-603>90 
53. Vaginal Bleeding 1Mild 2Mod 3Severe 11-3 
   24-6  3>7 1Mild  2Mod 3Severe 11-3 
   24-6  3>7 
54. Chronic Disease 1Mild 2Mod 3Severe 1<14 215-303>30 1Mild  2Mod 3Severe 11<30 231-603>90 
55. Asthma 1Mild 2Mod 3Severe 11-3 24-63>7 1Mild  2Mod 3Severe 11-3 24-6 3>7 
56. Abdominal pain 1Mild 2Mod 3Severe 1<14 215-303>30 1Mild  2Mod 3Severe 1<14 215-303>30 
  57. Severe morning sickness 1 1st month 22nd month 33rd month 4all 11-10 day211-20day 321-30  
58. Threatened Abortion 1 1st month 22nd month 33rd month 5all 11-10day 211-20day 321-30  
59. Other, please list 
a. e.g. Migraine 
b.  
c. 
 
1Mild 2Mod 3Severe 
 
1<14 215-303>30 
 
1Mild  2Mod 3Severe 
 
1<14 215-303>30 
60. Were you exposed to any chemicals in your home/work environment?  1Yes (answer 61-67)  2No 
(go to 68)     
Type of chemical Before pregnancy 1
st
 trimester 
Amount  # days Amount # days 
61. Cyanides  11-3  24-6  3>7 days  11-3  24-6  3>7 days 
62. Pesticides 1 1 room 
2 >1room 
11-3  24-6  3>7 days  11-3  24-6  3>7 days 
63. Solvents (thinner Acetone)  11-3  24-6  3>7 days  11-3  24-6  3>7 days 
64. Pollutant  1 1 room 
2 >1room 
  1<30 231-60 3>90      1<30 231-60 3>90 
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65. Computer, copying machine (<2m away) # of hours/day     1<30 231-60 3>90  # of hours/day     1<30 231-60 3>90 
66. Microwaves (mobile, cooking, others) # of hours/day 1<30 231-60 3>90  # of hours/day 1<30 231-60 3>90 
67. Other, please list  
 
 
 
Section 1 Environmental information  
68. Do you smoke?           1Yes (answer Q69 to Q72)     2No     (go to Q73)     
Type of Smoking Before pregnancy # 1
st
 trimester # 
# /day #days /week #of weeks # /day # days /week  #of weeks 
69. Smoking tobacco  0 1 2 3 4 5 6 7    0 1 2 3 4 5 6 7   
70. Non smoking tobacco  0 1 2 3 4 5 6 7    0 1 2 3 4 5 6 7   
71. Sheesha (Jorak) 0 1 2 3 0 1 2 3 4 5 6 7   0 1 2 3  0 1 2 3 4 5 6 7   
72. Sheesha (Moasel) 0 1 2 3 0 1 2 3 4 5 6 7   0 1 2 3  0 1 2 3 4 5 6 7   
Tambak (used in Yaman)       
73. Does the father of the child smoke? 1Yes    2No (go to Q78)  
Type of Smoking Before pregnancy # 1
st
 trimester # 
# /day #days /week #of weeks # /day # days /week  #of weeks 
74. Smoking tobacco  0 1 2 3 4 5 6 7    0 1 2 3 4 5 6 7   
75. Non smoking tobacco  0 1 2 3 4 5 6 7    0 1 2 3 4 5 6 7   
76. Sheesha(Jorak) 0 1 2 3 0 1 2 3 4 5 6 7   0 1 2 3  0 1 2 3 4 5 6 7   
77. Sheesha (Moasel) 0 1 2 3 0 1 2 3 4 5 6 7   0 1 2 3  0 1 2 3 4 5 6 7   
78. How many cigarettes are smoked around you at home or work? Hours/day______ days/ week 
______ 
79. Have you suffered from any family problems during your pregnancy?      1Yes                   
2No          
80. Do you think you were under any pressure during your pregnancy?            1Yes                   
2No      
81. What sort of water do you drink            1Tap       2Bottled     3Well       4Others_______    
82. For drinking bottled water, what is the name of the company? ( look at the Show 
card):_____________ 
83. How many days do you eat food containing flour per week? (Circle the # of days):        0  1  2  3  
4  5  6  7  
84. How many days you cook with flour per week? (Circle the # of days):                              0  1  2  3  
4  5  6  7  
85. What kind of flour do you use? ___________________________    
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86. Do any of your relatives have birth defects?      1Yes (answer 87-95)  2No(go to Q96)   3Do 
not know  (go to Q96)    
If yes, please specify the relation to the child and type of defect: 
Relation to the child Defect Type * Date of birth or age 
87. 88. 89 
90. 91. 92. 
93. 92. 95. 
 *1cleft lip and palate  2only cleft palate    3limb abnormality      4CV      5other orofacial defects   
6genitourea                                                                               7multiple defects      8others________   
96. Are the parents related (Consanguinity)?          1Yes (answer Q96)                   2No(go to Q97)          
97. What is the relation?  11st degree cousin   21st cousin once removed   32nd degree cousin  
4Same tribe. 5double 1st degree cousin    
 
Section 2: Child examination 
 
98. Have photos been taken:   1Yes  (Frontal, lateral, occlusal)     2No          
99. Was the cleft prenatally diagnosed?   1□Yes   2□No  
100. Any associated anomalies with cleft lip and palate?   1Yes (answer Q100)   2No (go to 
Q101)          
101. Describe the associated anomaly: 
___________________________________________________ 
1Congenital heart disease    2Limbs malformation   3Polydactyly      4Hydrocephaly   5UT defects             
6Other facial anomaly: ________________             7Others: ______________________ 
Type of cleft: 
102. Is the cleft: 
1Syndromic                  Name or code of the Syndrome: ______________________ 
 
2Non-syndromic.        3Multi-malformed infant         4Part of Pierre Robin sequence  
 
Cleft description: 
Name of category Right Left 
Simonart band 103. 1□Yes  2□No 104.1□Yes  2□No 
Cleft lip 105.
.1□Yes  2□No 106.
.1□Yes  2□No 
Alveolus 107. 1□Yes  2□No 108.1□Yes  2□No 
Hard palate 109.
.1□Yes  2□No 
Soft palate 110.
.1□Yes  2□No 
Thank you for making a difference in another child’s life!!  
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A6: Technique for collecting Saliva from adult using 500 Oragene kit 
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A7: Technique for collecting Saliva from infants using 575 Oragene kit.  
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 eriannoitseuq ni dna mrof tnesnoc cibarA :8A
 mrof tnesnoc cibarA :1.8A
 
 الحلق سقف وشق الأرنبية الشفة حدوث أسباب دراسة
 ..المواطن عزيزي
 ، الدراسة إجراءات الإقرار هذا يصف و .عليك وتأثيرها الدراسة هذه محتويات البحث فريق من عضو لك سيشرح
 لكي الأسئلة طرح في الكافي الوقت اخذ الرجاء .المعلومات سرية على الحفاظ وكيفية ، المشاركة من والفوائد والمخاطر
 ،  الدراسة هذه في المشاركة قررت إذا .المستنيرة  الموافقة تسمى الموافقة ذهوه .لا أم ستشارك كنت إذا ما قرارك تتخذ
 إلى أو إليك يشير سوف "أنت" اللفظ، الإقرار هذا وطوال .لسجلاتك نسخة وستعطي الإقرار هذا على التوقيع منك سيطلب
  .الاقتضاء حسب ، طفلك 
 
 الدراسة؟ هذه تجري لماذا
 المستقبل في الحلق سقف شق و الأرنبيه الشفة حدوث و إنتشار من للحد
 
 ؟ الدراسة هذه في المشاركين عدد وكم
 ووالديهم طفل 003
 
 ؟ الدراسة هذه في شاركت إذا سيحدث ماذا
 الشفة أو الحلق تكوين في خلل لهم يحدت أن من المستقبل في سيولدون الذين الأطفال حماية في ستشارك
  لي؟ دراسة خلال من متوقع هو ما
 إلى سنحتاج لأننا كما .بالحمل المتعلقة والأحداث الأدوية و الأمور بعض وعن عنك العامة المعلومات بعض منك خذسنأ
 دم عينة تعطي أن تريد لا كنت أن لعابية عينة فقط أو الحالات بعض في أمكن إن دم عينة
 الدراسة؟ هذه في المشاركة مدة هي ما.
 سنوات 2 إلى 1 لمدة فستستمر نفسها لدراسها أما .واحده زيارة إلا نحتاج لا منك
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 ؟ المشاركة إنهاء أستطيع هل
 لا .بأمان مشاركتك إنهاء كيفية لك ليوضح .التوقف قررت إذا الطبيب  اخبر فقط .وقت أي في التوقف تقرر أن يمكنك .نعم
 رأيك تغيير علي سيحملك أحد
 ؟ الدراسة في المشاركة أنهيت إذا متوقعة مخاطر هناك هل
 مخاطر أي يوجد لا ,لا
  
  الدراسة؟ في المشاركة جراء من حدوثها يمكن التي الجانبية الآثار أو المخاطر هي ما
 دم عينة أخذ على وافقت إن الإبرة غزة إلا يوجد لا
 
 ؟ الدراسة في المشاركة من فوائد هناك هل
 المستقبل فبي سيولدون الذين الأطفال من لغيرك فائده هناك ,نعم
 طريق عن لغيرك مفيد الاجراء يكون أن  الأطباء يأمل ولكن.حالتك تحسن إلي تؤدي لا قد  الدراسة هذه في كتكمشار
 الآن حتى ذلك على دليل يوجد ولا أسبابه و للمرض أكثر فهمن
  
 ؟ الدراسة في المشاركة تكاليف هي وما 
  .الدراسة  أنشطة من أي  تكاليف تتحمل لن 
  
  ?الدراسة هذه في مشاركةال نظير اجر سأتقاضى هل 
  .الدراسة هذه في للمشاركة ،05 لك سيدفع السفر ونفقات جهدك وقتك، مقابل في 
  
 ؟ بسرية بي الخاصة الطبية المعلومات علي الحفاظ سيتم هل
 نضمن أن يمكننا لا ، ذلك ومع .بالسرية تحظى الطبي سجلك في الشخصية المعلومات أن من للتأكد جهدنا قصارى سنبذل
 عن الإفصاح يتم لن .القانون بموجب وذلك الأمر اقتضى إذا الشخصية معلوماتك عن يفصح أن يمكن .التامة الخصوصية
 العلمية الاجتماعات في عرضت أو نشرت  الدراسة هذه  نتائج نشر تم إذا الشخصية المعلومات أو اسمك
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 المشاركة إنهاء يمكنك كما. لا أو الدراسة هذه في اركةالمش اختيار حرية لك .اختيارك من الدراسة هذه في المشاركة قرار
 لن  الدراسة ترك .بك الخاصة العادية الفوائد من أي تفقد لن و عقوبة أي هناك يكون لن ، قرارك كان مهما .وقت أي في
 .سةلدرا تترك أن قبل  جمعها تم التي المعلومات يستخدم  قد هبه .د .لك المقدمة الطبية الرعاية علي يؤثر
 على أو صحتك على تؤثر أن يمكن التي  الدراسة في التغييرات أو والمستجدات المعلومات بكل نبلغك سوف ونحن
 .الدراسة لمواصلة استعدادك
 
 البحث؟ نتائج على أحصل أن يمكنني هل
 .سنتين خلال منها الإنتهاء بعد أحببت إن بالنتائج إبلاغك يمكننا ,نعم
 
 .....لأبنائنا أفضل مستقبل أجل من الرسالة هذه من جزأ تكونوا أن على وحرصكم معنا تعاونكم لكم نشكر 
 
 
 :التوقيع
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 السعودية العربية المملكه في الحلق سقف وشق الأرنبية الشفة حدوث أسباب عن بحث
 
 
 
 الطفل عن معلومات
 ______ _________ ________ ________الأسم .1
 رمز__________ب ص_________مدينة__________شارع________حي  :المنزل عنوان .2
 __________بريدي
 جوال  ____________________الأب جوال _________________  الهاتف رقم .3
 ________________الأم
 ________________________:الأم عمل______________________:الأب عمل .4
 ______________________________________:الأب عمل عنوان .5
 _______________________________________:الأم عمل عنوان .6
       00051 -00001     □ 0006-0004     □0009 -0007 رس 0004 أقل من □للأسرة          الشهري الدخل .7
 00003 من أكثر□00041-00001         00003-00012□             00002-0006□  
   :الأب عمر .8
   الجنسية___________________ .9
 □   ذكر□        أنثى :الجنس .11
 _____________:الولادة تاريخ .11
         ___________المنطقة__________المدينة   ________ :المستشفى اسم :الولادة مكان .21
 كجم____________ الولادة عند وزنه .31
 ___________محيط مدار الرأس__ .41
 طوله عند الولادة________________ .51
______________________________________________________________________
 _________
 الأم عن معلومات
 الاسم  .61
 الأم عمر .71
 ______________________الجنسية .81
 __________________الحمل أثناء إقامتها مكان .91
 ________________المنطقة_________ المدينة .12
           -□171-161          □161-151           □سم151-141سم     141من أقل   □ لطول: .12
-19     □19-18    □18-17    □17-16     □16-15    □15-14   □سم14مباشرة:أقل من  الحمل قبل الوزن .22
   □111أكثر من       □111
 التعليم مستوى .32
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  □  جامعي□             ثانوي□                   متوسط□                  ابتدائي□                 متعلم غير
 __________________:المهنة .42
          41 31 21 11 01 9 8 7 6 5 4 3 2 1                         :للأم الأبناء على دائرة ضع .52
       01 9 8 7 6 5 4 3 2 1     إخوانه؟ بين الطفل هذا ترتيب على دائرة ضع .62
 6أكثر من □ 6-5□   4-3□   3-2□   2-1 □   1أقل من □:  قبله ومن الطفل بهذا حملك بين الزمنية الفترة هو ما .72
 □لا□                    نعم                    إسلابات؟ هنا كان هل .82
 .....بنعم الإجابة كانت إذا
                                         6 5 4 3 2 1                            :عددها على دائرة ضع. .92
 لا□                    □نعم              له؟ مخطط الطفل بهذا حملك كان هل .13
  3  2 1الولاده قبل الحمل؟   و النساء لطبيب الأولى عدد زيارتك  كان كم  .13
 3  2 1شهر الأولى للحمل؟  أ3الولاده في  و النساء لطبيب الأولى عدد زيارتك  كان كم  .23
 لا□                    نعم       الدخان؟ تستعملين هل .33
 .....بنعم الإجابة كانت إذا
 :نوعه ما .43
 الأولى أشهر 3 .53 الحمل قبل التدخين نوع
              سجائر .63
  
  
   شيشة .73
   أخرى .83
 □لا□                    نعم مدخن؟      الأب هل .93
 :نوعه ما .14
 الأولى أشهر 3 .14 الحمل قبل خينالتد نوع
              سجائر .24
  
  
   شيشة .34
   أخرى .44
 
 □لا□                 ابن)؟   نعم ,أب ,يدخن (أخ كثيرا بهم تحتكين الذين الأقارب من هل أحد .54
 □لا □                   نعم      :الحمل أثناء أدوية أخذت هل .64
 الأولى الأشهر3 الحمل قبل النوع
  .94  .84 ناتفيتامي .74
  .25  .15 حديد .15
  .55  .45 أس فولك .35
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  .85  .75 انسولين .65
  .16  .16 حيوي مضاد .95
  .46  .36  للغثيان أدوية .26
  .76  .66  .56
  .17  .96  .86
 
 
 الحمل؟ أثناء مرض بأي أصبت هل  .17
 لا□                    نعم□ .27
 الأولى أشهر3 الحمل قبل النوع
  .57  .47 زكام .37
  .87  .77 فيروسي التهاب .67
  .18  .18 سخونة .97
  .48  .38 الغثيان .28
  .78  .68 ضغط .58
  .19  .98 سكر .88
  .39  .29  .19
 
 معروف غير□       ____أخرى□     تحلية □    أبار□    صحة□      زمزم      تشربينه؟ الذي الماء نوع ما .49
 □لا□                  نعم:    الحمل أثناء مضرة لمواد تعرضت هل .59
 الأولى أشهر 3 .89 الحمل قبل .79 النوع .69
  .111  .111 مبيدات حشريه .99
  .411  .311 مذيبات  .211
  .711  .611 بخور .511
  .111  .911 جوالات .811
  .311  .211 كمبيوتر .111
 
 □لا□                    نعم     الحمل؟ ناءأث عليك عاديه غير ضغوط هناك كان هل .411
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 □لا□                    نعم                   الحمل؟ أثناء عائلية مشاكل هناك كان هل .511
 لا    نعم الحلق؟      سقف شق أو الأرنبية بالشفة مصاب العائلة في أخر شخص هناك هل .611
 .....بنعم الإجابة كانت إذا
 نعلم لا □      الاثنين□          الحلق سقف شق□              لأرنبيةا ِبشفة□   :الشق مانوع .711
 العائلة؟ في من .811
 □        الأب من الجدة□       الأب من الجد□        الأم من الجدة □        الأم من الجد□          الأب□         الأم
                أخت□                     أخ□          الخال أبناء□   العم أبناء□       الأخوال□      الأعمام
 ____________أخرى□
 لا□                    الخلقية؟     نعم التشوهات من أخر نوع بأي مصاب العائلة في أخر شخص هناك هل .911
 .....بنعم الإجابة كانت إذا .121
 _______________التشوه؟ نوع ما .121
 العائلة؟ في من .221
 □        الأب من الجدة□       الأب من الجد□        الأم من الجدة □        الأم من الجد□          الأب□         الأم .321
                أخت□                     أخ□          الخال أبناء□   العم أبناء□       الأخوال□      الأعمام
 ____________أخرى□
 أقارب؟ الوالدين هل.52 .421
 لا□                    نعم□ .521
 .....بنعم الإجابة كانت إذا .621
                الأم أو الأب عم أو خال أبناء□                   عم أبناء □    العائلة؟ في من .721
 ______________أخرى□
 
 
  .... معنا تعاونكم على نشكركم
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A9: List of questionnaire code; Hospital code and code for each question: 
The Saudicleft main  
code the first two digit as the hospital code 
  the third digit is the group code(study or control) 
  the rest is the serial number of the patient 
Information: 
 
  Father's information   
DOB DOB in Hejry,  Gregorian  or just right the age. Whatever the patient remembers 
age 1=less than 20, 2=21-40, 3=41-60 
Work Type of occupation: teacher, physician, engineer, military…etc 
Monthly income This include the total monthly income of the family (father's salary+ mother's salary+ any other incomes) 
Education level His last educational level he reached at school 
  Child's information   
DOB da/mo/year 
place of birth name of hospital 
 government+Tertiary hospital=11 
 government+2ry  hospital=12 
 Private+Tertiary hospital=21 
 Private+2ry  hospital= 22 
  name of the city 
  name of the country 
child's nationality 
Saudi, middle east countries (other than Saudi), Asian countries, western countries, North Africa, other African 
countries. 
Neonatal weight ranging from 1 Kg to 4.5 KG 
Gestation weeks of pregnancy (from conception to delivery) 
Head circumference in CM 
Neonatal length in CM 
Is the child is single or 
twin 0=no twins 
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Description of the twins sex (1= same or 2= different) 
  1= both affected or only 2= one affected 
  Mother’s  information   
Name   
Nationality 1=Saudi 
  2= middle east countries (other than Saudi) 
  3=Asian countries, 
  4=western countries 
  5=North Africa 
  6= Other African countries 
residency name of the city country and region where she lived 3 months before and 3 months after her pregnancy  
describe the area you 
live in 1= Rural: if she lived in a community with a population less than one hundred thousand                    
  2=Metropolis/urban: if she lived in a big city with population greater than one million 
  3= Urban: if she lived in a population of about 500,000   
  4= Industrial: if she is living in a zone that is less than 10Km from industries and factories 
Work Type of occupation: teacher, physician, engineer, military…etc 
Education level Her last educational level she reached at school 
region In which of he 13 regions in Saudi Arabia you lived 3 months before and 3 months after your pregnancy  
Height In cm to measure BMI of the mother 
Weight  the mother weight just before she got pregnant in Kg to measure her BMI  
number of children The total number of children the mother delivered including the cleft child and the still-berths 
The order of the child 
between his siblings The cleft child position among sibs (including abortions and stillbirths from the same mother) 
  1= 1st 
  2= 2nd 
  etc... 
duration between 
mother pregnancy with 
cleft child and the one 
before The number of years between the delivery of the cleft child  and the child before. 
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  1= if  1 year or less 
  2= if 2 year or less but more than 1 year 
  etc... 
The number of 
miscarriages the mother 
had 0= no miscarriage 
  1= only one miscarriage 
  2= two miscarriages 
  3= three miscarriages 
  etc... 
  Water intake:   
The type of water the 
mother drank during the 
3months before and 
after pregnancy  1= tap water 
  2= bottled water 
  3= Zamzam 
If the mother drank 
bottled water, please 
specify the origin of the 
water by writing the name of the product we can find out where the water came from 
The amount of flour 
intake:   
How many days per 
week you cook with flour 0= do not cook with flour 
  1= once a week 
  2=twice a week 
  etc... 
How many days per 
week you eat food 
containing flour  like bread, cereals and other containing flour product 
The name of flour 
product they use To know the origin of the flour. Most of the Saudi people either use Saudi or Kuwaiti flour  
  1=Saudi flour 
  2=Kuwaiti flour 
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Pregnancy: 
 Follow up with Dr:   
Before pregnancy 0=never 
  1=once 
  2=twice 
  3=three times 
In the first trimester 0=never 
  1=once 
  2=twice 
  3=three times 
Was the pregnancy 
planned 1=yes 
  2=no 
Medication used   
Antibiotics In the three 
months before 
pregnancy 1=yes: dose & duration 
  2=no 
Antibiotics In the three 
months after pregnancy 1=yes: dose & duration 
  2=no 
Folic acid In the three 
months before 
pregnancy 1=yes: dose & duration 
  2=no 
Folic Acid In the three 
months after pregnancy 1=yes: dose & duration 
  2=no 
Folic acid with 
multivitamins In the 
three months before 
pregnancy 1=yes: dose & duration 
  2=no 
Folic Acid with 
multivitamins In the 
1=yes: dose & duration 
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three months after 
pregnancy 
  2=no 
Multivitamins In the 
three months before 
pregnancy 1=yes: dose & duration 
  2=no 
Multivitamins In the 
three months after 
pregnancy 1=yes: dose & duration 
  2=no 
Iron In the three months 
before pregnancy 1=yes: dose & duration 
  2=no 
Iron In the three months 
after pregnancy 1=yes: dose & duration 
  2=no 
Sickness Drug  In the 
three months before 
pregnancy 1=yes: dose & duration 
  2=no 
Sickness Drug  In the 
three months before 
pregnancy 1=yes: dose & duration 
  2=no 
Cortisone In the three 
months after pregnancy 1=yes: dose & duration 
  2=no 
Cortisone In the three 
months before 
pregnancy 1=yes: dose & duration 
  2=no 
Anticonvulsant In the 
three months after 
pregnancy 1=yes: dose & duration 
  2=no 
Anticonvulsant In the 
three months before 
1=yes: dose & duration 
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pregnancy 
  2=no 
Insulin In the three 
months after pregnancy 1=yes: dose & duration 
  2=no 
Insulin In the three 
months before 
pregnancy 1=yes: dose & duration 
  2=no 
Contraceptive In the 
three months before 
pregnancy 1=yes: dose & duration 
  2=no 
Contraceptive In the 
three months after 
pregnancy 1=yes: dose & duration 
  2=no 
Exposure to X-ray 3 
month before pregnancy 1=yes: number of times 
  2=no 
Exposure to X-ray 3 
month after pregnancy 1=yes: dose & duration 
  2=no 
Frequency of 
Ultrasound examination 
before pregnancy  1=yes: number of times 
  2=no 
Frequency of 
Ultrasound examination 
3 months after 
pregnancy  1=yes: number of times 
  2=no 
  Disease    
Viral infection in the 3 
month before pregnancy Onset of the disease and duration 
  0=not affected 
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  1= mild infection 
  2= mod 
  3=severe 
viral infection in the 3 
month after pregnancy Onset of the disease and duration 
  0=no 
  1= mild  
  2= mod 
  3=severe 
  2=no 
Flu in the 3 month 
before pregnancy Onset of the disease and duration 
  1= mild  flu 
  2= mod 
  3=severe 
Flu in the 3 month after 
pregnancy Onset of the disease and duration 
  1= mild  flu 
  2= mod 
  3=severe 
Fever in the 3 month 
before pregnancy Onset of the disease and duration 
  0=no fever 
  1= mild  
  2= mod 
  3=severe 
Fever in the 3 month 
after pregnancy Onset of the disease and duration 
  0=no fever 
  1= mild  
  2= mod 
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  3=severe 
High blood pressure in 
the 3 month before 
pregnancy 0=no HBP 
  1=mild, when the BP range from 140/90 to 160/110 
  2=sever if BP was greater than 160/110 
High blood pressure in 
the 3 month after 
pregnancy 0=no HBP 
  1=mild, when the BP range from 140/90 to 160/110 
  2=sever if BP was greater than 160/110 
Diabetes in the 3 month 
before pregnancy 1=yes: onset of the disease and duration 
  2=no 
Diabetes in the 3 month 
after pregnancy 1=yes: onset of the disease and duration 
  2=no 
49. Depression  in the 3 
month before pregnancy 1=yes: onset of the disease and duration 
  2=no 
49. Depression  in the 3 
month after pregnancy 1=yes: onset of the disease and duration 
  2=no 
50. Convulsion in the 3 
month before pregnancy 1=yes: onset of the disease and duration 
  2=no 
50. Convulsion in the 3 
month after pregnancy 1=yes: onset of the disease and duration 
  2=no 
51. Renal disease in the 
3 month before 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
51. Renal disease in the 
3 month after pregnancy 1=yes: onset of the disease and duration 
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  2=no 
52. Liver Disease in the 
3 month before 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
52. Liver Disease in the 
3 month after pregnancy 1=yes: onset of the disease and duration 
  2=no 
53. Vaginal Bleeding in 
the 3 month before 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
53. Vaginal Bleeding in 
the 3 month after 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
54. Chronic Disease in 
the 3 month before 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
54. Chronic Disease in 
the 3 month after 
pregnancy 1=yes: onset of the disease and duration 
  2=no 
55. Asthma in the 3 
month before pregnancy onset of the disease and duration 
  0=no Asthma 
  1= mild Asthma 
  2= mod 
  3=severe 
55. Asthma in the 3 
month after pregnancy onset of the disease and duration 
  0=no Asthma 
  1= mild Asthma 
  2= mod 
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  3=severe 
56. Abdominal pain in 
the 3 month before 
pregnancy  by giving the patient a pain score from 1 to 10 
  0=no pain 
  1=mild, if the patient give a score less than 5 
  2=moderate, if the patient give a score of 5 
  3=severe, if the patient give a score more than 5 
56. Abdominal pain in 
the 3 month after 
pregnancy  by giving the patient a pain score from 1 to 10 
  0=no pain 
  1=mild, if the patient give a score less than 5 
  2=moderate, if the patient give a score of 5 
  3=severe, if the patient give a score more than 5 
57. Severe morning 
sickness in the 1st 
trimester 1=yes, if the number of vomiting is more than 6, then mention the duration 
  2=no 
58. Threatened Abortion 
in the first trimester 1=yes: onset of the disease and duration 
  2=no 
    
Exposed to chemicals   
Cyanides 3 months before 
pregnancy 0=not exposed 
  1= exposed 1-3 days 
  2=exposed 4-6 days 
  3 exposed more than 7 days 
Cyanides exposure in the 
1st trimester 0=not exposed 
  1= exposed 1-3 days 
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  2=exposed 4-6 days 
  3 exposed more than 7 days 
Pesticides exposure 3 
months before pregnancy 0=not exposed 
  1= exposed 1-3 days 
  2=exposed 4-6 days 
  3 exposed more than 7 days 
Pesticides exposure in the 
1st trimester 0=not exposed 
  1= exposed 1-3 days 
  2=exposed 4-6 days 
  amount: 1=one room (low amount) , 2=all the house(large amount) 
  3 exposed more than 7 days 
Pollutant exposure 3 
months before pregnancy 0=not exposed 
  1= exposed 1-3 days 
  2=exposed 4-6 days 
  3 exposed more than 7 days 
Pollutant exposure in the 
1st trimester 0=not exposed 
  1= exposed 1-3 days 
  2=exposed 4-6 days 
  3 exposed more than 7 days 
Computer exposure in the 
3 months before 
pregnancy 
multiply the numbers of hours per day with the days to get the total hours exposure in the 3 months before 
pregnancy 
  0=not exposed 
  1= exposed <30 hours  
  2=exposed 30-60 hours 
  3= exposed more than 60 hours 
Computer exposure in the multiply the numbers of hours per day with the days to get the total hours exposure in the 3 months before 
388 
 
1st trimester pregnancy 
  0=not exposed 
  1= exposed <30 hours  
  2=exposed 30-60 hours 
  3= exposed more than 60 hours 
Microwaves exposure in 
the 3 months before 
pregnancy 
multiply the numbers of hours per day with the days to get the total hours exposure in the 3 months before 
pregnancy 
  0=not exposed 
  1= exposed <30 hours  
  2=exposed 30-60 hours 
  3= exposed more than 60 hours 
Microwaves exposure in 
the 1st trimester 
multiply the numbers of hours per day with the days to get the total hours exposure in the 3 months before 
pregnancy 
  0=not exposed 
  1= exposed <30 hours  
  2=exposed 30-60 hours 
  3= exposed more than 60 hours 
  Smoking   
Did the mother smoke 
smoking tobacco 3 months 
before pregnancy 
multiply the number of cigarette with the number of days in the three months to get the total cigarette used per 
3months 
  0=did not 
  1=30 cigarette /3 month before pregnancy 
  2=31-60 cigarette /3 month before pregnancy 
  3=61-90 
  4=91-180 
  5=181-270 
  6=171-450 
  6=more than 450 
Did the mother smoke 
multiply the number of cigarette with the number of days in the three months 
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smoking tobacco in the 1st 
trimester 
  0=did not 
  1=30 or less cigarette /3 month after pregnancy 
  2=31-60 
  3=61-90 
  4=91-180 
  5=181-270 
  6=171-450 
  6=more than 450 
Did the mother smoke 
Sheesha 3 months 
before pregnancy multiply the number of sheesha with the number of days in the three months 
  0=did not 
  1=<10 times smoked sheesha in 3 months before pregnancy 
  2=11-30 times 
  3=31-60 times 
  more than 60 
Did the mother smoke 
Sheesha in the 1st 
trimester multiply the number of sheesha with the number of days in the three months 
  0=did not 
  1=<10 times smoked sheesha in 3 months after pregnancy 
  2=11-30 times 
  3=31-60 times 
  more than 60 
Did the father smoke 
smoking tobacco 3 months 
before pregnancy multiply the number of cigarette with the number of days in the three months 
  0=did not 
  1=30 or less cigarette /3 month before pregnancy 
  2=31-60 
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  3=61-90 
  4=91-180 
  5=181-270 
  6=171-450 
  6=more than 450 
Did the father smoke 
smoking tobacco 3 months 
after pregnancy multiply the number of cigarette with the number of days in the three months 
  0=did not 
  1=30 or less  cigarette /3 month after pregnancy 
  2=31-60 
  3=61-90 
  4=91-180 
  5=181-270 
  6=171-450 
  6=more than 450 
Did the father smoke 
Sheesha 3 months 
before pregnancy multiply the number of sheesha with the number of days in the three months 
  0=did not 
  1=<10 times smoked sheesha in 3 months before pregnancy 
  2=11-30 times 
  3=31-60 times 
  more than 60 
Did the father smoke 
Sheesha in the 1st 
trimester multiply the number of sheesha on the number of days in the three months 
  0=did not 
  1=<10 times 
  2=11-30 times 
  3=31-60 times 
  more than 60 
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passive smoking exposure to someone else's smoking during 3 months before or after conception 
  1= yes 
  2= no 
  Stress   
Family problems  including divorce, death in the family and conflicts during the 3 month before pregnancy and the 1st trimester 
  1= yes 
  2= no 
Do you think you were 
under pressure during 
the 3 month before 
pregnancy and the 1st 
trimester?   
  1= yes 
  2= no 
  sanguinity:   
are the parents 
relatives? 1= yes 
  2= no 
what is the relation 
between the parents 0=no relation 
  1=1st degree cousin 
  2=1st cousin once removed 
  3=2nd degree cousin 
  4=same tribe 
  Family History:   
Any other member of 
the family affected? affected with any birth defect 
  1= yes 
  2= no 
What is the defect this 
family member has 0=no 
392 
 
  1=CLP 
  2=CP 
  3=limb abnormality 
  4=CV 
  5=other orofacial defects 
  6=genitourea 
  7=multiple defects 
  8=others 
What is his relation to 
the child? 1=sibling 
  2=parents 
  3=grandparents 
  4=uncle or aunt 
  5=cousin 
  Examination   
Have photos been taken 1= yes 
  2= no 
Was there prenatal 
diagnosis 1= yes 
  2= no 
    
Does the child have 
Pierre Robin  It is a malformation  or a sequence associated with micrognathia 
  1= yes 
Any associated 
abnormalities? 2= no 
  1= yes 
  2= no 
What is the associated 
abnormality 0=no 
  1=CV 
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  2=limbs malformation 
  polydactyly 
  Hydrocephaly 
  UT 
  other facial abnormality 
  others 
  Type of cleft   
Is the cleft syndromic or 
non-syndromic 1=Syndromic 
  2=nonsyndromic 
Name of the syndrome 0=no syndrome  
  1=Apert 
  2=Achondroplasia 
  3=Binder 
  4=Cleft lip and Palate - Di George's 
  5=Cleft lip and Palate - Pierre-Robin 
  6=Cleido-cranal dysplasia 
  7=Cranofacial microsomia 
  8=Crouzon 
  9=Goldenhar 
  10=Hemifacial microsomia 
  11=Mandibulofacial dysplasia (Treacher Collin's syndrome) 
  12=Oro-facial-digital 
    
Name of category of the 
cleft   
Simonart band   
Right side 1= yes 
  2= no 
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left side 1= yes 
  2= no 
    
cleft lip   
Right side 1= yes 
  2= no 
left side 1= yes 
  2= no 
    
Alveolus   
Right side 1= yes 
  2= no 
left side 1= yes 
  2= no 
    
Hard Palate 1= yes 
  2= no 
    
Soft Palate 1= yes 
  2= no 
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A10: Final list of included medical centers, principle investigator (PI), date of research approval request and 
acceptance.  
City Name of the Hospital Person to contact Date of 
request 
Received 
Acceptance 
Jeddah King Fahad Hospital Dr. Hussain Alamary 21/8/2010 20/10/2010 
Al-Mesaadia Maternity Hospital Zamzam 21/8/2010 20/10/2010 
Al-Azeezia Maternity Hoapital Ibtissam 21/8/2010 20/10/2010 
King Abdulaziz University Hospital Prof. Najlaa Alamoudi 26/6/2010 26/7/2010 
King Abdulaziz Medical City (KAMC)  Mamoon Daghistani 
 Danya 
 Dr. Mosleh 
28/9/2010 12/12/2010 
King Fahad Military Hospital (KFMH) Dr. Manal Almalik 1/12/2010 16/2/2011 
Riyadh King Fahad Medical City (KFMC) Dr. Sari 7/9/2010 17/11/2010 
King Faisal Specialized Hospital (KFSH) Dr. Al-Johar 21/8/2010 IRB rejected the 
request  
King Abdulaziz Medical City (KAMC) Dr. Naser 27/12/2010 11/6/2011 
Maternity and Children Hospital+ King 
Saud Medical City (KSMC) 
Dr. Mostafa 
 
10/10/2010 25/3/2011 
King Fahad Armed Hospital Dr. Eman 1/4/2011 10/8/2011 
Maddina Maternity and children Hospital Dr. Fatma Daood 20/9/2010 2/2/2011 
1 
 
A11: DNA extraction using QAGEN Kit 
Laboratory procedure to Extract DNA using Qagen kit:  
 In a tube, add: Proteinase enzyme (20µl ) + buffer (200µl) +saliva sample (200µl) 
 Incubation 56ºC for 10 Min 
 Centrifuge 20S 
 Add to the mix:  ethanol (200µl) 
 Put on Vortex Maxi for 20 S to mix 
 Put on centrifuge for 20 S 
 Pour the mix in a spin columns tube that has Silica gel 
 Centrifuge for 1 Min/8000RPM 
 Add washing buffer to the mix twice. The first time with AW1 high concentration (500µl) 
then centrifuge 8000RPM for 1Min. the second time with AW2 low concentration (500µl) 
14,000RPM for 2Min then 8000RPM for 4Min. In each time remove the leftover liquid in the 
tube 
 Finally, add elution buffer and incubate for 30 Min. 
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A12: Research ethical approvals  
3 
 
 
4 
 
 
 
5 
 
 
 
 
6 
 
 
 
 
7 
 
 
 
 
8 
 
 
9 
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A13: Distribution of the sample according to cleft phenotype and hospital 
of referral. 
City Hospital CL (%) CLP (%) CP (%) NSOFC (%) Control  
Jeddah 
71 cases 
104 controls 
 
 
King Fahad hospital 
and Mossadia 
Maternity Hoswpital 
5 (29.4) 5 (29.4) 7 (41.2) 17 (100) 24 
King Abdulaziz 
University Hospital 
5 (25) 11 (55) 4 (20) 20 (100) 30 
King Abdulaziz 
Medical City 
7 (31.8) 14 (63.6) 1 (4.5) 22 (100) 33 
King Fahad Armed 
Hospital 
7 (77.8) 1 (11.1) 1 (11.1) 9 (100) 12 
Alazizia Maternity 
Hospital  
2 (66.7) 0 1 (33.3) 3 (100) 5 
Riyadh  
100 case 
103 controls 
King Fahad Medical 
City 
5 (29.4) 5 (29.4) 7 (41.2) 17 (100) 17 
King Saud Medical 
City 
14 (46.7) 8 (26.7) 8 (26.7) 30 (100) 33 
Riyadh Armed Hospital 11 (44) 11 (44) 3 (12) 25 (100) 24 
Riyadh NGH 7 (25) 10 (35.7) 11 (39.3) 28 (100) 29 
Maddina  
34 cases  
37 controls 
Maddina maternity and 
children hospital 
15 (44.1) 9 (26.5) 10 (29.4) 34 (100) 37 
Total  78 (38) 74 (36.8) 53 (25.8) 205* (100) 244  
*The number is less than the total number of cases (208) as the phenotype for three cases was missing.  
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A14: Distribution of the sample according to child's nationality 
Countries  Study (%) Control (%) Total (%) 
Saudi  183 (88.4) 214 (87.7) 400 (88.1) 
Other Middle East countries 16 (7.7) 15 (6.1) 31 (6.8) 
Asian country  6 (2.9) 6 (2.5) 12 (2.6) 
North Africa 2 (1) 5 (2) 7 (1.5) 
Other African countries  0 4 (1.6) 4 (0.9) 
Total 208 (100) 244 (100) 454 (100) 
P= 0.32 
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A15: Case-control comparison according to cleft phenotype and maternal 
ingestion of multivitamins in the pre-gestation and 1st trimester 
periods. 
 
Duration     Multi-
vitamins use 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-gestation 
X
2
 =2.37 
df=3 
P= 0.5  
Yes  9 (4.4) 3 (3.9) 5 (6.8) 1 (1.9) 8 (3.3) 
No  194 (95.6) 73 (96.1) 69 (93.2) 52 (98.1) 236 (96.7) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.401 0.79 0.19 0.58  
OR  
(95% CI) 
1.5  
(0.58–3.9) 
1.2  
(0.31–4.67) 
2.12  
(0.67–6.69) 
0.56  
(0.07–4.58) 
 
1st trimester 
X
2
 =2.4 
df=3 
 P= 0.494 
Yes 38 (18.8) 13 (17.1) 12 (16.4) 13 (24.5) 53 (21.7) 
No 164 (81.2) 63 (82.9) 61 (83.6) 40 (75.5) 191 (78.3) 
Total 202
C
 (100) 76
C
 (100) 73
C
 (100) 53 (100) 244 (100) 
P-value 0.465 0.38 0.31 0.656  
(95% CI) 0.84  
(0.53–1.3) 
0.74  
(0.38–1.45) 
0.7  
(0.35–1.4) 
1.15  
(0.58–2.31) 
 
C 
number less than the total sample (NSOFC: 205; CL; 78 and CLP: 74) because of missing 
information 
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A16: Case-control comparison according to cleft sub-phenotype and 
maternal ingestion of iron during the three month pre-gestation and 
1st trimester periods. 
 
Duration  Iron use NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-gestation 
X
2
 =1.5 
df=3 
P= 0.683 
 
Yes  15 (7.4) 7 (9.2) 6 (8.2) 2 (3.8) 12 (4.9) 
No  187 (92.6) 69 (90.8) 67 (91.8) 51 (96.2) 232 (95.1) 
Total 202
C 
(100) 76
C 
 (100) 73
C 
 (100) 53 (100) 244 (100) 
P-value 0.213   0.17 0.29 0.71  
OR  
(95% CI) 
1.63  
(0.75–3.53) 
1.95  
(0.74–5.15) 
1.72  
(0.62–4.75) 
0.75  
(0.16–3.45) 
 
1st
 
Trimester 
X
2
 =5.04 
df=3 
P= 0.169 
Yes  69 (34.1) 25 (32.9) 24 (32.9) 20 (37.7) 92 (37.7) 
No  133 (65.9) 51 (67.1) 49 (67.1) 33 (62.3) 152(62.3) 
Total 202 (100) 76
 C 
 (100) 73
 C 
 (100) 53 (100) 244 (100) 
P-value 0.353 0.43 0.43 0.95  
OR  
(95% CI) 
     0.83  
(0.56–1.23) 
     0.81  
(0.47–1.39) 
0.8  
(0.46–1.39) 
     0.98  
(0.53–1.8) 
 
C 
number less than the total sample (NSOFC: 205; CL; 78 and CLP: 74) because of missing information 
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A17: Case-control comparison according to cleft phenotype and maternal 
renal disease during the three month pre-gestation and 
the1st trimester periods. 
 
Duration  Renal 
disease 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) 
Controls 
(%) 
Pre-gestation  
X
2
 =3.54 
df= 3 
P= 0.316 
Yes  6 (3.4) 1 (1.3) 2 (2.7) 3 (5.7) 4 (1.7) 
No  198 (96.6) 76 (98.9) 72 (97.7) 50 (94.3) 238 (98.3) 
Total 204
C
 (100) 77
C
  (100) 74 (100) 53 (100) 242 (100) 
P-value 0.234 0.84 0.56 0.09  
OR  
(95% CI) 
2.09  
(0.6–7.25) 
0.8  
(0.09–7.28) 
1.67 (0.3-
9.34) 
3.53  
(0.77–16.24) 
 
1st trimester 
 X
2
 =3.55 
df= 3 
P= 0.314 
Yes  6 (2.9) 4 (5.3) 0 2 (3.8) 8 (3.3) 
No  198 (97.1) 73 (94.7) 74 (100) 51 (96.2) 234 (96.7) 
Total 204
c
 (100) 77
c
  (100) 74 (100) 53 (100) 242 (100) 
P-value 0.957 0.452 0.252 0.88  
OR  
(95% CI) 
1.03  
(0.37–2.9) 
1.6  
(0.48–5.61) 
a 
1.13  
(0.23–5.49) 
 
a. The OR and CI were not measured because one group contains zero value. 
C
 Number less than the total cases (NSOFC: 205; CL: 78; and CP:53) because of missing information. 
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A18: Case-control comparison according to cleft phenotype and maternal 
asthma during the three month pre-gestation and 1st trimester 
periods. 
Duration  Asthma NSOFC (%) CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-gestation 
X
2
 =2.63 
df= 3 
P= 0.452 
Yes  5 (2.4) 1 (1.3) 3 (4.1) 1 (1.9) 3 (1.2) 
No  199 (97.6) 76 (98.7) 71 (95.9) 52 (98.1) 239 (98.8) 
Total 204
 c
 (100) 77
c
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.34 0.968 0.143 0.714  
OR  
(95% 
CI) 
1.9  
(0.47–8.4) 
1.05  
(0.11–10.46) 
3.39  
(0.67–17.15) 
1.5  
(0.15–14.84) 
 
1st 
trimester 
X
2
 =0.49 
df= 3 
P= 0.92 
Yes  4 (1.9) 1 (1.3) 2 (2.7) 1 (1.9) 6 (2.5) 
No  202 (98.1) 76 (98.7) 72 (97.3) 52 (98.1) 233 (97.5) 
Total 206 (100) 77 (100) 74 (100) 53 (100) 239 (100) 
P-value 0.701 0.55 0.91 0.79  
OR  
(95% CI) 
0.78  
(0.22–2.8) 
0.53  
(0.06–4.47) 
1.1  
(0.22–5.56) 
0.75  
(0.09–6.34) 
 
C
 Number less than the total cases (NSOFC: 205; CL: 78; and CP:53) because of missing information. 
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A19: Case-control comparison according to maternal convulsions during the 3 
month pregestation period. 
 
Convulsions NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes  1 (0.4) 0 1 (1.4) 0 1 (0.4) 
No 204 (99.6) 78 (100) 73 (98.6) 53 (100) 238 (99.6) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 239
C
 (100) 
P-value 0.91 0.57 0.37 0.64  
OR 
(95% CI) 
1.17 
(0.073–18.8) 
a 
3.32 
(0.21–53.7) 
a 
 
X
2
 =6.65, df= 3, P= 0.585 
a. The OR and CI were not measured because one group contains zero value. 
C
 Number less than the total number (controls: 244) because of missing information. 
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A20: Case-control comparison according to maternal high blood pressure during the three 
months pre-gestation and 1st trimester periods. 
Duration 
High blood 
pressure 
NSOFC (%) CL (%) CLP (%) CP (%) Controls(%) 
Pre-
gestation  
X
2
 =0.84 
df= 3 
P= 0.84 
Yes  4 (1.9) 1 (1.3) 2 (2.7) 1 (1.9) 4 (1.7) 
No  201 (98.1) 77 (98.7) 72 (97.3) 52 (98.1) 238 (98.3) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 242
C 
(100) 
P-value 0.824 0.819 0.573 0.91  
OR  
(95% CI) 
1.17 
(0.29–4.75) 
0.77 
(0.09–7.02) 
21.65 
(0.3–9.2) 
1.14 
(0.13–
10.45) 
 
1st 
trimester  
X
2
 =1.91 
df= 3 
P= 0.592 
Yes  5 (2.4) 1 (1.3) 3 (4.1) 1 (1.9) 5 (1.7) 
No  200 (97.6) 77 (98.7) 71 (95.9) 52 (98.1) 237(98.3) 
Total 205(100) 78 (100) 74 (100) 53 (100) 242
C
 (100) 
P-value 0.93 0.66 0.226 0.914  
OR  
(95% CI) 
0.94 
(0.25–3.54) 
0.62 
(0.07–5.35) 
2.48 
(0.54–11.35) 
1.14 
(0.12–10.3) 
 
C
 Number less than the total number (controls: 244) because of missing information. 
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A21: Case-control comparison according to cleft phenotype and 
vaginal bleeding during the 1st trimester. 
 
vaginal bleeding NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes  15 (7.4) 4 (5.3) 7 (9.6) 4 (7.5) 10 (4.1) 
No  189 (92.6) 73 (94.7) 67 (90.4) 49 (92.5) 232 (95.9) 
Total 204
C 
 (100) 77
 C 
(100) 74 (100) 53 (100) 242
C 
 (100) 
P-value 0.1 0.692 0.07 0.3  
OR  
(95% CI) 
2 (0.87–4.4) 
1.3 (0.4–
4.28) 
2.44 (0.89–
6.66) 
1.87 (0.56–
6.21) 
 
X
2
 =3.37, df=3 and P= 0.338
 
C
 Number less than the total number (NSOFC: 205 cases, CL: 78 cases and controls: 244) 
because of missing information. 
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A22: Case-control comparison according to cleft phenotype and maternal 
use of contraceptives in the pre-gestation and 1st trimester periods. 
Duration  Contra-
ceptives 
NSOFC (%) CL (%) CLP (%) CP (%) Controls 
(%)   
Pre-gestation 
X
2
 =3.73 
df=3 
P= 0.292 
Yes 15 (7.8) 3 (3.9) 7 (9.7) 5 (9.4) 27 (11.1) 
No 189 (92.2) 75 (96.1) 66 (90.3) 48 (90.6) 217 (88.9) 
Total 204
C
  (100) 78 (100) 73
C
 (100) 53 (100) 244 (100) 
P-value 0.249 0.069 0.721 0.71  
OR 
(95% CI) 
0.68 
(0.36–1.31) 
0.32 
(0.1–1.09) 
0.85 
(0.36–2.05) 
0.83 
(0.3–2.25) 
 
1st trimester 
X
2
 =1.5 
df=3 
P= 0.884 
Yes 3 (1.5) 1 (1.3) 1 (1.4) 1 (1.9) 6 (2.5) 
No 202 (98.5) 77 (98.7) 73 (98.9) 52 (98.1) 238 (97.5) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 244 (100) 
P-value 0.449 0.55 0.57 0.79  
OR 
(95% CI) 
0.59 
(0.15–2.37) 
0.53 
(0.06–4.45) 
0.55 
(0.07–4.61) 
0.75 
(0.09–6.39) 
 
C 
number less than the total sample (NSOFC: 205; and CLP: 74) because of missing information 
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A23: Case-control comparison according to cleft phenotype and maternal 
use of progesterone tablet in the pre-gestation and 1st trimester 
periods. 
 
Progesterone NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes  13 (6.3) 5 (6.4) 6 (8) 2 (3.8) 24 (10) 
No 192 (93.7) 73 (93.6) 68 (92.0) 51 (96.2) 217 (90) 
Total 205 (100) 78 (100) 74 (100) 53 (100) 241
C
 (100) 
P value 0.171 0.347 0.636 0.168  
OR  
(95% CI) 
0.61 
(0.3-1.24) 
0.62  
(0.23-
1.68) 
0.8  
(0.31-2.03) 
0.35  
(0.08-1.55) 
 
X
2
=2.55, df=2 and P= 0.279
                                                                                                                                                                           
C 
number less than the total controls (244) because of missing information 
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A24: Case-control comparison according to cleft phenotype and maternal 
experience of threatened abortion in the 1st trimester period. 
 
Threatened 
abortion 
NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Yes  12 (6.3) 4 (5.3) 6 (8.2) 2 (3.8) 11 (4.5) 
No  192 (93.7) 73 (94.7) 68 (91.8) 51 (96.2) 231 (95.5) 
Total 204
C
 (100) 77
C
  (100) 74 (100) 53 (100) 242 (100) 
P-value 0.533  0.815  0.241  0.79  
OR 
(95% CI) 
1.31 
(0.56–3.03) 
1.18 
(0.36–3.81) 
1.86 
(0.67–5.23) 
0.804 
(0.18–3.78) 
 
X
2
 =1.66, df=3, P= 0.654  
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A25: Case-control comparison according to cleft phenotype and 
severe morning sickness in the 1st trimester period. 
Severe morning 
sickness 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls (%)   
Yes  21 (10.3) 8 (10.7) 6 (8.2) 7 (13.2) 20 (8.3) 
No 183 (89.7) 69 (89.3) 68 (91.8) 46 (868) 222 (91.7) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.38 0.567 0.966 0.27  
OR 
(95% CI) 
1.33 
(0.7–2.5) 
1.29 
(0.54–3.05) 
0.98 
(0.38–2.55) 
1.67 
(0.67–4.17) 
 
X
2
 =1.44, df= 3, P= 0.7 
C 
number less than the total sample (NSOFC: 205; and CL:78) because of missing information 
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A26: Case-control comparison according to NSOFC phenotype and maternal 
abdominal pain in the three month pre-gestation and 1st trimester 
periods. 
Duration  Pain NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Pre-
gestation  
X
2
 =3.05 
df=3 
P= 0.385 
Yes  10 (4.9) 3 (4) 4 (5.7) 3 (5.7) 5 (2.1) 
No  194 (95.1) 74 (96) 70 (94.3) 50 (94.3) 237 (97.9) 
Total 204
C
 (100) 77
C 
(100) 74 (100) 53 (100) 242 (100) 
P-value 0.100 0.379 0.126 0.15  
OR  
(95% CI) 
2.43 
(0.82–7.23) 
1.97 
(0.46–8.4) 
2.71 
(0.7–10.36) 
2.81 
(0.65–12.13) 
 
1st 
trimester X
2
 
=8.15 
df=3 
P= 0.043** 
Yes  23 (11.2) 7 (8) 7 (9.6) 9 (17) 14 (5.8) 
No  181 (88.8) 70 (92) 67 (90.4) 44 (83) 228 (94.2) 
Total 204
C
 (100) 77
C
 (100) 74 (100) 53 (100) 242 (100) 
P-value 0.041** 0.312 0.272 0.004**  
OR 
(95% CI) 
2.06 
(1.03–4.11) 
1.63 
(0.63–4.19) 
1.7 
(0.7–4.39) 
3.56 
(1.43–8.83) 
 
** Significance value P≤ 0.05 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information 
 
 
 
 
 
 
24 
 
A27: Distribution of the sample according to cleft phenotypes and; their 
relationship to paternal waterpipe smoking types (Moasel and Jorak 
smoking); and maternal second hand paternal smoking, in the three 
month pregestation and 1st trimester period  
A27.1 case-controls comparison according to cleft phenotype and paternal Moasel smoking in the 
three month pregestation and 1st trimester period 
Period  Paternal 
Moasel 
NSOFC 
(%) 
CL (%) CLP (%) CP (%) Controls 
(%)   
Three 
month 
pregestation  
Yes  15 (7.3) 6 (8) 8 (10.8) 1 (1.9) 12 (4.9) 
No  190 (92.7) 70 (92) 66 (89.2) 52 (98.1) 232 (95.1) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P value       0.287 0.338 0.072 0.321   
OR (CI) 1.53 (0.7-
3.34) 
1.64 (0.59-
4.52) 
2.31 (0.91-
6) 
0.37 (0.05-
2.89) 
 
1
st
 trimester  Yes  
10 (5) 
7 (5.3) 8 (10.8) 0 9 (3.7) 
No  
191 (95) 
69 (94.7) 66 (89.2) 53 (100) 234 (96.3) 
Total 
203
C
 (100) 
76
C
 (100) 74 (100) 53 (100) 243 (100) 
P value 
0.51 
0.178 0.087 0.15  
OR (CI) 1.36 (0.54-
3.42) 
1.93 (0.73-
5.09) 
2.22 (0.87-
5.66) 
1.23 (1.16-
1.3) 
 
C
 Number less than the total number (NSOFC: 205 cases, and CL: 78 cases) because of missing 
information. 
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A27.2 case-controls comparison according to cleft phenotype and paternal Jorak smoking in 
the three month pregestation and 1st trimester period           
Period Smoking NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
pregestation 
Yes 15 (7.3) 5 (6.7) 8 (10.8) 1 (1.9) 3 (1.2) 
No 190 (93) 71 (93.3) 66 (89.2) 52 (98.1) 241 (98.8) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P value 0.001** 0.01** 0.000** 0.715  
OR (CI) 
6.34 (1.8-
22.23) 
5.58(1.3-
23.95) 
9.62 (2.48-
37.27) 
1.53 (0.16-
14.96) 
 
1
st
 trimester 
Yes 11 (5.5) 4 (5.4) 6 (8.2) 1(1.9) 3 (1.2) 
No 189 (94.5) 70 (94.6) 67 (91.8) 52 (98.1) 240 (98.8) 
Total 200
C
 (100) 74
C
 (100) 73
C
 (100) 53 (100) 243 (100) 
P value 0.01** 0.03** 0.002** 0.72  
OR (CI) 
4.66 (1.28-
16.93) 
4.55 (1-2-
.82) 
7.1 (1.73-
29.16) 
1.52 (0.16-
14.9) 
 
** Significant value P<0.05 
C
 Number less than the total number (NSOFC: 205 cases, and CL: 78 cases) because of missing 
information. 
 
A27.3 Case-control comparison according to cleft phenotype and maternal second-hand smoking 
among fathers using smoking tobacco in the pregestation and/or 1st trimester periods  
 
Fathers using 
smoking 
tobacco 
cases=57 
controls=77 
Maternal 2nd 
hand 
smoking 
CL (%) CLP (%) CP (%) 
Controls 
(%) 
Yes 7 (77.8) 18 (72) 13 (56.5) 35 (46.1) 
No 2 (22.2) 7 (28) 10 (43.5) 42 (53.9) 
Total 9 (100) 25 (100) 23 (100) 77 (100) 
OR 
(95% CI) 
4.1 
(0.8-21.03) 
10.54** 
(2.29-48.64) 
15.23** 
(1.9-122.3) 
 
X
2
 =7.28, df=3 and P= 0.063 
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A28: Case-control comparison according to cleft phenotype and maternal 
exposure to pesticides during the three month pre-gestation and 1st 
trimester periods. 
 
Duration  Pesticides  NSOFC (%) CL (%) CLP CP (%) Controls (%)   
Pre-
gestation 
X
2
=1.52 
df= 3 
P= 0.678 
Yes  31(15.1) 9 (11.8) 13 (17.6) 9 (17) 42 (17.2) 
No  173 (84.9) 68 (88.2) 61 (82.4) 44 (83) 202 (82.8) 
Total 204
C
 (100) 77
 C
  (100) 74 (100) 53(100) 244 (100) 
P-value 0.55 0.248 0.978 0.938  
OR  
(95% CI) 
0.86  
(0.52 - 1.42) 
0.64  
(0.29 - 1.38) 
1.01  
(0.51 - 2) 
0.97 
 (0.44 - 2.14) 
 
1st 
trimester 
X
2
=0.66df
= 3 
P= 0.882 
Yes  37 (18.1) 12 (15.8) 14 (18.9) 11 (20.8) 43 (17.6) 
No  167 (81.9) 65 (84.2) 60 (81.1) 42 (79.2) 201 (82.4) 
Total 204
C
 (100) 77
 C
  (100) 74 (100) 53 (100) 244 (100) 
P-value 0.99 0.741 0.769 0.568  
OR 
(95% CI) 
1 
(0.61 - 1.6) 
0.89 
(0.44 - 1.79) 
1.11 
(0.57 - 2.16) 
1.24 
(0.59 - 2.61) 
 
C 
number less than the total sample (NSOFC: 205; and CL: 78) because of missing information 
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A29: Distribution of the sample according to maternal exposure to 
microwaves and computers in the three month pregestation and the 
1st trimester 
 
A29.1: Distribution of the sample according to maternal exposure to microwaves in the 
three month pregestation and the 1st trimester 
Period  Microwaves use NSOFC (%) CL (%) CLP (%) CP (%) Controls (%)   
Three 
month 
pregestation  
Yes  84 (40.8) 34 (44.7) 25 (33.8) 22 (41.5) 117 (48) 
No  122 (59.2) 42 (55.3) 49 (66.2) 31 (58.5) 127 (52) 
Total 206 (100)  76 (100) 74 (100) 53 (100) 244 (100) 
P value 0.13 0.605 0.03** 0.38  
OR  
(95% CI) 
0.75 
(0.5-1.1) 
0.87 
(0.52-1.46) 
0.55  
(0.32-0.95) 
0.77 
(0.42-1.4) 
 
1
st
 trimester  Yes  84 (40.8) 36 (47.4) 24 (32.4) 23 (43.4) 117 (48) 
No  122 (59.2) 40 (52.6) 50 (67.6) 30 (56.6) 127 (52) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P value 0.127 0.958 0.021** 0.57  
OR (CI) 0.75 
(0.5-1.1) 
0.99  
(0.59-1.65) 
0.52 
(0.30-0.91) 
0.84 
(0.46-1.5) 
 
** Significant value P<0.05 
C
 Number less than the total number (NSOFC: 205 cases, and CL: 78 cases) because of missing 
information. 
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A29.2: Distribution of the sample according to maternal use of Computer in the three 
month pregestation and 1st trimester  
Period  Computer use NSOFC (%) CL (%) CLP (%) CP (%) Controls (%) 
Three month 
pregestation  
Yes 54 (26.3) 21 (27.6) 18 (24.7) 14 (26.4) 133 (29.6) 
No 151 (73.7) 55 (72.4) 55 (75.3) 39 (73.6) 316 (70.4) 
Total 202
C
 (100) 76
C
 (100) 73 (100) 53 (100) 449 (100) 
P value 0.16 0.478 0.235 0.43  
OR (CI) 0.75 (0.5-1.13) 0.81 (0.46-
1.44) 
0.7 (0.38-
1.27) 
0.77 (0.39-
1.49) 
 
1
st
 trimester  Yes 50 (24.3) 19 (25) 17 (23) 13 (24.5) 75 (30.7) 
No 155 (75.)7 57 (75) 57 (77) 40 (75.5) 169 (69.3) 
Total 203
C
 (100) 76
C
 (100) 74 (100) 53 (100) 244 (100) 
P value 0.13 0.376 0.223 0.4  
OR (CI) 0.72 (0.48-
1.1) 
0.77 (0.43-
1.38) 
0.69 
(0.37-
1.26) 
0.7(0.38-1.48)  
C
 Number less than the total number (NSOFC: 205 cases, and CL: 78 cases) because of missing 
information. 
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A30: P values for variables that showed statistical significant relationship 
with NSOFC, CL, CLP and/or CP in chi square, but were not 
statistically significant in logistic regression analysis. 
Variables NSOFC CL CLP CP 
Singletons Vs. Twins 0.39 0.912 0.12 a 
Antibiotic pregestation 0.063 a 0.14 a 
Anti-emetic medication a 0.131 a a 
Folic acid 1
st
 trimester 0.103 a a a 
Multivitamins 1
st
 trimester 0.901 a a a 
Illness pregestation 0.14 0.44 0.45 0.287 
Illness 1
st
 trimester 0.18 a a a 
Common cold/flu pregestation a 0.295 a 0.376 
Common cold/flu 1
st
 trimester 0.64 a a a 
Fever pregestation .0.4 a 0.33 a 
Mother under stress a 0.912 a a 
Family problems 0.37 a 0.85 0.604 
Abdominal pain 1
st
 trimester 0.21 a a a 
Paternal water pipe smoking a 0.23 a a 
Maternal incense exposure 
pregestation 
a 0.502 a a 
Chemical 1
st
 trimester a a 0.12 a 
Solvent pregestation a  0.33 a 
a. No values either because the variable were entered in the logistic regression or had 
significant relationship with cleft.  
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A31: Distribution of infant VAX1 rs4752028 genotypes in cases and control 
according to parental consanguinity. 
 
Consanguinity TT* CC CT Total 
Yes (%) 133 (57.8) 10 (76.9) 35 (45.5) 178 (55.6) 
No (%) 97(42.2) 3(23.1) 42 (54.4) 142 (44.4) 
Total (%) 230 (100) 13 (100) 77(100) 320(100) 
X
2
=6, df=2, P= 0.043** 
* Homozygous common allele genotype 
**Significant at the 0.05 level 
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A32: Distribution of infant VAX1 rs4752028 genotypes in cases and controls according to parental consanguinity.  
 
Consanguinity NSOFC CL/P CP Control 
 TT* CC CT TT* CC CT TT* CC CT TT* CC CT 
Yes    (%) 56 (60.9) 7  (70) 24 (45.1) 42 (60) 6 (66.7) 17 (43.6) 14 (63.6) 1 (100) 6 (50) 77 (55.8) 3 (100) 12 (46.2) 
No     (%) 36 (39.1) 3  (30) 28 (54.9) 28 (40) 3 (33.3) 22 (56.4) 8 (36.4) 0 6 (50) 61 (54.2) 0 14 (55.8) 
Total (%) 92 (100) 10 (100) 51 (100) 70 (100) 9 (100) 39 (100) 22 (100) 1 (100) 12 (100) 138 (100) 3 (100) 26 (100) 
Total infants 153
C
 118
C
 35
C
 167
C
 
X (df), P-value 4.19 (2), 0.123 4.88 (2), 0.087 1.89 (2), 0.39 3.31 (2), 0.19 
* Homozygous common allele genotype  
C
 Out of 120 CL/P, 35 CP, and 188controls recorded, two CL/P, and 22 controls did not have their genotyping and/or paternal consanguinity information 
completed
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A33: Comparison between case and control infant VAX1 rs4752028 genotypes and their relationship to parental 
consanguinity. 
 
Consanguinity TT* CC CT 
NSOFC CL/P CP Control NSOFC CL/P CP Contr
ol 
NSOFC CL/P CP Control 
Yes (%) 56         
(60.9) 
42          
(60) 
14  
(63.6) 
77 
(55.8) 
7      
(70) 
6    
(66.7) 
1   
(100) 
3   
(100) 
23     
(45.1) 
17       
(43.6) 
6       
(50) 
12 
(46.2) 
No (%) 36         
(39.1) 
28          
(40) 
8    
(36.4) 
61 
(54.2) 
3      
(30) 
3      
(33.3) 
0 0 28     
(54.9) 
22       
(56.4) 
6       
(50) 
14 
(55.8) 
Total (100%) 92 70 22 138 10 9 1 3 51 39 12 26 
OR       
   (95% CI) 
1.23      
(0.72-2.11) 
1.9      
(0.66-2.13) 
1.3   
(0.5-3.5) 
 a a a  1       
(0.39-2.57) 
0.9      
(0.33-2.44) 
1.17 
(0.3-4.6) 
 
X (df), P-value  1.17 (3), 0.77  1.33 (1), 0.514  0.41 (2), 0.813 
* Homozygous common allele genotype 
a. Not possible to analyse because the groups contain zero values  
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A34: Distribution of infant VAX1 rs7078160 genotypes in cases and 
controls according to parental consanguinity. 
 
Consanguinity GG* (%) AA (%) AG (%) Total (%) 
Yes 152 (59) 8 (61.5) 17 (39.5) 177 (56.5) 
No 105(41) 5(38.5) 26 (60.5) 136 (43.5) 
Total 257(100) 13 (100) 43(100) 313(100) 
X
2
=5.83, df=2, P= 0.054 
* Homozygous common allele genotype is the reference 
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A35: Comparison between case and control infant VAX1 r rs7078160 
genotypes and their relationship to parental consanguinity. 
 
Consang
uinity 
GG* AA AG 
NSOF
C 
CL/P CP Contr
ol 
NSO
FC 
CL/
P 
C
P 
Cont
rol 
NSO
FC 
CL/P CP Cont
rol 
Yes (%) 73 
(62) 
53 
(60.9
) 
20 
(66.7) 
79 
(56.4) 
6 
(54.5
) 
6 
(54
.4) 
0 2 
(100
) 
7 
(33.3
) 
6 
(33.3
) 
1 
(33.
3) 
10 
(45.5
) 
No (%) 44 
(38) 
34 
(39.1
) 
10 
(33.3) 
61 
(43.6) 
5 
(45.5
) 
5 
(45
.5) 
0 0 14 
(66.7
) 
12 
(66.7
) 
2 
(66.
7) 
12 
(54.5
) 
Total 
(100%) 
117 87 30 140 11 11 0 2 21 18 3 22 
OR 
(95% CI) 
1.26 
(0.77-
2.07) 
1.2 
(0.7-
2.08) 
1.29 
(0.5-
2.84) 
 a a a  0.6 
(0.17
-
2.06) 
0.6 
(0.16
-
2.18) 
0.6 
(0.0
4-
7.63
) 
 
X
2
(df), 
P-value 
 1.24 (2), 0.537  1.48 (1), 0.224  0.66 (2), 0.719 
* Homozygous common allele genotype 
a. Not possible to analyse because the groups contain zero values  
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A36: Distribution of infant VAX1 rs7078160 alleles in cases and 
controls with consanguineous parents. 
Allele type NSOFC (%) CL/P (%) CP (%) Control (%) 
G* 153 (89) 112 (86.6) 41 (97.7) 168 (92.3) 
A 19 (11) 18 (13.4) 1 (2.3) 14 (7.7) 
Total 172 (100) 134 (100) 42 (100) 182 (100) 
P-value 
OR (95% CI) 
0.28 
1.49 (0.72 - 3.07) 
0.081 
1.93 (0.92 - 4.04) 
0.29 
0.29 (0.04 – 2.29) 
 
X
2
=6.11, df=2, P= 0.047**  
* Common allele is the reference 
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A37: Maternal infant gene-gene interaction using log-linear model 
Table1: Interaction between the maternal and infant genotype variants among NSOFC 
for IRF6 rs2013162 
Mother gene 
variant 
Infant gene 
variant 
P value 
95% Confidence Interval 
Lower Bound Upper Bound 
CC CC 0.215 -.150- .669 
AA 0.000** -4.925- -1.666- 
CA 0.067 -.958- .033 
AA CC 0.000** -3.171- -1.223- 
AA 0.000** -2.887- -1.106- 
CA 0.000** -3.541- -1.357- 
CA CC 0.151 -.831- .128 
AA 0.000** -2.887- -1.106- 
CA a a a 
a. This parameter is set to zero because it is redundant.                                                    
Goodness of fit test was zero. 
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Table 2: Interaction between the maternal and infant genotype variants among 
NSOFC for IRF6 rs2235375 gene 
Mother gene 
variant 
Infant gene 
variant 
P value 
95 % CI 
Lower Bound Upper Bound 
CC GG 0.001** -2.525 -0.694 
CC 0.187 -.986 0.193 
CG 0.021** -1.457 -0.120 
GG GG 0.029** 0.054 0.997 
CC 0.001** -4.552 -1.266 
CG 0.393 -0.810 0.318 
CG GG 0.678 -0.660 0.429 
CC 0.071 -1.196 0.049 
CG a a a 
.a. This parameter is set to zero because it is redundant.                                                    
Goodness of fit test was zero. 
 
Table 3: Interaction between the maternal and infant genotype variants among 
NSOFC for VAX1 rs4752028 SNP 
Mother 
genotype 
Infant 
genotype 
P value CI 
Upper level Lower level 
CC CC 0.000** 3.273 3.922 
TT 0.000** -3.072 -1.114 
CT 0.000** -4.825 -1.559 
TT CC 0.000** -2.560 -0.891 
TT 0.003** -7.081 -1.500 
CT 0.000** 0.500 10.271 
CT CC 0.005** -1.451- -0.262 
TT 0.000** -2.789- -0.996 
CT 0.000** -2.368- -0.797 
Goodness of fit test was zero. 
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Table 4: Interaction between the maternal and infant genotype variants among 
NSOFC for VAX1 rs7078160 
Mother 
genotype 
Infant 
genotype 
P value CI 
Upper level Lower level 
GG AA 0.219 -1.678- 0.385 
AG 0.000** 1.721 2.987 
AA 1.000 -0.855- 0.855 
AA AA 0.075 -2.308- 0.111 
AG 0.219 -1.678- 0.385 
AA 0.075 -2.308- 0.111 
AG AA 0.133 -1.952- 0.257 
AG 0.426 -0.471- 1.117 
AA a a a 
a. This parameter is set to zero because it is redundant.                                                    
Goodness of fit test was zero. 
 
Goodness of fit test was zero. 
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A38: Relationship between maternal IRF6 rs2013162 variants and different 
environmental factors, including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic exposure using 
case-only study design. 
 
Maternal rs2013162 CC* (%) AA (%) CA (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
X
2
=2.88, df=2, P= 0.237 
N=163 
Yes 13 (17.3) 0 (0) 9 (11.7) 
No 62(82.7) 11 (100) 68 (88.3) 
P value 
OR (95% CI) 
 0.277 
a 
0.325 
0.63 (0.25-1.58) 
Antibiotic at 1st trimester 
X
2
=1.99, df=2, P= 0.369 
N=136 
Yes 9 (12.0) 1 (9.1) 15 (19.5) 
No 66 (88.0) 10 (90.9) 62 (80.5) 
P value 
OR (95% CI) 
 0.779 
0.73 (0.08-6.43)
 
0.21 
1.77 (0.72-4.35) 
Antipyretic medication pre-
gestation                               
X
2
=3.46, df=2, P= 0.177        
N=164 
Yes 6 (7.9) 2 (18.2) 3 (3.9) 
No 70 (92.1) 9 (81.8) 74 (96.1) 
P value 
OR (95% CI) 
 0.284 
2.59 (0.45-14.84) 
0.303 
0.47 (0.11-1.96) 
Antipyretic medication 1st 
trimester 
X
2
=7.67, df=2, P= 0.022** 
N=162 
Yes 4 (5.3) 3 (33.3) 9 (11.7) 
No 72 (94.7) 6 (66.7) 68 (88.3) 
P value 
OR (95% CI) 
 0.012** 
9 (1.62-49.91)
 
0.164 
2.38(0.7-8.1) 
Anti-emetic medication pre-
gestation 
X
2
=1.18, df=2, P= 0.554 
N=163 
Yes 1 (1.3) 0 (0) 0 (0) 
No 74 (98.7) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 
0.644 
a 
0.488 
a 
Anti-emetic medication 1st 
trimester 
X
2
=0.83, df=2, P= 0.659 
N=163 
Yes 9 (12.0) 2 (18.2) 13 (16.9) 
No 66 (88.0) 9 (81.8) 64 (83.1) 
P value 
OR (95% CI) 
 0.57 
1.63 (0.3-8.77)
 
0.39 
1.49 (0.6-3.73) 
Contraceptives pre-gestation 
X
2
=1.73, df=2, P= 0.421 
N=161 
 
Yes 8 (10.7) 0 (0) 5 (6.5) 
No 67 (89.3) 9 (100) 72 (93.5) 
P value 
OR (95% CI) 
 0.56 
a 
0.362 
0.58 (0.18-1.87) 
Contraceptives 1st trimester 
X
2
=0.56, df=2, P= 0.757 
N=163 
Yes 1 (1.3) 0 (0) 2 (2.6) 
No 74 (98.7) 11 (100) 75 (97.4) 
P value 
OR (95% CI) 
 
0.644 
a 
0.582 
1.97 (018-
22.23) 
Illness pre-gestation 
X
2
=2.24, df=2, P= 0.326 
N=163 
Yes 23 (30.7) 1 (9.1) 21 (27.3) 
No 52 (69.3) 10 (90.9) 56 (72.7) 
P value  0.168 0.64 
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OR (95% CI) 0.23 (0.03-1.87)  0.85 (0.42-1.71) 
Illness 1st trimester 
X
2
=1.37, df=2, P= 0.505 
N=163 
Yes 25 (33.3) 5 (45.5) 32 (51.6) 
No 50 (66.7) 6 (54.5) 45 (58.4) 
P value 
OR (95% CI) 
 0.434 
1.67 (0.46-6) 
0.3 
1.42 (0.73-2.75) 
Common cold/flu pre-gestation 
X
2
=5.25, df=2, P= 0.073 
N=145 
Yes 20 (26.7) 0 (0) 13 (16.9) 
No 55 (73.3) 11 (100) 46 (83.1) 
P value 
OR (95% CI) 
 0.145 
a 
0.537 
0.78 (0.35-1.73) 
Common cold/flu 1st trimester 
X
2
=6, df=2, P= 
N=163 
Yes 16 (21.3) 1 (9.1) 19 (24.7) 
No 59 (78.7) 10 (90.9) 58 (75.3)  
P value 
OR (95% CI) 
 0.358 
0.37 (0.04-3.1) 
0.625 
1.53 (0.74-3.16) 
Fever pre-gestation  
X
2
=7.37, df=2, P= 0.025** 
N=163 
Yes 13 (17.3) 0 (0) 4 (5.2) 
No 62 (82.7)  11 (100) 73 (94.8) 
P value 
OR (95% CI) 
 0.277 
a 
0.025** 
0.26 (0.08-0.84) 
Fever 1st trimester 
X
2
=4.37, df=2, P= 0.112 
N=163 
Yes 8 (10.7) 0 (0) 15 (19.5) 
No 67 (89.3)  11 (100) 62 (80.5) 
P value 
OR (95% CI) 
 0.475 
a 
0.135 
2.03 (0.8-5.11) 
Urinary tract infection pre-
gestation 
X
2
=45, df=2, P= 0.797 
N=162 
Yes 3 (4.0) 0 (0) 3 (3.9) 
No 72 (96.0) 11 (100) 73 (96.1) 
P value 
OR (95% CI) 
 0.946 
a
 
0.987 
0.99 (0.19-5.05) 
Urinary tract infection 1st 
trimester 
X
2
=0.61, df=2, P= 0.736 
N=162 
Yes 3 (4.0) 0 (0) 2 (2.6) 
No 72 (96.0) 11 (100) 74 (97.4) 
P value 
OR (95% CI) 
 
0.946 
a
 
0.641 
0.65 (0.11-34) 
High blood pressure pre-gestation 
X
2
=3.59, df=2, P= 0.166 
N=163 
Yes 3 (4.0) 0 (0) 0 (0) 
No 72 (96.0) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 
0.946 
a 
0.186 
a 
High blood pressure 1st trimester 
X
2
=4.81, df=2, P= 0.09 
N=163 
Yes 4 (5.3) 0 (0) 0 (0) 
No 71 (94.7) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 
0.808 
a 
0.129 
a
 
Diabetes pre-gestation 
a 
N=163 
Yes 0 (0) 0 (0) 0 (0) 
No 75 (100) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 
a a 
Diabetes 1st trimester 
X
2
=1.34, df=2, P= 0.51 
N=163 
Yes 1 (1.3) 0 (0) 3 (3.9) 
No 74 (98.7) 11 (100) 74 (96.1) 
P value 
OR (95% CI) 
 
0.644 
a 
0.346 
3 (0.31-29.51) 
Asthma pre-gestation Yes 2 (2.7) 0 (0) 1 (1.3) 
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X
2
=0.6, df=2, P= 0.74 
N=162 
No 73 (97.3) 11 (100) 75 (98.7) 
P value 
OR (95% CI) 
 
0.953 
a 
0.56 
2.9 (0.12-72.9) 
Asthma 1st trimester 
X
2
=3.55, df=2, P= 0.17 
N=162 
Yes 3 (4.0) 0 (0) 0 (0) 
No 72 (96.0) 11 (100) 76 (100) 
P value 
OR (95% CI) 
 0.946 
a 
0.189 
a 
Convulsions pre-gestation 
a 
N=163 
Yes 0 (0) 0 (0) 0(0) 
No 75 (100) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 a a 
Convulsions 1st trimester 
a 
N=163 
Yes 0 (0) 0 (0) 0(0) 
No 75 (100) 11 (100) 77 (100) 
P value 
OR (95% CI) 
 a a 
Vaginal bleeding 
X
2
=2.55, df=2, P= 0.28 
N=162 
Yes 3 (4.0) 0 (0) 7 (9.2) 
No 72 (96.0) 11 (100) 69 (90.8) 
P value 
OR (95% CI) 
 
0.946 
a 
0.21 
2.43 (0.61-9.8) 
Maternal exposure to X-ray 1st 
trimester 
X
2
=1.22, df=2, P= 0.544 
N=145 
Yes 23 (31.1)
 
1 (9.1) 3 (4.9) 
No 46 (62.2)
 
10 (90.9) 62 (95.4) 
P value 
OR (95% CI) 
 
0.136 
0.2 (0.02-1.66) 
<0.001**   0.09 
(0.03-0.34) 
Maternal supplement use 
Folic acid pre-gestation 
X
2
=8.24, df=2,P= 0.016** 
N=164 
Yes 2 (2.6) 2 (18.2) 12 (15.6) 
No 74 (97.4) 9 (81.8) 65 (84.4) 
P value 
OR (95% CI) 
 0.047** 
8.22 (1.03-65.72) 
0.014** 
6.83 (1.47-
31.66) 
Folic acid 1st trimester 
X
2
=3.17, df=2,P= 0205 
N=164 
Yes 43 (56.6) 4 (36.4) 49 (63.6) 
No 33 (43.4) 7 (63.6) 28 (36.4) 
P value 
OR (95% CI) 
 0.217 
0.44 (0.12-1.62) 
0.373 
1.34 (0.7-2.57) 
Multivitamins pre-gestation 
X
2
=3.01, df=2,P= 0.222 
N=164 
Yes 4 (5.3) 2 (18.2) 4 (5.2) 
No 72 (94.7) 9 (81.8) 73 (94.8) 
P value 
OR (95% CI) 
 
0.138 
4 (0.64-25.02) 
0.985 
0.99 (0.24-4.1) 
Multivitamins 1st trimester 
X
2
=4.65, df=2,P= 0.098 
N=163 
Yes 14 (18.7) 5 (45.5) 14 (18.2) 
No 61 (81.3) 6 (54.5) 63 (81.8) 
P value 
OR (95% CI) 
 3.63 (0.97-13.61) 0.97 (0.43-2.2) 
Iron pre-gestation 
X
2
=1.79, df=2,P= 0.408 
N=163 
Yes 6 (8.0) 2 (18.2) 5 (6.5) 
No 69 (92.0) 9 (81.8) 72 (93.5) 
P value 
OR (95% CI) 
 
0.292 
2.56 (0.45-14.63) 
0.721 
0.8 (0.23-2.74) 
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Iron 1st trimester 
X
2
=5, df=2,P= 0.082 
N=163 
Yes 29 (38.7) 1 (9.1) 21 (27.3) 
No 46 (61.3) 10 (90.9) 56 (72.7) 
P value 
OR (95% CI) 
 0.087 
0.16 (0.02-1.3) 
0.137 
0.59 (0.3-1.18) 
Calcium 1st trimester 
X
2
=1.23, df=2,P= 0.54 
N=163 
Yes 5 (6.7) 0 (0) 3 (3.9) 
No 70 (93.36) 11 (100) 74 (96.1) 
P value 
OR (95% CI) 
 0.699 
a  
0.45 
0.57 (0.13-2.46) 
Smoking 
Maternal smoking 
X
2
=6, df=2, P= 0.021** 
N=162 
Yes 3 (4.0) 2 (18.2) 1 (1.3) 
No 72 (96.0) 9 (81.8) 75 (98.7) 
P value 
OR (95% CI) 
 0.087 
5.33 (0.78-36.33) 
0.329 
0.32 (0.03-3.15) 
Paternal smoking 
X
2
=0.63, df=2, P= 0.731 
N=162 
Yes 25 (33.3) 5 (45.5) 27 (35.5) 
No 50 (66.7) 6 (54.5) 49 (64.5) 
P value 
OR (95% CI) 
 0.434 
1.67 (0.46-6) 
0.777 
1.1 (0.56-2.16) 
Paternal tobacco 
X
2
=2.27, df=2, P= 0.322 
N=162 
Yes 18 (24.0) 5 (54.5) 20 (26.3) 
No 57 (76.0) 6 (54.5) 56 (73.7) 
P value 
OR (95% CI) 
 0.143 
2.64 (0.72-9.68) 
0.743 
1.13 (0.54-2.36) 
Paternal waterpipe 
X
2
=1.96, df=2, P= 0.376 
N=162 
Yes 10 (13.3) 3 (27.3) 9 (11.8) 
No 65 (86.7) 8 (72.7) 67 (88.2) 
P value 
OR (95% CI) 
 0.24 
2.44 (0.55-10.76) 
0.783 
0.87 (0.33-2.29) 
Maternal passive smoking 
X
2
=5.29, df=2, P= 0.071 
N=162 
Yes 16 (21.3) 5 (45.5) 12 (15.8) 
No 59 (78.7) 6 (54.5) 64 (84.2) 
P value 
OR (95% CI) 
 
0.09 
3.07 (0.83-11.38) 
0.382 
0.69 (0.3-1.58) 
Maternal stress 
Family problems 
X
2
=3.41, df=2, P= 0.182 
N=162 
Yes 26 (34.7) 7 (63.6) 30 (39.5) 
No 49 (65.3) 4 (36.4) 46 (60.5) 
P value 
OR (95% CI) 
 0.076 
3.3 (0.88-12.31) 
0.541 
1.23 (0.63-2.38) 
Mother complains of being under 
stress 
X
2
=1.71, df=2, P= 0.425 
N=162 
Yes 32 (42.7) 7 (63.6) 34 (44.7) 
No 43 (57.3) 4 (36.4) 42 (55.3) 
P value 
OR (95% CI) 
 0.201 
2.35 (0.63-8.72) 
0.798 
1.08 (0.57-2.07) 
Depression pre-gestation 
X
2
=3.41, df=2, P= 0.181 
N=163 
Yes 0 (0) 0 (0) 3 (3.9) 
No 75 (100) 11 (100) 74(96.1) 
P value 
OR (95% CI) 
 
a a
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Depression 1st trimester 
X
2
=5.68, df=2, P= 0.059 
N=163 
Yes 2 (2.7) 2 (18.2) 3 (3.9) 
No 73 (97.3) 9 (81.8) 74(96.1) 
P value 
OR (95% CI) 
 
0.048** 
8.11 (1.01-64.84) 
0.673 
1.48 (0.24-9.12) 
Severe morning sickness 
X
2
=1.66, df=2, P= 0.44 
N=162 
Yes 10 (13.3) 0 (0) 10 (13.2) 
No 65 (86.7) 11 (100) 66 (86.8) 
P value 
OR (95% CI) 
 0.379 
a 
0.975 
0.98 (0.38-2.52) 
Threatened abortion 
X
2
=2.96, df=2, P= 0.23 
N=162 
Yes 2 (2.7) 1 (9.1) 7 (9.2) 
No 73(97.3) 10 (90.9) 69 (90.8)  
P value 
OR (95% CI) 
 
0.308 
3.65 (0.3-44.02) 
0.11 
3.7 (0.74-18.44) 
Abdominal pain pre-gestation 
X
2
=1.17, df=2, P= 0.558 
N=162 
Yes 2 (2.7) 0 (0) 4 (5.3) 
No 73 (97.3) 11 (100) 72 (94.7) 
P value 
OR (95% CI) 
 
0.877 
a 
0.423 
2.03 (0.36-
11.42) 
Abdominal pain 1st trimester 
X
2
=7.86, df=2, P= 0.02** 
N=162 
Yes 6 (8.0) 4 (36.4) 8 (10.5) 
No 69 (92.0) 7 (63.6) 68 (89.5) 
P value 
OR (95% CI) 
 0.013** 
6.57 (1.49-29.01) 
0.594 
1.35 (0.45-4.1) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-
gestation 
X
2
=3.77, df=2, P= 0.152 
Yes 25 (33.3) 6 (54.5) 20 (26.3) 
No 50 (66.7) 5 (45.5) 56 (73.7) 
P value 
OR (95% CI) 
 0.18 
2.4 (0.67-8.63) 
0.347 
0.71 (0.35-1.44) 
Exposure to chemicals 1st 
trimester 
X
2
=4.97, df=2, P= 0.083 
N=160 
Yes 25 (33.3) 6 (54.5) 18 (23.7) 
No 50 (66.7) 5 (45.5) 56 (76.3) 
P value 
OR (95% CI) 
 0.18 
2.4 (0.67-8.63) 
0.226 
0.64 (0.31-1.32) 
Exposure to solvents pre-gestation 
X
2
=1.83, df=2, P= 0.401 
N=162 
Yes 12 (16.0) 2 (18.2) 7 (9.2) 
No 63 (84.0) 9 (81.8) 69 (90.8) 
P value 
OR (95% CI) 
 
0.855 
1.17 (0.22-6.09) 
0.214 
0.53 (0.2-1.44) 
Exposure to solvents 1st trimester 
X
2
=4.07, df=2, P= 0.13 
N=162 
Yes 11 (14.7) 0 (0)  5 (6.6) 
No 64 (85.3) 11 (100) 71 (93.4) 
P value 
OR (95% CI) 
 0.34 
a 
0.115 
0.41 (0.14-1.24) 
Exposure to pesticides pre-
gestation 
X
2
=0.34, df=2, P= 0.84 
N=162 
Yes 11 (14.7) 1 (9.1) 12 (15.8) 
No 64 (85.3) 10 (90.9) 64 (84.2) 
P value 
OR (95% CI) 
 0.622 
0.58 (0.07-5) 
0.848 
1.09 (0.45-2.65) 
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Exposure to pesticides 1st 
trimester 
X
2
=0.86, df=2, P= 0.652 
N=162 
Yes 12 (16.0) 3 (27.3) 13 (17.1) 
No 63 (84.0) 8 (72.7) 63 (82.9) 
P value 
OR (95% CI) 
 0.364 
1.97 (0.46-8.51) 
0.855 
1.08 (0.46-2.56) 
Exposure to incense pre-gestation 
X
2
=2.01, df=2, P= 0.365 
N=162 
Yes 31 (41.3) 4 (36.4) 23 (30.3) 
No 44 (58.7) 7 (63.6) 53 (69.7) 
P value 
OR (95% CI) 
 0.754 
0.81 (0.22-3.01) 
0.157 
0.62 (0.31-1.21) 
Exposure to incense 1st trimester 
X
2
=1.17, df=2, P= 0.558 
N=162 
Yes 30 (40.0) 4 (36.4) 24 (31.6) 
No 45 (60.0) 7 (63.6) 52 (68.4) 
P value 
OR (95% CI) 
 
0.81 
0.86 (0.23-3.18) 
0.281 
0.69 (0.35-1.35) 
Type of maternal drinking water 
X
2
=7.96, df=2, P= 0.241 
N=147 
Tap 23 (31.1) 1 (9.1) 12 (19.4) 
Bottled 46 (62.2) 10 (90.9) 45 (72.6) 
P value 
OR (95% CI) 
 0.136 
0.2 (0.02-1.66) 
0.128 
0.53 (0.24-1.2) 
Well 5 (6.8) 0 3 (4.8) 
P value 
OR (95% CI) 
 0.84 
a 
0.863 
0.87 (0.18-4.27) 
Zamzam 0 0 2 (3.2) 
P value 
OR (95% CI) 
a a 0.16 
a 
Consanguinity 
X
2
=7.96, df=2, P= 0.241 
N=157 
Yes 40 (57.1) 6 (50) 42 (56) 
No 30 (42.9) 6 (50) 33 (44) 
P value 
OR (95% CI) 
 0.646 
0.75 (0.22-2.56) 
0.89 
0.95 (0.49-1.84) 
Family history 
X
2
=0.37, df=2, P= 0.985 
N=162 
Yes 30 (40.0) 5 (54.5) 34 (44.7) 
No 45 (60.0) 6 (54.5) 42 (55.3) 
P value 
OR (95% CI) 
 0.731 
1.25 (0.35-4.47) 
0.556 
1.2 (0.64-2.32) 
*Homozygous common allele genotype.                    
      **The Chi-square statistic is significant at the 0.05 level.  
a
 Could not analyse because the groups contained zero values.                            
If one of the cells contained a zero value, the OR and 95% CI were not calculated.  
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A39: Relationship between Maternal IRF6 rs2013162 allele and 
different environmental factors, including: maternal illness, 
medication, stress, supplements, paternal smoking and 
maternal domestic exposure using case-only study design. 
   
Maternal IRF6 rs2013162 C* (%) A (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
N=326 
 
Yes 35 (15.4) 9 (9.1) 
No 192 (84.6) 90 (90.9) 
X
2
 (df), P value 
OR (95% CI) 
2.36 (1), 0.129 
0.55 (0.25-1.19) 
Antibiotic at 1st trimester 
N=279 
Yes 33 (18.3) 17 (17.2) 
No 147 (81.7) 82 (82.8) 
X
2
 (df), P value 
OR (95% CI) 
0.06 (1), 0.809 
0.92 (0.48-1.76) 
Antipyretic medication pre-
gestation 
N=328 
Yes 15 (6.6) 7 (7.1) 
No 214 (93.4) 92 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1), 0.863 
1.09 (0.43-2.75)  
Antipyretic medication 1st 
trimester 
N=324 
Yes 17 (7.4) 15 (15.8) 
No 212 (92.6) 80 (84.2) 
X
2
 (df), P value 
OR (95% CI) 
5.28 (1), 0.025** 
2.34 (1.12-4.9) 
Anti-emetic medication pre-
gestation 
N=326 
Yes 2 (0.9) 0 
No 225 (99.1) 99 (100) 
X
2
 (df), P value 0.88 (1), 0.35 
Anti-emetic medication 1st 
trimester 
N=326 
Yes 31 (13.7) 17 (17.2) 
No 196 (86.3) 82 (82.8) 
X
2
 (df), P value 
OR (95% CI) 
0.68 (1), 0.411 
1.31 (0.69-2.5) 
Contraceptives pre-gestation 
N=322 
 
Yes 21 (9.3) 5 (5.3) 
No 206 (90.7) 90 (94.7) 
X
2
 (df), P value 
OR (95% CI) 
1.44 (1), 0.23 
0.55 (0.2-1.49) 
Contraceptives 1st trimester 
N=326 
Yes 4 (1.8) 2 (2) 
No 223 (98.2) 97 (98) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1), 0.87 
1.15 (0.21-6.38) 
Illness pre-gestation 
N=326 
Yes 67 (29.5) 23 (23.2) 
No 160 (70.5) 76 (76.8) 
X
2
 (df), P value 
OR (95% CI) 
1.36 (1), 0.244 
0.72 (0.42-1.25) 
Illness 1st trimester Yes 82 (26.1) 42 (42.4) 
No 145 (63.9) 57 (57.6) 
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N=326 X
2
 (df), P value 
OR (95% CI) 
1.16 (1), 0.282 
1.3 (0.8-2.11) 
Common cold/flu pre-
gestation 
N=290 
Yes 53 (25.4) 13 (16.1) 
No 156 (74.6) 68 (83.9) 
X
2
 (df), P value 
OR (95% CI) 
2.88 (1), 0.90 
0.56 (0.29-1.1) 
Common cold/flu 1st 
trimester 
N=326 
Yes 51 (22.5) 21 (21.2) 
No 176 (77.5) 78 (78.8) 
X
2
 (df), P value 
OR (95% CI) 
0.06 (1), 0.802 
0.93 (0.52-1.65) 
Fever pre-gestation 
N=326 
Yes 30 (13.2) 4 (4) 
No 197 (86.8) 95 (96) 
X
2
 (df), P value 
OR (95% CI) 
6.21 (1), 0.019** 
0.28 (0.09-0.81) 
Fever 1st trimester 
N=326 
Yes 31 (13.7) 15 (15.2) 
No 196 (86.3) 84 (84.8) 
X
2
 (df), P value 
OR (95% CI) 
0.13 (1), 0.72 
1.13 (0.58-2.2) 
Urinary tract infection pre-
gestation 
N=324 
Yes 9 (4) 3 (3.1) 
No 217 (96) 95 (96.9) 
X
2
 (df), P value 
OR (95% CI) 
0.16 (1), 0.69 
0.76 (0.2-2.88) 
Urinary tract infection 1st 
trimester 
N=324 
Yes 8 (3.5) 2 (2) 
No 218 (96.5) 96 (98) 
X
2
 (df), P value 
OR (95% CI) 
0.51 (1) 0.479 
0.57 (0.12-2.72) 
High blood pressure pre-
gestation 
N=326 
Yes 6 (2.6) 0 
No 221 (97.4) 99 (100) 
X
2
 (df), P value 2.67 (1), 0.10 
High blood pressure 1st 
trimester 
N=326 
Yes 8 (3.5) 0 
No 219 (96.5) 99 (100) 
X
2
 (df), P value 3.57 (1), 0.06 
Diabetes pre-gestation 
N=290 
Yes 0 0 
No 191 (100) 99 (100) 
X
2
 (df), P value a 
Diabetes 1st trimester 
N=326 
Yes 5 (2.2)  3 (3) 
No 222 (97.8) 96 (97) 
X
2
 (df), P value 
OR (95% CI) 
0.20 (1), 0.658 
1.39 (0.33-5.92) 
Asthma pre-gestation 
N=324 
Yes 5 (2.2) 1 (1) 
No 221 (97.8) 97  (99) 
X
2
 (df), P value 
OR (95% CI) 
0.53 (1), 0.476 
0.46 (0.05-3.95) 
Asthma 1st trimester 
N=324 
Yes 6 (2.7) 0 
No 220 (97.3) 98 (100) 
X
2
 (df), P value 2.65 (1), 0.10 
Convulsions pre-gestation 
N=326 
Yes 0 0 
No 227 (100) 99 (100) 
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X
2
 (df), P value a 
Convulsions 1st trimester 
N=326 
Yes 0 0 
No 227 (100) 99 (100) 
X
2
 (df), P value a 
Vaginal bleeding 
N=324 
Yes 13 (5.8) 7 (7.1) 
No 213 (94.2) 91 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.23 (1), 0.634 
1.26 (0.49-3.26) 
Maternal supplement use 
Folic acid pre-gestation 
N=328 
Yes 16 (7) 16 (16.2) 
No 213 (93) 83 (83.8) 
X
2
 (df), P value 
OR (95% CI) 
6.61 (1), 0.012** 
2.57 (1.23-5.37) 
Folic acid 1st trimester 
N=328 
Yes 135 (59) 57 (57.6) 
No 94 (41) 42 (42.4) 
X
2
 (df), P value 
OR (95% CI) 
0.05 (1), 0.816 
0.95 (0.59-1.52) 
Multivitamins pre-gestation 
N=328 
Yes 12 (5.2) 8 (8.1) 
No 217 (94.8) 91 (91.9) 
X
2
 (df), P value 
OR (95% CI) 
0.97 (1), 0.327 
1.59 (0.63-4.02) 
Multivitamins 1st trimester 
N=326 
Yes 42 (18.5) 24 (24.2)  
No 185 (81.5) 75 (75.8) 
X
2
 (df), P value 
OR (95% CI) 
1.41 (1), 0.24 
1.41 (0.8-2.49) 
Iron pre-gestation 
N=326 
Yes 17 (7.5) 9 (9) 
No 210 (92.5) 90 (90) 
X
2
 (df), P value 
OR (95% CI) 
0.24 (1), 0.62 
1.24 (0.53-2.88) 
Iron 1st trimester 
N=326 
Yes 79 (34.8) 23 (23.2) 
No 148 (65.2) 76 (76.8) 
X
2
 (df), P value 
OR (95% CI) 
4.29 (1), 0.04** 
0.57 (0.33-0.97) 
Calcium 1st trimester 
N=326 
Yes 13 (5.7) 3 (3) 
No 214 (94.3) 96 (97) 
X
2
 (df), P value 
OR (95% CI) 
1.07 (1), 0.30 
0.51 (0.14-1.85) 
Smoking 
Maternal smoking 
N=324 
Yes 7 (3.1) 5 (5.1) 
No 219 (96.9) 93 (94.9) 
X
2
 (df), P value 
OR (95% CI) 
0.77 (1), 0.38 
1.68 (0.52-5.44) 
Paternal smoking 
N=324 
Yes 77 (34.1) 37 (37.8) 
No 149 (65.9) 61 (62.2) 
X
2
 (df), P value 
OR (95% CI) 
0.41 (1), 0.52 
1.17 (0.72-1.92) 
Paternal tobacco 
N=310 
Yes 56 (25.6) 30 (33) 
No 163 (74.4) 61 (67) 
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X
2
 (df), P value 
OR (95% CI) 
1.75 (1), 0.19 
1.43 (0.84-2.44) 
Paternal waterpipe 
N=324 
Yes 29 (12.8) 15 (15.3) 
No 197 (87.1) 83 (84.7) 
X
2
 (df), P value 
OR (95% CI) 
0.36 (1), 0.55 
1.22 (0.63-2.41) 
Maternal passive smoking 
N=324 
Yes 44 (19.5) 22 (22.5) 
No 182 (80.5) 76 (77.5) 
X
2
 (df), P value 
OR (95% CI) 
0.37 (1) 0.54 
 1.2 (0.67-2.13) 
Maternal stress 
Family problems 
N=324 
Yes 82 (36.3) 44 (44.9) 
No 144 (63.7) 54 (55.1) 
X
2
 (df), P value 
OR (95% CI) 
2.13 (1) 0.14 
1.43 (0.88-2.32) 
Mother complains of being 
under stress 
N=324 
Yes 98 (43.4) 48 (49) 
No 128 (56.6) 50 (51) 
X
2
 (df), P value 
OR (95% CI) 
0.87 (1), 0.35 
1.25 (0.78-2.02) 
Depression pre-gestation 
N=326 
Yes 3 (1.3) 3 (3) 
No 224 (98.7) 96 (97) 
X
2
 (df), P value 
OR (95% CI) 
1.11 (1), 0.29 
2.33 (0.46-11.77) 
Depression 1st trimester 
N=326 
Yes 7 (3.1) 7 (7.1) 
No 220 (96.9) 92 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
2.67 (1), 0.10 
2.39 (0.82-7.01) 
Severe morning sickness 
N=324 
Yes 30 (12.3) 10 (10.2)  
No 196 (86.7) 88 (88.8) 
X
2
 (df), P value 
OR (95% CI) 
0.60 (1) 0.441 
0.74 (0.35-1.59) 
Threatened abortion 
N=344 
Yes 11 (4.9) 9 (7.6) 
No 215 (95.1) 109 (92.4) 
X
2
 (df), P value 
OR (95% CI) 
1.08 (1) 0.302 
1.61 (0.65-4.01) 
Abdominal pain pre-
gestation 
N=324 
Yes 8 (3.5) 4 (4.1) 
No 218 (96.5) 94 (95.9) 
X
2
 (df), P value 
OR (95% CI) 
0.06 (1) 0.81 
1.16 (0.34-3.94) 
Abdominal pain 1st 
trimester 
N=324 
Yes 20 (8.9) 16 (16.3) 
No 206 (91.1) 82 (83.7) 
X
2
 (df), P value 
OR (95% CI) 
3.87 (1) 0.053 
2 (0.99-4.07) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-
gestation 
N=324 
Yes 70 (31) 32 (32.7) 
No 156 (69) 66 (67.3) 
X
2
 (df), P value 
OR (95% CI) 
0.09 (1) 0.76 
1.08 (0.65-1.8) 
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Exposure to chemicals 1st 
trimester 
N=320 
Yes 68 (30.4) 30 (31.3) 
No 156 (69.6) 66 (68.7) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1) 0.874 
1.04 (0.62-1.75) 
Exposure to solvents pre-
gestation 
N=324 
Yes 31 (13.7) 11 (11.2) 
No 195 (86.3) 87 (88.8) 
X
2
 (df), P value 
OR (95% CI) 
0.38 (1) 0.54 
0.8 (0.38-1.66) 
Exposure to solvents 1
st
 
 trimester 
N=324 
 
Yes 27 (12) 5 (5.1) 
No 199 (88) 93 (94.9( 
X
2
 (df), P value 
OR (95% CI) 
3.60 (1) 0.066 
0.4 (0.15-1.07) 
Exposure to pesticides pre-
gestation 
N=324 
Yes 34 (15) 14 (14.3) 
No 192 (85) 84 (85.7) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1) 0.86 
0.94 (0.48-1.85) 
Exposure to pesticides 1st 
trimester 
N=324 
 
Yes 37 (16.4) 19 (19.4) 
No 189 (83.6) 79 (80.6) 
X
2
 (df), P value 
OR (95% CI) 
0.44 (1) 0.51 
1.23 (0.67-2.27) 
Exposure to incense pre-
gestation 
N=324 
Yes 85 (37.6) 31 (31.6) 
No 141 (62.4) 67 (68.4) 
X
2
 (df), P value 
OR (95% CI) 
1.06 (1) 0.303 
0.77 (0.36-1.27) 
Exposure to incense 1st 
trimester 
N=324 
Yes 84 (37.2) 32 (32.7) 
No 142 (62.8) 66 (67.3) 
X
2
 (df), P value 
OR (95% CI) 
0.61 (1) 0.44 
0.82 (0.5-1.35) 
Maternal exposure to X-ray 
1st trimester 
N=290 
Yes 49 (24.1) 5 (5.8) 
No 154 (75.9) 82 (94.2) 
X
2
 (df), P value 
OR (95% CI) 
13.59 (1) <0.001** 
0.19 (0.07-0.5) 
Type of maternal drinking 
water 
N=290 
 
Tap (reference) 58 (27.9) 14 (17.1) 
Bottle 137 (65.9) 65 (79.3) 
X
2
 (df), P value 
OR (95% CI) 
4.19 (1) 0.04** 
0.51 (0.26-0.98) 
Well 13 (6.2) 3 (3.6) 
X
2
 (df), P value 
OR (95% CI) 
0.004 (1) 0.949 
1.05 (0.26-4.18) 
Zamzam 0 0 
OR (95% CI) a 
Consanguinity 
N=314 
Yes 122 (56.7) 54 (54.6) 
No 93 (43.3) 45 (45.4) 
P value 
OR (95% CI) 
0.13 (1) 0.715 
0.91 (0.57-1.48) 
Family history Yes 94 (41.6) 44 (44.9) 
No 132 (58.4) 54 (55.1) 
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N=324 X
2
 (df), P value 
OR (95% CI) 
0.31 (1) 0.58 
1.14 (0.71-1.85) 
*Common allele  
**Significance level P ≤0.05  
a
 Not possible to analyse because the groups contain zero values  
If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A40: Comparison between cases and controls for maternal IRF6 
rs2013162 genotypes in relationship to different environmental 
factors including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic 
exposure. 
Maternal IRF6 
rs2013162 genotype 
 CC* (%) AA (%) CA (%) 
Environmental factors  Study Control Study Control Study Control 
Maternal medication use and illness 
Antibiotic use pre-
gestation 
Study Group N = 163 
Control Group N=175 
Yes 13 (17.3) 3 (3.5) 0 (0) 1 (3.7) 9 (11.7) 4 (6.5) 
No 62(82.7) 83 (96.5) 11 (100) 26 (96.3) 68 (88.3) 58 (93.5) 
X
2
 (df), P 
value 
OR (95% CI) 
8.58 (1), 0.003** 
5.8(1.58-21.24) 
0.42 (1), 0.518
 
1.11 (1), 0.292 
Antibiotic use 1st 
trimester Study Group 
N = 163 
Control Group N=175 
Yes 9 (12.0) 7 (8.1) 1 (9.1) 2 (7.4) 15 (19.5) 9 (14.5) 
No 66 (88.0) 79 (91.9) 10 (90.9) 25 (29.6) 62 (80.5) 53 (85.5) 
X
2
 (df), P 
value 
0.67 (1), 0.414 0.03 (1), 0.861
 
0.59 (1), 0.441 
Antipyretic medication 
pre-gestation 
Study Group N = 164 
Control Group N=175 
Yes 6 (7.9) 10 (11.6) 2 (18.2) 3 (11.1) 3 (3.9) 5 (8.1) 
No 70 (92.1) 76 (88.4) 9 (81.8) 24 (88.9) 74 (96.1) 57 (91.9) 
X
2
 (df), P 
value 
0.63 (1), 0.427 0.34 (1), 0.559 1.1 (1), 0.294 
Antipyretic medication 
1st trimester 
Study Group N = 162 
Control Group N=172 
Yes 4 (5.3) 12 (14.1) 3 (33.3) 2 (7.4) 9 (11.7) 11 (18.3) 
No 72 (94.7) 73 (85.9) 6 (66.7) 25 (92.6) 68 (88.3) 49 (81.7) 
X
2
 (df), P 
value 
3.51 (1), 0.061 3.79 (1), 0.051
 
1.19 (1), 0.274 
Anti-emetic medication 
pre-gestation 
Study Group N = 163 
Control Group N=175 
Yes 1 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
No 74 (98.7) 86 (100) 11 (100) 27 (100) 77 (100) 62 (100) 
X
2
 (df), P 
value 
1.15 (1), 0.283
 
a a 
Anti-emetic medication 
1st trimester 
Study Group N = 163 
Control Group N=175 
Yes 9 (12.0) 5 (5.8) 2 (18.2) 3 (11.1) 13 (16.9) 6 (9.7) 
No 66 (88.0) 81 (94.2) 9 (81.8) 24 (88.9) 64 (83.1) 56 (90.3) 
X
2
 (df), P 
value 
1.93 (1), 0.165 0.34 (1), 0.559
 
1.51 (1), 0.219 
Contraceptives pre- Yes 8 (10.7) 6 (7.0) 0 (0) 2 (7.4) 5 (6.5) 6 (9.7) 
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gestation 
Study Group N = 161 
Control Group N=175 
 
No 67 (89.3) 80 (93.0) 9 (100) 25 (92.6) 72 (93.5) 56 (90.3) 
X
2
 (df), P 
value 
0.69 (1), 0.407 0.71 (1), 0.401
 
0.48 (1), 0.489
 
Contraceptives 1st 
trimester 
Study Group N = 163 
Control Group N=175 
Yes 1 (1.3) 1 (1.2) 0 (0) 2 (7.4) 2 (2.6) 2 (3.2) 
No 74 (98.7) 85 (98.8) 11 (100) 25 (92.6) 75 (97.4) 60 (96.8) 
X
2
 (df), P 
value 
0.009 (1), 0.922
 
0.86 (1), 0.354
 
0.05 (1), 0.826
 
Illness pre-gestation 
Study Group N = 163 
Control Group N=174 
Yes 23 (30.7) 12 (14.0) 1 (9.1) 2 (7.4) 21 (27.3) 5 (8.2) 
No 52 (69.3) 74 (86.0) 10 (90.9) 25 (92.6) 56 (72.7) 56 (91.8) 
X
2
 (df), P 
value 
OR (95% CI) 
6.59 (1), 0.010** 
2.73 (1.25-5.97) 
0.03 (1), 0.86
 8.1 (1), 0.004** 
4.2 (1.48-11.92) 
Illness 1st trimester 
Study Group N = 163 
Control Group N=173 
Yes 25 (33.3) 23 (26.7) 5 (45.5) 7 (25.9) 32 (51.6) 17 (28.3) 
No 50 (66.7) 63 (73.3) 6 (54.5) 20 (74.1) 45 (58.4) 43 (71.7) 
X
2
 (df), P 
value 
0.83 (1), 0.362 1.38 (1), 0.240
 
2.56 (1), 0.109 
Common cold/flu pre-
gestation 
Study Group N = 145 
Control Group N=173 
Yes 20 (26.7) 3 (3.5) 0 (0) 1 (3.7) 13 (16.9) 3 (5.0) 
No 55 (73.3) 83 (96.5) 11 (100) 26 (96.3) 46 (83.1) 57 (95.0) 
X
2
 (df), P 
value 
OR (95% CI) 
17.58 (1), <0.001** 
10.06 (2.85-35.48) 
0.42 (1), 0.518
 04.62 (1), .032** 
5.37 (1.44-19.98) 
Common cold/flu 1st 
trimester 
Study Group N = 163 
Control Group N=173 
Yes 16 (21.3) 9 (10.5) 1 (9.1) 3 (11.1) 19 (24.7) 12 (20.0) 
No 59 (78.7) 77 (89.5) 10 (90.9) 24 (88.9) 58 (75.3)  48 (80.0) 
X
2
 (df), P 
value 
3.61 (1), 0.058 0.03 (1), 0.854
 
0.42 (1), 0.516 
Fever pre-gestation 
Study Group N = 163 
Control Group N=173 
Yes 13 (17.3) 4 (4.7) 0 (0) 1 (3.7) 4 (5.2) 3 (5.0) 
No 62 (82.7) 82 (95.3)  11 (100) 26 (96.3) 73 (94.8) 57 (95.0) 
X
2
 (df), P 
value 
OR (95% CI) 
6.82 (1), 0.009** 
4.3 (1.34-13.82) 
0.42 (1), 0.518
 
0.003 (1), 0.959
 
Fever 1st trimester 
Study Group N = 163 
Control Group N=173 
Yes 8 (10.7) 7 (8.1) 0 (0) 2 (7.4) 15 (19.5) 6 (10.0) 
No 67 (89.3) 79 (91.9)  11 (100) 25 (92.6) 62 (80.5) 54 (90.0) 
X
2
 (df), P 
value 
0.3 (1), 0.582 0.86 (1), 0.354
 
2.34 (1), 0.126 
Urinary tract infection 
pre-gestation 
Yes 3 (4.0) 1 (1.2) 0 (0) 1 (3.7) 3 (3.9) 2 (3.3) 
No 72 (96.0) 85 (98.8) 11 (100) 26 (96.3) 73 (96.1) 58 (96.7) 
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Study Group N = 162 
Control Group N=173 
X
2
 (df), P 
value 
1.33 (1), 0.249 0.42 (1), 0.518
 
0.04 (1), 0.850
 
Urinary tract infection 
1st trimester 
Study Group N = 162 
Control Group N=173 
Yes 3 (4.0) 4 (4.7) 0 (0) 1 (3.7) 2 (2.6) 2 (3.3) 
No 72 (96.0) 82 (95.3) 11 (100) 26 (96.3) 74 (97.4) 58 (96.7) 
X
2
 (df), P 
value 
0.04 (1), 0.840
 
0.42 (1), 0.518
 
0.06 (1), 0.810
 
High blood pressure 
pre-gestation 
Study Group N = 163 
Control Group N=173 
Yes 3 (4.0) 1 (1.2) 0 (0) 0 (0)  0 (0) 0 (0) 
No 72 (96.0) 85 (98.8) 11 (100) 27 (100) 77 (100) 60 (100) 
X
2
 (df), P 
value 
1.33 (1), 0.249
 
a a 
High blood pressure 1st 
trimester 
Study Group N = 163 
Control Group N=173 
Yes 4 (5.3) 1 (1.2) 0 (0) 0 (0) 0 (0) 1 (1.7) 
No 71 (94.7) 85 (98.8) 11 (100) 27 (100) 77 (100) 59 (98.3) 
X
2
 (df), P 
value 
2.32 (1), 0.128
 
a 1.29 (1) 0.256
 
Diabetes pre-gestation 
Study Group N = 145 
Control Group N=173 
Yes 0 (0) 1 (1.2) 0 (0) 0 (0) 0 (0) 0 (0) 
No 57 (100) 85(98.8) 11 (100) 27 (100) 77 (100) 60 (100) 
X
2
 (df), P 
value 
0.88 (1), 0.349
 
a a 
Diabetes 1st trimester 
Study Group N = 163 
Control Group N=173 
Yes 1 (1.3) 3 (3.5) 0 (0) 0 (0) 3 (3.9) 0 (0) 
No 74 (98.7) 83 (96.5) 11 (100) 27 (100) 74 (96.1) 60 (100) 
X
2
 (df), P 
value 
 
0.77 (1), 0.381
 
a 0.122
 
Asthma pre-gestation 
Study Group N = 162 
Control Group N=173 
Yes 2 (2.7) 0 (0) 0 (0) 0 (0) 1 (1.3) 1 (1.7) 
No 73 (97.3) 86 (100) 11 (100) 27 (100) 75 (98.7) 59 (98.3) 
X
2
 (df), P 
value 
 
2.32 (1), 0.128
 
a 0.028 (1), 0.866
 
Asthma 1st trimester 
Study Group N = 162 
Control Group N=173 
Yes 3 (4.0) 1 (1.2) 0 (0) 1 (3.7) 0 (0) 2 (3.3) 
No 72 (96.0) 85 (98.8) 11 (100) 26 (96.3) 76 (100) 58 (96.7) 
X
2
 (df), P 
value 
 
1.33 (1), 0.249
 
0.42 (1), 0.518
 
2.57 (1), 0.109
 
Convulsions pre-
gestation 
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0(0) 0 (0) 
No 75 (100) 86 (100) 11 (100) 27 (100) 77 (100) 60 (100) 
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Study Group N = 163 
Control Group N=173 
X
2
 (df), P 
value 
 
a a a 
Convulsions 1st 
trimester 
Study Group N = 163 
Control Group N=173 
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0(0) 0 (0) 
No 75 (100) 86 (100) 11 (100) 27 (100) 77 (100) 60 (100) 
X
2
 (df), P 
value 
 
a a a 
Vaginal bleeding 
Study Group N = 162 
Control Group N=173 
Yes 3 (4.0) 1 (1.2) 0 (0) 1 (3.7) 7 (9.2) 3 (5.0) 
No 72 (96.0) 85 (98.8) 11 (100) 26 (96.3) 69 (90.8) 57 (95.0) 
X
2
 (df), P 
value 
 
1.33 (1), 0.249
 
0.42 (1), 0.518
 
0.87 (1), 0.350
 
Maternal exposure to 
X-ray 1st trimester 
Study Group N = 164 
Control Group N=175 
Yes 4 (5.3) 1 (1.2) 0 1 (3.7) 2 (2.6) 0 
No 72 (94.7) 85 (98.8) 11 (100) 26 (96.3) 75 (97.4) 62 (100) 
X
2
 (df), P 
value 
2.27 (1), 0.132 0.42 (1), 0.518 1.63 (1), 0.201 
Maternal supplement use 
Folic acid pre-gestation 
Study Group N = 164 
Control Group N=175 
Yes 2 (2.6) 5 (5.8) 2 (18.2) 0 (0) 12 (15.6) 12 (19.4) 
No 74 (97.4) 81 (94.2) 9 (81.8) 27 (100) 65 (84.4) 50 (80.6) 
X
2
 (df), P 
value 
1 (1), 0.320 5.18 (1), 0.023**
 
0.34 (1), 0.559 
Folic acid 1st trimester  
Study Group N = 164 
Control Group N=175 
Yes 43 (56.6) 56 (65.1) 4 (36.4) 23 (85.2) 49 (63.6) 46 (74.2) 
No 33 (43.4) 30 (34.9) 7 (63.6) 4 (14.8) 28 (36.4) 16 (25.8) 
X
2
 (df), P 
value 
OR (95% CI) 
1.24 (1), 0.226 
9.06 (1), 0.003**
 
0.1 (0.02-0.50) 
1.77 (1), 0.183 
Multivitamins pre-
gestation 
Study Group N = 164 
Control Group N=175 
Yes 4 (5.3) 2 (2.3) 2 (18.2) 0 (0) 4 (5.2) 2 (3.2) 
No 72 (94.7) 84 (97.7) 9 (81.8) 27 (100) 73 (94.8) 60 (96.8) 
X
2
 (df), P 
value 
0.98 (1), 0.323
 
5.18 (1), 0.023
** 
0.32 (1),0.570
 
Multivitamins 1st 
trimester 
Study Group N = 163 
Control Group N=175 
Yes 14 (18.7) 15 (17.4) 5 (45.5) 6 (22.2) 14 (18.2) 11 (17.7) 
No 61 (81.3) 71 (82.6) 6 (54.5) 21 (77.8) 63 (81.8) 51 (82.3) 
X
2
 (df), P 
value 
0.04 (1), 0.840 2.05 (1), 0.152
 
0.005 (1), 0.946 
Iron pre-gestation 
Study Group N = 163 
Yes 6 (8.0) 3 (3.5) 2 (18.2) 1 (3.7) 5 (6.5) 6 (9.7) 
No 69 (92.0) 83 (96.5) 9 (81.8) 26 (96.3) 72 (93.5) 56 (90.3) 
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Control Group N=175 X
2
 (df), P 
value 
1.55 (1),0.214 
 
2.25 (1) 0.133
 
0.48 (1), 0.489
 
Iron 1st trimester 
Study Group N = 163 
Control Group N=175 
Yes 29 (38.7) 28 (32.6) 1 (9.1) 9 (33.3) 21 (27.3) 23 (37.1) 
No 46 (61.3) 58 (67.4) 10 (90.9) 18 (66.7) 56 (72.7) 39 (62.9) 
X
2
 (df), P 
value 
0.654 (1), 0.419 2.37 (1), 0.124
 
1.53 (1), 0.216 
Calcium 1st trimester 
Study Group N = 163 
Control Group N=175 
Yes 5 (6.7) 10 (11.6) 0 (0) 4 (14.8) 3 (3.9) 6 (9.7) 
No 
70 
(93.36) 
76 (88.4) 11 (100) 23 (85.2) 74 (96.1) 56 (90.3) 
X
2
 (df), P 
value 
1.17 (1), 0.280 1.18 (1), 0.177
 
1.9 (1), 0.169
 
Smoking  
Maternal smoking 
Study Group N = 162 
Control Group N=175  
Yes 3 (4.0) 6 (7.0) 2 (18.2) 1 (3.7) 1 (1.3) 1 (1.6) 
No 72 (96.0) 80 (93.0) 9 (81.8) 26 (96.3) 75 (98.7) 61 (98.4) 
X
2
 (df), P 
value 
0.67 (1), 0.412 2.25 (1), 0.133 0.02 (1), 0.884 
Paternal smoking 
Study Group N = 162 
Control Group N=175 
Yes 25 (33.3) 30 (34.9) 5 (45.5) 8 (29.6) 27 (35.5) 22 (35.5) 
No 50 (66.7) 56 (65.1) 6 (54.5) 19 (70.4) 49 (64.5) 40 (64.5) 
X
2
 (df), P 
value 
0.04 (1), 0.836 0.87 (1), 0.351
 
<0.001** (1), 0.996 
Paternal tobacco 
Study Group N = 162 
Control Group N=175 
Yes 18 (24.0) 27 (31.4) 5 (54.5) 7 (25.9) 20 (26.3) 17 (27.4) 
No 57 (76.0) 59 (68.6) 6 (54.5) 20 (74.1) 56 (73.7) 45 (72.6) 
X
2
 (df), P 
value 
1.08 (1), 0.297 1.38 (1), 0.240
 
0.02 (1), 0.884 
Paternal waterpipe 
smoking 
Study Group N = 162 
Control Group N=175 
Yes 10 (13.3) 3 (3.5) 3 (27.3) 1 (3.7) 9 (11.8) 5 (8.1) 
No 65 (86.7) 83 (96.5) 8 (72.7) 26 (96.3) 67 (88.2) 57 (91.9) 
X
2
 (df), P 
value 
5.23 (1), 0.022** 
4.26 (1.13-16.1) 
4.6 (1), 0.06 0.54 (1), 0.465 
Paternal Jorak 
Study Group N = 162 
Control Group N=175 
Yes 6 (8.0) 0 (0) 3 (27.3) 0 (0) 4 (5.3) 1 (1.6) 
No 69 (92.0) 86 (100) 8 (72.7) 27 (100) 72 (94.7) 61 (98.4) 
X
2
 (df), P 
value 
7.15 (1), 0.008** 8 (1), 0.005**
 
1.3 (1)0.254
 
Paternal Moasel 
Study Group N = 162 
Control Group N=175 
Yes 5 (6.7) 3 (3.5) 1 (9.1) 1 (3.7) 6 (7.9) 4 (6.5) 
No 70 (93.3) 83 (96.5) 10 (90.9) 26 (96.3) 70 (92.1) 58 (93.5) 
X
2
 (df), P 
value 
0.86 (1), 0.335
 
0.46 (1), 0.5
 
0.11 (1), 0.745
 
Maternal passive Yes 16 (21.3) 18 (20.9) 5 (45.5) 2 (7.4) 12 (15.8) 12 (19.4) 
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smoking 
Study Group N = 162 
Control Group N=165 
No 59 (78.7) 58 (79.1) 6 (54.5) 25 (92.6) 64 (84.2) 50 (80.6) 
X
2
 (df), P 
value 
OR (95% CI) 
0.004 (1), 0.950
 7.53 (1), 0.006** 
10.42 (1.61-67.34) 
0.3 (1), 0.583
 
Maternal stress 
Family problems 
Study Group N = 162 
Control Group N=175 
Yes 26 (34.7) 25 (29.1) 7 (63.6) 4 (14.8) 30 (39.5) 14 (22.6) 
No 49 (65.3) 61 (70.9) 4 (36.4) 23 (85.7) 46 (60.5) 48 (77.4) 
X
2
 (df), P 
value 
OR (95% CI) 
0.58 (1), 0.446 
9.06 (1), 0.003** 
10.06 (1.98-51.04) 
4.49 (1), 0.034** 
2.24 (1.05-4.74) 
Mother complains of 
being under stress 
Study Group N = 162 
Control Group N=175 
Yes 32 (42.7) 31 ( 36.0) 7 (63.6) 6 (22.2) 34 (44.7) 17 (27.4) 
No 43 (57.3) 55 (64.0) 4 (36.4) 21 (77.8) 42 (55.3) 45 (72.6) 
X
2
 (df), P 
value 
OR (95% CI) 
0.74 (1), 0.391 
5.96 (1), 0.015** 
6.13 (1.33-28.21) 
4.4 (1), 0.036** 
2.14 (1.04-4.39) 
Depression pre-
gestation 
Study Group N = 163 
Control Group N=173 
Yes 0 (0) 1 (1.2) 0 (0) 0 (0) 3 (3.9) 1 (1.7) 
No 75 (100) 85 (98.8) 11 (100) 27 (100) 74(96.1) 59 (98.3) 
X
2
 (df), P 
value 
0.88 (1), 0.349
 
a 0.59 (1), 0.442
 
Depression 1st 
trimester 
Study Group N = 163 
Control Group N=173 
Yes 2 (2.7) 3 (3.5) 2 (18.2) 0 (0) 3 (3.9) 0 (0) 
No 73 (97.3) 83 (96.5) 9 (81.8) 27 (100) 74(96.1) 60 (100) 
X
2
 (df), P 
value 
0.09  (1), 0.764
 
5.18 (1), 0.023**
 
2.39 (1), 0.122
 
Severe morning 
sickness 
Study Group N = 162 
Control Group N=173  
Yes 10 (13.3) 7 (8.1) 0 (0) 2 (7.4) 10 (13.2) 3 (5.0) 
No 65 (86.7) 79 (91.9) 11 (100) 25 (92.6) 66 (86.8) 57 (95.0) 
X
2
 (df), P 
value 
1.14 (1), 0.285 0.86 (1), 0.354
 
2.58 (1), 0.108 
Threatened abortion  
Study Group N = 162 
Control Group N=173 
Yes 2 (2.7) 0 (0) 1 (9.1) 2 (7.4) 7 (9.2) 5 (8.3) 
No 73(97.3) 86 (100) 10 (90.9) 25 (92.6) 69 (90.8)  55 (91.7) 
X
2
 (df), P 
value 
2.32 (1), 0.128
 
0.03 (1), 0.861
 
0.03 (1), 0.858
 
Abdominal pain pre-
gestation 
Study Group N = 162 
Control Group N=173 
Yes 2 (2.7) 4 (4.7) 0 (0) 0 (0) 4 (5.3) 1 (1.7) 
No 73 (97.3) 82 (95.3) 11 (100) 27 (100) 72 (94.7) 59 (98.3) 
X
2
 (df), P 
value 
0.44 (1), 0.507
 
a 1.22 (1), 0.17 
Abdominal pain 1st 
trimester 
Yes 6 (8.0) 7 (6.1) 4 (36.4) 1 (3.7) 8 (10.5) 3 (5.0) 
No 69 (92.0) 79 (91.9) 7 (63.6) 26 (96.3) 68 (89.5) 57 (95.0) 
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Study Group N = 162 
Control Group N=173 
X
2
 (df), P 
value 
OR (95% CI) 
0.001 (1), 0.974 
7.3 (1), 0.007
**
 
14.86 (1.42-154.99) 
1.38 (1), 0.241
 
Maternal domestic environmental exposure 
Exposure to chemicals 
pre-gestation 
Study Group N = 162 
Control Group N=173 
Yes 25 (33.3) 24 (27.9) 6 (54.5) 4 (14.8) 20 (26.3) 19 (31.7) 
No 50 (66.7) 62 (72.1) 5 (45.5) 23 (85.7) 56 (73.7) 41 (68.3) 
X
2
 (df), P 
value 
OR (95% CI) 
0.56 (1), 0.455 
6.36 (1), 0.012** 
6.9 (1.4-33.92) 
0.47 (1), 0.493 
Exposure to chemicals 
1st trimester 
Study Group N = 160 
Control Group N=173 
Yes 25 (33.3) 26 (30.2) 6 (54.5) 4 (14.8) 18 (23.7) 19 (31.7) 
No 50 (66.7) 60 (69.8) 5 (45.5) 23 (85.7) 56 (76.3) 41 (68.3) 
X
2
 (df), P 
value 
OR (95% CI) 
0.18 (1), 0.673 
6.36 (1), 0.012** 
6.9 (1.4-33.92) 
0.94 (1), 1.07 (1), 0.299 
Exposure to solvent 
pre-gestation 
Study Group N = 162 
Control Group N=175 
Yes 12 (16.0) 12 (14.0) 2 (18.2) 2 (7.4) 7 (9.2) 9 (14.5) 
No 63 (84.0) 74 (86.0) 9 (81.8) 25 (92.6) 69 (90.8) 53 (85.5) 
X
2
 (df), P 
value 
0.13 (1), 0.673
 
0.96 (1), 0.34 0.299
 
Exposure to solvent 1st 
trimester 
Study Group N = 162 
Control Group N=175 
Yes 11 (14.7) 10 (11.6) 0 (0)  2 (7.4) 5 (6.6) 8 (12.9) 
No 64 (85.3) 76 (88.4) 11 (100) 25 (92.6) 71 (93.4) 54 (87.1) 
X
2
 (df), P 
value 
0.33 (1), 0.568 0.86 (1), 0.354
 
1.6 (1), 0.206 
Exposure to pesticides 
pre-gestation 
Study Group N = 162 
Control Group N=175 
Yes 11 (14.7) 14 (16.3) 1 (9.1) 5 (18.5) 12 (15.8) 13 (21.0) 
No 64 (85.3) 72 (83.7) 10 (90.9) 22 (81.5) 64 (84.2) 49 (79.0) 
X
2
 (df), P 
value 
0.08 (1), 0.778 0.52 (1), 0.470
 
0.62 (1), 0.432 
Exposure to pesticides 
1st trimester 
Study Group N = 162 
Control Group N=175 
Yes 12 (16.0) 15 (17.4) 3 (27.3) 3 (11.1) 13 (17.1) 12 (19.4) 
No 63 (84.0) 71 (82.6) 8 (72.7) 24 (88.9) 63 (82.9) 50 (80.6) 
X
2
 (df), P 
value 
0.06 (1), 0.807 1.54 (1), 0.215
 
0.12 (1), 0.733 
Exposure to incense 
pre-gestation 
Study Group N = 162 
Control Group N=175 
Yes 31 (41.3) 45 (52.3) 4 (36.4) 9 (33.3) 23 (30.3) 30 (48.4) 
No 44 (58.7) 41 (47.7) 7 (63.6) 18 (66.7) 53 (69.7) 32 (51.6) 
X
2
 (df), P 
value 
OR (95% CI) 
1.94 (1), 0.163 0.03 (1), 0.858
 4.74 (1), 0.029** 
0.46 (0.23-0.93) 
Exposure to incense in 
the 1st trimester 
Yes 30 (40.0) 46 (53.5) 4 (36.4) 8 (29.6) 24 (31.6) 31 (50.0) 
No 45 (60.0) 40 (46.5) 7 (63.6) 19 (70.4) 52 (68.4) 31 (50.0) 
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Study Group N = 162 
Control Group N=175 
X
2
 (df), P 
value 
OR (95% CI) 
2.9 (1), 0.087
 
0.16 (1), 0.685 
4.8 (1), 0.028** 
0.46 (0.23-0.92) 
Type of maternal 
drinking water 
X2= 
Study Group N = 160 
Control Group N=172 
Tap 23 (31.1) 17 (20) 1 (9.1) 2 (7.4) 16 (21.3) 15 (25) 
Bottled 46 (62.2) 57 (67.1) 10 (90.9) 20 (74.1) 51 (68) 40 (66.7) 
 0.17 1  0.67 
Well 5 (6.8) 1 (1.2) 0 5 (18.5) 5 (6.7) 1 (1.7) 
 0.252 0.3 0.18 
Zamzam 0 10 (11.8) 0 0 3 (4) 4 (6.7) 
P-value 0.024** 0.309 0.68 
Type of maternal 
drinking water 
X
2
 (df), P 
value 
14.05 (3), 0.003 2.35 (3), 0.309 2.54 (3), 0.469 
Consanguinity  
Study Group N = 157 
Control Group N=164 
Yes 40 (57.1) 39 (49.4) 6 (50) 17 (68) 42 (56) 34 (56.7) 
No 30 (42.9) 40 (50.6) 6 (50) 8 (32) 33 (44) 26 (43.3) 
X
2
 (df), P 
value 
0.9 (1), 0.343 1.12 (1), 0.291 0.006 (1), 0.938 
Family history of birth 
defects 
Study Group N = 162 
Control Group N=172 
Yes 30 (40.0) 24 (28.9) 5 (54.5) 9 (33.3) 34 (44.7) 14 (22.6) 
No 45 (60.0) 59 (71.1) 6 (54.5) 18 (66.7) 42 (55.3) 48 (77.4) 
X
2
 (df), P 
value 
OR (95% CI) 
3.11 (1), 0.211 0.49 (1), 0.482 
6.61 (1), 0.037** 
2.78 (1.31—5.86) 
*The common homozygous allele genotype                                 
         **The Chi-square statistic is significant at the 0.05 level 
a Not possible to analyse because the groups contain zero values          
     If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A41: Relationship between maternal IRF6 rs2235375 genotypes and 
different environmental factors, including: maternal illness, 
medication, stress, supplements, paternal smoking and maternal 
domestic exposure using case-only study design. 
Maternal IRF6 rs2235375 CC* (%) GG (%) CG (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
X
2
=0.1, df=2, P= 0.949 
N=163 
 
Yes 5 (14.7) 9 (13.8) 8 (12.5) 
No 29 (85.3) 56 (86.2) 56 (87.5) 
P value 
OR (95% CI) 
 0.907 
0.93 (0.29-3.04) 
0.76 
0.83 (0.25-2.76) 
Antibiotic at 1st trimester 
X
2
=2.01, df=2, P= 0.365 
N=163 
Yes 4 (11.8) 8 (12.3) 13 (20.3) 
No 30 (88.2) 57 (87.7) 51 (79.7) 
P value 
OR (95% CI) 
 0.937 
1.05 (0.29-3.78) 
0.293 
1.9 (0.57-6.4) 
Antipyretic medication pre-
gestation 
X
2
=2.86, df=2, P= 0.239 
N=164 
Yes 4 (11.8) 5 (7.7) 2 (3.1) 
No 30 (88.2) 60 (92.3) 63 (96.9) 
P value 
OR (95% CI) 
 0.506 
0.63 (0.16-2.5) 
0.108 
0.24 (0.04-1.37) 
Antipyretic medication 1st 
trimester 
X
2
=3.21, df=2, P= 0.201 
N=162 
Yes 6 (18.2) 5 (7.8) 5 (7.7) 
No 27 (81.8) 59 (92.2) 60 (92.3) 
P value 
OR (95% CI) 
 0.137 
0.38 (0.11-1.35) 
0.13 
0.38 (0.11-1.33 
Anti-emetic medication pre-
gestation 
X
2
=1.52, df=2, P= 0.468 
N=163 
Yes 0 1 (1.5) 0 
No 34 (100) 64 (98.5) 64 (100) 
P value 
OR (95% CI) 
 a a 
Anti-emetic medication 1st 
trimester 
X
2
=0.29, df=2, P= 0.863 
N=163 
Yes 6 (17.6) 9 (13.8) 9 (14.1) 
No 28 (82.4) 56 (86.2) 55 (85.9) 
P value 
OR (95% CI) 
 0.617 
0.75 (0.24-2.38) 
0.64 
0.75 (0.25-2.36) 
Contraceptives pre-gestation 
X
2
=2.7, df=2, P= 0.259 
N=161 
 
Yes 2 (6.2) 8 (12.3) 3 (4.7) 
No 30 (93.8) 57 (87.7) 61 (95.3) 
P value 
OR (95% CI) 
 0.365 
2.11 (0.42-10.55) 
0.746 
0.74 (0.12-4.65) 
Contraceptives 1st trimester 
X
2
=2.9, df=2, P= 0.866 
N=130 
Yes 1 (2.9) 1 (3.5) 1 (1.6) 
No 33 (97.1) 31 (96.9) 63 (98.4) 
P value 
OR (95% CI) 
 0.965 
1.06 (0.06-17.7) 
0.651 
0.52 (0.03-8.65) 
Illness pre-gestation Yes 10 (29.4) 17 (26.2) 18 (28.1) 
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X
2
=0.13, df=2, P= 0.936 No 24 (70.6) 48 (73.8) 46 (71.9) 
P value 
OR (95% CI) 
 0.73 
0.85 (0.34-2.14) 
0.893 
0.94 (0.38-2.35) 
Illness 1st trimester 
X
2
=2.81, df=2, P= 0.245 
N=163 
Yes 16 (47.1) 20 (30.8) 26 (40.6) 
No 18 (52.9) 45 (69.2) 38 (59.4) 
P value 
OR (95% CI) 
 0.112 
0.5 (0.23-1.17) 
0.541 
0.77 (0.33-1.78) 
Common cold/flu pre-
gestation 
X
2
=1.62, df=2, P= 0.445 
N=163 
Yes 7 (20.6) 16 (24.6) 10 (15.6) 
No 27 (79.4) 49 (75.4) 54 (84.4) 
P value 
OR (95% CI) 
 0.653 
1.26 (0.56-3.44) 
0.538 
0.7 (0.24-2.08) 
Common cold/flu 1st 
trimester 
X
2
=0.27, df=2, P= 0.872 
N=163 
Yes 8 (23.5) 13 (20) 15 (23.4) 
No 26 (76.5) 52 (80) 49 (76.6) 
P value 
OR (95% CI) 
 0.684 
0.81 (0.3-2.2) 
0.684 
0.99 (0.37-2.65) 
Fever pre-gestation 
X
2
=4.03, df=2, P= 0.13 
N=163 
Yes 4 (11.8) 10 (15.4) 3 (4.7) 
No 30 (88.2) 55 (84.6) 61 (95.3) 
P value 
OR (95% CI) 
 0.625 
1.36 (0.39-4.7) 
0.21 
0.37 (0.08-1.75) 
Fever 1st trimester 
X
2
=1.07, df=2, P= 0.585 
N=163 
Yes 6 (17.6) 7 (10.8) 10 (15.6) 
No 28 (82.4)  58(89.2) 54 (84.4) 
P value 
OR (95% CI) 
 0.34 
0.56 (0.17-1.83) 
0.797 
0.86 (0.28-2.62) 
Urinary tract infection pre-
gestation 
X
2
=0.33, df=2, P= 0.85 
N=162 
Yes 1 (2.9) 2 (3.1) 3 (4.8) 
No 33 (97.1) 63 (96.9) 60 (95.2) 
P value 
OR (95% CI) 
 0.97 
1.05 (0.09-11.99) 
0.67 
1.65 (0.17-16.5) 
Urinary tract infection 1st 
trimester 
X
2
=1.67, df=2, P= 0.433 
N=162 
Yes 0 2 (3.1) 3 (4.8) 
No 34 (100) 63 (96.9) 60 (95.2) 
P value 
OR (95% CI) 
 0.523 
a 
0.365 
a 
High blood pressure pre-
gestation 
X
2
=4.61, df=2, P= 0.1 
N=163 
 
Yes 0 3 (4.6) 0 
No 34 (100) 62 (100) 64 (100) 
P value 
OR (95% CI) 
 0.376 
a 
a 
High blood pressure 1st 
trimester 
X
2
=6.18, df=2, P= 0.045** 
N=163 
Yes 0 4 (6.2) 0 
No 34 (100) 61 (93.8) 64 (100) 
P value 
OR (95% CI) 
 0.282 
a 
a 
Diabetes pre-gestation 
 
N=163 
Yes 0 0 0 
No 34 (100) 65 (100) 64 (100) 
P value  a a 
61 
 
OR (95% CI) 
Diabetes 1st trimester 
X
2
=3.43, df=2, P= 0.18 
N=163 
Yes 2 (5.9) 0 2 (3.1) 
No 32 (94.1) 65 (100) 62 (96.9) 
P value 
OR (95% CI) 
 a 0.518 
0.52 (0.06-3.85) 
Asthma pre-gestation 
X
2
=1.2, df=2, P= 0.548 
N=162 
Yes 0 2 (3.1) 1 (1.6) 
No 34 (100) 63 (96.9) 62 (100) 
P value 
OR (95% CI) 
 0.523a a 
Asthma 1st trimester 
X
2
=4.56, df=2, P= 0.102 
N=162 
Yes 0 3 (4.6) 0 
No 34 (100) 62 (95.4) 63 (100) 
P value 
OR (95% CI) 
 0.376a a 
Convulsions pre-gestation 
A 
N=163 
Yes 0 0 0 
No 34 (100) 65 (100) 64 (100) 
P value 
OR (95% CI) 
 a a 
Convulsions 1st trimester 
A 
N=163 
Yes 0 0 0 
No 34 (100) 65 (100) 64 (100) 
P value 
OR (95% CI) 
 a a 
Vaginal bleeding 
X
2
=3.32, df=2, P= 0.19 
N=162 
Yes 2 (5.9) 2 (3.1) 7 (11.1) 
No 32 (94.1) 63 (96.9) 56 (88.9) 
P value 
OR (95% CI) 
 0.508 
0.51 (0.069-3.77) 
0.405 
2 (0.39-10.21) 
Maternal exposure to X-ray 
1st trimester 
X
2
=1.63, df=2, P= 0.443 
N=164 
Yes 0 3 (4.9) 3 (4.9) 
No 34 (100) 62 (95.4) 62 (95.4) 
P value 
OR (95% CI) 
 0.376 0.376 
Maternal supplement use 
Folic acid pre-gestation 
X
2
=4.43, df=2, P= 0.109 
N=164 
Yes 6 (17.6) 3 (4.6) 7 (10.8) 
No 28 (82.4) 62 (95.4) 58 (89.2) 
P value 
OR (95% CI) 
 0.045** 
0.23 (0.05-0.97) 
0.34 
0.56 (0.17-1.83) 
Folic acid 1st trimester 
X
2
=0.13, df=2, P= 0.938 
N=164 
Yes 20 (58.8) 37 (56.9) 39 (60) 
No 14 (41.2) 28 (43.1) 26 (40) 
P value 
OR (95% CI) 
 0.856 
.93 (0.4-2.15) 
0.91 
1.05 (0.45-2.44) 
Multivitamins pre-gestation 
X
2
=2.41, df=2, P= 0.3 
Yes 4 (11.2) 3 (4.6) 3 (4.6) 
No 30 (88.2) 62 (95.4) 62 (95.4) 
62 
 
N=164 P value 
OR (95% CI) 
 0.203 
0.36 (0.08-1.73) 
0.203 
0.36 (0.08-1.73) 
Multivitamins 1st trimester 
X
2
=2.27, df=2, P= 0.32 
N=181 
Yes 10 (29.4) 12 (18.5) 11 (17.2) 
No 42 (70.6) 53 (81.5) 53 (82.8) 
P value 
OR (95% CI) 
 0.916 
0.95 (0.37-2.41) 
0.776 
0.87 (0.34-2.25) 
Iron pre-gestation 
X
2
=1.22, df=2, P= 0.543 
N=164 
 
Yes 4 (11.8) 4 (6.2) 8 (2.9) 
No 30 (88.2) 61 (93.8) 57 (97.1) 
P value 
OR (95% CI) 
 0.339 
0.49 (0.11-2.1) 
0.937 
1.05 (0.29-3.78) 
Iron 1st trimester 
X
2
=2.39, df=2, P= 0.302 
N=164 
Yes 13 (38.2) 23 (51.4) 18 (25.7) 
No 21 (61.8) 42 (64.6) 47 (74.3) 
P value 
OR (95% CI) 
 0.78 
0.88 (0.37-2.09) 
0.285 
0.62 (0.26-1.49) 
Calcium 1st trimester 
X
2
=0.5, df=2, P= 0.777 
N=196 
Yes 1 (2.9) 4 (6.2) 3 (4.7) 
No 66 (97.1) 61 (93.8) 61 (95.3) 
P value 
OR (95% CI) 
 0.196 
.33 (0.47-39.8) 
0.314 
3.25 (0.33-
32.05) 
Smoking 
Maternal smoking 
X
2
=5.38, df=2, P= 0.068 
N=162 
Yes 1 (2.9) 5 (7.7) 0 
No 33 (97.1) 60 (92.3) 63 (100) 
P value 
OR (95% CI) 
 0.365 
2.7 (0.31-24.5) 
0.291 
a 
Paternal smoking 
X
2
=1.49, df=2, P= 0.476 
N=162 
Yes 9 (26.5) 25 (38.5) 23 (36.5) 
No 25 (73.5) 40 (61.5) 40 (63.5) 
P value 
OR (95% CI) 
 0.235 
1.7 (0.7-4.32) 
0.318 
1.6 (0.64-4) 
Paternal tobacco 
X
2
=1.75, df=2, P= 0.416 
N=171 
Yes 6 (17.6) 19 (29.2) 18 (28.6) 
No 28 (82.4) 46 (70.8) 54 (71.4) 
P value 
OR (95% CI) 
 0.212 
1.93 (0.69-5.41) 
0.4 
1.56 (0.56-4.36) 
Paternal waterpipe 
X
2
=3.31, df=2, P= 0.191 
N=162 
Yes 7 (20.6) 10 (15.4) 5 (7.9) 
No 27 (79.4) 55 (84.6) 58 (92.1) 
P value 
OR (95% CI) 
 0.516 
0.7 (0.24-2.04) 
0.08 
0.33 (0.1-1.14) 
Paternal Jorak 
X
2
=0.89, df=2, P= 0.64 
N=162 
Yes 4 (11.8) 5 (7.7) 4 (6.3) 
No 30 (88.2) 60 (92.3) 59 (93.7) 
P value 
OR (95% CI) 
 0.506 
0.63 (0.16-2.5) 
0.362 
0.51 (0.12-2.18) 
63 
 
Paternal Moasel 
X
2
=2.9, df=2, P= 0.234 
N=162 
Yes 4 (11.8) 6 (9.2) 2 (3.2) 
No 30 (88.2) 59 (90.8) 61 (96.8) 
P value 
OR (95% CI) 
 0.692 
0.76 (0.2-2.91) 
0.117 
0.25 (0.04-1.42) 
Maternal passive smoking 
X
2
=1.29, df=2, P= 0.525 
N=162 
Yes 8 (23.5) 15 (23.1) 10 (15.9) 
No 26 (76.5) 50 (76.9) 53 (84.1) 
P value 
OR (95% CI) 
 0.96 
0.98 (0.37-2.6) 
0.357 
0.61 (0.22-1.74) 
Maternal stress 
Family problems 
X
2
=2.48, df=2, P= 0.29 
N=162 
Yes 17 (50) 22 (33.8) 24 (38.1) 
No 17 (50) 43 (66.2) 39 (61.9) 
P value 
OR (95% CI) 
 0.121 
0.51 (0.22-1.19) 
0.259 
0.62 (0.26-1.43) 
Mother complains of being 
under stress 
X
2
=0.69, df=2, P= 0.71 
N=147 
Yes 17 (50) 12 (41.5) 29 (46) 
No 17 (50) 38 (58.5) 34 (54) 
P value 
OR (95% CI) 
 0.016** 
0.3 (0.1-0.8) 
0.709 
0.85 (0.37- 
1.97) 
Depression pre-gestation 
X
2
=4.73, df=2, P= 0.094 
N=163 
Yes 0 0 3 (4.7) 
No 34 (100) 65 (100) 61 (95.3) 
P value 
OR (95% CI) 
 a 0.37 
a 
Depression 1st trimester 
X
2
=0.47, df=2, P= 0.792 
N=163 
Yes 2 (5.9) 2 (3.1) 3 (4.7) 
No 32 (94.1) 63 (96.9) 61 (95.3) 
P value 
OR (95% CI) 
 0.51 
0.51 (0.07-3.77) 
0.799 
0.79 (0.13-5) 
Severe morning sickness 
X
2
=0.02, df=2, P= 0.991 
N=162 
Yes 4 (11.8) 8 (12.3) 8 (12.7) 
No 30 (88.2) 57 (87.7) 55 (87.3) 
P value 
OR (95% CI) 
 0.937 
.05 (0.29-3.78) 
0.894 
1.09 (0.3-3.9) 
Threatened abortion 
X
2
=2.3, df=2, P= 0.316 
N=162 
Yes 2 (5.9) 2 (3.1) 6 (9.5) 
No 32 (94.1) 63 (96.9) 57 (90.5) 
P value 
OR (95% CI) 
 0.508 
0.51 (0.069-3.77) 
0.538 
1.68 (0.32-8.84) 
Abdominal pain pre-
gestation 
X
2
=057, df=2, P= 0.751 
N=162 
Yes 2 (5.9) 2 (3.1) 2 (3.2) 
No 32 (94.1) 63 (96.9) 61 (96.8)  
P value 
OR (95% CI) 
 0.508 
0.51 (0.069-3.77) 
0.529 
0.52 (0.07-3.9) 
Abdominal pain 1st trimester 
X
2
=1.86, df=2, P= 0.394 
Yes 6 (17.6) 6 (9.2) 6 (9.5) 
No 28 (82.4) 59 (90.8) 57 (90.5) 
64 
 
N=162 
 
P value 
OR (95% CI) 
 0.23 
0.47 (0.14-1.6) 
0.253 
0.49 (0.15-1.66) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-
gestation 
X
2
=0.99, df=2, P= 0.61 
N=162 
Yes 12 (35.3) 22 (33.8) 17 (27) 
No 22 (64.7) 43 (66.2) 46 (73) 
P value 
OR (95% CI) 
 0.886 
0.94 (0.39-2.24) 
0.395 
0.68 (0.28-1.66) 
Exposure to chemicals 1st 
trimester 
X
2
=0.73, df=2, P= 0.695 
Yes 10 (29.4) 22 (33.8) 17 (27) 
No 24 (70.6) 43 (66.2) 46 (73) 
P value 
OR (95% CI) 
 0.654 
1.23 (0.5-3.02) 
0.799 
0.89 (0.35-2.23) 
Exposure to solvents pre-
gestation 
X
2
=0.57, df=2, P= 0.751 
N=162 
Yes 4 (11.8) 10 (15.4) 7 (11.1) 
No 30 (88.2 55 (84.6) 56 (88.9) 
P value 
OR (95% CI) 
 0.625 
1.36 (0.39-4.72) 
0.923 
0.94 (0.25-3.46) 
Exposure to solvents 1st 
trimester 
X
2
=0.77, df=2, P= 0.679 
N=162 
Yes 2 (5.9) 7 (10.8) 7 (11.1) 
No 32 (94.1) 58 (89.2) 56 (88.9) 
P value 
OR (95% CI) 
 0.429 
0.93 (0.38-9.85) 
0.405 
2 (0.39-10.23) 
Exposure to pesticides pre-
gestation 
X
2
=0.11, df=2, P= 0.949 
N=162 
Yes 5 (14.7) 9 (13.8) 10 (15.9) 
No 29 (85.3) 56 (86.2) 53 (84.1) 
P value 
OR (95% CI) 
 0.907 
0.93 (0.29-3.04) 
0.88 
1.09 (0.34-3.5) 
Exposure to pesticides 1st 
trimester 
X
2
=0.22, df=2, P= 0.895 
N=131 
Yes 5 (14.7) 5 (14.7) 11 (17.5) 
No 29 (85.3) 29 (85.3) 52 (82.5) 
P value 
OR (95% CI) 
 1 
1 (0.26-3.83) 
0.728 
1.23 (0.39-3.9) 
Exposure to incense pre-
gestation 
X
2
=1.86, df=2, P= 0.395 
N=139 
Yes 9 (26.5) 25 (38.5) 13 (32.5) 
No 25 (73.5) 40 (61.5) 27 (67.5) 
P value 
OR (95% CI) 
 0.235 
1.7 (0.7-4.32) 
0.572 
1.34 (0.49-3.67) 
Exposure to incense 1st 
trimester 
X
2
=1.86, df=2, P= 0.395 
N=139 
Yes 9 (26.5) 25 (38.5) 12 (30) 
No 25 (73.5) 40 (61.5) 28 (70) 
P value 
OR (95% CI) 
 0.235 
1.7 (0.7-4.32) 
0.737 
1.19 (0.43-3.3) 
Maternal exposure to X-ray Yes 0 3 (4.9) 3 (4.9) 
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1st trimester 
X
2
=1.63, df=2, P= 0.443 
N=164 
No 34 (100) 62 (95.4) 62 (95.4) 
P value 
OR (95% CI) 
 0.376 
a 
0.376 
a 
Type of maternal drinking 
water 
X
2
=4.93, df=2, P= 0.553 
N=160 
Tap 
(reference) 
8 (23.5) 20 (31.2) 12 (19.4) 
Bottled 23 (67.6) 
 
39 (60.9) 45 (72.6) 
P value 
OR (95% CI) 
 0.432 
1.47 (0.56-2.38) 
0.612 
0.77 (0.27-2.14) 
Well 2 (5.9) 5 (7.8) 3 (4.8) 
P value 
OR (95% CI) 
 1 
1 (0.16-6.26) 
1  
1(0.14-7.39) 
Zamzam 1 (2.9) 0 2 (3.2) 
P value 
OR (95% CI) 
 0.24 
a 
0.826 
0.75 (0.06-9.72) 
OR (95% CI) a a a 
Consanguinity 
X
2
=3.85, df=2, P= 0.146 
N=157 
Yes 15 (42.9) 38 (63.3) 36 (58.1) 
No 20 (57.1) 22 (36.7) 26 (41.9) 
P value 
OR (95% CI) 
 0.551 
2.3 (0.98-5.39) 
0.15 
1.85 (0.8-4.27) 
Family history 
X
2
=2.61, df=2, P= 0.626 
N=160 
Yes 14 (41.2) 24 (36.9) 29 (46) 
No 19 (55.9) 40 (61.5) 34 (54) 
P value 
OR (95% CI) 
 0.638 
0.81 (0.35-1.92) 
0.736 
1.16 (0.49-2.71) 
*Homozygous common allele genotype.                  
**The Chi-square statistic is significant at the 0.05 level.  
a
 Could not analyse because the groups contained zero values.                            
If one of the cells contained a zero value, the OR and 95% CI were not calculated.  
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A42: Relationship between maternal IRF6 rs2235375 allele frequency 
and different environmental factors, including: maternal illness, 
medication, stress, supplements, paternal smoking and maternal 
domestic exposure using case-only study design. 
Maternal IRF6 rs2235375 C* (%) G (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
N=326 
 
Yes 18 (13.6) 26 (13.4) 
No 114 (86.4) 168 (86.6) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.952 
0.98 (0.51-1.87) 
Antibiotic at 1st trimester 
N=326 
Yes 21 (15.9) 29 (14.9) 
No 111(84.1) 165 (85.1) 
X
2
 (df), P value 
OR (95% CI) 
0.06 (1) 0.81 
0.93 (0.5-1.7) 
Antipyretic medication 
pre-gestation 
N=328 
Yes 10 (7.5) 12 (6.2) 
No 123 (92.5) 183 (93.8) 
X
2
 (df), P value 
OR (95% CI) 
0.24 (1) 0.628 
0.81 (0.34-1.92) 
Antipyretic medication 
1st trimester 
N=324 
Yes 17 (13) 15 (7.8) 
No 114 (87) 178 (92.2) 
X
2
 (df), P value 
OR (95% CI) 
2.38 (1) 0.127 
0.57 (0.27-1.18) 
Anti-emetic medication 
pre-gestation 
N=326 
Yes 0 2 (1) 
No 132 (100) 192 (99) 
X
2
 (df), P value 
OR (95% CI) 
1.37 (1) 0.24 
3.44 (0.16-72.27) 
Anti-emetic medication 
1st trimester 
N=326 
Yes 21 (15.9) 27 (13.9) 
No 111 (84.1) 167 (86.1) 
X
2
 (df), P value 
OR (95% CI) 
0.25 (1) 0.62 
0.85 (0.46-1.59) 
Contraceptives pre-
gestation 
 
Yes 7 (5.5) 19 (9.8) 
No 121 (94.5) 175 (90.2) 
X
2
 (df), P value 
OR (95% CI) 
1.94 (1) 0.16 
1.88 (0.77-4.6 
Contraceptives 1st 
trimester 
N=260 
Yes 3 (2.3) 3 (2.3) 
No 129 (97.7) 125 (97.7) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.97 
1.03 (0.2-5.21) 
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Illness pre-gestation 
N=326 
Yes 38 (28.8) 52 (26.8) 
No 94 (71.2) 142 (73.2) 
X
2
 (df), P value 
OR (95% CI) 
0.15 (1) 0.69 
0.91 (0.55-1.48) 
Illness 1st trimester 
N=326 
Yes 58 (43.9) 66 (34) 
No 74 (56.1) 128 (66) 
X
2
 (df), P value 
OR (95% CI) 
3.28 (1) 0.071 
0.66 (0.42-1.04) 
Common cold/flu pre-
gestation 
N=326 
Yes 24 (18.2) 42 (21.7) 
No 108 (81.8) 152 (78.3) 
X
2
 (df), P value 
OR (95% CI) 
0.59 (1) 0.44 
1.24 (0.71-2.17) 
Common cold/flu 1st 
trimester 
N=326 
Yes 31 (23.5) 41 (21.1) 
No 101 (76.5) 153 (78.9) 
X
2
 (df), P value 
OR (95% CI) 
0.25 (1) 0.62 
0.87 (0.51-1.48) 
Fever pre-gestation 
N=326 
Yes 11 (8.3) 23 (11.9) 
No 121 (91.7) 171 (88.1) 
X
2
 (df), P value 
OR (95% CI) 
1.04 (1) 0.309 
1.48 (0.7-3.15) 
Fever 1st trimester 
N=326 
Yes 22 (16.7) 24 (12.4) 
No 110 (83.3) 170 (87.6) 
X
2
 (df), P value 
OR (95% CI) 
1.20 (1) 0.27 
0.71 (0.38-1.32) 
Urinary tract infection 
pre-gestation 
N=324 
Yes 5 (3.8) 7 (3.6) 
No 126 (96.2) 186 (96.4) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.93 
0.95 (0.29-3.05) 
Urinary tract infection 1st 
trimester 
N=324 
Yes 3 (2.3) 7 (3.6) 
No 128 (97.7) 186 (96.4) 
X
2
 (df), P value 
OR (95% CI) 
0.47 (1) 0.49 
1.61 (0.41-6.33) 
High blood pressure pre-
gestation 
N=326 
Yes 0 6 (3.1) 
No 132 (100) 188 (96.9) 
X
2
 (df), P value 4.16 (1) 0.04 
High blood pressure 1st 
trimester 
N=334 
Yes 0 8 (4) 
No 132 (100) 194 (96) 
X
2
 (df), P value 5.36 (1) 0.02 
Diabetes pre-gestation 
N=326 
Yes 0 0 
No 132 (100) 194 (100) 
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X
2
 (df), P value a 
Diabetes 1st trimester 
N=326 
Yes 6 (4.6) 2 (1) 
No 126 (95.4) 192 (99) 
X
2
 (df), P value 
OR (95% CI) 
4.05 (1) 0.04 
0.22 (0.04-1.1) 
Asthma pre-gestation 
N=324 
Yes 1 (0.8) 5 (2.6) 
No 130 (99.2) 188 (97.4) 
X
2
 (df), P value 
OR (95% CI) 
1.43 (1) 0.23 
3.46 (0.4-29.94) 
Asthma 1st trimester 
N=324 
Yes 0 6 (3.1) 
No 131 (100) 187 (96.9) 
X
2
 (df), P value 4.15 (1) 0.04 
Convulsions pre-
gestation 
N=326 
Yes 0 0 
No 132 (100) 194 (100) 
X
2
 (df), P value a 
Convulsions 1st trimester 
N=326 
Yes 0 0 
No 132 (100) 194 (100) 
X
2
 (df), P value a 
Vaginal bleeding 
N=324 
Yes 11 (8.4) 11 (5.7) 
No 120 (91.6) 182 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
0.90 (1) 0.346 
0.66 (0.28-1.57) 
Maternal supplement use 
Folic acid pre-gestation 
N=324 
Yes 11 (8.4) 11 (5.7) 
No 120 (91.6) 182 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
0.89 (1) 0.34 
0.83 (0.54-1.27) 
Folic acid 1st trimester 
N=328 
Yes 79 (59.4) 113 (58) 
No 54 (40.6) 82 (42) 
X
2
 (df), P value 
OR (95% CI) 
0.07 (1) 0.793 
0.98 (0.81-1.17) 
Multivitamins pre-
gestation 
N=328 
Yes 11 (8.3) 9 (4.6) 
No 122 (91.7) 186 (95.4) 
X
2
 (df), P value 
OR (95% CI) 
1.85 (1), 0.17 
0.75 (0.46-1.22) 
Multivitamins 1st trimester 
N=362 
Yes 31 (18.5) 35 (18) 
No 137 (81.5) 159 (82) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1), 0.92 
0.97 (0.57-1.66) 
Iron pre-gestation 
N=328 
Yes 16 (12) 16 (8.2) 
No 117 (88) 179 (91.8) 
X
2
 (df), P value 1.31 (1), 0.254 
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OR (95% CI) 0.65 (0.31-1.36) 
Iron 1st trimester 
N=328 
Yes 44 (33.1) 64 (32.8) 
No 89 (66.9) 131 (67.2) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.96 
0.99 (0.62-1.58) 
Calcium 1st trimester 
N=392 
Yes 5 (2.5) 11 (5.7) 
No 193 (97.5) 183 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
2.48 (1) 0.125 
2.32 (0.79-6.81) 
Smoking 
Maternal smoking 
N=324 
Yes 2 (1.5) 10 (5.2) 
No 129 (98.5) 183 (94.8) 
X
2
 (df), P value 
OR (95% CI) 
2.92 (1) 0.09 
3.52 (0.76-16.36) 
Paternal smoking 
N=324 
Yes 41 (31.3) 73 (37.8) 
No 90 (68.7) 120 (62.2) 
X
2
 (df), P value 
OR (95% CI) 
1.46 (1) 0.23 
1.34 (0.83-2.14) 
Paternal tobacco 
N=342 
Yes 30 (21.4) 56 (37.7) 
No 110 (78.6) 146 (72.3) 
X
2
 (df), P value 
OR (95% CI) 
1.74 (1) 0.19 
1.41 (0.85-2.34) 
Paternal waterpipe 
N=324 
Yes 19 (14.5) 25 (13) 
No 112 (85.5) 168 (87) 
X
2
 (df), P value 
OR (95% CI) 
0.16 (1) 0.689 
0.88 (0.46-1.67) 
Maternal passive smoking 
N=366 
Yes 26 (17.7) 40 (18.3) 
No 121 (82.3) 179 (81.7) 
X
2
 (df), P value 
OR (95% CI) 
0.02 (1) 0.89 
1.04 (0.6-1.79) 
Maternal stress 
Family problems 
N=324 
Yes 58(44.3) 68 (35.2) 
No 73 (55.7) 125 (64.8) 
X
2
 (df), P value 
OR (95% CI) 
2.68 (1) 0.10 
0.68 (0.423-1.08) 
Mother complains of being 
under stress 
N=294 
Yes 63 (48.1) 53 (32.5) 
No 68 (51.9) 110 (67.5) 
X
2
 (df), P value 
OR (95% CI) 
7.38 (1) 0.01** 
0.52 (0.32-0.84) 
Depression pre-gestation 
N=326 
Yes 3 (2.3) 3 (1.6) 
No 129 (97.7) 191 (98.4) 
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X
2
 (df), P value 
OR (95% CI) 
0.23 (1) 0.634 
0.675 (0.13-3.4) 
Depression 1st trimester 
N=326 
Yes 7 (5.3) 7 (3.6) 
No 125 (94.7) 187 (96.4) 
X
2
 (df), P value 
OR (95% CI) 
0.55 (1) 0.46 
0.67 (0.23-1.95) 
Severe morning sickness 
N=324 
Yes 16 (21.2) 24 (12.4) 
No 115 (87.8) 169 (87.6) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.95 
1.02 (0.52-2.01) 
Threatened abortion 
N=324 
Yes 10 (7.6) 10 (5.2) 
No 121 (92.4) 183 (94.8) 
X
2
 (df), P value 
OR (95% CI) 
0.81 (1) 0.37 
0.66 (0.27-1.64) 
Abdominal pain pre-
gestation 
N=324 
Yes 6 (4.6) 6 (3.1) 
No 125 (95.4) 187 (96.9) 
X
2
 (df), P value 
OR (95% CI) 
0.47 (1) 0.49 
0.48 (0.15-01.52) 
Abdominal pain 1st 
trimester 
N=344 
Yes 18 (11.9) 18 (9.3) 
No 133 (88.1) 175 (90.7) 
X
2
 (df), P value 
OR (95% CI) 
0.61 (1) 0.44 
0.76 (0.38-1.52) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-
gestation 
N=324 
Yes 41 (31.3) 61 (31.6) 
No 90 (68.7) 132 (68.4) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.953 
1.01 (0.63-1.634) 
Exposure to chemicals 1st 
trimester 
N=320 
Yes 37 (29.1) 61 (31.6) 
No 90 (70.9) 132 (68.4) 
X
2
 (df), P value 
OR (95% CI) 
0.22 (1) 0.639 
1.12 (0.69-1.69) 
Exposure to solvents pre-
gestation 
N=324 
Yes 15 (11.5) 27 (14) 
No 116 (88.5) 166 (86) 
X
2
 (df), P value 
OR (95% CI) 
0.45 (1) 0.505 
1.26 (0.64-2.47) 
Exposure to solvents 1st 
trimester 
N=324 
Yes 11 (8.4) 21 (10.9) 
No 120 (91.6) 172 (89.1) 
X
2
 (df), P value 
OR (95% CI) 
0.54 (1) 0.463 
1.33 (0.62-2.86) 
Exposure to pesticides pre-
gestation 
Yes 20 (15.3) 28 (14.5) 
No 111 (84.7) 165 (85.5) 
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N=324 X
2
 (df), P value 
OR (95% CI) 
0.04 (1) 0.85 
0.94 (0.51-1.75) 
Exposure to pesticides 1st 
trimester 
N=262 
Yes 21 (16) 21 (16) 
No 110 (84) 110 (84) 
X
2
 (df), P value 
OR (95% CI) 
0 (1) 1 
1 (0.52-1.94) 
Exposure to incense pre-
gestation 
N=278 
Yes 31 (28.7) 63 (37.1) 
No 77 (71.3) 107 (62.9) 
X
2
 (df), P value 
OR (95% CI) 
2.06 (1) 0.15 
1.46 (0.87-2.46) 
Exposure to incense 1st 
trimester 
N=278 
Yes 30 (27.8) 62 (36.5) 
No 78 (72.1) 108 (63.5) 
X
2
 (df), P value 
OR (95% CI) 
2.25 (1) 0.13 
1.49 (0.88-2.52) 
Maternal exposure to X-ray 
1st trimester 
N=211 
Yes 3 (2.3) 9 (4.6) 
No 13( 97.7) 186 (95.4) 
X
2
 (df), P value 
OR (95% CI) 
5.51 (1) 0.02** 
0.21 (0.05-0.87) 
Type of maternal drinking 
water 
3.32 (1) 0.35 
N=320 
 
Tap (reference) 28 (21.5) 52 (27.4) 
Bottled 91 (70) 123 (74.7) 
X
2
 (df), P value 
OR (95% CI) 
1.37 (1) 0.243 
1.37 (0.8-2.34) 
Well 7 (5.4) 13 (6.8) 
OR (95% CI) 1 1 (0.36-2.79) 
Zamzam 4 (3.1) 2 (1.1) 
P value 
OR (95% CI) 
0.144 3.71 (0.64-21.56) 
Consanguinity 
N=314 
Yes 66 (50) 112 (61.5) 
No 66 (50) 70 (38.5) 
X
2
 (df), P value 
OR (95% CI) 
4.15 (1) 0.04** 
1.6 (1.02-2.52) 
Family history 
N=320 
Yes 57 (44.2) 77 (40.3) 
No 72 (55.8) 114 (59.7) 
X
2
 (df), P value 
OR (95% CI) 
0.47 (1) 0.491 
0.85 (0.54-1.34) 
*Common allele.  
**Significant level P≤ 0.05 
a
 Not possible to analyse because the groups contain zero values  
If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A43: Comparison between cases and controls for maternal IRF6 
rs2235375 genotypes in relationship to different environmental 
factors including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic 
exposure. 
 
Maternal IRF6 rs2235375 CC* (%) GG  (%) CG (%) 
Environmental factors Study Control Study Control Study Control 
Maternal medication use and illness 
Antibiotic pre-gestation 
Study Group N=163 
Control Group N=179 
Yes 5 (14.7) 1 (2.5) 9 (13.8) 4 (5.2) 8 (12.5) 4 (6.5) 
No 29 (85.3) 39 (97.5) 56 (86.2) 73 (94.8) 56 (87.5) 58 (93.5) 
X
2
 (df), P value 3.68 (1), 0.055 3.17 (1), 0.075 1.34 (1), 0.248 
Antibiotic at 1st 
trimester 
Study Group N=163 
Control Group N=179 
Yes 4 (11.8) 2 (5) 8 (12.3) 6 (7.8) 13 (20.3) 10 (16.1) 
No 30 (88.2) 38 (95) 57 (87.7) 71 (92.2) 51 (79.7) 52 (83.9) 
X
2
 (df), P value 1.13 (1), 0.288 0.81 (1), 0.369 0.37 (1), 0.543 
Antipyretic medication 
pre-gestation 
Study Group N=164 
Control Group N=179 
Yes 4 (11.8) 5 (12.5) 5 (7.7) 8 (10.4) 2 (3.1) 5 (8.1) 
No 30 (88.2) 35 (87.5) 60 (92.3) 69 (89.6) 63 (96.9) 57 (91.9) 
X
2
 (df), P value 0.009 (1), 0.923 0.31 (1), 0.579 1.52 (1), 0.218 
Antipyretic medication 
1st trimester 
Study Group N=162 
Control Group N=176 
Yes 6 (18.2) 3 (7.7) 5 (7.8) 11 (14.5) 5 (7.7) 11 (18) 
No 27 (81.8) 36 (92.3) 59 (92.2) 65 (85.5) 60 (92.3) 50 (82) 
X
2
 (df), P value 1.8 (1), 0.18 1.52 (1), 0.217 3.04 (1), 0.081 
Anti-emetic medication 
pre-gestation 
Study Group N=162 
Control Group N=179 
Yes 0 0 1 (1.5) 0 0 0 
No 34 (100) 40 (100) 64 (98.5) 77 (100) 64 (100) 62 (100) 
X
2
 (df), P value a 1.19 (1), 0.275 a 
Anti-emetic medication 
1st trimester 
Study Group N=163 
Control Group N=179 
Yes 6 (17.6) 3 (7.5) 9 (13.8) 5 (6.6) 9 (14.1) 6 (9.7) 
No 28 (82.4) 37 (92.5) 56 (86.2) 72 (91) 
55 
(85.9)(1),  
56 (90.3) 
X
2
 (df), P value 1.77 (1), 0.183 2.14 (1), 0.143 0.58(1), 0.447 
Contraceptives pre-
gestation 
Study Group N=161 
Control Group N=179 
 
Yes 2 (6.2) 4 (10) 8 (12.3) 4 (5.2) 3 (4.7) 6 (9.7) 
No 30 (93.8) 36 (90) 57 (87.7) 73 (94.8) 61 (95.3) 56 (90.3) 
X
2
 (df), P value 0.32 (1), 0.567 2.31 (1), 0.129 1.18 (1), 0.227 
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Contraceptives 1st 
trimester 
Study Group N=130 
Control Group N=138 
Yes 1 (2.9) 2 (5) 1 (1.5) 2 (2.6) 1 (1.6) 1 (1.6) 
No 33 (97.1) 38 (95) 31 (96.9) 34 (97.1) 63 (98.4) 61 (98.4) 
X
2
 (df), P value 0.19 (1), 0.654 0.2 (1), 0.662 0.001 (1), 0.982 
Illness pre-gestation 
Study Group N=163 
Control Group N=178 
Yes 10 (29.4) 2 (5) 17 (26.2) 11 (14.3) 18 (28.1) 6 (9.8) 
No 24 (70.6) 38 (95) 48 (73.8) 66 (85.7) 46 (71.9) 55 (90.2) 
X
2
 (df), P value 
OR (95% CI) 
8.06 (1), 0.005** 
7.92 (1.639.29) 
3.14 (1), 0.077 
6.73 (1), 0.009** 
3.59 (1.31-9.78) 
Illness 1st trimester 
Study Group N=163 
Control Group N=177 
Yes 16 (47.1) 8 (20) 20 (30.8) 21 (27.6) 26 (40.6) 18 (29.5) 
No 18 (52.9) 32 (80) 45 (69.2) 55 (72.4) 38 (59.4) 43 (70.5) 
X
2
 (df), P value 
OR (95% CI) 
6.14 (1), 0.013** 
3.56(1.27-9.92) 
0.17 (1), 0.683 1.69 (1), 0.193 
Common cold/flu pre-
gestation 
Study Group N=163 
Control Group N=177 
Yes 7 (20.6) 1 (2.5) 16 (24.6) 2 (2.6) 10 (15.6) 4 (6.6) 
No 27 (79.4) 39 (97.5) 49 (75.4) 74 (97.4) 54 (84.4) 57 (93.4) 
X
2
 (df), P value 
OR (95% CI) 
6.24 (1), 0.013** 
10.11 (1.18-86.98) 
15.2 (1), <0.001** 
12.08 (2.66-54.89) 
2.58 (1), 0.108 
Common cold/flu 1st 
trimester 
Study Group N=163 
Control Group N=177 
Yes 8 (23.5) 3 (7.5) 13 (20) 9 (11.8) 15 (23.4) 12 (19.7) 
No 26 (76.5) 37 (92.5) 52 (80) 67 (88.2) 49 (76.6) 49 (80.3) 
X
2
 (df), P value 3.73 (1), 0.053 1.77 (1), 0.183 0.26 (1), 0.609 
Fever pre-gestation 
Study Group N=163 
Control Group N=177 
Yes 4 (11.8) 1 (2.5) 10 (15.4) 2 (2.6) 3 (4.7) 5 (8.2) 
No 30 (88.2) 39 (97.5) 55 (84.6) 74 (97.4) 61 (95.3) 56 (91.8) 
X
2
 (df), P value 
OR (95% CI) 
2.5 (1), 0.114 
7.32 (1), 0.007** 
6.73 (1.42-31.94) 
0.64 (1), 0.423 
Fever 1st trimester 
Study Group N=163 
Control Group N=177 
Yes 6 (17.6) 2 (5) 7 (10.8) 7 (9.2) 10 (15.6) 6 (9.8) 
No 28 (82.4) 38 (95)  58(89.2) 69 (90.8) 54 (84.4) 55 (90.2) 
X
2
 (df), P value 3.05 (1), 0.081 0.1 (1), 0.758 0.94 (1), 0.333 
Urinary tract infection 
pre-gestation 
Study Group N=162 
Control Group N=177 
Yes 1 (2.9) 1 (2.5) 2 (3.1) 1 (1.3) 3 (4.8) 2 (3.3) 
No 33 (97.1) 39 (97.5) 63 (96.9) 75 (98.7) 60 (95.2) 59 (96.7) 
X
2
 (df), P value 0.01 (1), 0.907 0.52 (1), 0.483 0.18 (1), 0.676 
Urinary tract infection 
1st trimester 
Study Group N=162 
Control Group N=177 
Yes 0 1 (2.5) 2 (3.1) 3 (3.9) 3 (4.8) 3 (4.9) 
No 34 (100) 39 (97.5) 63 (96.9) 73 (96.1) 60 (95.2) 58 (95.1) 
X
2
 (df), P value 0.86 (1), 0.57 0.08 (1), 0.781 0.002 (1), 0.29 
High blood pressure pre-
gestation 
Yes 0 0 3 (4.6) 0 0 1 (1.6) 
No 34 (100) 40 (100) 62 (100) 76 (100) 64 (100) 60 (98.4) 
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Study Group N=163 
Control Group N=177 
X
2
 (df), P value a 3.58 (1), 0.058 1.05 (1), 0.479 
High blood pressure 1st 
trimester 
Study Group N=163 
Control Group N=177 
Yes 0 0 4 (6.2) 0 0 2 (3.3) 
No 34 (100) 40 (100) 61 (93.8) 76 (100) 64 (100) 59 (100) 
X
2
 (df), P value a 4.81 (1), 0.028** 0.473 
Diabetes pre-gestation 
Study Group N=163 
Control Group N=177 
Yes 0 0 0 1 (1.3)  0 0 
No 34 (100) 40 (100) 65 (100) 75 (98.7) 64 (100) 61 (100) 
X
2
 (df), P value a 0.86 (1), 0.353 a 
Diabetes 1st trimester 
Study Group N=163 
Control Group N=177 
Yes 2 (5.9) 1 (2.5) 0 2 (2.6) 2 (3.1) 0 
No 32 (94.1) 39 (97.5) 65 (100) 74 (97.4) 62 (96.9) 61 (100) 
X
2
 (df), P value 0.462 0.188 0.164 
Asthma pre-gestation 
Study Group N=162 
Control Group N=177 
Yes 0 0 2 (3.1) 0 1 (1.6) 1 (1.6) 
No 34 (100) 40 (100) 63 (96.9) 76 (100) 62 (100) 60 (98.4) 
X
2
 (df), P value a 2.37 (1), 0.124 0.001 (1),  0.822 
Asthma 1st trimester 
Study Group N=162 
Control Group N=177 
Yes 0 2 (5) 3 (4.6) 1 (1.3) 0 1 (1.6) 
No 34 (100) 38 (95) 62 (95.4) 75 (98.7) 63 (100) 60 (98.4) 
X
2
 (df), P value 1.75 (1), 0.186 1.38 (1), 0.239 1.04 (1), 0.308 
Convulsions pre-
gestation 
Study Group N=163 
Control Group N=177 
Yes 0 0 0 0 0 0 
No 34 (100) 40 (100) 65 (100) 76 (100) 64 (100) 61 (100) 
X
2
 (df), P value a a a 
Convulsions 1st 
trimester 
Study Group N=163 
Control Group N=177 
Yes 0 0 0 0 0 0 
No 34 (100) 40 (100) 65 (100) 76 (100) 64 (100) 61 (100) 
X
2
 (df), P value a a a 
Vaginal bleeding 
Study Group N=162 
Control Group N=177 
Yes 2 (5.9) 1 (2.5) 2 (3.1) 1 (1.3) 7 (11.1) 3 (4.9) 
No 32 (94.1) 39 (97.5) 63 (96.9) 75 (98.7) 56 (88.9) 58 (95.1) 
X
2
 (df), P value 0.54 (1), 0.462 0.52 (1), 0.47 1.6 (1), 0.205 
Maternal exposure to X-
ray 1st trimester 
Study Group N=164 
Control Group N=179 
Yes 0  1 (2.5) 3 (4.9) 1 (1.3) 3 (4.9) 0  
No 34 (100) 39 (97.5) 62 (95.4) 76 (98.7) 62 (95.4) 62 (100) 
X
2
 (df), P value 0.86 (1), 0.353 1.42 (1), 0.234 2.93 (1), 0.087 
Maternal supplement use 
Folic acid pre-gestation 
Study Group N=164 
Control Group N=179 
Yes 6 (17.6) 71(2.5) 3 (4.6) 4 (5.2) 7 (10.8) 12 (19.4) 
No 28 (82.4) 39 (97.5) 62 (95.4) 73 (94.8) 58 (89.2) 50 (80.6) 
X
2
 (df), P value 
OR (95% CI) 
4.92 (1), 0.026** 
0.12 (0.04-0.31) 
0.03 (1), 0.874 1.84 (1), 0.175 
Folic acid 1st trimester Yes 20 (58.8) 28 (70) 37 (56.9) 51 (66.2) 39 (60) 49 (79) 
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Study Group N=164 
Control Group N=179 
No 14 (41.2) 12 (30) 28 (43.1) 26 (33.8) 26 (40) 13 (21) 
X
2
 (df), P value 
OR (95% CI) 
1.01 (1), 0.316 1.3 (1), 0.255 
5.4 (1), 0.02** 
0.4 (0.18-0.87) 
Multivitamins pre-
gestation 
Study Group N=164 
Control Group N=179 
Yes 4 (11.2) 0  3 (4.6) 2 (2.6) 3 (4.6) 2 (3.2) 
No 30 (88.2) 40 (100) 62 (95.4) 75 (97.4) 62 (95.4) 60 (96.8) 
X
2
 (df), P value 4.98 (1), 0.026 0.42 (1), 0.516 0.16 (1), 0.687 
Multivitamins 1st 
trimester 
Study Group N=181 
Control Group N=179 
Yes 10 (29.4) 9 (22.5) 12 (18.5) 13 (16.9) 11 (17.2) 11 (17.7) 
No 42 (70.6) 31 (77.5) 53 (81.5) 64 (83.1) 53 (82.8) 51 (82.3) 
X
2
 (df), P value 0.46 (1), 0.498 0.06 (1), 0.806 0.01 (1), 0.935 
Iron pre-gestation 
Study Group N=164 
Control Group N=218 
Yes 4 (11.8) 5 (6.4) 4 (6.2) 1 (5.6) 8 (2.9) 4 (6.2) 
No 30 (88.2) 73 (93.6) 61 (93.8) 75 (97.4) 57 (97.1) 60 (93.8) 
X
2
 (df), P value 1.13 (1), 0.288 1.1 (1), 0.294 0.51 (1), 0.477 
Iron 1st trimester 
Study Group N=164 
Control Group N=219 
Yes 13 (38.2) 24 (30.8) 23 (51.4) 25 (32.5) 18 (25.7) 26 (40.6) 
No 21 (61.8) 54 (69.2) 42 (64.6) 52 (67.5) 47 (74.3) 38 (59.4) 
X
2
 (df), P value 0.61 (1), 0.714 0.71 (1), 0.607 0.14 (1), 0.142 
Calcium 1st trimester 
Study Group N=196 
Control Group N=179 
Yes 
1 (2.9) 
6 (15) 
4 (6.2) 
9 (11.7) 3 (4.7) 5 (8.1) 
No 66 (97.1) 34 (85) 61 (93.8) 68 (88.3) 61 (95.3) 57 (91.9) 
X
2
 (df), P value 3.12 (1), 0.077 1.3 (1), 0.255 0.6 (1), 0.437 
Smoking  
Maternal smoking 
Study Group N=162 
Control Group N=179 
Yes 1 (2.9) 1 (2.5) 5 (7.7) 5 (6.5) 0 2 (3.2) 
No 33 (97.1) 39 (97.5) 60 (92.3) 72 (93.5) 63 (100) 60 (96.8) 
X
2
 (df), P value 0.014 (1), 0.907 0.08 (1), 0.781 2.06 (1), 0.151 
Paternal smoking 
Study Group N=162 
Control Group N=179 
Yes 9 (26.5) 13 ( 32.5) 25 (38.5) 28 (36.4) 23 (36.5) 22 (35.5) 
No 25 (73.5) 27 (67.5) 40 (61.5) 49 (63.6) 40 (63.5) 40 (64.5) 
X
2
 (df), P value  0.32 (1), 0.572 0.07 (1),  0.797 0.01 (1),0.905 
Paternal tobacco 
Study Group N=171 
Control Group N=179 
Yes 6 (17.6) 11 (27.5) 19 (29.2) 26 (33.8) 18 (28.6) 16 (25.8) 
No 28 (82.4) 29 (72.5) 46 (70.8) 51 (66.2) 54 (71.4) 46 (74.2) 
X
2
 (df), P value 1 (1), 0.315 0.34 (1), 0.563 0,12 (1), 0.728 
Paternal waterpipe 
Study Group N=162 
Control Group N=179 
Yes 7 (20.6) 2 (5) 10 (15.4) 3 (3.9) 5 (7.9) 5 (8.1) 
No 27 (79.4) 38 (95) 55 (84.6) 74 (96.1) 58 (92.1) 57 (91.9) 
X
2
 (df), P value 
OR (95% CI) 
4.2 (1), 0.041** 
4.93 (0.95-25.58) 
5.59 (1), 0.018** 
4.48 (1.18-17.07) 
0.001 (1), 0.979 
Paternal Jorak 
Study Group N=162 
Yes 4 (11.8) 0 5 (7.7) 0 4 (6.3) 2 (3.2) 
No 30 (88.2) 40 (100) 60 (92.3) 77 (100) 59 (93.7) 60 (96.8) 
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Control Group N=179 X
2
 (df), P value 0.498 (1), 0.026** 6.14 (1) 0.013** 0.67 (1), 0.414 
Paternal Moasel 
Study Group N=162 
Control Group N=179 
Yes 4 (11.8) 2 (5) 6 (9.2) 3 (3.9) 2 (3.2) 4 (6.5) 
No 30 (88.2) 38 (95) 59 (90.8) 74 (96.1) 61 (96.8) 58 (93.5) 
X
2
 (df), P value 1.13 (1), 0.288 1.69 (1), 0.194 0.73 (1), 0.391 
Maternal passive 
smoking 
Study Group N=162 
Control Group N=179 
Yes 8 (23.5) 4 (10) 15 (23.1) 17 (22.1) 10 (15.9) 11 (17.7) 
No 26 (76.5) 36 (90) 50 (76.9) 60 (77.9) 53 (84.1) 51 (82.3) 
X
2
 (df), P value 5.25 (2), 0.072 1.45 (2), 0.484 2.62 (2), 0.27 
Maternal stress 
Family problems 
Study Group N=162 
Control Group N=179 
Yes 17 (50) 6 (15) 22 (33.8) 24 (31.2) 24 (38.1) 13 (21) 
No 17 (50) 34 (85) 43 (66.2) 53 (68.8) 39 (61.9) 49 (79) 
X
2
 (df), P value 
OR (95% CI) 
10.51 (1), 0.001** 
5.67 (1.89-16.99) 
0.12 (1), 0.734 
4.39 (1), 0.036** 
2.32 (1.05-5.14) 
Mother complains of 
being under stress 
Study Group N=147 
Control Group N=179 
Yes 17 (50) 9 ( 22.5) 12 (41.5) 29 (37.7) 29 (46) 16 (25.8) 
No 17 (50) 31 (77.5) 38 (58.5) 48 (62.3) 34 (54) 46 (74.2) 
X
2
 (df), P value 
OR (95% CI) 
6.1 (1), 0.014** 
4.22 (1.57-11.36) 
0.22 (1), 0.638 
5.54 (1), 0.019** 
2.45 (1.15-5.21) 
Depression pre-gestation 
Study Group N=163 
Control Group N=177 
Yes 0 0 0 1 (1.3) 3 (4.7) 1 (1.6) 
No 34 (100) 40 (100) 65 (100) 75 (98.7) 61 (95.3) 60 (98.4) 
X
2
 (df), P value a 0.86 (1), 0.353 0.09 (1), 0.333 
Depression 1st trimester 
Study Group N=163 
Control Group N=177 
Yes 2 (5.9) 0 2 (3.1) 2 (2.6) 3 (4.7) 1 (1.6) 
No 32 (94.1) 40 (100) 63 (96.9) 74 (97.4) 61 (95.3) 60 (98.4) 
X
2
 (df), P value 2.42 (1), 0.12 0.03 (1), 0.874 0.93 (1), 0.333 
Severe morning sickness 
Study Group N=162 
Control Group N=177  
Yes 4 (11.8) 2 (5) 8 (12.3) 6 (7.9) 8 (12.7) 4 (6.6) 
No 30 (88.2) 38 (95) 57 (87.7) 70 (92.1) 55 (87.3) 57 (93.4) 
X
2
 (df), P value 1.13 (1), 0.288 0.76 (1), 0.382 1.33 (1), 0.248 
Threatened abortion  
Study Group N=162 
Control Group N=177 
Yes 2 (5.9) 2 (5) 2 (3.1) 0 6 (9.5) 5 (8.2) 
No 32 (94.1) 38 (95) 63 (96.9) 76 (100) 57 (90.5) 56 (91.8) 
X
2
 (df), P value 0.03 (1), 0.867  2.37 (1), 0.124 0.06 (1), 0.795 
Abdominal pain pre-
gestation 
Study Group N=162 
Control Group N=177 
Yes 2 (5.9) 0 2 (3.1) 4 (5.3) 2 (3.2) 1 (1.6) 
No 32 (94.1) 40 (100) 63 (96.9) 72 (94.7) 61 (96.8)  60 (98.4) 
X
2
 (df), P value 0.12 0.521 0.578 
Abdominal pain 1st 
trimester 
Study Group N=162 
Control Group N=177 
Yes 6 (17.6) 2 (5) 6 (9.2) 7 (9.2) 6 (9.5) 2 (3.3) 
No 28 (82.4) 38 (95) 59 (90.8) 69 (90.8) 57 (90.5) 59 (96.7) 
X
2
 (df), P value 3.05 (1), 0.081 0.000 (1), 0.997 2 (1), 0.157 
Maternal domestic environmental exposure 
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Exposure to chemicals 
pre-gestation 
Study Group N=162 
Control Group N=177 
Yes 12 (35.3) 10 (25) 22 (33.8) 20 (26.3) 17 (27) 18 (29.5) 
No 22 (64.7) 30 (75) 43 (66.2) 56 (73.7) 46 (73) 43 (70.5) 
X
2
 (df), P value 0.93 (1), 0.334 0.95 (1), 0.33 0.09 (1), 0.755 
Exposure to chemicals 
1st trimester 
Study Group N=162 
Control Group N=177 
Yes 10 (29.4) 9 (22.5) 22 (33.8) 22 (28.9) 17 (27) 18 (29.5) 
No 24 (70.6) 31 (77.5) 43 (66.2) 54 (71.1) 46 (73) 43 (70.5) 
X
2
 (df), P value 0.46 (1), 0.498 0.39 (1), 0.531 0.1 (1), 0.755 
Exposure to solvents 
pre-gestation 
Study Group N=162 
Control Group N=179 
Yes 4 (11.8) 7 (17.5) 10 (15.4) 8 (10.4) 7 (11.1) 8 (12.9) 
No 30 (88.2 33 (82.5) 55 (84.6) 69 (98.6) 56 (88.9) 54 (87.1) 
X
2
 (df), P value 0.48 (1), 0.489 0.79 (91)0.373 0.1 (1), 0.758 
Exposure to solvents 1st 
trimester 
Study Group N=162 
Control Group N=179 
Yes 2 (5.9) 6 (15) 7 (10.8) 6 (7.8) 7 (11.1) 8 (12.9) 
No 32 (94.1) 34 (85) 58 (89.2) 71 (92.2) 56 (88.9) 54 (87.1) 
X
2
 (df), P value 1.59 (1), 0.208 0.38 (), 0.54 0.1 (1), 0.758 
Exposure to pesticides 
pre-gestation 
Study Group N=162 
Control Group N=179 
Yes 5 (14.7) 9 (22.5) 9 (13.8) 12 (15.6) 10 (15.9) 12 (19.4) 
No 29 (85.3) 31 (77.5) 56 (86.2) 65 (84.4) 53 (84.1) 50 (80.6) 
X
2
 (df), P value 0.73 (1), 0.394 0.09 (1), 0.771 0.26 (1), 0.609 
Exposure to pesticides 
1st trimester 
Study Group N=131 
Control Group N=179 
Yes 5 (14.7) 14 (18.2) 5 (14.7) 5 (12.5) 11 (17.5) 11 (17.7) 
No 29 (85.3) 63 (81.8) 29 (85.3) 35(87.5) 52 (82.5) 51 (82.3) 
X
2
 (df), P value 0.08 (1), 0.782 0.002 (1), 0.966 0.002 (1), 0.967 
Exposure to incense pre-
gestation 
Study Group N=139 
Control Group N=193 
Yes 9 (26.5) 13 (32.5) 25 (38.5) 40 (51.9) 13 (32.5) 25 (39.7) 
No 25 (73.5) 40 (57.5) 40 (61.5) 37 (48.1) 27 (67.5) 38 (60.3) 
X
2
 (df), P value 0.32 (1), 0.572 2.6 (1), 0.108 1.79 (1), 0.181 
Exposure to incense 1st 
trimester 
Study Group N=139 
Control Group N=180 
Yes 9 (26.5) 12 (30) 25 (38.5) 41 (53.2) 12 (30) 25 (39.7) 
No 25 (73.5) 28 (70) 40 (61.5) 36 (46.8) 28 (70) 38 (60.3) 
X
2
 (df), P value 0.11 (1), 0.737 3.1 (1), 0.078 2.31 (1), 0.129 
Maternal drinking 
water  
X
2
= (df), 
Pvalue 
8.6 (3), 0.035** 12.53 (3), 0.006** 2.64 (3), 0.451 
Types of maternal 
drinking water  
Tap 8 (23.5) 3 (7.5) 20 (31.2) 16 (21.1) 12 (19.4) 16 (26.7) 
Bottled 23 (67.6) 31 (77.5) 39 (60.9) 50 (65.8) 45 (72.6) 39 (65) 
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Study Group N=160 
Control Group N=176 
 
 
P value 0.08 0.24 0.33 
Well 
P value 
2 (5.9) 0 5 (7.8) 1 (1.3) 3 (4.8) 1 (1.7) 
0.67 0.23 0.67 
Zamzam 
P value 
OR (95% CI) 
1 (2.9) 6 (15) 0 9 (11.8) 2 (3.2) 4 (6.7) 
0.03** 
16 (1.32-194.63) 
0.033** 0.451 
Consanguinity 
Study Group N=157 
Control Group N=168 
Yes 15 (42.9) 23 (60.5) 38 (63.3) 33 (47.1) 36 (58.1) 37 (61.7) 
No 20 (57.1) 15 (39.5) 22 (36.7) 37 (52.9) 26 (41.9) 23 (38.3) 
X
2
 (df), P value 0.014 (1), 0.131 0.08 (1), 0.065 2.06 (1), 0.685 
Family history 
Study Group N=160 
Control Group N=175 
Yes 14 (41.2) 10 (25) 24 (36.9) 22 (28.6) 29 (46) 15 (24.2) 
No 19 (55.9) 29 (72.5) 40 (61.5) 53 (68.8) 34 (54) 46 (74.2) 
X
2
 (df), P value 
OR (95% CI) 
2.28 (1), 0.32 1.23 (1), 0.54 
7.24 (1), 0.027** 
2.62 (1.22-5.62) 
Homozygous common allele genotype.                          
**The Chi-square statistic is significant at the 0.05 level.  
a
 Could not analyse because the groups contained zero values.                            
If one of the cells contained a zero value, the OR and 95% CI were not calculated.  
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A44: Comparison between cases and controls for maternal IRF6 
rs2235371 genotypes in relationship to the different environmental 
factors including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic exposure. 
Maternal IRF6 rs2235371 genotype CC* (%) TT (%) CT (%) 
Environmental factors  Study Control Study Control Study Control 
Maternal medication use and illness 
Antibiotic use pre-
gestation 
Study Group N=161 
Control Group N=179 
Yes 22 (13.7) 8 (4.6) 0 0 0 1 (20) 
No 139 (86.3) 166 (95.4) 0 0 0 4  (80) 
X
2
 (df), P value 8.43 (1), 0.004** a a 
Antibiotic use 1st 
trimester 
Study Group N=161 
Control Group N=179 
Yes 25 (15.5) 17 (9.8) 0 0 0 1 (20) 
No 136 (84.5) 157 (90.2) 0 0 0 4  (80) 
X
2
 (df), P value 2.5 (1), 0.112 a a 
Antipyretic medication 
pre-gestation 
Study Group N=162 
Control Group N=179 
Yes 11 (6.8) 17 (9.8) 0 0 0 1 (20) 
No 151 (93.2) 157 (90.2) 0 0 0 4  (80) 
X
2
 (df), P value 0.98 (1), 0.323 a a 
Antipyretic medication 
1st trimester 
Study Group N=160 
Control Group N=176 
Yes 16 (10) 22 (12.1) 0 0 0 3 (60) 
No 144 (90) 149 (87.1) 0 0 0 2 (40) 
X
2
 (df), P value 0.67 (1), 0.414 a a 
Anti-emetic medication 
pre-gestation 
Study Group N=161 
Control Group N=179 
Yes 1 (0.6) 0 0 0 0 0 
No 160 (99.4) 174 (100) 0 0 0 5 (100) 
X
2
 (df), P value 1.08 (1), 0.289
 
a a 
Anti-emetic medication 
1st trimester 
Study Group N=161 
Control Group N=179 
Yes 23 (14.3) 12 (6.9) 0 0 0 2 (40) 
No 138 (85.7) 162 (93.1) 0 0 0 3 (60) 
X
2
 (df), P value 4.88 (1), 0.027** a a 
Contraceptives pre- Yes 13 (8.2) 14 (8) 0 0 0 0 
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gestation 
Study Group N=159 
Control Group N=179 
 
No 146 (91.8) 160 (92) 0 0 0 5 (100) 
X
2
 (df), P value 0.002 (1), 0.965 a 
a 
Contraceptives 1st 
trimester 
Study Group N=161 
Control Group N=179 
Yes 3 (1.9) 5 (2.9) 0 0 0 0 
No 158 (98.1) 169 (97.1) 0 0 0 5 (100) 
X
2
 (df), P value 0.37 (1), 0.545
 
a a 
Illness pre-gestation 
Study Group N=161 
Control Group N=178 
Yes 45 (28) 17 (9.8) 0 0 0 2 (40) 
No 116 (72) 156 (90.2) 0 0 0 3 (60) 
X
2
 (df), P value 18.12 (1), <0.001** a a 
Illness 1st trimester 
Study Group N=161 
Control Group N=177 
 
Yes 62 (38.5) 44 (25.6) 0 0 0 3 (60) 
No 99 (61.5) 128 (74.4) 0 0 0 2 (40) 
X
2
 (df), P value 6.4 (1) 0.011** a a 
Common cold/flu pre-
gestation 
Study Group N=161 
Control Group N=91 
Yes  33 (20.5) 3 (3.5) 0 0 0 2 (40) 
No 128 (79.5) 83 (96.5) 0 0 0 3 (60) 
X
2
 (df), P value 25.45 (1), <0.001** a a 
Common cold/flu 1st 
trimester 
Study Group N=161 
Control Group N=177 
Yes 36 (22.4) 23 (13.4) 0 0 0 1 (20) 
No 125 (77.6) 149 (86.6) 0 0 0 4  (80) 
X
2
 (df), P value 4.61 (1), 0.032** a a 
Fever pre-gestation 
Study Group N=161 
Control Group N=177 
Yes 17 (10.6) 6 (3.5) 0 0 0 2 (40) 
No 144 (89.4) 166 (96.5) 0 0 0 3 (60) 
X
2
 (df), P value 6.47 (1), 0.011** a a 
Fever 1st trimester 
Study Group N=161 
Control Group N=177 
Yes 23 (14.3) 14 (8.1) 0 0 0 1 (20) 
No 138 (85.7) 158 (91.9) 0 0 0 4  (80) 
X
2
 (df), P value 3.18 (1), 0.075 a a 
Urinary tract infection 
pre-gestation 
Study Group N=160 
Yes 6 (3.8) 3 (1.7) 0 0 0 0 
No 154 (96.2) 169 (98.3) 0 0 0 5 (100) 
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Control Group N=177 X
2
 (df), P value 1.27 (1), 0.261 a a 
Urinary tract infection 1st 
trimester 
Study Group N=160 
Control Group N=177 
Yes 5 (3.1) 7 (4.1) 0 0 0 1 (20) 
No 155 (96.9) 165 (95.9) 0 0 0 4  (80) 
X
2
 (df), P value 0.21 (1), 0.645 a a 
High blood pressure pre-
gestation 
Study Group N=161 
Control Group N=177 
Yes 3 (1.9) 1 (0.6) 0 0 0 0 
No 158 (98.1) 171 (99.4) 0 0 0 5 (100) 
X
2
 (df), P value 1.15 (1), 0.283 a a 
High blood pressure 1st 
trimester 
Study Group N=161 
Control Group N=177 
Yes 4 (2.5) 2 (1.2) 0 0 0 0 
No 157 (97.5) 170 (98.8) 0 0 0 5 (100) 
X
2
 (df), P value 0.82 (1), 0.365 a a 
Diabetes pre-gestation 
Study Group N=161 
Control Group N=177 
Yes 0 (0) 1 (0.6) 0 0 0 0 
No 161 (100) 171 (99.4) 0 0 0 5 (100) 
X
2
 (df), P value 0.94 (1), 0.333
 
a a 
Diabetes 1st trimester 
Study Group N=161 
Control Group N=177 
Yes 4 (2.5) 3 (1.7) 0 0 0 0 
No 157 (97.5) 169 (98.3) 0 0 0 5 (100) 
X
2
 (df), P value 0.22 (1), 0.638
 
a a 
Asthma pre-gestation 
Study Group N=161 
Control Group N=177 
Yes 3 (1.9) 1 (0.6) 0 0 0 0 
No 158 (98.1) 171 (99.4) 0 0 0 5 (100) 
X
2
 (df), P value 1.17 (1), .28
 
a a 
Asthma 1st trimester 
Study Group N=161 
Control Group N=177 
Yes 3 (1.9) 4 (2.3) 0 0 0 0 
No 158 (98.1) 168 (97.7) 0 0 0 5 (100) 
X
2
 (df), P value 0.08, 0.775
   
Convulsion pre-gestation 
Study Group N=161 
Control Group N=177 
Yes 0 (0) 0 (0) 0 0 0 0 
No 161 (100) 172 (100) 0 0 0 5 (100) 
X
2
 (df), P value a a a 
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Convulsion 1st trimester 
Study Group N=161 
Control Group N=177 
Yes 0 (0) 0 (0) 0 0 0 0 
No 161 (100) 172 (100) 0 0 0 5 (100) 
X
2
 (df), P value a a a 
Vaginal bleeding 
Study Group N=160 
Control Group N=177 
Yes 11 (6.9) 5 (2.9) 0 0 0 0 
No 149 (93.1) 167 (97.1) 0 0 0 5 (100) 
X
2
 (df), P value 0.249
 
a
 a 
Maternal supplement use 
Folic acid pre-gestation 
Study Group N=162 
Control Group N=179 
Yes 16 (9.9) 16 (9.2) 0 0 0 1 (20) 
No 146 (90.1) 158 (90.8) 0 0 0 4  (80) 
X
2
 (df), P value 0.05 (1), 0.832 a
 a 
Folic acid 1st trimester  
Study Group N=162 
Control Group N=179 
Yes 96 (59.3) 124 (71.3) 0 0 0 4  (80) 
No 66 (40.7) 50 (28.7) 0 0 0 1 (20) 
X
2
 (df), P value 4.35 (1), 0.021* a
 a 
Multivitamins pre-
gestation 
Study Group N=162 
Control Group N=91 
Yes 10 (5.3) 2 (2.3) 0 0 0 0 
No 152 (94.7) 84 (97.7) 0 0 0 5 (100) 
X
2
 (df), P value 3.15 (1), 0.076 a
 a 
Multivitamins 1st 
trimester 
Study Group N=161 
Control Group N=179 
Yes 31 (19.3) 32 (18.4) 0 0 0 1 (20) 
No 130 (80.7) 142 (81.6) 0 0 0 4  (80) 
X
2
 (df), P value 0.04 (1), 0.84 a
 a 
Iron pre-gestation 
Study Group N=161 
Control Group N=179 
Yes 12 (7.5) 9 (5.2) 0 0 0 1 (20) 
No 149 (92.5) 165 (94.8) 0 0 0 4  (80) 
X
2
 (df), P value 0.74 (1), 0.39 a
 a 
Iron 1st trimester 
Study Group N=161 
Control Group N=179 
Yes 51 (31.7) 58 (33.3) 0 0 0 3 (60) 
No 110 (68.3) 116 (66.7) 0 0 0 2 (40) 
X
2
 (df), P value 0.11 (1), 0.746 a
 a 
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Calcium 1st trimester 
Study Group N=143 
Control Group N=179 
Yes 8 (5) 20 (11.5) 
0 0 0 0 
No 135 (95) 154 (88.5) 0 0 0 5 (100) 
X
2
 (df), P value 4.65 (1), 0.031** a a 
Smoking 
Maternal smoking  
Study Group N=151 
Control Group N=179 
Yes 6 (3.8) 7 (4) 0 0 0 1 (20) 
No 145 (96.2) 167 (96) 0 0 0 4  (80) 
X
2
 (df), P value 0.02 (1), 0.897 a a 
Paternal smoking 
Study Group N=160 
Control Group N=179 
Yes 57 (35.6) 62 (35.6) 0 0 0 1 (20) 
No 103 (64.4) 112 (64.4) 0 0 0 4  (80) 
X
2
 (df), P value 0.000 (1), , 0.999 a a 
Paternal tobacco 
Study Group N=160 
Control Group N=179 
Yes 43 (26.9) 52 (29.9) 0 0 0 1 (20) 
No 117 (73.1) 122 (70.1) 0 0 0 4  (80) 
X
2
 (df), P value 0.37 (1), 0.542 a a 
Paternal water-pipe 
smoking 
Study Group N=160 
Control Group N= 179 
Yes 22 10 0 0 0 0 
No 138 164 0 0 0 5 
X
2
 (df), P value 6.16 (1), 0.013** a a 
Paternal Jorak 
Study Group N=160 
Control Group N=179 
Yes 13 (8.1) 2 (1.1) 0 0 0 0 
No 147 (91.9) 172 (98.9) 0 0 0 5 (100) 
X
2
 (df), P value 9.46 (1), 0.002** a a 
Paternal Moasel 
Study Group N=160 
Control Group N=179 
Yes 12 (7.5) 9 (5.2) 0 0 0 0 
No 148 (92.5) 165 (94.8) 0 0 0 5 (100) 
X
2
 (df), P value 0.77 (1), 0.381 a a 
Maternal passive smoking 
Study Group N=160 
Control Group N=179 
Yes 33 (20.6) 31 (17.8) 0 0 0 0 
No 127 (79.4) 143 (82.2) 0 0 0 5 (100) 
X
2
 (df), P value 0.43 (1), 0.515 a a 
Maternal stress 
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Mother complains of 
being under stress 
Study Group N=160 
Control Group N=179 
Yes 63 (39.4) 42 (24.1) 0 0 0 1 (20) 
No 97 (60.6) 132 (75.9) 0 0 0 4  (80) 
X
2
 (df), P value 8.98 (1), 0.003** a a 
Depression pre-gestation 
Study Group N=161 
Control Group N=177 
Yes 73 (45.6) 52 (29.9) 0 0 0 2 (40) 
No 87 (54.4) 122 (70.1) 0 0 0 3 (60) 
X
2
 (df), P value 8.82 (1), 0.003** a a 
Depression 1st trimester 
Study Group N=161 
Control Group N=177 
Yes 3 (1.9) 2 (1.2) 0 0 0 0 
No 158 (98.1) 170 (98.8) 0 0 0 5 (100) 
X
2
 (df), P value 0.28 (1), 0.599 a a 
Severe morning sickness  
Study Group N=160 
Control Group N=177 
Yes 7 (4.3) 2 (1.2) 0 0 0 1 (20) 
No 154 (95.7) 170 (98.8) 0 0 0 4  (80) 
X
2
 (df), P value 3.21 (`), 0.073 a a 
Threatened abortion 
Study Group N=160 
Control Group N= 168 
Yes 20 (12.5) 11 (6.4) 0 0 0 1 (20) 
No 140 (87.5) 161 (93.6) 0 0 0 4  (80) 
X
2
 (df), P value 3.65 (1), 0.056 a a 
Abdominal pain pre-
gestation 
Study Group N=160 
Control Group N=177 
Yes 10 (6.2) 7 (4.1) 0 0 0 0 
No 150 (93.8) 156 (95.9) 0 0 0 5 (100) 
X
2
 (df), P value 0.81 (1), 0.368 a a 
Abdominal pain 1st 
trimester 
Study Group N=160 
Control Group N=177 
Yes 6 (3.8) 5 (2.9) 0 0 0 0 
No 154 (96.2) 167 (97.1) 0 0 0 5 (100) 
X
2
 (df), P value 0.18 (1), 0.67 a a 
Mother complains of 
being under stress 
Study Group N=160 
Control Group N=179 
Yes 18 (11.2) 11 (6.4) 0 0 0 0 
No 142 (88.8) 161 (93.6) 0 0 0 5 (100) 
X
2
 (df), P value 2.45 (1), 0.974 a a 
Maternal domestic environmental exposure 
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Exposure to chemicals 
pre-gestation 
Study Group N=160 
Control Group N=177 
Yes 50 (31.2) 47 (27.3) 0 0 0 1 (20) 
No 110 (68.8) 125 (72.7) 0 0 0 4  (80) 
X
2
 (df), P value 0.62 (1), 0.432 a a 
Exposure to chemicals 1st 
trimester 
Study Group N=160 
Control Group N=155 
Yes 48 (30) 26 (27.9) 0 0 0 1 (20) 
No 112 (70) 124 (72.1) 0 0 0 4  (80) 
X
2
 (df), P value 0.674 a a 
Exposure to solvent pre-
gestation 
Study Group N=160 
Control Group N=155 
Yes 
20 (10.18 
(1), 2.5) 
23 (13.2) 
0 0 0 0 
No 140 (87.5) 151 (86.6) 0 0 0 5 (100) 
X
2
 (df), P value 0.04 (1), 0.845 a a 
Exposure to solvent 1st 
trimester 
Study Group N=160 
Control Group N=179 
 
Yes 15 (9.4) 20 (11.5) 0 0 0 0 
No 145 (90.6) 154 (88.5) 0 0 0 5 (100) 
X
2
 (df), P value 0;.4 (1), 0.528 a a 
Exposure to pesticides 
pre-gestation 
Study Group N=187 
Control Group N=179 
Yes 24 (14.7) 32 (18.4) 0 0 0 1 (20) 
No 163 (85.3) 142 (81.6) 0 0 0 4  (80) 
X
2
 (df), P value 0.69 (1), 0.407 a a 
Exposure to pesticides 1st 
trimester 
Study Group N=160 
Control Group N=179 
Yes 28 (17.5) 29 (16.7) 0 0 0 1 (20) 
No 132 (82.5) 145 (83.3) 0 0 0 4  (80) 
X
2
 (df), P value 0.04 (1), 0.84 a a 
Exposure to incense pre-
gestation 
Study Group N=160 
Control Group N=179 
Yes 58 (36.2) 84 (48.3) 0 0 0 1 (20) 
No 102 (63.8) 90 (51.7) 0 0 0 4  (80) 
X
2
 (df), P value 4.93 (1), 0.026** a a 
Exposure to incense in the 
1st trimester 
Study Group N=160 
Control Group N=179 
Yes 58 (36.2) 85 (48.9) 0 0 0 1 (20) 
No 102 (63.8) 89 (51.1) 0 0 0 4  (80) 
X
2
 (df), P value 5.4 (1), 0.02** a a 
Maternal exposure to X- Yes 6 (3.7) 2 (1.1) 0 0 0 0 
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ray in the 1st trimester 
Study Group N=162 
Control Group N=179 
No 156 (96.3) 172 (98.9) 0 0 0 5 (100) 
X
2
 (df), P value 2.36 (1), 0.125 
a a 
Type of maternal drinking 
water 
Study Group N=158 
Control Group N=176 
Tap 40 (25.3) 35 (20.5) 0 0 0 0 
Bottled 105 (66.5) 116 (67.8) 0 0 0 4 (80) 
Well 10 (6.3) 2 (1.2) 0 0 0 0 
Zamzam 3 (1.9) 18 (10.5) 0 0 0 1 (20) 
X
2
 (df), P value 16.4 (3),  0.001** a a 
Consanguinity  
Study Group N=156 
Control Group N=168 
Yes 88 (56.4) 91 (55.8) 0 0 0 2 (40) 
No 68 (43.6) 72 (44.2) 0 0 0 3 (60) 
X
2
 (df), P value 0.01 (1), 0.917 a a 
Family history of birth 
defects 
Study Group N=158 
Control Group N=175 
Yes 65 (40.6) 45 (25.2) 0 0 0 2 (40) 
No 93 (58.1) 125 (71.8) 0 0 0 3 (60) 
X
2
 (df), P value 8.43 (1), 0.015** a a 
**The Chi-square statistic is significant at the 0.05 level              
  * Homozygous common allele genotype 
a
 Not possible to analyse because the groups contain zero values          
       If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A45: Relationship between maternal VAX1 rs4752028 genotypes and 
different environmental factors, including: maternal illness, medication, 
stress, supplements, paternal smoking and maternal domestic exposure 
using case-only study design. 
Maternal VAX1 rs4752028 TT* (%) CC (%) CT (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
X
2
=8.83, df=2, P= 0.012** 
N=162 
Yes 16 (15.5) 4 (36.4) 2 (4.2) 
No 87 (84.5) 7 (63.6) 46 (95.8) 
P value 
OR (95% CI) 
 0.097 
3.11 (0.81-11.86) 
0.062 
0.24 (0.05-1.07) 
Antibiotic at 1st trimester 
X
2
=1.98, df=2, P= 0.371 
N=162 
Yes 19(18.4) 1 (9.1) 5 (10.4) 
No 84 (81.6) 10 (90.9) 43 (89.6) 
P value 
OR (95% CI) 
 0.449 
0.44 (0.05-3.67) 
0.215 
0.51 (0.18-1.47) 
Antipyretic medication pre-gestation 
X
2
=0.12, df=2, P= 0.944 
N=163 
Yes 7 (6.7) 1 (9.1) 3 (6.2) 
No 97 (93.3) 10 (90.9) 45 (93.8) 
P value 
OR (95% CI) 
 0.771 
1.39 (0.15-12.43) 
0.991 
0.92 (0.23-3.74) 
Antipyretic medication 1st trimester 
X
2
=0.041, df=2, P= 0.98 
N=161 
Yes 10 (9.7) 1 (9.1) 5 (10.6) 
No 93 (90.3) 10 (90.9) 42 (89.4) 
P value 
OR (95% CI) 
 0.947 
0.93 (0.11-8.04) 
0.86 
1.11 (0.36-3.44) 
Anti-emetic medication pre-gestation 
X
2
=0.58, df=2, P=750 
N=162 
Yes 1 (1) 0 0 
No 102 (99) 11 (100) 48 (100) 
P value 
OR (95% CI) 
 0.512 
a 
0.831 
A 
Anti-emetic medication 1st trimester 
X
2
=3.97, df=2, P= 0.138 
N=162 
Yes 19 (18.4) 2 (18.2) 3 (6.2) 
No 84 (81.6) 9 (81.8) 45 (93.8) 
P value 
OR (95% CI) 
 0.983 
0.98 (0.2-4.92) 
0.059 
0.29 (0.08-1.05) 
Contraceptives pre-gestation 
X
2
=0.323, df=2, P= 0.851 
N=160 
 
Yes 9 (8.9) 1 (9.1) 3 (6.2) 
No 92 (91.1) 10 (90.9) 45 (93.8) 
P value 
OR (95% CI) 
 0.984 
1.02 (0.12-8.92) 
0.579 
0.68 (0.18-2.64) 
Contraceptives 1st trimester 
X
2
=2.06, df=2, P= 0.357 
N=162 
Yes 1 (1) 0 2 (4.2) 
No 102 (99) 11 (100) 46 (95.8) 
P value 
OR (95% CI) 
 0.512 
a 
0.229 
0.44 (0.09-2.14) 
Illness pre-gestation 
X
2
=1.92, df=2, P= 0.384 
N=162  
Yes 28 (27.2) 5 (45.5) 12 (25) 
No 75 (72.8) 6 (54.5) 36 (75) 
P value 
OR (95% CI) 
 0.213 
2.23 (0.63-7.9) 
0.777 
0.89 (0.41-1.96) 
Illness 1st trimester 
X
2
=4.3, df=2, P= 0.116 
Yes 43 (41.7) 6 (54.5) 13 (27.1) 
No 60 (58.3) 5 (45.5) 35 (72.9) 
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N=162 P value 
OR (95% CI) 
 0.419 
1.67 (0.48-5.84) 
0.085 
0.52 (0.25-1.09) 
Common cold/flu pre-gestation 
X
2
=0.4, df=2, P= 0.818 
N=162 
Yes 21 (20.4) 3 (23.5) 9 (18.8) 
No 82 (79.6) 8 (76.5) 39 (81.2) 
P value 
OR (95% CI) 
 0.596 
1.46 (0.36-6) 
0.814 
0.9 (0.38-2.15) 
Common cold/flu 1st trimester 
X
2
=1.37, df=2, P= 0.504 
N=162 
 
Yes 22 (21.4) 4 (36.4) 10 (20.8) 
No 81 (78.6) 7 (63.6) 38 (79.2) 
P value 
OR (95% CI) 
 0.268 
2.1 (0.56-7.84) 
0.941 
0.97 (0.42-2.25) 
Fever pre-gestation 
X
2
=1.44, df=2, P= 0.487 
N=162 
Yes 13 (12.6) 1 (9.1) 3 (6.2) 
No 90 (87.4) 10 (90.9) 45 (93.8) 
P value 
OR (95% CI) 
 0.736 
0.69 (0.08-5.86) 
0.246 
0.46 (0.13-1.7) 
Fever 1st trimester  
X
2
=2.5, df=2, P= 0.287 
N=162 
Yes 18 (17.5) 1 (9.1) 4 (8.3) 
No  85 (82.5) 10 (90.9) 44 (91.7) 
P value 
OR (95% CI) 
 0.487 
0.47 (0.06-3.92) 
0.147 
0.43 (0.135-1.35) 
Urinary tract infection pre-gestation 
X
2
=0.46, df=2, P= 0.794 
N=161 
Yes 4 (3.9) 0 2 (4.2) 
No 98 (96.1) 11 (100) 46 (95.8) 
P value 
OR (95% CI) 
 0.974 
a 
0.943 
1.07 (0.19-6.03) 
Urinary tract infection 1st trimester 
X
2
=0.54, df=2, P= 0.763 
N=161 
Yes 3 (2.9) 0 2 (4.2) 
No 99 (97.1) 11 (100) 46 (95.8) 
P value 
OR (95% CI) 
 0.891 
a  
0.698 
1.4 (0.23-8.88) 
High blood pressure pre-gestation 
X
2
=4.08, df=2, P= 0.13 
N=162 
Yes 2 (1.9) 1 (9.1) 0 
No 101 (98.1) 10 (90.9) 48 (100) 
P value 
OR (95% CI) 
  0.202 
5.05 (0.42-60.7)  
0.576  
High blood pressure 1st trimester 
X
2
=12.61, df=2, P= 0.002** 
N=162 
Yes 2 (1.9) 2 (18.2 0 
No 101 (98.1) 9 (81.8) 48 (100) 
P value 
OR (95% CI) 
 0.022** 
11.22 (1.41-89.4) 
0.576  
Diabetes pre-gestation 
a 
N=162 
Yes 0 0 0 
No 103 (100) 11 (100) 48 (100) 
P value 
OR (95% CI) 
 a  a  
Diabetes 1st trimester 
X
2
=3.3, df=2, P= 0.192 
Yes 0 1 (9.1) 0 
No 103 (100) 10 (90.9) 48 (100) 
89 
 
N=162 P value 
OR (95% CI) 
 0.042** 
a 
a  
Asthma pre-gestation 
X
2
=2.04, df=2, P= 0.361 
N=176 
Yes 1 (1) 0 1 (1.6) 
No 101 (99) 11 (100) 62 (100) 
P value 
OR (95% CI) 
 0.516 
a 
0.732 
1.63 (0.1-26.52) 
Asthma 1st trimester 
X
2
=2.04, df=2, P= 0.361 
N=176 
Yes 1 (1) 0 1 (1.6) 
No 101 (99) 11 (100) 62 (100) 
P value 
OR (95% CI) 
 0.516 
a 
0.732 
1.63 (0.1-26.52) 
Convulsions pre-gestation 
a 
N=162 
Yes 0 0 0 
No 103 (100) 11 (100) 48 (100) 
P value 
OR (95% CI) 
 a  a  
Convulsions 1st trimester 
a 
N=162 
Yes 0 0 0 
No 103 (100) 11 (100) 48 (100) 
P value 
OR (95% CI) 
  a a  
Vaginal bleeding 
X
2
=0.8, df=2, P= 0.669 
N=161 
Yes 7 (6.9) 0 3 (6.2) 
No 95 (93.1) 11 (100) 45 (93.8) 
P value 
OR (95% CI) 
 0.692  0.888 
0.9 (0.22-3.66) 
Maternal exposure to X-ray 1st 
trimester 
X
2
=4.26, df=2, P= 0.119 
N=163 
Yes 2 (1.9) 0 4 (8.3) 
No 102 (98.1) 11 (100) 44 (91.7) 
OR (95% CI)  0.715 0.083 
4.64 (0.82-26.25) 
Maternal supplement use 
Folic acid pre-gestation 
X
2
=0.03, df=2, P= 0.985 
N=133 
Yes 10 (9.6) 1 (9.1) 5 (10.4) 
No 64 (90.4) 10 (90.9) 43 (89.6) 
P value 
OR (95% CI) 
 0.686 
0.64 (0.07-5.56) 
0.612 
0.74 (0.24-2.33) 
Folic acid 1st trimester 
X
2
=1.52, df=2, P= 0.467 
N=163 
Yes 60 (57.7) 5 (45.5) 31 (64.6) 
No 44 (42.7) 6 (54.5) 17 (35.4) 
P value 
OR (95% CI) 
 0.44 
0.61 (0.18-2.13) 
0.421 
1.34 (0.66-2.71) 
Multivitamins pre-gestation 
X
2
=0.78, df=2, P= 0.676 
N=163 
Yes 7 (6.7) 0 3 (6.2) 
No 97 (93.3) 11 (100) 45 (93.8) 
P value 
OR (95% CI) 
 0.702 
a 
0.912 
0.92 (0.23-3.74) 
Multivitamins 1st trimester 
X
2
=0.17, df=2, P= 0.917 
Yes 22 (21.4) 2 (18.2 9 (18.8) 
No 81 (78.6) 9 (81.8) 39 (81.2) 
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N=162 P value 
OR (95% CI) 
 0.806 
0.82 (0.16-4.06) 
0.712 
0.84 (0.36-2.02) 
Iron pre-gestation 
X
2
=1.57, df=2, P= 0.456 
N=162 
Yes 7 (6.8) 0 5 (10.4) 
No 96 (93.2) 11 (100) 43 (89.6) 
P value 
OR (95% CI) 
 0.697 
a 
0.447 
1.59 (0.48-5.31) 
Iron 1st trimester 
X
2
=0.66, df=2, P= 0.718 
N=179 
Yes 34 (33) 4 (36.4) 18 (25.7) 
No 69 (67) 7 (63.6) 47 (74.3) 
P value 
OR (95% CI) 
 0.823 
1.16 (0.32-4.24) 
0.468 
0.78 (0.39-1.54) 
Calcium 1st trimester 
X
2
=0.81, df=2, P= 0.669 
N=162 
Yes 6 (5.8) 0 2 (4.2) 
No 97 (94.2) 11 (100) 46 (95.8) 
P value 
OR (95% CI) 
 0.776a 0.673 
0.7 (0.14-3.62) 
Smoking 
Maternal smoking 
X
2
=1.08, df=2, P= 0.582 
N=161 
Yes 3 (2.9) 1 (9.1) 2 (4.2) 
No 99 (97.1) 10 (90.9) 46 (95.8) 
P value 
OR (95% CI) 
 0.32 
0.3 (0.31-34.77) 
0.698 
1.43 (0.23-8.88) 
Paternal smoking 
X
2
=1.95, df=2, P= 0.337 
N=161 
Yes 34 (33.3) 6 (54.5) 17 (35.4) 
No 68 (66.7) 5 (45.5) 31 (64.6) 
P value 
OR (95% CI) 
 0.172 
2.4 (0.68-8.43) 
0.802 
0.1 (0.53-2.25) 
Paternal tobacco 
X
2
=2.46, df=2, P= 0.293 
N=161 
Yes 30 (29.4) 4 (36.4) 9 (18.8) 
No 72 (70.6) 7 (63.6) 39 (81.2) 
P value 
OR (95% CI) 
 0.634 
1.37 (90.37-5.03) 
0168 
0.55 (0.24-1.28) 
Paternal waterpipe 
X
2
=2.81, df=2, P= 0.245 
N=161 
Yes 11 (10.8) 3 (27.3) 8 (16.7) 
No 91 (89.2) 8 (72.7) 40 (83.3) 
P value 
OR (95% CI) 
 0.13 
3.1 (0.72-13.45) 
0.316 
1.65 (0.62-4.42) 
Maternal passive smoking 
X
2
=2.8, df=2, P= 0.246 
N=161 
Yes 22 (21.6) 4 (36.4) 7 (14.6) 
No 80 (78.4) 7 (63.6) 41 (85.4) 
P value 
OR (95% CI) 
 0.276 
2.08 (0.56-7.75) 
0.315 
0.62 (0.24-1.57) 
Maternal stress 
Family problems 
X
2
=2.73, df=2, P= 0.255 
N=161 
Yes 35 (34.3) 5 (45.5) 23 (47.9) 
No 67 (65.7) 6 (54.5) 25 (52.1) 
P value 
OR (95% CI) 
 0.466 
1.6 (0.45-5.6) 
0.112 
1.76 (0.88-3.54) 
Mother complains of being under 
stress 
Yes 42 (41.2) 5 (45.5) 26 (54.2) 
No 60 (58.8) 6 (54.5) 22 (45.8) 
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N=161 P value 
OR (95% CI) 
 0.785 
1.19 (0.34-4.16) 
0.138 
1.69 (0.85-3.37) 
Depression pre-gestation 
X
2
=1.75, df=2, P= 0.417 
N=162 
Yes 3 (2.9) 0 0 
No 100 (97.1) 11 (100) 48 (100) 
P value 
OR (95% CI) 
 0.885 
a 
0.424 
a 
Depression 1st trimester 
X
2
=4.19, df=2, P= 0.1.23 
N=162 
Yes 7 (6.8) 0 0 
No 96 (93.2) 11 (100) 48 (100) 
P value 
OR (95% CI) 
 0.697 
a  
0.169 
a 
Severe morning sickness 
X
2
=1.23, df=2, P= 0.54 
N=161 
Yes 14 (13.7) 2 (18.2) 4 (8.3) 
No 88 (86.3) 9 (81.8) 44 (91.7) 
P value 
OR (95% CI) 
 0.688 
1.4 (0.27-7.15) 
0.348 
0.57 (0.18-1.84) 
Threatened abortion 
X
2
=0.18, df=2, P= 0.916 
N=161 
Yes 6 (5.9) 1 (9.1) 3 (6.2) 
No 96 (94.1) 10 (90.9) 45 (93.8) 
P value 
OR (95% CI) 
 0.678 
1.6 (0.17-14.66) 
0.93 
1.06 (0.26-4.46) 
Abdominal pain pre-gestation 
X
2
=2.04, df=2, P= 0.361 
N=124 
Yes 2 (3.1) 0 4 (8.3) 
No 63 (96.9) 11 (100) 44 (91.7)  
P value 
OR (95% CI) 
 0.95 
a  
0.236 
2.86 (0.5-16.32) 
Abdominal pain 1st trimester 
X
2
=0.662, df=2, P= 0.794 
N=161 
Yes 11 (10.8) 3 (23.5) 2 (4.2) 
No 91 (89.2) 8 (76.5) 46 (95.8) 
P value 
OR (95% CI) 
 0.13 
3.1 (0.72-13.45) 
0.195 
0.36 (0.08-1.69) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-gestation 
X
2
=0.894, df=2, P= 0.639 
N=161 
Yes 35 (34.3) 3 (23.5) 13 (27.1) 
No 67 (65.7) 8 (76.5) 35 (72.9) 
P value 
OR (95% CI) 
 0.64 
0.72 (0.18-2.88) 
0.377 
0.71 (0.33-1.52) 
Exposure to chemicals 1st trimester 
X
2
=0.48, df=2, P= 0.785 
N=161 
Yes 33 (32.4) 3 (23.5) 13 (27.1) 
No 69 (97.6) 8 (76.5) 35 (72.9) 
P value 
OR (95% CI) 
 0.732 
0.78 (0.19-3.15) 
0.514 
0.78 (0.36-1.66) 
Exposure to solvents pre-gestation 
X
2
=2.58, df=2, P= 0.276 
N=161 
Yes 10 (9.8) 2 (18.2 9 (18.8) 
No 92 (90.2) 9 (81.8) 39 (81.2) 
P value 
OR (95% CI) 
 0.4 
2.04 (0.39-10.81) 
0.13 
2.12 (0.8-5.63) 
Exposure to solvents 1st trimester 
X
2
=3.07, df=2, P=215 
N=161 
Yes 7 (6.9) 2 (18.2 7 (14.6) 
No 95 (93.1) 9 (81.8) 41 (85.4) 
P value  0.207 0.138 
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OR (95% CI) 3.02 (0.54-16.74) 2.32 (0.76-7.03) 
Exposure to pesticides pre-gestation 
X
2
=3.04, df=2, P=219 
N=161 
Yes 19 (13.8) 1 (9.1) 4 (8.3) 
No 83 (86.2) 10 (90.9) 44 (91.7)  
P value 
OR (95% CI) 
 0.443 
0.44 (0.05-3.62) 
0.112 
0.4 (0.13-1.24) 
Exposure to pesticides 1st trimester 
X
2
=2.05, df=2, P= 0.358 
N=161 
Yes 21 (20.6) 1 (9.1) 6 (12.5) 
No 81 (79.4) 10 (90.9) 42 (87.5) 
P value 
OR (95% CI) 
 0.376 
0.39 (0.05-3.18) 
0.234 
0.55 (0.21-1.47) 
Exposure to incense pre-gestation 
X
2
=0.73, df=2, P= 0.693 
N=161 
Yes 39 (38.2) 3 (23.5) 16 (33.3) 
No 63 (61.8) 8 (76.5) 32 (66.7) 
P value 
OR (95% CI) 
 0.478 
0.61 (0.15-2.42) 
0.561 
0.81 (0.39-1.66) 
Exposure to incense 1st trimester 
X
2
0.44=, df=2, P= 0.802 
N=161 
Yes 38 (37.3) 3 (23.5) 17 (35.4) 
No 64 (62.7) 8 (76.5) 31 (64.6) 
P value 
OR (95% CI) 
 0.516 
0.63 (0.16-2.53) 
0.828 
0.92 (0.45-1.89) 
Type of maternal drinking water 
X
2
=5.21, df=2, P= 0.517 
N=159 
Tap 21 (31.2) 4 (36.4) 15 (31.2) 
Bottled 72 (60.9) 6 (54.5) 28 (58.3) 
P value 
OR (95% CI) 
 0.232 
2.29 (0.59-8.86) 
0.13 
1.84 (0.83-4.06) 
Well 6 (7.8) 1 (9.1) 3 (6.2) 
P value 
OR (95% CI) 
 0.91 
1.14 (0.11-12.24) 
0.649 
1.43 (0.31-6.64) 
Zamzam 1 (0.07) 0 2 (4.2) 
P value 
OR (95% CI) 
 0.786 
a 
0.418 
0.36 (0.03-4.31) 
Consanguinity 
X
2
=1.41, df=2, P= 0.495 
N=156 
Yes 57 (58.2) 8 (66.7) 23 (50) 
No 41 (41.8) 4 (33.3) 23 (50) 
P value 
OR (95% CI) 
 0.573 
1.44 (0.41-5.1) 
0.359 
0.72 (0.36-1.45) 
Family history 
X
2
=6.18, df=2, P= 0.186 
N=159 
Yes 46 (45.1) 5 (45.5) 16 (33.3) 
No 56 (54.9) 6 (54.5) 30 (62.5) 
P value 
OR (95% CI) 
 0.982 
1.01 (0.29-3.54) 
0.241 
0.65 (0.32-1.34) 
* Homozygous common allele genotype                  
**The Chi-square statistic is significant at the 0.05 level 
                             
a
 Not possible to analyse because the groups contain zero values  
If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A46: Maternal VAX1 rs4752028 allele frequency in relationship to 
different environmental factors including: maternal illness, 
medication, stress, supplements, paternal smoking and 
maternal domestic exposure using case-only study design. 
Maternal VAX1 rs4752028 T* (%) C (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
N=324 
Yes 34 (13.4) 10 (14.3) 
No 220 (86.6) 60 (85.7) 
X
2
 (df), P value 
OR (95% CI) 
0.04 (1) 0.846 
1.08 (0.5-2.3) 
Antibiotic at 1st trimester 
N=324 
Yes 43 (16.9) 7 (10.0) 
No 211(83.1) 63 (90.0) 
X
2
 (df), P value 
OR (95% CI) 
2.02 (1) 0.16 
0.55 (0.23-1.27) 
Antipyretic medication 
pre-gestation 
N=326 
Yes 17 (6.6) 5 (7.14) 
No 239 (93.4) 65 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.02 (1) 0.882 
1.08 (0.38-3.04) 
Antipyretic medication 1st 
trimester 
N=322 
Yes 25 (9.9) 7 (10.1) 
No 228 (90.1) 62 (89.9) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.948 
1.03 (0.43-2.49) 
Anti-emetic medication 
pre-gestation 
N=324 
Yes 2 (0.8) 0 (0.0) 
No 252 (99.2) 70 (100.0) 
X
2
 (df), P value 0.55 (1) 0.46 
Anti-emetic medication 1st 
trimester 
N=324 
Yes 41 (16.1) 7 (10.0) 
No 213 (83.9) 63 (90.0) 
X
2
 (df), P value 
OR (95% CI) 
1.64 (1) 0.205 
0.58 (0.25-1.35) 
Contraceptives pre-
gestation 
N=320 
 
Yes 21 (8.4) 5 (7.1) 
No 229 (91.6) 65 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.12 (1) 0.734 
0.84 (0.3-2.31) 
Contraceptives 1st 
trimester 
N=324 
Yes 4 (1.57) 2 (2.9) 
No 250 (98.4) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.50 (1) 0.487 
1.84 (0.33-10.25) 
Illness pre-gestation 
N=324 
Yes 68 (26.8) 22 (31.4) 
No 186 (73.2) 48 (68.6) 
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X
2
 (df), P value 
OR (95% CI) 
0.59 (1) 0.442 
1.25 (0.7-2.23) 
Illness 1st trimester 
N=324 
Yes 99 (39.0) 25 (35.7) 
No 155 (61.0) 45 (64.3) 
X
2
 (df), P value 
OR (95% CI) 
0.25 (1) 0.619 
0.87 (0.5-1.51) 
Common cold/flu pre-
gestation 
N=324 
Yes 51 (20.1) 15 (21.4) 
No 203 (79.9) 55 (78.6) 
X
2
 (df), P value 
OR (95% CI) 
0.06 (1) 0.80 
1.09 (0.57-2.08) 
Common cold/flu 1st 
trimester 
N=324 
Yes 54 (21.3) 18 (25.7) 
No 200 (78.7)  52 (74.3) 
X
2
 (df), P value 
OR (95% CI) 
0.63 (1) 0.428 
1.28 (0.69-2.37) 
Fever pre-gestation 
N=324 
Yes 29 (11.4) 5 (7.1) 
No 225 (88.6) 65 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
1.07 (1) 0.306 
0.6 (0.22-1.6) 
Fever 1st trimester 
N=468 
Yes 184 (42.2) 6(8.6) 
No 214 (53.8) 64 (91.4) 
X
2
 (df), P value 
OR (95% CI) 
35.01 (1) <0.001** 
0.11 (0.05-0.26) 
Urinary tract infection pre-
gestation 
N=322 
Yes 10 (4.0) 2 (2.9) 
No 242 (96 .0) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.19 (1) 0.66 
0.71 (0.15-2.22) 
Urinary tract infection 1st 
trimester 
N=322 
Yes 8 (3.2) 2 (2.9) 
No 244 (96.8) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.89 
0.918 (0.26-3.23) 
High blood pressure pre-
gestation 
N=324 
Yes 4 (1.6) 2 (2.9) 
No 250 (98.4) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.49 (1) 0.48 
0.987 (0.19-4.32) 
High blood pressure 1st 
trimester 
N=324 
Yes 4 (1.6) 4 (5.7) 
No 250 (98.4) 66 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
3.90 (1) 0.05** 
3.77 (0.92-15.55) 
Diabetes pre-gestation 
N=324 
Yes 0 0  
No 254 (100.0) 70 (100.0) 
X
2
 (df), P value a 
Diabetes 1st trimester Yes 0  2 (2.9) 
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N=324 No 254 (100.0) 68 (97.1) 
X
2
 (df), P value 7.30 (1) 0.01** 
Asthma pre-gestation 
N=352 
Yes 3 (1.1) 1 (1.2) 
No 264 (98.9) 84 (98.8) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.968 
1.05 (0.11-10.21) 
Asthma 1st trimester 
N=248 
Yes 8 (4.5) 2 (2.9) 
No 170 (95.5) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.35 (1) 0.56 
0.91 (0.19-4.37) 
Convulsions pre-gestation 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 254 (100.0) 70 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Convulsions 1st trimester 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 254 (100.0) 70 (100.0) 
X
2
 (df), P value a 
Vaginal bleeding 
N=322 
Yes 17 (6.8) 3 (4.3) 
No 235 (93.3) 67 (95.7) 
X
2
 (df), P value 
OR (95% CI) 
0.57 (1) 0.455 
0.62 (0.18-2.18) 
Maternal supplement use 
Folic acid pre-gestation 
N=266 
Yes 25 (0.8) 7 (10.0) 
No 171 (87.2) 63 (90.0) 
X
2
 (df), P value 
OR (95% CI) 
0.37 (1) 0.544 
0.76 (0.31-1.84) 
Folic acid 1st trimester 
N=326 
Yes 151 (59.0) 41 (58.6) 
No 105 (41.0) 29 (41.4) 
X
2
 (df), P value 
OR (95% CI) 
0.00(1) 0.95 
0.98 (0.57-1.68) 
Multivitamins pre-
gestation 
N=326 
Yes 17 (6.6) 3 (4.3) 
No 239 (93.4) 67 (95.7) 
X
2
 (df), P value 
OR (95% CI) 
0.53 (1) 0.471 
0.63 (0.18-2.21) 
Multivitamins 1st trimester 
N=324 
Yes 53 (20.9) 13 (18.6) 
No 201 (79.1) 57 (81.4) 
X
2
 (df), P value 
OR (95% CI) 
0.18 (1) 0.673 
0.86 (0.44-1.7) 
Iron pre-gestation 
N=324 
Yes 19 (7.5) 5 (7.1) 
No 235 (92.5) 65 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.92 
0.95 (0.34-2.65) 
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Iron 1st trimester 
N=358 
Yes 86 (31.7) 26 (29.9) 
No 185 (68.3) 61 (70.1) 
X
2
 (df), P value 
OR (95% CI) 
0.10 (1) 0.746 
0.92 (0.54-1.55) 
Calcium 1st trimester 
N=324 
Yes 14 (5.5) 2 (2.9) 
No 240 (94.5) 68 (97.1) 
X
2
 (df), P value 
OR (95% CI) 
0.82 (1) 0.36 
0.5 (0.11-2.27) 
Smoking 
Maternal smoking 
N=322 
Yes 8 (3.2) 4 (5.7) 
No 244 (96.8) 66 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
0.98 (1) 0.328 
1.85 (0.54-6.33) 
Paternal smoking 
N=322 
Yes 85 (33.7) 29 (41.4) 
No 167 (66.3) 41 (58.6) 
X
2
 (df), P value 
OR (95% CI) 
1.42 (1) 0.235 
1.39 (0.81-2.39) 
Paternal tobacco 
N=322 
Yes 69 (27.4) 17 (24.3) 
No 183 (72.6) 53 (75.7) 
X
2
 (df), P value 
OR (95% CI) 
0.27 (1) 0.605 
0.85 (0.46-1.57) 
Paternal waterpipe 
N=322 
Yes 30 (11.9) 14 (20.0) 
No 222 (88.1) 56 (80.0) 
X
2
 (df), P value 
OR (95% CI) 
3.04 (1) 0.085 
1.85 (0.92-3.72) 
Maternal passive smoking 
N=322 
Yes 51 (20.4) 15 (21.4) 
No 201 (79.8) 55 (78.6) 
X
2
 (df), P value 
OR (95% CI) 
0.05 (1) 0.827 
1.07 (0.56-2.06) 
Maternal stress 
Family problems 
N=322 
Yes 93 (36.9) 33 (41.4) 
No 159 (63.1) 37 (52.9) 
X
2
 (df), P value 
OR (95% CI) 
2.41 (1) 0.122 
1.52 (0.89-2.6) 
Mother complains of being 
under stress 
N=322 
Yes 110 (43.7) 36 (51.4) 
No 142 (56.4) 34 (48.6) 
X
2
 (df), P value 
OR (95% CI) 
1.34 (1) 0.25 
1.37 (0.8-2.32) 
Depression pre-gestation 
N=324 
Yes 6 (2.4) 0 (0.0) 
No 248 (97.6) 70 (100.0) 
X
2
 (df), P value 1.68 (1) 0.19 
Depression 1st trimester Yes 14 (5.5) 0 (0.0) 
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N=324 No 240 (94.5) 70 (100.0) 
X
2
 (df), P value 4.03 (1) 0.04** 
Severe morning sickness 
N=322 
Yes 32 (12.7) 8 (11.4) 
No 220 (87.3) 62 (88.6) 
X
2
 (df), P value 
OR (95% CI) 
0.08 (1) 0.776 
0.89 (0.39-2.02) 
Threatened abortion 
N=322 
Yes 15 (6.0) 5 (7.1) 
No 237 (94.1) 65 (92.9) 
X
2
 (df), P value 
OR (95% CI) 
0.13 (1) 0.715 
1.22 (0.43-3.46) 
Abdominal pain pre-
gestation 
N=248 
Yes 8 (4.5) 4 (5.7) 
No 170 (95.5) 66 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
0.16 (1) 0.688 
1.29 (0.38-4.42) 
Abdominal pain 1st 
trimester 
N=322 
Yes 24 (9.5) 8 (11.4) 
No 228 (90.5) 62 (88.6) 
X
2
 (df), P value 
OR (95% CI) 
0.22 (1) 0.638 
1.23 (0.53-2.86) 
Maternal domestic environmental exposure 
Exposure to chemicals 
pre-gestation 
N=322 
Yes 83 (32.9) 19 (27.1) 
No 169 (67.1) 51 (72.9) 
X
2
 (df), P value 
OR (95% CI) 
0.85 (1) 0.358 
0.76 (0.42-1.37) 
Exposure to chemicals 1st 
trimester 
N=322 
Yes 79 (31.4) 19 (27.1) 
No 173 (68.7) 51 (72.9) 
X
2
 (df), P value 
OR (95% CI) 
0.46 (1) 0.499 
0.82 (0.45-1.47) 
Exposure to solvents pre-
gestation 
N=322 
Yes 29 (11.5) 13 (18.6) 
No 223 (88.5) 57 (81.4) 
X
2
 (df), P value 
OR (95% CI) 
2.41 (1) 0.124 
1.75 (0.86-3.59) 
Exposure to solvents 1st 
trimester 
N=322 
Yes 21 (8.3) 11 (15.7) 
No 231 (91.7) 59 (84.3) 
X
2
 (df), P value 
OR (95% CI) 
3.33 (1) 0.072 
2.05 (0.94-4.49) 
Exposure to pesticides pre-
gestation 
N=322 
Yes 42 (16.7) 6 (8.6) 
No 210 (83.3) 64 (91.4) 
X
2
 (df), P value 
OR (95% CI) 
2.83 (1) 0.099 
0.47 (0.19-1.15) 
Exposure to pesticides 1st 
trimester 
N=322 
Yes 48 (19.1) 8 (11.4) 
No 204 (81.0) 62 (88.6) 
X
2
 (df), P value 2.21 (1) 0.141 
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OR (95% CI) 0.55 (0.25-1.22) 
Exposure to incense pre-
gestation 
N=322 
Yes 94 (37.3) 22 (31.4) 
No 158 (62.7) 48 (68.6) 
X
2
 (df), P value 
OR (95% CI) 
0.82 (1) 0.37 
0.79 (0.45-1.39) 
Exposure to incense 1st 
trimester 
N=322 
Yes 93 (36.9) 23 (32.7) 
No 159 (63.1) 47 (67.1) 
X
2
 (df), P value 
OR (95% CI) 
0.39 (1) 0.533 
0.84 (0.48-1.47) 
Maternal exposure to X-
ray 1st trimester 
N=326 
Yes 8 (3.1) 4 (5.7) 
No 248 (96.9) 66 (94.3) 
X
2
 (df), P value 
OR (95% CI) 
1.04 (1) 0.315 
1.88 (0.55-6.43) 
Type of maternal drinking 
water 
X
2
=2.5, df=1 and P= 0.47 
N=323 
Tap 57 (23) 23 (30.7) 
Bottled 172 (69.4) 45 (60) 
P value 
OR (95% CI) 
2.13 (1) 0.147 
1.54 (0.86-2.77) 
Well 15 (6) 5 (6.7) 
P value 
OR (95% CI) 
0.739 
1.21 (0.39-3.72) 
Zamzam 4 (1.6) 2 (2.7) 
P-value 
OR (95% CI) 
0.076 
0.2 (0.03-1.18) 
Consanguinity 
N=312 
Yes 137 (56.6) 39 (55.7) 
No 105 (43.4) 31 (44.3) 
X
2
 (df), P value 
OR (95% CI) 
0.02 (1) 0.893 
0.96 (0.56-1.65) 
Family history 
N=317 
Yes 108 (43.2) 25 (38.2) 
No 142 (56.8) 42 (61.8) 
X
2
 (df), P value 
OR (95% CI) 
0.75 (1) 0.387 
0.78 (0.45-1.36) 
* Homozygous common allele genotype                              
**The Chi-square statistic is significant at the 0.05 level  
a
 Not possible to analyse because the groups contain zero values           
  If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A47: Comparison between cases and controls for maternal VAX1 
rs4752028 genotypes in relationship to different environmental 
factors including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic exposure.  
 
Maternal VAX1 rs4752028 TT* (%) CC (%) CT (%) 
Environmental factors Study Control Study Control Study Control 
Maternal medication use and illness 
Antibiotic use pre-
gestation 
Study Group N=162 
Control Group 
N=177 
Yes 16 (15.5) 7 (4.9) 4 (36.4) 1 (33.3) 2 (4.2) 1 (3.3) 
No 87 (84.5) 137 (95.1) 7 (63.6) 2 (66.7) 46 (95.8) 29 (96.7) 
X
2
 (df), P value 
OR (95% CI) 
8.1 (1), 0.004** 
3.6 (1.42-9.1) 
0.009 (1), 0.923 0.04 (1), 0.852 
Antibiotic use 1st 
trimester 
Study Group N=162 
Control Group 
N=177 
Yes 19(18.4) 15 (10.4) 1 (9.1) 0 5 (10.4) 3 (10) 
No 84 (81.6) 129 (89.6) 10 (90.9) 3 (100) 43 (89.6) 27 (90) 
X
2
 (df), P value 
OR (95% CI) 
3.26 (1), 0.071 
1.95 (0.94-4.04) 
0.29 (1), 0.588 0.003 (1), 0.953 
Antipyretic 
medication pre-
gestation 
Study Group N=163 
Control Group 
N=177 
Yes 7 (6.7) 14 (9.7) 1 (9.1) 1 (33.3) 3 (6.2) 3 (10) 
No 97 (93.3) 130 (90.3) 10 (90.9) 2 (66.7) 45 (93.8) 27 (90) 
X
2
 (df), P value 0.7 (1), 0.404 1.13 (1), 0.287 0.37 (1), 0.545 
Antipyretic 
medication 1st 
trimester 
Study Group N=161 
Control Group 
N=206 
Yes 10 (9.7) 20 (14.1) 1 (9.1) 2 (66.7) 5 (10.6) 11 (18) 
No 93 (90.3) 122 (85.9) 10 (90.9) 1 (33.3) 42 (89.4) 50 (82) 
X
2
 (df), P value 
1.06 (1), 0.302 
1.07  
4.64 (1), 0.063 
(0.002-1.18) 
0.008  (1), 0.929 
Anti-emetic 
medication pre-
gestation 
Study Group N=162 
Control Group 
N=177 
Yes 1 (1) 0 0 0 0 0 
No 102 (99) 144 (100) 11 (100) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value 1.4 (1), 0.236 
  
Anti-emetic 
medication 1st
 
trimester 
Study Group N=162 
Control Group 
N=177 
Yes 19 (18.4) 12 (8.3) 2 (18.2) 1 (33.3) 3 (6.2) 1 (3.3) 
No 84 (81.6) 132 (91.7) 9 (81.8) 2 (66.7) 45 (93.8) 29 (96.7) 
X
2
 (df), P value 
OR (95% CI) 
5.6 (1), 0.018* 
2.49 (1.15-5.39) 
0.32 (1), 0.571 0.32 (1), 0.57 
Contraceptives pre- Yes 9 (8.9) 13 (9) 1 (9.1) 1 (33.3) 3 (6.2) 0 
100 
 
gestation 
Study Group N=160 
Control Group 
N=177 
No 92 (91.1) 131 (91) 10 (90.9) 2 (66.7) 45 (93.8) 30 (100) 
X
2
 (df), P value 0.001 (1), 0.975 1.13 (1), 0.287 1.95 (1), 0.163 
Contraceptives 1st 
trimester 
Study Group N=162 
Control Group 
N=177 
Yes 1 (1) 5 (3.5) 0 0 2 (4.2) 0 
No 102 (99) 139 (96.5) 11 (100) 3 (100) 46 (95.8) 30 (100) 
X
2
 (df), P value 1.59 (1), 0.208 
 
1.28 (1), 0.257 
Illness pre-gestation 
Study Group N=162 
Control Group 
N=176 
Yes 28 (27.2) 11 (7.7) 5 (45.5) 1 (33.3) 12 (25) 7 (23.3) 
No 75 (72.8) 132 (92.3) 6 (54.5) 2 (66.7) 36 (75) 23 (76.7) 
X
2
 (df), P value 
OR (95% CI) 
17.05 (1), <0.001** 
4.48 (2.11-9.51) 
0.14 (1), 0.707 0.03 (1), 0.868 
Illness 1st trimester 
Study Group N=162 
Control Group 
N=175 
Yes 43 (41.7) 37 (26.1) 6 (54.5) 2 (66.7) 13 (27.1) 8 (26.7) 
No 60 (58.3) 105 (73.9) 5 (45.5) 1 (33.3) 35 (72.9) 22 (73.3) 
X
2
 (df), P value 
OR (95% CI) 
6.68 (1), 0.01** 
2.03 (1.18-3.5) 
0.14 (1), 0.707 0.002 (1), 0.968 
Common cold/flu 
pre-gestation 
Study Group N=162 
Control Group 
N=175 
Yes 21 (20.4) 5 (3.5) 3 (23.5) 0 9 (18.8) 2 (6.7) 
No 82 (79.6) 137 (96.5) 8 (76.5) 3 (100) 39 (81.2) 28 (93.3) 
X
2
 (df), P value 
OR (95% CI) 
17.9 (1), <0.001** 
7.02 (2.55-19.32) 
1.04 (1), 0.308 2.22 (1), 0.136 
Common cold/flu 1st 
trimester 
Study Group N=162 
Control Group 
N=175 
Yes 22 (21.4) 21 (14.8) 4 (36.4) 0 10 (20.8) 3 (10) 
No 81 (78.6) 121 (85.2) 7 (63.6) 3 (100) 38 (79.2) 27 (90) 
X
2
 (df), P value 1.78 (1), 0.182 1.53 (1), 0.217 1.56 (1), 0.212 
Fever pre-gestation 
Study Group N=162 
Control Group 
N=175 
Yes 13 (12.6) 7 (4.9) 1 (9.1) 0 3 (6.2) 1 (3.3) 
No 90 (87.4) 135 (95.1) 10 (90.9) 3 (100) 45 (93.8) 29 (96.7) 
X
2
 (df), P value 
OR (95% CI) 
4.71 (1), 0.03** 
2.79 (1.07-7.25) 
0.29 (1), 0.588 0.32 (1), 0.57 
Fever 1st trimester 
Study Group N=163 
Control Group 
N=175 
Yes 19 (17.5) 13 (9.2) 1 (9.1) 0 4 (8.3) 2 (6.7) 
No 85 (82.5) 129 (90.8) 10 (90.9) 3 (100) 44 (91.7) 28 (93.3) 
X
2
 (df), P value 3.74 (1), 0.053 0.29 (1), 0.588 0.07 (1), 0.788 
Urinary tract 
infection pre-
gestation 
Study Group N=161 
Control Group 
N=175 
Yes 4 (3.9) 2 (1.4) 0 0 2 (4.2) 2 (6.7) 
No 98 (96.1) 140 (98.6) 11 (100) 3 (100) 46 (95.8) 28 (93.3) 
X
2
 (df), P value 1.56 (1), 0.211 a 0.23 (1), 0.626 
Urinary tract 
infection 1st trimester 
Study Group N=161 
Control Group 
N=175 
Yes 3 (2.9) 5 (3.5) 0 0 2 (4.2) 2 (6.7) 
No 99 (97.1) 137 (96.5) 11 (100) 3 (100) 46 (95.8) 28 (93.3) 
X
2
 (df), P value 0.06 (1), 0.808 a 0.24 (1), 0.626 
High blood pressure Yes 2 (1.9) 1 (0.7) 1 (9.1) 0 0 0 
101 
 
pre-gestation 
Study Group N=162 
Control Group 
N=175 
No 
101 
(98.1) 
141 (99.3) 10 (90.9) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value 0.76 (1), 0.385 0.29 (1), 0.588 a 
High blood pressure 
1st trimester 
Study Group N=162 
Control Group 
N=175 
Yes 2 (1.9) 1 (0.7) 2 (18.2 1 (33.3) 0 0 
No 
101 
(98.1) 
141 (99.3) 9 (81.8) 2 (66.7) 48 (100) 30 (100) 
X
2
 (df), P value 0.76 (1), 0.385 0.32 (1), 0.57 a 
Diabetes pre-
gestation 
Study Group N=162 
Control Group 
N=175 
Yes 0 1 (0.7) 0 0 0 0 
No 
103 
(100) 
141 (99.3) 11 (100) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value 0.73 (1), 0.393 a a 
Diabetes 1st trimester 
Study Group N=162 
Control Group 
N=175 
Yes 0 3 (2.1) 1 (9.1) 0 0 0 
No 
103 
(100) 
139 (97.9) 10 (90.9) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value 0.16 (1), 0.689 0.29 (1), 0.588 a 
Asthma pre-gestation 
Study Group N=176 
Control Group 
N=175 
Yes 1 (1) 0 0 1 (33.3) 1 (1.6) 0 
No 101 (99) 142 (100) 11 (100) 2 (66.7) 62 (100) 30 (100) 
X
2
 (df), P value 1.4 (1), 0.237 3.95 (1), 0.047** 1.28 (1), 0.257 
Asthma 1st trimester 
Study Group N=124 
Control Group 
N=175 
Yes 3 (4.6) 3 (2.1) 0 0 2 (4.2) 1 (3.3) 
No 62 (95.4) 139 (97.9) 11 (100) 3 (100) 46 (95.8) 29 (96.7) 
X
2
 (df), P value 0.47 (1), 0.492 a 0.04 (1), 0.852 
Convulsions pre-
gestation 
Study Group N=162 
Control Group 
N=175 
Yes 0 0 0 0 0 0 
No 
103 
(100) 
142 (100) 11 (100) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value a a a 
Convulsions 1st 
trimester 
Study Group N=162 
Control Group 
N=175 
Yes 0 0 0 0 0 0 
No 
103 
(100) 
142 (100) 11 (100) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value a a a 
Vaginal bleeding 
Study Group N=161 
Control Group 
N=175 
Yes 7 (6.9) 5 (3.5) 0 0 3 (6.2) 0 
No 95 (93.1) 137 (96.5) 11 (100) 3 (100) 45 (93.8) 30 (100) 
X
2
 (df), P value 1.42 (1), 0.234 a 1.95 (1), 0.163 
Maternal exposure to 
X-ray in the 1st 
trimester 
Study Group N=163 
Control Group 
N=177 
Yes 2 (1.9) 2 (1.3) 0 0 4 (8.3) 0 
No 
102 
(98.1) 
142 (98.7) 11 (100) 3 (100) 44 (91.7) 30 (100) 
X
2
 (df), P value 0.11 (1), 0.742 a 2.6 (1), 1.05 
Maternal supplement use 
Folic acid pre-
gestation 
Yes 10 (9.6) 13 (9) 1 (9.1) 0 5 (10.4) 4 (13.3) 
No 64 (90.4) 131 (91) 10 (90.9) 3 (100) 43 (89.6) 26 (86.7) 
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Study Group N=133 
Control Group 
N=177 
X
2
 (df), P value 0.03 (1), 0.875 0.29 (1), 0.588 0.15 (1), 0.695 
Folic acid 1st 
trimester 
Study Group N=163 
Control Group 
N=156 
Yes 60 (57.7) 103 (71.5) 5 (45.5) 2 (66.7) 31 (64.6) 7 (76.7) 
No 44 (42.7) 41 (28.5) 6 (54.5) 1 (33.3) 17 (35.4) 2 (23.3) 
X
2
 (df), P value 
OR (95% CI) 
5.13 (1), 0.023** 
0.54 (0.32-0.92) 
0.42 (1), 0.515 1.27 (1), 0.261 
Multivitamins pre-
gestation 
Study Group N=163 
Control Group 
N=177 
Yes 7 (6.7) 2 (1.4) 0 0 3 (6.2) 2 (6.7) 
No 97 (93.3) 142 (98.6) 11 (100) 3 (100) 45 (93.8) 28 (93.3) 
X
2
 (df), P value 
OR (95% CI) 
4.93 (1), 0.044** 
5.12 (1.04-25.19) 
a 0.005 (1), 0.942 
Multivitamins 1st 
trimester 
Study Group N=162 
Control Group 
N=177 
Yes 22 (21.4) 26 (18.1) 2 (18.2 0 9 (18.8) 7 (23.3) 
No 81 (78.6) 118 (81.9) 9 (81.8) 3 (100) 39 (81.2) 23 (76.7) 
X
2
 (df), P value 0.42 (1), 0.518 0.64 (1), 0.425 0.24 (1), 0.626 
Iron pre-gestation 
Study Group N=162 
Control Group 
N=177 
Yes 7 (6.8) 8 (5.6) 0 1 (33.3) 5 (10.4) 1 (3.3) 
No 96 (93.2) 136 (94.4) 11 (100) 2 (66.7) 43 (89.6) 29 (96.7) 
X
2
 (df), P value 0.16 (1), 0.687 3.95 (1), 0.139 1.31 (1), 0.253 
Iron 1st trimester 
Study Group N=179 
Control Group 
N=110 
Yes 34 (33) 25 (32.5) 4 (36.4) 0 18 (25.7) 11 (36.7) 
No 69 (67) 52 (67.5) 7 (63.6) 3 (100) 47 (74.3) 
19 
(63.3.4) 
X
2
 (df), P value 0.42 (1), 0.779 0.64 (1), 0.217 0.24 (1), 0.372 
Calcium 1st trimester 
Study Group N=162 
Control Group 
N=177 
Yes 6 (5.8) 14 (9.7) 0 0 2 (4.2) 6 (20) 
No 97 (94.2) 130 (90.3) 11 (100) 3 (100) 46 (95.8) 24 (80) 
X
2
 (df), P value 1.22 (1), .268 a 
5.03 (1), 0.025** 
0.17 (0.033-0.93) 
Smoking 
Maternal smoking 
Study Group N=161 
Control Group 
N=177 
Yes 3 (2.9) 5 (3.5) 1 (9.1) 0 2 (4.2) 3 (10) 
No 99 (97.1) 139 (96.5) 10 (90.9) 3 (100) 46 (95.8) 27 (90) 
X
2
 (df), P value 0.005 (1), 0.817 0.29 (1), 0.588 1.05 (1), 0.306 
Paternal smoking 
Study Group N=161 
Control Group 
N=177 
Yes 34 (33.3) 54 (37.5) 6 (54.5) 0 17 (35.4) 9 (30) 
No 68 (66.7) 90 (62.5) 5 (45.5) 3 (100) 31 (64.6) 21 (70) 
X
2
 (df), P value 0.45 (1), 0.502 2.86 (1), 0.091 0.24 (1), 0.622 
Paternal tobacco 
Study Group N=161 
Control Group 
N=177 
Yes 30 (29.4) 44 (30.6) 4 (36.4) 0 9 (18.8) 9 (30) 
No 72 (70.6) 100 (69.4) 7 (63.6) 3 (100) 39 (81.2) 21 (70) 
X
2
 (df), P value 0.04 (1), 0.847 1.53 (1), 0.217 1.32 (1), 0.251 
Paternal waterpipe 
smoking 
Study Group N=161 
Control Group 
Yes 11 (10.8) 10 (6.9) 3 (27.3) 0 8 (16.7) 0 
No 91 (89.2) 134 (93.1) 8 (72.7) 3 (100) 40 (83.3) 30 (100) 
X
2
 (df), P value 1.13 (1), 0.288 1.04 (1), 0.308 5.57 (1), 0.018** 
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N=177 
Paternal Jorak 
Study Group N=161 
Control Group 
N=177 
Yes 7 (6.9) 2 (1.4) 1 (9.1) 0 5 (10.4) 0 
No 95 (93.1) 142 (98.6) 10 (90.9) 3 (100) 43 (89.6) 30 (100) 
X
2
 (df), P value 
OR (95% CI) 
5.08 (1), 0.024** 
5.23 (1.06-25.73) 
0.29 (1), .588 3.34 (1), 0.068 
Paternal Moasel 
Study Group N=161 
Control Group 
N=177 
Yes 6 (5.9) 9 (6.2) 2 (18.2 0 4 (8.3) 0 
No 96 (94.1) 135 (93.8) 9 (81.8) 3 (100) 44 (91.7) 30 (100) 
X
2
 (df), P value 0.01 (1), 0.905 0.64 (1), 0.425 2.64 (1), 0.105 
Maternal passive 
smoking 
Study Group N=161 
Control Group 
N=177 
Yes 22 (21.6) 26 (18.1) 4 (36.4) 0 7 (14.6) 6 (20) 
No 80 (78.4) 118 (81.9) 7 (63.6) 3 (100) 41 (85.4) 24 (80) 
X
2
 (df), P value 0.47 (1), 0.493 1.53 (1), 0.217 0.39 (1), 0.532 
Maternal stress 
Family problems 
Study Group N=162 
Control Group 
N=177 
Yes 35 (34.3) 
34 
(23.6.2) 
5 (45.5) 0 23 (47.9) 8 (26.7) 
No 67 (65.7) 110 (76.4) 6 (54.5) 3 (100) 25 (52.1) 22 (73.3) 
X
2
 (df), P value 3.39 (1), 0.066 2.12 (1), 0.145 3.48 (1), 0.062 
Mother complains of 
being under stress 
Study Group N=161 
Control Group 
N=177 
Yes 42 (41.2) 42 (29.2) 5 (45.5) 0 26 (54.2) 11 (36.7) 
No 60 (58.8) 102 (70.8) 6 (54.5) 3 (100) 22 (45.8) 
19 
(63.3.4) 
X
2
 (df), P value 
OR (95% CI) 
3.83 (1), 0.05** 
1.7 (1-2.9) 
2.12 (1), 0.145 2.27 (1), 0.132 
Depression pre-
gestation 
Study Group N=162 
Control Group 
N=175 
Yes 3 (2.9) 2 (1.4) 0 0 0 0 
No 
100 
(97.1) 
140 (98.6) 11 (100) 3 (100) 48 (100) 30 (100) 
X
2
 (df), P value 0.68 (1), 0.411 a a 
Depression 1st 
trimester 
Study Group N=162 
Control Group 
N=175 
Yes 7 (6.8) 2 (1.4) 0 0 0 1 (3.3) 
No 96 (93.2) 140 (98.6) 11 (100) 3 (100) 48 (100) 29 (96.7) 
X
2
 (df), P value 
OR (95% CI) 
4.9 (1), 0.027** 
5.1 (1.04-25.1) 
a 1.62 (1), 0.203 
Severe morning 
sickness 
Study Group N=161 
Control Group 
N=175 
Yes 14 (13.7) 9 (6.3) 2 (18.2 0 4 (8.3) 3 (10) 
No 88 (86.3) 133 (93.7) 9 (81.8) 3 (100) 44 (91.7) 27 (90) 
X
2
 (df), P value 3.79 (91), 0.051 0.64 (1), 0.425 0.06 (1), 0.802 
Threatened abortion 
Study Group N=161 
Control Group 
N=175 
Yes 6 (5.9) 4 (2.8) 1 (9.1) 1 (33.3) 3 (6.2) 2 (6.7) 
No 96 (94.1) 138 (97.2) 10 (90.9) 2 (66.7) 45 (93.8) 28 (93.3) 
X
2
 (df), P value 1.42 (1), 0.234 1.13 (1), 0.287 0.005 (1), 0.942 
Abdominal pain pre-
gestation 
Study Group N=124 
Yes 2 (3.1) 4 (2.8) 0 0 4 (8.3) 1 (3.3) 
No 63 (96.9) 138 (97.2) 11 (100) 3 (100) 44 (91.7) 29 (96.7) 
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Control Group 
N=175 
X
2
 (df), P value 0.23 (1), 0.633 
 
0.04 (1), 0.852 
Abdominal pain 1st 
trimester 
Study Group N=161 
Control Group 
N=175 
Yes 11 (10.8) 8 (5.6) 3 (23.5) 1 (33.3) 2 (4.2) 1 (3.3) 
No 91 (89.2) 134 (94.4) 8 (76.5) 2 (66.7) 46 (95.8) 29 (96.7) 
X
2
 (df), P value 2.19 (1), 0.139 0.04 (1), 0.837 0.07 (1), 0.788 
Maternal domestic environmental exposure 
Exposure to 
chemicals pre-
gestation 
Study Group N=161 
Control Group 
N=126 
Yes 35 (34.3) 37 (26.1) 3 (23.5) 1 (33.3) 13 (27.1) 7 (23.3) 
No 67 (65.7) 56 (73.9) 8 (76.5) 2 (66.7) 35 (72.9) 23 (76.7) 
X
2
 (df), P value 1.95 (1), 0.163 5.09 (1), 0.837 0.14 (1), 0.712 
Exposure to 
chemicals 1st 
trimester 
Study Group N=161 
Control Group 
N=126 
Yes 33 (32.4) 37 (26.1) 3 (23.5) 1 (33.3) 13 (27.1) 8 (26.7) 
No 69 (97.6) 56 (73.9) 8 (76.5) 2 (66.7) 35 (72.9) 22 (73.3) 
X
2
 (df), P value 1.15 (1), 0.284 5.09 (1), 0.837 0.002 (1), 0.968 
Exposure to solvent 
pre-gestation 
Study Group N=161 
Control Group 
N=177 
Yes 10 (9.8) 18 (12.5) 2 (18.2 1 (33.3) 9 (18.8) 3 (10) 
No 92 (90.2) 126 (87.5) 9 (81.8) 2 (66.7) 39 (81.2) 27 (90) 
X
2
 (df), P value 0.43 (1), 0.512 0.32 (1), 0.571 1.09 (1), 0.297 
Exposure to solvent 
1st trimester 
Study Group N=161 
Control Group 
N=177 
Yes 7 (6.9) 17 (11.8) 2 (18.2 1 (33.3) 7 (14.6) 1 (3.3) 
No 95 (93.1) 127 (88.2) 9 (81.8) 2 (66.7) 41 (85.4) 29 (96.7) 
X
2
 (df), P value 1.66 (1|), 0.198 0.32 (1), 0.571 2.58 (1), 0.111 
Exposure to 
pesticides pre-
gestation 
Study Group N=161 
Control Group 
N=177 
Yes 19 (13.8) 26 (18.1) 1 (9.1) 1 (33.3) 4 (8.3) 6 (20) 
No 83 (86.2) 118 (81.9) 10 (90.9) 2 (66.7) 44 (91.7) 24 (80) 
X
2
 (df), P value 0.01 (1), 0.909 1.13 (1), 0.287 2.25 (1), 0.134 
Exposure to 
pesticides 1st 
trimester 
Study Group N=161 
Control Group 
N=177 
Yes 21 (20.6) 22 (15.3) 1 (9.1) 1 (33.3) 6 (12.5) 7 (23.3) 
No 81 (79.4) 122(84.7) 10 (90.9) 2 (66.7) 42 (87.5) 23 (76.7) 
X
2
 (df), P value 1.17 (1), 0.28 1.13 (1), 0.287 1.56 (1), 0.212 
Exposure to incense 
pre-gestation 
Study Group N=161 
Control Group 
N=177 
Yes 39 (38.2) 67 (46.5) 3 (23.5) 3 (100) 16 (33.3) 13 (43.3) 
No 63 (61.8) 77 (53.5) 8 (76.5) 0 32 (66.7) 17 (56.7) 
X
2
 (df), P value 1.67 (1), 0.196 5.09 (1), 0.024** 0.79 (1), 0.374 
Exposure to incense 
in the 1st trimester 
Yes 38 (37.3) 69 (47.9) 3 (23.5) 3 (100) 17 (35.4) 12 (40) 
No 64 (62.7) 75 (52.1) 8 (76.5) 0 31 (64.6) 18 (60) 
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Study Group N=161 
Control Group 
N=177 
X
2
 (df), P value 2.76 (1), 0.097 5.09 (1), 0.024** 0.17 (1), 0.684 
Type of maternal 
drinking water 
X
2
 (df), P value 16.23 (3), 0.001** 0.34 (2), 0.844 2.82 (3), 0.42 
Type of maternal 
drinking water 
Study Group 
N=159 
Control Group 
N=174 
Tap 21 (31.2) 29 (20.6) 4 (36.4) 1 (33.3) 15 (31.2) 5 (16.7) 
Bottled 
P value 
72 (60.9) 93 (66) 6 (54.5) 2 (66.7) 28 (58.3) 23 (76.7) 
0.838 0.835 0.125 
Well 
P value 
6 (7.8) 1 (0.7) 1 (9.1) 0 3 (6.2) 1 (3.3) 
0.059 a 1 
Zamzam 
X
2
 (df), P value 
OR (95% CI) 
1 (0.07) 18 (12.8) 0 0 2 (4.2) 1 (3.3) 
0.016** 
0.07 (0.01-0.62) 
a 0.76 
Consanguinity 
Study Group N=156 
Control Group 
N=166 
Yes 57 (58.2) 77 (57) 8 (66.7) 1 (33.3) 23 (50) 14 (50) 
No 41 (41.8) 58 (43) 4 (33.3) 2 (66.7) 23 (50) 14 (50) 
X
2
 (df), P value 0.29 (1), 0.864 1.11 (1), 0.292 0.000 (1), 1 
Family history 
Study Group N=159 
Control Group 
N=173 
Yes 46 (45.1) 39 (27.9) 5 (45.5) 1 (33.3) 16 (33.3) 6 (20) 
No 56 (54.9) 101 (70.1) 6 (54.5) 2 (66.7) 30 (62.5) 24 (80) 
X
2
 (df), P value 
OR (95% CI) 
10.6 (2), 0.005** 
2.13 (1.24-3.64) 
0.14 (1), 0.707 3.23 (2), 0.199 
**The Chi-square statistic is significant at the 0.05 level                   
           * Homozygous common allele genotype 
a
 Not possible to analyse because the groups contain zero values                                         
If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A48: Relationship between maternal VAX 7078160 genotypes and 
different environmental factors, including: maternal illness, 
medication, stress, supplements, paternal smoking and maternal 
domestic exposure using case-only study design.  
Maternal VAX_7078160 GG** (%)  AA (%) AG (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
X
2
=5.13, df=2, P= 0.077 
N=162 
Yes 18 (14.8) 3 (30.0) 1 (3.3) 
No 104 (85.2) 7 (70.0) 29 (96.7) 
P value 
OR (95% CI) 
 
0.219 
2.48 (0.59-10) 
0.124 
0.2 (0.03-1.56) 
Antibiotic at 1st trimester 
X
2
=2.63, df=2, P= 0.269 
N=162 
Yes 22 (18.0) 1 (10.0) 2 (6.7) 
No 100 (82.0) 9 (90.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.527 
0.51 (0.06-4.19) 
0.143 
0.32 (0.07-1.47) 
Antipyretic medication pre-
gestation 
X
2
=1.15, df=2, P= 0.562 
N=163 
Yes 8 (6.6) 0 (0.0) 3 (9.7) 
No 114 (93.4) 10 (100.0) 28 (90.3) 
P value 
OR (95% CI) 
 
0.766 
a 
0.551 
1.53 (0.8-6.13) 
Antipyretic medication 1st 
trimester 
X
2
=0.033, df=2, P= 0.999 
N=161 
Yes 12 (10.0) 1 (10.0) 3 (9.7) 
No 108 (90.0) 9 (90.0) 28 (90.3) 
P value 
OR (95% CI) 
 
1 
1 (0.12-8.59) 
0.957 
0.96 (0.25-3.65) 
Anti-emetic medication pre-
gestation 
X
2
=0.33, df=2, P=848 
N=162 
Yes 1 (0.8) 0 (0.0) 0 (0.0) 
No 121 (99.2) 10 (100.0) 30 (100.0) 
P value 
OR (95% CI) 
 
0.417 
a 
0.863 
a 
Anti-emetic medication 1st 
trimester 
X
2
=2.03, df=2, P= 0.362 
N=162 
Yes 20 (16.4) 2 (20.0) 2 (6.7) 
No 102 (83.6) 8 (80.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.769 
1.28 (0.25-6.46) 
0.191 
0.36 (0.08-1.65) 
Contraceptives pre-gestation 
X
2
=1.03, df=2, P= 0.597 
N=160 
 
Yes 10 (8.3) 0 (0.0) 3 (10.0) 
No 110 (91.7) 10 (100.0) 27 (90.0) 
P value 
OR (95% CI) 
 
0.641 
a 
0.772 
1.22 (0.31-4.75) 
Contraceptives 1st trimester 
X
2
=0.58, df=2, P= 0.748 
N=162 
Yes 2 (1.6) 0 (0.0) 1 (3.3) 
No 120 (98.4) 10 (100.0) 29 (96.7) 
P value 
OR (95% CI) 
 
0.6 
a 
0.558 
2.22 (0.2-25.37) 
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Illness pre-gestation 
X
2
=2.54, df=2, P=280 
N=162 
Yes 30 (24.6) 4 (40.0) 11 (36.7) 
No 92 (75.4) 6 (60.0) 19 (63.3) 
P value 
OR (95% CI) 
 
0.29 
2.04 (0.54-7.7) 
0.19 
1.78 (0.76-4.15) 
Illness 1st trimester 
X
2
=0.63, df=2, P= 0.729 
N=162 
Yes 46 (37.7) 5 (50.0) 11 (36.7) 
No 76 (62.3) 5 (50.0) 19 (63.3) 
P value 
OR (95% CI) 
 
0.446 
1.65 (0.45-6.02) 
0.916 
0.96 (0.42-2.19) 
Common cold/flu pre-
gestation 
X
2
=2.13, df=2, P= 0.345 
N=162 
Yes 22 (18.0) 2 (20.06) 9 (30.0) 
No 100 (82.0) 8 (80.0) 21 (70.0) 
P value 
OR (95% CI) 
 
0.877 
1.14 (0.23-5.72) 
0.15 
1.95 (0.79-4.83) 
Common cold/flu 1st 
trimester 
X
2
=2.06, df=2, P= 0.357 
N=162 
 
Yes 25 (20.5) 4 (40.0) 7 (23.3) 
No 97 (79.5) 6 (60.0) 23 (76.7) 
P value 
OR (95% CI) 
 
0.164 
2.59 (0.68-9.87) 
0.733 
1.28 (0.46-3.06) 
Fever pre-gestation 
X
2
=0.32, df=2, P= 0.854 
N=162 
Yes 12 (9.8) 1 (10.0) 4 (13.3) 
No 110 (90.2) 9 (90.0) 26 (86.7) 
P value 
OR (95% CI) 
 
0.987 
1.02 (0.12-8.75) 
0.578 
1.4 (0.42-4.73) 
Fever 1st trimester 
X
2
=0.74, df=2, P= 0.69 
N=162 
Yes 18 (14.8) 2 (20.0) 3 (10.0) 
No 104(85.2) 8 (80.0) 27 (90.0) 
P value 
OR (95% CI) 
 
0.658 
1.44 (0.28-7.36) 
0.502 
0.64 (0.18-2.34) 
Urinary tract infection pre-
gestation 
X
2
=2.31, df=2, P= 0.314 
N=161 
Yes 5 (4.1) 1 (10.0) 0 (0.0) 
No 116 (95.9) 9 (90.0) 30 (100.0) 
P value 
OR (95% CI) 
 
0.41 
2.58 (0.27-24.5) 
0.478 
a 
Urinary tract infection 1st 
trimester 
X
2
=1.71, df=2, P= 0.426 
N=161 
Yes 5 (4.1) 0 (0.0) 0 (0.0) 
No 116 (95.9) 10 (100) 30 (100.0) 
P value 
OR (95% CI) 
0.93 
0.996 
a 
0.478 
a 
High blood pressure pre-
gestation 
X
2
=4.25, df=2, P= 0.119 
N=162 
Yes 2 (1.6) 1 (10.0) 0 (0.0) 
No 120 (98.4) 9 (90.0) 30 (100.0) 
P value 
OR (95% CI) 
 6.67 (0.55-80.75) a 
High blood pressure 1st 
trimester 
N=162 
Yes 2 (1.6) 2 (20.0) 0 (0.0) 
No 120 (98.4) 8 (80.0) 30 (100.0) 
P value 
OR (95% CI) 
 
0.011** 
15 (1.86-120.86) 
0.88 
a 
High blood pressure 1st Yes 2 (1.6) 2 (20.0) 0 (0.0) 
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trimester 
X
2
=13.87, df=2, P= 0.001** 
N=162 
No 120 (98.4) 8 (80.0) 30 (100.0) 
P value 
OR (95% CI) 
 
0.011** 
15 (1.86-120.86) 
0.88 
a 
Diabetes pre-gestation 
a 
N=162 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
No 
122 
(100.0) 
10 (100.0) 30 (100.0) 
P value 
OR (95% CI) 
 a a 
Diabetes 1st trimester 
X
2
=3.12, df=2, P= 0.211 
N=162 
Yes 3 (2.5) 1 (10.0) 0 (0.0) 
No 119 (97.5) 9 (90.0) 30 (100.0) 
P value 
OR (95% CI) 
 
0.219 
4.41 (0.42-46.79) 
0.704 
a 
Asthma pre-gestation 
X
2
=4.69, df=2, P= 0.096 
N=161 
Yes 1 (0.8) 0 (0.0) 2 (6.7) 
No 120 (99.2) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.42 
a 
0.084 
8.57 (0.75-97.9) 
Asthma 1st trimester 
X
2
=4.69, df=2, P= 0.096 
N=161 
Yes 1 (0.8) 0 (0.0) 2 (6.7) 
No 120 (99.2) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.42 
a 
0.084 
8.57 (0.75-97.9) 
Convulsions pre-gestation 
a 
N=162 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
No 
122 
(100.0) 
10 (100.0) 30 (100.0) 
P value 
OR (95% CI) 
 a a 
Convulsions 1st trimester 
a 
N=161 
Yes 8 (6.6) 0 (0.0) 2 (6.7) 
No 113 (93.4) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.761 
a 
0.991 
1 (0.2-5.02) 
Maternal exposure to X-ray 
1st trimester 
X
2
=1.11, df=2, P= 0.574 
N=163 
Yes 4 (3.3) 0 (0.0) 2 (6.5) 
No 118 (96.7) 10 (100.0) 29 (93.5) 
P value 
OR (95% CI) 
 
0.882 
a 
0.798 
2.03 (0.36-11.65) 
Maternal supplement use 
Folic acid pre-gestation 
N=162 
Yes 10 (8.2) 2 (20.0) 4 (12.9) 
No 112 (91.8) 8 (80.0) 26 (87.1) 
P value 
OR (95% CI) 
 
0.229 
2.8 (0.52-15.01) 
0.388 
1.72 (0.5-5.93) 
Folic acid 1st trimester 
X
2
=0.72, df=2, P= 0.697 
N=163 
Yes 72 (59.0) 7 (70.0) 17 (54.8) 
No 50 (41.0) 3 (30.0) 14 (45.2) 
P value 
OR (95% CI) 
 
0.499 
1.62 (0.4-6.57) 
0.67 
0.84 (0.38-1.87) 
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Multivitamins pre-gestation 
X
2
=3.43, df=2, P= 0.18 
N=163 
Yes 6 (4.9) 0 (0.0) 4 (12.9) 
No 116 (95.1) 10 (100.0) 27 (87.1) 
P value 
OR (95% CI) 
 
0.916 
a 
0.122 
2.86 (0.76-10.86) 
Multivitamins 1st trimester 
X
2
=0.61, df=2, P= 0.737 
N=162 
Yes 24 (19.7) 3 (30.0) 6 (20.0) 
No 98 (80.3) 7 (70.0) 24 (80.0) 
P value 
OR (95% CI) 
 
0.441 
1.75 (0.42-7.27) 
0.968 
1.02 (0.38-2.77) 
Iron pre-gestation 
X
2
=8.84, df=2, P= 0.012** 
N=162 
Yes 6 (4.9) 0 (0.0) 6 (20.0) 
No 116 (95.1) 10 (100.0) 24 (80.0) 
P value 
OR (95% CI) 
 0.916a 
0.011** 
4.83 (1.44-16.27) 
Iron 1st trimester 
X
2
=1.86, df=2, P= 0.395 
N=162 
Yes 36 (29.5) 5 (50.0) 10 (33.3) 
No 86 (70.5) 5 (50.0) 20 (66.7) 
P value 
OR (95% CI) 
 
0.189 
2.39 (0.65-8.76) 
0.683 
1.19 (0.51-2.8) 
Calcium 1st trimester 
X
2
=0.85, df=2, P= 0.654 
N=162 
Yes 7 (5.7) 0 (0.0) 1 (3.3) 
No 115 (94.3) 10 (100.0) 29 (96.7) 
P value 
OR (95% CI) 
 
0.836 
a 
0.602 
0.57 (0.07-4.79) 
Smoking 
Maternal smoking 
X
2
=1.17, df=2, P= 0.557 
N=161 
Yes 4 (3.3) 0 (0.0) 2 (6.7) 
No 117 (96.7) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.886 
a 
0.408 
2.09 (0.36-11.98) 
Paternal smoking 
X
2
=3.65, df=2, P= 0.161 
N=161 
Yes 43 (35.5) 6 (60.0) 8 (26.7) 
No 78 (64.5) 4 (40.0) 22 (73.3) 
P value 
OR (95% CI) 
 
0.137 
2.72 (0.73-10.17) 
0.36 
0.66 (0.27-1.61) 
Paternal tobacco 
X
2
=3.95, df=2, P= 0.139 
N=161 
Yes 35 (28.9) 4 (40.0) 4 (13.3) 
No 86 (71.7) 6 (60.0) 26 (86.7) 
P value 
OR (95% CI) 
 
0.465 
1.64 (0.44-6.16) 
0.09 
0.38 (0.12-1.16) 
Paternal waterpipe 
X
2
=6.98, df=2, P= 0.03** 
N=161 
Yes 13 (10.7) 4 (40) 5 (16.7) 
No 108 (89.3) 6 (60) 25 (83.3) 
P value 
OR (95% CI) 
 
0.016** 
5.54 (1.38-22.23) 
0.374 
1.66 (0.54-5.09) 
Maternal passive smoking 
X
2
=3.28, df=2, P= 0.194 
N=161 
Yes 25 (20.7) 4 (40.0) 4 (13.3) 
No 96 (79.3) 6 (60.0) 26 (86.7) 
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P value 
OR (95% CI) 
 
0.169 
2.56 (0.67-9.77) 
0.366 
0.59 (0.19-1.85) 
Maternal stress 
Family problems 
X
2
=2.64, df=2, P= 0.267 
N=161 
Yes 43 (35.5) 5 (50.0) 15 (50.0) 
No 78 (64.5) 5 (50.0) 15 (50.0) 
P value 
OR (95% CI) 
 
0.367 
1.81 (0.5-6.62) 
0.148 
1.81 (0.81-4.06) 
Mother complains of being 
under stress 
X
2
=3.21, df=2, P= 0.201 
N=161 
Yes 50 (41.3) 6 (60.0) 17 (56.7) 
No 71 (58.7) 4 (40.0) 13 (43.3) 
P value 
OR (95% CI) 
 
0.26 
2.13 (0.57-7.94) 
0.133 
1.86 (0.83-4.16) 
Depression pre-gestation 
X
2
=0.58, df=2, P= 0.748 
N=162 
Yes 2 (1.6) 0 (0.0) 1 (3.3) 
No 120 (98.4) 10 (100.0) 29 (96.7) 
P value 
OR (95% CI) 
 
0.6 
a 
0.558 
2.07 (0.18-23.61) 
Depression 1st trimester 
X
2
=0.63, df=2, P= 0.731 
N=162 
Yes 6 (4.9) 0 (0.0) 1 (3.3) 
No 116 (95.1) 10 (100.0) 29 (96.7) 
P value 
OR (95% CI) 
 
0.916 
a 
0.712 
0.67 (0.08-5.76) 
Severe morning sickness 
X
2
=1.95, df=2, P= 0.377 
N=161 
Yes 13 (10.7) 1 (10) 6 (20) 
No 108 (89.3) 9 (90) 24 (80) 
P value 
OR (95% CI) 
 
0.942 
0.92 (0.11-7.88) 
0.178 
2.07 (0.72-6.02) 
Threatened abortion 
X
2
=0.706, df=2, P= 0.702 
N=161 
Yes 8 (6.6) 0 (0.0) 2 (6.7) 
No 113 (93.4) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.761 
a 
0.991 
1.01 (0.2-5.02) 
Abdominal pain pre-gestation 
X
2
=1.17, df=2, P= 0.557 
N=161 
Yes 4 (3.3) 0 (0.0) 2 (6.7) 
No 117 (96.7) 10 (100.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.886 
a 
0.408 
2.09 (0.36-11.98) 
Abdominal pain 1st trimester 
X
2
=2.23, df=2, P= 0.329 
N=161 
Yes 11 (9.1) 2 (20.0) 5 (16.7) 
No 110 (90.9) 8 (80.0) 25 (83.3) 
P value 
OR (95% CI) 
 
0.282 
2.5 (0.47-13.27) 
0.235 
2 (0.64-6.27) 
Maternal domestic environmental exposure 
Exposure to chemicals pre-
gestation 
Yes 37 (30.6) 2 (20.0) 12 (40.0) 
No 84 (69.4) 80 (80.0) 18 (60.0) 
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X
2
=1.66, df=2, P= 0.437 
N=161 
P value 
OR (95% CI) 
 
<0.001**          
0.06 (0.01-0.24) 
1.5 (0.66-3.46) 
Exposure to chemicals 1st 
trimester 
X
2
=0.64, df=2, P= 0.728 
N=161 
Yes 37 (30.6) 2 (20.0) 10 (33.3) 
No 84 (69.4) 8 (80.0) 20 (66.7) 
P value 
OR (95% CI) 
 
0.487 
0.57 (0.11-2.8) 
0.771 
1.14 (0.48-2.66) 
Exposure to solvents pre-
gestation 
X
2
=2.27, df=2, P= 0.321 
N=161 
Yes 13 (10.7) 2 (20.0) 6 (20.0) 
No 108 (89.3) 8 (80.0) 24 (80.0) 
P value 
OR (95% CI) 
 
0.386 
2.08 (0.4-10.85) 
0.178 
2.07 (0.72-6.02) 
Exposure to solvents 1st 
trimester 
X
2
=1.9, df=2, P= 0.387 
N=161 
Yes 10 (8.3) 2 (20.0) 4 (13.3) 
No 111 (91.7) 8 (80.0) 26 (86.7) 
P value 
OR (95% CI) 
 
0.234 
2.78 (0.52-14.88 
0.396 
1.71 (0.5-5.88) 
Exposure to pesticides pre-
gestation 
X
2
=2.37, df=2, P= 0.306 
N=161 
Yes 21 (17.4) 1 (10.0) 2 (6.7) 
No 100 (82.6) 9 (90.0) 28 (93.3) 
P value 
OR (95% CI) 
 
0.556 
0.53 (0.06-4.4) 
0.162 
0.34 (0.07-1.54) 
Exposure to pesticides 1st 
trimester 
X
2
=2.02, df=2, P= 0.364 
N=161 
Yes 24 (19.8) 1 (10.0) 3 (10.0) 
No 97 (80.2) 9 (90.0) 27 (90.0) 
P value 
OR (95% CI) 
 
0.449 
0.45 (0.05-3.72) 
0.218 
0.45 (0.13-1.61) 
Exposure to incense pre-
gestation 
X
2
=2, df=2, P= 0.367 
N=161 
Yes 47 (38.8) 2 (20.0) 9 (30.0) 
No 74 (61.2) 8 (80.0) 21 (70.0) 
P value 
OR (95% CI) 
 
0.251 
0.39 (0.08-1.93) 
0.371 
0.67 (0.28-1.6) 
Exposure to incense 1st 
trimester 
X
2
=1.42, df=2, P= 0.492 
N=143 
Yes 46 (38.0) 2 (20.0) 10 (83.3) 
No 75 (62.0) 8 (80.0) 2 (16.7) 
P value 
OR (95% CI) 
 
0.269 
0.41 (0.08-2) 
0.008** 
8.15 (1.71-38.87) 
Type of maternal drinking 
water 
X
2
=5.68, df=2, P= 0.46 
Tap 31 (26.1) 4 (40.0) 5 (16.7) 
Bottled 80 (67.2) 6 (60.0) 20 (66.7) 
P value 
OR (95% CI) 
 
0.424 
1.72 (0.45-6.51) 
0.42 
0.65 (0.22-1.87) 
Well 6 (5.0) 0 (0.0) 4 (13.3) 
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N=159 P value 
OR (95% CI) 
 
0.69 
a 
0.078 
0.24 (0.05-1.17) 
Zamzam 2 (1.7) 0 (0.0) 1 (3.3) 
P value 
OR (95% CI) 
 
0.836 
a 
0.39 
0.32 (0.02-4.26) 
Consanguinity 
X
2
=5.66, df=2, P= 0.059 
N=156 
Yes 69 (59.5) 8 (72.7) 11 (37.9) 
No 47 (40.5) 3 (27.3) 18 (62.1) 
P value 
OR (95% CI) 
 
0.396 
1.82 (0.46-7.2) 
0.04** 
0.42 (0.18-0.96) 
Family history 
X
2
=1.91, df=2, P= 0.753 
N=159 
Yes 49 (40.8) 4 (40.0) 14 (48.3) 
No 71 (59.2) 6 (60.0) 15 (51,7) 
P value 
OR (95% CI) 
 
0.96 
0.97 (0.26-3.6) 
0.468 
1.35 (0.6-3.05) 
**The Chi-square statistic is significant at the 0.05 level                          
* Homozygous common allele genotype 
a
 Not possible to analyse because the groups contain zero values                             
            If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A49: Maternal VAX1 7078160 allele frequency in relationship to 
different environmental factors including: maternal illness, 
medication, stress, supplements, paternal smoking and 
maternal domestic exposure using case-only study design. 
Maternal VAX_7078160 G* (%) A (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
N=324 
Yes 37 (13.5) 7 (14.0) 
No 237 (86.5) 43 (86.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.925 
1.04 (0.44-2.49) 
Antibiotic at 1st trimester 
N=324 
Yes 46 (16.8) 4 (8.0) 
No 228 (83.2) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
2.50 (1) 0.11 
0.43 (0.15-1.26) 
Antipyretic medication 
pre-gestation 
N=326 
Yes 19 (6.9) 3 (5.9) 
No 256 (93.1) 48 (94.1) 
X
2
 (df), P value 
OR (95% CI) 
0.07 (1) 0.79 
0.85 (0.24-2.99) 
Antipyretic medication 
1st trimester 
N=328 
Yes 27 (9.9) 5 (9.1) 
No 246 (90.1) 50 (90.9) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1) 0.855 
0.91 (0.33-2.48) 
Anti-emetic medication 
pre-gestation 
N=324 
Yes 2 (0.7) 0.(0.0) 
No 272 (99.3) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
 
0.37 (1) 0.54 
Anti-emetic medication 
1st trimester 
N=324 
Yes 42 (15.3) 6 (12) 
No 232 (84.7) 44 (88.0) 
X
2
 (df), P value 
OR (95% CI) 
0.37 (1) 0.544 
0.75 (0.3-1.88) 
Contraceptives pre-
gestation 
N=320 
 
Yes 23 (8.5) 3 (6.0) 
No 247 (91.5) 47 (94.0) 
X
2
 (df), P value 
OR (95% CI) 
0.36 (1) 0.552 
0.69 (0.2-2.38) 
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Contraceptives 1st 
trimester 
N=324 
Yes 5 (1.8) 1 (2.0) 
No 269 (98.8) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.933 
1.1 (0.13-9.6) 
Illness pre-gestation 
N=324 
Yes 71 (28.7 0) 19 (38.0) 
No 203 (82.2) 31 (62.0) 
X
2
 (df), P value 
OR (95% CI) 
3.08 (1) 0.082 
1.75 (0.93-3.3) 
Illness 1st trimester 
N=324 
Yes 103 (41.7) 21 (42.0) 
No 171 (69.2) 29 (58.) 
X
2
 (df), P value 
OR (95% CI) 
0.35 (1) 0.56 
1.2 (0.65-2.2) 
Common cold/flu pre-
gestation 
N=324 
Yes 53 (21.5) 13 (26.0) 
No 221 (89.5) 37 (74.0) 
X
2
 (df), P value 
OR (95% CI) 
1.16 (1) 0.285 
1.47 (0.73-2.95) 
Common cold/flu 1st 
trimester 
N=324 
Yes 57 (23.1) 15 (30.0) 
No 217 (87.9) 35 (70.0) 
X
2
 (df), P value 
OR (95% CI) 
2.07 (1) 0.15 
1.66 (0.85-3.25) 
Fever pre-gestation 
N=324 
Yes 28 (11.3) 6 (12.0) 
No 246 (99.6) 44 (88.0) 
X
2
 (df), P value 
OR (95% CI) 
0.14 (1) 0.71 
1.2 (0.47-3.06) 
Fever 1st trimester 
N=324 
Yes 39 (15.8) 7 (14.0) 
No 235 (95.1) 43 (86.0) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.965 
0.98 (0.41-2.34) 
Urinary tract infection 
pre-gestation 
N=322 
Yes 10 (4.1) 2 (4.0) 
No 262 (106.9) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.91 
1.05 (0.22-4.93) 
Urinary tract infection 
1st trimester 
N=322 
Yes 10 (4.1) 0  
No 262 (106.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
 
1.90 (1) 0.17 
High blood pressure pre- Yes 4 (1.6) 2 (4.0) 
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gestation 
N=324 
No 270 (109.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
1.50 (1) 0.22 
2.81 (0.5-15.78) 
High blood pressure 1st 
trimester 
N=324 
Yes 4 (1.6) 4 (8.0) 
No 270 (109.3) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
7.51 (1) 0.01** 
5.87 (1.42-24.3) 
Diabetes pre-gestation 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Diabetes 1st trimester 
N=324 
Yes 6 (2.4) 2 (4.0) 
No 268 (108.5) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.58 (1) 0.45 
1.65 (0.48-5.62) 
Asthma pre-gestation 
N=322 
Yes 4 (1.6) 2 (4.0) 
No 268 (109.4) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
1.48 (1) 0.22 
2.19 (0.69-7) 
Asthma 1st trimester 
N=322 
Yes 4 (1.6) 2 (4.0) 
No 268 (109.4) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
1.48 (1) 0.22 
2.19 (0.69-7) 
Convulsions pre-
gestation 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Convulsions 1st trimester 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Vaginal bleeding 
N=322 
Yes 18 (7.4) 2 (4.0) 
No 254 (103.7) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.50 (1) 0.498 
0.63 (0.16-2.4) 
Maternal supplement use 
Folic acid pre-gestation Yes 24 (9.7) 8 (16.0) 
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N=324 No 250 (101.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
2.49 (1) 0.11 
1.74 (0.9-3.37) 
Folic acid 1st trimester 
N=326 
Yes 161 (65.2) 31 (61.8) 
No 114 (46.2) 20 (39.2) 
X
2
 (df), P value 
OR (95% CI) 
0.09 (1) 0.766 
1.08 (0.65-1.81) 
Multivitamins pre-
gestation 
N=326 
Yes 16 (6.5) 4 (7.8) 
No 259 (104.9) 47 (92.2) 
X
2
 (df), P value 
OR (95% CI) 
0.31 (1) 0.572 
1.3 (0.52-3.25) 
Multivitamins 1st 
trimester 
N=324 
Yes 54 (21.9) 12 (24.0) 
No 220 (89.1) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.48 (1) 0.484 
1.23 (0.68-2.23) 
Iron pre-gestation 
N=324 
Yes 18 (7.3) 6 (12) 
No 256 (103.6) 44 (88.0) 
X
2
 (df), P value 
OR (95% CI) 
1.82 (1) 0.18 
1.7 (0.81-3.59) 
Iron 1st trimester 
N=324 
Yes 82 (33.2) 20 (40.0) 
No 192 (77.7) 30 (60.0) 
X
2
 (df), P value 
OR (95% CI) 
1.99 (1) 0.157 
1.45 (0.87-2.43) 
Calcium 1st trimester 
N=324 
Yes 15 (6.1) 1 (2.0) 
No 259 (104.9) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
1.09 (1) 0.30 
0.39 (0.06-2.67) 
Smoking 
Maternal smoking 
N=322 
Yes 10 (3.7) 2 (4.0) 
No 262 (96.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.91 
1.08 (0.3-3.92) 
Paternal smoking 
N=322 
Yes 94 (34.6) 20 (40.0) 
No 178 (65.4) 30 (60.0) 
X
2
 (df), P value 
OR (95% CI) 
0.55 (1) 0.458 
1.22 (0.72-2.04) 
Paternal tobacco Yes 74 (27.2) 12 (24.0) 
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N=322 No 198 (72.8) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.22 (1) 0.64 
0.87 (0.48-1.58) 
Paternal waterpipe 
N=324 
Yes 31 (11.4) 13 (25.5) 
No 242(88.6) 38 (74.5) 
X
2
 (df), P value 
OR (95% CI) 
7.32 (1) 0.01** 
2.67 (1.28-5.56) 
Maternal passive 
smoking 
N=322 
Yes 54 (19.9) 12 (24.0) 
No 218 (80.2) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.45 (1) 0.50 
1.22 (0.68-2.21) 
Maternal stress  
Family problems 
N=322 
Yes 101 (37.1) 25 (50) 
No 171 (62.9) 25 (50.0) 
X
2
 (df), P value 
OR (95% CI) 
2.94 (1) 0.088 
1.69 (0.92-3.1) 
Mother complains of 
being under stress 
N=322 
Yes 117 (43.0) 29 (58.0) 
No 155 (57.0) 21 (42.0) 
X
2
 (df), P value 
OR (95% CI) 
3.83 (1) 0.053 
1.83 (0.99-3.37) 
Depression pre-gestation 
N=324 
Yes 5 (1.8)  1 (2.0) 
No 269 (98.2) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.932 
1.08 (0.18-6.59) 
Depression 1st trimester 
N=324 
Yes 13 (4.7) 1 (2.0) 
No 261 (95.3) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.77 (1) 0.38 
0.45 (0.07-3.04) 
Severe morning sickness 
N=322 
Yes 32 (11.8) 8 (16.0) 
No 240 (88.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
0.70 (1) 0.40 
1.34 (0.68-2.65) 
Threatened abortion 
N=322 
Yes 18 (6.6) 2 (4.0) 
No 254 (93.4) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.50 (1) 0.498 
0.63 (0.16-2.4) 
Abdominal pain pre- Yes 10 (3.7) 2 (4.0) 
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gestation 
N=322 
No 262 (96.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.911 
1.08 (0.3-3.92) 
Abdominal pain 1st 
trimester 
N=322 
Yes 27 (9.93) 9 (18.0) 
No 245 (90.1) 41 (82.0) 
X
2
 (df), P value 
OR (95% CI) 
2.77 (1) 0.10 
1.74 (0.93-3.28) 
Maternal domestic environmental exposure  
Exposure to chemicals 
pre-gestation 
N=466 
Yes 86 (31.6) 16 (8.25) 
No 186 (68.4) 178 (91.8) 
X
2
 (df), P value 
OR (95% CI) 
36.17 (1) <0.001** 
0.19 (0.11-0.34) 
Exposure to chemicals 
1st trimester 
N=318 
Yes 84 (31.1) 14 (29.1) 
No 186 (68.9) 34 (70.8) 
X
2
 (df), P value 
OR (95% CI) 
0.07 (1) 0.80 
0.92 (0.52-1.64) 
Exposure to solvents pre-
gestation 
N=322 
Yes 32 (11.8) 10 (20.0) 
No 240 (8.2) 40 (80) 
X
2
 (df), P value 
OR (95% CI) 
2.53  (1) 0.117 
1.67 (0.9-3.07) 
Exposure to solvents 1st 
trimester 
N=322 
Yes 24 (8.8) 8 (16.0) 
No 248 (91.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
2.43 (1) 0.12 
1.73 (0.89-3.35) 
Exposure to pesticides 
pre-gestation 
N=322 
Yes 44 (16.2) 4 (8.0) 
No 228 (83.8) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
2.23 (1) 0.14 
0.5 (0.19-1.32) 
Exposure to pesticides 
1st trimester 
N=322 
Yes 51 (18.8) 5 (10.0) 
No 221 (81.3) 45 (90.0) 
X
2
 (df), P value 
OR (95% CI) 
2.25 (1) 0.13 
0.53 (0.22-1.27) 
Exposure to incense pre-
gestation 
N=322 
Yes 103 (37.9) 13 (26.0) 
No 169 (62.1) 37 (74.0) 
X
2
 (df), P value 
OR (95% CI) 
2.58 (1) 0.11 
0.62 (0.35-1.13) 
Exposure to incense 1st Yes 102 (40.2) 14 (43.8) 
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trimester 
N=286 
No 152 (59.8) 18 (56.3) 
X
2
 (df), P value 
OR (95% CI) 
0.15 (1) 0.70 
1.14 (0.59-2.2) 
Maternal exposure to X-
ray 1st trimester 
N=326 
Yes 10 (3.6) 2 (3.9) 
No 265 (96.4) 49 (96.1) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.92 
1.07 (0.29-3.88) 
Type of maternal 
drinking water 
0.36 (1) 0.95 
N=318 
Tap 67 (25) 13 (26) 
Bottled 180 (67.2) 32 (64) 
P value 
OR (95% CI) 
0.06 (1) 0.81 
0.92 (0.45-1.9) 
Well 16(6) 4 (8) 
P value 
OR (95% CI) 
0.686 
1.29 (0.37-4.48) 
Zamzam 5 (1.9) 1 (2) 
P value 
OR (95% CI) 
0.979 
1.03 (0.11-9.56) 
Consanguinity 
N=312 
Yes 149 (57.1) 27 (52.9) 
No 112 (42.9) 24 (47.1) 
X
2
 (df), P value 
OR (95% CI) 
0.30 (1) 0.58 
0.87 (0.53-1.44) 
Family history 
N=318 
Yes 112 (41.6) 22 (44.9) 
No 157 (58.4) 27 (55.1) 
X
2
 (df), P value 
OR (95% CI) 
0.18 (1) 0.67 
1.12 (0.67-1.88) 
Maternal VAX_7078160 G* (%) A (%) 
Maternal medication use and illness 
Antibiotic pre-gestation 
N=324 
Yes 37 (13.5) 7 (14.0) 
No 237 (86.5) 43 (86.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.925 
1.04 (0.44-2.49) 
Antibiotic at 1st trimester 
N=324 
Yes 46 (16.8) 4 (8.0) 
No 228 (83.2) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
2.50 (1) 0.11 
0.43 (0.15-1.26) 
Antipyretic medication 
pre-gestation 
Yes 19 (6.9) 3 (5.9) 
No 256 (93.1) 48 (94.1) 
120 
 
N=326 X
2
 (df), P value 
OR (95% CI) 
0.07 (1) 0.79 
0.85 (0.24-2.99) 
Antipyretic medication 
1st trimester 
N=328 
Yes 27 (9.9) 5 (9.1) 
No 246 (90.1) 50 (90.9) 
X
2
 (df), P value 
OR (95% CI) 
0.03 (1) 0.855 
0.91 (0.33-2.48) 
Anti-emetic medication 
pre-gestation 
N=324 
Yes 2 (0.7) 0.(0.0) 
No 272 (99.3) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
 
0.37 (1) 0.54 
Anti-emetic medication 
1st trimester 
N=324 
Yes 42 (15.3) 6 (12) 
No 232 (84.7) 44 (88.0) 
X
2
 (df), P value 
OR (95% CI) 
0.37 (1) 0.544 
0.75 (0.3-1.88) 
Contraceptives pre-
gestation 
N=320 
 
Yes 23 (8.5) 3 (6.0) 
No 247 (91.5) 47 (94.0) 
X
2
 (df), P value 
OR (95% CI) 
0.36 (1) 0.552 
0.69 (0.2-2.38) 
Contraceptives 1st 
trimester 
N=324 
Yes 5 (1.8) 1 (2.0) 
No 269 (98.8) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.933 
1.1 (0.13-9.6) 
Illness pre-gestation 
N=324 
Yes 71 (28.7 0) 19 (38.0) 
No 203 (82.2) 31 (62.0) 
X
2
 (df), P value 
OR (95% CI) 
3.08 (1) 0.082 
1.75 (0.93-3.3) 
Illness 1st trimester 
N=324 
Yes 103 (41.7) 21 (42.0) 
No 171 (69.2) 29 (58.) 
X
2
 (df), P value 
OR (95% CI) 
0.35 (1) 0.56 
1.2 (0.65-2.2) 
Common cold/flu pre-
gestation 
N=324 
Yes 53 (21.5) 13 (26.0) 
No 221 (89.5) 37 (74.0) 
X
2
 (df), P value 
OR (95% CI) 
1.16 (1) 0.285 
1.47 (0.73-2.95) 
Common cold/flu 1st 
trimester 
Yes 57 (23.1) 15 (30.0) 
No 217 (87.9) 35 (70.0) 
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N=324 X
2
 (df), P value 
OR (95% CI) 
2.07 (1) 0.15 
1.66 (0.85-3.25) 
Fever pre-gestation 
N=324 
Yes 28 (11.3) 6 (12.0) 
No 246 (99.6) 44 (88.0) 
X
2
 (df), P value 
OR (95% CI) 
0.14 (1) 0.71 
1.2 (0.47-3.06) 
Fever 1st trimester 
N=324 
Yes 39 (15.8) 7 (14.0) 
No 235 (95.1) 43 (86.0) 
X
2
 (df), P value 
OR (95% CI) 
0.00 (1) 0.965 
0.98 (0.41-2.34) 
Urinary tract infection 
pre-gestation 
N=322 
Yes 10 (4.1) 2 (4.0) 
No 262 (106.9) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.91 
1.05 (0.22-4.93) 
Urinary tract infection 
1st trimester 
N=322 
Yes 10 (4.1) 0  
No 262 (106.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
 
1.90 (1) 0.17 
High blood pressure pre-
gestation 
N=324 
Yes 4 (1.6) 2 (4.0) 
No 270 (109.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
1.50 (1) 0.22 
2.81 (0.5-15.78) 
High blood pressure 1st 
trimester 
N=324 
Yes 4 (1.6) 4 (8.0) 
No 270 (109.3) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
7.51 (1) 0.01 
5.87 (1.42-24.3) 
Diabetes pre-gestation 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Diabetes 1st trimester 
N=324 
Yes 6 (2.4) 2 (4.0) 
No 268 (108.5) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.58 (1) 0.45 
1.65 (0.48-5.62) 
Asthma pre-gestation 
N=322 
Yes 4 (1.6) 2 (4.0) 
No 268 (109.4) 48 (96.0) 
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X
2
 (df), P value 
OR (95% CI) 
1.48 (1) 0.22 
2.19 (0.69-7) 
Asthma 1st trimester 
N=322 
Yes 4 (1.6) 2 (4.0) 
No 268 (109.4) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
1.48 (1) 0.22 
2.19 (0.69-7) 
Convulsions pre-
gestation 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Convulsions 1st trimester 
N=324 
Yes 0 (0.0) 0 (0.0) 
No 274 (110.9) 50 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
a 
Vaginal bleeding 
N=322 
Yes 18 (7.4) 2 (4.0) 
No 254 (103.7) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.50 (1) 0.498 
0.63 (0.16-2.4) 
Maternal supplement use 
Folic acid pre-gestation 
N=324 
Yes 24 (9.7) 8 (16.0) 
No 250 (101.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
2.49 (1) 0.11 
1.74 (0.9-3.37) 
Folic acid 1st trimester 
N=326 
Yes 161 (65.2) 31 (61.8) 
No 114 (46.2) 20 (39.2) 
X
2
 (df), P value 
OR (95% CI) 
0.09 (1) 0.766 
1.08 (0.65-1.81) 
Multivitamins pre-
gestation 
N=326 
Yes 16 (6.5) 4 (7.8) 
No 259 (104.9) 47 (92.2) 
X
2
 (df), P value 
OR (95% CI) 
0.31 (1) 0.572 
1.3 (0.52-3.25) 
Multivitamins 1st 
trimester 
N=324 
Yes 54 (21.9) 12 (24.0) 
No 220 (89.1) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.48 (1) 0.484 
1.23 (0.68-2.23) 
Iron pre-gestation 
N=324 
Yes 18 (7.3) 6 (12) 
No 256 (103.6) 44 (88.0) 
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X
2
 (df), P value 
OR (95% CI) 
1.82 (1) 0.18 
1.7 (0.81-3.59) 
Iron 1st trimester 
N=324 
Yes 82 (33.2) 20 (40.0) 
No 192 (77.7) 30 (60.0) 
X
2
 (df), P value 
OR (95% CI) 
1.99 (1) 0.157 
1.45 (0.87-2.43) 
Calcium 1st trimester 
N=324 
Yes 15 (6.1) 1 (2.0) 
No 259 (104.9) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
1.09 (1) 0.30 
0.39 (0.06-2.67) 
Smoking 
Maternal smoking 
N=322 
Yes 10 (3.7) 2 (4.0) 
No 262 (96.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.91 
1.08 (0.3-3.92) 
Paternal smoking 
N=322 
Yes 94 (34.6) 20 (40.0) 
No 178 (65.4) 30 (60.0) 
X
2
 (df), P value 
OR (95% CI) 
0.55 (1) 0.458 
1.22 (0.72-2.04) 
Paternal tobacco 
N=322 
Yes 74 (27.2) 12 (24.0) 
No 198 (72.8) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.22 (1) 0.64 
0.87 (0.48-1.58) 
Paternal waterpipe 
N=324 
Yes 31 (11.4) 13 (25.5) 
No 242(88.6) 38 (74.5) 
X
2
 (df), P value 
OR (95% CI) 
7.32 (1) 0.01 
2.67 (1.28-5.56) 
Maternal passive 
smoking 
N=322 
Yes 54 (19.9) 12 (24.0) 
No 218 (80.2) 38 (76.0) 
X
2
 (df), P value 
OR (95% CI) 
0.45 (1) 0.50 
1.22 (0.68-2.21) 
Maternal stress  
Family problems 
N=322 
Yes 101 (37.1) 25 (50) 
No 171 (62.9) 25 (50.0) 
X
2
 (df), P value 
OR (95% CI) 
2.94 (1) 0.088 
1.69 (0.92-3.1) 
Mother complains of Yes 117 (43.0) 29 (58.0) 
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being under stress 
N=322 
No 155 (57.0) 21 (42.0) 
X
2
 (df), P value 
OR (95% CI) 
3.83 (1) 0.053 
1.83 (0.99-3.37) 
Depression pre-gestation 
N=324 
Yes 5 (1.8)  1 (2.0) 
No 269 (98.2) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.932 
1.08 (0.18-6.59) 
Depression 1st trimester 
N=324 
Yes 13 (4.7) 1 (2.0) 
No 261 (95.3) 49 (98.0) 
X
2
 (df), P value 
OR (95% CI) 
0.77 (1) 0.38 
0.45 (0.07-3.04) 
Severe morning sickness 
N=322 
Yes 32 (11.8) 8 (16.0) 
No 240 (88.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
0.70 (1) 0.40 
1.34 (0.68-2.65) 
Threatened abortion 
N=322 
Yes 18 (6.6) 2 (4.0) 
No 254 (93.4) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.50 (1) 0.498 
0.63 (0.16-2.4) 
Abdominal pain pre-
gestation 
N=322 
Yes 10 (3.7) 2 (4.0) 
No 262 (96.3) 48 (96.0) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.911 
1.08 (0.3-3.92) 
Abdominal pain 1st 
trimester 
N=322 
Yes 27 (9.93) 9 (18.0) 
No 245 (90.1) 41 (82.0) 
X
2
 (df), P value 
OR (95% CI) 
2.77 (1) 0.10 
1.74 (0.93-3.28) 
Maternal domestic environmental exposure  
Exposure to chemicals 
pre-gestation 
N=466 
Yes 86 (31.6) 16 (8.25) 
No 186 (68.4) 178 (91.8) 
X
2
 (df), P value 
OR (95% CI) 
36.17 (1) <0.001 
0.19 (0.11-0.34) 
Exposure to chemicals 
1st trimester 
N=318 
Yes 84 (31.1) 14 (29.1) 
No 186 (68.9) 34 (70.8) 
X
2
 (df), P value 
OR (95% CI) 
0.07 (1) 0.80 
0.92 (0.52-1.64) 
Exposure to solvents pre- Yes 32 (11.8) 10 (20.0) 
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gestation 
N=322 
No 240 (8.2) 40 (80) 
X
2
 (df), P value 
OR (95% CI) 
2.53  (1) 0.117 
1.67 (0.9-3.07) 
Exposure to solvents 1st 
trimester 
N=322 
Yes 24 (8.8) 8 (16.0) 
No 248 (91.2) 42 (84.0) 
X
2
 (df), P value 
OR (95% CI) 
2.43 (1) 0.12 
1.73 (0.89-3.35) 
Exposure to pesticides 
pre-gestation 
N=322 
Yes 44 (16.2) 4 (8.0) 
No 228 (83.8) 46 (92.0) 
X
2
 (df), P value 
OR (95% CI) 
2.23 (1) 0.14 
0.5 (0.19-1.32) 
Exposure to pesticides 
1st trimester 
N=322 
Yes 51 (18.8) 5 (10.0) 
No 221 (81.3) 45 (90.0) 
X
2
 (df), P value 
OR (95% CI) 
2.25 (1) 0.13 
0.53 (0.22-1.27) 
Exposure to incense pre-
gestation 
N=322 
Yes 103 (37.9) 13 (26.0) 
No 169 (62.1) 37 (74.0) 
X
2
 (df), P value 
OR (95% CI) 
2.58 (1) 0.11 
0.62 (0.35-1.13) 
Exposure to incense 1st 
trimester 
N=286 
Yes 102 (40.2) 14 (43.8) 
No 152 (59.8) 18 (56.3) 
X
2
 (df), P value 
OR (95% CI) 
0.15 (1) 0.70 
1.14 (0.59-2.2) 
Maternal exposure to X-
ray 1st trimester 
N=326 
Yes 10 (3.6) 2 (3.9) 
No 265 (96.4) 49 (96.1) 
X
2
 (df), P value 
OR (95% CI) 
0.01 (1) 0.92 
1.07 (0.29-3.88) 
Type of maternal 
drinking water 
0.36 (1) 0.95 
N=318 
Tap 67 (25) 13 (26) 
Bottled 180 (67.2) 32 (64) 
P value 
OR (95% CI) 
0.06 (1) 0.81 
0.92 (0.45-1.9) 
Well 16(6) 4 (8) 
P value 
OR (95% CI) 
0.686 
1.29 (0.37-4.48) 
Zamzam 5 (1.9) 1 (2) 
P value 
OR (95% CI) 
0.979 
1.03 (0.11-9.56) 
126 
 
Consanguinity 
N=312 
Yes 149 (57.1) 27 (52.9) 
No 112 (42.9) 24 (47.1) 
X
2
 (df), P value 
OR (95% CI) 
0.30 (1) 0.58 
0.87 (0.53-1.44) 
Family history 
N=318 
Yes 112 (41.6) 22 (44.9) 
No 157 (58.4) 27 (55.1) 
X
2
 (df), P value 
OR (95% CI) 
0.18 (1) 0.67 
1.12 (0.67-1.88) 
**The Chi-square statistic is significant at the 0.05 level                  
        * Homozygous common allele genotype 
a
 Not possible to analyse because the groups contain zero values                          
If one of the cells contains zero value, the OR and 95% CI are not calculated  
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A50: Comparison between cases and controls for maternal VAX1 
rs7078160 genotypes in relationship to different environmental 
factors including: maternal illness, medication, stress, 
supplements, paternal smoking and maternal domestic exposure.  
 
Maternal VAX_7078160 GG** (%) AA (%) AG (%) 
Environmental factors 
  
Study Control Study Control Study Control 
Antibiotic use pre-
gestation 
Study Group 
N=162 
Control Group 
N=177 
Yes 18 (14.8) 9 (5.8) 3 (30.0) 0 (0.0) 1 (3.3) 0 (0.0) 
No 104 
(85.2) 
146 (94.2) 7 (70.0) 5 (100.0) 29 (96.7) 17 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
6.21 (1), 0.013** 
2.81 (1.21-6.5) 
1.88 (1), 0.171 0.58 (1), 0.447 
Antibiotic use 1st 
trimester 
Study Group 
N=162 
Control Group 
N=177 
Yes 22 (18.0) 16 (10.3) 1 (10.0) 0 (0.0) 2 (6.7) 2 (11.8) 
No 
100 
(82.0) 
139 (89.7) 9 (90.0) 5 (100.0) 28 (93.3) 15 (88.2) 
X
2
 (df), P 
value 
3.43 (1), 0.064 0.54 (1), 0.464  0.36 (1), 0.547 
Antipyretic 
medication pre-
gestation 
Study Group 
N=162 
Control Group 
N=177 
Yes 8 (6.6) 16 (10.3) 0 (0.0) 0 (0.0) 3 (9.7) 2 (11.8) 
No 
114 
(93.4) 
139 (89.7) 
10 
(100.0) 
5 (100.0) 28 (90.3) 15 (88.2) 
X
2
 (df), P 
value 
1.22 (1), 0.269 a 0.051 (1), 0.218 
Antipyretic 
medication 1st 
trimester 
Study Group 
N=161 
Control Group 
N=174 
Yes 12 (10.0) 21 (13.7) 1 (10.0) 0 (0.0) 3 (9.7) 4 (25.0) 
No 
108 
(90.0) 
132 (86.3) 9 (90.0) 5 (100.0) 28 (90.3) 12 (75.0) 
X
2
 (df), P 
value 
0.88 (1), 0.349 0.54 (1), 0.464  1.96 (1), 0.162 
Anti-emetic 
medication pre-
gestation 
Study Group 
N=162 
Control Group 
N=177 
Yes 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
121 
(99.2) 
155 
(100.0) 
10 
(100.0) 
5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
1.28 (1|), 0.259  a  a  
Anti-emetic 
medication 1st
 
trimester 
Yes 20 (16.4) 13 (8.4) 2 (20.0) 0 (0.0) 2 (6.7) 1 (5.9) 
No 102 
(83.6) 
142 (91.6) 8 (80.0) 5 (100.0) 28 (93.3) 16 (94.1) 
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Study Group 
N=162 
Control Group 
N=177 
X
2
 (df), P value 
OR (95% CI) 
4.17 (1), 0.041** 
2.14 (1.02-4.5) 
1.15 (1), 0.283 0.01 (1), 0.916 
Contraceptives pre-
gestation 
Study Group 
N=160 
Control Group 
N=177 
Yes 10 (8.3) 14 (9.0) 0 (0.0) 0 (0.0) 3 (10.0) 0 (0.0) 
No 
110 
(91.7) 
141 (91.0) 
10 
(100.0) 
5 (100.0) 27 (90.0) 17 (100.0) 
X
2
 (df), P 
value  
1.82 (1), 0.839 a  0.178 
Contraceptives 1st 
trimester 
Study Group 
N=162 
Control Group 
N=177 
Yes 2 (1.6) 5 (3.2) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 
No 
120 
(98.4) 
150 (96.8) 
10 
(100.0) 
5 (100.0) 29 (96.7) 17 (100.0) 
X
2
 (df), P 
value 
0.7 (1), 0.404  a 0.58 (1), 0.447 
Illness pre-gestation 
Study Group 
N=162 
Control Group 
N=176 
Yes 30 (24.6) 13 (8.4) 4 (40.0) 1 (20.0) 11 (36.7) 5 (29.4) 
No 92 (75.4) 141 (91.6) 6 (60.0) 4 (80.0) 19 (63.3) 12 (70.6) 
X
2
 (df), P value 
OR (95% CI) 
13.5 (1), <0.001** 
3.54 (1.75-7.13) 
0.6 (1), 0.439 0.25 (1), 0.614 
Illness 1st trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 46 (37.7) 39 (25.5) 5 (50.0) 2 (40.0) 11 (36.7) 6 (35.3) 
No 76 (62.3) 114 (74.5) 5 (50.0) 3 (60.0) 19 (63.3) 11 (64.7) 
X
2
 (df), P value 
OR (95% CI) 
43.74 (1), 0.029** 
1.77 (1.06-2.96) 
0.13 (1), 0.714  0.009 (1), 0.925 
Common cold/flu 
pre-gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 22 (18.0) 6 (3.9) 2 (20.06) 0 (0.0) 9 (30.0) 1 (5.9) 
No 100 (82) 147 (96.1) 8 (80.0) 5 (100.0) 21 (70.0) 16 (94.1) 
X
2
 (df), P value 
OR (95% CI) 
14.78 (1), <0.001** 
5.39 (2.11-13.77) 
1.15 (1), 0.283 3.77 (1), 0.052 
Common cold/flu 1st 
trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 25 (20.5) 21 (13.7) 4 (40.0) 0 (0.0) 7 (23.3) 3 (17.6) 
No 97 (79.5) 132 (86.3) 6 (60.0) 5 (100.0) 23 (76.7) 14 (82.4) 
X
2
 (df), P 
value 
2.23 (1), 0.135 2.73 (1), 0.099 0.21 (1), 0.647 
Fever pre-gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 12 (9.8) 7 (4.6) 1 (10.0) 1 (20.0) 4 (13.3) 0 (0.0) 
No 
110 
(90.2) 
146 (95.4) 9 (90.0) 4 (80.0) 26 (86.7) 17 (100.0) 
X
2
 (df), P 
value 
2.92 (1), 0.087 0.29 (1), 0.591 2.48 (1), 0.115 
Fever 1st trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 18 (14.8) 12 (7.8) 2 (20.0) 1 (20.0) 3 (10.0) 2 (11.8) 
No 
104 
(85.2) 
141 (92.2) 8 (80.0) 4 (80.0) 27 (90.0) 15 (88.2) 
X
2
 (df), P 
value 
3.34 (1), 0.068 0.000 (1), 1  0.04 (1), 0.85 
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Urinary tract 
infection pre-
gestation 
Study Group 
N=161 
Control Group 
N=175 
Yes 5 (4.1) 3 (2.0) 1 (10.0) 0 (0.0) 0 (0.0) 1 (5.9) 
No 
116 
(95.9) 
150 (98.0) 9 (90.0) 5 (100.0) 30 (100.0) 16 (94.1) 
X
2
 (df), P 
value 
1.12 (1), 0.289 0.54 (1), 0.464 1.8 (1), 0.179 
Urinary tract 
infection 1st 
trimester 
Study Group 
N=161 
Control Group 
N=175 
Yes 5 (4.1) 6 (3.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.9) 
No 
116 
(95.9) 
147 (96.1) 10 (100) 5 (100.0) 30 (100.0) 16 (94.1) 
X
2
 (df), P 
value 
0.008 (1), 0.93  a 1.8 (1), 0.179 
High blood pressure 
pre-gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 2 (1.6) 1 (0.7) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
120 
(98.4) 
152 (99.3) 9 (90.0) 5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
0.61 (1), 0.434 0.54 (1), 0.646 a  
High blood pressure 
1st trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 2 (1.6) 2 (1.3) 2 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
120 
(98.4) 
151 (98.7) 8 (80.0) 5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
0.05 (1), 0.819 1.15 (1), 0.283 a  
Diabetes pre-
gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
122 
(100.0) 
152 (99.3) 
10 
(100.0) 
5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
0.8 (1), 0.371  a a  
Diabetes 1st 
trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 3 (2.5) 3 (2.0)  1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
119 
(97.5) 
150 (98.0) 9 (90.0) 5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
0.779 0.464 a  
Asthma pre-gestation 
Study Group 
N=161 
Control Group 
N=175 
Yes 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 1 (5.9) 
No 
120 
(99.2) 
153 
(100.0) 
10 
(100.0) 
5 (100.0) 28 (93.3) 16 (94.1) 
X
2
 (df), P 
value 
1.27 (1), 0.26  a 0.01 (1), 0.916 
Asthma 1st trimester 
Study Group 
N=161 
Control Group 
N=175 
Yes 1 (0.8) 3 (2.0) 0 (0.0) 0 (0.0) 2 (6.7) 1 (5.9) 
No 
120 
(99.2) 
150 (98.0) 
10 
(100.0) 
5 (100.0) 28 (93.3) 16 (94.1) 
X
2
 (df), P 
value 
0.6 (1), 0.437 a  0.92 (1),0.916 
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Convulsions pre-
gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
122 
(100.0) 
153 
(100.0) 
10 
(100.0) 
5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
a  a  a  
Convulsions 1st 
trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No 
122 
(100.0) 
153 
(100.0) 
10 
(100.0) 
5 (100.0) 30 (100.0) 17 (100.0) 
X
2
 (df), P 
value 
 a  a a  
Vaginal bleeding 
Study Group 
N=161 
Control Group 
N=175 
Yes 8 (6.6) 5 (3.3) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 
No 
113 
(93.4) 
148 (96.7) 
10 
(100.0) 
5 (100.0) 28 (93.3) 17 (100.0) 
X
2
 (df), P 
value 
1.67 (1), 0.196 a  1.18 (1), 0.277 
Maternal exposure to 
x-ray in the 1st 
trimester 
Study Group 
N=163 
Control Group 
N=177 
Yes 4 (3.3) 2 (1.3) 0 (0.0)  0 (0.0) 2 (6.5) 0 (0.0)  
No 
118 
(96.7) 
153 (98.7) 
10 
(100.0) 
5 (100.0) 29 (93.5) 17 (100.0) 
X
2
 (df), P 
value 
1.27 (1), 0.259 a  1.14 (1), 0.285 
Maternal supplement use 
Folic acid pre-
gestation 
Study Group 
N=162 
Control Group 
N=204 
Yes 10 (8.2) 41 (9.0) 2 (20.0) 1 (20.0) 4 (12.9) 1 (5.9) 
No 
112 
(91.8) 
141 (91.0) 8 (80.0) 4 (80.0) 26(87.1) 16 (94.1) 
X
2
 (df), P 
value 
0.06 (1), 0.806 0.000 (1), 1 0.58 (1), 0.446 
Folic acid 1st 
trimester 
Study Group 
N=163 
Control Group 
N=177 
Yes 72 (59.0) 111 (71.6) 7 (70.0) 4 (80.0) 17 (54.8) 11 (64.7) 
No 50 (41.0) 44 (28.4) 3 (30.0) 1 (20.0) 14 (45.2) 6 (35.3) 
X
2
 (df), P value 
OR (95% CI) 
4.8 (1), 0.028** 
0.57 (0.35-0.94) 
0.17 (1), 0.68 0.44 (1), 0.507 
Multivitamins pre-
gestation 
Study Group 
N=163 
Control Group 
N=177 
Yes 6 (4.9) 3 (1.9) 0 (0.0) 1 (20.0)  4 (12.9) 0 (0.0) 
No 
116 
(95.1) 
152 (98.1) 
10 
(100.0) 
4 (80) 27 (87.1) 17 (100.0) 
X
2
 (df), P 
value 
1.93 (1), 0.165 2.15 (1), 0.143 2.39 (1), 0.122 
Multivitamins 1st 
trimester 
Study Group 
N=162 
Control Group 
N=177 
Yes 24 (19.7) 26 (16.8) 3 (30.0) 3 (60.0) 6 (20.0) 3 (17.6) 
No 98 (80.3) 129 (83.2) 7 (70.0) 2 (40.0) 24 (80.0) 14 (82.4) 
X
2
 (df), P 
value 
0.39 (1), 0.534 1.25 (1), 0.264 0.4 (1), 0.844 
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Iron pre-gestation 
Study Group 
N=162 
Control Group 
N=177 
Yes 6 (4.9) 8 (5.2) 0 (0.0) 0 (0.0) 6 (20.0) 2 (11.8) 
No 
116 
(95.1) 
147 (94.8) 
10 
(100.0) 
5 (100.0) 24 (80.0) 15 (88.2) 
X
2
 (df), P 
value 
0.008 (1),  0.927 a  0.52 (1), 0.47 
Iron 1st trimester 
Study Group 
N=162 
Control Group 
N=177 
Yes 36 (29.5) 53 (34.2) 5 (50.0) 3 (60.0) 10 (33.3) 4 (23.5) 
No 86 (70.5) 102 (65.8) 5 (50.0) 2 (40.0) 20 (66.7) 13 (76.5) 
X
2
 (df), P 
value 
0.69 (1), 0.407 0.13 (1), 0.714 0.5 (1), 0.48 
Calcium 1st trimester 
Study Group 
N=162 
Control Group 
N=177 
Yes 7 (5.7) 16 (10.3) 0 (0.0) 1 (20.0) 1 (3.3) 3 (17.6) 
No 
115 
(94.3) 
139 (89.7) 
10 
(100.0) 
4 (80.0) 29 (96.7) 14 (82.4) 
X
2
 (df), P 
value 
1.89 (1), 0.17 2.14 (1), 0.143 2.86 (1), 0.091 
Smoking  
Maternal smoking 
Study Group 
N=161 
Control Group 
N=177 
Yes 4 (3.3) 5 (3.2) 0 (0.0) 2 (40.0) 2 (6.7) 1 (5.9) 
No 
117 
(96.7) 
150 (96.8) 
10 
(100.0) 
3 (60.0) 28 (93.3) 16 (94.1) 
X
2
 (df), P 
value 
0.001 (1), 0.97 4.62 (1), 0.032** 00.01 (1), 0.916 
Paternal smoking 
Study Group 
N=161 
Control Group 
N=177 
Yes 43 (35.5) 56 (36.1) 6 (60.0) 3 (60.0) 8 (26.7) 3 (17.6) 
No 78 (64.5) 99 (63.9) 4 (40.0) 2 (40.0) 22 (73.3) 14 (82.4) 
X
2
 (df), P 
value 
0.01 (1), 0.919 0.000 (1), 1 0.49 (1), 0.483 
Paternal tobacco 
Study Group 
N=161 
Control Group 
N=177 
Yes 35 (28.9) 46 (29.7) 4 (40.0) 3 (60.0) 4 (13.3) 3 (17.6) 
No 86 (71.7) 109 (70.3) 6 (60.0) 2 (40.0) 26 (86.7) 14 (82.4) 
X
2
 (df), P 
value 
0.02 (1), 0.892 0.54 (1), 0.464 0.16 (1), 0.69 
Waterpipe smoking 
Study Group 
N=161 
Control Group 
N=177 
Yes 13 (10.7) 10 (6.5) 4 (40) 0 5 (16.7) 0 
No 
108 
(89.3) 
145 (93.5) 6 (60) 5 (100) 25 (83.3) 17 (100) 
X
2
 (df), P 
value 
1.64 (1), 0.2 2.73 (1), 0.099 3.17 (1), 0.075 
Paternal Jorak 
Study Group 
N=161 
Control Group 
N=177 
Yes 9 (7.4) 2 (1.3) 1 (10.0) 0 (0.0) 3 (10.0) 0 (0.0) 
No 
112 
(92.6) 
153 (98.7) 9 (90.0) 5 (100.0) 27 (90.0) 17 (100.0) 
X
2
 (df), P value 
OR (95% CI) 
6.7 (1), 0.010** 
6.15 (1.3-29) 
0.54 (1), 0.464 1.82 (1), 0.178 
Paternal Moasel 
Study Group 
N=161 
Control Group 
N=177 
Yes 6 (5.0) 9 (5.8) 3 (30.0) 0 (0.0) 3 (10.0) 0 (0.0) 
No 
115 
(95.0) 
146 (94.2) 7 (70.0) 5 (100.0) 27 (90.0) 17 (100.0) 
X
2
 (df), P 
value 
01 (1), 0.758 1.88 (1), 0.171 1.82 (1), 0.178 
Maternal passive Yes 25 (20.7) 27 (17.4) 4 (40.0) 2 (40.0) 4 (13.3) 3 (17.6) 
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smoking 
Study Group 
N=161 
Control Group 
N=177 
No 96 (79.3) 128 (82.6) 6 (60.0) 3 (60.0) 26 (86.7) 14 (82.4) 
X
2
 (df), P 
value 
0.35 (2), 0.494 0.83 (2), 1 2.24 (2), 0.69 
Maternal stress 
Family problems 
Study Group 
N=161 
Control Group 
N=177 
Yes 43 (35.5) 36 (23.2) 5 (50.0) 2 (40.0) 15 (50.0) 5 (29.4) 
No 78 (64.5) 119 (76.8) 5 (50.0) 3 (60.0) 15 (50.0) 12 (70.6) 
X
2
 (df), P value 
OR (95% CI) 
5.04 (1), 0.025** 
1.82 (1.08-3.09) 
0.13 (1), 0.714 1.88 (1), 0.17 
Mother complains of 
being under stress 
Study Group 
N=161 
Control Group 
N=177 
Yes 50 (41.3) 45 (29.0) 6 (60.0) 3 ( 60.0) 17 (56.7) 6 (35.3) 
No 71 (58.7) 110 (71.0) 4 (40.0) 2 (40.0) 13 (43.3) 11 (64.7) 
X
2
 (df), P value 
OR (95% CI) 
4.55 (1), 0.033** 
1.7 (1.04-2.84) 
0.000 (1), 1 1.98 (1), 0.159 
Depression pre-
gestation 
Study Group 
N=162 
Control Group 
N=175 
Yes 2 (1.6) 2 (1.3) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 
No 
120 
(98.4) 
151 (98.7) 
10 
(100.0) 
5 (100) 29 (96.7) 17 (100.0) 
X
2
 (df), P 
value 
0.05 (1), 0.819 a  0.58 (1), 0.447 
Depression 1st 
trimester 
Study Group 
N=162 
Control Group 
N=175 
Yes 6 (4.9) 3 (2.0) 0 (0.0) 0(0.0) 1 (3.3) 0 (0.0) 
No 
116 
(95.1) 
150 (98.0) 
10 
(100.0) 
5 (100.0) 29 (96.7) 17 (100.0) 
X
2
 (df), P 
value 
1.88 (1), 0.171 a  0.58 (1), 0.447 
Severe morning 
sickness 
Study Group 
N=161 
Control Group 
N=175 
Yes 13 (10.7) 10 (6.5) 1 (10) 1 (20) 6 (6.5) 1 (5.9) 
No 
108 
(89.3) 
143 (93.5) 9 (90) 4 (80) 24 (93.5) 16 (94.1) 
X
2
 (df), P 
value 
1.56 (1), 0.212 0.29 (1), 0.591 1.71 (1), 0.191 
Threatened abortion  
Study Group 
N=161 
Control Group 
N=175 
Yes 8 (6.6) 4 (2.6) 0 (0.0) 0 (0.0) 2 (6.7) 3 (17.6) 
No 
113 
(93.4) 
149 (97.4) 
10 
(100.0) 
5 (100.0) 28 (93.3) 14 (82.4) 
X
2
 (df), P 
value 
2.58 (1, 0.108 a  1.38 (1), 0.241 
Abdominal pain pre-
gestation 
Study Group 
N=161 
Control Group 
N=175 
Yes 4 (3.3) 4 (2.6) 0 (0.0) 1 (20.0) 2 (6.7) 0 (0.0) 
No 
117 
(96.7) 
149 (97.4) 
10 
(100.0) 
4 (80.0) 28 (93.3)  17 (100.0) 
X
2
 (df), P 
value 
0.11 (1), 0.736 2.14 (1), 0.143 1.18 (1), 0.277 
Abdominal pain 1st 
trimester 
Study Group 
Yes 11 (9.1) 7 (4.6) 2 (20.0) 1 (20.0) 5 (16.7) 3 (17.6) 
No 
110 
(90.9) 
146 (95.4) 8 (80.0) 4 (80.0) 25 (83.3) 14 (82.4) 
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N=161 
Control Group 
N=175 
X
2
 (df), P 
value 
2.25 (1), 0.134 0.000 (1), 1 0.007 (1), 0.932 
Maternal domestic environmental exposure 
Exposure to 
chemicals pre-
gestation 
Study Group 
N=161 
Control Group 
N=175 
Yes 37 (30.6) 40 (26.1) 2 (20.0) 1 (20.0) 12 (40.0) 7 (41.2) 
No 84 (69.4) 113 (73.9) 8 (80.0) 4 (80.0) 18 (60.0) 10 (58.8) 
X
2
 (df), P 
value 
0.66 (1), 0.417 0.000 (1), 1 0.006 (1), 0.937 
Exposure to 
chemicals 1st 
trimester 
Study Group 
N=161 
Control Group 
N=175 
Yes 37 (30.6) 41 (26.8) 2 (20.0) 1 (20.0) 10 (33.3) 7 (41.2) 
No 84 (69.4) 112 (73.2) 8 (80.0) 4 (80.0) 20 (66.7) 10 (58.8) 
X
2
 (df), P 
value 
0.47 (1), 0.491 0.000 (1), 1 0.29 (1), 0.591 
Exposure to solvent 
pre-gestation 
Study Group 
N=161 
Control Group 
N=177 
Yes 13 (10.7) 19 (12.3) 2 (20.0) 1 (20.0) 6 (20.0) 3 (17.6) 
No 
108 
(89.3) 
136 (87.7) 8 (80.0) 4 (80.0) 24 (80.0) 14 (82.4) 
X
2
 (df), P 
value 
0.15 (1), 0.697 0.000 (1), 1 0.04 (1), 0.844 
Exposure to solvent 
1st trimester 
Study Group 
N=161 
Control Group 
N=177 
Yes 10 (8.3) 18 (11.6) 2 (20.0) 0 (0.0) 4 (13.3) 2 (11.8) 
No 
111 
(91.7) 
137 (88.4) 8 (80.0) 5 (100.0) 26 (86.7) 15 (88.2) 
X
2
 (df), P 
value 
0.84 (1) 0.361 1.15 (1), 0.283 0.02 (1), 0.877 
Exposure to 
pesticides pre-
gestation 
Study Group 
N=161 
Control Group 
N=177 
Yes 21 (17.4) 28 (18.1) 1 (10.0) 0 (0.0) 2 (6.7) 5 (29.4) 
No 
100 
(82.6) 
127 (81.9) 9 (90.0) 5 (100.0) 28 (93.3) 12 (70.6) 
X
2
 (df), P 
value 
0.02 (1), 0.878 0.54 (1), 0.464 4.43 (1), 0.035 
Exposure to 
pesticides 1st 
trimester 
Study Group 
N=161 
Control Group 
N=177 
Yes 24 (19.8) 25 (16.1) 1 (10.0) 0 (0.0) 3 (10.0) 5 (29.4) 
No 97 (80.2) 130(83.9) 9 (90.0) 5 (100.0) 27 (90.0) 12 (70.6) 
X
2
 (df), P 
value 
0.64 (1), 0.424 0.54 (1), 0.464 2.9 (1), 0.089 
Exposure to incense 
pre-gestation 
Study Group 
N=161 
Control Group 
Yes 47 (38.8) 73 (47.1) 2 (20.0) 3 (60.0) 9 (30.0) 9 (52.9) 
No 74 (61.2) 82 (52.9) 8 (80.0) 2 (40.0) 21 (70.0) 8 (47.1) 
X
2
 (df), P 
value 
1.88 (1), 0.17 2.4 (1), 0.121 2.4 (1), 0.12 
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N=177 
Exposure to incense 
in the 1st trimester 
Study Group 
N=161 
Control Group 
N=177 
Yes 46 (38.0) 75 (84.4) 2 (20.0) 3 (60.0) 10 (33.3) 8 (47.1) 
No 75 (62.0) 80 (51.6) 8 (80.0) 2 (40.0) 20 (66.7) 9 (52.9) 
X
2
 (df), P 
value 
2.97 (1), 0.085 2.4 (1), 0.121 0.87 (1), 0.352 
Type of maternal 
drinking water 
X
2
 (df), P 
value 
15.6 (3), 0.001** 2.24 (1),0.134 1.68 (3), 0.642 
Type of maternal 
drinking water 
Study Group 
N=158 
Control Group 
N=175 
Tap 31 (26.1) 33 (21.4) 4 (40.0) 0 (0.0) 5 (16.7) 2 (11.8) 
Bottled 
P value 
80 (67.2) 101 (65.6) 6 (60.0) 4 (100.0) 20 (66.7) 14 (82.4) 
0.558 0.256 0.537 
Well 
P value 
6 (5.0) 1 (0.6) 0 (0.0) 0 (0.0) 4 (13.3) 1 (5.9) 
0.094 a 0.099 
Zamzam 
P value 
OR (95% CI) 
2 (1.7) 19 (12.3) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 
0.005** 
8.92 (1.92-41.52) 
a 0.863 
Consanguinity  
Study Group 
N=156 
Control Group 
N=167 
Yes 69 (59.5) 81 (55.1) 8 (72.7) 1 (20.0) 11 (37.9) 10 (66.7) 
No 47 (40.5) 66 (44.9) 3 (27.3) 4 (80.0) 18 (62.1) 5 (33.3) 
X
2
 (df), P 
value 
0.51 (1), 0.476 3.88 (1), 0.07 3.27 (1), 0.07 
Family history 
Study Group 
N=159 
Control Group 
N=173 
Yes 49 (40.8) 43 (28.5) 4 (40.0) 0 (0.0) 14 (48.3) 4 (23.5) 
No 71 (59.2) 108 (71.5) 6 (60.0) 5 (100.0) 15 (51,7) 13 (76.5) 
X
2
 (df), P value 
OR (95% CI) 
5.74 (2), 0.033** 
1.73 (1.04-2.89) 
2.73 (1), 0.099 3.36 (2), 0.097 
*The Chi-square statistic is significant at the 0.05 level                           
** Homozygous common allele genotype 
a
 Not possible to analyse because the groups contain zero values                 
            If one of the cells contains zero value, the OR and 95% CI are not calculated  
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Abstract: 
Background 
Studies have found a consistent positive association between maternal smoking and 
non-syndromic orofacial clefts (NSOFC). However, no comprehensive assessment of 
the association between NSOFC and passive smoking has been undertaken. This 
systematic review and meta-analysis explores the relationship between maternal 
passive smoking and NSOFC, and compares the associations between passive and 
active smoking. 
 
Methods and findings: 
Search strategy, inclusion /exclusion criteria, and data extraction from studies 
reporting maternal passive smoking and NSOFC was implemented without language 
restrictions. Risks of bias in the identified studies were assessed and this information 
was used in sensitivity analyses to explain heterogeneity. Meta-analysis and meta-
regression of the extracted data were performed. Egger's test was used to test for small 
study effects. 
Fourteen eligible articles were identified. Maternal passive smoking exposure was 
associated with a twofold increase in risk of NSOFC (odds ratio: 2.11, 95% 
confidence interval: 1.54-2.89); this was apparent for both cleft lip with and without 
palate (OR: 2.05, 95% CI: 1.27-3.3) and cleft palate (OR: 2.11, 95% CI: 1.23-3.62). 
There was substantial heterogeneity between studies. In the studies that provided data 
enabling crude and adjusted odd ratios to be compared, adjustment for potential 
confounders attenuated the magnitude of association to about a 1.5-fold increase in 
risk.  
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Conclusion: 
Overall, maternal passive smoking exposure results in a 1.5 fold increase in risk of 
NSOFC, similar to the magnitude of risk reported for active smoking, but there is 
marked heterogeneity between studies. This heterogeneity is not explained by 
differences in the distribution of cleft types, adjustment for covariates, broad 
geographic region, or study bias/quality. This thorough meta-analysis provides further 
evidence to minimize exposure to environmental tobacco smoke in policy making fora 
and in health promotion initiatives. 
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Introduction 
Today’s best evidence suggests that non-syndromic orofacial clefts (NSOFC) are 
multifactorial in origin involving both genetic and environmental risk factors
 (1)
. 
Better understanding of the etiology of environmental factors can provide the basis for 
prevention through avoidance of exposure to risk factors. 
Previous studies have been consistent in finding a positive association between active 
maternal smoking and NSOFC.
(2)
 A meta-analysis has suggested a modest positive 
association between active smoking and NSOFC; for cleft lip with or without cleft 
palate (CL/P) the relative risk was 1.34 (95 % CI: 1.25 to 1.44) and for cleft palate 
(CP) relative risk was 1.22 (95% CI: 1.10 to 1.35).
(3)
  Avoidance of smoking to reduce 
this risk is a common public health message.
(4)
 However, the risk of maternal smoking 
exposure may be underestimated, as non-smoking pregnant women might still be 
exposed to passive smoking (environmental tobacco exposure) at home or work 
(5)
 
and this is not usually taken into account, especially in developing countries. The 
2014 Surgeon General’s Report highlights a wide range of acute and chronic adverse 
health effects in infants and increased risk of adverse health outcomes resulting from 
second hand smoking.
(6)
 The Report also noted that tobacco control measures are not 
sufficient to end the tobacco epidemic.   Furthermore, although the association 
between passive smoking and congenital anomalies has been studied, the relationship 
has not been found to be consistent,
(7)
 and no comprehensive assessment of the 
association between NSOFC and maternal passive smoking exposure has been 
undertaken. This systematic review and meta-analysis (1) in non-smoking mothers, 
assesses the relationship between maternal passive smoking and having an infant with 
NSOFC; and (2) for all mothers in the included studies, compares the associations 
between maternal passive smoking and maternal active smoking. We propose that 
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through confirmation of this relationship we will inform public health messages and 
support planning of community awareness programs around the adverse consequences 
of passive smoking during pregnancy, which is likely to be especially relevant to 
developing countries. 
 
Material and methods 
Search strategy and data extraction 
We prepared a research protocol to investigate the relationship between orofacial 
clefts and passive smoking, defined as maternal exposure to environmental tobacco 
smoke in any location at any time during the pregnancy. The search strategy 
comprised key words listed separately and in combination; ((cleft lip) OR (cleft 
palate) OR (orofacial cleft)) AND ((passive smoking) OR (tobacco smoke pollution) 
OR (environmental tobacco smoke pollution) OR (smoking)). These key words were 
run in three search engines (PubMed, Scopus, Scholar Google) from 1980 to 2013. 
For Google Scholar, the search yielded 1140 articles, too numerous for review. 
Therefore, a modification was carried out by pooling titles from key word 
combinations of; ((cleft lip) OR (cleft palate) OR (orofacial cleft)) AND ((passive 
smoking) OR (tobacco smoke pollution) OR (environmental tobacco smoke 
pollution)). This revised search strategy gave a total of 1,006 articles across the three 
search engines: PubMed (215), Scopus (366), Google Scholar (425), (see Figure 1). 
The searches were run in March 2013 and did not exclude any languages. Full details 
of the search strategy are available in Figure S1.  
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The titles of all articles were reviewed by two authors independently (HJ and HK). 
Data presented more than once were excluded. Abstracts of articles selected on the 
basis of their titles were then reviewed. Articles were excluded where it was obvious 
from the title or abstract that the paper did not discuss the relationship of maternal 
passive smoking with NSOFC. The references of remaining articles were reviewed, 
then full texts were screened according to the following inclusion criteria;  
 studies reporting passive smoking and its relationship to NSOFC ; and 
 case-control, cohort or cross-sectional studies where there was a control or 
comparison group. 
The exclusion criteria were; 
 studies that discussed smoking as a whole but did not provide information on 
the specific association between passive smoking and  NSOFC;  
 studies that reported associations with genes reported to modulate the effect of 
smoking or gene-environmental joint effects related to NSOFC but which did 
not report the marginal effect of passive smoking; and 
 studies that included syndromic clefts in which data on non-syndromic clefts 
could not be extracted. 
 
Data extracted from these studies included; 
 passive smoking definition;  
 study design and setting;  
 sample size, description and base population;  
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 prevalence and intensity of maternal passive smoking prior to pregnancy and 
in the first trimester for cases and controls;  
 the frequency of maternal passive smoking for cleft lip with or without cleft 
palate (CL/P) and cleft palate (CP). Reported odds ratios (OR) and confidence 
intervals (CI) without frequencies were also considered; and 
 prevalence and intensity of active maternal smoking. 
Data were extracted, using a data extraction form (Figure S2), independently by two 
authors (HJ and HK). Any disagreement was resolved by discussion with a third 
author (MH). When possible, authors of included studies were contacted for further 
information on the topic. We received a response from three authors.
(8-10) 
 
Assessing risk of bias 
The quality of included articles was assessed independently by two of the authors 
using the Newcastle-Ottawa Scale (NOS).
(11)
 The scale measures three items; 
selection of cases and controls including their definition and representativeness; 
comparability of cases and controls in design and analysis; and exposure 
ascertainment. The scale has a minimum score of 0 and a maximum score of 9. 
Studies scoring 6 or more (correspond to 67% of the maximum score) were regarded 
as having a low risk of bias ("good" quality)
 (12)
; 3–5 a modest risk of bias ("fair" 
quality); and studies < 3 were considered to be at substantial risk of bias ("poor" 
quality) Spearman's rank correlation coefficient was used to measure the degree of 
agreement between the authors' judgments. Disagreements were resolved through 
discussion. No exclusion based on risk of bias was performed. Studies were further 
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classified into those at substantial to modest risk of bias versus those at low risk for 
sensitivity analysis. Details of study quality are presented in Figure S3. 
 
Consideration of possible small study effects 
We used funnel plots to visually assess the possibility of small study effects for all 
studies together and also for those assessing the relationship between passive smoking 
and NSOFC phenotype (CL/P and CP).
(13)
 In addition, Egger’s test was used to test 
for small study effects.  
 
Statistical analysis 
Meta-analysis was performed using the free software Review Manager (Cochrane 
Collaboration).
(14)
 The Mantel-Haenszel method was used for combining studies to 
calculate summary ORs and 95% CIs for passive smoking versus no smoking. To 
decide whether the results of the separate studies could be combined meaningfully, a 
statistical test of homogeneity was carried out. Based on the chi-square test, an 
inconsistency coefficient was computed (I
2
 statistic) where a value more than 50% 
indicated moderate, and greater than 75% indicated high, heterogeneity
 (15)
. Odds 
ratios were pooled with a fixed effect model for homogeneous studies and a random 
effects model for heterogeneous studies. Odds ratios with their 95% confidence limits 
for the individual studies and summary estimate of effect were graphically displayed 
in a forest plot.  
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For comparing the result of crude OR with the reported adjusted OR, meta-analysis 
was carried out using OR and standard error (SE) values that were estimated from the 
95% CI.  
Meta-DiSc version 1.4 (http://www.hrc.es/investigacion/metadisc_en.htm) was used 
to perform meta-regression for assessing the possible effect of study quality and type 
of cleft on the relationship between passive smoking and NSOFC. Inverse variance 
weights and restricted maximum likelihood estimation were used. 
       
Sensitivity analysis 
To assess stability of the results, subgroup analyses were carried out based on (a) type 
of NSOFC (CL/P and CP), (b) study risk of bias (NOS score >6 vs. ≤6), (c) reported 
adjusted OR compared to crude OR, (d) periods of measured maternal passive 
smoking exposure (1
st
 trimester including and not including the pregestation period, 
or the pregestation period alone), (e) sequential exclusion of studies with ORs for the 
association between NSOFC and passive smoking greater than 3, and (f) broad 
geographic region in which the study was carried out (China, US and Europe, Other). 
These areas of subgrouping were considered likely sources of heterogeneity. 
 
Results 
The searches yielded 1,006 potentially eligible titles. After removing duplicate articles 
and reviewing the abstracts, the full text of 70 articles were obtained and compared to 
the inclusion criteria.  Fifty-five articles were excluded (Figure 1) because they; did 
not include control group (two articles), discussed congenital anomalies in general 
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(two articles) or did not study passive smoking (51 articles). This resulted in 15 
eligible articles (Table 1 and Figure 2).
 (8-10,16-27)
 These were all retrospective case-
control studies using self-report questionnaires for non-smoking mothers. 
Shaw et al (1996)
10 
 reported positive associations between specific types of NSOFC 
and passive smoking, defined as when a non-smoking mother frequented, worked or 
lived in a place where others smoked within six feet of her (for CL/P OR: 2, 95% CI: 
1.2 to 3.4; for CP OR:1.6, 95 % CI: 0.7 to 3.4). However, as the study did not report 
the number of exposed cases and controls, it was excluded from meta-analysis, 
resulting in the meta-analysis being based on 14 studies.  Wang et al (2009)
(26)
 did not 
exclude smoking mothers from their analysis of maternal passive smoking. However, 
we included the study in our meta-analysis as this sample comprised very few mothers 
who reported smoking actively during pregnancy (2% in cases and 1.4% in control).   
The definition of maternal passive smoking was similar in all 14 studies included in 
the meta-analysis. However, Li et al (2010)
(23)
 defined passive smoking as the 
exposure of non-smoking mothers to at least one cigarette /week from a smoker in any 
place.  Lie et al. (2008)
(24)
 and Li et al. (2011)
(22) 
defined it as non-smoking mother 
frequenting, working or living in a place where others smoked nearby, with Lie et al. 
(2008)
(24)
 specifying a distance within two meters for at least two hours per day. 
All studies measured maternal exposure to smoke during the three months of the first 
trimester apart from two studies which included only the first two months of the 1
st
 
trimester
 (22, 25)
.
 
 However, seven studies compared maternal exposure to smoke for the 
1
st
 trimester combined with the pregestation period: one month pregestation;
(10, 23, 26, 
27)
 three month pregestation;
(18, 20)
 or one year pregestation.
(9, 21)
 (Table 1).  
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Honein et al (2007)
(18)
 and Mirilas et al (2011)
(9)
 measured the relationship between 
NSOFC and maternal passive smoking exposure in the pregestation period alone  (see 
Table 1).  Honein et al (2007)
(18)
 have furthered analyzed the relationship with 
NSOFC type and found a significant relationship for CP (OR: 2.3, 95% CI: 1 to 5.3) 
but not with CL/P (OR: 1.3, 95% CI: 0.5 to 3.1).  
The intensity of smoking was reported by two studies but with different measurement 
methods
23, 27
.  Li et al (2010)
(23)
 measured the number of maternal smoking exposure 
in hour per week, while Zhang et al (2011)
(27)
 measured the number of hours of 
maternal exposure any time during one month pregestation and through the 1
st
 
trimester.   
Meta-Analyses 
Figure 2 shows the forest plot for the relationship between maternal passive smoking 
and having an infant with NSOFC in the fourteen studies with complete information 
on the frequency of maternal exposure to passive smoking. 
There was a significant relationship between passive maternal smoking and NSOFC. 
The risk of having an infant with NSOFC was doubled following maternal exposure 
to environmental tobacco (OR: 2.11, 95% CI: 1.54 to 2.89). When studies with ORs 
greater than 3 were excluded, the relationship continued to be significant; after 
excluding the study of Mirilas et al (2011)
(9)
 the OR was 2.04 (95% CI: 1.49 to 2.8); 
after excluding that of Jia et al (2011)
(19)
 in addition to that of Mirilas et al (2011)
(9)
 
the OR was 1.8 (95% CI: 1.4 to 2.32); after excluding the study of Zhang et al 
(2011)
(27)
 in addition to these two studies, the OR was 1.66 (95% CI: 1.34 to 2.06); 
and after excluding all studies with an OR greater than 3, the OR was 1.55 (95% CI: 
1.28 to 1.87). 
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Figure 3 shows the forest plot for the relationship between maternal smoking and 
having an infant with NSOFC in studies that reported passive smoking and active 
smoking. Maternal active smoking and passive smoking was reported by eleven 
studies and found to be significantly related to NSOFC; OR: 2.07, 95% CI: 1.42 to 
3.01 for passive smoking; and OR: 1.5, 95% CI: 1.17 to 1.93 for active smoking. 
Although the OR=1.5 for active smoking was less than the OR=2.07 for maternal 
passive smoking, the difference was not statistically significant (P= 0.17).  
Figure 4 included studies that reported adjusted OR for the association between 
NSOFC and passive smoking. Both meta-analysis; for the crude OR and the reported 
adjusted OR found a significant relationship between NSOFC and passive smoking 
(OR: 1.79, 95% CI: 1.34 to 2.4 and OR: 1.54, 95% CI: 1.11 to 2.12) respectively. In 
addition, there were no significant differences between the two meta-analyses (P= 
0.49). The factors for which adjustment was made in each study are listed in Table 1 
and differed between studies.   
Figure 5 shows forest plot for meta-analysis of the association between maternal 
passive smoking exposure period and NSOFC. The period of maternal exposure was 
divided into two groups; studies reporting maternal passive smoking exposure during 
the 1
st
 trimester including or not including the pregestation period and studies 
reporting maternal passive smoking exposure prior to pregnancy alone. NSOFC was 
significantly associated with maternal exposure to passive smoking during the first 
trimester period including or not including pregestation period (OR: 2.03, 95% CI: 
1.49 to 2.76). However, no significant relationship was found for maternal exposure 
prior to pregnancy alone (OR 1.62, 95% CI: 0.93 to 2.82). The difference between the 
two periods was not statistically significant (P= 0.49). 
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Figure 6 shows the relationship between passive smoking and the different types of 
NSOFC; CL/P and CP. The risk of having an infant with either CL/P or CP associated 
with passive smoking was approximately doubled (for CL/P OR: 2.05, 95% CI: 1.27 
to 3.3; for CP OR: 2.11, 95% CI: 1.23 to 3.62).  
Papers assessing the relationship between maternal smoking and having an infant with 
NSOFC were also sub-grouped according to region (China, United State and Europe, 
and other countries) (Figure 7). There was a significant difference between the three 
regions (P= 0.01) with a higher OR (OR: 3.08, 95% CI: 1.96 to 4.87) for China than 
the other two regions.  However, there remained high heterogeneity between studies 
within China, and within the US and European group. 
The magnitude of association between maternal passive smoking and NSOFC was 
significantly higher (P= 0.0003) in the studies assessed as of “fair” or “poor” quality 
than in the other studies. However, differences in study quality and risk of bias do not 
account for the substantial heterogeneity of effect between studies (Figure 8).  Each 
meta- analyses showed significant heterogeneity with I
2
 more than 75% for the 
majority of subgrouping.  
 
Assessing risk of bias 
Figure 8 shows the included studies distributed according to NOS risk of bias scores.  
Out of the 14 studies, 11 had a low risk of bias score
(8, 9), (16-18), (20, 21), (23-26)
 (OR: 1.57, 
95% CI: 1.26 to 1.96); while three of the studies were rated being at moderate to high 
risk 
(19, 22, 27)
 (OR: 4.92, 95% CI: 2.74 to 8.81). The main reason for the lower NOS in 
some studies was lack of comparability and matching. There was a significant 
150 
 
difference in the maternal passive smoking risk OR between these two groupings (P= 
0.0003).  
 
Sensitivity analysis  
The sensitivity analysis demonstrated stability and reliability of the meta-analyses 
results through consistency of meta-analyses results, between different study 
subgroupings; the significant relationships between maternal passive smoking and 
NSOFC persisted in all of the situations evaluated (Figures 3, 4, 5, 6 and 7). 
 
Meta regression 
Table 2 shows that the association between passive smoking and NSOFC varies by 
study quality, region but not cleft type. The magnitude of the association is lower in 
studies appraised as of good quality than in other studies and higher for Asian studies. 
 
Evaluation of small study effects 
Figure 9 shows the funnel plots for all studies together assessing the relationship 
between NSOFC and passive smoking. Figure 9 shows studies assessing the 
relationship between passive smoking and NSOFC phenotype (CL/P and CP). Though 
the graph did not have the shape of a funnel it is almost symmetrical around the 
central line, indicating absence of small study effect.  No statistically significant small 
study effect was detected by Egger’s test (to further assess small study effect), either 
for all studies together and for studies of specific cleft types (P>0.05).   
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Discussion 
This systematic review and meta-analysis found around a twofold increase in the risk 
of NSOFC associated with environmental tobacco exposure. Not all studies adjusted 
for potential confounding factors, and in those that did, the covariates differed 
between studies. In the studies that presented both crude and adjusted estimates of 
effect, there was a modest attenuation of the magnitude of association (OR reduced 
from (1.79 to 1.54) and it was noteworthy that the magnitude of association in studies 
appraised as having a low risk of bias was about 1.5. Overall, the magnitude of 
association was similar between CL/P and CP, but there was substantial heterogeneity 
between studies.  
 
Prevention and protecting against having an infant with NSOFC could be possible 
through understanding the associated risk factors. In 2014, the Surgeon General 
considered the evidence in the literatures to be sufficient to infer a causal relationship 
between maternal smoking in early pregnancy and orofacial clefts
 (6)
.  
However, the effects of passive smoking have not been fully evaluated and a single 
study would provide insufficient evidence
 (28)
. In addition, passive smoke could have a 
more potent adverse effect on infants in a domestic environment as pregnant women 
and nursing mothers might be unaware of its existence or its importance as a risk 
factor. In some countries, smoking has been prohibited in enclosed public places to 
protect non-smoking individuals from passive smoking.  However, many other 
countries, both developing and some developed countries, have not introduced 
smoking restriction legislation
 (29)
; and mothers may be exposed to passive smoke in 
the domestic environment due to heating and cooking as well as tobacco smoke. 
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Environmental smoking exposure is difficult to measure. The main methods of 
assessment are self-report and biochemical assays of nicotine or cotinine
 (30)
. All 
studies included in this meta-analysis used self-reported questionnaires.  Kvalvik et al 
(2012)
(30)
 validated maternal self-reported tobacco use during pregnancy with plasma 
cotinine in the Norwegian Mother and Child Cohort Study. They concluded that self-reported 
tobacco use was a valid marker for tobacco smoke exposure including passive smoking. In 
addition, Salmasi et al (2010)
(31)
 compared the results of the association between 
perinatal outcomes and maternal self-reported exposure to passive smoking and 
biochemical analysis (2–10 ng/ml of cotinine) and found similar findings with both 
methods of exposure assessment.  
Eleven out of the 14 studies included in the meta-analysis presented data on maternal 
active smoking as well as on the effects of passive smoking in non-smoking mothers. 
In aggregate, passive smoking increased the risk of NSOFC (OR: 2.07, 95% CI: 1.42 
to 3.01) more than active smoking (OR: 1.5, 95% CI: 1.17 to 1.93), although this 
difference was not statistically significant (P= 0.17) and there was considerable 
heterogeneity between studies. Given that active smokers are exposed both to direct 
inhalation and to sidestream smoke, a stronger association for passive smoking than 
for active smoking is unexpected. A possible explanation for this finding could be 
under-reporting of active smoking as the studies rely on self-report and active 
smoking mothers may be compelled to under-report their smoking because of the 
associated stigma.  This sense of shame would not influence reporting of the passive 
smoking reports to the same extent.  Another explanation or contributory factor could 
be that duration/ dose response might influence the high association for passive 
smoking compared to active smoking; mothers may be exposed to passive smoke 
under occupational circumstances which would lead to a longer duration of exposure.  
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However, there was insufficient detail in the reports to be able to extract this level of 
data. 
Such a difference might be due to active smoking mothers tending to stop smoking 
when they are pregnant but being unaware that environmental tobacco exposure is 
harmful to the health of the developing infant. Therefore, public health awareness and 
further studies on passive smoking are important.  
Our search focused on manuscripts of passive smoking studies.  Whilst active 
smoking results are reported in some of these passive smoking studies’ papers, our 
results do not represent a complete picture of the active smoking literature.   However, 
active smoking has only been used for the purpose of comparison in assessing the 
passive smoking effect In order to probe the association between passive smoking and 
NSOFC further, in the eleven studies that reported adjusted OR, we compared the 
adjusted OR and crude OR. Although the differences between the estimates were not 
formally significant (P= 0.49), there was some attenuation of the OR by adjustment. 
We found a higher risk of association between NSOFC and maternal passive smoking 
in the 1
st
 trimester including or not including the pregestation period (OR: 2.03, 95% 
CI: 1.49 to 2.76) compared to those who were exposed to environmental tobacco only 
in the period prior to pregnancy (OR: 1.62, 95% CI: 0.93 to 2.82) but the difference 
between the two periods is not statistically significant (P= 0.49). This could indicate 
that if mothers were exposed to passive smoking prior to pregnancy, there is still an 
opportunity to protect their embryo from NSOFC through avoiding passive smoking. 
However, this finding needs more investigation as there were only two studies that 
reported maternal passive smoking exposure prior to pregnancy.  
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The magnitude of association (OR=4.92) in the three studies with a NOS lower than 6 
was significantly higher odds ratio than for the studies with a NOS scoring 6 or more. 
These studies were all carried out in China, which could in part explain the significant 
difference between the three different regions (Figure 7), with the higher OR in 
studies carried out in China (OR: 3.08) compared to other regions (OR: 1.39 for the 
studies in Europe and US; and OR: 1.54 for the studies in Iran and Brazil).   It is 
noteworthy that in all but one
23
 of the Chinese studies, the prevalence of reported 
passive smoking in control mothers was substantially lower than has been reported in 
pregnant women 
32
or women of reproductive age
33, 34 
in large surveys in China. 
 
The two categories associated with low NOS study scoring were "exposure 
ascertainment" and "comparability". The ascertainment of exposure was affected 
because information on smoking was gathered through questionnaire or interview, 
which is not usually considered to provide optimal information on smoking, although 
there is evidence that suggests that self-reported passive smoking gives information of 
comparable quality to cotinine assessment.
30
 The comparability between cases and 
controls in terms of minimizing the effects of potential confounding by means of 
matching and/or adjustment for confounding variables was also limited in studies with 
low quality (Figure S3). Therefore, we strongly advise careful consideration of the 
comparability of source populations in recruiting cases and controls in future studies.  
Further research on the intensity, duration of exposure and agreement on standardized 
methods for recording and reporting will aid further investigation of this 
environmental hazard. 
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Tobacco use is rapidly increasing among women of reproductive age in many 
countries because they are actively targeted by tobacco marketing campaigns 
(35, 36)
 
and this would be likely to result in an increase in the prevalence of exposure to 
environmental tobacco smoke. In the U.S., a decline in the prevalence of exposure to 
passive smoking from the late 1980s has leveled off since about 2002
 (37)
. There also 
continues to be substantial exposure to passive smoking in Canada
 (38)
. In England, the 
impact of smoke-free legislation on exposure to passive smoking was greater than the 
underlying long-term decline in exposure, demonstrating a positive effect of 
legislation
 (39)
. An increased risk of cleft palate associated with passive smoking has 
been mentioned in a paper making a case for a worldwide ban on smoking in public 
places
 (40)
. Therefore, we suggest that the results of the present meta-analysis provide 
a more solid basis to argue for interventions to minimize exposure to environmental 
tobacco smoke in policy making fora and in health promotion initiatives. 
Conclusion 
In studies that adjust for potential confounding and/or are adjudged to have low risk 
of bias, maternal passive smoking exposure is associated with approximately a 1.5 
fold increase in the risk of having an infant with NSOFC. There is marked 
heterogeneity between studies, which is not explained by differences in the 
distribution of cleft type, adjustment for covariates, difference in regions, or study 
quality. This thorough meta-analysis provides further evidence to argue for 
interventions to minimize exposure to environmental tobacco smoke in policy making 
fora and in health promotion initiatives. 
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Table 1.Characteristics of studies of risk of NSOFC in the offspring of non-smoking mothers exposed to passive smoking included in meta-analysis 
Reference Site and Country 
Duration of 
data collection 
Study design 
Total 
Sample size 
(smoking+ 
non-
smoking) 
mothers 
Reported 
period of 
maternal 
exposure 
Non-smoking mothers exposed to 
passive smoking/ total non-smoking 
mothers (%) 
Reported 
adjusted OR 
(95% CI) for 
passive smoking  
with adjusted 
factors 
Active smoking 
mothers/total sample 
size (%) 
NSOFC 
Type of 
NSOFC (CL/P 
and CP) 
Controls Cases Control 
Beaty et al (2001)16  Treatment centers, Maryland 
craniofacial clinics, Children's 
National Medical Centre , 
Washington DC, US   
1992-1998 
Case-control 171 cases 
182 control 
1st trimester 
 
24/107 
(22.4) 
 
 
CL/P: 14/73 
(19.2) 
CP: 10/34 
(29.4) 
18/130 
(13.8) 
CL/P:1.04 
(0.067-1.62) 
CP: 1.17 (0.68-
2.02) 
Maternal age and 
education 
27/171 
(15.8) 
25/182 
(13.7) 
Chevrier et al 
(2008)17 
Maxillofacial departments in; Lyon; 
Grenoble; Rhône-Alpes region; 
Paris; Clermont-Ferrand; Auvergne, 
France   
1998– 
2001 
Matched case-
control (age, sex, 
origin, place of 
residence  
240 cases,  
236 controls 
1st trimester 
 
97/173 
(56.1)  
 
 
CL/P: 65/119 
(54.6) 
 
CP: 32/54 
(59.3) 
70/167 
(41.9) 
1.8 (1.2-3.4) 
Region and 
Child sex 
67/240 
(27.9) 
69/230 (30) 
Honein et al 
(2007)18 
Coordinated by the Centers for 
Disease Control and Prevention 
(CDC). Eight Centers for Birth 
Defects Research and Prevention 
contributed data: Arkansas, 
California, Iowa, Massachusetts, 
New Jersey, New York, Texas, and 
CDC (Atlanta,GA), US 
 
___ 
Population based, 
multicenter, 
matched case- 
control (site, 
frequency of 
births per month) 
 
Random sample 
of live births in 
controls:  
 
933 CL/P 
528 CP 
3390 control 
Three month 
pregestation
+ 1st 
trimester  
 
Pregestation 
 
 
 
 
1st trimester 
235/1104 
(21.3) 
 
 
 
14/1104 
(1.3) 
 
 
 
13/1104 
(11.4) 
 
 
 
CL/P: 
147/699 
CP:88/528 
(22) 
 
CL/P:7/699(1
) 
CP:7/405(1.7
) 
 
CL/P: 9/6991 
(0.1) 
CP: 4/405 
(0.99) 
554/2699 
(20.5) 
 
 
 
21/2699 
 
 
 
 
39/2699 
(1.4) 
1.1 (0.09-1.3) 
Child sex, folic 
acid exposure, 
maternal age, 
ethnicity, 
gravidity 
1st degree 
relative with birth 
defect were 
excluded 
352/1461 
(24.1) 
684/3390 
(20.2) 
Jia et al (2011)19 West China College of Stomatology, 
Sichuan University, Department of 
Cleft Lip and Palate Surgery, China 
2008 and 2010. 
Hospital based, 
Case–control 
537 CL/P 
176 CP 
221 controls 
1st trimester 
 
402/713 
(56.4) 
 
CL/P: 
302/537 
(56.2) 
CP: 100/176 
27/221 
(12.2) 
11.42 (6.87-19) 
Child sex, birth 
weight, maternal 
18/713 
(2.5) 
2/221 (0.9) 
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(56.8) age, and weight, 
multi-vitamins, 
calcium and 
folic acid 
exposure 
Jianyan et al 
(2010)20 
China 
___ 
Hospital-based, 
matched case-
control (sex age, 
socio-economic 
status) 
200  CL/P 
200 controls 
Three month 
Pregestation
+ 1st 
trimester 
 
121/200 
(60.5) 
 87/200 
(43.5) 
1.72 (1.08-2.74 
Maternal and 
paternal schooling 
a a 
Leite and Koifman 
(2009)21 
city of Rio de Janeiro 
Brazil 
___ 
Hospital-based, 
matched case–
control (sex, age, 
location of 
parents resident)  
274 cases 
548 controls  
One year 
pregestation
+ 1st 
trimester 
166/274 
(60.6) 
 281/548 
(52.3) 
1.48 (1.09-2.01) 
Maternal 
education, age and 
alcohol intake 
68/274 
(24.8) 
94/548 (17.1) 
Li et al (2010)22 Data from a population-based case-
control study of external malformations 
in 4 counties (Pingding, Xiyang, 
Taigu, Zezhou) of Shanxi Province,38 
China 
2003-2006 
Population-based 
Matched  case–
control (county, 
sex, maternal 
ethnic, 
conception date) 
88 cases 
(CL/P)  
651 controls 
One month 
pregestation
+ 1st 
trimester 
 
59/88 (67) 
 
1-6 
times/wee
k:31/88 
(35.2) 
>6times: 
28/88(32) 
 348/651 
(54) 
 
1-6 
times/wee
k 
234/651(3
5.9) 
>6times: 
114/651 
(17.5) 
CL/P: 2 (1.2-3.4) 
Maternal 
occupation, 
fever and flu 
pregestation, 
child sex 
a a 
Li et al (2011)23 Study: College of Stomatology, West 
China  
Control: Women’s and Children’s 
Hospital, West China, 
China 
Study: 2005-
2008 
Control:2006 -
2007 
 162 cases 
304 control 
 69/162 
(42.6) 
 54/304 
(17.4) 
 a a 
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Lie et al (2008)24 Norway 
1996-2001 
Matched case–
control (time) 
random selected 
control  
573 cases 
763 controls 
1st trimester 90/334 
(26.9) 
 
1st trimester  
CL/P: 58/210 
(27.6) 
CP:32/196(16.
3) 
106/520 
(20.4) 
CLP: 1.59 (1.02-
2.47) 
CP: 1.05 (0.55-2) 
Maternal 
education, 
occupation, 
alcohol intake, 
folic acid 
supplement, diet 
and 
multivitamins, 
paternal income, 
child date of 
birth 
239/432 
(55.3) 
243/763 
(31.8) 
Little et al  (2004)8 Scotland, 
Manchester, Merseyside  
UK 
1997-2000 
Population-based 
Matched case-
control  (sex, date 
of birth, region)  
190 cases 
248 controls 
1st trimester 67/110 
(60.9) 
 
 
1st trimester  
CL/P: 
40/76 (52.6) 
 
CP 27/78 
(34.6) 
111/189 
(58.7) 
1 (0.6-1.6) 
Child sex, season 
of birth maternal 
education, ethnicity 
80/190 
(42.1) 
59/248 (23.8) 
Mirilas et al 
(2011)9 
Pediatric Surgery Department, Greece 
2004 & 2009 
Residency 
Matched case-
control 
35 case 
control 35 
matched 
(place) 
One year 
pregestation 
or 1st 
trimester  
 
One year 
pregestation
+ 1st 
trimester  
 
Pregestation: 
34/35 
(97.1) 
 
 
 
 
16/35 
(45.7) 
 
 
 
 
18/35 
(51.4) 
CL/P: 
16/35 (45.7) 
 
 
25/35 
(71.4) 
 
 
 
11/35 
(31.4) 
 
 
 
14/35 (40) 
 15/35 
(42.9) 
 
 
 
9/53 (17) 
20/35 (57.3) 
 
 
 
 
7/35 (20) 
Taghafi et al 
(2012)25 
Bahrami Hospital, Tahran, Iran 
2005-2010 
Hospital base 
Case-control 
300cases  
300 controls 
Three month 
Pregestation
+ 1st 
113/300 
(37.7) 
 
CL/P 113/300 
(37.7) 
80/ 300 
(26.7) 
0.613 (0.43-0.87) 
Child sex, maternal 
age, education, 
7/300 (2.3) 5/300 (2) 
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trimester 
 
socioeconomic 
state, iron 
exposure, vitamin 
use, medication, 
smoking X-ray 
exposure, 
consanguinity 
Wang et al (2009)26 Thirteen districts and counties, 
Shenyang, China.  
2000 to 2007 
population-based 
control matched 
(gender, place,  
date of birth) 
(2 control for 
each case) 
 One month 
Pregestation
+ 1st 
trimester 
 
168/ 586 
(28.7) 
 192/ 1172 
(16.4) 
2.05 (1.47-2.87) 
Maternal age and 
weight 
12/586 
(2) 
16/1172 
(1.4) 
Zhang et al 
(2010)27 
Centre for the Rehabilitation 
of Craniofacial Anomalies,  
Harbin Medical 
University, Harbin,  
China 
2006-2009 
Case-control 
Not matched 
304 cases  
CLP140 
 CP77  
CL86  
453 controls 
One month 
Pregestation
+ 1st 
trimester 
 
224/323 
(69.3) 
CL:79/106 
(74.5) 
CLP: 96/140 
(68.6) 
CP 
49/77(63.6) 
169/454 
(37.2) 
 14/300 
(4.7) 
6/545 (1.1) 
 
a. missing information. 
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Table 2: Univariate meta-regression analysis relating cleft type and study quality to 
effect size estimates of the relation between passive smoking and NSOFC  
 
Variable Coeffici
ent 
Standard 
error 
p value Relative odds ratio 
(95% CI) 
Tau-squared 
Constant  0.579 0.636 0.379 ----  
Cleft type 0.132 0.411 0.752 1.14 (0.47 to 2.77) 0.566 
Constant  1.579 0.188 0.000 ----  
Quality -1.144 0.214 0.000 0.32(0.20 to 0.51) 0.067 
Constant 0.221 0.067 0.007 ----  
Region 0.407 0.134 0.011 1.50(1.12 to 2.02 0.090 
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Figure 1: Flow diagram of study selection process. 
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Figure 2: Forest plot for meta-analysis of the association between maternal passive smoking and 
the risk of having an infant with NSOFC 
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Figure 3: Forest plot for meta-analysis of the association between maternal passive smoking and 
the risk of having an infant with NSOFC, comparing the different types of maternal smoking 
exposure (active and passive)  
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Figure 4: Forest plot for meta-analysis showing the crude and reported adjusted OR for the 
association between maternal passive smoking and NSOFC 
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Figure 5: Forest plot for meta-analysis of the association between NSOFC and maternal passive 
smoking exposure in the 1st trimester including or not including the pregestation period compared to 
maternal exposure prior to pregnancy period alone.  
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Figure 6: Forest plot for meta-analysis of the association between NSOFC phenotype (CL/P and CP) 
and maternal passive smoking 
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Figure 7: Forest plot for meta-analysis of the association between maternal passive smoking and 
NSOFC according to region 
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Figure 8: Forest plot for meta-analysis of the association between maternal passive smoking and 
NSOFC according to study quality (NOS scale) 
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Figure 9: Funnel plot for studies showing the relationship between passive smoking and both CL/P and 
CP.  
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Abstract 
Objectives: Non-syndromic orofacial clefting (NSOFC) is the most prevalent craniofacial birth defect 
worldwide with geographic and ethnic variation. We describe the characteristics and prevalence of 
NSOFC in Riyadh and in three main cities of Saudi Arabia together,  and assess the effects of 
parental consanguinity on NSOFC phenotypes.  
Methods: All infants (114,035) born at three referral centers in Riyadh and six hospitals in Jeddah 
and Medina from January 1, 2010 to December 31, 2011 were screened. NSOFC cases (133) were 
identified and data were collected from clinical examination records and parent interviews. A 
NSOFC diagnosis was confirmed by reviewing medical records and contacting the infants' 
pediatricians. Infants (233) matched for sex and born in the same hospitals during the same period, 
were selected as controls to further analyze the effects of consanguinity on NSOFC.  
Results: The prevalence of NSOFC was 1.07/1000 births in Riyadh, and 1.17/1000 births overall; 
cleft lip (CL) was 0.47/1000 births, cleft lip and palate (CLP) was 0.42/1000 births, and cleft palate 
(CP) was 0.28/1000 births. CP was significantly associated with consanguinity (P= 0.047, OR: 2.5, and 
95% CI: 1 to 6.46), particularly for 1st cousin marriages (72.7% for NSOFC compared to 58.9% for 
controls).  
Conclusion: The prevalence of NSOFC in Riyadh alone, and in the three main cities in Saudi Arabia, 
was marginally lower than the mean global prevalence (1.25/1000 births). CL was higher than CLP, 
in contrast to the global pattern.  
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Introduction 
Non-syndromic orofacial clefting (NSOFC), including isolated cleft lip (CL), cleft lip and palate 
(CLP), and isolated cleft palate (CP), is the most common craniofacial defect worldwide with an 
estimated mean global prevalence of 1.25/1000 live births (1). However, the prevalence of NSOFC 
varies geographically and across different ethnic groups (2). Although the ethnicity of the Middle 
East is considered Caucasian (3, 4), geographically it is located between three continents (Asia, 
Africa and Europe) which makes it unique and, in reality, a mixture of three ethnicities. A small 
number of studies have measured the prevalence of NSOFC in Middle East countries with the 
reported prevalence ranging from 0.3 to 2.19/1000 births (5-9) In addition, consanguineous 
relationships have been suggested to increase the prevalence of congenital anomalies, particularly 
for recessive gene disorders (10).  
Saudi Arabia, one of the largest countries in the Middle East, has a high rate of 
consanguineous marriage that varies between regions. Thus, the aim of this study was to (1) 
describe the characteristics and prevalence of NSOFC (CL, CLP, and CP) in Riyadh (the capital city in 
the central region of Saudi Arabia) and (2) describe the prevalence of NSOFC phenotypes and its 
relationship to consanguinity in Saudi Arabia.  
  
Methods 
Subjects 
This study was conducted at three medical referral hospitals in Riyadh: King Fahad Medical 
City, King Saud Medical City, and Riyadh National Guard Hospital. Riyadh is the capital city of 
Saudi Arabia and constitutes 25% of the Saudi population {MINISTRY OF ECONOMY AND PLANNING,  
2013 #348). Data from two previously published studies, conducted in Jeddah and Medina, were 
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also included(11, 12)  Jeddah and Medina are two major cities in the Western Region of Saudi 
Arabia that constitute approximately 35% of the Saudi population (13). 
The inclusion criteria for Riyadh were the same as that for the studies of Jeddah and Medina: 
all infants born at the study hospitals between January 1, 2010 and December 31, 2011 were 
included. The prevalence was calculated as the proportion of infants with NSOFC to the total 
number of births, excluding cases of syndromic orofacial clefting.  
The sample size was calculated using Open Source Epidemiologic Statistics for Public Health 
(OpenEpi) online software (http://www.openepi.com/oe2.3/menu/openepimenu.htm). Factors 
used in the calculation were the estimated population size (98,000 births/year (14)) and the 
predicted prevalence based on the mean global prevalence figures (1.25/1000 births) and 95% 
confidence intervals (CI). This gave a sample size of 61,055 infants to measure the prevalence of 
NSOFC in Saudi Arabia. We screened 40,005 infants from three hospitals in Riyadh and, by adding 
data from the Jeddah and Medina studies, collected data on a total of 114,035 infants. A case-
control study design was used to assess the relationship between parental consanguinity and 
NSOFC. The study group included infants born with NSOFC (133) in Riyadh, Jeddah, and Medina and 
the control group included 233 unaffected infants matched for sex and location. 
This study was approved by the King Abdulaziz University research committee, the 
Institutional Research Review Board (IRB) of the Ministry of Health, and the military hospital. 
Consent to participate was given by parents. 
 
Procedure 
Infants born with NSOFC were identified and the information was passed to a research 
coordinator. To ensure optimal enrolment, eligible patients were actively pursued every two weeks 
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through nursing staff working at the neonatal units or neonatal intensive care units of the 
respective hospitals. 
Data was collected through clinical examinations and parent interviews. In addition, a NSOFC 
diagnosis was confirmed by reviewing medical records and contacting the infants’ pediatricians. The 
total number of infants born with NSOFC in these hospitals over the study period was retrieved 
from the statistical records of each of the hospitals for that period. NSOFC prevalence was 
measured by comparing the number of NSOFC cases to the total number of births at each hospital.  
NSOFC phenotypes were classified according to LAHSHAL classification (15), which subdivides 
cleft lip (CL) according to side (right, left, or bilateral) and complete/incomplete (with/without 
Simonart's band). These subdivisions were used to classify the extent or severity of clefting of the lip 
in cases of cleft lip (CL) and cleft lip with or without cleft palate (CL/P) (1). 
A questionnaire interview with mothers was conducted to obtain data on family history, 
parental consanguinity, and type of consanguinity (1st cousins, 1st cousins once removed, second 
cousins, and other type of relatives). The matched control group was used to measure the effects of 
consanguinity on NSOFC phenotypes and severity.  
 
Statistical analysis 
Data were analyzed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics, 
such as frequency and percentage, on the epidemiology of NSOFC were analyzed. The Chi square 
test was used to test for association between consanguinity and the type of NSOFC and severity of 
CL/P. The significance level was set at p < 0.05. The Odds Ratio (OR) and 95% CI were used to 
measure the effect of consanguinity on NSOFC risk. 
Results 
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Prevalence of NSOFC in Riyadh 
At the 3 hospitals in Riyadh, 43 infants were born with NSOFC between January 1, 2010 and 
December 31, 2011 out of 40,005 births, giving a prevalence of 1.07/1000 births. The prevalence of 
CL was 0.32/1000 births, of CLP 0.35/1000 births, and of CP 0.4/1000 births (Table 1). Left 
incomplete CL was the most common NSOFC sub-phenotype, seen in 6 (22.2%) infants (Table 2). 
 
Overall prevalence of NSOFC in Saudi Arabia 
When the data from Jeddah and Medina (11, 12)) were added to that from Riyadh, to give a 
total of 133 births during the study period, a prevalence of 1.17/1000 births was obtained. The 
prevalence of CL was 0.47/1000 births, of CLP 0.42/1000 births, and of CP 0.28/1000 births. The 
prevalence of NSOFC was higher in Medina (1.88/1000 births) than in Jeddah (0.81/1000 births), 
and Riyadh (1.07/1000 births) (Table 1). Associated anomalies were diagnosed in 22.5% of cases. A 
family history of birth defects was reported in 42.1% of cases, and a family history of orofacial 
clefting was reported in 22.5% of cases. 
Table 2 shows the distribution of NSOFC sub-phenotype according to sex in all three cities. Of 
the 70 cases of unilateral CL/P, the prevalence of left sided CL/P (CL 28 cases, 21.1%, and CLP 16 
cases, 12%) was higher than that of right sided CL/P (CL 13 cases, 9.8%, and CLP 13 cases, 9.8%). The 
frequency of bilateral CLP (19 cases, 14.2%) was higher than that of bilateral CL (12 cases, 9%). Out 
of the 101 CL/P cases; the frequency of incomplete clefting of the lip (58 (57.4%)) was higher than 
complete clefting of the lip (43 (42.6%)).  
The prevalence of NSOFC was higher in males (82 cases, 61.7%) than females (51 cases, 
38.3%). On the other hand, the prevalence of CP was higher in females (16 cases, 31.4%) than males 
(16 cases, 19.5%). There was a statistically significant difference in the distribution of the three 
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NSOFC phenotypes (CL, CLP, and CP) according to sex (P= 0.035). After Chi square adjustment using 
Bonferroni correction, CL was significantly higher in males than in females (P<0.05). 
 
Effects of city of birth and consanguinity on NSOFC phenotype severity  
The prevalence of parental consanguinity was measured for all infants born with NSOFC. 
Parental consanguinity information was missing in 10 cases, and these were excluded from the 
analysis. The prevalence of consanguinity among infants with NSOFC in Saudi Arabia was 65.9% (81 
cases): 56.1% in Riyadh (23 cases), 77.4% in Medina (41 cases), and 58.6% in Jeddah (17 cases). 
There was no relationship between sex and parental consanguinity (P= 0.559). The 
prevalence of consanguinity was higher for CP (78.6%) than for CL/P (61.1%); however, the 
difference was not significant (P= 0.11). In addition, the prevalence of severe CL/P (complete 
clefting of the lip or a bilateral cleft) was higher in infants with consanguineous parents than that in 
infants with non-consanguineous parents; however, these differences were not significant (P= 0.12 
and P= 0.53 respectively, Table 3). 
Consanguinity was more prevalent in infants with NSOFC, including all its phenotypes, 
compared to controls (Table 4). However, the relationship was only statistically significant for CP (P= 
0.047, OR: 2.5, and 95% CI: 1 to 6.46). The highest prevalence for CP was for 1st cousin 
consanguinity, at 72.7% compared to 58.9% for controls. 
 
 
Discussion 
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This study describes the characteristics and prevalence of NSOFC in Riyadh, and overall for 
the cities of Riyadh, Jeddah, and Medina, in Saudi Arabia. We have also assessed the impact of 
consanguinity on the pattern and severity of NSOFC in Saudi Arabia. Although the data for Jeddah 
and Medina have been published previously, this paper combines these data with our dataset for a 
third major city, Riyadh, allowing a more comprehensive picture of oral cleft prevalence in Saudi 
Arabia. 
The prevalence of NSOFC for Riyadh over the 2-year period of the study was 1.07/1000 live births, 
which is higher than the 0.3/1000 births reported by Kumar et al. (1991) for Riyadh. However, that 
study was hospital based and was conducted in 1991{Kumar, 1991 #154}. Moreover, the prevalence 
of NSOFC in Riyadh (1.07/1000 live births) and overall 1.17/1000 live births) was lower than the 
mean global prevalence (1.25/1000 live births) (1). Jeddah showed the lowest prevalence of all 
cities, while Medina showed the highest; the prevalence for Medina was also higher than the mean 
global prevalence. This suggests a genetic and geographical influence on the prevalence of NSOFC 
between regions of Saudi Arabia related to the fact that NSOFC is a multifactorial birth defect (16). 
Furthermore, that the prevalence of CL is higher than that of CLP, particularly in Medina, differs 
from global findings with previous studies reporting a higher prevalence of CLP than of CL (17, 18).  
The higher consanguinity in Medina compared to Jeddah (19) suggests that consanguinity 
might have played a role in NSOFC phenotype and, thus, the higher prevalence of CL. Furthermore, 
studies in countries with low consanguinity show a higher prevalence of CLP than that of CL(20, 21) 
(20, 21). The higher prevalence of CL/P in males and CP in females is similar to global findings (1). 
In children with unilateral CL/P left-sided clefts were more common than right, This is similar 
to other studies  (9, 22, 23) although there is no clear explanation as to why the left side of the lip is 
more prone to clefting (1). Nevertheless, Johnston and Brown (1980) raised the possibility that the 
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right side may have better hemodynamic perfusion as fetal head vessels on the right side leave the 
aortic arch closer to the heart (24). 
The prevalence of bilateral clefts was similar to previous studies, which showed 
approximately 10% for CL and 30% for CLP (25-27). Understanding the pattern of NSOFC sub-
phenotypes could inform future genetic research and establish a more personalized approach 
towards controlling NSOFC in the future. 
The prevalence of associated anomalies in this study (22.5%) was higher than those in 
previous reports on Middle East countries which ranged from 13 to 18% (28) and the mean global . 
However, other studies have reported values as high as 63% (6, 29, 30). This could be related to 
methodological differences, variable diagnoses of associated anomalies, and ascertainment. Rittler 
et al. 2011 reported that 7.1% of NSOFC cases diagnosed as isolated cleft at birth, were found to be 
associated with other birth anomalies after one year (31). 
Family history of orofacial clefting was reported in 22.5% of cases, similar to previous studies 
carried out across Middle East countries (32-34).   
Parental consanguinity and its relationship to oral clefting was assessed in a systematic 
review carried out on all case-control papers that reported the effect of parental consanguinity on 
NSOFC. Although the systematic review suggested a positive relationship, it reported a high level of 
heterogeneity among the included studies(35). Saudi Arabia has a high rate of consanguineous 
marriage that varies between regions(36). The prevalence of consanguinity in NSOFC in this study 
was 65.9%, higher than the prevalence of 54.4% reported by Aljohar et al. (2008) (37)for a hospital-
based cross sectional study of craniofacial cases in King Faisal Specialized Hospital and Research 
Centre in Riyadh. It is also higher than the prevalence reported by El Mouzan et al. (2008)(19) and 
El-Hazmi et al. (1995) (36)for the general Saudi population (57% and 57.7% respectively). The 
prevalence of consanguinity in NSOFC infants in Medina (77.4%), Riyadh (56.1%), and Jeddah 
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(58.6%) seen here are similar to those reported by El Mouzan et al. (2008)(19) at 67.2%, 60%, and 
44% respectively. Of all NSOFC infants with consanguineous parents, 44 couples (54.3%) were 1st 
cousins, similar to El-Hazmi et al. (1995)(36) at 41% for the general population.  
The higher prevalence of consanguineous marriages in NSOFC compared to the general 
population could indicate that it is a risk factor in the etiology of NSOFC; this is supported by 
previous research.(21, 38)  However, to confirm this relationship, we used a case-control study 
design. The prevalence of parental consanguinity was higher for NSOFC and its sub-phenotypes 
compared to controls; however, the relationship was only statistically significant for CP, with a 
doubling of the risk. Sabbagh et al. (2014)(35) in their systematic review reported a higher OR for CP 
(OR: 1.89 and 95% CI: 1.14 to 3.13) compared to CL/P (OR: 1.56 and 95% CI: 1.18 to 2.07 for CL/P). 
In addition, in the Alamoudi et al. (2014) (12)study conducted in Jeddah, a significant relationship 
was reported between consanguinity and CP (P= 0.039). This could explain why the prevalence of CP 
in Riyadh and Medina, where consanguinity was high, was higher than Jeddah. Moreover, the 
higher prevalence of consanguinity in severe CL/P cases support could indicate that parental 
consanguinity could influence the pattern and severity of NSOFC. Future research on the prevalence 
of cleft palate sub-phenotypes and its etiology in each region in Saudi Arabia is recommended.  
Additionally, stillbirths were not included in this study, which might have caused some bias(5, 
39).  However, the impact of stillbirth on prevalence is expected to be low as it accounts for 
15.7/1000 births recorded by the Ministry of Health, Saudi Arabia (14). 
Larger scale national research that includes the private sector, which provides healthcare to 
approximately 20% of the Saudi population (40), should be considered to describe NSOFC 
prevalence in the future. Studies that define the relationship between each NSOFC sub-phenotype 
and, different environmental and genetic risk factors are recommended. 
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This study contributes to the World Health Assembly (WHA) recommendation in 2010 that all 
member states should pay attention to birth defects (including OFC) as a significant contributor to the 
global burden of disease, both in terms of mortality and morbidity.   
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Table 1: Prevalence of NSOFC from Jan 1, 2010 to December 31, 2011 by place of birth and phenotype  
City 
 
Total births CL CLP CP Total NSOFC 
NSOFC prevalence/1000 
births 
Riyadh 
King Saud Medical City 13,252 6 4 6 16 1.2 
Riyadh National Guard Hospital 16,926 2 6 9 17 1 
King Fahad Medical City  9,827 5 4 1 10 1 
Total 40,005 13 14 16 43  
Prevalence/1000 births 1000 0.32 0.35 0.4  1.07 
 
Jeddah 45,896 16 15 6 37  
Prevalence/1000 births 1000 0.35 0.33 0.13  0.81 
 
Medina 28134 24 19 10 53  
Prevalence/1000 births 1000 0.85 0.67 0.36  1.88 
 
Overall births  114,035 53 48 32 133  
Overall prevalence/1000 births 1000 0.47 0.42 0.28  1.17 
 
NSOFC: non-syndromic orofacial clefting; CL: cleft lip; CLP: cleft lip and palate; CP: cleft palate. 
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Table 2: Distribution of NSOFC sub-phenotypes by place of birth and sex 
  Riyadh Overall, Saudi Arabia 
Phenotype 
Sub-
phenotype 
Male 
(%) 
Female 
(%) 
Total 
(%) 
Male (%) Female (%) 
Total 
(%) 
CL 
N=53 
Male: 40 
Female: 13 
Right 
incomplete  
1 (3.7) 1 (6.3) 1 (3.7) 7 (8.5) 2 (3.9) 9 (6.8) 
Right 
complete  
0 1 (6.3) 0 2 (2.4) 2 (3.9) 4 (3) 
Left 
incomplete  
6 (22.2) 1 (6.3) 
6 
(22.2) 
13 (15.9) 5 (9.8) 
18 
(13.5) 
Left 
complete  
1 (3.7) 1 (6.3) 1 (3.7) 9 (11) 1 (2) 
10 
(7.5) 
Bilateral 
incomplete  
1 (3.7) 0 1 (3.7) 8 (9.8) 2 (3.9) 
10 
(7.5) 
Bilateral 
complete  
0 0 0 1 (1.2) 1 (2) 2 (1.5) 
CLP 
N=48 
Male: 26 
Right 
incomplete  
0 0 0 5 (6.1) 6 (11.8) 
11 
(8.2) 
Right 
complete  
1 (3.7) 1 (6.3) 1 (3.7) 2 (2.4) 0 2 (1.5) 
196 
 
Female: 22 Left 
incomplete  
1 (3.7) 1 (6.3) 1 (3.7) 2 (2.4) 2 (3.9) 4 (3) 
Left 
complete  
1 (3.7) 3 (18.8) 1 (3.7) 3 (3.7) 9 (17.6) 12 (9) 
Bilateral 
incomplete  
1 (3.7) 0 1 (3.7) 4 (4.9) 2 (3.9) 6 (4.5) 
Bilateral 
complete  
4 (14.8) 1 (6.3) 
4 
(14.8) 
10 (12.2) 3 (5.9) 
13 
(9.8) 
CP N=32  
Male: 16   
Female: 16 
CP 10 (37) 6 (37.5) 
10 
(37) 
16 (12) 16 (31.4) 
32 
(24.1) 
 
Total 27 (100) 16 (100) 
27 
(100) 
82 (100) 51 (100) 
133 
(100) 
NSOFC: non-syndromic orofacial clefting; CL: cleft lip; CLP: cleft lip and palate; CP: cleft palate. 
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Table 3: Consanguinity and NSOFC phenotype, sex, and severity 
Variables  
Consanguinity 
(%) 
Non-consanguinity  
(%) 
Total (%) P value 
Gender  
Male 49 (63.6) 28 (36.4) 77 (100) 
0.559 Female 32 (69.6) 14 (30.4) 46 (100) 
Total  81 (65.9) 42 (34.1) 123* (100) 
Type of NSOFC 
CL/P 59 (62.1) 36 (37.9) 95 (100) 0.11 
 
CP 22 (78.6) 6 (21.4) 28 (100) 
Total 81 (65.9) 42 (34.1) 123* (100) 
CL in CL/P 
Complete  33 (70.2) 14 (29.8) 47 (100) 0.12  
 
Incomplete  24 (54.5) 20 (45.5) 44 (100) 
Total 57 (62.6) 34 (34.4) 91 (100) 
CL site in CL/P 
Bilateral  20 (66.7) 10 (33.3) 30 (100) 0.53 
 
Unilateral  39 (60) 26 (40) 46 (100) 
Total 59 (62.1) 36 (37.9) 65 (100) 
NSOFC: non-syndromic orofacial clefting; CL: cleft lip; CL/P: cleft lip with/without cleft palate. *The 
total number is less than 133 due to 10 cases of missing information  
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Table 4: Comparison of NSOFC and controls for frequency and type of consanguineous marriage 
Consanguinity NSOFC (%) CL (%) CLP (%) CP (%) Control (%) 
Yes 81 (65.9) 31 (63.3) 28 (60.9) 22 (78.6) 138 (59.2) 
No 42 (34.1) 18 (36.7) 18 (39.1) 6 (21.4) 95 (40.8) 
Total 123 (100) 49 (100) 46 (100) 28 (100) 233 (100) 
P value 
OR 95% (CI) 
0.222 0.6 0.836 0.047† 
2.5 (1-6.46) 
 
Type of consanguinity 
1
st
 cousins 44 (56.4) 16 (53.3) 12 (46.2) 16 (72.8) 76 (58.9) 
1
st
 cousins once 
removed 
4 (5.1) 3 (10) 1 (3.8) 0 8 (6.2) 
2
nd
 cousins 14 (18) 6 (20) 5 (19.2) 3 (13.6) 18 (14) 
Relatives 16 (20.5) 5 (16.7) 8 (30.8) 3 (13.6) 27 (20.9) 
Total 78* (100) 30* (100) 26* (100) 22 (100) 129 (100) 
NSOFC: non-syndromic orofacial clefting; CL: cleft lip; CLP: cleft lip and palate; CP: cleft palate. 
*The total number is low due to missing information †Significant relationship 
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B7: Environmental risk factors in the aetiology of non-syndromic orofacial 
clefts in the Western Region of Saudi Arabia  
 
Environmental risk factors in the aetiology of non-syndromic orofacial clefts in the Western 
Region of Saudi Arabia 
 
Introduction: 
 Non-syndromic orofacial clefting (NSOFC) is described in the literature as orofacial 
congenital defects that either occur in isolation, or are associated with one major, or several rare, 
congenital abnormalities (Tolarova and Cervenka 1998). They show significant ethnic and 
geographic variation and are the most common craniofacial birth defects in the world (Mossey and 
Modell, 2012). The aetiology of NSOFCs has not been elucidated although it is considered likely that 
they are multifactorial birth defects, caused by environmental and genetic factors working alone or 
in combination (Mossey et al., 2009).  Previous research has proposed a number of factors, 
including; maternal medication use, infections, contact with chemicals/ smoking during the first 
trimester and consanguinity (Al-Bustan et al., 2002; Al-Sahafi, 2010; Czeizel et al., 1984; Elahi et al., 
2009; Leitte and Koifman, 2009; Rittler et al., 2001; Taghavi et al., 2012).  
Geographic and ethnic variations have been shown to play a part in influencing the aetiology and 
prevalence of NSOFC (Mossey et al., 2009).  There has been little investigation into these factors in 
the Middle East. Yet it provides a good location to study environmental interactions for NSOFC 
because the different geographic environments present a variety of factors that can be explored as 
possibly influencing NSOFC development.  Also, the region has a wide mix of ethnicity, again 
allowing a variety of factors to be explored. This variation makes Saudi Arabia, the largest country in 
the Middle East (with over 300,000 births/year), a useful part of the world for studying NSOFC and 
looking into factors influencing the development of these anomalies.  This setting also provided the 
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opportunity to investigate a number of different factors, unique to the Middle East and not 
previously investigated, including maternal drinking water supply and different types of tobacco 
smoking. 
One third of Saudi Arabian births are in the Western Region (Ministry of Health, 2008). The cities of 
Jeddah and Maddina have the highest populations of each area, Makkah and Medina in the 
Western Region (Department of Statistics and Information, 2013). This study is expected to be the 
first multi-centre case-control study in Saudi Arabia. 
 The aim of this study was to investigate environmental risk factors and identify those with a  
relationship to NSOFC in the Western Region of Saudi Arabia.  
 
Materials and methods: 
 This study is a multi-hospital based case-control study carried out in Jeddah and Maddina 
cities. It forms part of a series of studies recording baseline data on the prevalence and aetiology of 
NSOFC in Saudi Arabia.  
 
Study setting and subjects: 
 Two of the largest, main cities in the Western Region (Jeddah and Maddina) were included 
in this research. Jeddah city was divided geographically into five districts with a referral center 
selected for each district (Ministry of Health, 2008 These were: Alazizia Maternity Hospital; King 
Fahad Hospital; King Abdulaziz University Hospital; King Abdulaziz Medical City; and King Fahad 
Armed Hospital/Al Mesadia Maternity Hospital (these two hospitals were considered as one center 
as they are located in the same district and cases were ombined). In Maddina, a single center, 
Maddina Maternity and Children Hospital, was selected as it was the main child, maternity and cleft 
referral center.  
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 The study group comprised 112 infants with non-syndromic orofacial clefting (NSOFC), 
diagnosed by each hospitals’ paediatricians (Tolarova and Cervenka 1998). These were infants born 
or referred to the designated hospitals (e.g. orthodontic clinics for nasal- alveolar molding or plastic 
surgical department), age 18 months or less (0-18 months) (Table 1). The control group consisted of 
138 infants unaffected by orofacial clefting and born at, or attending the designated hospitals for 
vaccination. The groups were matched for age, gender, and hospital attendance. Both groups were 
recruited from January 2010 to January 2012. The control infants were picked up and matched by 
one researcher (HS).  
 
Method: 
Ethical approvals for all centers were granted by the Ministry of Health and the Military hospitals 
research centers. A WHO questionnaire on events in the three month pregestation and the first 
trimester periods for congenital anomalies was piloted, modified and validated for the Saudi 
population with additional relevant questions included. Mothers were interviewed face to face. The 
following information were collected as yes/no responses: 
 pregnancy planning, which was defined according to Mossey et al. (2007), as any 
lifestyle or behavioral changes undertaken prior to conception and/or in early 
pregnancy to achieve a favourable pregnancy outcome; maternal illnesses and use of 
medication and supplements; common cold/flu were recorded when mothers self-
reported two or more of the following symptoms- fever, feeling feverish, cough, sore 
throat, runny or stuffy nose, body aches, chills, and fatigue 
•   maternal stress; threatened abortion; family problems (adverse interactions or events 
among family members) and severe morning sickness; 
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•   maternal domestic exposure with questions related to solvents (such as; thinner and 
acetone), pesticides, incense (a certain type of wood producing a fragrant odor when 
burned produces a fragrant odor) ; 
 maternal main drinking water supply during the pregestation three months and first  
pregnancy trimester such as; tap water, bottled water, or Zamzam water (containing 
high mineral concentrations and with alkaline pH. This comes from a specific historical 
well in Makkah city considered to be holy as it is related to two of the prophets; Ibrahim 
and Ismail); and 
•    parental tobacco smoking, Jorak smoking (water-pipe or Hookah) and maternal passive 
smoking (maternal second hand tobacco exposure at home or work) 
In addition, further detail was asked for some data areas: 
•   parental age (maternal age: <20, 21-24, 25-29, 30-34, >34 years; and paternal age: <25, 
26-34, 35-39, 40-49, >49 years), infants neonatal weight, and infants’ family 
socioeconomic status (SES) derived from; parental education (high school and/or more; 
or less), family monthly income (less than 4000RS (threshold for Saudi Salary, 
https://online.hrdf.org.sa/FAQ/faq.html),4000 to 10,000, more than 10,000) and 
description of infant's mother living area (urban vs. rural areas); and 
•   The number of twin cases and family history of congenital abnormalities, and parental 
consanguinity;  
 Infant clinical examinations were carried out by two clinicians experienced in the field of 
cleft lip and palate, to identify NSOFC and classify cleft type as cleft lip (CL), cleft lip and palate (CLP) 
and cleft palate (CP).   
 
Statistical analysis: 
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 Data was analyzed with SPSS version 16 (SPSS Inc., Chicago, IL, USA). Descriptive statistics 
for the epidemiology of NSOFC were presented with frequency and percentages. Chi square was 
used to test for significant differences in NSOFC risk between the case group and the control group 
for each exposure variable. The level of significance was set at P <0.05. For significant P values, odd 
ratios (OR) and 95% confidence of intervals (CI) were calculated to measure the level of risk. To 
compare the different types of maternal main drinking water supply and their relationship to 
NSOFC, chi square tests were adjusted using Bonferroni correction. For quantitative variables, t-test 
was used to compare means.  Stepwise forward unconditional logistic regression analysis was 
carried out on all variables to identify NSOFC risk factors.   
Results: 
 The study included 112 cases (78 from Jeddah and 34 from Maddina) and 138 controls (100 
from Jeddah and 38 from Maddina). The 112 cases (66 (58.9%) born in the same hospitals as the 
control children) comprised; CL (44), CLP (43) and CP (25) cases. Although children with recognized 
syndromes where orofacial cleft was a feature were excluded, those with other congenital 
anomalies were included.  Anomalies associated with NSOFC were found in 18 cases (15.9%); 
craniofacial deformities (n=6), cardiovascular anomalies (n=4), genitourinary anomalies (n=4), non-
specific failure to thrive (n=2), Central Anomaly (n=1) and multiple anomalies (n=1). The controls 
comprised 90 (65.2%) infants born in the same hospitals. 
 The distribution of cleft phenotype for all 112 case infants by cities is described in Table 1. 
The overall proportion of CL cases (39.3%) is similar to proportion of CLP (38.4%).  
 Infant neonatal weight in cases (from 1.5 to 4.5kg, with mean=2.98kg) was similar to control 
(from 1.4 to 4.1kg, with mean=2.89kg) (P= 0.61). Parental age and SES showed no statistically 
significant differences between cases and controls (P>0.05) (see Table 2). Only one child in each pair 
of twins was affected with a cleft.  The number of twins was significantly higher in the case group 
(7/108) compared to the control group (1/138) (P= 0.01, OR=9.5, 95% CI: 1.15-78.4). The twins in 
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the cases group included one affected infant and one non-affected infant.  Although there were 
higher numbers of cases with a family history of consanguineous marriages and congenital 
abnormalities in cases compared to controls, the differences were not statistically significant (P= 
0.24 and P= 0.74 respectively) (see Table 3).  
Table 4 details the distribution of different maternal factors among cases and controls and the risk 
of having an infant with NSOFC. Other medications and diseases that were not mentioned in the 
table were rarely reported by mothers. These included; urinary tract infection in the pregestation 
period (six cases and three controls), urinary tract infection in the 1st trimester (three cases and 
four controls), diabetes (one control), asthma (one case), contraceptives in pregestation period 
(eight cases and 13 controls), contraceptives in the 1st trimester (three cases and three controls), 
cortisone (one control), antifungal medication (one case), hypothyroidism and thyroxin (one 
control), depression (three cases and three controls) antidepressant (one case and one control).  
 Maternal use of antibiotics during the pregestation and first trimester periods were higher 
in cases than controls, but the difference was significant only for the pregestation period (P= 0.021, 
OR=2.71, 95% CI: 1.11-6.62); anti-emetic medication use  in the first trimester (P= 0.005, OR=2.85, 
95% CI: 1.3-6) was significantly higher in cases than controls.  
 Also, maternal illness was reported by mothers in the three months pregestation period 
significantly more often in cases than controls (P= 0.009, OR=2.19, 95% CI: 1.17-4.08) with common 
cold in the pregestation period being reported significantly more frequently in mothers of NSOFC 
children than in control group mothers (P= 0.003, OR=3.2, 95% CI: 1.48-7.58).  
 For maternal supplement use, significantly higher folic acid (P= 0.04, OR=0.58, 95% CI: 0.34-
0.98) and calcium (P= 0.02, OR=0.32, 95% CI: 0.11-0.86) taken during the first trimester showed a 
protective effect against having an infant with NSOFC but was statistically significant only for 
calcium supplementation use. 
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Maternal experience of stress, threatened abortion and family problems were more 
frequently recorded in NSOFC mothers than mothers in the control group but the differences were 
not significant (P= 0.08 and P= 0.1 respectively).  However, severe morning sickness showed a 
statistically significant association for risk in cases compared with controls (P= 0.006, OR=3.6, 95% 
CI: 1.34-9.65) 
 With regard to domestic chemical exposure, significantly more controls were exposed to 
incense compared to cases (P= 0.03, OR=0.58, 95% CI: 0.34-0.98). Finally, maternal use of mains 
water supply in the three months pregestation and 1st trimester periods showed a significant 
difference between cases and controls (P= 0.01). There was no significant difference between 
drinking tap and bottled water in cases and controls (P=1). However, Zamzam water showed a 
significant protective effect compared to other types of drinking water (P= 0.004, OR: 0.16, 95% CI: 
0.04-0.6 compared to tap water and P= 0.005, OR: 0.2, 95% CI: 0.06-0.7 compared to bottled water) 
being the main water supply used significantly more often by the control group (P<0.05). 
 Maternal smoking was rarely reported in the three-month pregestation and 1st trimester 
period (five times in cases and four in the controls for the pregestation period and only one case in 
the 1st trimester period). Therefore, only paternal types of smoking were analyzed. Although there 
was a higher prevalence of paternal smoking in the case group than the control group, the 
difference was not significant (P> 0.05). However, when looking at the different types of smoking, 
paternal Jorak smoking was associated with a statistically significantly increased risk of having an 
infant with NSOFC (P= 0.004, OR=14.07, 95% CI: 1.55-128.1). Maternal passive smoking was also 
statistically significantly associated with NSOFC (P= 0.05, OR= 2.05, 95% CI: 1.05-4.01) (see Table 5).  
 Logistic regression analysis was carried out for all variables and their relationship to NSOFC 
(Table 6). The stepwise logistic regression identified six significant factors as predictors for NSOFC 
risk: maternal common cold/flu three months pregestation (P= 0.002, OR=4.63, 95% CI: 1.78-12.02); 
maternal use of antibiotics in the first trimester (P= 0.047, OR 2.36, 95% CI: 1.01-5.5);  having a 
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severe morning sickness (P= 0.001, OR=6.23, 95% CI: 2.04-19.03); paternal Jorak smoking (P= 0.014, 
OR=15.1, 95% CI: 1.73-131.6); twin pregnancies (P= 0.034, OR 10.77, 95% CI:1.19-97.5); and 
maternal exposure to incense in the three month pregestation period (P= 0.006, OR=0.42, 95% CI: 
0.22-0.77) as predictor variables for NSOFC. Identification of these six factors was implemented in 
four steps explaining 68% of the risk. Paternal Jorak smoking was identified as the strongest 
predictor (OR=15.1).  
 
Discussion: 
 This case-control study is the first investigation into the environmental risk factors for 
NSOFC in the Western Region of Saudi Arabia. It also the first, to the best of our knowledge to look 
into the association between the different type of tobacco smoking and maternal drinking water 
source and NSOFC.  
The proportion of CP (22.3%) in the included sample is similar to the global proportion ranging from 
20-25% (Mossey and Modell, 2012). The overall proportions of CL (39.3%) were similar to CLP 
(38.4%), which differs from the global figures where there is a higher CLP proportion (40-45%) 
compared to CL (20 to 25%) (Mossey and Modell, 2012). Also, the proportion of the different 
phenotypes of NSOFC in Jeddah differed from that of Maddina. These variations could be due to 
different hospital facilities resulting in more infants with CLP than CL being referred to Jeddah 
Hospitals where there are more established treatment facilities. However, it could also indicate the 
need for studies that detect specific environmental risk factors for different geographic areas. These 
kinds of studies have an important role in disease prevention (Mossey and Castilla, 2001).  
 Previous studies have suggested a significant relationship between parental SES and having 
a child with NSOFC and have related their finding to the parental healthcare and life style (Taghavi 
et al., 2012). Others have reported a higher risk of NSOFC in rural areas compared to urban (Messer 
et al., 2010; Al-Sahafi, 2010). However, our study found no significant relationship between SES and 
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NSOFC and this might be related to the general higher SES of Saudis compared to other 
communities, availability of free governmental healthcare and generally high living standards.  
 In common with other studies (Jamilian, 2007; Kanaan, 2008; Al-Sahafi, 2010), we found no 
association with parental age and NSOFC. In 2012, a meta-analysis carried out to assess the 
relationship between parental age and NSOFC found heterogeneity between studies looking at 
parental age and their relationship to cleft lip with or without cleft palate (CL±P). A relationship was 
only noted between parental age and cleft palate only (Herkrath et al., 2012).  Neonatal weight was 
similar in both case and control groups, confirming previous findings (Leitte and Koifman, 2009; 
Welch and Hunter, 1980), although Bonaiti et al (1982), in their epidemiological study set in France, 
reported lower birth weight for CP (Bonaiti et al., 1982). 
 Congenital anomalies have been reported to be higher in twins compared to singletons 
(Glinianaia et al., 2008). Although the number of twins in this study sample was low, there was a 
significantly higher number of twins in the study group compared to controls (P= 0.04). However, in 
2012, Danish national research found no increased risk of NSOFC in twins compared to singletons 
although they did note that the recurrence risk for clefts was greater in twins than in non-twin 
siblings and that heritability estimates were over 90% (Grosen et al., 2012).  
 Maternal illnesses and medication use in the three-month pregestation period were 
significantly related to having an infant with NSOFC. However, this relationship was not significant 
for maternal illness in the first trimester. Mothers may not be aware of their pregnancy until the 
end of the second gestation month, which is a critical time for craniofacial development.  Also, the 
three months pregestation period covers the time around conception which could affect the 
embryonic development (Mossey and Castilla, 2001). The positive relationship between maternal 
illness and having a child with NSOFC was supported by Hashmi et al (2010) study who reported a 
protective effect with maternal antipyretic medication use. This study also found a higher number 
of mothers taking antipyretics in the control group than in the NSOFC group although there was no 
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statistically significant differences (P>0.05). The effect of antipyretic medications could explain the 
relationship between maternal illness and NSOFC. It could suggest that the disease symptoms, 
possibly pyrexia, lie behind this relationship. 
Our finding that maternal use of antibiotics increased risk of NSOFC (P= 0.01, OR=3) is supported by 
another study (Lin et al., 2012). In a nationwide cohort study of 806,011 live births in Denmark it 
was concluded that although maternal antibiotic use was not a major risk factor for NSOFC, there 
was a significant relationship between certain classifications of antibiotics (tetracyclin, 
sulfamethizole, doxycycline, trimethoprim) and NSOFC (Mølgaard-Nielsen and Hviid, 2012).    
 Maternal supplement use during the first trimester showed a protective effect against 
having a child with NSOFC for both folic acid and calcium supplement use (P= 0.04, OR= 0.58, 95% 
CI: 0.34-0.98 and P= 0.02, OR=0.32, 95% CI: 0.11-0.88 respectively). For folic acid, the finding is 
supported by a meta-analysis carried out by Bodovinac et al (2007), including five prospective 
studies, where a significant relationship was identified between folic acid and NSOFC occurrence 
(OR=0.55, 95% CI: 0.32-0.95) (Badovinac, et al., 2007). Like this study, Jia et al (2011) noted a 
significantly protective effect with calcium supplement use for CL±P (0.02, OR= 0.66, 95% CI: 0.47-
0.93). This relationship could be related to the severe Vitamin D deficiency level in Saudi women ; 
one of the highest Vitamin D deficiency level in the world (Elshafie et al., 2012). Vitamin D is known 
to play an important role in the maintenance of serum (ionised) calcium levels (Nordin, 2010). 
 Smoking was more frequent in NSOFC group than the control group but the differences 
were not significant for all types of smoking. Passive smoking and Jorak had a statistically significant 
relationship with NSOFC (P= 0.05 and P= 0.004 respectively). Previous researchers have reported a 
positive significant relationship between smoking or passive smoking and having an infant with 
NSOFC (Jia et al., 2011; Little et al., 2004; Zhang et al., 2011). However, this is the first study looking 
at the type of smoking device. Previous research has found that Jorak smokers have significantly 
higher carboxyhaemoglobin concentration than cigaratte smokers, higher carbon monoxide and 
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have higher serum cotinine levels due to the larger amount of tobacco consumed during water-pipe 
smoking compared with cigarette smoking (Ardawi et al., 2007; Zahran et al., 1985). Water-pipe 
smoking has recently been indicated to be an emerging global epidemic concern and is largely 
understudied (Fakhreddine et al. 2014). This paper provides further evidence and supports the need 
to study the association between different smoking exposure devices and mechanisms including 
water-pipe and passive smoking in relation to congenital anomalies. 
 The positive significant relationship between NSOFC infants and mothers experiencing 
severe morning sickness or use of anti-emetic medication is supported by Miller (2002), who 
suggested that severe morning sickness can lead to loss of around 5% of maternal original weight, 
and could result in birth defects. Also, Jia et al (2011) found a significant protective effect for 
maternal weight gain during pregnancy and having a cleft child (OR = 0.15, 95% CI: 0.034–0.63). 
However, this is not a clear picture as other studies suggest protective effects or no relationship 
between NSOFC and maternal nausea and vomiting (Czeizel et al., 2002; Molina-Solana et al., 2013; 
Czeizel et al., 1984; Molina-Solana et al., 2013; Badovinac et al., 2007).  
 To the best of our knowledge, this research is the first to find associations in two areas, 
between the occurrence of NSOFC and 1) maternal use of incense and 2) source of maternal 
drinking water. These are interesting preliminary observations that, if confirmed in future studies, 
could raise the possibility for community prevention programs through water supplication and air 
incense exposure in different closed areas. The relationship between maternal water supply and 
NSOFC could be related to the concentration of mineral water content with a greater mineral 
content in Zamzam water compared to tap and bottled water. It contains the highest amount of 
minerals such as: calcium, fluoride, zinc and magnesium (Al Zuhair and Khounganian; Shomar, 2012; 
Zamzam Studies and Research Centre, 2011; Alfadul and Khan, 2011). Two of these minerals (zinc 
and calcium) have been previously found to have a significant relationship with NSOFC (Hozyasz et 
al., 2009; Jia et al., 2011; Krapels et al., 2004; Munger et al., 2009; Tamura and Goldenberg , 1996).  
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  The protective effect found for maternal incense exposure (P= 0.03, OR=0.58, 95% CI: 0.34-
0.98) could be related to the putative antibacterial effects on the surrounding air of burned incense 
(Bevilacqua et al., 1997; Twort and Baker, 1940). In addition, a Hong Kong study looking at the 
confounding effect of the association between air pollution and female lung cancer found that 
incense had no effect on lung cancer risk among nonsmokers and significantly reduced the risk of 
cancer in smokers (P= 0.01) (Koo and Ho, 1996).  
 As well as the inherent bias of recall bias found in all case-control studies of this nature, one 
of its limitations was that some of the significant environmental factor exposures were found in five 
or less mothers, reducing the reliability of the statistical result (twins, paternal Jorak smoking and 
maternal drinking water). However, these were still mentioned to complete the data picture. Also, 
this study assessed NSOFC as a single group and because of the small sample size we were not able  
to subdivide them according to their sub-phenotypes (cleft lip with or without cleft palate (CL/P) 
and CP). However, future research with larger sample sizes that assesses the risk factors for CL/P 
and CP individually is recommended.  
Finally, there is a confounding factor effect that might bias the results. In order to overcome this 
limitation, logistic analysis was carried out. Variables that were found to be significant with logistic 
regression analysis and increased NSOFC risk included; maternal common cold/flu three months 
pregestation, maternal use of antibiotics in the first trimester, having a severe morning sickness, 
paternal Jorak use and, and twin pregnancies. On the other hand, maternal exposure to incense in 
the three-month pregestation period significantly decreased NSOFC risk in logistic regression 
analysis. Variables which were excluded by the logistic regression analysis might be considered to 
be confounding factors in the aetiology of NSOFC.  
 
Conclusion: 
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 In this Middle Eastern population, maternal use of antibiotics, maternal common cold/flu, 
paternal Jorak smoking and maternal passive smoking and twin births were found to be risk factors 
for NSOFC. Folic acid and calcium supplement use had a tendency to decrease the risk of having an 
infant with NSOFC. In addition, incense and Zamzam water showed a protective effect against 
having an infant with NSOFC. These findings, if confirmed in future studies, could raise the 
possibility of introducing community preventive programs through changing water mineral content 
and recommending use of incense. Further studies are also required to verify this and to identify the 
potential role of gene—environment interaction, and the interaction between different 
environmental risk factors in primary prevention.  
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Table 1: Distribution of cleft phenotype by city for all case infants aged 18 months or less 
(n=112), for the two year recruitment period. 
 
City CL (%) CLP (%) CP (%) Total 
Jeddah 29 (37.2) 34 (43.6) 15 (19.2) 78 (100) 
Maddina 15 (44.1) 9 (26.5) 10 (29.4) 34 (100) 
Total 44 (39.3) 43 (38.4) 25 (22.3) 112 (100) 
 
Table 2: Distribution of case infants and control infants according to parental age and 
socioeconomic status. Responses were not received for all questions and response numbers 
are given. 
 
Variables Cases/ total (%) Controls/total (%) P value 
Parental Age (cases=104
 a
, controls=138) 
Maternal age  
<20 6 (5.8) 3 (2.2) 
0.419 
20-24 18 (17.3) 26 (18.8) 
25-29 28 (26.9) 48 (34.8) 
30-34 31 (29.8) 34 (24.6) 
>34 21 (20.2) 27 (19.6) 
Paternal age 
<25 6 (5.8) 6 (4.3) 
0.425 
25-39 69 (66.3) 101 (73.2) 
40-49 23 (22.1) 28 (20.3) 
>49 6 (5.8) 3 (2.2) 
Socioeconomic status 
Parental education (Less than high school) 
Paternal education  28/104
a
 (26.9) 45/138 (32.3) 0.34 
Maternal education  27/103
a
 (27.3) 51/138 (37) 0.08 
Family monthly income in Saudi Ryal (RS) (cases=104
 a
, controls=137
a
) 
Less than 4000 (RS) 26 (25) 38 (27.7) 
0.2 4000 to 10,000 (RS) 64 (61.5) 90 (65.7) 
More than 10,000 (RS) 14 (13.5) 9 (6.6) 
Description of living place (Rural) 17/103
a
 (16.5) 17/136
a
 (12.5) 0.38 
*Statistically significant differences P≤0.05.                                                                                                                                                                                                       
a
 number was less than the total due to missing information  
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Table 3: Distribution of case infants and control infants according to number of twin cases, 
pregnancy planning and family history variables; odds ratio adjusted for maternal age 
Variables and risk factor Cases/ total (%) Controls/total (%) P value 
OR 95 % (CI) 
Number of cases with twins  7/108
a,c
 (6.2) 1/138
a
 (0.7) 0.01* 
9.5 (1.15-78.4) 
Pregnancy planning 
39/104
a
 (37.5) 54/138 (39.1) 
0.8 
0.93 (0.55-1.58) 
Family history 
Infants with positive family history 
for congenital abnormalities 45/101
a
 (44.6) 50/137
a
 (38) 
0.24 
1.2 (0.72-2.08) 
Parental consanguinity 
59/103
a
 (57.3) 75/136
a
 (55.1) 
0.74 
1.04 (0.62-1.77) 
Type of parental consanguinity: 
1
st
 cousins  39 (66.1) 52 (70.3) 
0.83 
2
nd
 cousins 11 (16.8) 12 (14.9) 
Relatives 9 (15.3) 11 (14.9) 
Total   59 (100) 75 (100) 
*Statistically significant differences P≤0.05                                                                                                                                                                         
a
 number was less than the total due to missing information 
c
 the included twins had one affected infant and one no-affected infant (non-cleft infant). 
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Table 4: Distribution of cases and controls according to different maternal factors and their 
risk factors with odds ratio adjusted for maternal age. 
Variables and risk factors Cases/ total (%) Controls/total (%) 
P value  
OR 95 % (CI) 
Maternal medication use and illness: 
Antibiotic use pregestation 16/102
a
 (15.7) 8/138 (5.8) 
0.021* 
2.71 (1.11-6.62) 
Antibiotic use 1
st
 trimester 
18/103
a
 (17.5) 13/138 (9.4) 0.058 
2.09 (0.96-4.53) 
Antipyretic medication pregestation 16/104
a
 (15.4) 26/138 (18.8) 
0.58 
0.82 (0.4-1.64) 
Antipyretic medication 1
st
 trimester 18/104
a
 (17.3) 30/138 (21.7) 
0.39 
0.76 (0.4-1.43) 
Anti-emetic medication first trimester 22/103
a
 (21.4) 12/138 (8.7) 
0.005* 
2.85 (1.3-6) 
Illness pregestation  31/103
a
 (30.1) 22/138 (16.1) 
0.009* 
2.19 (1.17-4.08) 
Illness 1
st
 trimester 38/103
a
 (36.9) 48/138 (35.8) 
0.87 
1.03 (0.59-1.78) 
Common cold/flu pregestation 20/103
a
 (19.4) 9/136
a
 (6.6) 
0.003* 
3.32 (1.48-7.58) 
Common cold/flu 1
st
 trimester 22/103
a
 (21.4) 26/136
a
 (19.1) 
0.67 
1.09 (0.57-2.08) 
Fever pregestation 13/10
2a
 (12.7) 9/136
a
 (6.6) 
0.11 
2.08 (0.85-5.08) 
Fever 1
st
 trimester 13/103
a
 (12.6) 18/136
a
 (13.2) 0.89 
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0.93 (0.43-1.99) 
Maternal  supplements use 
Folic acid pregestation 8/96
a
 (7.7) 10/128 (7.2) 
0.91 
1.06 (0.4-2.81) 
Folic acid 1
st
 trimester 60/104
a
 (57.7) 97/138 (70.3) 
0.043 
0.58 (0.34-0.98) 
Multivitamins pregestation 6/104
a
 (5.8) 5/138 (3.6) 
0.44 
1.84 (0.53-6.34) 
Multivitamins 1
st
 trimester 16/103
a
 (15.5) 17/137
a
 (12.4) 
0.49 
1.22 (0.58-3.96) 
Iron pregestation 8/103
a
 (7.8) 8/138 (5.8) 
0.54 
1.43 (0.51-3.96) 
Iron 1
st
 trimester 20/103
a
 (19.4) 40/138 (29) 
0.09 
0.62 (0.33-1.15) 
Calcium 1
st
 trimester 5/104
a
 (4.8) 19/138 (13.8) 
0.02* 
0.32 (0.11-0.86) 
Maternal stress 
Threatened abortion 7/102
a
 (6.9) 3/136
a
 (2.2) 0.08
C
 
Severe morning sickness 15/102
a
 (14.7) 6/136
a
 (4.4) 
0.006* 
3.6 (1.34-9.65) 
Family problem 33/99
a
 (33.3) 32/136
a
 (23.5) 
0.1 
1.7 (0.96-3.05) 
Maternal domestic environmental exposure 
Maternal exposure to solvent 
pregestation 
19/102
a
 (18.6) 22/138 (15.9) 
0.59 
1.16 (0.59-2.29) 
Maternal exposure to solvent 1
st
 14/102
a
 (13.7) 21/138 (15.2) 0.9 
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trimester 0.89 (0.4-1.83) 
Maternal exposure to pesticides 
pregestation 
23/102
a
 (22.5) 30/138 (20.7) 
0.43 
1.08 (0.58-2) 
Maternal exposure to pesticides 1
st
 
trimester 
25/102
a
 (24.5) 32/138 (23.2) 
0.81 
1.09 (0.6-2) 
Maternal exposure to incense 
pregestation 
54/102 (52.9) 91/138 (65.9) 
0.053 
0.6 (0.36-1.02) 
Maternal exposure to incense in the 1
st
 
trimester 
53/102
a
 (52) 91/138 (66) 
0.03* 
0.58 (0.34-0.98) 
Maternal main drinking water type 
Tap water 28 (28.6) 29 (21.5) 
0.01* Bottled water 67 (68.4) 87 (64.4) 
Zamzam water 3 (3.1) 19 (14.1) 
*Statistically significant differences P≤0.05                                                                                                                                                                         
a
 number was less than the total due to missing information                                                                                                                                                                                                                                             
c
 OR can't be  adjusted because one of the table numbers was zero 
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Table 5: Distribution of cases and controls according to different forms of smoking with 
odds ratio adjusted for maternal age. 
Variables and risk factors Cases/ total (%) Controls/total (%) P value 
OR 95 % (CI) 
Paternal smoking 37/102
a
 (36.3) 42/137
a
 (30.7) 
0.36 
1.73 (0.7-2.37) 
Paternal tobacco smoking 26/102
a
 (25.5) 35/138 (25.4) 
0.98 
1.03 (0.57-1.86) 
Paternal Jorak smoking 8/102
a
 (7.8) 1/138 (0.7) 
0.004* 
14.07 (1.55-128.1)  
Maternal passive smoking 25/102
a
 (24.5) 21/137
a
 (15.3) 
0.05* 
2.05 (1.05-4.01) 
*Statistically significant differences P≤0.05 
a
 number was less than the total due to missing information 
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Table 6: Multiple logistic regression analysis for all variables showing the most significant 
factors related to NSOFC with a cutoff value of 0.5, probability for stepwise entry 5% and 
probability for stepwise exclusion 10%. 
 . 
 
 
 
 
 
 
 
 
 
 
*Statistically significant differences P≤0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factors P value OR and 95% (CI) 
Factors associated with increased risk of NSOFC 
Twin pregnancies 0.03* 10.79 (1.9-97.5) 
Common cold/flu pregestation 0.002* 4.63 (1.78-12.02) 
Maternal antibiotic use in the 1
st
 
trimester  
0.047* 
2.36 (1.01-5.5) 
Severe morning sickness 0.001* 6.23(2.04-19.03) 
Paternal Jorak smoking  0.014* 15.1 (1.73-131.6) 
Factors associated with decreased risk of NSOFC: 
Incense pregestation 0.006* 0.42 (0.22-0.77) 
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